Dokumentvorlage, Version vom 16.12.2021

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Quizartinib (VANFLYTA)

Daiichi Sankyo Europe GmbH

Modul 4 A – Anhang 4-H

Erwachsene Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) mit FLT3-ITD-Mutation

Medizinischer Nutzen und
medizinischer Zusatznutzen,
Patientengruppen mit therapeutisch
bedeutsamem Zusatznutzen

Stand: 30.01.2024

Inhaltsverzeichnis

Seite

Anhang 4-H: Ergebnisse der Subgruppenanalysen der Studie QuANTUM-First

Anhang 4-H1: Gesamtüberleben

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 1.1.1 Overall survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4677
<60	161	63 (39.1)	98 (60.9)	NE (NE, NE)	162	83 (51.2)	79 (48.8)	23.0 (13.0, NE)	0.684 (0.493, 0.949)	0.0224	
≥60 - <65	37	22 (59.5)	15 (40.5)	25.5 (15.3, NE)	44	26 (59.1)	18 (40.9)	21.9 (9.7, NE)	0.941 (0.533, 1.661)	0.8352	
≥65	70	48 (68.6)	22 (31.4)	14.5 (10.6. 21.0)	65	49 (75.4)	16 (24.6)	13.1 (8.0, 14.7)	0.868 (0.583, 1.294)	0.4884	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 14JUL2023 – 16:23; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_1_1_1_OS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 1.1.1 Overall survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95% CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3364
Male	124	70 (56.5)	54 (43.5)	21.0 (13.7, NE)	121	73 (60.3)	48 (39.7)	14.7 (9.7. 26.2)	0.859 (0.619, 1.193)	0.3662	
Female	144	63 (43.8)	81 (56.3)	NE (28.9, NE)	150	85 (56.7)	65 (43.3)	18.5 (13.0. 42.5)	0.693 (0.500, 0.961)	0.0271	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 14JUL2023 – 16:23; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_1_1_1_OS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 1.1.1 Overall survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8919
White	159	85 (53.5)	74 (46.5)	23.8 (13.9, NE)	163	103 (63.2)	60 (36.8)	13.8 (9.7. 18.5)	0.796 (0.597, 1.061)	0.1186	
Non-white	109	48 (44.0)	61 (56.0)	NE (26.6, NE)	108	55 (50.9)	53 (49.1)	28.3 (13.6, NE)	0.754 (0.512, 1.112)	0.1532	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 14JUL2023 – 16:23; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_1_1_1_OS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 1.1.1 Overall survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7227
North America	16	8 (50.0)	8 (50.0)	40.4 (12.1, NE)	18	8 (44.4)	10 (55.6)	NE (10.3, NE)	1.025 (0.385, 2.733)	0.9604	
Europe	163	83 (50.9)	80 (49.1)	26.9 (15.6, NE)	163	104 (63.8)	59 (36.2)	13.4 (9.7. 17.3)	0.730 (0.546, 0.974)	0.0316	
Asia/Other Regions	89	42 (47.2)	47 (52.8)	NE (17.0, NE)	90	46 (51.1)	44 (48.9)	25.8 (13.2, NE)	0.830 (0.546, 1.261)	0.3826	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 14JUL2023 – 16:23; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_1_1_1_OS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 1.1.1 Overall survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0756
< 40x10/L	132	66 (50.0)	66 (50.0)	39.3 (16.5, NE)	135	71 (52.6)	64 (47.4)	28.3 (14.7, NE)	0.961 (0.687, 1.343)	0.8139	
≥ 40x10/L	136	67 (49.3)	69 (50.7)	31.9 (18.5, NE)	136	87 (64.0)	49 (36.0)	12.9 (9.2. 15.7)	0.621 (0.451, 0.855)	0.0032	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 14JUL2023 – 16:23; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_1_1_1_OS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 1.1.1 Overall survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9971
Daunorubicin	124	64 (51.6)	60 (48.4)	30.0 (19.3, NE)	95	57 (60.0)	38 (40.0)	14.2 (10.0. 30.1)	0.768 (0.538, 1.099)	0.1482	
Idarubicin	144	69 (47.9)	75 (52.1)	NE (16.5, NE)	173	99 (57.2)	74 (42.8)	17.2 (13.2. 30.1)	0.769 (0.565, 1.047)	0.0939	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 14JUL2023 – 16:23; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_1_1_1_OS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 1.1.1 Overall survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.1575
Favorable	14	8 (57.1)	6 (42.9)	31.6 (2.1, NE)	19	6 (31.6)	13 (68.4)	NE (11.7, NE)	2.068 (0.717, 5.967)	0.1694	
Intermediate	197	96 (48.7)	101 (51.3)	40.4 (19.3, NE)	193	112 (58.0)	81 (42.0)	14.8 (12.8. 30.1)	0.759 (0.578, 0.997)	0.0472	
Unfavorable	19	8 (42.1)	11 (57.9)	NE (5.5, NE)	27	19 (70.4)	8 (29.6)	13.1 (5.4. 21.9)	0.450 (0.194, 1.043)	0.0566	
Unknown	38	21 (55.3)	17 (44.7)	25.5 (9.6, NE)	31	21 (67.7)	10 (32.3)	14.2 (7.5. 40.7)	0.746 (0.406, 1.368)	0.3436	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 14JUL2023 – 16:23; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_1_1_1_OS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 1.1.1 Overall survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9929
0 - Fully Active	87	39 (44.8)	48 (55.2)	NE (21.8, NE)	98	50 (51.0)	48 (49.0)	22.4 (9.7, NE)	0.764 (0.502, 1.161)	0.2061	
1 - Restricted in Physically Strenuous Activity	134	71 (53.0)	63 (47.0)	29.4 (16.5, NE)	136	88 (64.7)	48 (35.3)	14.7 (12.9, 21.9)	0.762 (0.557, 1.042)	0.0878	
2 - Ambulatory and Capable of All Selfcare	47	23 (48.9)	24 (51.1)	28.9 (12.1, NE)	36	20 (55.6)	16 (44.4)	15.7 (6.9, NE)	0.792 (0.434, 1.445)	0.4454	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 14JUL2023 – 16:23; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_1_1_1_OS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 1.1.1 Overall survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4488
≥3 to ≤25%	94	43 (45.7)	51 (54.3)	NE (21.0, NE)	98	51 (52.0)	47 (48.0)	28.3 (14.8, NE)	0.869 (0.579, 1.304)	0.4959	
>25% to ≤ 50%	143	71 (49.7)	72 (50.3)	39.3 (19.3, NE)	138	79 (57.2)	59 (42.8)	14.8 (11.1, 42.5)	0.774 (0.562, 1.067)	0.1170	
>50%	30	18 (60.0)	12 (40.0)	13.8 (8.0, NE)	35	28 (80.0)	7 (20.0)	8.7 (6.3. 11.2)	0.526 (0.290, 0.955)	0.0317	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 14JUL2023 – 16:23; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_1_1_1_OS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 1.1.1 Overall survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0565
Yes	142	60 (42.3)	82 (57.7)	NE (28.5, NE)	140	81 (57.9)	59 (42.1)	15.1 (11.7. 35.4)	0.637 (0.456, 0.890)	0.0077	
No	116	70 (60.3)	46 (39.7)	19.1 (13.3, 29.4)	120	70 (58.3)	50 (41.7)	17.3 (12.9. 47.8)	1.014 (0.728, 1.413)	0.9320	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 14JUL2023 – 16:23; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_1_1_1_OS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 1.1.1 Overall survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1770
≤60	166	66 (39.8)	100 (60.2)	NE (NE, NE)	165	86 (52.1)	79 (47.9)	19.7 (13.6, NE)	0.684 (0.496, 0.943)	0.0196	
>60	102	67 (65.7)	35 (34.3)	17.7 (13.4. 25.8)	106	72 (67.9)	34 (32.1)	13.8 (9.7. 22.4)	0.929 (0.666, 1.296)	0.6658	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 14JUL2023 – 16:23; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_1_1_1_OS_SUB_ITT.rtf

Anhang 4-H2: Rückfallfreies Überleben

Anhang 4-H2a: Rückfallfreies Überleben für Patient*innen, die eine CRc nach Induktion erreichten

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.2 Relapse-Free Survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2174
<60	118	44 (37.3)	74 (62.7)	NE (28.9, NE)	105	55 (52.4)	50 (47.6)	17.2 (10.3, NE)	0.599 (0.403, 0.891)	0.0107	
≥60 - <65	27	15 (55.6)	12 (44.4)	23.3 (11.9, NE)	28	16 (57.1)	12 (42.9)	14.8 (6.3, NE)	0.753 (0.372, 1.526)	0.4320	
≥65	47	36 (76.6)	11 (23.4)	14.3 (7.0. 18.1)	43	31 (72.1)	12 (27.9)	9.7 (6.3. 27.3)	1.031 (0.637, 1.668)	0.9028	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_18_2_RFS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.2 Relapse-Free Survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5668
Male	87	49 (56.3)	38 (43.7)	21.5 (14.8. 29.4)	72	43 (59.7)	29 (40.3)	11.1 (7.4. 21.6)	0.770 (0.511, 1.161)	0.2116	
Female	105	46 (43.8)	59 (56.2)	48.6 (20.6, NE)	104	59 (56.7)	45 (43.3)	19.7 (10.3. 42.5)	0.670 (0.455, 0.986)	0.0408	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_18_2_RFS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.2 Relapse-Free Survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9608
White	114	62 (54.4)	52 (45.6)	22.6 (14.4, NE)	106	66 (62.3)	40 (37.7)	10.6 (6.6. 23.7)	0.742 (0.524, 1.050)	0.0911	
Non-white	78	33 (42.3)	45 (57.7)	39.3 (18.1, NE)	70	36 (51.4)	34 (48.6)	21.6 (9.7, NE)	0.697 (0.434, 1.118)	0.1321	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_18_2_RFS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.2 Relapse-Free Survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5943
North America	7	4 (57.1)	3 (42.9)	25.8 (9.5, NE)	14	6 (42.9)	8 (57.1)	NE (6.9, NE)	1.236 (0.348, 4.398)	0.7427	
Europe	122	64 (52.5)	58 (47.5)	23.3 (15.4, NE)	103	67 (65.0)	36 (35.0)	10.5 (6.9. 20.0)	0.680 (0.482, 0.958)	0.0266	
Asia/Other Regions	63	27 (42.9)	36 (57.1)	39.3 (17.0, NE)	59	29 (49.2)	30 (50.8)	19.7 (8.9, NE)	0.724 (0.428, 1.224)	0.2265	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_18_2_RFS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.2 Relapse-Free Survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6709
< 40x10/L	88	40 (45.5)	48 (54.5)	39.3 (19.8, NE)	87	49 (56.3)	38 (43.7)	13.3 (9.3. 47.8)	0.678 (0.446, 1.031)	0.0672	
≥ 40x10/L	104	55 (52.9)	49 (47.1)	22.6 (14.6, NE)	89	53 (59.6)	36 (40.4)	11.1 (7.3. 23.9)	0.776 (0.532, 1.133)	0.1887	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_18_2_RFS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.2 Relapse-Free Survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8546
Daunorubicin	86	45 (52.3)	41 (47.7)	23.3 (16.6, NE)	62	37 (59.7)	25 (40.3)	10.5 (6.3. 27.3)	0.695 (0.449, 1.076)	0.1010	
Idarubicin	106	50 (47.2)	56 (52.8)	28.9 (16.5, NE)	113	65 (57.5)	48 (42.5)	14.8 (9.7. 31.6)	0.734 (0.507, 1.061)	0.0993	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_18_2_RFS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.2 Relapse-Free Survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3721
Favorable	8	3 (37.5)	5 (62.5)	39.3 (4.1, NE)	14	5 (35.7)	9 (64.3)	NE (4.9, NE)	1.105 (0.259, 4.706)	0.8927	
Intermediate	148	75 (50.7)	73 (49.3)	23.3 (15.4, NE)	121	68 (56.2)	53 (43.8)	14.8 (8.9. 42.5)	0.811 (0.584, 1.127)	0.2127	
Unfavorable	10	4 (40.0)	6 (60.0)	NE (3.4, NE)	17	12 (70.6)	5 (29.4)	11.3 (5.9. 17.2)	0.319 (0.099, 1.029)	0.0456	
Unknown	26	13 (50.0)	13 (50.0)	28.9 (17.0, NE)	23	17 (73.9)	6 (26.1)	9.3 (6.0. 23.7)	0.509 (0.246, 1.054)	0.0641	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_18_2_RFS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.2 Relapse-Free Survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7491
0 - Fully Active	63	27 (42.9)	36 (57.1)	NE (19.8, NE)	63	35 (55.6)	28 (44.4)	13.6 (7.3, NE)	0.641 (0.388, 1.060)	0.0805	
1 - Restricted in Physically Strenuous Activity	97	51 (52.6)	46 (47.4)	22.4 (14.8, NE)	91	53 (58.2)	38 (41.8)	15.2 (9.3. 30.1)	0.809 (0.550, 1.189)	0.2791	
2 - Ambulatory and Capable of All Selfcare	32	17 (53.1)	15 (46.9)	25.8 (8.0, NE)	22	14 (63.6)	8 (36.4)	8.9 (5.5, NE)	0.657 (0.321, 1.344)	0.2451	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_18_2_RFS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.2 Relapse-Free Survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4465
≥3 to ≤25%	67	34 (50.7)	33 (49.3)	29.4 (17.5, NE)	60	33 (55.0)	27 (45.0)	20.0 (10.5, NE)	0.816 (0.505, 1.317)	0.4038	
>25% to ≤ 50%	99	45 (45.5)	54 (54.5)	39.3 (17.0, NE)	94	52 (55.3)	42 (44.7)	14.2 (7.2. 47.8)	0.729 (0.489, 1.088)	0.1214	
>50%	25	15 (60.0)	10 (40.0)	11.8 (7.0, NE)	22	17 (77.3)	5 (22.7)	6.0 (3.4. 7.8)	0.485 (0.241, 0.977)	0.0380	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_18_2_RFS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.2 Relapse-Free Survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2824
Yes	120	56 (46.7)	64 (53.3)	35.3 (19.8, NE)	115	68 (59.1)	47 (40.9)	11.3 (6.9. 30.1)	0.652 (0.457, 0.930)	0.0174	
No	65	35 (53.8)	30 (46.2)	22.6 (11.9, NE)	52	29 (55.8)	23 (44.2)	17.2 (10.5, NE)	0.899 (0.550, 1.471)	0.6718	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_18_2_RFS_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.2 Relapse-Free Survival - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1043
≤60	120	45 (37.5)	75 (62.5)	NE (28.9, NE)	105	55 (52.4)	50 (47.6)	17.2 (10.3, NE)	0.601 (0.405, 0.892)	0.0106	
>60	72	50 (69.4)	22 (30.6)	16.5 (11.9, 23.3)	71	47 (66.2)	24 (33.8)	9.7 (6.9, 23.7)	0.956 (0.642, 1.426)	0.8295	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_18_2_RFS_SUB_ITT.rtf

Anhang 4-H2b: Rückfallfreies Überleben für Patient*innen, die eine CR nach Induktion erreichten

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.4 Relapse-Free Survival based on CR (without a 42-day window) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

		Quizartinib (N=268)				Placebo (N=271)			Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0440
<60	90	26 (28.9)	64 (71.1)	NE (NE, NE)	90	47 (52.2)	43 (47.8)	17.2 (10.5, NE)	0.425 (0.263, 0.687)	0.0003	
≥60 - <65	22	12 (54.5)	10 (45.5)	23.3 (11.9, NE)	25	15 (60.0)	10 (40.0)	9.7 (6.0, NE)	0.663 (0.309, 1.420)	0.2884	
≥65	35	27 (77.1)	8 (22.9)	13.9 (6.6, 18.5)	35	26 (74.3)	9 (25.7)	9.7 (6.0, 27.3)	1.060 (0.618, 1.818)	0.8368	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:05; Program name: DE_T_4_18_4.sas; Output name: DE_T_4_18_4_RFSCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.4 Relapse-Free Survival based on CR (without a 42-day window) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4249
Male	65	34 (52.3)	31 (47.7)	23.3 (16.6, NE)	60	36 (60.0)	24 (40.0)	11.1 (7.2, 21.6)	0.678 (0.423, 1.087)	0.1045	
Female	82	31 (37.8)	51 (62.2)	48.6 (35.0, NE)	90	52 (57.8)	38 (42.2)	20.0 (8.4, 31.6)	0.534 (0.342, 0.833)	0.0050	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:05; Program name: DE_T_4_18_4.sas; Output name: DE_T_4_18_4_RFSCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.4 Relapse-Free Survival based on CR (without a 42-day window) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9085
White	86	41 (47.7)	45 (52.3)	48.6 (18.5, NE)	90	57 (63.3)	33 (36.7)	10.6 (6.6, 23.7)	0.617 (0.412, 0.922)	0.0173	
Non-white	61	24 (39.3)	37 (60.7)	39.3 (22.4, NE)	60	31 (51.7)	29 (48.3)	21.6 (9.7, NE)	0.596 (0.350, 1.018)	0.0551	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:05; Program name: DE_T_4_18_4.sas; Output name: DE_T_4_18_4_RFSCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.4 Relapse-Free Survival based on CR (without a 42-day window) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6332
North America	7	4 (57.1)	3 (42.9)	25.8 (9.5, NE)	12	6 (50.0)	6 (50.0)	NE (4.6, NE)	0.996 (0.280, 3.541)	0.9947	
Europe	94	44 (46.8)	50 (53.2)	35.3 (19.8, NE)	87	56 (64.4)	31 (35.6)	10.6 (7.2 , 23.7)	0.601 (0.405, 0.893)	0.0108	
Asia/Other Regions	46	17 (37.0)	29 (63.0)	NE (21.5, NE)	51	26 (51.0)	25 (49.0)	17.2 (7.2, NE)	0.537 (0.291, 0.992)	0.0436	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:05; Program name: DE_T_4_18_4.sas; Output name: DE_T_4_18_4_RFSCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.4 Relapse-Free Survival based on CR (without a 42-day window) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5014
< 40x10^9/L	66	26 (39.4)	40 (60.6)	NE (28.5, NE)	74	43 (58.1)	31 (41.9)	13.3 (7.2, 47.8)	0.541 (0.332, 0.882)	0.0123	
≥ 40x10^9/L	81	39 (48.1)	42 (51.9)	26.6 (17.5, NE)	76	45 (59.2)	31 (40.8)	14.2 (8.1, 27.3)	0.677 (0.440, 1.042)	0.0743	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:05; Program name: DE_T_4_18_4.sas; Output name: DE_T_4_18_4_RFSCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.4 Relapse-Free Survival based on CR (without a 42-day window) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6540
Daunorubicin	69	32 (46.4)	37 (53.6)	39.3 (18.5, NE)	53	33 (62.3)	20 (37.7)	10.5 (6.1 , 23.7)	0.544 (0.334, 0.887)	0.0132	
Idarubicin	78	33 (42.3)	45 (57.7)	NE (22.6, NE)	96	55 (57.3)	41 (42.7)	17.2 (9.7 , 31.6)	0.635 (0.412, 0.978)	0.0378	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:05; Program name: DE_T_4_18_4.sas; Output name: DE_T_4_18_4_RFSCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.4 Relapse-Free Survival based on CR (without a 42-day window) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3262
Favorable	5	2 (40.0)	3 (60.0)	39.3 (4.1, NE)	11	4 (36.4)	7 (63.6)	NE (4.6, NE)	1.191 (0.217, 6.529)	0.8402	
Intermediate	112	51 (45.5)	61 (54.5)	48.6 (19.8, NE)	105	60 (57.1)	45 (42.9)	14.8 (8.4, 42.5)	0.690 (0.475, 1.004)	0.0513	
Unfavorable	9	3 (33.3)	6 (66.7)	NE (3.4, NE)	14	9 (64.3)	5 (35.7)	12.6 (5.9, 21.6)	0.277 (0.072, 1.074)	0.0497	
Unknown	21	9 (42.9)	12 (57.1)	NE (17.5, NE)	19	15 (78.9)	4 (21.1)	7.3 (5.9, 23.7)	0.350 (0.151, 0.810)	0.0105	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:05; Program name: DE_T_4_18_4.sas; Output name: DE_T_4_18_4_RFSCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.4 Relapse-Free Survival based on CR (without a 42-day window) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8819
0 - Fully Active	52	20 (38.5)	32 (61.5)	NE (22.6, NE)	55	31 (56.4)	24 (43.6)	13.6 (7.3, NE)	0.540 (0.308, 0.949)	0.0297	
1 - Restricted in Physically Strenuous Activity	68	32 (47.1)	36 (52.9)	39.3 (17.5, NE)	75	45 (60.0)	30 (40.0)	15.2 (8.1, 30.1)	0.670 (0.425, 1.057)	0.0833	
2 - Ambulatory and Capable of All Selfcare	27	13 (48.1)	14 (51.9)	28.9 (9.5, NE)	20	12 (60.0)	8 (40.0)	9.7 (5.9, NE)	0.615 (0.278, 1.360)	0.2235	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:05; Program name: DE_T_4_18_4.sas; Output name: DE_T_4_18_4_RFSCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.4 Relapse-Free Survival based on CR (without a 42-day window) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3ITD category at Baseline											0.6622
≥3 to ≤25%	46	21 (45.7)	25 (54.3)	NE (22.4, NE)	50	28 (56.0)	22 (44.0)	22.4 (10.3, NE)	0.686 (0.389, 1.208)	0.1891	
>25% to ≤50%	82	34 (41.5)	48 (58.5)	48.6 (19.8, NE)	83	48 (57.8)	35 (42.2)	13.3 (7.2, 42.5)	0.591 (0.380, 0.918)	0.0182	
>50%	19	10 (52.6)	9 (47.4)	23.3 (7.4, NE)	17	12 (70.6)	5 (29.4)	5.7 (3.4, 17.2)	0.462 (0.198, 1.075)	0.0664	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:05; Program name: DE_T_4_18_4.sas; Output name: DE_T_4_18_4_RFSCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.4 Relapse-Free Survival based on CR (without a 42-day window) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6422
Yes	98	42 (42.9)	56 (57.1)	48.6 (25.8, NE)	97	58 (59.8)	39 (40.2)	12.6 (7.2, 30.1)	0.575 (0.386, 0.857)	0.0059	
No	44	20 (45.5)	24 (54.5)	39.3 (12.3, NE)	44	25 (56.8)	19 (43.2)	17.2 (8.1, 47.8)	0.675 (0.375, 1.217)	0.1877	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:05; Program name: DE_T_4_18_4.sas; Output name: DE_T_4_18_4_RFSCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.18.4 Relapse-Free Survival based on CR (without a 42-day window) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0215
≤60	92	27 (29.3)	65 (70.7)	NE (NE, NE)	90	47 (52.2)	43 (47.8)	17.2 (10.5, NE)	0.431 (0.268, 0.692)	0.0003	
>60	55	38 (69.1)	17 (30.9)	16.6 (10.5 , 25.8)	60	41 (68.3)	19 (31.7)	9.7 (6.3, 23.7)	0.933 (0.599, 1.452)	0.7583	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:05; Program name: DE_T_4_18_4.sas; Output name: DE_T_4_18_4_RFSCR_SUB_ITT.rtf

Anhang 4-H3: Ereignisfreies Überleben

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.17.2 Event-Free Survival 1 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5877
<60	161	107 (66.5)	54 (33.5)	0.0 (0.0, 7.6)	162	121 (74.7)	41 (25.3)	0.5 (0.0, 5.1)	0.859 (0.662, 1.115)	0.1162	
≥60 - <65	37	29 (78.4)	8 (21.6)	1.0 (0.0, 12.3)	44	35 (79.5)	9 (20.5)	1.9 (0.0, 6.3)	0.890 (0.543, 1.459)	0.5845	
≥65	70	62 (88.6)	8 (11.4)	0.0 (0.0, 0.7)	65	57 (87.7)	8 (12.3)	0.3 (0.0, 5.1)	1.085 (0.757, 1.555)	0.6419	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_17_2_EFS1_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.17.2 Event-Free Survival 1 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6260
Male	124	94 (75.8)	30 (24.2)	0.0 (0.0, 1.9)	121	97 (80.2)	24 (19.8)	0.0 (0.0, 3.4)	0.861 (0.648, 1.145)	0.2152	
Female	144	104 (72.2)	40 (27.8)	0.1 (0.0, 5.0)	150	116 (77.3)	34 (22.7)	2.8 (0.0, 5.1)	0.957 (0.735, 1.248)	0.5570	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_17_2_EFS1_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.17.2 Event-Free Survival 1 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9401
White	159	120 (75.5)	39 (24.5)	0.1 (0.0, 2.4)	163	131 (80.4)	32 (19.6)	1.7 (0.0, 3.8)	0.930 (0.726, 1.192)	0.4483	
Non-white	109	78 (71.6)	31 (28.4)	0.0 (0.0, 8.3)	108	82 (75.9)	26 (24.1)	0.0 (0.0, 5.5)	0.901 (0.660, 1.230)	0.3303	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_17_2_EFS1_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.17.2 Event-Free Survival 1 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5136
North America	16	12 (75.0)	4 (25.0)	0.0 (0.0, 12.3)	18	13 (72.2)	5 (27.8)	5.7 (0.0, 15.2)	1.250 (0.570, 2.743)	0.6320	
Europe	163	120 (73.6)	43 (26.4)	0.2 (0.0, 4.3)	163	132 (81.0)	31 (19.0)	0.3 (0.0, 3.2)	0.851 (0.665, 1.091)	0.1532	
Asia/Other Regions	89	66 (74.2)	23 (25.8)	0.0 (0.0, 0.3)	90	68 (75.6)	22 (24.4)	1.5 (0.0, 5.5)	0.991 (0.706, 1.392)	0.6825	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_17_2_EFS1_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.17.2 Event-Free Survival 1 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7367
< 40x10^9/L	132	97 (73.5)	35 (26.5)	0.0 (0.0, 1.8)	135	104 (77.0)	31 (23.0)	2.1 (0.0, 5.1)	0.952 (0.722, 1.256)	0.5268	
≥ 40x10^9/L	136	101 (74.3)	35 (25.7)	0.1 (0.0, 5.0)	136	109 (80.1)	27 (19.9)	0.4 (0.0, 3.4)	0.891 (0.680, 1.169)	0.3116	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_17_2_EFS1_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.17.2 Event-Free Survival 1 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3835
Daunorubicin	124	97 (78.2)	27 (21.8)	0.0 (0.0, 0.3)	95	75 (78.9)	20 (21.1)	1.8 (0.0, 5.1)	1.007 (0.744, 1.362)	0.7600	
Idarubicin	144	101 (70.1)	43 (29.9)	0.2 (0.0, 6.6)	173	136 (78.6)	37 (21.4)	0.4 (0.0, 4.1)	0.842 (0.650, 1.089)	0.1365	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_17_2_EFS1_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.17.2 Event-Free Survival 1 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6492
Favorable	14	12 (85.7)	2 (14.3)	0.0 (0.0, 4.1)	19	13 (68.4)	6 (31.6)	0.0 (0.0, NE)	1.449 (0.658, 3.191)	0.2669	
Intermediate	197	146 (74.1)	51 (25.9)	0.0 (0.0, 3.4)	193	151 (78.2)	42 (21.8)	0.0 (0.0, 3.6)	0.917 (0.730, 1.152)	0.3405	
Unfavorable	19	13 (68.4)	6 (31.6)	0.0 (0.0, 35.3)	27	22 (81.5)	5 (18.5)	1.0 (0.0, 6.0)	0.772 (0.383, 1.553)	0.3652	
Unknown	38	27 (71.1)	11 (28.9)	0.2 (0.0, 22.6)	31	27 (87.1)	4 (12.9)	4.1 (0.0, 6.9)	0.814 (0.475, 1.394)	0.3012	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_17_2_EFS1_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.17.2 Event-Free Survival 1 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2158
0 - Fully Active	87	57 (65.5)	30 (34.5)	2.4 (0.0, 18.5)	98	75 (76.5)	23 (23.5)	1.2 (0.0, 5.1)	0.779 (0.551, 1.100)	0.1053	
1 - Restricted in Physically Strenuous Activity	134	107 (79.9)	27 (20.1)	0.0 (0.0, 0.1)	136	108 (79.4)	28 (20.6)	1.7 (0.0, 5.1)	1.092 (0.836, 1.428)	0.7308	
2 - Ambulatory and Capable of All Selfcare	47	34 (72.3)	13 (27.7)	0.3 (0.0, 9.5)	36	29 (80.6)	7 (19.4)	0.2 (0.0, 5.9)	0.772 (0.469, 1.271)	0.2921	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_17_2_EFS1_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.17.2 Event-Free Survival 1 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7664
≥3 to ≤25%	94	73 (77.7)	21 (22.3)	0.0 (0.0, 0.5)	98	78 (79.6)	20 (20.4)	0.0 (0.0, 3.0)	0.946 (0.687, 1.302)	0.6879	
>25% to ≤50%	143	102 (71.3)	41 (28.7)	0.2 (0.0, 6.1)	138	105 (76.1)	33 (23.9)	3.2 (0.0, 5.7)	0.937 (0.713, 1.231)	0.4809	
>50%	30	22 (73.3)	8 (26.7)	0.1 (0.0, 20.6)	35	30 (85.7)	5 (14.3)	1.8 (0.0, 4.6)	0.748 (0.429, 1.304)	0.1970	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_17_2_EFS1_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.17.2 Event-Free Survival 1 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6445
Yes	142	95 (66.9)	47 (33.1)	6.1 (0.2, 13.9)	140	104 (74.3)	36 (25.7)	5.6 (2.9, 6.3)	0.856 (0.647, 1.131)	0.2135	
No	116	94 (81.0)	22 (19.0)	0.0 (NE, NE)	120	101 (84.2)	19 (15.8)	0.0 (NE, NE)	0.959 (0.724, 1.271)	0.5413	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_17_2_EFS1_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.17.2 Event-Free Survival 1 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2635
≤60	166	111 (66.9)	55 (33.1)	0.0 (0.0, 7.6)	165	124 (75.2)	41 (24.8)	0.2 (0.0, 4.6)	0.849 (0.657, 1.098)	0.1004	
>60	102	87 (85.3)	15 (14.7)	0.0 (0.0, 1.9)	106	89 (84.0)	17 (16.0)	1.7 (0.0, 4.0)	1.058 (0.787, 1.422)	0.7529	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 17AUG2023 – 12:57; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_4_17_2_EFS1_SUB_ITT.rtf

Anhang 4-H4: Remission

Anhang 4-H4a: Komplettremission nach Induktion mit 42-Tage Fenster

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Pooled Age Group 2: <60			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	161	162	
Number of subjects with events, n (%)	70 (43.5)	79 (48.8)	
95 % CI [a]	(35.7, 51.5)	(40.8, 56.7)	
Odds ratio (95 % CI) [b]			0.81 (0.52, 1.25)
Relative risk (95 % CI) [b]			0.89 (0.70, 1.13)
Absolute risk reduction (95 % CI) [c]			-5.29 (-16.76, 6.19)
p-value [d]			0.3454

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Pooled Age Group 2: ≥60 - <65			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	37	44	
Number of subjects with events, n (%)	18 (48.6)	22 (50.0)	
95 % CI [a]	(31.9, 65.6)	(34.6, 65.4)	
Odds ratio (95 % CI) [b]			0.95 (0.40, 2.27)
Relative risk (95 % CI) [b]			0.97 (0.62, 1.52)
Absolute risk reduction (95 % CI) [c]			-1.35 (-25.69, 22.99)
p-value [d]			0.8016

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Pooled Age Group 2: ≥65			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	70	65	
Number of subjects with events, n (%)	26 (37.1)	31 (47.7)	
95 % CI [a]	(25.9, 49.5)	(35.1, 60.5)	
Odds ratio (95 % CI) [b]			0.65 (0.33, 1.29)
Relative risk (95 % CI) [b]			0.78 (0.52, 1.16)
Absolute risk reduction (95 % CI) [c]			-10.55 (-28.63, 7.53)
p-value [d]			0.2880
Subgroup Interaction p-value [e]			0.7513

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Sex: Male			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	124	121	
Number of subjects with events, n (%)	51 (41.1)	54 (44.6)	
95 % CI [a]	(32.4, 50.3)	(35.6, 53.9)	
Odds ratio (95 % CI) [b]			0.87 (0.52, 1.44)
Relative risk (95 % CI) [b]			0.92 (0.69, 1.23)
Absolute risk reduction (95 % CI) [c]			-3.50 (-16.70, 9.71)
p-value [d]			0.6165

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Sex: Female			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	144	150	
Number of subjects with events, n (%)	63 (43.8)	78 (52.0)	
95 % CI [a]	(35.5, 52.3)	(43.7, 60.2)	
Odds ratio (95 % CI) [b]			0.72 (0.45, 1.14)
Relative risk (95 % CI) [b]			0.84 (0.66, 1.07)
Absolute risk reduction (95 % CI) [c]			-8.25 (-20.31, 3.81)
p-value [d]			0.1991
Subgroup Interaction p-value [e]			0.6352

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Race by 2 categories: White			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	159	163	
Number of subjects with events, n (%)	68 (42.8)	81 (49.7)	
95 % CI [a]	(35.0, 50.8)	(41.8, 57.6)	
Odds ratio (95 % CI) [b]			0.76 (0.49, 1.17)
Relative risk (95 % CI) [b]			0.86 (0.68, 1.09)
Absolute risk reduction (95 % CI) [c]			-6.93 (-18.41, 4.56)
p-value [d]			0.2335

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Race by 2 categories: Non-white			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	109	108	
Number of subjects with events, n (%)	46 (42.2)	51 (47.2)	
95 % CI [a]	(32.8, 52.0)	(37.5, 57.1)	
Odds ratio (95 % CI) [b]			0.82 (0.48, 1.39)
Relative risk (95 % CI) [b]			0.89 (0.66, 1.20)
Absolute risk reduction (95 % CI) [c]			-5.02 (-19.16, 9.12)
p-value [d]			0.4910
Subgroup Interaction p-value [e]			0.8457

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Geographic Region 1: North America			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	16	18	
Number of subjects with events, n (%)	6 (37.5)	11 (61.1)	
95 % CI [a]	(15.2, 64.6)	(35.7, 82.7)	
Odds ratio (95 % CI) [b]			0.38 (0.10, 1.53)
Relative risk (95 % CI) [b]			0.61 (0.30, 1.28)
Absolute risk reduction (95 % CI) [c]			-23.61 (-62.22, 15.00)
p-value [d]			0.2024

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Geographic Region 1: Europe			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	163	163	
Number of subjects with events, n (%)	75 (46.0)	77 (47.2)	
95 % CI [a]	(38.2, 54.0)	(39.4, 55.2)	
Odds ratio (95 % CI) [b]			0.95 (0.62, 1.47)
Relative risk (95 % CI) [b]			0.97 (0.77, 1.23)
Absolute risk reduction (95 % CI) [c]			-1.23 (-12.67, 10.22)
p-value [d]			0.8267

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Geographic Region 1: Asia/Other Regions			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	89	90	
Number of subjects with events, n (%)	33 (37.1)	44 (48.9)	
95 % CI [a]	(27.1, 48.0)	(38.2, 59.7)	
Odds ratio (95 % CI) [b]			0.62 (0.34, 1.12)
Relative risk (95 % CI) [b]			0.76 (0.54, 1.07)
Absolute risk reduction (95 % CI) [c]			-11.81 (-27.33, 3.71)
p-value [d]			0.1140
Subgroup Interaction p-value [e]			0.3035

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

WBC at initial diagnosis: < 40x10^9/L			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	132	135	
Number of subjects with events, n (%)	55 (41.7)	67 (49.6)	
95 % CI [a]	(33.2, 50.6)	(40.9, 58.4)	
Odds ratio (95 % CI) [b]			0.72 (0.45, 1.18)
Relative risk (95 % CI) [b]			0.84 (0.64, 1.09)
Absolute risk reduction (95 % CI) [c]			-7.96 (-20.62, 4.70)
p-value [d]			0.2067

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

WBC at initial diagnosis: ≥ 40x10^9/L			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	136	136	
Number of subjects with events, n (%)	59 (43.4)	65 (47.8)	
95 % CI [a]	(34.9, 52.1)	(39.2, 56.5)	
Odds ratio (95 % CI) [b]			0.84 (0.52, 1.35)
Relative risk (95 % CI) [b]			0.91 (0.70, 1.18)
Absolute risk reduction (95 % CI) [c]			-4.41 (-16.97, 8.15)
p-value [d]			0.4698
Subgroup Interaction p-value [e]			0.6798

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Choice of Anthracycline: Daunorubicin			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	124	95	
Number of subjects with events, n (%)	48 (38.7)	48 (50.5)	
95 % CI [a]	(30.1, 47.9)	(40.1, 60.9)	
Odds ratio (95 % CI) [b]			0.62 (0.36, 1.06)
Relative risk (95 % CI) [b]			0.77 (0.57, 1.03)
Absolute risk reduction (95 % CI) [c]			-11.82 (-25.96, 2.33)
p-value [d]			0.0734

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Choice of Anthracycline: Idarubicin			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	144	173	
Number of subjects with events, n (%)	66 (45.8)	83 (48.0)	
95 % CI [a]	(37.5, 54.3)	(40.3, 55.7)	
Odds ratio (95 % CI) [b]			0.92 (0.59, 1.43)
Relative risk (95 % CI) [b]			0.96 (0.75, 1.21)
Absolute risk reduction (95 % CI) [c]			-2.14 (-13.81, 9.52)
p-value [d]			0.7207
Subgroup Interaction p-value [e]			0.2547

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML Cytogenetic Risk Score: Favorable			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	14	19	
Number of subjects with events, n (%)	4 (28.6)	8 (42.1)	
95 % CI [a]	(8.4, 58.1)	(20.3, 66.5)	
Odds ratio (95 % CI) [b]			0.55 (0.13, 2.40)
Relative risk (95 % CI) [b]			0.68 (0.25, 1.81)
Absolute risk reduction (95 % CI) [c]			-13.53 (-52.18, 25.12)
p-value [d]			0.7681

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML Cytogenetic Risk Score: Intermediate			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	197	193	
Number of subjects with events, n (%)	86 (43.7)	92 (47.7)	
95 % CI [a]	(36.6, 50.9)	(40.4, 55.0)	
Odds ratio (95 % CI) [b]			0.85 (0.57, 1.27)
Relative risk (95 % CI) [b]			0.92 (0.74, 1.14)
Absolute risk reduction (95 % CI) [c]			-4.01 (-14.41, 6.38)
p-value [d]			0.4257

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML Cytogenetic Risk Score: Unfavorable			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	19	27	
Number of subjects with events, n (%)	7 (36.8)	13 (48.1)	
95 % CI [a]	(16.3, 61.6)	(28.7, 68.1)	
Odds ratio (95 % CI) [b]			0.63 (0.19, 2.08)
Relative risk (95 % CI) [b]			0.77 (0.38, 1.55)
Absolute risk reduction (95 % CI) [c]			-11.31 (-44.52, 21.91)
p-value [d]			0.7645

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML Cytogenetic Risk Score: Unknown			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	38	31	
Number of subjects with events, n (%)	17 (44.7)	18 (58.1)	
95 % CI [a]	(28.6, 61.7)	(39.1, 75.5)	
Odds ratio (95 % CI) [b]			0.58 (0.22, 1.52)
Relative risk (95 % CI) [b]			0.77 (0.48, 1.22)
Absolute risk reduction (95 % CI) [c]			-13.33 (-39.74, 13.09)
p-value [d]			0.4072
Subgroup Interaction p-value [e]			0.8369

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

ECOG Performance Status at Baseline: 0 - Fully Active			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	87	98	
Number of subjects with events, n (%)	44 (50.6)	48 (49.0)	
95 % CI [a]	(39.6, 61.5)	(38.7, 59.3)	
Odds ratio (95 % CI) [b]			1.07 (0.60, 1.90)
Relative risk (95 % CI) [b]			1.03 (0.77, 1.38)
Absolute risk reduction (95 % CI) [c]			1.60 (-13.92, 17.11)
p-value [d]			0.6298

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

ECOG Performance Status at Baseline: 1 - Restricted in Physically Strenuous Activity			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	134	136	
Number of subjects with events, n (%)	49 (36.6)	67 (49.3)	
95 % CI [a]	(28.4, 45.3)	(40.6, 58.0)	
Odds ratio (95 % CI) [b]			0.59 (0.37, 0.97)
Relative risk (95 % CI) [b]			0.74 (0.56, 0.98)
Absolute risk reduction (95 % CI) [c]			-12.70 (-25.15, -0.25)
p-value [d]			0.0487

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

ECOG Performance Status at Baseline: 2 - Ambulatory and Capable of All Selfcare			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	47	36	
Number of subjects with events, n (%)	21 (44.7)	17 (47.2)	
95 % CI [a]	(30.2, 59.9)	(30.4, 64.5)	
Odds ratio (95 % CI) [b]			0.90 (0.38, 2.16)
Relative risk (95 % CI) [b]			0.95 (0.59, 1.51)
Absolute risk reduction (95 % CI) [c]			-2.54 (-26.63, 21.54)
p-value [d]			0.8837
Subgroup Interaction p-value [e]			0.2628

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

FLT3-ITD category at Baseline: ≥3 to ≤25%			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	94	98	
Number of subjects with events, n (%)	35 (37.2)	41 (41.8)	
95 % CI [a]	(27.5, 47.8)	(31.9, 52.2)	
Odds ratio (95 % CI) [b]			0.82 (0.46, 1.47)
Relative risk (95 % CI) [b]			0.89 (0.63, 1.26)
Absolute risk reduction (95 % CI) [c]			-4.60 (-19.46, 10.26)
p-value [d]			0.4393

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

FLT3-ITD category at Baseline: >25% to ≤50%			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	143	138	
Number of subjects with events, n (%)	66 (46.2)	74 (53.6)	
95 % CI [a]	(37.8, 54.7)	(44.9, 62.1)	
Odds ratio (95 % CI) [b]			0.74 (0.46, 1.18)
Relative risk (95 % CI) [b]			0.86 (0.68, 1.09)
Absolute risk reduction (95 % CI) [c]			-7.47 (-19.84, 4.90)
p-value [d]			0.2095

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

FLT3-ITD category at Baseline: >50%			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	30	35	
Number of subjects with events, n (%)	13 (43.3)	17 (48.6)	
95 % CI [a]	(25.5, 62.6)	(31.4, 66.0)	
Odds ratio (95 % CI) [b]			0.81 (0.30, 2.16)
Relative risk (95 % CI) [b]			0.89 (0.52, 1.52)
Absolute risk reduction (95 % CI) [c]			-5.24 (-32.59, 22.12)
p-value [d]			0.5005
Subgroup Interaction p-value [e]			0.9842

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML with Mutated NPM1: Yes			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	142	140	
Number of subjects with events, n (%)	75 (52.8)	85 (60.7)	
95 % CI [a]	(44.3, 61.2)	(52.1, 68.9)	
Odds ratio (95 % CI) [b]			0.72 (0.45, 1.16)
Relative risk (95 % CI) [b]			0.87 (0.71, 1.07)
Absolute risk reduction (95 % CI) [c]			-7.90 (-20.13, 4.34)
p-value [d]			0.2299

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML with Mutated NPM1: No			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	116	120	
Number of subjects with events, n (%)	36 (31.0)	39 (32.5)	
95 % CI [a]	(22.8, 40.3)	(24.2, 41.7)	
Odds ratio (95 % CI) [b]			0.93 (0.54, 1.62)
Relative risk (95 % CI) [b]			0.95 (0.66, 1.39)
Absolute risk reduction (95 % CI) [c]			-1.47 (-14.19, 11.26)
p-value [d]			0.8816
Subgroup Interaction p-value [e]			0.6685

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Age by 2 categories: ≤60			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	166	165	
Number of subjects with events, n (%)	72 (43.4)	79 (47.9)	
95 % CI [a]	(35.7, 51.3)	(40.1, 55.8)	
Odds ratio (95 % CI) [b]			0.83 (0.54, 1.29)
Relative risk (95 % CI) [b]			0.91 (0.72, 1.15)
Absolute risk reduction (95 % CI) [c]			-4.51 (-15.83, 6.82)
p-value [d]			0.3454

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.23.2 Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Age by 2 categories: >60			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	102	106	
Number of subjects with events, n (%)	42 (41.2)	53 (50.0)	
95 % CI [a]	(31.5, 51.4)	(40.1, 59.9)	
Odds ratio (95 % CI) [b]			0.70 (0.40, 1.21)
Relative risk (95 % CI) [b]			0.82 (0.61, 1.11)
Absolute risk reduction (95 % CI) [c]			-8.82 (-23.27, 5.62)
p-value [d]			0.2037
Subgroup Interaction p-value [e]			0.6244

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_23_2_CR_DE_SUB_ITT.rtf

Anhang 4-H4b: Komplettremission nach Induktion

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Pooled Age Group 2: <60			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	161	162	
Number of subjects with events, n (%)	90 (55.9)	90 (55.6)	
95 % CI [a]	(47.9, 63.7)	(47.6, 63.4)	
Odds ratio (95 % CI) [b]			1.01 (0.65, 1.57)
Relative risk (95 % CI) [b]			1.01 (0.83, 1.22)
Absolute risk reduction (95 % CI) [c]			0.35 (-11.11, 11.80)
p-value [d]			0.9447

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Pooled Age Group 2: ≥60 - <65			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	37	44	
Number of subjects with events, n (%)	22 (59.5)	25 (56.8)	
95 % CI [a]	(42.1, 75.2)	(41.0, 71.7)	
Odds ratio (95 % CI) [b]			1.11 (0.46, 2.71)
Relative risk (95 % CI) [b]			1.05 (0.72, 1.52)
Absolute risk reduction (95 % CI) [c]			2.64 (-21.40, 26.68)
p-value [d]			0.9442

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Pooled Age Group 2: ≥65			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	70	65	
Number of subjects with events, n (%)	35 (50.0)	35 (53.8)	
95 % CI [a]	(37.8, 62.2)	(41.0, 66.3)	
Odds ratio (95 % CI) [b]			0.86 (0.44, 1.69)
Relative risk (95 % CI) [b]			0.93 (0.67, 1.28)
Absolute risk reduction (95 % CI) [c]			-3.85 (-22.18, 14.49)
p-value [d]			0.6676
Subgroup Interaction p-value [e]			0.8790

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Sex: Male			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	124	121	
Number of subjects with events, n (%)	65 (52.4)	60 (49.6)	
95 % CI [a]	(43.3, 61.5)	(40.4, 58.8)	
Odds ratio (95 % CI) [b]			1.12 (0.68, 1.85)
Relative risk (95 % CI) [b]			1.06 (0.83, 1.35)
Absolute risk reduction (95 % CI) [c]			2.83 (-10.50, 16.16)
p-value [d]			0.6885

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Sex: Female			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	144	150	
Number of subjects with events, n (%)	82 (56.9)	90 (60.0)	
95 % CI [a]	(48.4, 65.2)	(51.7, 67.9)	
Odds ratio (95 % CI) [b]			0.88 (0.55, 1.40)
Relative risk (95 % CI) [b]			0.95 (0.78, 1.15)
Absolute risk reduction (95 % CI) [c]			-3.06 (-15.00, 8.89)
p-value [d]			0.5747
Subgroup Interaction p-value [e]			0.4989

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Race by 2 categories: White			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	159	163	
Number of subjects with events, n (%)	86 (54.1)	90 (55.2)	
95 % CI [a]	(46.0, 62.0)	(47.2, 63.0)	
Odds ratio (95 % CI) [b]			0.96 (0.62, 1.48)
Relative risk (95 % CI) [b]			0.98 (0.80, 1.20)
Absolute risk reduction (95 % CI) [c]			-1.13 (-12.62, 10.37)
p-value [d]			0.9380

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Race by 2 categories: Non-white			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	109	108	
Number of subjects with events, n (%)	61 (56.0)	60 (55.6)	
95 % CI [a]	(46.1, 65.5)	(45.7, 65.1)	
Odds ratio (95 % CI) [b]			1.02 (0.59, 1.74)
Relative risk (95 % CI) [b]			1.01 (0.79, 1.28)
Absolute risk reduction (95 % CI) [c]			0.41 (-13.73, 14.55)
p-value [d]			0.8928
Subgroup Interaction p-value [e]			0.8596

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Geographic Region 1: North America			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	16	18	
Number of subjects with events, n (%)	7 (43.8)	12 (66.7)	
95 % CI [a]	(19.8, 70.1)	(41.0, 86.7)	
Odds ratio (95 % CI) [b]			0.39 (0.10, 1.56)
Relative risk (95 % CI) [b]			0.66 (0.34, 1.25)
Absolute risk reduction (95 % CI) [c]			-22.92 (-61.46, 15.62)
p-value [d]			0.1990

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Geographic Region 1: Europe			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	163	163	
Number of subjects with events, n (%)	94 (57.7)	87 (53.4)	
95 % CI [a]	(49.7, 65.4)	(45.4, 61.2)	
Odds ratio (95 % CI) [b]			1.19 (0.77, 1.84)
Relative risk (95 % CI) [b]			1.08 (0.89, 1.31)
Absolute risk reduction (95 % CI) [c]			4.29 (-7.10, 15.69)
p-value [d]			0.4400

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Geographic Region 1: Asia/Other Regions			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	89	90	
Number of subjects with events, n (%)	46 (51.7)	51 (56.7)	
95 % CI [a]	(40.8, 62.4)	(45.8, 67.1)	
Odds ratio (95 % CI) [b]			0.82 (0.45, 1.47)
Relative risk (95 % CI) [b]			0.91 (0.70, 1.20)
Absolute risk reduction (95 % CI) [c]			-4.98 (-20.68, 10.72)
p-value [d]			0.5102
Subgroup Interaction p-value [e]			0.2607

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

WBC at initial diagnosis: < 40x10^9/L			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	132	135	
Number of subjects with events, n (%)	66 (50.0)	74 (54.8)	
95 % CI [a]	(41.2, 58.8)	(46.0, 63.4)	
Odds ratio (95 % CI) [b]			0.82 (0.51, 1.33)
Relative risk (95 % CI) [b]			0.91 (0.73, 1.15)
Absolute risk reduction (95 % CI) [c]			-4.81 (-17.53, 7.90)
p-value [d]			0.4459

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

WBC at initial diagnosis: ≥ 40x10^9/L			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	136	136	
Number of subjects with events, n (%)	81 (59.6)	76 (55.9)	
95 % CI [a]	(50.8, 67.9)	(47.1, 64.4)	
Odds ratio (95 % CI) [b]			1.16 (0.72, 1.88)
Relative risk (95 % CI) [b]			1.07 (0.87, 1.31)
Absolute risk reduction (95 % CI) [c]			3.68 (-8.79, 16.15)
p-value [d]			0.5447
Subgroup Interaction p-value [e]			0.3198

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Choice of Anthracycline: Daunorubicin			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	124	95	
Number of subjects with events, n (%)	69 (55.6)	53 (55.8)	
95 % CI [a]	(46.5, 64.6)	(45.2, 66.0)	
Odds ratio (95 % CI) [b]			0.99 (0.58, 1.70)
Relative risk (95 % CI) [b]			1.00 (0.79, 1.27)
Absolute risk reduction (95 % CI) [c]			-0.14 (-14.35, 14.06)
p-value [d]			0.9584

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Choice of Anthracycline: Idarubicin			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	144	173	
Number of subjects with events, n (%)	78 (54.2)	96 (55.5)	
95 % CI [a]	(45.7, 62.5)	(47.8, 63.0)	
Odds ratio (95 % CI) [b]			0.95 (0.61, 1.48)
Relative risk (95 % CI) [b]			0.98 (0.80, 1.19)
Absolute risk reduction (95 % CI) [c]			-1.32 (-12.96, 10.31)
p-value [d]			0.8751
Subgroup Interaction p-value [e]			0.8921

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML Cytogenetic Risk Score: Favorable			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	14	19	
Number of subjects with events, n (%)	5 (35.7)	11 (57.9)	
95 % CI [a]	(12.8, 64.9)	(33.5, 79.7)	
Odds ratio (95 % CI) [b]			0.40 (0.10, 1.68)
Relative risk (95 % CI) [b]			0.62 (0.28, 1.37)
Absolute risk reduction (95 % CI) [c]			-22.18 (-61.89, 17.53)
p-value [d]			0.2683

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML Cytogenetic Risk Score: Intermediate			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	197	193	
Number of subjects with events, n (%)	112 (56.9)	105 (54.4)	
95 % CI [a]	(49.6, 63.9)	(47.1, 61.6)	
Odds ratio (95 % CI) [b]			1.10 (0.74, 1.65)
Relative risk (95 % CI) [b]			1.05 (0.88, 1.25)
Absolute risk reduction (95 % CI) [c]			2.45 (-7.92, 12.82)
p-value [d]			0.6192

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML Cytogenetic Risk Score: Unfavorable			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	19	27	
Number of subjects with events, n (%)	9 (47.4)	14 (51.9)	
95 % CI [a]	(24.4, 71.1)	(31.9, 71.3)	
Odds ratio (95 % CI) [b]			0.84 (0.26, 2.71)
Relative risk (95 % CI) [b]			0.91 (0.50, 1.66)
Absolute risk reduction (95 % CI) [c]			-4.48 (-38.28, 29.31)
p-value [d]			0.6690

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML Cytogenetic Risk Score: Unknown			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	38	31	
Number of subjects with events, n (%)	21 (55.3)	19 (61.3)	
95 % CI [a]	(38.3, 71.4)	(42.2, 78.2)	
Odds ratio (95 % CI) [b]			0.78 (0.30, 2.05)
Relative risk (95 % CI) [b]			0.90 (0.60, 1.35)
Absolute risk reduction (95 % CI) [c]			-6.03 (-32.28, 20.22)
p-value [d]			0.8095
Subgroup Interaction p-value [e]			0.5777

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

ECOG Performance Status at Baseline: 0 - Fully Active			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	87	98	
Number of subjects with events, n (%)	52 (59.8)	55 (56.1)	
95 % CI [a]	(48.7, 70.1)	(45.7, 66.1)	
Odds ratio (95 % CI) [b]			1.16 (0.65, 2.09)
Relative risk (95 % CI) [b]			1.06 (0.83, 1.36)
Absolute risk reduction (95 % CI) [c]			3.65 (-11.67, 18.97)
p-value [d]			0.5435

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

ECOG Performance Status at Baseline: 1 - Restricted in Physically Strenuous Activity			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	134	136	
Number of subjects with events, n (%)	68 (50.7)	75 (55.1)	
95 % CI [a]	(42.0, 59.5)	(46.4, 63.7)	
Odds ratio (95 % CI) [b]			0.84 (0.52, 1.35)
Relative risk (95 % CI) [b]			0.92 (0.73, 1.15)
Absolute risk reduction (95 % CI) [c]			-4.40 (-17.04, 8.24)
p-value [d]			0.4423

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

ECOG Performance Status at Baseline: 2 - Ambulatory and Capable of Al l Selfcare			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	47	36	
Number of subjects with events, n (%)	27 (57.4)	20 (55.6)	
95 % CI [a]	(42.2, 71.7)	(38.1, 72.1)	
Odds ratio (95 % CI) [b]			1.08 (0.45, 2.59)
Relative risk (95 % CI) [b]			1.03 (0.71, 1.52)
Absolute risk reduction (95 % CI) [c]			1.89 (-22.09, 25.87)
p-value [d]			0.7835
Subgroup Interaction p-value [e]			0.6727

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

FLT3-ITD category at Baseline: ≥3 to ≤25%			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	94	98	
Number of subjects with events, n (%)	46 (48.9)	50 (51.0)	
95 % CI [a]	(38.5, 59.5)	(40.7, 61.3)	
Odds ratio (95 % CI) [b]			0.92 (0.52, 1.62)
Relative risk (95 % CI) [b]			0.96 (0.72, 1.27)
Absolute risk reduction (95 % CI) [c]			-2.08 (-17.27, 13.10)
p-value [d]			0.6814

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

FLT3-ITD category at Baseline: >25% to ≤50%			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	143	138	
Number of subjects with events, n (%)	82 (57.3)	83 (60.1)	
95 % CI [a]	(48.8, 65.6)	(51.5, 68.4)	
Odds ratio (95 % CI) [b]			0.89 (0.55, 1.43)
Relative risk (95 % CI) [b]			0.95 (0.78, 1.16)
Absolute risk reduction (95 % CI) [c]			-2.80 (-15.02, 9.42)
p-value [d]			0.7258

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

FLT3-ITD category at Baseline: >50%			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	30	35	
Number of subjects with events, n (%)	19 (63.3)	17 (48.6)	
95 % CI [a]	(43.9, 80.1)	(31.4, 66.0)	
Odds ratio (95 % CI) [b]			1.83 (0.68, 4.95)
Relative risk (95 % CI) [b]			1.30 (0.84, 2.02)
Absolute risk reduction (95 % CI) [c]			14.76 (-12.24, 41.76)
p-value [d]			0.3161
Subgroup Interaction p-value [e]			0.4231

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML with Mutated NPM1: Yes			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	142	140	
Number of subjects with events, n (%)	98 (69.0)	97 (69.3)	
95 % CI [a]	(60.7, 76.5)	(60.9, 76.8)	
Odds ratio (95 % CI) [b]			0.99 (0.60, 1.64)
Relative risk (95 % CI) [b]			1.00 (0.85, 1.16)
Absolute risk reduction (95 % CI) [c]			-0.27 (-11.76, 11.22)
p-value [d]			0.9669

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML with Mutated NPM1: No			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	116	120	
Number of subjects with events, n (%)	44 (37.9)	44 (36.7)	
95 % CI [a]	(29.1, 47.4)	(28.1, 45.9)	
Odds ratio (95 % CI) [b]			1.06 (0.62, 1.79)
Relative risk (95 % CI) [b]			1.03 (0.74, 1.44)
Absolute risk reduction (95 % CI) [c]			1.26 (-11.92, 14.45)
p-value [d]			0.6894
Subgroup Interaction p-value [e]			0.8394

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Age by 2 categories: ≤60			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	166	165	
Number of subjects with events, n (%)	92 (55.4)	90 (54.5)	
95 % CI [a]	(47.5, 63.1)	(46.6, 62.3)	
Odds ratio (95 % CI) [b]			1.04 (0.67, 1.60)
Relative risk (95 % CI) [b]			1.02 (0.84, 1.23)
Absolute risk reduction (95 % CI) [c]			0.88 (-10.45, 12.20)
p-value [d]			0.9447

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.25.2 Complete Remission (without a 42-day window) Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Age by 2 categories: >60			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	102	106	
Number of subjects with events, n (%)	55 (53.9)	60 (56.6)	
95 % CI [a]	(43.8, 63.8)	(46.6, 66.2)	
Odds ratio (95 % CI) [b]			0.90 (0.52, 1.55)
Relative risk (95 % CI) [b]			0.95 (0.75, 1.22)
Absolute risk reduction (95 % CI) [c]			-2.68 (-17.16, 11.79)
p-value [d]			0.6559
Subgroup Interaction p-value [e]			0.6864

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_25_2_CR2_DE_SUB_ITT.rtf

Anhang 4-H4c: Dauer der Komplettremission (bei Patient*innen mit CR nach Induktion mit 42-Tage Fenster)

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.26.1 Duration of Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1065
<60	70	17 (24.3)	53 (75.7)	NE (NE, NE)	79	39 (49.4)	40 (50.6)	19.0 (8.7, NE)	0.362 (0.204, 0.641)	0.0003	
≥60 - <65	18	10 (55.6)	8 (44.4)	22.7 (11.2, NE)	22	13 (59.1)	9 (40.9)	8.0 (4.2, NE)	0.677 (0.296, 1.550)	0.3524	
≥65	26	18 (69.2)	8 (30.8)	17.4 (7.2, 34.6)	31	23 (74.2)	8 (25.8)	9.0 (5.0, 29.5)	0.865 (0.466, 1.606)	0.6484	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission with a 42-day window; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_26_1_DOCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.26.1 Duration of Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8908
Male	51	21 (41.2)	30 (58.8)	NE (19.2, NE)	54	31 (57.4)	23 (42.6)	9.1 (6.5, NE)	0.506 (0.290, 0.885)	0.0152	
Female	63	24 (38.1)	39 (61.9)	47.7 (27.9, NE)	78	44 (56.4)	34 (43.6)	21.6 (6.6, 41.9)	0.549 (0.334, 0.903)	0.0167	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission with a 42-day window; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_26_1_DOCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.26.1 Duration of Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8129
White	68	30 (44.1)	38 (55.9)	47.7 (21.9, NE)	81	50 (61.7)	31 (38.3)	10.0 (6.0, 26.5)	0.571 (0.363, 0.899)	0.0143	
Non-white	46	15 (32.6)	31 (67.4)	NE (26.0, NE)	51	25 (49.0)	26 (51.0)	21.0 (8.0, NE)	0.480 (0.253, 0.913)	0.0224	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission with a 42-day window; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_26_1_DOCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.26.1 Duration of Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6812
North America	6	3 (50.0)	3 (50.0)	24.9 (8.5, NE)	11	6 (54.5)	5 (45.5)	14.4 (2.1, NE)	0.754 (0.188, 3.021)	0.6887	
Europe	75	32 (42.7)	43 (57.3)	47.7 (21.9, NE)	77	47 (61.0)	30 (39.0)	10.9 (6.5, 26.5)	0.575 (0.366, 0.901)	0.0146	
Asia/Other Regions	33	10 (30.3)	23 (69.7)	NE (19.2, NE)	44	22 (50.0)	22 (50.0)	16.5 (6.0, NE)	0.401 (0.189, 0.851)	0.0138	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission with a 42-day window; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_26_1_DOCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)

Table 4.26.1 Duration of Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7927
< 40x10^9/L	55	20 (36.4)	35 (63.6)	NE (27.9, NE)	67	37 (55.2)	30 (44.8)	12.4 (6.4, NE)	0.512 (0.296, 0.884)	0.0144	
≥ 40x10^9/L	59	25 (42.4)	34 (57.6)	47.7 (21.9, NE)	65	38 (58.5)	27 (41.5)	10.2 (7.7, 41.9)	0.569 (0.343, 0.945)	0.0273	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission with a 42-day window; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.

[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.

[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.

[c] Two-sided p-value from unstratified log-rank test.

[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.

Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\

Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_26_1_DOCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.26.1 Duration of Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8781
Daunorubicin	48	21 (43.8)	27 (56.3)	38.6 (19.2, NE)	48	29 (60.4)	19 (39.6)	9.1 (5.3, 26.5)	0.499 (0.284, 0.878)	0.0138	
Idarubicin	66	24 (36.4)	42 (63.6)	NE (26.0, NE)	83	46 (55.4)	37 (44.6)	16.5 (8.7, 41.9)	0.535 (0.326, 0.877)	0.0119	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission with a 42-day window; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_26_1_DOCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.26.1 Duration of Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.1913
Favorable	4	2 (50.0)	2 (50.0)	38.6 (3.7, NE)	8	2 (25.0)	6 (75.0)	NE (2.1, NE)	2.106 (0.291, 15.232)	0.4507	
Intermediate	86	35 (40.7)	51 (59.3)	47.7 (19.9, NE)	92	51 (55.4)	41 (44.6)	12.4 (7.7, NE)	0.616 (0.400, 0.948)	0.0265	
Unfavorable	7	2 (28.6)	5 (71.4)	NE (10.8, NE)	13	8 (61.5)	5 (38.5)	11.7 (2.8, NE)	0.199 (0.039, 0.999)	0.0331	
Unknown	17	6 (35.3)	11 (64.7)	NE (21.9, NE)	18	14 (77.8)	4 (22.2)	7.7 (5.3, 22.7)	0.280 (0.106, 0.738)	0.0062	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission with a 42-day window; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_26_1_DOCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.26.1 Duration of Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7014
0 - Fully Active	44	14 (31.8)	30 (68.2)	NE (26.0, NE)	48	25 (52.1)	23 (47.9)	22.8 (6.6, NE)	0.483 (0.251, 0.930)	0.0265	
1 - Restricted in Physically Strenuous Activity	49	23 (46.9)	26 (53.1)	38.6 (15.9, NE)	67	40 (59.7)	27 (40.3)	13.6 (6.5, 29.5)	0.637 (0.381, 1.066)	0.0843	
2 - Ambulatory and Capable of All Selfcare	21	8 (38.1)	13 (61.9)	NE (8.5, NE)	17	10 (58.8)	7 (41.2)	8.0 (5.0, NE)	0.446 (0.174, 1.142)	0.0841	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission with a 42-day window; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_26_1_DOCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.26.1 Duration of Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4528
≥3 to ≤25%	35	14 (40.0)	21 (60.0)	NE (21.9, NE)	41	21 (51.2)	20 (48.8)	22.8 (8.7, NE)	0.624 (0.317, 1.228)	0.1681	
>25% to ≤50%	66	26 (39.4)	40 (60.6)	47.7 (18.7, NE)	74	42 (56.8)	32 (43.2)	12.4 (6.5, 41.9)	0.557 (0.341, 0.909)	0.0177	
>50%	13	5 (38.5)	8 (61.5)	NE (5.7, NE)	17	12 (70.6)	5 (29.4)	5.0 (2.7, 16.5)	0.336 (0.117, 0.966)	0.0342	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission with a 42-day window; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_26_1_DOCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.26.1 Duration of Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4723
Yes	75	28 (37.3)	47 (62.7)	47.7 (34.0, NE)	85	50 (58.8)	35 (41.2)	11.7 (6.5, 41.9)	0.490 (0.308, 0.779)	0.0021	
No	36	15 (41.7)	21 (58.3)	38.6 (19.2, NE)	39	20 (51.3)	19 (48.7)	19.0 (6.6, NE)	0.653 (0.334, 1.279)	0.2111	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission with a 42-day window; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_26_1_DOCR_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)

Table 4.26.1 Duration of Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0444
≤60	72	18 (25.0)	54 (75.0)	NE (NE, NE)	79	39 (49.4)	40 (50.6)	19.0 (8.7, NE)	0.371 (0.212, 0.650)	0.0003	
>60	42	27 (64.3)	15 (35.7)	21.9 (11.2, 34.6)	53	36 (67.9)	17 (32.1)	9.0 (5.4, 26.5)	0.821 (0.498, 1.354)	0.4387	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission with a 42-day window; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.

[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.

[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.

[c] Two-sided p-value from unstratified log-rank test.

[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.

Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\

Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_26_1_DOCR_SUB_ITT.rtf

Anhang 4-H4d: Dauer der Komplettremission (bei Patient*innen mit CR nach Induktion)

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.27.1 Duration of Complete Remission (without a 42-day window) - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0445
<60	90	26 (28.9)	64 (71.1)	NE (NE, NE)	90	47 (52.2)	43 (47.8)	16.5 (9.4, NE)	0.432 (0.267, 0.699)	0.0004	
≥60 - <65	22	12 (54.5)	10 (45.5)	22.7 (11.2, NE)	25	15 (60.0)	10 (40.0)	9.1 (5.1, NE)	0.671 (0.313, 1.436)	0.3002	
≥65	35	27 (77.1)	8 (22.9)	13.4 (5.7, 26.0)	35	26 (74.3)	9 (25.7)	8.8 (5.0, 26.5)	1.078 (0.628, 1.849)	0.7847	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_27_1_DOCR2_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.27.1 Duration of Complete Remission (without a 42-day window) - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3960
Male	65	34 (52.3)	31 (47.7)	22.7 (15.3, NE)	60	36 (60.0)	24 (40.0)	9.1 (6.5, 21.0)	0.702 (0.438, 1.125)	0.1405	
Female	82	31 (37.8)	51 (62.2)	47.7 (34.0, NE)	90	52 (57.8)	38 (42.2)	19.0 (7.6, 30.9)	0.535 (0.343, 0.836)	0.0052	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_27_1_DOCR2_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)

Table 4.27.1 Duration of Complete Remission (without a 42-day window) - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9089
White	86	41 (47.7)	45 (52.3)	47.7 (17.4, NE)	90	57 (63.3)	33 (36.7)	10.2 (6.0, 22.7)	0.625 (0.418, 0.934)	0.0209	
Non-white	61	24 (39.3)	37 (60.7)	38.6 (21.0, NE)	60	31 (51.7)	29 (48.3)	20.1 (9.1, NE)	0.601 (0.352, 1.026)	0.0597	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_27_1_DOCR2_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.27.1 Duration of Complete Remission (without a 42-day window) - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6476
North America	7	4 (57.1)	3 (42.9)	24.9 (8.5, NE)	12	6 (50.0)	6 (50.0)	NE (2.1, NE)	1.028 (0.289, 3.653)	0.9655	
Europe	94	44 (46.8)	50 (53.2)	34.6 (18.7, NE)	87	56 (64.4)	31 (35.6)	10.1 (6.5, 22.7)	0.611 (0.411, 0.907)	0.0136	
Asia/Other Regions	46	17 (37.0)	29 (63.0)	NE (19.2, NE)	51	26 (51.0)	25 (49.0)	16.5 (6.5, NE)	0.540 (0.292, 0.997)	0.0459	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_27_1_DOCR2_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)

Table 4.27.1 Duration of Complete Remission (without a 42-day window) - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5026
< 40x10^9/L	66	26 (39.4)	40 (60.6)	NE (27.2, NE)	74	43 (58.1)	31 (41.9)	12.4 (6.5, 46.2)	0.549 (0.336, 0.894)	0.0146	
≥ 40x10^9/L	81	39 (48.1)	42 (51.9)	26.0 (16.4, NE)	76	45 (59.2)	31 (40.8)	13.6 (7.7, 26.5)	0.685 (0.446, 1.054)	0.0838	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_27_1_DOCR2_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.27.1 Duration of Complete Remission (without a 42-day window) - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6663
Daunorubicin	69	32 (46.4)	37 (53.6)	38.6 (17.7, NE)	53	33 (62.3)	20 (37.7)	9.4 (5.3, 21.6)	0.556 (0.341, 0.907)	0.0171	
Idarubicin	78	33 (42.3)	45 (57.7)	NE (21.9, NE)	96	55 (57.3)	41 (42.7)	16.5 (9.0, 30.9)	0.641 (0.416, 0.988)	0.0425	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_27_1_DOCR2_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.27.1 Duration of Complete Remission (without a 42-day window) - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3355
Favorable	5	2 (40.0)	3 (60.0)	38.6 (3.7, NE)	11	4 (36.4)	7 (63.6)	NE (2.1, NE)	1.126 (0.205, 6.181)	0.8917	
Intermediate	112	51 (45.5)	61 (54.5)	47.7 (18.7, NE)	105	60 (57.1)	45 (42.9)	13.7 (8.0, 41.9)	0.702 (0.483, 1.021)	0.0635	
Unfavorable	9	3 (33.3)	6 (66.7)	NE (2.1, NE)	14	9 (64.3)	5 (35.7)	11.7 (4.8, 21.0)	0.283 (0.073, 1.097)	0.0541	
Unknown	21	9 (42.9)	12 (57.1)	NE (16.4, NE)	19	15 (78.9)	4 (21.1)	6.6 (5.3, 22.7)	0.362 (0.157, 0.837)	0.0133	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_27_1_DOCR2_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.27.1 Duration of Complete Remission (without a 42-day window) - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8763
0 - Fully Active	52	20 (38.5)	32 (61.5)	NE (21.9, NE)	55	31 (56.4)	24 (43.6)	12.4 (6.6, NE)	0.544 (0.309, 0.955)	0.0315	
1 - Restricted in Physically Strenuous Activity	68	32 (47.1)	36 (52.9)	38.6 (16.4, NE)	75	45 (60.0)	30 (40.0)	14.4 (7.7, 29.5)	0.683 (0.433, 1.077)	0.0991	
2 - Ambulatory and Capable of All Selfcare	27	13 (48.1)	14 (51.9)	27.9 (8.5, NE)	20	12 (60.0)	8 (40.0)	9.1 (5.0, NE)	0.619 (0.280, 1.367)	0.2316	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_27_1_DOCR2_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.27.1 Duration of Complete Remission (without a 42-day window) - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7127
≥3 to ≤25%	46	21 (45.7)	25 (54.3)	NE (21.0, NE)	50	28 (56.0)	22 (44.0)	20.1 (9.4, NE)	0.687 (0.390, 1.211)	0.1916	
>25% to ≤50%	82	34 (41.5)	48 (58.5)	47.7 (18.7, NE)	83	48 (57.8)	35 (42.2)	12.4 (6.5, 41.9)	0.599 (0.385, 0.931)	0.0213	
>50%	19	10 (52.6)	9 (47.4)	22.7 (5.7, NE)	17	12 (70.6)	5 (29.4)	5.0 (2.7, 16.5)	0.492 (0.211, 1.145)	0.0931	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_27_1_DOCR2_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.27.1 Duration of Complete Remission (without a 42-day window) - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6459
Yes	98	42 (42.9)	56 (57.1)	47.7 (24.9, NE)	97	58 (59.8)	39 (40.2)	11.7 (6.5, 29.5)	0.583 (0.391, 0.869)	0.0073	
No	44	20 (45.5)	24 (54.5)	38.6 (11.2, NE)	44	25 (56.8)	19 (43.2)	16.5 (7.7, 46.2)	0.684 (0.379, 1.234)	0.2049	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_27_1_DOCR2_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.27.1 Duration of Complete Remission (without a 42-day window) - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0219
≤60	92	27 (29.3)	65 (70.7)	NE (NE, NE)	90	47 (52.2)	43 (47.8)	16.5 (9.4, NE)	0.438 (0.272, 0.704)	0.0005	
>60	55	38 (69.1)	17 (30.9)	15.9 (8.9, 26.0)	60	41 (68.3)	19 (31.7)	9.0 (5.4, 21.6)	0.939 (0.603, 1.462)	0.7807	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_27_1_DOCR2_SUB_ITT.rtf

Anhang 4-H4e: Zusammengesetzte Komplettremission nach Induktion

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Pooled Age Group 2: <60			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	161	162	
Number of subjects with events, n (%)	118 (73.3)	105 (64.8)	
95 % CI [a]	(65.8, 79.9)	(56.9, 72.1)	
Odds ratio (95 % CI) [b]			1.49 (0.93, 2.40)
Relative risk (95 % CI) [b]			1.13 (0.98, 1.31)
Absolute risk reduction (95 % CI) [c]			8.48 (-2.18, 19.14)
p-value [d]			0.0942

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Pooled Age Group 2: ≥60 - <65			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	37	44	
Number of subjects with events, n (%)	27 (73.0)	28 (63.6)	
95 % CI [a]	(55.9, 86.2)	(47.8, 77.6)	
Odds ratio (95 % CI) [b]			1.54 (0.60, 3.99)
Relative risk (95 % CI) [b]			1.15 (0.85, 1.54)
Absolute risk reduction (95 % CI) [c]			9.34 (-13.32, 31.99)
p-value [d]			0.5125

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Pooled Age Group 2: ≥65			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	70	65	
Number of subjects with events, n (%)	47 (67.1)	43 (66.2)	
95 % CI [a]	(54.9, 77.9)	(53.4, 77.4)	
Odds ratio (95 % CI) [b]			1.05 (0.51, 2.14)
Relative risk (95 % CI) [b]			1.01 (0.80, 1.29)
Absolute risk reduction (95 % CI) [c]			0.99 (-16.41, 18.39)
p-value [d]			0.8804
Subgroup Interaction p-value [e]			0.7259

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Sex: Male			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	124	121	
Number of subjects with events, n (%)	87 (70.2)	72 (59.5)	
95 % CI [a]	(61.3, 78.0)	(50.2, 68.3)	
Odds ratio (95 % CI) [b]			1.60 (0.94, 2.72)
Relative risk (95 % CI) [b]			1.18 (0.98, 1.42)
Absolute risk reduction (95 % CI) [c]			10.66 (-2.05, 23.36)
p-value [d]			0.0815

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Sex: Female			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	144	150	
Number of subjects with events, n (%)	105 (72.9)	104 (69.3)	
95 % CI [a]	(64.9, 80.0)	(61.3, 76.6)	
Odds ratio (95 % CI) [b]			1.19 (0.72, 1.97)
Relative risk (95 % CI) [b]			1.05 (0.91, 1.22)
Absolute risk reduction (95 % CI) [c]			3.58 (-7.45, 14.61)
p-value [d]			0.5359
Subgroup Interaction p-value [e]			0.3436

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Race by 2 categories: White			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	159	163	
Number of subjects with events, n (%)	114 (71.7)	106 (65.0)	
95 % CI [a]	(64.0, 78.5)	(57.2, 72.3)	
Odds ratio (95 % CI) [b]			1.36 (0.85, 2.18)
Relative risk (95 % CI) [b]			1.10 (0.95, 1.28)
Absolute risk reduction (95 % CI) [c]			6.67 (-4.08, 17.42)
p-value [d]			0.1348

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Race by 2 categories: Non-white			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	109	108	
Number of subjects with events, n (%)	78 (71.6)	70 (64.8)	
95 % CI [a]	(62.1, 79.8)	(55.0, 73.8)	
Odds ratio (95 % CI) [b]			1.37 (0.77, 2.42)
Relative risk (95 % CI) [b]			1.10 (0.92, 1.33)
Absolute risk reduction (95 % CI) [c]			6.74 (-6.54, 20.03)
p-value [d]			0.2305
Subgroup Interaction p-value [e]			0.9908

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Geographic Region 1: North America			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	16	18	
Number of subjects with events, n (%)	7 (43.8)	14 (77.8)	
95 % CI [a]	(19.8, 70.1)	(52.4, 93.6)	
Odds ratio (95 % CI) [b]			0.22 (0.05, 0.98)
Relative risk (95 % CI) [b]			0.56 (0.31, 1.03)
Absolute risk reduction (95 % CI) [c]			-34.03 (-70.91, 2.85)
p-value [d]			0.0518

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Geographic Region 1: Europe			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	163	163	
Number of subjects with events, n (%)	122 (74.8)	103 (63.2)	
95 % CI [a]	(67.5, 81.3)	(55.3, 70.6)	
Odds ratio (95 % CI) [b]			1.73 (1.08, 2.79)
Relative risk (95 % CI) [b]			1.18 (1.02, 1.37)
Absolute risk reduction (95 % CI) [c]			11.66 (1.08, 22.23)
p-value [d]			0.0219

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Geographic Region 1: Asia/Other Regions			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	89	90	
Number of subjects with events, n (%)	63 (70.8)	59 (65.6)	
95 % CI [a]	(60.2, 79.9)	(54.8, 75.3)	
Odds ratio (95 % CI) [b]			1.27 (0.68, 2.39)
Relative risk (95 % CI) [b]			1.08 (0.88, 1.32)
Absolute risk reduction (95 % CI) [c]			5.23 (-9.51, 19.97)
p-value [d]			0.4487
Subgroup Interaction p-value [e]			0.0605

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

WBC at initial diagnosis: < 40x10^9/L			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	132	135	
Number of subjects with events, n (%)	88 (66.7)	87 (64.4)	
95 % CI [a]	(57.9, 74.6)	(55.8, 72.5)	
Odds ratio (95 % CI) [b]			1.10 (0.67, 1.83)
Relative risk (95 % CI) [b]			1.03 (0.87, 1.23)
Absolute risk reduction (95 % CI) [c]			2.22 (-9.92, 14.37)
p-value [d]			0.6792

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

WBC at initial diagnosis: ≥ 40x10^9/L			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	136	136	
Number of subjects with events, n (%)	104 (76.5)	89 (65.4)	
95 % CI [a]	(68.4, 83.3)	(56.8, 73.4)	
Odds ratio (95 % CI) [b]			1.72 (1.01, 2.92)
Relative risk (95 % CI) [b]			1.17 (1.00, 1.36)
Absolute risk reduction (95 % CI) [c]			11.03 (-0.42, 22.47)
p-value [d]			0.0460
Subgroup Interaction p-value [e]			0.3034

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Choice of Anthracycline: Daunorubicin			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	124	95	
Number of subjects with events, n (%)	86 (69.4)	62 (65.3)	
95 % CI [a]	(60.4, 77.3)	(54.8, 74.7)	
Odds ratio (95 % CI) [b]			1.20 (0.68, 2.13)
Relative risk (95 % CI) [b]			1.06 (0.88, 1.28)
Absolute risk reduction (95 % CI) [c]			4.09 (-9.39, 17.57)
p-value [d]			0.6543

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Choice of Anthracycline: Idarubicin			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	144	173	
Number of subjects with events, n (%)	106 (73.6)	113 (65.3)	
95 % CI [a]	(65.6, 80.6)	(57.7, 72.4)	
Odds ratio (95 % CI) [b]			1.48 (0.91, 2.41)
Relative risk (95 % CI) [b]			1.13 (0.97, 1.30)
Absolute risk reduction (95 % CI) [c]			8.29 (-2.45, 19.03)
p-value [d]			0.0972
Subgroup Interaction p-value [e]			0.6284

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML Cytogenetic Risk Score: Favorable			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	14	19	
Number of subjects with events, n (%)	8 (57.1)	14 (73.7)	
95 % CI [a]	(28.9, 82.3)	(48.8, 90.9)	
Odds ratio (95 % CI) [b]			0.48 (0.11, 2.07)
Relative risk (95 % CI) [b]			0.78 (0.46, 1.31)
Absolute risk reduction (95 % CI) [c]			-16.54 (-55.36, 22.28)
p-value [d]			0.4424

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML Cytogenetic Risk Score: Intermediate			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	197	193	
Number of subjects with events, n (%)	148 (75.1)	121 (62.7)	
95 % CI [a]	(68.5, 81.0)	(55.5, 69.5)	
Odds ratio (95 % CI) [b]			1.80 (1.16, 2.78)
Relative risk (95 % CI) [b]			1.20 (1.05, 1.37)
Absolute risk reduction (95 % CI) [c]			12.43 (2.81, 22.06)
p-value [d]			0.0075

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML Cytogenetic Risk Score: Unfavorable			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	19	27	
Number of subjects with events, n (%)	10 (52.6)	17 (63.0)	
95 % CI [a]	(28.9, 75.6)	(42.4, 80.6)	
Odds ratio (95 % CI) [b]			0.65 (0.20, 2.15)
Relative risk (95 % CI) [b]			0.84 (0.50, 1.40)
Absolute risk reduction (95 % CI) [c]			-10.33 (-43.73, 23.06)
p-value [d]			0.9177

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML Cytogenetic Risk Score: Unknown			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	38	31	
Number of subjects with events, n (%)	26 (68.4)	23 (74.2)	
95 % CI [a]	(51.3, 82.5)	(55.4, 88.1)	
Odds ratio (95 % CI) [b]			0.75 (0.26, 2.17)
Relative risk (95 % CI) [b]			0.92 (0.68, 1.24)
Absolute risk reduction (95 % CI) [c]			-5.77 (-30.05, 18.50)
p-value [d]			0.6682
Subgroup Interaction p-value [e]			0.1307

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

ECOG Performance Status at Baseline: 0 - Fully Active			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	87	98	
Number of subjects with events, n (%)	63 (72.4)	63 (64.3)	
95 % CI [a]	(61.8, 81.5)	(54.0, 73.7)	
Odds ratio (95 % CI) [b]			1.46 (0.78, 2.73)
Relative risk (95 % CI) [b]			1.13 (0.93, 1.37)
Absolute risk reduction (95 % CI) [c]			8.13 (-6.31, 22.56)
p-value [d]			0.1600

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

ECOG Performance Status at Baseline: 1 - Restricted in Physically Strenuous Activity			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	134	136	
Number of subjects with events, n (%)	97 (72.4)	91 (66.9)	
95 % CI [a]	(64.0, 79.8)	(58.3, 74.7)	
Odds ratio (95 % CI) [b]			1.30 (0.77, 2.18)
Relative risk (95 % CI) [b]			1.08 (0.92, 1.27)
Absolute risk reduction (95 % CI) [c]			5.48 (-6.21, 17.16)
p-value [d]			0.3487

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

ECOG Performance Status at Baseline: 2 - Ambulatory and Capable of All Selfcare			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	47	36	
Number of subjects with events, n (%)	32 (68.1)	22 (61.1)	
95 % CI [a]	(52.9, 80.9)	(43.5, 76.9)	
Odds ratio (95 % CI) [b]			1.36 (0.55, 3.37)
Relative risk (95 % CI) [b]			1.11 (0.80, 1.54)
Absolute risk reduction (95 % CI) [c]			6.97 (-16.24, 30.19)
p-value [d]			0.4445
Subgroup Interaction p-value [e]			0.9491

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

FLT3-ITD category at Baseline: ≥3 to ≤25%			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	94	98	
Number of subjects with events, n (%)	67 (71.3)	60 (61.2)	
95 % CI [a]	(61.0, 80.1)	(50.8, 70.9)	
Odds ratio (95 % CI) [b]			1.57 (0.86, 2.87)
Relative risk (95 % CI) [b]			1.16 (0.95, 1.43)
Absolute risk reduction (95 % CI) [c]			10.05 (-4.28, 24.39)
p-value [d]			0.2096

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

FLT3-ITD category at Baseline: >25% to ≤50%			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	143	138	
Number of subjects with events, n (%)	99 (69.2)	94 (68.1)	
95 % CI [a]	(61.0, 76.7)	(59.6, 75.8)	
Odds ratio (95 % CI) [b]			1.05 (0.64, 1.74)
Relative risk (95 % CI) [b]			1.02 (0.87, 1.19)
Absolute risk reduction (95 % CI) [c]			1.11 (-10.45, 12.67)
p-value [d]			0.6264

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

FLT3-ITD category at Baseline: >50%			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	30	35	
Number of subjects with events, n (%)	25 (83.3)	22 (62.9)	
95 % CI [a]	(65.3, 94.4)	(44.9, 78.5)	
Odds ratio (95 % CI) [b]			2.95 (0.91, 9.61)
Relative risk (95 % CI) [b]			1.33 (0.98, 1.79)
Absolute risk reduction (95 % CI) [c]			20.48 (-3.45, 44.41)
p-value [d]			0.1557
Subgroup Interaction p-value [e]			0.2545

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML with Mutated NPM1: Yes			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	142	140	
Number of subjects with events, n (%)	120 (84.5)	115 (82.1)	
95 % CI [a]	(77.5, 90.0)	(74.8, 88.1)	
Odds ratio (95 % CI) [b]			1.19 (0.63, 2.22)
Relative risk (95 % CI) [b]			1.03 (0.93, 1.14)
Absolute risk reduction (95 % CI) [c]			2.36 (-7.04, 11.77)
p-value [d]			0.6241

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

AML with Mutated NPM1: No			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	116	120	
Number of subjects with events, n (%)	65 (56.0)	52 (43.3)	
95 % CI [a]	(46.5, 65.2)	(34.3, 52.7)	
Odds ratio (95 % CI) [b]			1.67 (1.00, 2.79)
Relative risk (95 % CI) [b]			1.29 (1.00, 1.68)
Absolute risk reduction (95 % CI) [c]			12.70 (-0.80, 26.21)
p-value [d]			0.0317
Subgroup Interaction p-value [e]			0.1103

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Age by 2 categories: ≤60			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	166	165	
Number of subjects with events, n (%)	120 (72.3)	105 (63.6)	
95 % CI [a]	(64.8, 78.9)	(55.8, 71.0)	
Odds ratio (95 % CI) [b]			1.49 (0.94, 2.37)
Relative risk (95 % CI) [b]			1.14 (0.98, 1.32)
Absolute risk reduction (95 % CI) [c]			8.65 (-1.96, 19.27)
p-value [d]			0.0942

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.24.2 Composite Complete Remission Dichotomous Endpoints - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

Age by 2 categories: >60			
	Quizartinib (N=268)	Placebo (N=271)	Quizartinib vs Placebo
Number of subjects in subgroup category, n	102	106	
Number of subjects with events, n (%)	72 (70.6)	71 (67.0)	
95 % CI [a]	(60.7, 79.2)	(57.2, 75.8)	
Odds ratio (95 % CI) [b]			1.18 (0.66, 2.13)
Relative risk (95 % CI) [b]			1.05 (0.88, 1.27)
Absolute risk reduction (95 % CI) [c]			3.61 (-9.94, 17.15)
p-value [d]			0.6036
Subgroup Interaction p-value [e]			0.5333

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in subgroup category.
[a] Exact confidence interval based on Clopper-Pearson method for single proportion.
[b] Confidence interval is the Wald asymptotic confidence interval. In case of zero cells a correction value of 0.5 is added to each cell frequency of the corresponding 2x2 table.
[c] Absolute risk reduction is presented on percentage point scale. Confidence interval is the continuity corrected Wald asymptotic confidence interval for the risk differences
[d] Two-sided p-value based on the Cochran-Mantel-Haenszel test adjusted for randomization stratification factors.[e] Two-sided p-value from Cochrane's Q test for heterogeneity of relative risk.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_23_2_DE_sub.sas; Output name: DE_T_4_24_2_CRC_DE_SUB_ITT.rtf

Anhang 4-H4f: Dauer der zusammengesetzten Komplettremission nach Induktion

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.28.1 Duration of Composite Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2374
<60	118	44 (37.3)	74 (62.7)	NE (27.9, NE)	105	55 (52.4)	50 (47.6)	16.5 (9.1, NE)	0.610 (0.410, 0.908)	0.0139	
≥60 - <65	27	15 (55.6)	12 (44.4)	22.7 (11.1, NE)	28	16 (57.1)	12 (42.9)	13.7 (5.4, NE)	0.760 (0.375, 1.538)	0.4452	
≥65	47	36 (76.6)	11 (23.4)	13.4 (6.2, 17.4)	43	31 (72.1)	12 (27.9)	8.8 (5.3, 26.5)	1.041 (0.643, 1.685)	0.8717	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Composite Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_28_1_DOCRC_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)

Table 4.28.1 Duration of Composite Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5275
Male	87	49 (56.3)	38 (43.7)	19.4 (14.1, 28.5)	72	43 (59.7)	29 (40.3)	9.1 (6.7, 21.0)	0.792 (0.525, 1.195)	0.2666	
Female	105	46 (43.8)	59 (56.2)	47.7 (19.9, NE)	104	59 (56.7)	45 (43.3)	18.6 (8.4, 41.9)	0.672 (0.457, 0.988)	0.0421	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Composite Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_28_1_DOCRC_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)

Table 4.28.1 Duration of Composite Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9583
White	114	62 (54.4)	52 (45.6)	21.9 (13.7, NE)	106	66 (62.3)	40 (37.7)	10.2 (5.4, 21.6)	0.752 (0.531, 1.064)	0.1064	
Non-white	78	33 (42.3)	45 (57.7)	38.6 (17.7, NE)	70	36 (51.4)	34 (48.6)	20.1 (8.7, NE)	0.703 (0.438, 1.128)	0.1433	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Composite Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_28_1_DOCRC_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.28.1 Duration of Composite Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5982
North America	7	4 (57.1)	3 (42.9)	24.9 (8.5, NE)	14	6 (42.9)	8 (57.1)	NE (6.4, NE)	1.273 (0.358, 4.526)	0.7084	
Europe	122	64 (52.5)	58 (47.5)	22.7 (14.5, NE)	103	67 (65.0)	36 (35.0)	9.1 (6.0, 18.6)	0.688 (0.488, 0.970)	0.0315	
Asia/Other Regions	63	27 (42.9)	36 (57.1)	38.6 (17.7, NE)	59	29 (49.2)	30 (50.8)	19.0 (8.0, NE)	0.732 (0.433, 1.238)	0.2442	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Composite Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_28_1_DOCRC_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.28.1 Duration of Composite Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6688
< 40x10^9/L	88	40 (45.5)	48 (54.5)	38.6 (18.7, NE)	87	49 (56.3)	38 (43.7)	12.4 (8.4, 46.2)	0.688 (0.452, 1.045)	0.0779	
≥ 40x10^9/L	104	55 (52.9)	49 (47.1)	21.8 (13.4, NE)	89	53 (59.6)	36 (40.4)	10.2 (6.7, 22.8)	0.786 (0.539, 1.148)	0.2106	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Composite Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_28_1_DOCRC_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.28.1 Duration of Composite Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8854
Daunorubicin	86	45 (52.3)	41 (47.7)	22.7 (15.3, NE)	62	37 (59.7)	25 (40.3)	9.4 (5.3, 26.5)	0.711 (0.459, 1.100)	0.1228	
Idarubicin	106	50 (47.2)	56 (52.8)	27.9 (15.9, NE)	113	65 (57.5)	48 (42.5)	13.7 (8.7, 30.9)	0.739 (0.511, 1.069)	0.1072	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Composite Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_28_1_DOCRC_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.28.1 Duration of Composite Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3738
Favorable	8	3 (37.5)	5 (62.5)	38.6 (3.7, NE)	14	5 (35.7)	9 (64.3)	NE (4.4, NE)	1.096 (0.257, 4.671)	0.8870	
Intermediate	148	75 (50.7)	73 (49.3)	22.7 (14.5, NE)	121	68 (56.2)	53 (43.8)	13.7 (8.0, 41.9)	0.825 (0.593, 1.146)	0.2499	
Unfavorable	10	4 (40.0)	6 (60.0)	NE (2.1, NE)	17	12 (70.6)	5 (29.4)	10.6 (4.8, 16.5)	0.326 (0.101, 1.053)	0.0505	
Unknown	26	13 (50.0)	13 (50.0)	27.9 (16.4, NE)	23	17 (73.9)	6 (26.1)	8.7 (5.3, 22.7)	0.517 (0.250, 1.071)	0.0695	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Composite Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_28_1_DOCRC_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.28.1 Duration of Composite Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7598
0 - Fully Active	63	27 (42.9)	36 (57.1)	NE (18.7, NE)	63	35 (55.6)	28 (44.4)	12.4 (6.6, NE)	0.646 (0.391, 1.067)	0.0861	
1 - Restricted in Physically Strenuous Activity	97	51 (52.6)	46 (47.4)	21.9 (14.1, NE)	91	53 (58.2)	38 (41.8)	14.4 (8.4, 41.9)	0.821 (0.559, 1.208)	0.3173	
2 - Ambulatory and Capable of All Selfcare	32	17 (53.1)	15 (46.9)	24.9 (6.0, NE)	22	14 (63.6)	8 (36.4)	8.0 (4.8, NE)	0.656 (0.321, 1.339)	0.2444	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Composite Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_28_1_DOCRC_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.28.1 Duration of Composite Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4975
≥3 to ≤25%	67	34 (50.7)	33 (49.3)	28.5 (16.4, NE)	60	33 (55.0)	27 (45.0)	19.0 (9.4, NE)	0.815 (0.505, 1.317)	0.4036	
>25% to ≤50%	99	45 (45.5)	54 (54.5)	38.6 (16.4, NE)	94	52 (55.3)	42 (44.7)	13.6 (6.6, 46.2)	0.736 (0.493, 1.098)	0.1323	
>50%	25	15 (60.0)	10 (40.0)	10.2 (6.2, NE)	22	17 (77.3)	5 (22.7)	4.6 (2.7, 7.2)	0.521 (0.259, 1.048)	0.0599	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Composite Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_28_1_DOCRC_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 4.28.1 Duration of Composite Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2780
Yes	120	56 (46.7)	64 (53.3)	34.6 (18.7, NE)	115	68 (59.1)	47 (40.9)	10.6 (6.4, 29.5)	0.659 (0.462, 0.939)	0.0201	
No	65	35 (53.8)	30 (46.2)	21.9 (11.2, NE)	52	29 (55.8)	23 (44.2)	16.5 (8.8, NE)	0.913 (0.558, 1.495)	0.7198	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Composite Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_28_1_DOCRC_SUB_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)

Table 4.28.1 Duration of Composite Complete Remission - subgroup analysis - DCO 13-Aug-2021 - Intent to Treat Analysis Set

	Quizartinib (N=268)				Placebo (N=271)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1138
≤60	120	45 (37.5)	75 (62.5)	NE (27.9, NE)	105	55 (52.4)	50 (47.6)	16.5 (9.1, NE)	0.612 (0.412, 0.908)	0.0138	
>60	72	50 (69.4)	22 (30.6)	15.3 (11.1, 22.7)	71	47 (66.2)	24 (33.8)	9.0 (6.0, 21.6)	0.961 (0.645, 1.432)	0.8432	

N: number of subjects in analysis set; n: number of subjects in subgroup category with Composite Complete Remission; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 22DEC2023 – 17:14; Program name: DE_T_4_26_1_sub.sas; Output name: DE_T_4_28_1_DOCRC_SUB_ITT.rtf

Anhang 4-H5: EQ-5D-5L VAS

Anhang 4-H5a: Zeit zur bestätigten Verschlechterung

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.3 EQ-5D-5L VAS - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9956
<60	150	19 (12.7)	131 (87.3)	NE (NE, NE)	151	12 (7.9)	139 (92.1)	NE (NE, NE)	1.488 (0.722, 3.067)	0.2750	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	42	3 (7.1)	39 (92.9)	NE (NE, NE)	1.280 (0.283, 5.779)	0.7478	
≥65	64	11 (17.2)	53 (82.8)	24.4 (12.9, NE)	59	9 (15.3)	50 (84.7)	NE (26.5, NE)	1.592 (0.656, 3.861)	0.2954	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_3_EQ5D_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.3 EQ-5D-5L VAS - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4062
Male	120	13 (10.8)	107 (89.2)	NE (NE, NE)	108	10 (9.3)	98 (90.7)	NE (NE, NE)	1.090 (0.477, 2.489)	0.8309	
Female	131	21 (16.0)	110 (84.0)	NE (NE, NE)	144	14 (9.7)	130 (90.3)	NE (NE, NE)	1.713 (0.871, 3.370)	0.1138	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_3_EQ5D_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.3 EQ-5D-5L VAS - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8272
White	148	21 (14.2)	127 (85.8)	NE (NE, NE)	152	14 (9.2)	138 (90.8)	NE (NE, NE)	1.475 (0.749, 2.901)	0.2554	
Non-white	103	13 (12.6)	90 (87.4)	NE (NE, NE)	100	10 (10.0)	90 (90.0)	NE (NE, NE)	1.317 (0.577, 3.007)	0.5065	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_3_EQ5D_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.3 EQ-5D-5L VAS - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4372
North America	16	3 (18.8)	13 (81.3)	NE (1.6, NE)	17	2 (11.8)	15 (88.2)	NE (26.5, NE)	3.494 (0.564, 21.644)	0.1544	
Europe	148	19 (12.8)	129 (87.2)	NE (NE, NE)	148	10 (6.8)	138 (93.2)	NE (NE, NE)	1.803 (0.838, 3.878)	0.1249	
Asia/Other Regions	87	12 (13.8)	75 (86.2)	NE (NE, NE)	87	12 (13.8)	75 (86.2)	NE (NE, NE)	0.967 (0.433, 2.157)	0.9426	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_3_EQ5D_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.3 EQ-5D-5L VAS - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2022
< 40x10^9/L	127	19 (15.0)	108 (85.0)	NE (28.2, NE)	124	11 (8.9)	113 (91.1)	NE (NE, NE)	1.985 (0.944, 4.173)	0.0642	
≥ 40x10^9/L	124	15 (12.1)	109 (87.9)	NE (NE, NE)	128	13 (10.2)	115 (89.8)	NE (NE, NE)	0.999 (0.474, 2.105)	0.9982	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_3_EQ5D_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.3 EQ-5D-5L VAS - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4456
Daunorubicin	116	13 (11.2)	103 (88.8)	NE (NE, NE)	89	9 (10.1)	80 (89.9)	NE (NE, NE)	1.093 (0.467, 2.558)	0.8328	
Idarubicin	135	21 (15.6)	114 (84.4)	NE (NE, NE)	161	15 (9.3)	146 (90.7)	NE (NE, NE)	1.620 (0.835, 3.144)	0.1490	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_3_EQ5D_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.3 EQ-5D-5L VAS - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.2687
Favorable	12	1 (8.3)	11 (91.7)	NE (2.1, NE)	17	3 (17.6)	14 (82.4)	NE (26.5, NE)	1.160 (0.104, 12.943)	0.9040	
Intermediate	184	25 (13.6)	159 (86.4)	NE (NE, NE)	178	18 (10.1)	160 (89.9)	NE (NE, NE)	1.199 (0.654, 2.200)	0.5508	
Unfavorable	19	5 (26.3)	14 (73.7)	NE (0.7, NE)	26	2 (7.7)	24 (92.3)	NE (NE, NE)	5.435 (1.051, 28.121)	0.0232	
Unknown	36	3 (8.3)	33 (91.7)	NE (21.3, NE)	30	1 (3.3)	29 (96.7)	NE (NE, NE)	2.574 (0.265, 25.013)	0.3983	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_3_EQ5D_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.3 EQ-5D-5L VAS - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2225
0 - Fully Active	80	15 (18.8)	65 (81.3)	NE (24.4, NE)	90	7 (7.8)	83 (92.2)	NE (NE, NE)	2.516 (1.025, 6.174)	0.0366	
1 - Restricted in Physically Strenuous Activity	127	14 (11.0)	113 (89.0)	NE (NE, NE)	127	15 (11.8)	112 (88.2)	NE (NE, NE)	0.898 (0.433, 1.862)	0.7797	
2 - Ambulatory and Capable of All Selfcare	44	5 (11.4)	39 (88.6)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (4.4, NE)	1.779 (0.341, 9.269)	0.4882	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_3_EQ5D_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.3 EQ-5D-5L VAS - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1301
≥3 to ≤25%	88	11 (12.5)	77 (87.5)	NE (NE, NE)	93	5 (5.4)	88 (94.6)	NE (NE, NE)	2.570 (0.893, 7.400)	0.0700	
>25% to ≤50%	134	22 (16.4)	112 (83.6)	NE (28.2, NE)	126	15 (11.9)	111 (88.1)	NE (NE, NE)	1.314 (0.681, 2.534)	0.4097	
>50%	28	1 (3.6)	27 (96.4)	NE (NE, NE)	33	4 (12.1)	29 (87.9)	NE (NE, NE)	0.259 (0.029, 2.318)	0.1938	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_3_EQ5D_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.3 EQ-5D-5L VAS - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0802
Yes	129	19 (14.7)	110 (85.3)	NE (NE, NE)	129	16 (12.4)	113 (87.6)	NE (NE, NE)	1.174 (0.603, 2.285)	0.6321	
No	112	15 (13.4)	97 (86.6)	NE (NE, NE)	112	4 (3.6)	108 (96.4)	NE (NE, NE)	3.588 (1.190, 10.815)	0.0152	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_3_EQ5D_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.3 EQ-5D-5L VAS - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8172
≤60	155	20 (12.9)	135 (87.1)	NE (NE, NE)	154	12 (7.8)	142 (92.2)	NE (NE, NE)	1.544 (0.754, 3.160)	0.2282	
>60	96	14 (14.6)	82 (85.4)	NE (21.3, NE)	98	12 (12.2)	86 (87.8)	NE (NE, NE)	1.376 (0.635, 2.981)	0.4127	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_3_EQ5D_DD_SUB_PRO_ITT.rtf

Anhang 4-H5b: Zeit bis zur erstmaligen Verschlechterung

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.2 EQ-5D-5L VAS - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8984
<60	150	25 (16.7)	125 (83.3)	NE (NE, NE)	151	16 (10.6)	135 (89.4)	NE (NE, NE)	1.469 (0.784, 2.753)	0.2230	
≥60 - <65	37	5 (13.5)	32 (86.5)	NE (14.9, NE)	42	4 (9.5)	38 (90.5)	NE (NE, NE)	1.162 (0.309, 4.374)	0.8241	
≥65	64	13 (20.3)	51 (79.7)	24.4 (12.9, NE)	59	13 (22.0)	46 (78.0)	NE (26.5, NE)	1.211 (0.561, 2.614)	0.6197	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_2_EQ5D_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.2 EQ-5D-5L VAS - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1274
Male	120	17 (14.2)	103 (85.8)	NE (28.2, NE)	108	16 (14.8)	92 (85.2)	NE (NE, NE)	0.871 (0.439, 1.727)	0.6996	
Female	131	26 (19.8)	105 (80.2)	NE (17.0, NE)	144	17 (11.8)	127 (88.2)	NE (NE, NE)	1.760 (0.955, 3.245)	0.0652	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_2_EQ5D_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.2 EQ-5D-5L VAS - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7551
White	148	25 (16.9)	123 (83.1)	NE (NE, NE)	152	18 (11.8)	134 (88.2)	NE (NE, NE)	1.369 (0.746, 2.510)	0.3038	
Non-white	103	18 (17.5)	85 (82.5)	NE (24.4, NE)	100	15 (15.0)	85 (85.0)	NE (NE, NE)	1.193 (0.601, 2.369)	0.6075	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_2_EQ5D_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.2 EQ-5D-5L VAS - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5462
North America	16	3 (18.8)	13 (81.3)	NE (1.6, NE)	17	2 (11.8)	15 (88.2)	NE (26.5, NE)	3.494 (0.564, 21.644)	0.1544	
Europe	148	23 (15.5)	125 (84.5)	NE (NE, NE)	148	15 (10.1)	133 (89.9)	NE (NE, NE)	1.467 (0.765, 2.812)	0.2415	
Asia/Other Regions	87	17 (19.5)	70 (80.5)	NE (17.0, NE)	87	16 (18.4)	71 (81.6)	NE (NE, NE)	0.993 (0.501, 1.971)	0.9944	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_2_EQ5D_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.2 EQ-5D-5L VAS - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1399
< 40x10^9/L	127	25 (19.7)	102 (80.3)	NE (17.0, NE)	124	16 (12.9)	108 (87.1)	NE (NE, NE)	1.792 (0.956, 3.357)	0.0633	
≥ 40x10^9/L	124	18 (14.5)	106 (85.5)	NE (NE, NE)	128	17 (13.3)	111 (86.7)	NE (NE, NE)	0.915 (0.470, 1.779)	0.7974	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_2_EQ5D_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.2 EQ-5D-5L VAS - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5936
Daunorubicin	116	16 (13.8)	100 (86.2)	NE (28.2, NE)	89	11 (12.4)	78 (87.6)	NE (28.2, NE)	1.093 (0.507, 2.358)	0.8148	
Idarubicin	135	27 (20.0)	108 (80.0)	NE (24.4, NE)	161	22 (13.7)	139 (86.3)	NE (NE, NE)	1.406 (0.801, 2.470)	0.2290	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_2_EQ5D_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.2 EQ-5D-5L VAS - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8781
Favorable	12	2 (16.7)	10 (83.3)	NE (2.1, NE)	17	3 (17.6)	14 (82.4)	NE (26.5, NE)	2.376 (0.332, 17.005)	0.3741	
Intermediate	184	32 (17.4)	152 (82.6)	NE (NE, NE)	178	22 (12.4)	156 (87.6)	NE (NE, NE)	1.255 (0.729, 2.161)	0.4008	
Unfavorable	19	5 (26.3)	14 (73.7)	NE (0.7, NE)	26	5 (19.2)	21 (80.8)	NE (8.5, NE)	2.224 (0.642, 7.707)	0.1910	
Unknown	36	4 (11.1)	32 (88.9)	NE (24.4, NE)	30	3 (10.0)	27 (90.0)	NE (NE, NE)	1.220 (0.271, 5.498)	0.7950	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_2_EQ5D_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.2 EQ-5D-5L VAS - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4735
0 - Fully Active	80	16 (20.0)	64 (80.0)	NE (24.4, NE)	90	10 (11.1)	80 (88.9)	NE (NE, NE)	1.860 (0.844, 4.099)	0.1169	
1 - Restricted in Physically Strenuous Activity	127	22 (17.3)	105 (82.7)	NE (28.2, NE)	127	21 (16.5)	106 (83.5)	NE (NE, NE)	1.008 (0.554, 1.834)	0.9657	
2 - Ambulatory and Capable of All Selfcare	44	5 (11.4)	39 (88.6)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (4.4, NE)	1.779 (0.341, 9.269)	0.4882	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_2_EQ5D_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.2 EQ-5D-5L VAS - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1384
≥3 to ≤25%	88	16 (18.2)	72 (81.8)	NE (24.4, NE)	93	9 (9.7)	84 (90.3)	NE (NE, NE)	2.047 (0.904, 4.634)	0.0794	
>25% to ≤50%	134	26 (19.4)	108 (80.6)	NE (28.2, NE)	126	20 (15.9)	106 (84.1)	NE (26.5, NE)	1.161 (0.647, 2.082)	0.6018	
>50%	28	1 (3.6)	27 (96.4)	NE (NE, NE)	33	4 (12.1)	29 (87.9)	NE (NE, NE)	0.259 (0.029, 2.318)	0.1938	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_2_EQ5D_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.2 EQ-5D-5L VAS - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3331
Yes	129	24 (18.6)	105 (81.4)	NE (NE, NE)	129	20 (15.5)	109 (84.5)	NE (NE, NE)	1.207 (0.666, 2.186)	0.5318	
No	112	17 (15.2)	95 (84.8)	NE (17.0, NE)	112	8 (7.1)	104 (92.9)	NE (NE, NE)	1.933 (0.833, 4.484)	0.1162	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_2_EQ5D_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.2 EQ-5D-5L VAS - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5293
≤60	155	26 (16.8)	129 (83.2)	NE (NE, NE)	154	16 (10.4)	138 (89.6)	NE (NE, NE)	1.504 (0.806, 2.805)	0.1928	
>60	96	17 (17.7)	79 (82.3)	NE (14.9, NE)	98	17 (17.3)	81 (82.7)	NE (26.5, NE)	1.143 (0.583, 2.242)	0.6921	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:06; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_2_EQ5D_FD_SUB_PRO_ITT.rtf

Anhang 4-H5c: Zeit bis zur erstmaligen Verbesserung

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.4 EQ-5D-5L VAS - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8329
<60	150	77 (51.3)	73 (48.7)	2.6 (1.8, 5.1)	151	66 (43.7)	85 (56.3)	3.4 (1.8, 10.8)	1.020 (0.733, 1.420)	0.9090	
≥60 - <65	37	17 (45.9)	20 (54.1)	1.8 (0.8, 12.4)	42	20 (47.6)	22 (52.4)	1.9 (1.4, 9.6)	0.786 (0.403, 1.534)	0.4649	
≥65	64	24 (37.5)	40 (62.5)	3.3 (1.6, 15.6)	59	26 (44.1)	33 (55.9)	2.9 (1.8, 6.7)	0.900 (0.514, 1.574)	0.6978	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_4_EQ5D_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.4 EQ-5D-5L VAS - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4951
Male	120	53 (44.2)	67 (55.8)	2.7 (1.6, 5.2)	108	40 (37.0)	68 (63.0)	6.7 (3.1, 13.2)	1.107 (0.733, 1.672)	0.6298	
Female	131	65 (49.6)	66 (50.4)	2.8 (1.6, 10.1)	144	72 (50.0)	72 (50.0)	2.2 (1.6, 3.0)	0.886 (0.632, 1.241)	0.4663	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_4_EQ5D_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.4 EQ-5D-5L VAS - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7738
White	148	72 (48.6)	76 (51.4)	2.6 (1.6, 10.1)	152	68 (44.7)	84 (55.3)	2.9 (1.7, 9.3)	0.929 (0.664, 1.299)	0.6482	
Non-white	103	46 (44.7)	57 (55.3)	2.8 (1.8, 4.2)	100	44 (44.0)	56 (56.0)	3.1 (1.8, 8.7)	1.006 (0.665, 1.523)	0.9736	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_4_EQ5D_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.4 EQ-5D-5L VAS - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9823
North America	16	6 (37.5)	10 (62.5)	12.4 (0.7, NE)	17	10 (58.8)	7 (41.2)	1.7 (0.7, NE)	1.019 (0.367, 2.826)	0.9888	
Europe	148	73 (49.3)	75 (50.7)	2.4 (1.6, 10.1)	148	64 (43.2)	84 (56.8)	3.0 (2.1, 9.3)	0.952 (0.677, 1.338)	0.7649	
Asia/Other Regions	87	39 (44.8)	48 (55.2)	2.9 (1.9, 5.5)	87	38 (43.7)	49 (56.3)	3.4 (1.6, 10.8)	0.959 (0.612, 1.502)	0.8505	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_4_EQ5D_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.4 EQ-5D-5L VAS - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4030
< 40x10^9/L	127	54 (42.5)	73 (57.5)	3.2 (1.8, 14.3)	124	60 (48.4)	64 (51.6)	2.9 (1.9, 9.3)	0.851 (0.587, 1.232)	0.3845	
≥ 40x10^9/L	124	64 (51.6)	60 (48.4)	2.4 (1.5, 5.1)	128	52 (40.6)	76 (59.4)	3.4 (1.6, 8.7)	1.067 (0.738, 1.542)	0.7371	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_4_EQ5D_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.4 EQ-5D-5L VAS - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.0915
Daunorubicin	116	50 (43.1)	66 (56.9)	4.9 (1.8, 14.3)	89	41 (46.1)	48 (53.9)	1.7 (1.4, 9.3)	0.728 (0.479, 1.108)	0.1292	
Idarubicin	135	68 (50.4)	67 (49.6)	2.3 (1.6, 3.6)	161	70 (43.5)	91 (56.5)	3.3 (2.2, 6.9)	1.142 (0.817, 1.597)	0.4345	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_4_EQ5D_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.4 EQ-5D-5L VAS - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.2483
Favorable	12	7 (58.3)	5 (41.7)	2.4 (0.7, 5.2)	17	11 (64.7)	6 (35.3)	8.7 (1.3, 11.4)	1.551 (0.585, 4.112)	0.3854	
Intermediate	184	92 (50.0)	92 (50.0)	2.3 (1.6, 3.6)	178	74 (41.6)	104 (58.4)	2.9 (1.8, 6.9)	1.043 (0.768, 1.418)	0.7935	
Unfavorable	19	4 (21.1)	15 (78.9)	NE (1.2, NE)	26	11 (42.3)	15 (57.7)	2.6 (1.6, NE)	0.416 (0.128, 1.350)	0.1332	
Unknown	36	15 (41.7)	21 (58.3)	10.1 (1.8, NE)	30	15 (50.0)	15 (50.0)	3.3 (1.7, NE)	0.831 (0.394, 1.752)	0.6187	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_4_EQ5D_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.4 EQ-5D-5L VAS - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4088
0 - Fully Active	80	38 (47.5)	42 (52.5)	4.9 (1.9, 14.3)	90	41 (45.6)	49 (54.4)	3.3 (2.0, 11.3)	0.815 (0.519, 1.279)	0.3624	
1 - Restricted in Physically Strenuous Activity	127	65 (51.2)	62 (48.8)	2.4 (1.4, 2.9)	127	56 (44.1)	71 (55.9)	3.1 (1.9, 6.7)	1.118 (0.782, 1.600)	0.5375	
2 - Ambulatory and Capable of All Selfcare	44	15 (34.1)	29 (65.9)	4.2 (0.8, NE)	34	15 (44.1)	19 (55.9)	1.6 (0.7, NE)	0.779 (0.379, 1.600)	0.4776	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_4_EQ5D_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.4 EQ-5D-5L VAS - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.0554
≥3 to ≤25%	88	35 (39.8)	53 (60.2)	3.6 (1.5, 16.5)	93	45 (48.4)	48 (51.6)	3.0 (1.6, 9.3)	0.753 (0.483, 1.175)	0.2107	
>25% to ≤50%	134	62 (46.3)	72 (53.7)	4.0 (1.9, 12.1)	126	54 (42.9)	72 (57.1)	3.3 (2.0, 6.7)	0.931 (0.644, 1.345)	0.6961	
>50%	28	20 (71.4)	8 (28.6)	1.3 (0.7, 1.6)	33	13 (39.4)	20 (60.6)	1.6 (1.3, NE)	2.066 (1.022, 4.177)	0.0380	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_4_EQ5D_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.4 EQ-5D-5L VAS - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5567
Yes	129	65 (50.4)	64 (49.6)	2.8 (1.6, 10.1)	129	62 (48.1)	67 (51.9)	2.9 (1.8, 9.3)	1.003 (0.707, 1.423)	0.9994	
No	112	48 (42.9)	64 (57.1)	2.9 (1.6, 10.8)	112	45 (40.2)	67 (59.8)	2.2 (1.6, 6.9)	0.824 (0.546, 1.245)	0.3483	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_4_EQ5D_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.19.4 EQ-5D-5L VAS - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5586
≤60	155	78 (50.3)	77 (49.7)	2.8 (1.8, 5.1)	154	66 (42.9)	88 (57.1)	5.5 (1.8, 10.8)	1.024 (0.736, 1.423)	0.8944	
>60	96	40 (41.7)	56 (58.3)	3.3 (1.6, 10.8)	98	46 (46.9)	52 (53.1)	2.3 (1.6, 3.9)	0.839 (0.546, 1.289)	0.4128	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 15 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: DE_T_4_18_4.sas; Output name: DE_T_2_19_4_EQ5D_FI_SUB_PRO_ITT.rtf

Anhang 4-H6: EORTC QLQ-C30

Anhang 4-H6a: Zeit zur bestätigten Verschlechterung

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7535
<60	152	23 (15.1)	129 (84.9)	NE (NE, NE)	151	24 (15.9)	127 (84.1)	NE (NE, NE)	0.898 (0.507, 1.593)	0.7170	
≥60 - <65	36	4 (11.1)	32 (88.9)	NE (NE, NE)	43	8 (18.6)	35 (81.4)	NE (NE, NE)	0.535 (0.160, 1.793)	0.3058	
≥65	64	7 (10.9)	57 (89.1)	NE (24.4, NE)	59	9 (15.3)	50 (84.7)	NE (NE, NE)	0.823 (0.306, 2.211)	0.6991	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5008
Male	120	15 (12.5)	105 (87.5)	NE (NE, NE)	109	13 (11.9)	96 (88.1)	NE (NE, NE)	1.008 (0.479, 2.120)	0.9858	
Female	132	19 (14.4)	113 (85.6)	NE (NE, NE)	144	28 (19.4)	116 (80.6)	NE (NE, NE)	0.727 (0.405, 1.303)	0.2826	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6646
White	150	24 (16.0)	126 (84.0)	NE (NE, NE)	151	27 (17.9)	124 (82.1)	NE (NE, NE)	0.869 (0.501, 1.508)	0.6067	
Non-white	102	10 (9.8)	92 (90.2)	NE (NE, NE)	102	14 (13.7)	88 (86.3)	NE (NE, NE)	0.686 (0.304, 1.547)	0.3681	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4730
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	16	1 (6.3)	15 (93.8)	NE (17.8, NE)	1.382 (0.086, 22.142)	0.8185	
Europe	150	26 (17.3)	124 (82.7)	NE (NE, NE)	150	27 (18.0)	123 (82.0)	NE (NE, NE)	0.929 (0.542, 1.593)	0.7827	
Asia/Other Regions	86	7 (8.1)	79 (91.9)	NE (NE, NE)	87	13 (14.9)	74 (85.1)	NE (NE, NE)	0.502 (0.200, 1.263)	0.1391	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1693
< 40x10^9/L	128	23 (18.0)	105 (82.0)	NE (NE, NE)	125	24 (19.2)	101 (80.8)	NE (NE, NE)	1.068 (0.602, 1.892)	0.8232	
≥ 40x10^9/L	124	11 (8.9)	113 (91.1)	NE (NE, NE)	128	17 (13.3)	111 (86.7)	NE (NE, NE)	0.548 (0.256, 1.175)	0.1175	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1894
Daunorubicin	116	11 (9.5)	105 (90.5)	NE (NE, NE)	90	15 (16.7)	75 (83.3)	NE (NE, NE)	0.542 (0.249, 1.182)	0.1196	
Idarubicin	136	23 (16.9)	113 (83.1)	NE (NE, NE)	161	26 (16.1)	135 (83.9)	NE (NE, NE)	1.012 (0.577, 1.776)	0.9702	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.2962
Favorable	12	3 (25.0)	9 (75.0)	NE (1.4, NE)	16	1 (6.3)	15 (93.8)	NE (NE, NE)	6.272 (0.640, 61.414)	0.0726	
Intermediate	186	25 (13.4)	161 (86.6)	NE (NE, NE)	180	32 (17.8)	148 (82.2)	NE (NE, NE)	0.678 (0.401, 1.145)	0.1434	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (30.6, NE)	26	3 (11.5)	23 (88.5)	NE (NE, NE)	0.293 (0.025, 3.413)	0.3113	
Unknown	35	5 (14.3)	30 (85.7)	NE (24.4, NE)	30	5 (16.7)	25 (83.3)	NE (NE, NE)	0.988 (0.284, 3.440)	0.9806	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3418
0 - Fully Active	82	17 (20.7)	65 (79.3)	NE (28.3, NE)	92	16 (17.4)	76 (82.6)	NE (NE, NE)	1.129 (0.569, 2.240)	0.7297	
1 - Restricted in Physically Strenuous Activity	126	13 (10.3)	113 (89.7)	NE (NE, NE)	126	22 (17.5)	104 (82.5)	NE (NE, NE)	0.574 (0.289, 1.140)	0.1088	
2 - Ambulatory and Capable of All Selfcare	44	4 (9.1)	40 (90.9)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	1.208 (0.270, 5.400)	0.8087	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1267
≥3 to ≤25%	88	16 (18.2)	72 (81.8)	NE (NE, NE)	92	13 (14.1)	79 (85.9)	NE (NE, NE)	1.482 (0.713, 3.083)	0.2911	
>25% to ≤50%	135	15 (11.1)	120 (88.9)	NE (NE, NE)	128	23 (18.0)	105 (82.0)	NE (NE, NE)	0.557 (0.290, 1.071)	0.0735	
>50%	28	3 (10.7)	25 (89.3)	NE (NE, NE)	33	5 (15.2)	28 (84.8)	NE (4.1, NE)	0.574 (0.137, 2.416)	0.4477	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1695
Yes	130	16 (12.3)	114 (87.7)	NE (NE, NE)	131	25 (19.1)	106 (80.9)	NE (NE, NE)	0.625 (0.333, 1.172)	0.1405	
No	112	18 (16.1)	94 (83.9)	NE (28.3, NE)	111	14 (12.6)	97 (87.4)	NE (NE, NE)	1.220 (0.607, 2.453)	0.5783	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4931
≤60	157	24 (15.3)	133 (84.7)	NE (NE, NE)	154	24 (15.6)	130 (84.4)	NE (NE, NE)	0.930 (0.528, 1.639)	0.8030	
>60	95	10 (10.5)	85 (89.5)	NE (28.3, NE)	99	17 (17.2)	82 (82.8)	NE (NE, NE)	0.632 (0.289, 1.381)	0.2478	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4967
<60	150	50 (33.3)	100 (66.7)	22.6 (7.1, NE)	151	46 (30.5)	105 (69.5)	NE (5.5, NE)	0.977 (0.654, 1.459)	0.9335	
≥60 - <65	36	6 (16.7)	30 (83.3)	NE (NE, NE)	42	10 (23.8)	32 (76.2)	NE (4.1, NE)	0.597 (0.216, 1.654)	0.3164	
≥65	63	18 (28.6)	45 (71.4)	11.0 (1.9, NE)	59	17 (28.8)	42 (71.2)	NE (3.6, NE)	1.321 (0.680, 2.564)	0.4285	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9740
Male	119	38 (31.9)	81 (68.1)	19.2 (8.3, NE)	108	32 (29.6)	76 (70.4)	NE (4.7, NE)	0.996 (0.621, 1.597)	0.9815	
Female	130	36 (27.7)	94 (72.3)	NE (14.5, NE)	144	41 (28.5)	103 (71.5)	NE (6.9, NE)	0.991 (0.633, 1.550)	0.9749	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9533
White	147	45 (30.6)	102 (69.4)	NE (14.3, NE)	151	44 (29.1)	107 (70.9)	NE (6.9, NE)	1.000 (0.659, 1.517)	0.9997	
Non-white	102	29 (28.4)	73 (71.6)	NE (6.3, NE)	101	29 (28.7)	72 (71.3)	NE (5.3, NE)	1.018 (0.608, 1.704)	0.9394	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5233
North America	16	5 (31.3)	11 (68.8)	19.2 (0.8, NE)	16	4 (25.0)	12 (75.0)	NE (2.9, NE)	2.380 (0.634, 8.927)	0.1852	
Europe	147	45 (30.6)	102 (69.4)	NE (8.3, NE)	149	43 (28.9)	106 (71.1)	NE (13.8, NE)	0.993 (0.653, 1.509)	0.9799	
Asia/Other Regions	86	24 (27.9)	62 (72.1)	NE (8.7, NE)	87	26 (29.9)	61 (70.1)	NE (3.6, NE)	0.883 (0.506, 1.542)	0.6579	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6199
< 40x10^9/L	127	38 (29.9)	89 (70.1)	NE (7.1, NE)	125	39 (31.2)	86 (68.8)	NE (5.5, NE)	1.094 (0.700, 1.711)	0.6908	
≥ 40x10^9/L	122	36 (29.5)	86 (70.5)	NE (11.0, NE)	127	34 (26.8)	93 (73.2)	NE (6.8, NE)	0.945 (0.590, 1.513)	0.8157	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2599
Daunorubicin	114	39 (34.2)	75 (65.8)	8.3 (4.1, NE)	90	26 (28.9)	64 (71.1)	NE (6.8, NE)	1.201 (0.731, 1.974)	0.4678	
Idarubicin	135	35 (25.9)	100 (74.1)	NE (19.2, NE)	160	47 (29.4)	113 (70.6)	NE (5.5, NE)	0.841 (0.542, 1.303)	0.4382	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9823
Favorable	12	3 (25.0)	9 (75.0)	NE (0.6, NE)	16	7 (43.8)	9 (56.3)	NE (1.1, NE)	0.763 (0.196, 2.960)	0.6945	
Intermediate	185	57 (30.8)	128 (69.2)	NE (8.7, NE)	179	48 (26.8)	131 (73.2)	NE (13.8, NE)	1.041 (0.709, 1.529)	0.8256	
Unfavorable	17	4 (23.5)	13 (76.5)	22.6 (0.8, NE)	26	9 (34.6)	17 (65.4)	NE (1.6, NE)	0.983 (0.296, 3.262)	0.9820	
Unknown	35	10 (28.6)	25 (71.4)	NE (2.6, NE)	30	9 (30.0)	21 (70.0)	NE (2.0, NE)	0.979 (0.393, 2.439)	0.9537	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.0281
0 - Fully Active	80	33 (41.3)	47 (58.8)	11.0 (2.6, NE)	92	25 (27.2)	67 (72.8)	NE (13.8, NE)	1.662 (0.988, 2.796)	0.0524	
1 - Restricted in Physically Strenuous Activity	126	31 (24.6)	95 (75.4)	NE (19.2, NE)	125	42 (33.6)	83 (66.4)	NE (3.6, NE)	0.659 (0.413, 1.049)	0.0765	
2 - Ambulatory and Capable of All Selfcare	43	10 (23.3)	33 (76.7)	NE (2.8, NE)	34	6 (17.6)	28 (82.4)	NE (4.4, NE)	1.311 (0.472, 3.637)	0.5980	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3940
≥3 to ≤25%	86	24 (27.9)	62 (72.1)	NE (6.3, NE)	92	27 (29.3)	65 (70.7)	NE (6.9, NE)	1.040 (0.600, 1.804)	0.8872	
>25% to ≤50%	134	41 (30.6)	93 (69.4)	22.6 (8.3, NE)	127	33 (26.0)	94 (74.0)	NE (6.8, NE)	1.154 (0.729, 1.826)	0.5398	
>50%	28	9 (32.1)	19 (67.9)	NE (2.1, NE)	33	13 (39.4)	20 (60.6)	4.1 (1.1, NE)	0.578 (0.246, 1.362)	0.2132	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2457
Yes	128	36 (28.1)	92 (71.9)	NE (14.5, NE)	130	42 (32.3)	88 (67.7)	NE (5.5, NE)	0.871 (0.557, 1.360)	0.5387	
No	111	37 (33.3)	74 (66.7)	8.7 (4.1, NE)	111	28 (25.2)	83 (74.8)	NE (4.7, NE)	1.266 (0.775, 2.070)	0.3399	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9559
≤60	155	51 (32.9)	104 (67.1)	22.6 (7.1, NE)	154	46 (29.9)	108 (70.1)	NE (5.5, NE)	0.986 (0.661, 1.469)	0.9651	
>60	94	23 (24.5)	71 (75.5)	NE (8.3, NE)	98	27 (27.6)	71 (72.4)	NE (6.9, NE)	1.017 (0.583, 1.774)	0.9681	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4076
<60	151	44 (29.1)	107 (70.9)	NE (31.3, NE)	151	39 (25.8)	112 (74.2)	NE (20.4, NE)	1.019 (0.662, 1.570)	0.9354	
≥60 - <65	36	6 (16.7)	30 (83.3)	NE (15.8, NE)	41	8 (19.5)	33 (80.5)	NE (32.2, NE)	0.795 (0.274, 2.302)	0.6638	
≥65	64	15 (23.4)	49 (76.6)	21.1 (6.4, NE)	59	10 (16.9)	49 (83.1)	NE (NE, NE)	1.848 (0.828, 4.124)	0.1317	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7094
Male	119	27 (22.7)	92 (77.3)	NE (NE, NE)	107	23 (21.5)	84 (78.5)	NE (20.4, NE)	1.028 (0.590, 1.794)	0.9303	
Female	132	38 (28.8)	94 (71.2)	NE (11.8, NE)	144	34 (23.6)	110 (76.4)	35.0 (32.2, NE)	1.191 (0.749, 1.893)	0.4671	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6261
White	149	36 (24.2)	113 (75.8)	NE (31.3, NE)	150	31 (20.7)	119 (79.3)	NE (35.0, NE)	1.050 (0.648, 1.701)	0.8543	
Non-white	102	29 (28.4)	73 (71.6)	NE (6.4, NE)	101	26 (25.7)	75 (74.3)	NE (16.6, NE)	1.240 (0.730, 2.107)	0.4305	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8668
North America	16	3 (18.8)	13 (81.3)	NE (0.7, NE)	16	3 (18.8)	13 (81.3)	NE (2.9, NE)	1.765 (0.354, 8.805)	0.4828	
Europe	149	37 (24.8)	112 (75.2)	NE (21.3, NE)	148	31 (20.9)	117 (79.1)	NE (35.0, NE)	1.052 (0.652, 1.698)	0.8388	
Asia/Other Regions	86	25 (29.1)	61 (70.9)	NE (7.4, NE)	87	23 (26.4)	64 (73.6)	NE (4.7, NE)	1.144 (0.649, 2.017)	0.6535	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3375
< 40x10^9/L	127	32 (25.2)	95 (74.8)	NE (21.3, NE)	124	35 (28.2)	89 (71.8)	35.0 (32.2, NE)	0.961 (0.595, 1.553)	0.8759	
≥ 40x10^9/L	124	33 (26.6)	91 (73.4)	NE (15.8, NE)	127	22 (17.3)	105 (82.7)	NE (NE, NE)	1.374 (0.800, 2.360)	0.2607	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4028
Daunorubicin	116	29 (25.0)	87 (75.0)	NE (21.3, NE)	90	23 (25.6)	67 (74.4)	NE (20.4, NE)	0.917 (0.530, 1.587)	0.7386	
Idarubicin	135	36 (26.7)	99 (73.3)	NE (15.8, NE)	159	34 (21.4)	125 (78.6)	NE (35.0, NE)	1.248 (0.781, 1.995)	0.3570	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5221
Favorable	12	3 (25.0)	9 (75.0)	NE (0.7, NE)	16	4 (25.0)	12 (75.0)	NE (1.1, NE)	1.172 (0.262, 5.243)	0.8415	
Intermediate	185	49 (26.5)	136 (73.5)	NE (21.1, NE)	179	40 (22.3)	139 (77.7)	NE (32.2, NE)	1.087 (0.715, 1.651)	0.7029	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	26	5 (19.2)	21 (80.8)	NE (7.5, NE)	0.319 (0.037, 2.739)	0.2679	
Unknown	35	12 (34.3)	23 (65.7)	21.3 (3.3, NE)	29	7 (24.1)	22 (75.9)	35.0 (35.0, NE)	1.697 (0.667, 4.320)	0.2708	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4882
0 - Fully Active	82	30 (36.6)	52 (63.4)	21.3 (5.1, NE)	92	23 (25.0)	69 (75.0)	NE (NE, NE)	1.421 (0.825, 2.447)	0.2037	
1 - Restricted in Physically Strenuous Activity	126	27 (21.4)	99 (78.6)	NE (21.1, NE)	124	29 (23.4)	95 (76.6)	35.0 (32.2, NE)	0.910 (0.538, 1.539)	0.7159	
2 - Ambulatory and Capable of All Selfcare	43	8 (18.6)	35 (81.4)	NE (10.4, NE)	34	5 (14.7)	29 (85.3)	NE (2.9, NE)	1.347 (0.436, 4.157)	0.6062	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4898
≥3 to ≤25%	87	16 (18.4)	71 (81.6)	NE (NE, NE)	91	21 (23.1)	70 (76.9)	NE (32.2, NE)	0.843 (0.440, 1.618)	0.6090	
>25% to ≤50%	135	43 (31.9)	92 (68.1)	21.3 (7.4, NE)	127	30 (23.6)	97 (76.4)	NE (16.6, NE)	1.338 (0.839, 2.134)	0.2314	
>50%	28	6 (21.4)	22 (78.6)	NE (10.4, NE)	33	6 (18.2)	27 (81.8)	NE (2.9, NE)	0.786 (0.249, 2.474)	0.6817	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4013
Yes	130	31 (23.8)	99 (76.2)	NE (21.3, NE)	129	31 (24.0)	98 (76.0)	NE (32.2, NE)	0.973 (0.591, 1.603)	0.9047	
No	111	32 (28.8)	79 (71.2)	31.3 (4.8, NE)	111	23 (20.7)	88 (79.3)	NE (16.6, NE)	1.333 (0.780, 2.279)	0.2946	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5154
≤60	156	45 (28.8)	111 (71.2)	NE (31.3, NE)	154	39 (25.3)	115 (74.7)	NE (20.4, NE)	1.021 (0.665, 1.569)	0.9282	
>60	95	20 (21.1)	75 (78.9)	21.3 (15.8, NE)	97	18 (18.6)	79 (81.4)	NE (32.2, NE)	1.359 (0.718, 2.573)	0.3531	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3883
<60	152	38 (25.0)	114 (75.0)	NE (32.9, NE)	151	26 (17.2)	125 (82.8)	NE (NE, NE)	1.362 (0.827, 2.245)	0.2179	
≥60 - <65	36	4 (11.1)	32 (88.9)	NE (12.2, NE)	43	8 (18.6)	35 (81.4)	NE (4.5, NE)	0.541 (0.162, 1.807)	0.3112	
≥65	64	11 (17.2)	53 (82.8)	NE (NE, NE)	59	9 (15.3)	50 (84.7)	NE (NE, NE)	1.443 (0.598, 3.484)	0.4116	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.0121
Male	120	22 (18.3)	98 (81.7)	NE (NE, NE)	109	26 (23.9)	83 (76.1)	NE (NE, NE)	0.733 (0.415, 1.295)	0.2871	
Female	132	31 (23.5)	101 (76.5)	NE (32.9, NE)	144	17 (11.8)	127 (88.2)	NE (NE, NE)	2.065 (1.142, 3.733)	0.0141	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6882
White	150	34 (22.7)	116 (77.3)	NE (25.3, NE)	151	25 (16.6)	126 (83.4)	NE (NE, NE)	1.321 (0.788, 2.216)	0.2838	
Non-white	102	19 (18.6)	83 (81.4)	NE (32.9, NE)	102	18 (17.6)	84 (82.4)	NE (NE, NE)	1.130 (0.593, 2.154)	0.7122	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9341
North America	16	2 (12.5)	14 (87.5)	NE (1.6, NE)	16	2 (12.5)	14 (87.5)	NE (3.0, NE)	2.489 (0.348, 17.808)	0.3477	
Europe	150	35 (23.3)	115 (76.7)	NE (25.3, NE)	150	27 (18.0)	123 (82.0)	NE (NE, NE)	1.246 (0.754, 2.059)	0.3827	
Asia/Other Regions	86	16 (18.6)	70 (81.4)	NE (NE, NE)	87	14 (16.1)	73 (83.9)	NE (NE, NE)	1.168 (0.569, 2.397)	0.6765	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1284
< 40x10^9/L	128	31 (24.2)	97 (75.8)	NE (19.6, NE)	125	21 (16.8)	104 (83.2)	NE (NE, NE)	1.700 (0.977, 2.959)	0.0565	
≥ 40x10^9/L	124	22 (17.7)	102 (82.3)	NE (32.9, NE)	128	22 (17.2)	106 (82.8)	NE (NE, NE)	0.893 (0.494, 1.616)	0.7139	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6135
Daunorubicin	116	22 (19.0)	94 (81.0)	NE (32.9, NE)	90	16 (17.8)	74 (82.2)	NE (NE, NE)	1.078 (0.566, 2.053)	0.8131	
Idarubicin	136	31 (22.8)	105 (77.2)	NE (NE, NE)	161	27 (16.8)	134 (83.2)	NE (NE, NE)	1.340 (0.800, 2.246)	0.2621	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5631
Favorable	12	2 (16.7)	10 (83.3)	NE (1.5, NE)	16	5 (31.3)	11 (68.8)	NE (2.5, NE)	0.678 (0.131, 3.521)	0.6489	
Intermediate	186	39 (21.0)	147 (79.0)	NE (NE, NE)	180	29 (16.1)	151 (83.9)	NE (NE, NE)	1.227 (0.758, 1.984)	0.3977	
Unfavorable	19	5 (26.3)	14 (73.7)	19.6 (0.7, NE)	26	3 (11.5)	23 (88.5)	NE (NE, NE)	2.608 (0.611, 11.141)	0.1797	
Unknown	35	7 (20.0)	28 (80.0)	NE (12.2, NE)	30	6 (20.0)	24 (80.0)	NE (6.4, NE)	1.079 (0.360, 3.235)	0.9028	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7411
0 - Fully Active	82	20 (24.4)	62 (75.6)	NE (25.3, NE)	92	21 (22.8)	71 (77.2)	NE (9.9, NE)	1.034 (0.560, 1.910)	0.9073	
1 - Restricted in Physically Strenuous Activity	126	24 (19.0)	102 (81.0)	NE (NE, NE)	126	17 (13.5)	109 (86.5)	NE (NE, NE)	1.445 (0.776, 2.689)	0.2426	
2 - Ambulatory and Capable of All Selfcare	44	9 (20.5)	35 (79.5)	NE (32.9, NE)	34	5 (14.7)	29 (85.3)	NE (5.7, NE)	1.403 (0.466, 4.225)	0.5430	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1596
≥3 to ≤25%	88	22 (25.0)	66 (75.0)	NE (12.2, NE)	92	17 (18.5)	75 (81.5)	NE (NE, NE)	1.587 (0.842, 2.991)	0.1485	
>25% to ≤50%	135	29 (21.5)	106 (78.5)	NE (NE, NE)	128	20 (15.6)	108 (84.4)	NE (NE, NE)	1.347 (0.761, 2.382)	0.3016	
>50%	28	2 (7.1)	26 (92.9)	NE (25.3, NE)	33	6 (18.2)	27 (81.8)	NE (6.4, NE)	0.283 (0.056, 1.427)	0.1046	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0903
Yes	130	25 (19.2)	105 (80.8)	NE (NE, NE)	131	27 (20.6)	104 (79.4)	NE (NE, NE)	0.903 (0.523, 1.559)	0.7152	
No	112	26 (23.2)	86 (76.8)	NE (19.6, NE)	111	13 (11.7)	98 (88.3)	NE (NE, NE)	1.925 (0.989, 3.746)	0.0469	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4133
≤60	157	39 (24.8)	118 (75.2)	NE (32.9, NE)	154	26 (16.9)	128 (83.1)	NE (NE, NE)	1.384 (0.842, 2.275)	0.1940	
>60	95	14 (14.7)	81 (85.3)	NE (NE, NE)	99	17 (17.2)	82 (82.8)	NE (NE, NE)	0.974 (0.480, 1.976)	0.9439	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0104
<60	152	41 (27.0)	111 (73.0)	NE (25.0, NE)	151	50 (33.1)	101 (66.9)	9.8 (4.7, NE)	0.678 (0.447, 1.026)	0.0626	
≥60 - <65	36	9 (25.0)	27 (75.0)	18.4 (4.4, NE)	43	15 (34.9)	28 (65.1)	14.4 (2.6, NE)	0.726 (0.317, 1.664)	0.4407	
≥65	64	24 (37.5)	40 (62.5)	4.6 (1.5, 20.1)	59	15 (25.4)	44 (74.6)	26.3 (5.5, NE)	2.276 (1.171, 4.423)	0.0120	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9118
Male	120	34 (28.3)	86 (71.7)	NE (7.4, NE)	109	34 (31.2)	75 (68.8)	17.5 (4.8, NE)	0.867 (0.538, 1.395)	0.5477	
Female	132	40 (30.3)	92 (69.7)	25.6 (8.8, NE)	144	46 (31.9)	98 (68.1)	NE (4.6, NE)	0.908 (0.594, 1.389)	0.6485	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7171
White	150	43 (28.7)	107 (71.3)	NE (18.4, NE)	151	46 (30.5)	105 (69.5)	26.3 (6.2, NE)	0.847 (0.558, 1.287)	0.4228	
Non-white	102	31 (30.4)	71 (69.6)	25.0 (7.4, NE)	102	34 (33.3)	68 (66.7)	5.7 (4.2, NE)	0.951 (0.584, 1.548)	0.8347	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8027
North America	16	3 (18.8)	13 (81.3)	29.1 (0.7, NE)	16	6 (37.5)	10 (62.5)	14.4 (1.4, NE)	0.490 (0.091, 2.625)	0.3711	
Europe	150	47 (31.3)	103 (68.7)	NE (5.1, NE)	150	50 (33.3)	100 (66.7)	26.3 (4.6, NE)	0.848 (0.569, 1.264)	0.4093	
Asia/Other Regions	86	24 (27.9)	62 (72.1)	NE (8.7, NE)	87	24 (27.6)	63 (72.4)	NE (4.8, NE)	1.010 (0.573, 1.780)	0.9730	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9969
< 40x10^9/L	128	41 (32.0)	87 (68.0)	25.0 (8.7, NE)	125	48 (38.4)	77 (61.6)	9.8 (3.6, NE)	0.900 (0.593, 1.366)	0.6149	
≥ 40x10^9/L	124	33 (26.6)	91 (73.4)	NE (15.5, NE)	128	32 (25.0)	96 (75.0)	26.3 (4.9, NE)	0.907 (0.556, 1.478)	0.6832	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7717
Daunorubicin	116	34 (29.3)	82 (70.7)	25.0 (4.6, NE)	90	29 (32.2)	61 (67.8)	NE (2.9, NE)	0.838 (0.510, 1.377)	0.4848	
Idarubicin	136	40 (29.4)	96 (70.6)	29.1 (15.5, NE)	161	51 (31.7)	110 (68.3)	14.4 (4.9, NE)	0.884 (0.584, 1.339)	0.5506	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8469
Favorable	12	3 (25.0)	9 (75.0)	NE (0.7, NE)	16	5 (31.3)	11 (68.8)	NE (4.9, NE)	1.093 (0.259, 4.611)	0.9053	
Intermediate	186	57 (30.6)	129 (69.4)	25.6 (7.4, NE)	180	56 (31.1)	124 (68.9)	17.5 (4.6, NE)	0.899 (0.621, 1.301)	0.5628	
Unfavorable	19	5 (26.3)	14 (73.7)	29.1 (0.7, NE)	26	7 (26.9)	19 (73.1)	9.8 (2.6, NE)	0.931 (0.285, 3.038)	0.9025	
Unknown	35	9 (25.7)	26 (74.3)	NE (3.5, NE)	30	12 (40.0)	18 (60.0)	26.3 (1.8, NE)	0.580 (0.243, 1.386)	0.2160	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8179
0 - Fully Active	82	27 (32.9)	55 (67.1)	29.1 (5.1, NE)	92	34 (37.0)	58 (63.0)	26.3 (2.3, NE)	0.803 (0.483, 1.333)	0.3936	
1 - Restricted in Physically Strenuous Activity	126	37 (29.4)	89 (70.6)	25.0 (7.4, NE)	126	38 (30.2)	88 (69.8)	17.5 (5.5, NE)	0.973 (0.618, 1.530)	0.8947	
2 - Ambulatory and Capable of All Selfcare	44	10 (22.7)	34 (77.3)	NE (5.5, NE)	34	8 (23.5)	26 (76.5)	9.8 (2.9, NE)	0.889 (0.349, 2.268)	0.7974	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1623
≥3 to ≤25%	88	30 (34.1)	58 (65.9)	25.0 (2.6, NE)	92	33 (35.9)	59 (64.1)	9.8 (4.2, NE)	1.022 (0.623, 1.677)	0.9420	
>25% to ≤50%	135	41 (30.4)	94 (69.6)	25.6 (7.4, NE)	128	38 (29.7)	90 (70.3)	26.3 (4.7, NE)	0.990 (0.636, 1.540)	0.9560	
>50%	28	3 (10.7)	25 (89.3)	NE (8.7, NE)	33	9 (27.3)	24 (72.7)	NE (2.8, NE)	0.266 (0.071, 0.997)	0.0351	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9916
Yes	130	44 (33.8)	86 (66.2)	25.0 (7.4, NE)	131	48 (36.6)	83 (63.4)	14.4 (4.9, NE)	0.866 (0.574, 1.305)	0.4873	
No	112	28 (25.0)	84 (75.0)	NE (8.7, NE)	111	30 (27.0)	81 (73.0)	17.5 (3.3, NE)	0.869 (0.519, 1.456)	0.5776	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0303
≤60	157	42 (26.8)	115 (73.2)	NE (25.0, NE)	154	50 (32.5)	104 (67.5)	9.8 (4.7, NE)	0.689 (0.456, 1.041)	0.0725	
>60	95	32 (33.7)	63 (66.3)	15.5 (3.5, 25.6)	99	30 (30.3)	69 (69.7)	26.3 (5.5, NE)	1.411 (0.856, 2.326)	0.1743	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6376
<60	151	38 (25.2)	113 (74.8)	NE (33.5, NE)	151	36 (23.8)	115 (76.2)	NE (NE, NE)	0.934 (0.592, 1.474)	0.7959	
≥60 - <65	36	8 (22.2)	28 (77.8)	NE (35.0, NE)	43	11 (25.6)	32 (74.4)	NE (3.3, NE)	0.898 (0.360, 2.239)	0.7954	
≥65	64	17 (26.6)	47 (73.4)	21.3 (3.5, NE)	59	14 (23.7)	45 (76.3)	NE (3.6, NE)	1.405 (0.692, 2.852)	0.3524	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4564
Male	119	25 (21.0)	94 (79.0)	NE (NE, NE)	109	25 (22.9)	84 (77.1)	NE (NE, NE)	0.878 (0.504, 1.530)	0.6427	
Female	132	38 (28.8)	94 (71.2)	35.0 (21.3, NE)	144	36 (25.0)	108 (75.0)	NE (NE, NE)	1.133 (0.718, 1.789)	0.5851	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4870
White	149	42 (28.2)	107 (71.8)	NE (33.5, NE)	151	37 (24.5)	114 (75.5)	NE (NE, NE)	1.120 (0.719, 1.744)	0.6214	
Non-white	102	21 (20.6)	81 (79.4)	NE (32.9, NE)	102	24 (23.5)	78 (76.5)	NE (NE, NE)	0.871 (0.485, 1.565)	0.6538	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4927
North America	16	2 (12.5)	14 (87.5)	NE (0.7, NE)	16	1 (6.3)	15 (93.8)	NE (NE, NE)	4.177 (0.375, 46.584)	0.2075	
Europe	149	46 (30.9)	103 (69.1)	35.0 (21.3, NE)	150	42 (28.0)	108 (72.0)	NE (NE, NE)	1.047 (0.689, 1.591)	0.8344	
Asia/Other Regions	86	15 (17.4)	71 (82.6)	NE (32.9, NE)	87	18 (20.7)	69 (79.3)	NE (NE, NE)	0.791 (0.398, 1.571)	0.5054	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2708
< 40x10^9/L	127	34 (26.8)	93 (73.2)	NE (21.3, NE)	125	30 (24.0)	95 (76.0)	NE (NE, NE)	1.241 (0.760, 2.028)	0.3847	
≥ 40x10^9/L	124	29 (23.4)	95 (76.6)	NE (32.9, NE)	128	31 (24.2)	97 (75.8)	NE (NE, NE)	0.832 (0.501, 1.383)	0.4807	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3831
Daunorubicin	116	29 (25.0)	87 (75.0)	35.0 (21.3, NE)	90	18 (20.0)	72 (80.0)	NE (NE, NE)	1.232 (0.684, 2.219)	0.4677	
Idarubicin	135	34 (25.2)	101 (74.8)	NE (33.5, NE)	161	43 (26.7)	118 (73.3)	NE (NE, NE)	0.897 (0.572, 1.407)	0.6285	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3589
Favorable	12	2 (16.7)	10 (83.3)	NE (1.6, NE)	16	2 (12.5)	14 (87.5)	NE (NE, NE)	1.498 (0.210, 10.670)	0.6682	
Intermediate	185	48 (25.9)	137 (74.1)	NE (32.9, NE)	180	38 (21.1)	142 (78.9)	NE (NE, NE)	1.173 (0.766, 1.796)	0.4653	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (33.5, NE)	26	7 (26.9)	19 (73.1)	NE (2.6, NE)	0.320 (0.061, 1.669)	0.1573	
Unknown	35	11 (31.4)	24 (68.6)	21.3 (3.5, NE)	30	14 (46.7)	16 (53.3)	3.6 (0.7, NE)	0.635 (0.287, 1.402)	0.2627	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4292
0 - Fully Active	82	26 (31.7)	56 (68.3)	NE (18.9, NE)	92	25 (27.2)	67 (72.8)	NE (10.2, NE)	1.117 (0.644, 1.935)	0.6985	
1 - Restricted in Physically Strenuous Activity	126	29 (23.0)	97 (77.0)	NE (35.0, NE)	126	26 (20.6)	100 (79.4)	NE (NE, NE)	1.115 (0.656, 1.893)	0.6853	
2 - Ambulatory and Capable of All Selfcare	43	8 (18.6)	35 (81.4)	NE (32.9, NE)	34	10 (29.4)	24 (70.6)	9.8 (2.0, NE)	0.585 (0.229, 1.495)	0.2635	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9506
≥3 to ≤25%	87	17 (19.5)	70 (80.5)	NE (32.9, NE)	92	21 (22.8)	71 (77.2)	NE (NE, NE)	0.894 (0.471, 1.696)	0.7279	
>25% to ≤50%	135	39 (28.9)	96 (71.1)	NE (17.1, NE)	128	34 (26.6)	94 (73.4)	NE (10.2, NE)	1.029 (0.649, 1.631)	0.8950	
>50%	28	6 (21.4)	22 (78.6)	NE (NE, NE)	33	6 (18.2)	27 (81.8)	NE (NE, NE)	1.034 (0.333, 3.207)	0.9161	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4958
Yes	130	30 (23.1)	100 (76.9)	NE (35.0, NE)	131	34 (26.0)	97 (74.0)	NE (NE, NE)	0.871 (0.533, 1.425)	0.5871	
No	111	29 (26.1)	82 (73.9)	NE (12.9, NE)	111	24 (21.6)	87 (78.4)	NE (NE, NE)	1.115 (0.649, 1.916)	0.6900	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4233
≤60	156	38 (24.4)	118 (75.6)	NE (33.5, NE)	154	36 (23.4)	118 (76.6)	NE (NE, NE)	0.919 (0.582, 1.451)	0.7439	
>60	95	25 (26.3)	70 (73.7)	35.0 (12.9, NE)	99	25 (25.3)	74 (74.7)	NE (NE, NE)	1.240 (0.712, 2.160)	0.4612	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9208
<60	151	31 (20.5)	120 (79.5)	NE (NE, NE)	151	32 (21.2)	119 (78.8)	NE (NE, NE)	0.867 (0.528, 1.422)	0.5686	
≥60 - <65	36	7 (19.4)	29 (80.6)	NE (15.8, NE)	42	10 (23.8)	32 (76.2)	NE (4.4, NE)	0.709 (0.268, 1.871)	0.4838	
≥65	64	10 (15.6)	54 (84.4)	NE (18.9, NE)	59	11 (18.6)	48 (81.4)	37.9 (37.9, NE)	0.977 (0.415, 2.302)	0.9511	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9751
Male	119	25 (21.0)	94 (79.0)	NE (24.6, NE)	108	25 (23.1)	83 (76.9)	NE (37.9, NE)	0.851 (0.488, 1.483)	0.5670	
Female	132	23 (17.4)	109 (82.6)	NE (NE, NE)	144	28 (19.4)	116 (80.6)	NE (NE, NE)	0.864 (0.497, 1.500)	0.6002	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.0866
White	149	33 (22.1)	116 (77.9)	NE (24.6, NE)	151	27 (17.9)	124 (82.1)	NE (37.9, NE)	1.152 (0.692, 1.918)	0.5915	
Non-white	102	15 (14.7)	87 (85.3)	NE (NE, NE)	101	26 (25.7)	75 (74.3)	NE (28.2, NE)	0.566 (0.300, 1.070)	0.0760	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.1733
North America	16	2 (12.5)	14 (87.5)	NE (2.1, NE)	16	4 (25.0)	12 (75.0)	28.2 (2.9, NE)	0.734 (0.133, 4.046)	0.7215	
Europe	149	35 (23.5)	114 (76.5)	NE (22.6, NE)	149	28 (18.8)	121 (81.2)	NE (37.9, NE)	1.140 (0.693, 1.877)	0.6081	
Asia/Other Regions	86	11 (12.8)	75 (87.2)	NE (NE, NE)	87	21 (24.1)	66 (75.9)	NE (NE, NE)	0.508 (0.245, 1.054)	0.0634	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1627
< 40x10^9/L	128	27 (21.1)	101 (78.9)	NE (22.6, NE)	125	26 (20.8)	99 (79.2)	37.9 (37.9, NE)	1.125 (0.656, 1.930)	0.6758	
≥ 40x10^9/L	123	21 (17.1)	102 (82.9)	NE (NE, NE)	127	27 (21.3)	100 (78.7)	NE (NE, NE)	0.652 (0.367, 1.156)	0.1398	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4911
Daunorubicin	116	21 (18.1)	95 (81.9)	NE (NE, NE)	90	21 (23.3)	69 (76.7)	NE (15.4, NE)	0.721 (0.393, 1.322)	0.2884	
Idarubicin	135	27 (20.0)	108 (80.0)	NE (NE, NE)	160	31 (19.4)	129 (80.6)	37.9 (37.9, NE)	0.969 (0.577, 1.626)	0.8984	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5074
Favorable	12	1 (8.3)	11 (91.7)	NE (NE, NE)	16	4 (25.0)	12 (75.0)	NE (4.4, NE)	0.463 (0.051, 4.192)	0.4828	
Intermediate	185	34 (18.4)	151 (81.6)	NE (NE, NE)	179	38 (21.2)	141 (78.8)	37.9 (37.9, NE)	0.763 (0.480, 1.212)	0.2473	
Unfavorable	19	4 (21.1)	15 (78.9)	24.6 (1.9, NE)	26	5 (19.2)	21 (80.8)	NE (NE, NE)	0.947 (0.243, 3.689)	0.9496	
Unknown	35	9 (25.7)	26 (74.3)	NE (15.8, NE)	30	5 (16.7)	25 (83.3)	NE (NE, NE)	1.845 (0.617, 5.516)	0.2696	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9975
0 - Fully Active	82	17 (20.7)	65 (79.3)	NE (22.6, NE)	92	20 (21.7)	72 (78.3)	NE (28.2, NE)	0.877 (0.459, 1.675)	0.6909	
1 - Restricted in Physically Strenuous Activity	126	24 (19.0)	102 (81.0)	NE (24.6, NE)	125	27 (21.6)	98 (78.4)	37.9 (37.9, NE)	0.852 (0.491, 1.478)	0.5566	
2 - Ambulatory and Capable of All Selfcare	43	7 (16.3)	36 (83.7)	NE (NE, NE)	34	6 (17.6)	28 (82.4)	NE (3.2, NE)	0.901 (0.297, 2.739)	0.8510	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7807
≥3 to ≤25%	88	14 (15.9)	74 (84.1)	NE (NE, NE)	92	16 (17.4)	76 (82.6)	NE (NE, NE)	0.962 (0.469, 1.973)	0.9108	
>25% to ≤50%	135	27 (20.0)	108 (80.0)	NE (NE, NE)	127	27 (21.3)	100 (78.7)	NE (37.9, NE)	0.878 (0.514, 1.499)	0.6289	
>50%	27	7 (25.9)	20 (74.1)	24.6 (15.8, NE)	33	10 (30.3)	23 (69.7)	NE (2.2, NE)	0.640 (0.242, 1.694)	0.3617	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1846
Yes	129	22 (17.1)	107 (82.9)	NE (NE, NE)	130	30 (23.1)	100 (76.9)	NE (37.9, NE)	0.723 (0.417, 1.256)	0.2453	
No	112	26 (23.2)	86 (76.8)	NE (14.3, NE)	111	19 (17.1)	92 (82.9)	NE (NE, NE)	1.232 (0.682, 2.228)	0.4877	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7331
≤60	156	31 (19.9)	125 (80.1)	NE (NE, NE)	154	33 (21.4)	121 (78.6)	NE (NE, NE)	0.828 (0.506, 1.353)	0.4481	
>60	95	17 (17.9)	78 (82.1)	NE (15.8, NE)	98	20 (20.4)	78 (79.6)	37.9 (37.9, NE)	0.931 (0.487, 1.779)	0.8212	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7205
<60	152	43 (28.3)	109 (71.7)	NE (10.5, NE)	151	39 (25.8)	112 (74.2)	NE (7.5, NE)	0.955 (0.619, 1.475)	0.8344	
≥60 - <65	36	9 (25.0)	27 (75.0)	NE (15.8, NE)	43	15 (34.9)	28 (65.1)	4.5 (2.6, NE)	0.669 (0.291, 1.537)	0.3366	
≥65	63	13 (20.6)	50 (79.4)	NE (2.7, NE)	59	14 (23.7)	45 (76.3)	NE (7.8, NE)	1.008 (0.474, 2.147)	0.9769	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9155
Male	119	32 (26.9)	87 (73.1)	30.3 (7.5, NE)	109	29 (26.6)	80 (73.4)	NE (7.3, NE)	0.917 (0.554, 1.516)	0.7378	
Female	132	33 (25.0)	99 (75.0)	NE (NE, NE)	144	39 (27.1)	105 (72.9)	NE (7.8, NE)	0.921 (0.579, 1.465)	0.7196	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5118
White	149	39 (26.2)	110 (73.8)	NE (15.8, NE)	151	36 (23.8)	115 (76.2)	NE (NE, NE)	1.015 (0.645, 1.599)	0.9513	
Non-white	102	26 (25.5)	76 (74.5)	NE (7.4, NE)	102	32 (31.4)	70 (68.6)	NE (4.5, NE)	0.810 (0.483, 1.359)	0.4196	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5180
North America	16	6 (37.5)	10 (62.5)	2.4 (0.7, NE)	16	5 (31.3)	11 (68.8)	4.5 (2.1, NE)	1.352 (0.388, 4.715)	0.6349	
Europe	149	36 (24.2)	113 (75.8)	NE (15.8, NE)	150	34 (22.7)	116 (77.3)	NE (NE, NE)	1.002 (0.627, 1.601)	0.9984	
Asia/Other Regions	86	23 (26.7)	63 (73.3)	NE (7.4, NE)	87	29 (33.3)	58 (66.7)	21.9 (3.6, NE)	0.757 (0.438, 1.310)	0.3148	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2054
< 40x10^9/L	128	37 (28.9)	91 (71.1)	NE (8.3, NE)	125	35 (28.0)	90 (72.0)	NE (21.9, NE)	1.129 (0.711, 1.792)	0.6139	
≥ 40x10^9/L	123	28 (22.8)	95 (77.2)	NE (30.3, NE)	128	33 (25.8)	95 (74.2)	NE (6.9, NE)	0.711 (0.429, 1.179)	0.1849	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7776
Daunorubicin	116	24 (20.7)	92 (79.3)	NE (NE, NE)	90	17 (18.9)	73 (81.1)	NE (7.8, NE)	1.026 (0.551, 1.913)	0.9355	
Idarubicin	135	41 (30.4)	94 (69.6)	30.3 (7.5, NE)	161	50 (31.1)	111 (68.9)	NE (6.9, NE)	0.934 (0.618, 1.412)	0.7379	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4367
Favorable	12	1 (8.3)	11 (91.7)	NE (0.7, NE)	16	7 (43.8)	9 (56.3)	4.7 (1.1, NE)	0.226 (0.028, 1.841)	0.1285	
Intermediate	186	49 (26.3)	137 (73.7)	NE (17.0, NE)	180	46 (25.6)	134 (74.4)	NE (7.8, NE)	0.906 (0.606, 1.356)	0.6356	
Unfavorable	19	4 (21.1)	15 (78.9)	NE (0.7, NE)	26	7 (26.9)	19 (73.1)	NE (1.7, NE)	1.028 (0.301, 3.513)	0.9696	
Unknown	34	11 (32.4)	23 (67.6)	15.8 (3.3, NE)	30	8 (26.7)	22 (73.3)	NE (2.9, NE)	1.400 (0.562, 3.489)	0.4606	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1625
0 - Fully Active	82	22 (26.8)	60 (73.2)	NE (10.5, NE)	92	21 (22.8)	71 (77.2)	NE (NE, NE)	1.174 (0.645, 2.137)	0.5994	
1 - Restricted in Physically Strenuous Activity	125	33 (26.4)	92 (73.6)	NE (15.8, NE)	126	43 (34.1)	83 (65.9)	NE (2.6, NE)	0.704 (0.447, 1.109)	0.1267	
2 - Ambulatory and Capable of All Selfcare	44	10 (22.7)	34 (77.3)	NE (5.5, NE)	34	4 (11.8)	30 (88.2)	NE (3.6, NE)	1.716 (0.534, 5.519)	0.3589	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9715
≥3 to ≤25%	87	20 (23.0)	67 (77.0)	NE (8.3, NE)	92	24 (26.1)	68 (73.9)	NE (21.9, NE)	0.957 (0.529, 1.733)	0.8803	
>25% to ≤50%	135	36 (26.7)	99 (73.3)	NE (15.1, NE)	128	35 (27.3)	93 (72.7)	NE (7.3, NE)	0.872 (0.547, 1.392)	0.5665	
>50%	28	8 (28.6)	20 (71.4)	15.8 (5.5, NE)	33	9 (27.3)	24 (72.7)	NE (1.8, NE)	0.840 (0.322, 2.190)	0.7153	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4215
Yes	129	32 (24.8)	97 (75.2)	NE (30.3, NE)	131	37 (28.2)	94 (71.8)	NE (21.9, NE)	0.805 (0.500, 1.295)	0.3704	
No	112	30 (26.8)	82 (73.2)	NE (6.0, NE)	111	26 (23.4)	85 (76.6)	NE (4.7, NE)	1.072 (0.634, 1.814)	0.8073	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8198
≤60	157	43 (27.4)	114 (72.6)	NE (10.5, NE)	154	39 (25.3)	115 (74.7)	NE (7.5, NE)	0.938 (0.608, 1.449)	0.7720	
>60	94	22 (23.4)	72 (76.6)	NE (15.8, NE)	99	29 (29.3)	70 (70.7)	NE (4.4, NE)	0.893 (0.513, 1.555)	0.6871	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0806
<60	152	49 (32.2)	103 (67.8)	32.9 (14.3, NE)	151	39 (25.8)	112 (74.2)	NE (9.9, NE)	1.153 (0.756, 1.759)	0.5236	
≥60 - <65	36	5 (13.9)	31 (86.1)	NE (NE, NE)	43	13 (30.2)	30 (69.8)	13.8 (3.2, NE)	0.376 (0.133, 1.060)	0.0539	
≥65	64	19 (29.7)	45 (70.3)	11.8 (3.4, NE)	59	14 (23.7)	45 (76.3)	NE (15.2, NE)	1.584 (0.793, 3.162)	0.1870	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6862
Male	120	34 (28.3)	86 (71.7)	NE (9.6, NE)	109	28 (25.7)	81 (74.3)	NE (6.2, NE)	0.986 (0.596, 1.632)	0.9535	
Female	132	39 (29.5)	93 (70.5)	32.9 (11.8, NE)	144	38 (26.4)	106 (73.6)	NE (12.6, NE)	1.153 (0.737, 1.803)	0.5441	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5468
White	150	41 (27.3)	109 (72.7)	NE (14.3, NE)	151	39 (25.8)	112 (74.2)	NE (6.4, NE)	0.993 (0.639, 1.542)	0.9536	
Non-white	102	32 (31.4)	70 (68.6)	26.4 (6.3, NE)	102	27 (26.5)	75 (73.5)	NE (12.6, NE)	1.229 (0.736, 2.053)	0.4283	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5551
North America	16	1 (6.3)	15 (93.8)	NE (2.1, NE)	16	4 (25.0)	12 (75.0)	12.6 (3.2, NE)	0.371 (0.041, 3.325)	0.3560	
Europe	150	44 (29.3)	106 (70.7)	30.6 (10.2, NE)	150	36 (24.0)	114 (76.0)	NE (11.5, NE)	1.179 (0.758, 1.834)	0.4802	
Asia/Other Regions	86	28 (32.6)	58 (67.4)	26.4 (6.3, NE)	87	26 (29.9)	61 (70.1)	16.9 (3.7, NE)	1.033 (0.604, 1.764)	0.9018	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7630
< 40x10^9/L	128	38 (29.7)	90 (70.3)	30.6 (9.6, NE)	125	41 (32.8)	84 (67.2)	13.8 (6.2, NE)	1.050 (0.675, 1.633)	0.8416	
≥ 40x10^9/L	124	35 (28.2)	89 (71.8)	32.9 (11.8, NE)	128	25 (19.5)	103 (80.5)	NE (15.2, NE)	1.191 (0.711, 1.995)	0.5094	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1904
Daunorubicin	116	40 (34.5)	76 (65.5)	14.3 (4.8, NE)	90	24 (26.7)	66 (73.3)	21.6 (9.9, NE)	1.332 (0.802, 2.211)	0.2675	
Idarubicin	136	33 (24.3)	103 (75.7)	NE (30.6, NE)	161	42 (26.1)	119 (73.9)	NE (11.5, NE)	0.867 (0.548, 1.370)	0.5258	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3847
Favorable	12	3 (25.0)	9 (75.0)	NE (0.7, NE)	16	3 (18.8)	13 (81.3)	NE (9.9, NE)	1.907 (0.381, 9.537)	0.4244	
Intermediate	186	53 (28.5)	133 (71.5)	32.9 (11.9, NE)	180	49 (27.2)	131 (72.8)	15.2 (11.5, NE)	0.905 (0.613, 1.337)	0.6150	
Unfavorable	19	4 (21.1)	15 (78.9)	NE (1.1, NE)	26	7 (26.9)	19 (73.1)	NE (4.8, NE)	0.854 (0.241, 3.027)	0.8063	
Unknown	35	13 (37.1)	22 (62.9)	6.3 (0.8, NE)	30	7 (23.3)	23 (76.7)	NE (6.4, NE)	1.987 (0.792, 4.986)	0.1451	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5440
0 - Fully Active	82	30 (36.6)	52 (63.4)	11.9 (4.8, NE)	92	26 (28.3)	66 (71.7)	NE (9.9, NE)	1.288 (0.761, 2.180)	0.3494	
1 - Restricted in Physically Strenuous Activity	126	34 (27.0)	92 (73.0)	NE (14.3, NE)	126	36 (28.6)	90 (71.4)	16.9 (5.3, NE)	0.933 (0.583, 1.492)	0.7573	
2 - Ambulatory and Capable of All Selfcare	44	9 (20.5)	35 (79.5)	32.9 (14.3, NE)	34	4 (11.8)	30 (88.2)	NE (NE, NE)	1.477 (0.446, 4.890)	0.5229	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4228
≥3 to ≤25%	88	27 (30.7)	61 (69.3)	26.4 (6.3, NE)	92	23 (25.0)	69 (75.0)	NE (12.6, NE)	1.420 (0.813, 2.480)	0.2208	
>25% to ≤50%	135	39 (28.9)	96 (71.1)	30.6 (10.2, NE)	128	36 (28.1)	92 (71.9)	NE (3.7, NE)	0.913 (0.579, 1.438)	0.6930	
>50%	28	7 (25.0)	21 (75.0)	NE (2.9, NE)	33	7 (21.2)	26 (78.8)	NE (5.3, NE)	1.004 (0.351, 2.875)	0.9986	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6756
Yes	130	38 (29.2)	92 (70.8)	NE (11.9, NE)	131	37 (28.2)	94 (71.8)	NE (12.6, NE)	1.024 (0.650, 1.612)	0.9210	
No	112	33 (29.5)	79 (70.5)	30.6 (7.1, NE)	111	26 (23.4)	85 (76.6)	13.8 (5.3, NE)	1.176 (0.702, 1.970)	0.5506	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7561
≤60	157	49 (31.2)	108 (68.8)	32.9 (14.3, NE)	154	39 (25.3)	115 (74.7)	NE (9.9, NE)	1.130 (0.741, 1.724)	0.5874	
>60	95	24 (25.3)	71 (74.7)	NE (6.3, NE)	99	27 (27.3)	72 (72.7)	NE (12.6, NE)	1.017 (0.587, 1.763)	0.9502	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7798
<60	152	44 (28.9)	108 (71.1)	30.3 (10.4, NE)	151	31 (20.5)	120 (79.5)	NE (NE, NE)	1.318 (0.832, 2.088)	0.2329	
≥60 - <65	36	9 (25.0)	27 (75.0)	NE (4.8, NE)	43	9 (20.9)	34 (79.1)	NE (6.1, NE)	1.020 (0.403, 2.581)	0.9679	
≥65	64	10 (15.6)	54 (84.4)	NE (11.0, NE)	59	12 (20.3)	47 (79.7)	NE (6.8, NE)	0.946 (0.409, 2.191)	0.8942	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4496
Male	120	34 (28.3)	86 (71.7)	14.3 (8.0, NE)	109	28 (25.7)	81 (74.3)	NE (5.6, NE)	1.017 (0.616, 1.680)	0.9393	
Female	132	29 (22.0)	103 (78.0)	NE (18.3, NE)	144	24 (16.7)	120 (83.3)	NE (NE, NE)	1.367 (0.796, 2.348)	0.2556	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8915
White	150	35 (23.3)	115 (76.7)	NE (14.3, NE)	151	27 (17.9)	124 (82.1)	NE (NE, NE)	1.169 (0.707, 1.933)	0.5436	
Non-white	102	28 (27.5)	74 (72.5)	NE (8.0, NE)	102	25 (24.5)	77 (75.5)	NE (9.1, NE)	1.247 (0.727, 2.139)	0.4174	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9964
North America	16	3 (18.8)	13 (81.3)	30.3 (0.8, NE)	16	4 (25.0)	12 (75.0)	NE (2.9, NE)	1.248 (0.277, 5.622)	0.7729	
Europe	150	35 (23.3)	115 (76.7)	NE (14.3, NE)	150	27 (18.0)	123 (82.0)	NE (NE, NE)	1.198 (0.725, 1.980)	0.4786	
Asia/Other Regions	86	25 (29.1)	61 (70.9)	13.6 (7.4, NE)	87	21 (24.1)	66 (75.9)	NE (6.9, NE)	1.243 (0.695, 2.223)	0.4545	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.8593
< 40x10^9/L	128	30 (23.4)	98 (76.6)	33.5 (10.4, NE)	125	28 (22.4)	97 (77.6)	NE (NE, NE)	1.230 (0.734, 2.059)	0.4262	
≥ 40x10^9/L	124	33 (26.6)	91 (73.4)	NE (11.0, NE)	128	24 (18.8)	104 (81.3)	NE (9.1, NE)	1.150 (0.677, 1.952)	0.6015	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7806
Daunorubicin	116	28 (24.1)	88 (75.9)	33.5 (13.6, NE)	90	18 (20.0)	72 (80.0)	NE (9.9, NE)	1.127 (0.623, 2.040)	0.6843	
Idarubicin	136	35 (25.7)	101 (74.3)	NE (10.4, NE)	161	33 (20.5)	128 (79.5)	NE (NE, NE)	1.258 (0.782, 2.025)	0.3443	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7510
Favorable	12	3 (25.0)	9 (75.0)	8.0 (2.5, NE)	16	2 (12.5)	14 (87.5)	NE (6.1, NE)	3.741 (0.615, 22.752)	0.1251	
Intermediate	186	48 (25.8)	138 (74.2)	33.5 (13.2, NE)	180	39 (21.7)	141 (78.3)	NE (12.9, NE)	1.087 (0.712, 1.659)	0.6965	
Unfavorable	19	6 (31.6)	13 (68.4)	18.3 (0.8, NE)	26	7 (26.9)	19 (73.1)	NE (6.0, NE)	1.284 (0.428, 3.850)	0.6342	
Unknown	35	6 (17.1)	29 (82.9)	NE (11.0, NE)	30	4 (13.3)	26 (86.7)	NE (NE, NE)	1.440 (0.405, 5.124)	0.5715	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2319
0 - Fully Active	82	23 (28.0)	59 (72.0)	30.3 (8.7, NE)	92	18 (19.6)	74 (80.4)	NE (NE, NE)	1.435 (0.774, 2.660)	0.2480	
1 - Restricted in Physically Strenuous Activity	126	28 (22.2)	98 (77.8)	NE (14.3, NE)	126	30 (23.8)	96 (76.2)	NE (9.1, NE)	0.908 (0.542, 1.521)	0.7307	
2 - Ambulatory and Capable of All Selfcare	44	12 (27.3)	32 (72.7)	10.4 (3.2, NE)	34	4 (11.8)	30 (88.2)	12.9 (6.9, NE)	2.179 (0.696, 6.825)	0.1732	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3127
≥3 to ≤25%	88	23 (26.1)	65 (73.9)	18.3 (8.0, NE)	92	17 (18.5)	75 (81.5)	NE (NE, NE)	1.740 (0.928, 3.260)	0.0821	
>25% to ≤50%	135	32 (23.7)	103 (76.3)	NE (14.3, NE)	128	27 (21.1)	101 (78.9)	NE (9.1, NE)	0.978 (0.585, 1.637)	0.9391	
>50%	28	8 (28.6)	20 (71.4)	NE (5.1, NE)	33	8 (24.2)	25 (75.8)	NE (2.9, NE)	0.913 (0.341, 2.449)	0.8626	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3573
Yes	130	37 (28.5)	93 (71.5)	33.5 (11.0, NE)	131	27 (20.6)	104 (79.4)	NE (NE, NE)	1.414 (0.861, 2.324)	0.1690	
No	112	23 (20.5)	89 (79.5)	NE (10.4, NE)	111	21 (18.9)	90 (81.1)	NE (9.1, NE)	0.975 (0.539, 1.763)	0.9400	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4426
≤60	157	45 (28.7)	112 (71.3)	30.3 (10.4, NE)	154	31 (20.1)	123 (79.9)	NE (NE, NE)	1.333 (0.843, 2.107)	0.2127	
>60	95	18 (18.9)	77 (81.1)	NE (11.0, NE)	99	21 (21.2)	78 (78.8)	NE (9.1, NE)	0.962 (0.512, 1.806)	0.9033	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0884
<60	152	37 (24.3)	115 (75.7)	NE (NE, NE)	151	44 (29.1)	107 (70.9)	28.2 (9.9, NE)	0.770 (0.497, 1.194)	0.2345	
≥60 - <65	36	9 (25.0)	27 (75.0)	NE (3.4, NE)	43	11 (25.6)	32 (74.4)	NE (4.1, NE)	0.929 (0.384, 2.245)	0.8763	
≥65	64	17 (26.6)	47 (73.4)	NE (2.5, NE)	59	10 (16.9)	49 (83.1)	NE (NE, NE)	2.106 (0.963, 4.605)	0.0544	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3142
Male	120	31 (25.8)	89 (74.2)	NE (34.8, NE)	109	33 (30.3)	76 (69.7)	NE (4.7, NE)	0.821 (0.503, 1.342)	0.4357	
Female	132	32 (24.2)	100 (75.8)	NE (NE, NE)	144	32 (22.2)	112 (77.8)	NE (25.8, NE)	1.149 (0.704, 1.877)	0.5957	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8541
White	150	38 (25.3)	112 (74.7)	NE (34.8, NE)	151	39 (25.8)	112 (74.2)	25.8 (12.1, NE)	0.944 (0.603, 1.479)	0.7888	
Non-white	102	25 (24.5)	77 (75.5)	NE (NE, NE)	102	26 (25.5)	76 (74.5)	NE (12.6, NE)	1.031 (0.595, 1.786)	0.9103	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7060
North America	16	2 (12.5)	14 (87.5)	34.8 (34.8, NE)	16	3 (18.8)	13 (81.3)	28.2 (12.6, NE)	0.454 (0.046, 4.432)	0.4861	
Europe	150	39 (26.0)	111 (74.0)	NE (NE, NE)	150	43 (28.7)	107 (71.3)	25.8 (9.9, NE)	0.876 (0.567, 1.353)	0.5391	
Asia/Other Regions	86	22 (25.6)	64 (74.4)	NE (NE, NE)	87	19 (21.8)	68 (78.2)	NE (NE, NE)	1.220 (0.660, 2.255)	0.5179	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.8015
< 40x10^9/L	128	35 (27.3)	93 (72.7)	NE (13.6, NE)	125	41 (32.8)	84 (67.2)	15.0 (12.1, NE)	0.948 (0.603, 1.489)	0.7926	
≥ 40x10^9/L	124	28 (22.6)	96 (77.4)	NE (NE, NE)	128	24 (18.8)	104 (81.3)	NE (NE, NE)	1.093 (0.633, 1.886)	0.7447	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7411
Daunorubicin	116	29 (25.0)	87 (75.0)	NE (13.6, NE)	90	27 (30.0)	63 (70.0)	12.6 (6.5, NE)	0.879 (0.520, 1.486)	0.6206	
Idarubicin	136	34 (25.0)	102 (75.0)	NE (34.8, NE)	161	38 (23.6)	123 (76.4)	NE (25.8, NE)	1.020 (0.642, 1.622)	0.9392	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9776
Favorable	12	3 (25.0)	9 (75.0)	NE (1.5, NE)	16	5 (31.3)	11 (68.8)	NE (6.5, NE)	1.138 (0.270, 4.794)	0.8604	
Intermediate	186	48 (25.8)	138 (74.2)	NE (NE, NE)	180	45 (25.0)	135 (75.0)	NE (15.0, NE)	0.978 (0.651, 1.469)	0.9074	
Unfavorable	19	3 (15.8)	16 (84.2)	34.8 (0.7, NE)	26	6 (23.1)	20 (76.9)	NE (6.8, NE)	0.695 (0.169, 2.848)	0.6137	
Unknown	35	9 (25.7)	26 (74.3)	NE (3.4, NE)	30	9 (30.0)	21 (70.0)	NE (2.5, NE)	1.034 (0.410, 2.611)	0.9640	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7051
0 - Fully Active	82	25 (30.5)	57 (69.5)	NE (5.1, NE)	92	29 (31.5)	63 (68.5)	28.2 (4.6, NE)	0.989 (0.578, 1.694)	0.9541	
1 - Restricted in Physically Strenuous Activity	126	28 (22.2)	98 (77.8)	NE (NE, NE)	126	31 (24.6)	95 (75.4)	NE (12.6, NE)	0.908 (0.544, 1.513)	0.7161	
2 - Ambulatory and Capable of All Selfcare	44	10 (22.7)	34 (77.3)	NE (5.5, NE)	34	5 (14.7)	29 (85.3)	NE (2.5, NE)	1.584 (0.539, 4.651)	0.4129	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5622
≥3 to ≤25%	88	25 (28.4)	63 (71.6)	NE (4.3, NE)	92	24 (26.1)	68 (73.9)	NE (12.6, NE)	1.227 (0.700, 2.151)	0.4774	
>25% to ≤50%	135	30 (22.2)	105 (77.8)	NE (NE, NE)	128	32 (25.0)	96 (75.0)	NE (12.3, NE)	0.859 (0.522, 1.414)	0.5407	
>50%	28	7 (25.0)	21 (75.0)	NE (4.3, NE)	33	9 (27.3)	24 (72.7)	12.1 (2.8, NE)	0.798 (0.296, 2.154)	0.6565	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.8587
Yes	130	33 (25.4)	97 (74.6)	NE (NE, NE)	131	34 (26.0)	97 (74.0)	NE (12.6, NE)	1.003 (0.621, 1.620)	0.9984	
No	112	27 (24.1)	85 (75.9)	NE (34.8, NE)	111	27 (24.3)	84 (75.7)	NE (12.3, NE)	0.939 (0.550, 1.602)	0.8108	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0907
≤60	157	38 (24.2)	119 (75.8)	NE (NE, NE)	154	44 (28.6)	110 (71.4)	28.2 (9.9, NE)	0.782 (0.506, 1.209)	0.2589	
>60	95	25 (26.3)	70 (73.7)	NE (3.5, NE)	99	21 (21.2)	78 (78.8)	NE (12.6, NE)	1.481 (0.829, 2.646)	0.1808	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2568
<60	152	30 (19.7)	122 (80.3)	NE (NE, NE)	151	36 (23.8)	115 (76.2)	NE (NE, NE)	0.749 (0.461, 1.217)	0.2396	
≥60 - <65	36	3 (8.3)	33 (91.7)	NE (NE, NE)	43	6 (14.0)	37 (86.0)	NE (6.6, NE)	0.548 (0.136, 2.202)	0.3894	
≥65	64	14 (21.9)	50 (78.1)	NE (6.3, NE)	59	10 (16.9)	49 (83.1)	NE (NE, NE)	1.545 (0.686, 3.479)	0.2910	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1047
Male	120	21 (17.5)	99 (82.5)	NE (NE, NE)	109	28 (25.7)	81 (74.3)	NE (6.6, NE)	0.603 (0.342, 1.065)	0.0780	
Female	132	26 (19.7)	106 (80.3)	NE (NE, NE)	144	24 (16.7)	120 (83.3)	NE (NE, NE)	1.234 (0.708, 2.150)	0.4635	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1488
White	150	33 (22.0)	117 (78.0)	NE (NE, NE)	151	29 (19.2)	122 (80.8)	NE (NE, NE)	1.108 (0.672, 1.827)	0.6939	
Non-white	102	14 (13.7)	88 (86.3)	NE (NE, NE)	102	23 (22.5)	79 (77.5)	NE (NE, NE)	0.603 (0.310, 1.172)	0.1315	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3641
North America	16	2 (12.5)	14 (87.5)	NE (2.1, NE)	16	2 (12.5)	14 (87.5)	NE (NE, NE)	1.597 (0.224, 11.395)	0.6376	
Europe	150	31 (20.7)	119 (79.3)	NE (NE, NE)	150	28 (18.7)	122 (81.3)	NE (NE, NE)	1.043 (0.625, 1.741)	0.8747	
Asia/Other Regions	86	14 (16.3)	72 (83.7)	NE (NE, NE)	87	22 (25.3)	65 (74.7)	NE (7.5, NE)	0.606 (0.309, 1.186)	0.1379	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2563
< 40x10^9/L	128	28 (21.9)	100 (78.1)	NE (NE, NE)	125	28 (22.4)	97 (77.6)	NE (NE, NE)	1.092 (0.646, 1.844)	0.7438	
≥ 40x10^9/L	124	19 (15.3)	105 (84.7)	NE (NE, NE)	128	24 (18.8)	104 (81.3)	NE (NE, NE)	0.693 (0.379, 1.269)	0.2258	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6929
Daunorubicin	116	19 (16.4)	97 (83.6)	NE (NE, NE)	90	17 (18.9)	73 (81.1)	NE (NE, NE)	0.800 (0.415, 1.543)	0.5069	
Idarubicin	136	28 (20.6)	108 (79.4)	NE (NE, NE)	161	33 (20.5)	128 (79.5)	NE (NE, NE)	0.993 (0.600, 1.644)	0.9687	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5700
Favorable	12	1 (8.3)	11 (91.7)	NE (0.7, NE)	16	7 (43.8)	9 (56.3)	NE (1.3, NE)	0.245 (0.030, 1.996)	0.1544	
Intermediate	186	38 (20.4)	148 (79.6)	NE (NE, NE)	180	32 (17.8)	148 (82.2)	NE (NE, NE)	1.056 (0.659, 1.691)	0.8200	
Unfavorable	19	0	19 (100)	NE (NE, NE)	26	5 (19.2)	21 (80.8)	NE (NE, NE)	0.000 (0.000, NE)	0.0806	
Unknown	35	8 (22.9)	27 (77.1)	NE (3.3, NE)	30	8 (26.7)	22 (73.3)	NE (3.0, NE)	0.924 (0.346, 2.470)	0.8753	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9410
0 - Fully Active	82	14 (17.1)	68 (82.9)	NE (NE, NE)	92	17 (18.5)	75 (81.5)	NE (NE, NE)	0.875 (0.430, 1.780)	0.7063	
1 - Restricted in Physically Strenuous Activity	126	26 (20.6)	100 (79.4)	NE (NE, NE)	126	30 (23.8)	96 (76.2)	NE (NE, NE)	0.860 (0.508, 1.454)	0.5701	
2 - Ambulatory and Capable of All Selfcare	44	7 (15.9)	37 (84.1)	NE (14.3, NE)	34	5 (14.7)	29 (85.3)	NE (6.6, NE)	0.890 (0.276, 2.869)	0.8491	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8158
≥3 to ≤25%	88	16 (18.2)	72 (81.8)	NE (NE, NE)	92	19 (20.7)	73 (79.3)	NE (NE, NE)	0.923 (0.475, 1.796)	0.8039	
>25% to ≤50%	135	25 (18.5)	110 (81.5)	NE (NE, NE)	128	25 (19.5)	103 (80.5)	NE (NE, NE)	0.895 (0.513, 1.561)	0.6946	
>50%	28	5 (17.9)	23 (82.1)	NE (NE, NE)	33	8 (24.2)	25 (75.8)	NE (3.0, NE)	0.643 (0.210, 1.968)	0.4328	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7291
Yes	130	21 (16.2)	109 (83.8)	NE (NE, NE)	131	25 (19.1)	106 (80.9)	NE (NE, NE)	0.875 (0.489, 1.564)	0.6450	
No	112	24 (21.4)	88 (78.6)	NE (15.1, NE)	111	21 (18.9)	90 (81.1)	NE (NE, NE)	0.992 (0.552, 1.785)	0.9733	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2318
≤60	157	30 (19.1)	127 (80.9)	NE (NE, NE)	154	36 (23.4)	118 (76.6)	NE (NE, NE)	0.736 (0.453, 1.197)	0.2136	
>60	95	17 (17.9)	78 (82.1)	NE (NE, NE)	99	16 (16.2)	83 (83.8)	NE (NE, NE)	1.222 (0.617, 2.420)	0.5690	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0792
<60	152	37 (24.3)	115 (75.7)	NE (30.8, NE)	151	47 (31.1)	104 (68.9)	19.3 (9.9, NE)	0.683 (0.444, 1.052)	0.0824	
≥60 - <65	36	8 (22.2)	28 (77.8)	NE (2.6, NE)	43	15 (34.9)	28 (65.1)	4.4 (2.3, NE)	0.569 (0.239, 1.353)	0.1929	
≥65	64	18 (28.1)	46 (71.9)	5.4 (3.0, NE)	59	13 (22.0)	46 (78.0)	NE (4.1, NE)	1.589 (0.778, 3.245)	0.1988	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1379
Male	120	32 (26.7)	88 (73.3)	NE (5.8, NE)	109	25 (22.9)	84 (77.1)	NE (14.9, NE)	1.062 (0.628, 1.796)	0.8239	
Female	132	31 (23.5)	101 (76.5)	NE (NE, NE)	144	50 (34.7)	94 (65.3)	15.0 (4.4, NE)	0.650 (0.415, 1.019)	0.0584	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9685
White	150	34 (22.7)	116 (77.3)	NE (NE, NE)	151	38 (25.2)	113 (74.8)	NE (14.9, NE)	0.825 (0.519, 1.312)	0.4205	
Non-white	102	29 (28.4)	73 (71.6)	30.8 (4.0, NE)	102	37 (36.3)	65 (63.7)	5.7 (2.5, NE)	0.789 (0.485, 1.284)	0.3377	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8461
North America	16	3 (18.8)	13 (81.3)	NE (0.7, NE)	16	7 (43.8)	9 (56.3)	2.9 (0.8, NE)	0.592 (0.153, 2.300)	0.4396	
Europe	150	34 (22.7)	116 (77.3)	NE (NE, NE)	150	38 (25.3)	112 (74.7)	NE (14.9, NE)	0.806 (0.507, 1.281)	0.3626	
Asia/Other Regions	86	26 (30.2)	60 (69.8)	30.8 (4.0, NE)	87	30 (34.5)	57 (65.5)	12.4 (2.4, NE)	0.857 (0.506, 1.450)	0.5613	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6527
< 40x10^9/L	128	32 (25.0)	96 (75.0)	NE (5.8, NE)	125	41 (32.8)	84 (67.2)	NE (5.7, NE)	0.865 (0.544, 1.373)	0.5359	
≥ 40x10^9/L	124	31 (25.0)	93 (75.0)	NE (13.6, NE)	128	34 (26.6)	94 (73.4)	19.3 (4.4, NE)	0.713 (0.437, 1.164)	0.1746	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6168
Daunorubicin	116	28 (24.1)	88 (75.9)	NE (10.4, NE)	90	27 (30.0)	63 (70.0)	15.0 (4.1, NE)	0.731 (0.430, 1.242)	0.2416	
Idarubicin	136	35 (25.7)	101 (74.3)	NE (30.8, NE)	161	47 (29.2)	114 (70.8)	NE (5.7, NE)	0.865 (0.558, 1.341)	0.5203	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7172
Favorable	12	4 (33.3)	8 (66.7)	10.8 (0.7, NE)	16	9 (56.3)	7 (43.8)	4.4 (1.5, NE)	0.784 (0.241, 2.553)	0.6686	
Intermediate	186	49 (26.3)	137 (73.7)	NE (13.6, NE)	180	55 (30.6)	125 (69.4)	19.3 (3.1, NE)	0.748 (0.509, 1.100)	0.1399	
Unfavorable	19	5 (26.3)	14 (73.7)	10.4 (1.8, NE)	26	5 (19.2)	21 (80.8)	NE (3.0, NE)	1.550 (0.447, 5.381)	0.4865	
Unknown	35	5 (14.3)	30 (85.7)	NE (5.4, NE)	30	6 (20.0)	24 (80.0)	NE (4.1, NE)	0.777 (0.235, 2.563)	0.6773	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9970
0 - Fully Active	82	22 (26.8)	60 (73.2)	NE (5.8, NE)	92	29 (31.5)	63 (68.5)	NE (3.0, NE)	0.800 (0.460, 1.394)	0.4297	
1 - Restricted in Physically Strenuous Activity	126	31 (24.6)	95 (75.4)	NE (30.8, NE)	126	36 (28.6)	90 (71.4)	NE (4.1, NE)	0.808 (0.499, 1.307)	0.3857	
2 - Ambulatory and Capable of All Selfcare	44	10 (22.7)	34 (77.3)	NE (2.7, NE)	34	10 (29.4)	24 (70.6)	12.4 (2.0, NE)	0.728 (0.301, 1.764)	0.4840	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7227
≥3 to ≤25%	88	18 (20.5)	70 (79.5)	NE (NE, NE)	92	30 (32.6)	62 (67.4)	NE (3.1, NE)	0.649 (0.362, 1.164)	0.1433	
>25% to ≤50%	135	36 (26.7)	99 (73.3)	NE (10.4, NE)	128	37 (28.9)	91 (71.1)	19.3 (4.4, NE)	0.821 (0.517, 1.302)	0.4014	
>50%	28	8 (28.6)	20 (71.4)	NE (2.1, NE)	33	8 (24.2)	25 (75.8)	NE (2.9, NE)	1.007 (0.377, 2.686)	0.9863	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.8241
Yes	130	35 (26.9)	95 (73.1)	NE (10.8, NE)	131	44 (33.6)	87 (66.4)	NE (5.7, NE)	0.750 (0.481, 1.171)	0.2058	
No	112	26 (23.2)	86 (76.8)	NE (6.4, NE)	111	28 (25.2)	83 (74.8)	19.3 (4.1, NE)	0.832 (0.487, 1.419)	0.5006	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2640
≤60	157	38 (24.2)	119 (75.8)	NE (30.8, NE)	154	47 (30.5)	107 (69.5)	19.3 (9.9, NE)	0.695 (0.453, 1.067)	0.0949	
>60	95	25 (26.3)	70 (73.7)	NE (4.0, NE)	99	28 (28.3)	71 (71.7)	NE (3.6, NE)	1.006 (0.586, 1.728)	0.9860	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6069
<60	152	29 (19.1)	123 (80.9)	NE (36.7, NE)	151	27 (17.9)	124 (82.1)	NE (32.5, NE)	0.961 (0.568, 1.626)	0.8778	
≥60 - <65	36	5 (13.9)	31 (86.1)	NE (14.9, NE)	43	3 (7.0)	40 (93.0)	NE (8.0, NE)	1.721 (0.410, 7.225)	0.4531	
≥65	64	12 (18.8)	52 (81.3)	21.3 (11.7, NE)	59	15 (25.4)	44 (74.6)	NE (4.1, NE)	0.827 (0.386, 1.768)	0.6239	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7125
Male	120	20 (16.7)	100 (83.3)	NE (NE, NE)	109	16 (14.7)	93 (85.3)	NE (NE, NE)	1.108 (0.573, 2.139)	0.7596	
Female	132	26 (19.7)	106 (80.3)	NE (21.3, NE)	144	29 (20.1)	115 (79.9)	NE (22.6, NE)	0.914 (0.537, 1.555)	0.7366	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7250
White	150	31 (20.7)	119 (79.3)	NE (21.3, NE)	151	30 (19.9)	121 (80.1)	NE (22.6, NE)	0.909 (0.549, 1.505)	0.7056	
Non-white	102	15 (14.7)	87 (85.3)	NE (NE, NE)	102	15 (14.7)	87 (85.3)	NE (32.5, NE)	1.084 (0.530, 2.218)	0.8237	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8715
North America	16	2 (12.5)	14 (87.5)	NE (0.7, NE)	16	2 (12.5)	14 (87.5)	NE (2.9, NE)	2.042 (0.286, 14.564)	0.4673	
Europe	150	33 (22.0)	117 (78.0)	36.7 (21.3, NE)	150	31 (20.7)	119 (79.3)	NE (18.9, NE)	0.939 (0.574, 1.536)	0.7954	
Asia/Other Regions	86	11 (12.8)	75 (87.2)	NE (NE, NE)	87	12 (13.8)	75 (86.2)	NE (32.5, NE)	0.906 (0.400, 2.056)	0.8129	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4094
< 40x10^9/L	128	24 (18.8)	104 (81.3)	NE (21.3, NE)	125	22 (17.6)	103 (82.4)	NE (NE, NE)	1.180 (0.661, 2.105)	0.5742	
≥ 40x10^9/L	124	22 (17.7)	102 (82.3)	NE (36.7, NE)	128	23 (18.0)	105 (82.0)	NE (22.6, NE)	0.819 (0.455, 1.473)	0.4987	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.0936
Daunorubicin	116	24 (20.7)	92 (79.3)	36.7 (14.9, NE)	90	11 (12.2)	79 (87.8)	NE (NE, NE)	1.544 (0.755, 3.158)	0.2300	
Idarubicin	136	22 (16.2)	114 (83.8)	NE (NE, NE)	161	34 (21.1)	127 (78.9)	NE (32.5, NE)	0.750 (0.438, 1.282)	0.2855	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8999
Favorable	12	1 (8.3)	11 (91.7)	NE (11.7, NE)	16	3 (18.8)	13 (81.3)	NE (2.0, NE)	0.530 (0.055, 5.096)	0.5758	
Intermediate	186	32 (17.2)	154 (82.8)	NE (NE, NE)	180	27 (15.0)	153 (85.0)	NE (32.5, NE)	1.026 (0.614, 1.714)	0.9237	
Unfavorable	19	3 (15.8)	16 (84.2)	36.7 (0.7, NE)	26	3 (11.5)	23 (88.5)	18.9 (18.9, NE)	0.993 (0.155, 6.375)	0.9937	
Unknown	35	10 (28.6)	25 (71.4)	21.3 (5.3, NE)	30	11 (36.7)	19 (63.3)	8.5 (2.9, NE)	0.825 (0.349, 1.953)	0.6538	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4012
0 - Fully Active	82	18 (22.0)	64 (78.0)	NE (21.3, NE)	92	19 (20.7)	73 (79.3)	NE (18.9, NE)	0.988 (0.517, 1.889)	0.9667	
1 - Restricted in Physically Strenuous Activity	126	21 (16.7)	105 (83.3)	NE (NE, NE)	126	24 (19.0)	102 (81.0)	NE (NE, NE)	0.836 (0.465, 1.503)	0.5497	
2 - Ambulatory and Capable of All Selfcare	44	7 (15.9)	37 (84.1)	NE (9.0, NE)	34	2 (5.9)	32 (94.1)	32.5 (32.5, NE)	2.415 (0.491, 11.869)	0.2649	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3573
≥3 to ≤25%	88	17 (19.3)	71 (80.7)	NE (14.9, NE)	92	21 (22.8)	71 (77.2)	NE (18.9, NE)	0.906 (0.477, 1.718)	0.7601	
>25% to ≤50%	135	25 (18.5)	110 (81.5)	NE (36.7, NE)	128	17 (13.3)	111 (86.7)	NE (NE, NE)	1.324 (0.715, 2.454)	0.3691	
>50%	28	4 (14.3)	24 (85.7)	NE (NE, NE)	33	7 (21.2)	26 (78.8)	32.5 (3.0, NE)	0.600 (0.175, 2.055)	0.3952	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3433
Yes	130	22 (16.9)	108 (83.1)	NE (NE, NE)	131	26 (19.8)	105 (80.2)	NE (32.5, NE)	0.801 (0.453, 1.417)	0.4414	
No	112	22 (19.6)	90 (80.4)	36.7 (10.8, NE)	111	18 (16.2)	93 (83.8)	NE (18.9, NE)	1.176 (0.629, 2.199)	0.6123	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9475
≤60	157	30 (19.1)	127 (80.9)	NE (36.7, NE)	154	27 (17.5)	127 (82.5)	NE (32.5, NE)	0.981 (0.582, 1.653)	0.9379	
>60	95	16 (16.8)	79 (83.2)	NE (14.9, NE)	99	18 (18.2)	81 (81.8)	NE (NE, NE)	0.978 (0.498, 1.920)	0.9475	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5773
<60	149	45 (30.2)	104 (69.8)	NE (7.4, NE)	151	49 (32.5)	102 (67.5)	13.3 (6.7, NE)	0.804 (0.536, 1.207)	0.2933	
≥60 - <65	36	11 (30.6)	25 (69.4)	26.6 (1.7, NE)	42	11 (26.2)	31 (73.8)	NE (2.0, NE)	1.121 (0.483, 2.600)	0.7999	
≥65	63	15 (23.8)	48 (76.2)	24.4 (3.8, NE)	59	13 (22.0)	46 (78.0)	NE (5.6, NE)	1.213 (0.577, 2.551)	0.6081	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1678
Male	119	31 (26.1)	88 (73.9)	NE (8.0, NE)	109	35 (32.1)	74 (67.9)	15.5 (3.2, NE)	0.712 (0.438, 1.157)	0.1632	
Female	129	40 (31.0)	89 (69.0)	26.6 (5.5, NE)	143	38 (26.6)	105 (73.4)	NE (9.9, NE)	1.117 (0.716, 1.743)	0.6220	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3047
White	147	49 (33.3)	98 (66.7)	25.3 (4.3, NE)	150	45 (30.0)	105 (70.0)	13.3 (6.7, NE)	1.027 (0.685, 1.541)	0.8990	
Non-white	101	22 (21.8)	79 (78.2)	NE (24.4, NE)	102	28 (27.5)	74 (72.5)	NE (4.7, NE)	0.747 (0.426, 1.307)	0.3014	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6384
North America	16	4 (25.0)	12 (75.0)	NE (0.7, NE)	16	7 (43.8)	9 (56.3)	4.8 (1.2, NE)	0.969 (0.282, 3.330)	0.9560	
Europe	146	49 (33.6)	97 (66.4)	25.3 (4.3, NE)	149	44 (29.5)	105 (70.5)	15.5 (9.1, NE)	1.033 (0.687, 1.552)	0.8729	
Asia/Other Regions	86	18 (20.9)	68 (79.1)	NE (26.6, NE)	87	22 (25.3)	65 (74.7)	NE (6.7, NE)	0.755 (0.404, 1.412)	0.3706	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6230
< 40x10^9/L	127	37 (29.1)	90 (70.9)	NE (5.1, NE)	125	45 (36.0)	80 (64.0)	9.9 (4.8, NE)	0.867 (0.561, 1.341)	0.5059	
≥ 40x10^9/L	121	34 (28.1)	87 (71.9)	NE (7.4, NE)	127	28 (22.0)	99 (78.0)	NE (15.5, NE)	1.021 (0.618, 1.686)	0.9247	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6082
Daunorubicin	115	39 (33.9)	76 (66.1)	8.8 (4.2, NE)	89	29 (32.6)	60 (67.4)	13.3 (2.1, NE)	0.953 (0.588, 1.543)	0.8401	
Idarubicin	133	32 (24.1)	101 (75.9)	NE (26.6, NE)	161	43 (26.7)	118 (73.3)	NE (9.8, NE)	0.807 (0.510, 1.276)	0.3542	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7160
Favorable	12	5 (41.7)	7 (58.3)	5.1 (0.7, NE)	16	8 (50.0)	8 (50.0)	9.9 (0.9, NE)	1.219 (0.391, 3.802)	0.7244	
Intermediate	182	47 (25.8)	135 (74.2)	NE (26.6, NE)	179	45 (25.1)	134 (74.9)	NE (9.9, NE)	0.863 (0.573, 1.301)	0.4783	
Unfavorable	19	6 (31.6)	13 (68.4)	7.1 (1.1, NE)	26	8 (30.8)	18 (69.2)	27.1 (3.5, NE)	1.365 (0.470, 3.961)	0.5600	
Unknown	35	13 (37.1)	22 (62.9)	8.8 (1.1, NE)	30	11 (36.7)	19 (63.3)	9.1 (2.4, NE)	1.222 (0.546, 2.736)	0.6223	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2948
0 - Fully Active	81	30 (37.0)	51 (63.0)	24.4 (4.3, NE)	91	31 (34.1)	60 (65.9)	27.1 (3.2, NE)	1.016 (0.615, 1.680)	0.9499	
1 - Restricted in Physically Strenuous Activity	124	36 (29.0)	88 (71.0)	26.6 (5.1, NE)	126	34 (27.0)	92 (73.0)	NE (6.7, NE)	1.015 (0.635, 1.622)	0.9533	
2 - Ambulatory and Capable of All Selfcare	43	5 (11.6)	38 (88.4)	NE (NE, NE)	34	8 (23.5)	26 (76.5)	9.8 (3.2, NE)	0.424 (0.137, 1.313)	0.1241	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4078
≥3 to ≤25%	87	24 (27.6)	63 (72.4)	NE (7.1, NE)	91	30 (33.0)	61 (67.0)	13.3 (4.8, NE)	0.876 (0.511, 1.500)	0.6166	
>25% to ≤50%	133	40 (30.1)	93 (69.9)	NE (5.5, NE)	128	33 (25.8)	95 (74.2)	NE (9.9, NE)	1.050 (0.662, 1.666)	0.8258	
>50%	27	6 (22.2)	21 (77.8)	NE (4.3, NE)	33	10 (30.3)	23 (69.7)	NE (1.6, NE)	0.507 (0.183, 1.407)	0.1903	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5485
Yes	127	37 (29.1)	90 (70.9)	NE (8.8, NE)	131	41 (31.3)	90 (68.7)	NE (9.9, NE)	0.839 (0.537, 1.311)	0.4363	
No	111	31 (27.9)	80 (72.1)	25.3 (4.3, NE)	110	27 (24.5)	83 (75.5)	27.1 (4.8, NE)	1.052 (0.628, 1.763)	0.8419	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.3 EORTC QLQ-C30 - Definitive deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3418
≤60	154	46 (29.9)	108 (70.1)	NE (7.4, NE)	154	49 (31.8)	105 (68.2)	13.3 (6.7, NE)	0.813 (0.543, 1.217)	0.3135	
>60	94	25 (26.6)	69 (73.4)	24.4 (4.4, NE)	98	24 (24.5)	74 (75.5)	NE (5.6, NE)	1.152 (0.657, 2.018)	0.6256	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:09; Program name: .sas; Output name: DE_T_2_20_3_QLQC30_DD_SUB_PRO_ITT.rtf

Anhang 4-H6b: Zeit bis zur erstmaligen Verschlechterung

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7285
<60	152	35 (23.0)	117 (77.0)	NE (NE, NE)	151	33 (21.9)	118 (78.1)	NE (NE, NE)	0.968 (0.601, 1.558)	0.8943	
≥60 - <65	36	5 (13.9)	31 (86.1)	NE (NE, NE)	43	9 (20.9)	34 (79.1)	NE (4.1, NE)	0.627 (0.209, 1.878)	0.4023	
≥65	64	14 (21.9)	50 (78.1)	24.4 (6.9, NE)	59	18 (30.5)	41 (69.5)	NE (2.7, NE)	0.863 (0.429, 1.738)	0.6657	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5113
Male	120	21 (17.5)	99 (82.5)	NE (NE, NE)	109	22 (20.2)	87 (79.8)	NE (NE, NE)	0.775 (0.425, 1.414)	0.3968	
Female	132	33 (25.0)	99 (75.0)	NE (17.0, NE)	144	38 (26.4)	106 (73.6)	NE (17.8, NE)	0.997 (0.626, 1.591)	0.9913	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3863
White	150	36 (24.0)	114 (76.0)	NE (NE, NE)	151	36 (23.8)	115 (76.2)	NE (NE, NE)	1.019 (0.642, 1.619)	0.9597	
Non-white	102	18 (17.6)	84 (82.4)	NE (22.3, NE)	102	24 (23.5)	78 (76.5)	NE (17.8, NE)	0.683 (0.370, 1.261)	0.2240	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4636
North America	16	2 (12.5)	14 (87.5)	NE (0.7, NE)	16	1 (6.3)	15 (93.8)	NE (17.8, NE)	2.998 (0.271, 33.214)	0.3472	
Europe	150	36 (24.0)	114 (76.0)	NE (NE, NE)	150	39 (26.0)	111 (74.0)	NE (NE, NE)	0.916 (0.582, 1.441)	0.6834	
Asia/Other Regions	86	16 (18.6)	70 (81.4)	NE (22.3, NE)	87	20 (23.0)	67 (77.0)	NE (17.9, NE)	0.684 (0.353, 1.324)	0.2617	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4742
< 40x10^9/L	128	34 (26.6)	94 (73.4)	NE (7.1, NE)	125	38 (30.4)	87 (69.6)	NE (4.6, NE)	1.007 (0.634, 1.600)	0.9872	
≥ 40x10^9/L	124	20 (16.1)	104 (83.9)	NE (NE, NE)	128	22 (17.2)	106 (82.8)	NE (NE, NE)	0.774 (0.421, 1.422)	0.4063	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1538
Daunorubicin	116	18 (15.5)	98 (84.5)	NE (NE, NE)	90	21 (23.3)	69 (76.7)	NE (17.8, NE)	0.608 (0.324, 1.144)	0.1205	
Idarubicin	136	36 (26.5)	100 (73.5)	NE (22.3, NE)	161	39 (24.2)	122 (75.8)	NE (NE, NE)	1.082 (0.687, 1.703)	0.7482	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.1994
Favorable	12	5 (41.7)	7 (58.3)	4.6 (1.4, NE)	16	2 (12.5)	14 (87.5)	NE (NE, NE)	5.594 (1.076, 29.077)	0.0215	
Intermediate	186	39 (21.0)	147 (79.0)	NE (NE, NE)	180	43 (23.9)	137 (76.1)	NE (17.8, NE)	0.770 (0.499, 1.190)	0.2349	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (0.7, NE)	26	4 (15.4)	22 (84.6)	NE (NE, NE)	0.921 (0.169, 5.027)	0.9265	
Unknown	35	8 (22.9)	27 (77.1)	NE (24.4, NE)	30	11 (36.7)	19 (63.3)	17.9 (2.0, NE)	0.723 (0.289, 1.807)	0.4650	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2775
0 - Fully Active	82	27 (32.9)	55 (67.1)	24.4 (7.1, NE)	92	25 (27.2)	67 (72.8)	NE (4.1, NE)	1.254 (0.727, 2.163)	0.4202	
1 - Restricted in Physically Strenuous Activity	126	23 (18.3)	103 (81.7)	NE (NE, NE)	126	32 (25.4)	94 (74.6)	NE (17.9, NE)	0.664 (0.388, 1.137)	0.1313	
2 - Ambulatory and Capable of All Selfcare	44	4 (9.1)	40 (90.9)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	1.208 (0.270, 5.400)	0.8087	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3473
≥3 to ≤25%	88	25 (28.4)	63 (71.6)	NE (6.9, NE)	92	24 (26.1)	68 (73.9)	NE (17.8, NE)	1.229 (0.701, 2.152)	0.4799	
>25% to ≤50%	135	25 (18.5)	110 (81.5)	NE (NE, NE)	128	31 (24.2)	97 (75.8)	NE (17.9, NE)	0.704 (0.415, 1.194)	0.1897	
>50%	28	4 (14.3)	24 (85.7)	NE (NE, NE)	33	5 (15.2)	28 (84.8)	NE (4.1, NE)	0.804 (0.215, 3.005)	0.7473	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3267
Yes	130	26 (20.0)	104 (80.0)	NE (NE, NE)	131	34 (26.0)	97 (74.0)	NE (17.8, NE)	0.749 (0.449, 1.251)	0.2662	
No	112	27 (24.1)	85 (75.9)	NE (6.9, NE)	111	23 (20.7)	88 (79.3)	NE (17.9, NE)	1.093 (0.626, 1.907)	0.7607	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4828
≤60	157	36 (22.9)	121 (77.1)	NE (NE, NE)	154	33 (21.4)	121 (78.6)	NE (NE, NE)	0.986 (0.614, 1.583)	0.9530	
>60	95	18 (18.9)	77 (81.1)	NE (24.4, NE)	99	27 (27.3)	72 (72.7)	NE (3.9, NE)	0.750 (0.412, 1.362)	0.3384	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9889
<60	150	60 (40.0)	90 (60.0)	8.7 (3.0, 19.2)	151	55 (36.4)	96 (63.6)	7.2 (4.7, NE)	0.983 (0.681, 1.418)	0.9734	
≥60 - <65	36	9 (25.0)	27 (75.0)	NE (4.8, NE)	42	11 (26.2)	31 (73.8)	NE (4.1, NE)	0.876 (0.361, 2.125)	0.7694	
≥65	63	21 (33.3)	42 (66.7)	6.3 (0.8, NE)	59	25 (42.4)	34 (57.6)	3.6 (1.1, NE)	0.967 (0.541, 1.728)	0.8654	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7473
Male	119	43 (36.1)	76 (63.9)	11.3 (4.8, NE)	108	38 (35.2)	70 (64.8)	6.8 (2.4, NE)	0.926 (0.598, 1.435)	0.7411	
Female	130	47 (36.2)	83 (63.8)	8.5 (2.8, NE)	144	53 (36.8)	91 (63.2)	7.1 (3.7, NE)	1.018 (0.687, 1.508)	0.9152	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9733
White	147	53 (36.1)	94 (63.9)	14.3 (3.2, NE)	151	53 (35.1)	98 (64.9)	7.1 (4.1, NE)	0.972 (0.663, 1.424)	0.8861	
Non-white	102	37 (36.3)	65 (63.7)	8.5 (3.0, NE)	101	38 (37.6)	63 (62.4)	5.3 (2.5, NE)	0.981 (0.624, 1.543)	0.9544	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3774
North America	16	6 (37.5)	10 (62.5)	2.1 (0.7, NE)	16	5 (31.3)	11 (68.8)	NE (0.9, NE)	2.461 (0.737, 8.216)	0.1302	
Europe	147	51 (34.7)	96 (65.3)	14.3 (4.8, NE)	149	53 (35.6)	96 (64.4)	7.2 (3.7, NE)	0.893 (0.607, 1.313)	0.5644	
Asia/Other Regions	86	33 (38.4)	53 (61.6)	8.5 (3.0, NE)	87	33 (37.9)	54 (62.1)	4.7 (1.9, NE)	0.985 (0.607, 1.598)	0.9652	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6914
< 40x10^9/L	127	46 (36.2)	81 (63.8)	8.3 (2.2, NE)	125	50 (40.0)	75 (60.0)	6.9 (3.6, NE)	1.039 (0.696, 1.552)	0.8356	
≥ 40x10^9/L	122	44 (36.1)	78 (63.9)	13.8 (4.8, NE)	127	41 (32.3)	86 (67.7)	NE (2.9, NE)	0.941 (0.614, 1.442)	0.7881	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5619
Daunorubicin	114	43 (37.7)	71 (62.3)	7.1 (2.8, NE)	90	32 (35.6)	58 (64.4)	7.2 (2.9, NE)	1.055 (0.668, 1.669)	0.8195	
Idarubicin	135	47 (34.8)	88 (65.2)	11.3 (4.8, NE)	160	59 (36.9)	101 (63.1)	5.5 (3.6, NE)	0.898 (0.612, 1.318)	0.5969	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8470
Favorable	12	4 (33.3)	8 (66.7)	NE (0.6, NE)	16	8 (50.0)	8 (50.0)	7.1 (0.9, NE)	0.900 (0.269, 3.013)	0.8717	
Intermediate	185	70 (37.8)	115 (62.2)	8.7 (4.8, 19.2)	179	57 (31.8)	122 (68.2)	13.8 (4.1, NE)	1.074 (0.757, 1.524)	0.6738	
Unfavorable	17	4 (23.5)	13 (76.5)	NE (0.8, NE)	26	12 (46.2)	14 (53.8)	5.3 (1.1, NE)	0.802 (0.258, 2.500)	0.7184	
Unknown	35	12 (34.3)	23 (65.7)	11.0 (2.6, NE)	30	13 (43.3)	17 (56.7)	5.5 (0.8, NE)	0.785 (0.355, 1.733)	0.5351	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.0106
0 - Fully Active	80	37 (46.3)	43 (53.8)	5.1 (1.6, 19.2)	92	30 (32.6)	62 (67.4)	13.8 (4.3, NE)	1.601 (0.988, 2.592)	0.0536	
1 - Restricted in Physically Strenuous Activity	126	42 (33.3)	84 (66.7)	14.3 (4.8, NE)	125	55 (44.0)	70 (56.0)	3.6 (1.6, 6.9)	0.639 (0.427, 0.957)	0.0294	
2 - Ambulatory and Capable of All Selfcare	43	11 (25.6)	32 (74.4)	NE (2.6, NE)	34	6 (17.6)	28 (82.4)	NE (4.4, NE)	1.523 (0.560, 4.142)	0.4024	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2316
≥3 to ≤25%	86	31 (36.0)	55 (64.0)	7.1 (2.8, NE)	92	33 (35.9)	59 (64.1)	7.2 (3.7, NE)	1.157 (0.709, 1.889)	0.5547	
>25% to ≤50%	134	50 (37.3)	84 (62.7)	8.5 (2.6, NE)	127	44 (34.6)	83 (65.4)	6.8 (3.4, NE)	1.021 (0.680, 1.533)	0.9119	
>50%	28	9 (32.1)	19 (67.9)	NE (2.1, NE)	33	14 (42.4)	19 (57.6)	2.9 (0.7, NE)	0.499 (0.214, 1.168)	0.1085	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1035
Yes	128	42 (32.8)	86 (67.2)	NE (8.3, NE)	130	50 (38.5)	80 (61.5)	7.2 (4.1, NE)	0.827 (0.548, 1.248)	0.3598	
No	111	46 (41.4)	65 (58.6)	4.1 (2.0, 8.7)	111	35 (31.5)	76 (68.5)	13.8 (3.4, NE)	1.350 (0.869, 2.097)	0.1710	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8637
≤60	155	61 (39.4)	94 (60.6)	8.7 (3.0, 19.2)	154	55 (35.7)	99 (64.3)	7.2 (4.7, NE)	0.986 (0.685, 1.421)	0.9861	
>60	94	29 (30.9)	65 (69.1)	11.0 (3.2, NE)	98	36 (36.7)	62 (63.3)	4.4 (3.4, NE)	0.941 (0.576, 1.536)	0.7878	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4344
<60	151	56 (37.1)	95 (62.9)	22.3 (4.1, NE)	151	52 (34.4)	99 (65.6)	NE (2.2, NE)	0.941 (0.645, 1.373)	0.7473	
≥60 - <65	36	8 (22.2)	28 (77.8)	NE (4.8, NE)	41	11 (26.8)	30 (73.2)	NE (2.9, NE)	0.755 (0.302, 1.888)	0.5413	
≥65	64	20 (31.3)	44 (68.8)	6.4 (0.8, NE)	59	17 (28.8)	42 (71.2)	18.0 (3.5, NE)	1.501 (0.784, 2.873)	0.2355	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8327
Male	119	35 (29.4)	84 (70.6)	NE (6.4, NE)	107	30 (28.0)	77 (72.0)	NE (4.7, NE)	0.997 (0.612, 1.625)	0.9751	
Female	132	49 (37.1)	83 (62.9)	10.4 (2.3, NE)	144	50 (34.7)	94 (65.3)	NE (3.1, NE)	1.066 (0.718, 1.581)	0.7768	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1640
White	149	46 (30.9)	103 (69.1)	NE (10.4, NE)	150	48 (32.0)	102 (68.0)	NE (3.5, NE)	0.876 (0.584, 1.314)	0.4936	
Non-white	102	38 (37.3)	64 (62.7)	6.4 (2.6, 22.3)	101	32 (31.7)	69 (68.3)	NE (2.9, NE)	1.336 (0.834, 2.139)	0.2312	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3827
North America	16	3 (18.8)	13 (81.3)	NE (0.7, NE)	16	6 (37.5)	10 (62.5)	4.8 (0.9, NE)	0.802 (0.199, 3.229)	0.7540	
Europe	149	46 (30.9)	103 (69.1)	NE (10.4, NE)	148	45 (30.4)	103 (69.6)	NE (4.1, NE)	0.905 (0.600, 1.365)	0.6156	
Asia/Other Regions	86	35 (40.7)	51 (59.3)	6.4 (1.9, 22.3)	87	29 (33.3)	58 (66.7)	NE (2.0, NE)	1.339 (0.818, 2.193)	0.2533	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5338
< 40x10^9/L	127	41 (32.3)	86 (67.7)	NE (4.8, NE)	124	45 (36.3)	79 (63.7)	NE (2.5, NE)	0.939 (0.615, 1.434)	0.7684	
≥ 40x10^9/L	124	43 (34.7)	81 (65.3)	22.3 (3.6, NE)	127	35 (27.6)	92 (72.4)	NE (4.1, NE)	1.135 (0.726, 1.775)	0.6173	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4079
Daunorubicin	116	37 (31.9)	79 (68.1)	NE (2.4, NE)	90	32 (35.6)	58 (64.4)	4.1 (1.8, NE)	0.865 (0.538, 1.390)	0.5074	
Idarubicin	135	47 (34.8)	88 (65.2)	22.3 (4.9, NE)	159	48 (30.2)	111 (69.8)	NE (5.7, NE)	1.124 (0.752, 1.681)	0.5747	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3650
Favorable	12	6 (50.0)	6 (50.0)	1.8 (0.7, NE)	16	6 (37.5)	10 (62.5)	NE (1.1, NE)	1.597 (0.514, 4.966)	0.4130	
Intermediate	185	63 (34.1)	122 (65.9)	13.6 (4.9, NE)	179	51 (28.5)	128 (71.5)	NE (4.7, NE)	1.094 (0.756, 1.583)	0.6414	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (0.7, NE)	26	7 (26.9)	19 (73.1)	NE (2.0, NE)	0.477 (0.099, 2.299)	0.3409	
Unknown	35	13 (37.1)	22 (62.9)	NE (0.8, NE)	29	15 (51.7)	14 (48.3)	3.1 (1.1, NE)	0.775 (0.366, 1.639)	0.4608	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2968
0 - Fully Active	82	36 (43.9)	46 (56.1)	5.1 (1.6, NE)	92	33 (35.9)	59 (64.1)	18.0 (2.3, NE)	1.246 (0.776, 2.000)	0.3770	
1 - Restricted in Physically Strenuous Activity	126	37 (29.4)	89 (70.6)	NE (4.8, NE)	124	41 (33.1)	83 (66.9)	NE (3.1, NE)	0.809 (0.518, 1.262)	0.3459	
2 - Ambulatory and Capable of All Selfcare	43	11 (25.6)	32 (74.4)	NE (2.6, NE)	34	6 (17.6)	28 (82.4)	NE (2.9, NE)	1.524 (0.557, 4.172)	0.4236	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2704
≥3 to ≤25%	87	23 (26.4)	64 (73.6)	NE (4.8, NE)	91	28 (30.8)	63 (69.2)	NE (3.5, NE)	0.940 (0.541, 1.633)	0.8163	
>25% to ≤50%	135	55 (40.7)	80 (59.3)	6.4 (2.1, NE)	127	42 (33.1)	85 (66.9)	18.0 (2.5, NE)	1.199 (0.802, 1.792)	0.3949	
>50%	28	6 (21.4)	22 (78.6)	NE (10.4, NE)	33	10 (30.3)	23 (69.7)	NE (1.8, NE)	0.489 (0.176, 1.363)	0.1636	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7376
Yes	130	45 (34.6)	85 (65.4)	NE (5.1, NE)	129	45 (34.9)	84 (65.1)	NE (4.1, NE)	1.002 (0.662, 1.516)	0.9740	
No	111	36 (32.4)	75 (67.6)	11.1 (2.4, NE)	111	30 (27.0)	81 (73.0)	NE (3.5, NE)	1.119 (0.689, 1.816)	0.6499	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5187
≤60	156	57 (36.5)	99 (63.5)	22.3 (4.1, NE)	154	52 (33.8)	102 (66.2)	NE (2.3, NE)	0.949 (0.651, 1.382)	0.7747	
>60	95	27 (28.4)	68 (71.6)	NE (3.2, NE)	97	28 (28.9)	69 (71.1)	NE (4.1, NE)	1.172 (0.690, 1.990)	0.5830	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2382
<60	152	46 (30.3)	106 (69.7)	NE (14.3, NE)	151	29 (19.2)	122 (80.8)	NE (NE, NE)	1.501 (0.942, 2.390)	0.0794	
≥60 - <65	36	5 (13.9)	31 (86.1)	NE (12.2, NE)	43	10 (23.3)	33 (76.7)	NE (4.5, NE)	0.538 (0.183, 1.581)	0.2527	
≥65	64	13 (20.3)	51 (79.7)	NE (2.3, NE)	59	12 (20.3)	47 (79.7)	NE (4.3, NE)	1.316 (0.600, 2.887)	0.4936	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.0168
Male	120	27 (22.5)	93 (77.5)	NE (22.3, NE)	109	29 (26.6)	80 (73.4)	NE (4.3, NE)	0.792 (0.468, 1.339)	0.3871	
Female	132	37 (28.0)	95 (72.0)	NE (6.3, NE)	144	22 (15.3)	122 (84.7)	NE (NE, NE)	1.979 (1.167, 3.355)	0.0095	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8659
White	150	40 (26.7)	110 (73.3)	NE (25.3, NE)	151	30 (19.9)	121 (80.1)	NE (NE, NE)	1.308 (0.814, 2.101)	0.2597	
Non-white	102	24 (23.5)	78 (76.5)	NE (22.3, NE)	102	21 (20.6)	81 (79.4)	NE (NE, NE)	1.227 (0.683, 2.204)	0.4923	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9568
North America	16	2 (12.5)	14 (87.5)	NE (1.6, NE)	16	2 (12.5)	14 (87.5)	NE (3.0, NE)	2.489 (0.348, 17.808)	0.3477	
Europe	150	41 (27.3)	109 (72.7)	NE (14.3, NE)	150	32 (21.3)	118 (78.7)	NE (NE, NE)	1.227 (0.773, 1.950)	0.3742	
Asia/Other Regions	86	21 (24.4)	65 (75.6)	NE (22.3, NE)	87	17 (19.5)	70 (80.5)	NE (NE, NE)	1.282 (0.675, 2.432)	0.4472	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2532
< 40x10^9/L	128	36 (28.1)	92 (71.9)	NE (4.6, NE)	125	26 (20.8)	99 (79.2)	NE (NE, NE)	1.590 (0.960, 2.634)	0.0672	
≥ 40x10^9/L	124	28 (22.6)	96 (77.4)	NE (25.3, NE)	128	25 (19.5)	103 (80.5)	NE (NE, NE)	1.011 (0.588, 1.737)	0.9614	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6293
Daunorubicin	116	26 (22.4)	90 (77.6)	NE (14.3, NE)	90	18 (20.0)	72 (80.0)	NE (6.5, NE)	1.129 (0.618, 2.060)	0.6836	
Idarubicin	136	38 (27.9)	98 (72.1)	NE (22.3, NE)	161	33 (20.5)	128 (79.5)	NE (NE, NE)	1.361 (0.854, 2.171)	0.1900	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4812
Favorable	12	2 (16.7)	10 (83.3)	NE (1.5, NE)	16	6 (37.5)	10 (62.5)	NE (0.7, NE)	0.485 (0.098, 2.407)	0.3768	
Intermediate	186	48 (25.8)	138 (74.2)	NE (22.3, NE)	180	35 (19.4)	145 (80.6)	NE (NE, NE)	1.253 (0.810, 1.938)	0.3015	
Unfavorable	19	5 (26.3)	14 (73.7)	NE (0.7, NE)	26	4 (15.4)	22 (84.6)	NE (NE, NE)	2.309 (0.620, 8.602)	0.1972	
Unknown	35	9 (25.7)	26 (74.3)	NE (3.7, NE)	30	6 (20.0)	24 (80.0)	NE (6.4, NE)	1.447 (0.512, 4.088)	0.4976	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6372
0 - Fully Active	82	24 (29.3)	58 (70.7)	NE (22.3, NE)	92	25 (27.2)	67 (72.8)	NE (6.5, NE)	1.045 (0.596, 1.833)	0.8603	
1 - Restricted in Physically Strenuous Activity	126	29 (23.0)	97 (77.0)	NE (12.2, NE)	126	20 (15.9)	106 (84.1)	NE (NE, NE)	1.525 (0.863, 2.696)	0.1430	
2 - Ambulatory and Capable of All Selfcare	44	11 (25.0)	33 (75.0)	NE (6.3, NE)	34	6 (17.6)	28 (82.4)	NE (5.7, NE)	1.321 (0.482, 3.620)	0.5856	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2284
≥3 to ≤25%	88	26 (29.5)	62 (70.5)	NE (3.7, NE)	92	19 (20.7)	73 (79.3)	NE (NE, NE)	1.700 (0.940, 3.072)	0.0742	
>25% to ≤50%	135	34 (25.2)	101 (74.8)	NE (22.3, NE)	128	25 (19.5)	103 (80.5)	NE (NE, NE)	1.273 (0.759, 2.136)	0.3536	
>50%	28	4 (14.3)	24 (85.7)	NE (25.3, NE)	33	7 (21.2)	26 (78.8)	NE (6.4, NE)	0.480 (0.137, 1.677)	0.2447	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1052
Yes	130	32 (24.6)	98 (75.4)	NE (25.3, NE)	131	32 (24.4)	99 (75.6)	NE (7.5, NE)	0.976 (0.597, 1.596)	0.9272	
No	112	29 (25.9)	83 (74.1)	NE (4.2, NE)	111	15 (13.5)	96 (86.5)	NE (NE, NE)	1.909 (1.024, 3.562)	0.0358	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1929
≤60	157	47 (29.9)	110 (70.1)	NE (14.3, NE)	154	29 (18.8)	125 (81.2)	NE (NE, NE)	1.517 (0.955, 2.412)	0.0708	
>60	95	17 (17.9)	78 (82.1)	NE (NE, NE)	99	22 (22.2)	77 (77.8)	NE (5.7, NE)	0.917 (0.487, 1.727)	0.7887	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0465
<60	152	53 (34.9)	99 (65.1)	25.0 (4.6, NE)	151	59 (39.1)	92 (60.9)	4.8 (2.6, 9.8)	0.743 (0.511, 1.079)	0.1146	
≥60 - <65	36	11 (30.6)	25 (69.4)	18.4 (4.4, NE)	43	17 (39.5)	26 (60.5)	5.7 (2.0, NE)	0.765 (0.357, 1.640)	0.4836	
≥65	64	25 (39.1)	39 (60.9)	2.7 (1.1, 20.1)	59	18 (30.5)	41 (69.5)	NE (3.0, NE)	1.730 (0.942, 3.176)	0.0724	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4869
Male	120	39 (32.5)	81 (67.5)	20.1 (3.6, NE)	109	40 (36.7)	69 (63.3)	5.7 (2.9, 17.5)	0.806 (0.517, 1.255)	0.3335	
Female	132	50 (37.9)	82 (62.1)	7.6 (3.4, 31.2)	144	54 (37.5)	90 (62.5)	4.9 (2.9, NE)	1.004 (0.683, 1.476)	0.9962	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3736
White	150	49 (32.7)	101 (67.3)	31.2 (4.6, NE)	151	54 (35.8)	97 (64.2)	8.5 (2.9, NE)	0.824 (0.559, 1.217)	0.3153	
Non-white	102	40 (39.2)	62 (60.8)	6.3 (2.6, 20.1)	102	40 (39.2)	62 (60.8)	4.7 (2.9, 17.5)	1.055 (0.680, 1.637)	0.8106	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3654
North America	16	3 (18.8)	13 (81.3)	NE (0.7, NE)	16	6 (37.5)	10 (62.5)	NE (1.2, NE)	0.962 (0.240, 3.849)	0.9300	
Europe	150	53 (35.3)	97 (64.7)	18.4 (4.6, NE)	150	59 (39.3)	91 (60.7)	4.9 (2.5, 9.8)	0.787 (0.541, 1.144)	0.1983	
Asia/Other Regions	86	33 (38.4)	53 (61.6)	7.4 (3.0, 20.1)	87	29 (33.3)	58 (66.7)	5.7 (4.2, NE)	1.196 (0.726, 1.971)	0.4783	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.8592
< 40x10^9/L	128	48 (37.5)	80 (62.5)	7.6 (2.4, NE)	125	55 (44.0)	70 (56.0)	4.7 (2.5, 13.6)	0.950 (0.645, 1.399)	0.7889	
≥ 40x10^9/L	124	41 (33.1)	83 (66.9)	18.4 (4.8, NE)	128	39 (30.5)	89 (69.5)	5.7 (3.2, NE)	0.870 (0.559, 1.355)	0.5252	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5688
Daunorubicin	116	41 (35.3)	75 (64.7)	6.6 (3.4, NE)	90	34 (37.8)	56 (62.2)	4.2 (1.4, NE)	0.813 (0.515, 1.285)	0.3752	
Idarubicin	136	48 (35.3)	88 (64.7)	15.5 (4.4, NE)	161	60 (37.3)	101 (62.7)	5.7 (3.6, 13.6)	0.932 (0.637, 1.364)	0.7035	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8605
Favorable	12	3 (25.0)	9 (75.0)	NE (0.7, NE)	16	7 (43.8)	9 (56.3)	13.6 (1.3, NE)	0.643 (0.165, 2.497)	0.5162	
Intermediate	186	67 (36.0)	119 (64.0)	7.6 (4.6, NE)	180	63 (35.0)	117 (65.0)	4.9 (3.6, NE)	0.927 (0.656, 1.309)	0.6560	
Unfavorable	19	7 (36.8)	12 (63.2)	2.4 (0.7, NE)	26	10 (38.5)	16 (61.5)	8.5 (2.6, NE)	1.100 (0.395, 3.061)	0.8550	
Unknown	35	12 (34.3)	23 (65.7)	13.1 (3.0, NE)	30	13 (43.3)	17 (56.7)	2.5 (1.5, NE)	0.784 (0.355, 1.731)	0.5456	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7492
0 - Fully Active	82	32 (39.0)	50 (61.0)	20.1 (2.7, NE)	92	38 (41.3)	54 (58.7)	4.8 (2.0, NE)	0.888 (0.554, 1.425)	0.6190	
1 - Restricted in Physically Strenuous Activity	126	45 (35.7)	81 (64.3)	13.1 (3.4, NE)	126	48 (38.1)	78 (61.9)	5.7 (2.9, 17.5)	0.884 (0.588, 1.330)	0.5488	
2 - Ambulatory and Capable of All Selfcare	44	12 (27.3)	32 (72.7)	NE (2.6, NE)	34	8 (23.5)	26 (76.5)	9.8 (2.9, NE)	1.218 (0.497, 2.983)	0.6751	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4694
≥3 to ≤25%	88	34 (38.6)	54 (61.4)	3.5 (2.2, NE)	92	38 (41.3)	54 (58.7)	4.9 (2.6, NE)	1.005 (0.632, 1.599)	0.9938	
>25% to ≤50%	135	48 (35.6)	87 (64.4)	7.6 (4.4, NE)	128	45 (35.2)	83 (64.8)	5.7 (2.6, NE)	0.967 (0.643, 1.455)	0.8601	
>50%	28	7 (25.0)	21 (75.0)	NE (8.7, NE)	33	11 (33.3)	22 (66.7)	4.9 (1.3, NE)	0.515 (0.197, 1.349)	0.1736	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1558
Yes	130	50 (38.5)	80 (61.5)	13.1 (4.6, NE)	131	58 (44.3)	73 (55.7)	4.9 (2.6, 8.5)	0.762 (0.520, 1.115)	0.1571	
No	112	36 (32.1)	76 (67.9)	8.7 (2.4, NE)	111	31 (27.9)	80 (72.1)	17.5 (3.0, NE)	1.201 (0.743, 1.942)	0.4631	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0871
≤60	157	54 (34.4)	103 (65.6)	25.0 (4.6, NE)	154	59 (38.3)	95 (61.7)	4.8 (2.6, 9.8)	0.751 (0.518, 1.088)	0.1257	
>60	95	35 (36.8)	60 (63.2)	4.8 (2.4, 20.1)	99	35 (35.4)	64 (64.6)	5.7 (3.0, NE)	1.255 (0.785, 2.006)	0.3433	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3786
<60	151	53 (35.1)	98 (64.9)	NE (4.2, NE)	151	55 (36.4)	96 (63.6)	NE (3.0, NE)	0.818 (0.561, 1.193)	0.3205	
≥60 - <65	36	11 (30.6)	25 (69.4)	NE (0.7, NE)	43	14 (32.6)	29 (67.4)	5.7 (2.6, NE)	1.104 (0.499, 2.441)	0.8755	
≥65	64	19 (29.7)	45 (70.3)	18.9 (1.8, NE)	59	17 (28.8)	42 (71.2)	NE (2.2, NE)	1.375 (0.714, 2.647)	0.3608	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7424
Male	119	37 (31.1)	82 (68.9)	NE (7.1, NE)	109	36 (33.0)	73 (67.0)	NE (3.0, NE)	0.906 (0.572, 1.434)	0.6581	
Female	132	46 (34.8)	86 (65.2)	NE (2.0, NE)	144	50 (34.7)	94 (65.3)	NE (3.3, NE)	1.014 (0.679, 1.513)	0.9464	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3036
White	149	56 (37.6)	93 (62.4)	12.9 (1.9, NE)	151	52 (34.4)	99 (65.6)	NE (3.3, NE)	1.093 (0.749, 1.595)	0.6661	
Non-white	102	27 (26.5)	75 (73.5)	NE (7.1, NE)	102	34 (33.3)	68 (66.7)	NE (3.2, NE)	0.788 (0.475, 1.306)	0.3624	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4994
North America	16	2 (12.5)	14 (87.5)	NE (0.7, NE)	16	2 (12.5)	14 (87.5)	NE (2.1, NE)	1.931 (0.271, 13.787)	0.5041	
Europe	149	59 (39.6)	90 (60.4)	7.1 (1.9, NE)	150	55 (36.7)	95 (63.3)	9.7 (2.6, NE)	1.042 (0.722, 1.505)	0.8337	
Asia/Other Regions	86	22 (25.6)	64 (74.4)	NE (7.4, NE)	87	29 (33.3)	58 (66.7)	NE (3.2, NE)	0.727 (0.417, 1.267)	0.2566	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7745
< 40x10^9/L	127	43 (33.9)	84 (66.1)	NE (2.2, NE)	125	45 (36.0)	80 (64.0)	NE (3.3, NE)	1.007 (0.663, 1.529)	0.9791	
≥ 40x10^9/L	124	40 (32.3)	84 (67.7)	NE (4.2, NE)	128	41 (32.0)	87 (68.0)	NE (3.2, NE)	0.922 (0.596, 1.426)	0.7104	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3624
Daunorubicin	116	39 (33.6)	77 (66.4)	7.1 (2.0, NE)	90	28 (31.1)	62 (68.9)	NE (3.0, NE)	1.112 (0.684, 1.808)	0.6654	
Idarubicin	135	44 (32.6)	91 (67.4)	NE (7.4, NE)	161	58 (36.0)	103 (64.0)	9.7 (3.2, NE)	0.838 (0.566, 1.240)	0.3705	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.1624
Favorable	12	5 (41.7)	7 (58.3)	5.1 (0.7, NE)	16	6 (37.5)	10 (62.5)	NE (0.9, NE)	1.696 (0.503, 5.718)	0.3806	
Intermediate	185	63 (34.1)	122 (65.9)	NE (4.2, NE)	180	53 (29.4)	127 (70.6)	NE (4.7, NE)	1.104 (0.766, 1.592)	0.6049	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (1.8, NE)	26	11 (42.3)	15 (57.7)	6.8 (0.7, NE)	0.252 (0.056, 1.141)	0.0527	
Unknown	35	13 (37.1)	22 (62.9)	18.9 (0.8, NE)	30	16 (53.3)	14 (46.7)	3.3 (0.7, NE)	0.723 (0.347, 1.503)	0.3796	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4327
0 - Fully Active	82	35 (42.7)	47 (57.3)	6.6 (1.6, NE)	92	34 (37.0)	58 (63.0)	9.7 (3.2, NE)	1.180 (0.735, 1.892)	0.4973	
1 - Restricted in Physically Strenuous Activity	126	37 (29.4)	89 (70.6)	NE (5.1, NE)	126	40 (31.7)	86 (68.3)	NE (4.7, NE)	0.910 (0.582, 1.423)	0.6639	
2 - Ambulatory and Capable of All Selfcare	43	11 (25.6)	32 (74.4)	NE (1.3, NE)	34	12 (35.3)	22 (64.7)	NE (0.7, NE)	0.706 (0.311, 1.600)	0.4090	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9842
≥3 to ≤25%	87	26 (29.9)	61 (70.1)	NE (3.8, NE)	92	31 (33.7)	61 (66.3)	NE (2.2, NE)	0.959 (0.569, 1.615)	0.8559	
>25% to ≤50%	135	48 (35.6)	87 (64.4)	NE (2.0, NE)	128	47 (36.7)	81 (63.3)	6.8 (2.6, NE)	0.921 (0.616, 1.377)	0.6981	
>50%	28	8 (28.6)	20 (71.4)	NE (1.3, NE)	33	8 (24.2)	25 (75.8)	NE (NE, NE)	1.047 (0.393, 2.791)	0.8924	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7570
Yes	130	43 (33.1)	87 (66.9)	NE (6.6, NE)	131	50 (38.2)	81 (61.8)	NE (3.6, NE)	0.903 (0.601, 1.359)	0.6098	
No	111	35 (31.5)	76 (68.5)	12.9 (3.5, NE)	111	31 (27.9)	80 (72.1)	NE (2.6, NE)	0.993 (0.612, 1.611)	0.9840	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3118
≤60	156	55 (35.3)	101 (64.7)	NE (4.2, NE)	154	55 (35.7)	99 (64.3)	NE (3.0, NE)	0.848 (0.583, 1.233)	0.4128	
>60	95	28 (29.5)	67 (70.5)	NE (1.9, NE)	99	31 (31.3)	68 (68.7)	NE (3.6, NE)	1.194 (0.716, 1.992)	0.5400	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9289
<60	151	51 (33.8)	100 (66.2)	31.3 (5.1, NE)	151	41 (27.2)	110 (72.8)	NE (28.2, NE)	1.166 (0.772, 1.759)	0.4571	
≥60 - <65	36	13 (36.1)	23 (63.9)	15.8 (2.2, NE)	42	15 (35.7)	27 (64.3)	4.5 (2.9, NE)	0.940 (0.445, 1.983)	0.8668	
≥65	64	21 (32.8)	43 (67.2)	10.1 (1.6, NE)	59	22 (37.3)	37 (62.7)	6.7 (1.3, NE)	1.073 (0.590, 1.954)	0.8523	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1488
Male	119	38 (31.9)	81 (68.1)	18.9 (6.2, NE)	108	36 (33.3)	72 (66.7)	NE (1.6, NE)	0.851 (0.539, 1.343)	0.4916	
Female	132	47 (35.6)	85 (64.4)	15.8 (2.3, NE)	144	42 (29.2)	102 (70.8)	NE (6.7, NE)	1.329 (0.876, 2.015)	0.1852	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1048
White	149	54 (36.2)	95 (63.8)	14.3 (4.8, NE)	151	40 (26.5)	111 (73.5)	NE (NE, NE)	1.349 (0.895, 2.034)	0.1527	
Non-white	102	31 (30.4)	71 (69.6)	22.3 (3.5, NE)	101	38 (37.6)	63 (62.4)	5.3 (1.6, NE)	0.807 (0.502, 1.298)	0.3792	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5972
North America	16	4 (25.0)	12 (75.0)	NE (0.7, NE)	16	5 (31.3)	11 (68.8)	28.2 (2.9, NE)	1.389 (0.366, 5.273)	0.6453	
Europe	149	54 (36.2)	95 (63.8)	14.3 (4.3, NE)	149	42 (28.2)	107 (71.8)	NE (7.1, NE)	1.208 (0.806, 1.810)	0.3595	
Asia/Other Regions	86	27 (31.4)	59 (68.6)	22.3 (3.5, NE)	87	31 (35.6)	56 (64.4)	5.3 (1.6, NE)	0.866 (0.516, 1.453)	0.5825	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0982
< 40x10^9/L	128	48 (37.5)	80 (62.5)	7.6 (2.0, NE)	125	41 (32.8)	84 (67.2)	NE (5.3, NE)	1.407 (0.927, 2.136)	0.1057	
≥ 40x10^9/L	123	37 (30.1)	86 (69.9)	31.3 (15.8, NE)	127	37 (29.1)	90 (70.9)	NE (2.9, NE)	0.846 (0.535, 1.337)	0.4689	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.0559
Daunorubicin	116	33 (28.4)	83 (71.6)	NE (5.1, NE)	90	32 (35.6)	58 (64.4)	7.1 (4.1, NE)	0.743 (0.456, 1.211)	0.2284	
Idarubicin	135	52 (38.5)	83 (61.5)	8.5 (3.0, NE)	160	45 (28.1)	115 (71.9)	NE (NE, NE)	1.398 (0.938, 2.083)	0.0993	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7876
Favorable	12	3 (25.0)	9 (75.0)	NE (0.7, NE)	16	5 (31.3)	11 (68.8)	NE (4.4, NE)	1.251 (0.293, 5.334)	0.7635	
Intermediate	185	62 (33.5)	123 (66.5)	22.3 (5.1, NE)	179	55 (30.7)	124 (69.3)	NE (4.1, NE)	0.986 (0.686, 1.419)	0.9274	
Unfavorable	19	5 (26.3)	14 (73.7)	NE (0.7, NE)	26	7 (26.9)	19 (73.1)	NE (0.7, NE)	1.180 (0.374, 3.720)	0.7651	
Unknown	35	15 (42.9)	20 (57.1)	6.2 (1.6, NE)	30	10 (33.3)	20 (66.7)	NE (3.1, NE)	1.434 (0.641, 3.208)	0.3863	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7630
0 - Fully Active	82	30 (36.6)	52 (63.4)	22.3 (2.2, NE)	92	31 (33.7)	61 (66.3)	28.2 (4.1, NE)	1.039 (0.629, 1.717)	0.8787	
1 - Restricted in Physically Strenuous Activity	126	42 (33.3)	84 (66.7)	14.3 (4.8, NE)	125	39 (31.2)	86 (68.8)	NE (3.6, NE)	1.047 (0.677, 1.619)	0.8478	
2 - Ambulatory and Capable of All Selfcare	43	13 (30.2)	30 (69.8)	NE (1.0, NE)	34	8 (23.5)	26 (76.5)	NE (2.9, NE)	1.492 (0.617, 3.604)	0.3687	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4027
≥3 to ≤25%	88	30 (34.1)	58 (65.9)	10.1 (4.3, NE)	92	26 (28.3)	66 (71.7)	NE (6.7, NE)	1.358 (0.803, 2.297)	0.2468	
>25% to ≤50%	135	47 (34.8)	88 (65.2)	22.3 (4.1, NE)	127	41 (32.3)	86 (67.7)	NE (2.9, NE)	1.057 (0.695, 1.608)	0.8143	
>50%	27	8 (29.6)	19 (70.4)	NE (2.7, NE)	33	11 (33.3)	22 (66.7)	NE (0.7, NE)	0.714 (0.287, 1.780)	0.4736	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0615
Yes	129	43 (33.3)	86 (66.7)	NE (8.3, NE)	130	47 (36.2)	83 (63.8)	28.2 (3.6, NE)	0.902 (0.596, 1.366)	0.6107	
No	112	41 (36.6)	71 (63.4)	5.1 (2.1, 31.3)	111	26 (23.4)	85 (76.6)	NE (6.7, NE)	1.649 (1.008, 2.697)	0.0434	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7982
≤60	156	52 (33.3)	104 (66.7)	31.3 (5.1, NE)	154	42 (27.3)	112 (72.7)	NE (28.2, NE)	1.151 (0.766, 1.729)	0.4908	
>60	95	33 (34.7)	62 (65.3)	8.3 (2.2, NE)	98	36 (36.7)	62 (63.3)	4.5 (2.6, NE)	1.047 (0.652, 1.680)	0.8684	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8283
<60	152	58 (38.2)	94 (61.8)	8.3 (5.5, 30.3)	151	55 (36.4)	96 (63.6)	5.3 (3.0, NE)	0.871 (0.602, 1.262)	0.4615	
≥60 - <65	36	12 (33.3)	24 (66.7)	15.8 (1.8, NE)	43	16 (37.2)	27 (62.8)	4.5 (2.6, NE)	0.838 (0.394, 1.781)	0.6417	
≥65	63	21 (33.3)	42 (66.7)	2.7 (1.8, NE)	59	21 (35.6)	38 (64.4)	NE (1.7, NE)	1.037 (0.566, 1.900)	0.9045	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9082
Male	119	41 (34.5)	78 (65.5)	10.5 (5.8, 30.3)	109	35 (32.1)	74 (67.9)	7.5 (3.6, NE)	0.945 (0.601, 1.485)	0.8098	
Female	132	50 (37.9)	82 (62.1)	8.3 (2.4, NE)	144	57 (39.6)	87 (60.4)	4.4 (2.3, NE)	0.939 (0.642, 1.374)	0.7332	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1211
White	149	51 (34.2)	98 (65.8)	15.1 (6.0, NE)	151	55 (36.4)	96 (63.6)	4.9 (2.1, NE)	0.763 (0.520, 1.120)	0.1630	
Non-white	102	40 (39.2)	62 (60.8)	5.5 (2.3, NE)	102	37 (36.3)	65 (63.7)	6.9 (3.6, NE)	1.207 (0.772, 1.888)	0.4150	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.1144
North America	16	8 (50.0)	8 (50.0)	1.6 (0.7, NE)	16	5 (31.3)	11 (68.8)	4.5 (2.1, NE)	2.286 (0.720, 7.261)	0.1532	
Europe	149	47 (31.5)	102 (68.5)	15.8 (7.3, NE)	150	53 (35.3)	97 (64.7)	4.9 (2.9, NE)	0.742 (0.500, 1.100)	0.1327	
Asia/Other Regions	86	36 (41.9)	50 (58.1)	5.5 (1.6, NE)	87	34 (39.1)	53 (60.9)	5.3 (2.1, NE)	1.115 (0.697, 1.783)	0.6535	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5647
< 40x10^9/L	128	47 (36.7)	81 (63.3)	8.3 (3.8, NE)	125	49 (39.2)	76 (60.8)	5.3 (2.5, NE)	1.008 (0.675, 1.504)	0.9825	
≥ 40x10^9/L	123	44 (35.8)	79 (64.2)	14.1 (5.1, NE)	128	43 (33.6)	85 (66.4)	4.9 (3.0, NE)	0.836 (0.548, 1.276)	0.4060	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3807
Daunorubicin	116	34 (29.3)	82 (70.7)	NE (5.1, NE)	90	28 (31.1)	62 (68.9)	5.3 (4.1, NE)	0.784 (0.474, 1.296)	0.3401	
Idarubicin	135	57 (42.2)	78 (57.8)	7.3 (3.1, 15.8)	161	63 (39.1)	98 (60.9)	4.9 (2.1, NE)	1.067 (0.745, 1.527)	0.7327	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3406
Favorable	12	2 (16.7)	10 (83.3)	NE (0.7, NE)	16	10 (62.5)	6 (37.5)	4.7 (1.1, NE)	0.310 (0.068, 1.424)	0.1116	
Intermediate	186	72 (38.7)	114 (61.3)	7.3 (4.1, 17.0)	180	59 (32.8)	121 (67.2)	7.5 (4.1, NE)	1.030 (0.730, 1.454)	0.8584	
Unfavorable	19	5 (26.3)	14 (73.7)	NE (0.7, NE)	26	8 (30.8)	18 (69.2)	NE (1.7, NE)	1.214 (0.397, 3.713)	0.7466	
Unknown	34	12 (35.3)	22 (64.7)	10.5 (2.0, NE)	30	15 (50.0)	15 (50.0)	2.9 (1.5, NE)	0.686 (0.319, 1.473)	0.3298	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2518
0 - Fully Active	82	32 (39.0)	50 (61.0)	14.1 (3.3, 30.3)	92	33 (35.9)	59 (64.1)	4.9 (3.2, NE)	1.042 (0.640, 1.696)	0.8672	
1 - Restricted in Physically Strenuous Activity	125	45 (36.0)	80 (64.0)	8.3 (3.9, NE)	126	53 (42.1)	73 (57.9)	2.6 (1.7, NE)	0.767 (0.515, 1.143)	0.1902	
2 - Ambulatory and Capable of All Selfcare	44	14 (31.8)	30 (68.2)	7.3 (2.7, NE)	34	6 (17.6)	28 (82.4)	NE (3.6, NE)	1.635 (0.624, 4.285)	0.3135	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5959
≥3 to ≤25%	87	26 (29.9)	61 (70.1)	14.1 (5.8, NE)	92	34 (37.0)	58 (63.0)	6.9 (3.6, NE)	0.816 (0.489, 1.361)	0.4362	
>25% to ≤50%	135	52 (38.5)	83 (61.5)	6.0 (2.7, 30.3)	128	49 (38.3)	79 (61.7)	4.4 (2.0, NE)	0.898 (0.607, 1.329)	0.5857	
>50%	28	12 (42.9)	16 (57.1)	7.5 (1.6, NE)	33	9 (27.3)	24 (72.7)	NE (1.8, NE)	1.429 (0.597, 3.420)	0.4214	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1501
Yes	129	47 (36.4)	82 (63.6)	15.8 (6.3, NE)	131	54 (41.2)	77 (58.8)	4.9 (2.9, NE)	0.769 (0.519, 1.140)	0.1883	
No	112	41 (36.6)	71 (63.4)	5.5 (2.4, 15.1)	111	33 (29.7)	78 (70.3)	6.9 (2.5, NE)	1.187 (0.750, 1.878)	0.4696	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5619
≤60	157	58 (36.9)	99 (63.1)	10.5 (5.5, 30.3)	154	55 (35.7)	99 (64.3)	5.3 (3.0, NE)	0.853 (0.589, 1.236)	0.3969	
>60	94	33 (35.1)	61 (64.9)	12.1 (1.9, NE)	99	37 (37.4)	62 (62.6)	4.5 (2.6, NE)	1.053 (0.658, 1.685)	0.8311	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1846
<60	152	65 (42.8)	87 (57.2)	7.1 (3.4, 16.1)	151	50 (33.1)	101 (66.9)	10.6 (5.3, NE)	1.302 (0.900, 1.884)	0.1667	
≥60 - <65	36	8 (22.2)	28 (77.8)	NE (4.8, NE)	43	15 (34.9)	28 (65.1)	12.6 (2.5, NE)	0.577 (0.243, 1.366)	0.2020	
≥65	64	23 (35.9)	41 (64.1)	4.8 (1.1, NE)	59	19 (32.2)	40 (67.8)	15.2 (2.9, NE)	1.444 (0.785, 2.656)	0.2359	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1168
Male	120	42 (35.0)	78 (65.0)	14.3 (5.7, NE)	109	37 (33.9)	72 (66.1)	6.8 (3.2, NE)	0.902 (0.578, 1.408)	0.6421	
Female	132	54 (40.9)	78 (59.1)	4.8 (2.3, 26.4)	144	47 (32.6)	97 (67.4)	12.6 (5.3, NE)	1.497 (1.012, 2.214)	0.0431	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5826
White	150	53 (35.3)	97 (64.7)	14.3 (4.8, NE)	151	47 (31.1)	104 (68.9)	10.6 (5.3, NE)	1.126 (0.759, 1.670)	0.5767	
Non-white	102	43 (42.2)	59 (57.8)	6.3 (2.1, 11.9)	102	37 (36.3)	65 (63.7)	12.6 (2.8, NE)	1.340 (0.860, 2.089)	0.1936	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6455
North America	16	2 (12.5)	14 (87.5)	NE (2.1, NE)	16	5 (31.3)	11 (68.8)	12.6 (3.2, NE)	0.643 (0.124, 3.324)	0.5953	
Europe	150	54 (36.0)	96 (64.0)	10.2 (4.8, NE)	150	45 (30.0)	105 (70.0)	13.8 (6.2, NE)	1.186 (0.798, 1.764)	0.4142	
Asia/Other Regions	86	40 (46.5)	46 (53.5)	3.6 (1.6, 11.9)	87	34 (39.1)	53 (60.9)	5.3 (2.4, 38.0)	1.305 (0.825, 2.067)	0.2526	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9001
< 40x10^9/L	128	50 (39.1)	78 (60.9)	7.1 (2.4, 14.3)	125	51 (40.8)	74 (59.2)	6.8 (4.0, 13.8)	1.208 (0.817, 1.785)	0.3511	
≥ 40x10^9/L	124	46 (37.1)	78 (62.9)	10.2 (4.8, 31.3)	128	33 (25.8)	95 (74.2)	38.0 (6.4, NE)	1.304 (0.829, 2.051)	0.2533	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5483
Daunorubicin	116	47 (40.5)	69 (59.5)	5.7 (3.2, 14.3)	90	30 (33.3)	60 (66.7)	12.6 (5.3, NE)	1.289 (0.815, 2.040)	0.2763	
Idarubicin	136	49 (36.0)	87 (64.0)	11.9 (3.5, NE)	161	54 (33.5)	107 (66.5)	11.5 (3.7, NE)	1.099 (0.746, 1.619)	0.6557	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5003
Favorable	12	4 (33.3)	8 (66.7)	NE (0.7, NE)	16	5 (31.3)	11 (68.8)	21.6 (5.3, NE)	1.604 (0.426, 6.043)	0.4815	
Intermediate	186	69 (37.1)	117 (62.9)	9.6 (4.8, 22.3)	180	59 (32.8)	121 (67.2)	12.6 (3.7, 38.0)	1.031 (0.728, 1.461)	0.8653	
Unfavorable	19	7 (36.8)	12 (63.2)	1.8 (0.7, NE)	26	10 (38.5)	16 (61.5)	6.8 (1.9, NE)	1.591 (0.599, 4.223)	0.3449	
Unknown	35	16 (45.7)	19 (54.3)	3.4 (0.7, NE)	30	10 (33.3)	20 (66.7)	6.4 (2.5, NE)	1.893 (0.858, 4.179)	0.1252	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5993
0 - Fully Active	82	36 (43.9)	46 (56.1)	6.3 (2.6, 22.3)	92	32 (34.8)	60 (65.2)	11.5 (5.3, NE)	1.345 (0.835, 2.167)	0.2223	
1 - Restricted in Physically Strenuous Activity	126	47 (37.3)	79 (62.7)	10.2 (2.9, 31.3)	126	46 (36.5)	80 (63.5)	6.2 (3.5, 15.2)	1.084 (0.721, 1.629)	0.7204	
2 - Ambulatory and Capable of All Selfcare	44	13 (29.5)	31 (70.5)	8.9 (6.3, NE)	34	6 (17.6)	28 (82.4)	38.0 (3.2, NE)	1.883 (0.668, 5.305)	0.2266	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1489
≥3 to ≤25%	88	36 (40.9)	52 (59.1)	6.3 (2.4, 16.1)	92	29 (31.5)	63 (68.5)	12.6 (5.3, NE)	1.749 (1.071, 2.853)	0.0250	
>25% to ≤50%	135	51 (37.8)	84 (62.2)	10.2 (3.4, 31.3)	128	44 (34.4)	84 (65.6)	6.8 (2.5, NE)	1.034 (0.690, 1.550)	0.8778	
>50%	28	9 (32.1)	19 (67.9)	NE (2.9, NE)	33	11 (33.3)	22 (66.7)	6.4 (2.7, NE)	0.862 (0.348, 2.132)	0.7501	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3402
Yes	130	50 (38.5)	80 (61.5)	10.2 (3.4, NE)	131	49 (37.4)	82 (62.6)	12.6 (4.0, NE)	1.059 (0.713, 1.573)	0.7787	
No	112	42 (37.5)	70 (62.5)	7.1 (3.4, 16.1)	111	31 (27.9)	80 (72.1)	10.6 (4.8, NE)	1.390 (0.873, 2.213)	0.1681	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4269
≤60	157	66 (42.0)	91 (58.0)	7.1 (3.4, 16.1)	154	50 (32.5)	104 (67.5)	10.6 (5.3, NE)	1.312 (0.908, 1.896)	0.1545	
>60	95	30 (31.6)	65 (68.4)	10.2 (3.2, NE)	99	34 (34.3)	65 (65.7)	12.6 (3.7, NE)	1.030 (0.630, 1.685)	0.9082	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6803
<60	152	49 (32.2)	103 (67.8)	14.3 (8.0, NE)	151	33 (21.9)	118 (78.1)	NE (19.3, NE)	1.386 (0.891, 2.156)	0.1425	
≥60 - <65	36	10 (27.8)	26 (72.2)	NE (4.8, NE)	43	11 (25.6)	32 (74.4)	12.6 (6.1, NE)	0.952 (0.402, 2.250)	0.9079	
≥65	64	12 (18.8)	52 (81.3)	NE (4.9, NE)	59	14 (23.7)	45 (76.3)	NE (6.7, NE)	1.001 (0.463, 2.167)	0.9981	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2595
Male	120	37 (30.8)	83 (69.2)	11.0 (7.4, 33.5)	109	31 (28.4)	78 (71.6)	11.9 (5.6, NE)	0.981 (0.608, 1.583)	0.9463	
Female	132	34 (25.8)	98 (74.2)	NE (13.2, NE)	144	27 (18.8)	117 (81.3)	NE (19.3, NE)	1.474 (0.889, 2.443)	0.1296	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7829
White	150	39 (26.0)	111 (74.0)	33.5 (10.4, NE)	151	30 (19.9)	121 (80.1)	NE (11.9, NE)	1.182 (0.733, 1.904)	0.4919	
Non-white	102	32 (31.4)	70 (68.6)	11.0 (4.3, NE)	102	28 (27.5)	74 (72.5)	NE (6.3, NE)	1.304 (0.785, 2.167)	0.2985	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7826
North America	16	3 (18.8)	13 (81.3)	30.3 (0.8, NE)	16	5 (31.3)	11 (68.8)	12.6 (2.9, NE)	0.853 (0.201, 3.614)	0.8285	
Europe	150	39 (26.0)	111 (74.0)	NE (10.4, NE)	150	31 (20.7)	119 (79.3)	NE (11.9, NE)	1.167 (0.728, 1.872)	0.5169	
Asia/Other Regions	86	29 (33.7)	57 (66.3)	11.0 (4.8, NE)	87	22 (25.3)	65 (74.7)	NE (6.8, NE)	1.415 (0.812, 2.466)	0.2127	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.8470
< 40x10^9/L	128	34 (26.6)	94 (73.4)	33.5 (8.7, NE)	125	33 (26.4)	92 (73.6)	NE (9.9, NE)	1.187 (0.735, 1.917)	0.4764	
≥ 40x10^9/L	124	37 (29.8)	87 (70.2)	18.3 (8.0, NE)	128	25 (19.5)	103 (80.5)	NE (9.1, NE)	1.266 (0.761, 2.108)	0.3594	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4258
Daunorubicin	116	29 (25.0)	87 (75.0)	33.5 (13.6, NE)	90	20 (22.2)	70 (77.8)	NE (9.9, NE)	1.038 (0.587, 1.838)	0.8891	
Idarubicin	136	42 (30.9)	94 (69.1)	13.2 (7.4, NE)	161	37 (23.0)	124 (77.0)	NE (9.1, NE)	1.396 (0.897, 2.173)	0.1362	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7212
Favorable	12	3 (25.0)	9 (75.0)	8.0 (2.5, NE)	16	2 (12.5)	14 (87.5)	NE (6.1, NE)	3.741 (0.615, 22.752)	0.1251	
Intermediate	186	54 (29.0)	132 (71.0)	30.3 (8.7, NE)	180	43 (23.9)	137 (76.1)	NE (7.6, NE)	1.117 (0.748, 1.668)	0.5842	
Unfavorable	19	6 (31.6)	13 (68.4)	18.3 (0.8, NE)	26	8 (30.8)	18 (69.2)	NE (3.7, NE)	1.084 (0.373, 3.146)	0.8645	
Unknown	35	8 (22.9)	27 (77.1)	NE (4.3, NE)	30	5 (16.7)	25 (83.3)	NE (4.9, NE)	1.549 (0.505, 4.754)	0.4405	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1573
0 - Fully Active	82	26 (31.7)	56 (68.3)	18.3 (8.0, NE)	92	20 (21.7)	72 (78.3)	NE (NE, NE)	1.489 (0.831, 2.669)	0.1770	
1 - Restricted in Physically Strenuous Activity	126	32 (25.4)	94 (74.6)	33.5 (13.2, NE)	126	34 (27.0)	92 (73.0)	19.3 (6.3, NE)	0.915 (0.565, 1.484)	0.7352	
2 - Ambulatory and Capable of All Selfcare	44	13 (29.5)	31 (70.5)	8.0 (3.2, NE)	34	4 (11.8)	30 (88.2)	12.9 (6.9, NE)	2.438 (0.790, 7.525)	0.1110	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4860
≥3 to ≤25%	88	27 (30.7)	61 (69.3)	11.0 (4.8, NE)	92	22 (23.9)	70 (76.1)	NE (11.9, NE)	1.628 (0.926, 2.861)	0.0892	
>25% to ≤50%	135	35 (25.9)	100 (74.1)	33.5 (8.7, NE)	128	28 (21.9)	100 (78.1)	NE (7.6, NE)	1.037 (0.629, 1.708)	0.8797	
>50%	28	9 (32.1)	19 (67.9)	8.8 (3.9, NE)	33	8 (24.2)	25 (75.8)	NE (2.9, NE)	1.047 (0.402, 2.726)	0.9181	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4024
Yes	130	41 (31.5)	89 (68.5)	30.3 (7.4, NE)	131	31 (23.7)	100 (76.3)	NE (12.6, NE)	1.383 (0.867, 2.206)	0.1707	
No	112	26 (23.2)	86 (76.8)	14.3 (8.7, NE)	111	23 (20.7)	88 (79.3)	NE (6.3, NE)	1.005 (0.573, 1.762)	0.9793	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3429
≤60	157	50 (31.8)	107 (68.2)	14.3 (8.0, NE)	154	33 (21.4)	121 (78.6)	NE (19.3, NE)	1.397 (0.900, 2.170)	0.1310	
>60	95	21 (22.1)	74 (77.9)	NE (6.7, NE)	99	25 (25.3)	74 (74.7)	12.9 (6.7, NE)	0.968 (0.542, 1.730)	0.9134	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1466
<60	152	49 (32.2)	103 (67.8)	NE (8.8, NE)	151	53 (35.1)	98 (64.9)	12.3 (4.6, NE)	0.833 (0.564, 1.230)	0.3515	
≥60 - <65	36	11 (30.6)	25 (69.4)	18.6 (3.4, NE)	43	12 (27.9)	31 (72.1)	12.6 (4.1, NE)	1.014 (0.447, 2.301)	0.9677	
≥65	64	19 (29.7)	45 (70.3)	NE (1.3, NE)	59	13 (22.0)	46 (78.0)	NE (12.1, NE)	1.809 (0.892, 3.669)	0.0956	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3329
Male	120	38 (31.7)	82 (68.3)	NE (4.3, NE)	109	38 (34.9)	71 (65.1)	12.3 (3.1, NE)	0.878 (0.560, 1.377)	0.5725	
Female	132	41 (31.1)	91 (68.9)	NE (5.7, NE)	144	40 (27.8)	104 (72.2)	25.8 (9.9, NE)	1.170 (0.756, 1.809)	0.4958	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4926
White	150	44 (29.3)	106 (70.7)	NE (10.4, NE)	151	46 (30.5)	105 (69.5)	15.0 (6.8, NE)	0.938 (0.620, 1.420)	0.7384	
Non-white	102	35 (34.3)	67 (65.7)	8.8 (2.6, NE)	102	32 (31.4)	70 (68.6)	28.2 (4.7, NE)	1.170 (0.724, 1.891)	0.5087	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3300
North America	16	4 (25.0)	12 (75.0)	2.4 (0.7, NE)	16	3 (18.8)	13 (81.3)	28.2 (2.3, NE)	2.760 (0.606, 12.577)	0.1723	
Europe	150	45 (30.0)	105 (70.0)	NE (10.4, NE)	150	49 (32.7)	101 (67.3)	15.0 (4.6, NE)	0.877 (0.584, 1.315)	0.5074	
Asia/Other Regions	86	30 (34.9)	56 (65.1)	8.8 (2.6, NE)	87	26 (29.9)	61 (70.1)	NE (4.7, NE)	1.185 (0.701, 2.005)	0.5152	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9583
< 40x10^9/L	128	42 (32.8)	86 (67.2)	13.6 (4.3, NE)	125	47 (37.6)	78 (62.4)	12.6 (6.5, NE)	1.027 (0.677, 1.557)	0.9262	
≥ 40x10^9/L	124	37 (29.8)	87 (70.2)	NE (7.4, NE)	128	31 (24.2)	97 (75.8)	NE (5.7, NE)	1.068 (0.661, 1.724)	0.7906	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2673
Daunorubicin	116	32 (27.6)	84 (72.4)	NE (4.3, NE)	90	31 (34.4)	59 (65.6)	12.1 (4.1, NE)	0.824 (0.502, 1.352)	0.4316	
Idarubicin	136	47 (34.6)	89 (65.4)	13.2 (5.7, NE)	161	46 (28.6)	115 (71.4)	NE (12.6, NE)	1.187 (0.790, 1.783)	0.4131	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7254
Favorable	12	3 (25.0)	9 (75.0)	NE (1.5, NE)	16	8 (50.0)	8 (50.0)	9.9 (1.6, NE)	0.640 (0.168, 2.434)	0.5094	
Intermediate	186	61 (32.8)	125 (67.2)	NE (7.4, NE)	180	51 (28.3)	129 (71.7)	28.2 (5.7, NE)	1.114 (0.768, 1.616)	0.5786	
Unfavorable	19	4 (21.1)	15 (78.9)	NE (0.7, NE)	26	9 (34.6)	17 (65.4)	NE (1.1, NE)	0.698 (0.215, 2.268)	0.5552	
Unknown	35	11 (31.4)	24 (68.6)	18.6 (3.4, NE)	30	10 (33.3)	20 (66.7)	NE (1.9, NE)	1.080 (0.458, 2.549)	0.8739	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2399
0 - Fully Active	82	27 (32.9)	55 (67.1)	NE (2.6, NE)	92	36 (39.1)	56 (60.9)	6.5 (4.1, 28.2)	0.846 (0.513, 1.396)	0.5007	
1 - Restricted in Physically Strenuous Activity	126	38 (30.2)	88 (69.8)	18.6 (8.8, NE)	126	37 (29.4)	89 (70.6)	NE (12.3, NE)	1.033 (0.657, 1.625)	0.8836	
2 - Ambulatory and Capable of All Selfcare	44	14 (31.8)	30 (68.2)	10.4 (2.6, NE)	34	5 (14.7)	29 (85.3)	NE (2.5, NE)	2.140 (0.766, 5.976)	0.1442	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3263
≥3 to ≤25%	88	30 (34.1)	58 (65.9)	13.2 (2.5, NE)	92	26 (28.3)	66 (71.7)	28.2 (9.9, NE)	1.397 (0.826, 2.364)	0.2131	
>25% to ≤50%	135	37 (27.4)	98 (72.6)	NE (8.8, NE)	128	39 (30.5)	89 (69.5)	25.8 (4.7, NE)	0.846 (0.539, 1.327)	0.4583	
>50%	28	11 (39.3)	17 (60.7)	18.6 (0.8, NE)	33	13 (39.4)	20 (60.6)	4.6 (1.2, NE)	0.849 (0.376, 1.916)	0.6901	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5416
Yes	130	43 (33.1)	87 (66.9)	NE (7.4, NE)	131	40 (30.5)	91 (69.5)	28.2 (9.9, NE)	1.148 (0.746, 1.767)	0.5433	
No	112	32 (28.6)	80 (71.4)	NE (5.7, NE)	111	32 (28.8)	79 (71.2)	12.6 (4.1, NE)	0.929 (0.569, 1.517)	0.7662	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1121
≤60	157	50 (31.8)	107 (68.2)	NE (8.8, NE)	154	53 (34.4)	101 (65.6)	12.3 (4.6, NE)	0.840 (0.570, 1.238)	0.3690	
>60	95	29 (30.5)	66 (69.5)	18.6 (3.1, NE)	99	25 (25.3)	74 (74.7)	NE (12.1, NE)	1.449 (0.848, 2.475)	0.1740	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3486
<60	152	46 (30.3)	106 (69.7)	NE (11.2, NE)	151	48 (31.8)	103 (68.2)	NE (4.6, NE)	0.815 (0.543, 1.224)	0.3199	
≥60 - <65	36	7 (19.4)	29 (80.6)	NE (18.6, NE)	43	10 (23.3)	33 (76.7)	NE (4.5, NE)	0.775 (0.294, 2.043)	0.6047	
≥65	64	20 (31.3)	44 (68.8)	6.3 (1.6, NE)	59	16 (27.1)	43 (72.9)	NE (3.6, NE)	1.424 (0.738, 2.749)	0.2988	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.0813
Male	120	31 (25.8)	89 (74.2)	NE (8.0, NE)	109	36 (33.0)	73 (67.0)	7.5 (2.9, NE)	0.664 (0.410, 1.076)	0.0928	
Female	132	42 (31.8)	90 (68.2)	NE (5.1, NE)	144	38 (26.4)	106 (73.6)	NE (7.1, NE)	1.239 (0.799, 1.923)	0.3465	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2968
White	150	48 (32.0)	102 (68.0)	NE (8.0, NE)	151	42 (27.8)	109 (72.2)	NE (5.6, NE)	1.087 (0.717, 1.650)	0.7171	
Non-white	102	25 (24.5)	77 (75.5)	NE (7.4, NE)	102	32 (31.4)	70 (68.6)	NE (3.2, NE)	0.756 (0.448, 1.276)	0.2955	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9046
North America	16	4 (25.0)	12 (75.0)	2.8 (1.3, NE)	16	6 (37.5)	10 (62.5)	7.1 (2.3, NE)	1.307 (0.365, 4.675)	0.6796	
Europe	150	44 (29.3)	106 (70.7)	NE (14.3, NE)	150	40 (26.7)	110 (73.3)	NE (5.6, NE)	1.003 (0.652, 1.542)	0.9889	
Asia/Other Regions	86	25 (29.1)	61 (70.9)	NE (5.5, NE)	87	28 (32.2)	59 (67.8)	15.3 (3.2, NE)	0.847 (0.493, 1.454)	0.5465	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3056
< 40x10^9/L	128	41 (32.0)	87 (68.0)	15.1 (3.1, NE)	125	41 (32.8)	84 (67.2)	NE (5.6, NE)	1.118 (0.724, 1.724)	0.6218	
≥ 40x10^9/L	124	32 (25.8)	92 (74.2)	NE (14.1, NE)	128	33 (25.8)	95 (74.2)	NE (4.6, NE)	0.788 (0.482, 1.286)	0.3320	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1445
Daunorubicin	116	28 (24.1)	88 (75.9)	NE (8.0, NE)	90	27 (30.0)	63 (70.0)	6.7 (3.0, NE)	0.669 (0.392, 1.141)	0.1377	
Idarubicin	136	45 (33.1)	91 (66.9)	18.6 (7.4, NE)	161	45 (28.0)	116 (72.0)	NE (15.3, NE)	1.182 (0.781, 1.787)	0.4343	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5824
Favorable	12	3 (25.0)	9 (75.0)	NE (0.7, NE)	16	10 (62.5)	6 (37.5)	3.0 (1.3, NE)	0.513 (0.141, 1.869)	0.3031	
Intermediate	186	56 (30.1)	130 (69.9)	NE (7.6, NE)	180	45 (25.0)	135 (75.0)	NE (7.5, NE)	1.086 (0.733, 1.610)	0.6842	
Unfavorable	19	3 (15.8)	16 (84.2)	NE (7.1, NE)	26	7 (26.9)	19 (73.1)	NE (1.7, NE)	0.558 (0.140, 2.235)	0.4012	
Unknown	35	11 (31.4)	24 (68.6)	18.6 (2.6, NE)	30	12 (40.0)	18 (60.0)	6.7 (1.7, NE)	0.838 (0.368, 1.905)	0.6645	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5081
0 - Fully Active	82	26 (31.7)	56 (68.3)	NE (7.1, NE)	92	24 (26.1)	68 (73.9)	NE (5.6, NE)	1.172 (0.671, 2.048)	0.5844	
1 - Restricted in Physically Strenuous Activity	126	37 (29.4)	89 (70.6)	NE (6.9, NE)	126	43 (34.1)	83 (65.9)	15.3 (2.9, NE)	0.804 (0.518, 1.249)	0.3262	
2 - Ambulatory and Capable of All Selfcare	44	10 (22.7)	34 (77.3)	NE (5.5, NE)	34	7 (20.6)	27 (79.4)	NE (2.3, NE)	1.024 (0.386, 2.720)	0.9605	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7673
≥3 to ≤25%	88	26 (29.5)	62 (70.5)	NE (6.3, NE)	92	29 (31.5)	63 (68.5)	NE (3.2, NE)	0.991 (0.583, 1.686)	0.9627	
>25% to ≤50%	135	39 (28.9)	96 (71.1)	NE (7.6, NE)	128	35 (27.3)	93 (72.7)	NE (6.7, NE)	0.956 (0.605, 1.511)	0.8427	
>50%	28	7 (25.0)	21 (75.0)	NE (18.6, NE)	33	10 (30.3)	23 (69.7)	NE (2.3, NE)	0.688 (0.261, 1.812)	0.4450	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5425
Yes	130	36 (27.7)	94 (72.3)	NE (18.6, NE)	131	39 (29.8)	92 (70.2)	NE (NE, NE)	0.926 (0.588, 1.458)	0.7240	
No	112	35 (31.3)	77 (68.8)	11.2 (5.1, NE)	111	28 (25.2)	83 (74.8)	15.3 (3.0, NE)	1.089 (0.662, 1.793)	0.7418	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2313
≤60	157	46 (29.3)	111 (70.7)	NE (11.2, NE)	154	48 (31.2)	106 (68.8)	NE (4.6, NE)	0.800 (0.533, 1.201)	0.2773	
>60	95	27 (28.4)	68 (71.6)	NE (2.8, NE)	99	26 (26.3)	73 (73.7)	NE (7.1, NE)	1.224 (0.714, 2.098)	0.4717	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0839
<60	152	41 (27.0)	111 (73.0)	NE (13.6, NE)	151	49 (32.5)	102 (67.5)	15.0 (5.7, NE)	0.736 (0.486, 1.115)	0.1462	
≥60 - <65	36	10 (27.8)	26 (72.2)	NE (2.6, NE)	43	16 (37.2)	27 (62.8)	4.4 (1.9, NE)	0.602 (0.270, 1.342)	0.2075	
≥65	64	20 (31.3)	44 (68.8)	4.6 (2.5, NE)	59	14 (23.7)	45 (76.3)	NE (3.6, NE)	1.666 (0.841, 3.300)	0.1383	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2091
Male	120	36 (30.0)	84 (70.0)	30.8 (5.5, NE)	109	28 (25.7)	81 (74.3)	NE (3.1, NE)	1.070 (0.652, 1.757)	0.7910	
Female	132	35 (26.5)	97 (73.5)	NE (10.4, NE)	144	51 (35.4)	93 (64.6)	15.0 (4.1, NE)	0.720 (0.468, 1.108)	0.1346	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3617
White	150	41 (27.3)	109 (72.7)	NE (6.4, NE)	151	39 (25.8)	112 (74.2)	NE (14.9, NE)	0.996 (0.642, 1.544)	0.9895	
Non-white	102	30 (29.4)	72 (70.6)	30.8 (3.4, NE)	102	40 (39.2)	62 (60.8)	3.1 (2.3, 19.3)	0.720 (0.448, 1.157)	0.1719	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9640
North America	16	4 (25.0)	12 (75.0)	3.0 (0.7, NE)	16	7 (43.8)	9 (56.3)	2.9 (0.8, NE)	0.919 (0.268, 3.150)	0.8870	
Europe	150	40 (26.7)	110 (73.3)	NE (10.8, NE)	150	40 (26.7)	110 (73.3)	NE (9.9, NE)	0.907 (0.585, 1.407)	0.6649	
Asia/Other Regions	86	27 (31.4)	59 (68.6)	13.6 (3.4, NE)	87	32 (36.8)	55 (63.2)	4.4 (2.3, NE)	0.805 (0.482, 1.345)	0.4046	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.8264
< 40x10^9/L	128	34 (26.6)	94 (73.4)	NE (5.8, NE)	125	44 (35.2)	81 (64.8)	15.0 (3.1, NE)	0.833 (0.532, 1.303)	0.4218	
≥ 40x10^9/L	124	37 (29.8)	87 (70.2)	30.8 (5.5, NE)	128	35 (27.3)	93 (72.7)	19.3 (4.1, NE)	0.865 (0.544, 1.376)	0.5380	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7556
Daunorubicin	116	34 (29.3)	82 (70.7)	12.1 (5.4, NE)	90	27 (30.0)	63 (70.0)	15.0 (4.1, NE)	0.925 (0.557, 1.535)	0.7610	
Idarubicin	136	37 (27.2)	99 (72.8)	NE (5.8, NE)	161	51 (31.7)	110 (68.3)	NE (3.6, NE)	0.831 (0.544, 1.269)	0.3911	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5342
Favorable	12	4 (33.3)	8 (66.7)	10.8 (0.7, NE)	16	9 (56.3)	7 (43.8)	4.4 (1.5, NE)	0.784 (0.241, 2.553)	0.6686	
Intermediate	186	56 (30.1)	130 (69.9)	30.8 (5.6, NE)	180	58 (32.2)	122 (67.8)	14.9 (2.8, NE)	0.818 (0.566, 1.181)	0.2827	
Unfavorable	19	6 (31.6)	13 (68.4)	4.0 (1.8, NE)	26	5 (19.2)	21 (80.8)	NE (3.0, NE)	1.950 (0.593, 6.414)	0.2628	
Unknown	35	5 (14.3)	30 (85.7)	NE (5.4, NE)	30	7 (23.3)	23 (76.7)	NE (4.1, NE)	0.636 (0.200, 2.023)	0.4421	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7890
0 - Fully Active	82	26 (31.7)	56 (68.3)	NE (4.0, NE)	92	29 (31.5)	63 (68.5)	NE (3.0, NE)	0.985 (0.580, 1.673)	0.9537	
1 - Restricted in Physically Strenuous Activity	126	33 (26.2)	93 (73.8)	NE (12.1, NE)	126	39 (31.0)	87 (69.0)	19.3 (3.1, NE)	0.767 (0.482, 1.222)	0.2648	
2 - Ambulatory and Capable of All Selfcare	44	12 (27.3)	32 (72.7)	10.4 (2.6, NE)	34	11 (32.4)	23 (67.6)	12.4 (2.0, NE)	0.816 (0.358, 1.859)	0.6293	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5638
≥3 to ≤25%	88	20 (22.7)	68 (77.3)	NE (5.8, NE)	92	31 (33.7)	61 (66.3)	NE (2.8, NE)	0.696 (0.396, 1.221)	0.2034	
>25% to ≤50%	135	40 (29.6)	95 (70.4)	30.8 (4.8, NE)	128	40 (31.3)	88 (68.8)	12.4 (3.6, NE)	0.836 (0.538, 1.299)	0.4244	
>50%	28	10 (35.7)	18 (64.3)	NE (1.9, NE)	33	8 (24.2)	25 (75.8)	NE (2.9, NE)	1.305 (0.514, 3.312)	0.5725	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.8472
Yes	130	41 (31.5)	89 (68.5)	30.8 (5.8, NE)	131	46 (35.1)	85 (64.9)	14.9 (3.6, NE)	0.859 (0.564, 1.310)	0.4830	
No	112	28 (25.0)	84 (75.0)	NE (5.5, NE)	111	30 (27.0)	81 (73.0)	15.0 (2.5, NE)	0.819 (0.489, 1.371)	0.4479	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2426
≤60	157	42 (26.8)	115 (73.2)	NE (13.6, NE)	154	49 (31.8)	105 (68.2)	15.0 (5.7, NE)	0.746 (0.494, 1.128)	0.1633	
>60	95	29 (30.5)	66 (69.5)	10.4 (3.1, NE)	99	30 (30.3)	69 (69.7)	NE (3.1, NE)	1.069 (0.641, 1.782)	0.8019	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8683
<60	152	36 (23.7)	116 (76.3)	NE (36.7, NE)	151	32 (21.2)	119 (78.8)	NE (22.6, NE)	1.028 (0.638, 1.657)	0.9178	
≥60 - <65	36	6 (16.7)	30 (83.3)	26.6 (14.9, NE)	43	5 (11.6)	38 (88.4)	NE (5.5, NE)	1.324 (0.401, 4.374)	0.6439	
≥65	64	15 (23.4)	49 (76.6)	21.3 (4.9, NE)	59	17 (28.8)	42 (71.2)	NE (2.9, NE)	0.916 (0.457, 1.837)	0.8086	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9608
Male	120	25 (20.8)	95 (79.2)	NE (22.3, NE)	109	21 (19.3)	88 (80.7)	NE (9.0, NE)	1.049 (0.586, 1.875)	0.8719	
Female	132	32 (24.2)	100 (75.8)	36.7 (14.9, NE)	144	33 (22.9)	111 (77.1)	NE (22.6, NE)	1.011 (0.621, 1.647)	0.9697	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4476
White	150	35 (23.3)	115 (76.7)	NE (21.3, NE)	151	34 (22.5)	117 (77.5)	NE (18.9, NE)	0.915 (0.569, 1.470)	0.7038	
Non-white	102	22 (21.6)	80 (78.4)	NE (9.0, NE)	102	20 (19.6)	82 (80.4)	NE (32.5, NE)	1.235 (0.673, 2.264)	0.4887	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6890
North America	16	3 (18.8)	13 (81.3)	NE (0.7, NE)	16	3 (18.8)	13 (81.3)	NE (2.2, NE)	2.369 (0.469, 11.957)	0.2824	
Europe	150	36 (24.0)	114 (76.0)	36.7 (15.6, NE)	150	35 (23.3)	115 (76.7)	NE (8.5, NE)	0.906 (0.568, 1.445)	0.6720	
Asia/Other Regions	86	18 (20.9)	68 (79.1)	NE (22.3, NE)	87	16 (18.4)	71 (81.6)	NE (32.5, NE)	1.162 (0.592, 2.282)	0.6596	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4227
< 40x10^9/L	128	30 (23.4)	98 (76.6)	NE (14.3, NE)	125	27 (21.6)	98 (78.4)	NE (NE, NE)	1.198 (0.712, 2.015)	0.4938	
≥ 40x10^9/L	124	27 (21.8)	97 (78.2)	36.7 (22.3, NE)	128	27 (21.1)	101 (78.9)	32.5 (8.0, NE)	0.888 (0.520, 1.517)	0.6521	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4378
Daunorubicin	116	28 (24.1)	88 (75.9)	36.7 (14.3, NE)	90	16 (17.8)	74 (82.2)	NE (18.9, NE)	1.195 (0.645, 2.215)	0.5709	
Idarubicin	136	29 (21.3)	107 (78.7)	NE (26.6, NE)	161	38 (23.6)	123 (76.4)	NE (22.6, NE)	0.907 (0.560, 1.471)	0.6847	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5734
Favorable	12	1 (8.3)	11 (91.7)	NE (11.7, NE)	16	4 (25.0)	12 (75.0)	NE (2.0, NE)	0.385 (0.043, 3.452)	0.3762	
Intermediate	186	42 (22.6)	144 (77.4)	NE (22.3, NE)	180	34 (18.9)	146 (81.1)	NE (22.6, NE)	1.076 (0.684, 1.693)	0.7529	
Unfavorable	19	4 (21.1)	15 (78.9)	36.7 (0.7, NE)	26	3 (11.5)	23 (88.5)	18.9 (18.9, NE)	1.647 (0.322, 8.418)	0.5450	
Unknown	35	10 (28.6)	25 (71.4)	21.3 (2.6, NE)	30	12 (40.0)	18 (60.0)	4.1 (2.9, NE)	0.754 (0.324, 1.754)	0.5025	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6687
0 - Fully Active	82	20 (24.4)	62 (75.6)	36.7 (21.3, NE)	92	22 (23.9)	70 (76.1)	NE (8.0, NE)	0.932 (0.507, 1.711)	0.8150	
1 - Restricted in Physically Strenuous Activity	126	28 (22.2)	98 (77.8)	NE (15.6, NE)	126	28 (22.2)	98 (77.8)	NE (NE, NE)	0.984 (0.582, 1.663)	0.9521	
2 - Ambulatory and Capable of All Selfcare	44	9 (20.5)	35 (79.5)	NE (9.0, NE)	34	4 (11.8)	30 (88.2)	32.5 (3.6, NE)	1.562 (0.475, 5.143)	0.4661	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6096
≥3 to ≤25%	88	22 (25.0)	66 (75.0)	26.6 (14.3, NE)	92	25 (27.2)	67 (72.8)	NE (8.0, NE)	1.009 (0.569, 1.791)	0.9758	
>25% to ≤50%	135	30 (22.2)	105 (77.8)	36.7 (21.3, NE)	128	22 (17.2)	106 (82.8)	NE (NE, NE)	1.222 (0.704, 2.120)	0.4729	
>50%	28	5 (17.9)	23 (82.1)	NE (NE, NE)	33	7 (21.2)	26 (78.8)	32.5 (3.0, NE)	0.779 (0.247, 2.458)	0.6367	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6378
Yes	130	30 (23.1)	100 (76.9)	NE (22.3, NE)	131	31 (23.7)	100 (76.3)	NE (32.5, NE)	0.919 (0.555, 1.521)	0.7374	
No	112	25 (22.3)	87 (77.7)	36.7 (7.1, NE)	111	22 (19.8)	89 (80.2)	22.6 (7.6, NE)	1.093 (0.615, 1.943)	0.7629	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9810
≤60	157	37 (23.6)	120 (76.4)	NE (36.7, NE)	154	32 (20.8)	122 (79.2)	NE (22.6, NE)	1.041 (0.648, 1.673)	0.8755	
>60	95	20 (21.1)	75 (78.9)	21.3 (14.9, NE)	99	22 (22.2)	77 (77.8)	NE (8.5, NE)	1.020 (0.555, 1.874)	0.9458	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6415
<60	149	54 (36.2)	95 (63.8)	10.7 (5.1, NE)	151	53 (35.1)	98 (64.9)	9.9 (4.7, 27.1)	0.885 (0.605, 1.294)	0.5304	
≥60 - <65	36	12 (33.3)	24 (66.7)	26.6 (0.8, NE)	42	11 (26.2)	31 (73.8)	NE (2.0, NE)	1.303 (0.572, 2.967)	0.5381	
≥65	63	16 (25.4)	47 (74.6)	24.4 (3.1, NE)	59	14 (23.7)	45 (76.3)	NE (4.8, NE)	1.242 (0.606, 2.547)	0.5511	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1338
Male	119	35 (29.4)	84 (70.6)	24.4 (6.6, NE)	109	36 (33.0)	73 (67.0)	6.7 (2.8, NE)	0.765 (0.479, 1.222)	0.2551	
Female	129	47 (36.4)	82 (63.6)	11.0 (4.3, NE)	143	42 (29.4)	101 (70.6)	27.1 (9.1, NE)	1.234 (0.814, 1.871)	0.3235	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5302
White	147	54 (36.7)	93 (63.3)	7.1 (4.2, NE)	150	48 (32.0)	102 (68.0)	9.9 (5.6, NE)	1.069 (0.724, 1.577)	0.7417	
Non-white	101	28 (27.7)	73 (72.3)	26.6 (7.6, NE)	102	30 (29.4)	72 (70.6)	NE (3.2, NE)	0.909 (0.542, 1.523)	0.7093	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8687
North America	16	4 (25.0)	12 (75.0)	NE (0.7, NE)	16	7 (43.8)	9 (56.3)	4.8 (1.2, NE)	0.969 (0.282, 3.330)	0.9560	
Europe	146	55 (37.7)	91 (62.3)	7.1 (4.2, NE)	149	48 (32.2)	101 (67.8)	13.3 (5.6, NE)	1.066 (0.724, 1.570)	0.7459	
Asia/Other Regions	86	23 (26.7)	63 (73.3)	NE (13.6, NE)	87	23 (26.4)	64 (73.6)	NE (4.7, NE)	0.960 (0.537, 1.715)	0.8782	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5768
< 40x10^9/L	127	42 (33.1)	85 (66.9)	26.6 (4.2, NE)	125	48 (38.4)	77 (61.6)	9.1 (3.5, 27.1)	0.948 (0.626, 1.435)	0.7788	
≥ 40x10^9/L	121	40 (33.1)	81 (66.9)	13.6 (6.6, NE)	127	30 (23.6)	97 (76.4)	NE (9.9, NE)	1.126 (0.701, 1.811)	0.6141	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5630
Daunorubicin	115	46 (40.0)	69 (60.0)	5.1 (3.0, 13.6)	89	32 (36.0)	57 (64.0)	6.7 (2.0, 27.1)	1.033 (0.657, 1.626)	0.8969	
Idarubicin	133	36 (27.1)	97 (72.9)	NE (10.7, NE)	161	45 (28.0)	116 (72.0)	NE (9.1, NE)	0.867 (0.559, 1.345)	0.5192	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7385
Favorable	12	5 (41.7)	7 (58.3)	5.1 (0.7, NE)	16	8 (50.0)	8 (50.0)	9.9 (0.9, NE)	1.219 (0.391, 3.802)	0.7244	
Intermediate	182	57 (31.3)	125 (68.7)	26.6 (7.4, NE)	179	50 (27.9)	129 (72.1)	NE (5.6, NE)	0.936 (0.639, 1.370)	0.7235	
Unfavorable	19	6 (31.6)	13 (68.4)	7.1 (1.1, NE)	26	8 (30.8)	18 (69.2)	27.1 (3.5, NE)	1.365 (0.470, 3.961)	0.5600	
Unknown	35	14 (40.0)	21 (60.0)	4.2 (1.1, NE)	30	11 (36.7)	19 (63.3)	9.1 (2.4, NE)	1.396 (0.632, 3.085)	0.4047	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3075
0 - Fully Active	81	33 (40.7)	48 (59.3)	7.1 (3.1, NE)	91	33 (36.3)	58 (63.7)	13.3 (2.4, NE)	1.053 (0.649, 1.707)	0.8379	
1 - Restricted in Physically Strenuous Activity	124	42 (33.9)	82 (66.1)	11.0 (4.2, NE)	126	36 (28.6)	90 (71.4)	15.5 (4.8, NE)	1.141 (0.730, 1.782)	0.5644	
2 - Ambulatory and Capable of All Selfcare	43	7 (16.3)	36 (83.7)	NE (13.6, NE)	34	9 (26.5)	25 (73.5)	9.8 (2.0, NE)	0.499 (0.182, 1.366)	0.1664	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4693
≥3 to ≤25%	87	28 (32.2)	59 (67.8)	24.4 (3.8, NE)	91	32 (35.2)	59 (64.8)	9.8 (3.5, NE)	0.976 (0.586, 1.623)	0.9075	
>25% to ≤50%	133	46 (34.6)	87 (65.4)	10.7 (4.6, NE)	128	36 (28.1)	92 (71.9)	NE (6.7, NE)	1.113 (0.719, 1.723)	0.6241	
>50%	27	7 (25.9)	20 (74.1)	NE (3.5, NE)	33	10 (30.3)	23 (69.7)	NE (1.6, NE)	0.608 (0.229, 1.609)	0.3209	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5648
Yes	127	46 (36.2)	81 (63.8)	13.6 (6.6, NE)	131	46 (35.1)	85 (64.9)	13.3 (5.6, NE)	0.929 (0.616, 1.401)	0.7127	
No	111	33 (29.7)	78 (70.3)	17.1 (3.1, NE)	110	27 (24.5)	83 (75.5)	27.1 (4.8, NE)	1.137 (0.684, 1.892)	0.6143	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.2 EORTC QLQ-C30 - First deterioration - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3708
≤60	154	55 (35.7)	99 (64.3)	10.7 (5.1, NE)	154	53 (34.4)	101 (65.6)	9.9 (4.7, 27.1)	0.890 (0.609, 1.299)	0.5452	
>60	94	27 (28.7)	67 (71.3)	24.4 (4.2, NE)	98	25 (25.5)	73 (74.5)	NE (4.8, NE)	1.253 (0.726, 2.162)	0.4225	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:07; Program name: .sas; Output name: DE_T_2_20_2_QLQC30_FD_SUB_PRO_ITT.rtf

Anhang 4-H6c: Zeit bis zur erstmaligen Verbesserung

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2556
<60	152	100 (65.8)	52 (34.2)	1.3 (0.8, 1.7)	151	91 (60.3)	60 (39.7)	1.1 (0.7, 1.7)	1.017 (0.765, 1.352)	0.9012	
≥60 - <65	36	25 (69.4)	11 (30.6)	0.8 (0.7, 1.7)	43	21 (48.8)	22 (51.2)	1.9 (1.4, 9.6)	1.740 (0.970, 3.122)	0.0677	
≥65	64	35 (54.7)	29 (45.3)	1.8 (1.2, 2.6)	59	36 (61.0)	23 (39.0)	1.5 (0.8, 3.0)	1.089 (0.682, 1.738)	0.7111	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3898
Male	120	74 (61.7)	46 (38.3)	1.3 (0.8, 1.7)	109	67 (61.5)	42 (38.5)	1.4 (0.7, 1.8)	0.999 (0.717, 1.393)	0.9849	
Female	132	86 (65.2)	46 (34.8)	1.5 (0.8, 1.8)	144	81 (56.3)	63 (43.8)	1.5 (0.8, 2.0)	1.209 (0.893, 1.639)	0.2121	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2437
White	150	99 (66.0)	51 (34.0)	1.4 (0.8, 1.8)	151	83 (55.0)	68 (45.0)	1.5 (0.9, 2.3)	1.252 (0.935, 1.676)	0.1294	
Non-white	102	61 (59.8)	41 (40.2)	1.3 (0.8, 1.8)	102	65 (63.7)	37 (36.3)	1.4 (0.7, 1.7)	0.949 (0.668, 1.346)	0.7748	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6457
North America	16	10 (62.5)	6 (37.5)	1.3 (0.7, 2.6)	16	10 (62.5)	6 (37.5)	1.6 (0.7, 2.1)	1.501 (0.615, 3.664)	0.3915	
Europe	150	98 (65.3)	52 (34.7)	1.4 (0.8, 1.8)	150	84 (56.0)	66 (44.0)	1.5 (0.9, 2.8)	1.187 (0.887, 1.590)	0.2356	
Asia/Other Regions	86	52 (60.5)	34 (39.5)	1.4 (0.7, 2.0)	87	54 (62.1)	33 (37.9)	1.2 (0.7, 1.6)	0.964 (0.659, 1.412)	0.8542	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.8955
< 40x10^9/L	128	77 (60.2)	51 (39.8)	1.4 (0.8, 2.1)	125	78 (62.4)	47 (37.6)	1.5 (0.9, 2.2)	1.099 (0.802, 1.506)	0.5516	
≥ 40x10^9/L	124	83 (66.9)	41 (33.1)	1.3 (0.8, 1.7)	128	70 (54.7)	58 (45.3)	1.2 (0.7, 1.8)	1.124 (0.817, 1.545)	0.4726	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1059
Daunorubicin	116	76 (65.5)	40 (34.5)	0.8 (0.7, 1.3)	90	50 (55.6)	40 (44.4)	1.5 (0.8, 1.8)	1.385 (0.969, 1.980)	0.0830	
Idarubicin	136	84 (61.8)	52 (38.2)	1.7 (1.3, 2.5)	161	96 (59.6)	65 (40.4)	1.3 (0.8, 2.1)	0.959 (0.715, 1.286)	0.8265	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6800
Favorable	12	6 (50.0)	6 (50.0)	0.7 (0.7, NE)	16	11 (68.8)	5 (31.3)	1.6 (0.7, NE)	1.172 (0.429, 3.201)	0.9033	
Intermediate	186	126 (67.7)	60 (32.3)	1.1 (0.8, 1.5)	180	103 (57.2)	77 (42.8)	1.2 (0.8, 1.6)	1.201 (0.925, 1.559)	0.1653	
Unfavorable	19	10 (52.6)	9 (47.4)	1.8 (0.7, 2.9)	26	14 (53.8)	12 (46.2)	1.8 (0.7, 2.6)	1.118 (0.481, 2.600)	0.7696	
Unknown	35	18 (51.4)	17 (48.6)	3.1 (1.5, 6.5)	30	19 (63.3)	11 (36.7)	3.2 (0.8, 5.7)	0.730 (0.377, 1.414)	0.3462	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6898
0 - Fully Active	82	53 (64.6)	29 (35.4)	1.8 (0.8, 2.9)	92	56 (60.9)	36 (39.1)	1.6 (0.8, 2.5)	1.010 (0.693, 1.472)	0.9450	
1 - Restricted in Physically Strenuous Activity	126	83 (65.9)	43 (34.1)	1.3 (0.8, 1.6)	126	75 (59.5)	51 (40.5)	1.4 (0.8, 1.8)	1.230 (0.899, 1.682)	0.1928	
2 - Ambulatory and Capable of All Selfcare	44	24 (54.5)	20 (45.5)	1.0 (0.7, 1.7)	34	17 (50.0)	17 (50.0)	1.5 (0.7, 3.2)	0.983 (0.520, 1.857)	0.9259	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1072
≥3 to ≤25%	88	47 (53.4)	41 (46.6)	1.5 (1.2, 2.6)	92	58 (63.0)	34 (37.0)	1.4 (0.8, 2.1)	0.806 (0.548, 1.185)	0.2756	
>25% to ≤50%	135	91 (67.4)	44 (32.6)	1.2 (0.7, 1.7)	128	73 (57.0)	55 (43.0)	1.5 (0.8, 2.2)	1.273 (0.936, 1.733)	0.1274	
>50%	28	21 (75.0)	7 (25.0)	0.8 (0.7, 2.3)	33	17 (51.5)	16 (48.5)	1.5 (0.7, NE)	1.511 (0.795, 2.872)	0.1749	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0808
Yes	130	90 (69.2)	40 (30.8)	1.4 (0.8, 1.7)	131	79 (60.3)	52 (39.7)	1.5 (1.0, 2.2)	1.345 (0.993, 1.820)	0.0536	
No	112	63 (56.3)	49 (43.8)	1.4 (0.8, 2.1)	111	60 (54.1)	51 (45.9)	1.3 (0.7, 1.8)	0.894 (0.626, 1.277)	0.5012	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Global Health Status

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1774
≤60	157	102 (65.0)	55 (35.0)	1.3 (0.8, 1.8)	154	92 (59.7)	62 (40.3)	1.1 (0.7, 1.7)	0.998 (0.752, 1.323)	0.9920	
>60	95	58 (61.1)	37 (38.9)	1.5 (1.1, 2.1)	99	56 (56.6)	43 (43.4)	1.6 (1.3, 3.0)	1.385 (0.958, 2.001)	0.0820	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4689
<60	150	70 (46.7)	80 (53.3)	2.8 (1.8, 19.8)	151	68 (45.0)	83 (55.0)	2.5 (1.7, 5.5)	0.920 (0.657, 1.286)	0.5935	
≥60 - <65	36	18 (50.0)	18 (50.0)	1.4 (0.7, 12.4)	42	18 (42.9)	24 (57.1)	3.2 (1.6, 11.6)	1.490 (0.774, 2.868)	0.2505	
≥65	63	22 (34.9)	41 (65.1)	3.8 (1.3, NE)	59	27 (45.8)	32 (54.2)	2.9 (1.3, 9.8)	0.965 (0.549, 1.695)	0.8710	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9980
Male	119	46 (38.7)	73 (61.3)	12.2 (1.6, NE)	108	43 (39.8)	65 (60.2)	5.7 (1.8, 11.6)	0.997 (0.656, 1.513)	0.9185	
Female	130	64 (49.2)	66 (50.8)	2.4 (1.6, 5.0)	144	70 (48.6)	74 (51.4)	2.2 (1.6, 3.1)	0.987 (0.703, 1.387)	0.9142	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7377
White	147	68 (46.3)	79 (53.7)	2.6 (1.7, 11.2)	151	66 (43.7)	85 (56.3)	2.6 (1.7, 6.7)	1.035 (0.737, 1.454)	0.8868	
Non-white	102	42 (41.2)	60 (58.8)	2.8 (1.5, 28.0)	101	47 (46.5)	54 (53.5)	2.6 (1.8, 7.7)	0.907 (0.597, 1.380)	0.6122	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9946
North America	16	5 (31.3)	11 (68.8)	12.4 (0.7, NE)	16	7 (43.8)	9 (56.3)	2.5 (1.6, NE)	1.201 (0.367, 3.927)	0.7620	
Europe	147	66 (44.9)	81 (55.1)	2.6 (1.6, 11.2)	149	67 (45.0)	82 (55.0)	2.6 (1.7, 5.7)	0.980 (0.697, 1.378)	0.8673	
Asia/Other Regions	86	39 (45.3)	47 (54.7)	2.8 (1.5, 18.3)	87	39 (44.8)	48 (55.2)	3.1 (1.4, 9.7)	0.968 (0.619, 1.514)	0.8409	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4712
< 40x10^9/L	127	51 (40.2)	76 (59.8)	5.0 (1.8, 12.4)	125	62 (49.6)	63 (50.4)	2.3 (1.7, 5.7)	0.897 (0.619, 1.301)	0.5172	
≥ 40x10^9/L	122	59 (48.4)	63 (51.6)	1.9 (1.3, 8.2)	127	51 (40.2)	76 (59.8)	3.0 (1.7, 9.7)	1.078 (0.739, 1.572)	0.7299	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2690
Daunorubicin	114	47 (41.2)	67 (58.8)	2.6 (1.5, 19.8)	90	42 (46.7)	48 (53.3)	1.8 (1.5, 3.0)	0.828 (0.544, 1.262)	0.3562	
Idarubicin	135	63 (46.7)	72 (53.3)	2.6 (1.6, 12.4)	160	69 (43.1)	91 (56.9)	3.4 (2.1, 9.7)	1.105 (0.785, 1.557)	0.6130	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4243
Favorable	12	5 (41.7)	7 (58.3)	12.2 (0.7, NE)	16	8 (50.0)	8 (50.0)	2.5 (1.4, NE)	0.926 (0.294, 2.920)	0.8510	
Intermediate	185	89 (48.1)	96 (51.9)	1.9 (1.4, 5.0)	179	75 (41.9)	104 (58.1)	2.6 (1.8, 6.7)	1.114 (0.819, 1.516)	0.5318	
Unfavorable	17	4 (23.5)	13 (76.5)	11.2 (0.7, NE)	26	13 (50.0)	13 (50.0)	2.3 (0.7, NE)	0.455 (0.142, 1.457)	0.1744	
Unknown	35	12 (34.3)	23 (65.7)	8.2 (1.8, NE)	30	16 (53.3)	14 (46.7)	3.2 (0.9, NE)	0.672 (0.317, 1.423)	0.2902	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.0054
0 - Fully Active	80	29 (36.3)	51 (63.8)	28.0 (5.0, NE)	92	46 (50.0)	46 (50.0)	2.5 (1.6, 7.7)	0.607 (0.379, 0.973)	0.0320	
1 - Restricted in Physically Strenuous Activity	126	63 (50.0)	63 (50.0)	1.8 (1.3, 2.9)	125	47 (37.6)	78 (62.4)	5.5 (2.2, NE)	1.502 (1.029, 2.192)	0.0372	
2 - Ambulatory and Capable of All Selfcare	43	18 (41.9)	25 (58.1)	1.3 (0.7, NE)	34	20 (58.8)	14 (41.2)	1.5 (0.7, 2.6)	0.679 (0.354, 1.301)	0.2008	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4371
≥3 to ≤25%	86	36 (41.9)	50 (58.1)	2.8 (1.4, 28.0)	92	44 (47.8)	48 (52.2)	2.2 (1.7, 9.6)	0.909 (0.584, 1.413)	0.6408	
>25% to ≤50%	134	57 (42.5)	77 (57.5)	3.8 (1.8, 18.3)	127	57 (44.9)	70 (55.1)	3.0 (1.8, 6.7)	0.912 (0.630, 1.319)	0.5831	
>50%	28	16 (57.1)	12 (42.9)	0.8 (0.7, NE)	33	12 (36.4)	21 (63.6)	4.5 (1.3, NE)	1.746 (0.825, 3.697)	0.1438	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1935
Yes	128	63 (49.2)	65 (50.8)	1.8 (1.3, 7.6)	130	62 (47.7)	68 (52.3)	2.9 (1.8, 7.7)	1.155 (0.812, 1.642)	0.4810	
No	111	41 (36.9)	70 (63.1)	11.2 (2.5, 28.0)	111	44 (39.6)	67 (60.4)	2.3 (1.6, 9.7)	0.759 (0.494, 1.166)	0.2014	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Physical Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4415
≤60	155	71 (45.8)	84 (54.2)	2.8 (1.8, 19.8)	154	68 (44.2)	86 (55.8)	2.6 (1.7, 5.5)	0.924 (0.661, 1.291)	0.6077	
>60	94	39 (41.5)	55 (58.5)	1.9 (1.2, 12.4)	98	45 (45.9)	53 (54.1)	3.0 (1.7, 7.7)	1.135 (0.738, 1.744)	0.6073	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1716
<60	151	84 (55.6)	67 (44.4)	1.6 (1.3, 2.6)	151	85 (56.3)	66 (43.7)	1.5 (0.9, 1.7)	0.863 (0.638, 1.168)	0.3137	
≥60 - <65	36	23 (63.9)	13 (36.1)	0.8 (0.7, 1.8)	41	23 (56.1)	18 (43.9)	1.9 (1.3, 5.7)	1.808 (0.995, 3.285)	0.0543	
≥65	64	26 (40.6)	38 (59.4)	1.5 (1.3, 18.7)	59	30 (50.8)	29 (49.2)	1.7 (0.9, 4.2)	0.951 (0.561, 1.610)	0.8411	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8491
Male	119	59 (49.6)	60 (50.4)	1.4 (0.8, 2.4)	107	56 (52.3)	51 (47.7)	1.7 (0.9, 2.6)	0.937 (0.649, 1.352)	0.6883	
Female	132	74 (56.1)	58 (43.9)	1.5 (1.3, 1.8)	144	82 (56.9)	62 (43.1)	1.5 (0.9, 1.8)	0.980 (0.716, 1.343)	0.8931	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2916
White	149	87 (58.4)	62 (41.6)	1.4 (0.8, 1.8)	150	84 (56.0)	66 (44.0)	1.6 (1.2, 1.9)	1.066 (0.790, 1.439)	0.7095	
Non-white	102	46 (45.1)	56 (54.9)	1.8 (1.4, 8.5)	101	54 (53.5)	47 (46.5)	1.7 (0.8, 2.8)	0.813 (0.547, 1.206)	0.2823	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4797
North America	16	6 (37.5)	10 (62.5)	1.3 (0.7, NE)	16	12 (75.0)	4 (25.0)	1.7 (1.4, 2.0)	0.857 (0.318, 2.308)	0.7537	
Europe	149	86 (57.7)	63 (42.3)	1.4 (0.8, 1.7)	148	79 (53.4)	69 (46.6)	1.6 (1.3, 2.0)	1.092 (0.805, 1.483)	0.5888	
Asia/Other Regions	86	41 (47.7)	45 (52.3)	1.8 (1.4, 8.5)	87	47 (54.0)	40 (46.0)	1.3 (0.7, 5.5)	0.806 (0.530, 1.228)	0.2951	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2504
< 40x10^9/L	127	67 (52.8)	60 (47.2)	1.4 (0.9, 1.8)	124	72 (58.1)	52 (41.9)	1.6 (1.3, 2.1)	1.103 (0.791, 1.539)	0.5893	
≥ 40x10^9/L	124	66 (53.2)	58 (46.8)	1.6 (1.3, 2.9)	127	66 (52.0)	61 (48.0)	1.5 (0.8, 2.0)	0.803 (0.569, 1.134)	0.1950	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7633
Daunorubicin	116	61 (52.6)	55 (47.4)	1.3 (0.8, 1.8)	90	48 (53.3)	42 (46.7)	1.4 (0.9, 1.9)	0.997 (0.682, 1.457)	0.9371	
Idarubicin	135	72 (53.3)	63 (46.7)	1.5 (1.3, 2.2)	159	88 (55.3)	71 (44.7)	1.6 (1.3, 2.5)	0.924 (0.677, 1.262)	0.6110	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9393
Favorable	12	6 (50.0)	6 (50.0)	13.6 (0.7, NE)	16	11 (68.8)	5 (31.3)	1.8 (1.4, 8.3)	1.162 (0.425, 3.175)	0.8533	
Intermediate	185	99 (53.5)	86 (46.5)	1.5 (1.3, 1.8)	179	95 (53.1)	84 (46.9)	1.3 (0.9, 1.7)	0.939 (0.708, 1.244)	0.6332	
Unfavorable	19	10 (52.6)	9 (47.4)	1.8 (0.7, NE)	26	13 (50.0)	13 (50.0)	2.1 (0.7, 3.9)	1.000 (0.421, 2.378)	0.9890	
Unknown	35	18 (51.4)	17 (48.6)	1.8 (0.7, 8.2)	29	18 (62.1)	11 (37.9)	1.5 (0.7, 3.2)	0.832 (0.425, 1.629)	0.5735	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3393
0 - Fully Active	82	45 (54.9)	37 (45.1)	1.8 (1.5, 4.3)	92	52 (56.5)	40 (43.5)	1.4 (0.9, 2.0)	0.860 (0.576, 1.282)	0.4624	
1 - Restricted in Physically Strenuous Activity	126	69 (54.8)	57 (45.2)	1.4 (0.9, 1.7)	124	67 (54.0)	57 (46.0)	1.7 (1.3, 2.6)	1.131 (0.808, 1.583)	0.5141	
2 - Ambulatory and Capable of All Selfcare	43	19 (44.2)	24 (55.8)	1.4 (0.8, 18.7)	34	19 (55.9)	15 (44.1)	1.4 (0.7, 2.0)	0.679 (0.352, 1.310)	0.2125	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7271
≥3 to ≤25%	87	44 (50.6)	43 (49.4)	1.4 (0.8, 2.1)	91	51 (56.0)	40 (44.0)	1.7 (0.8, 2.1)	1.061 (0.708, 1.589)	0.8213	
>25% to ≤50%	135	71 (52.6)	64 (47.4)	1.6 (1.3, 2.3)	127	72 (56.7)	55 (43.3)	1.5 (0.9, 2.1)	0.883 (0.635, 1.227)	0.4402	
>50%	28	17 (60.7)	11 (39.3)	1.7 (0.8, 7.5)	33	15 (45.5)	18 (54.5)	1.5 (0.9, NE)	1.061 (0.525, 2.145)	0.8336	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4456
Yes	130	77 (59.2)	53 (40.8)	1.4 (0.9, 1.8)	129	78 (60.5)	51 (39.5)	1.5 (1.2, 1.8)	1.045 (0.762, 1.433)	0.8252	
No	111	51 (45.9)	60 (54.1)	1.7 (1.3, 2.9)	111	53 (47.7)	58 (52.3)	1.7 (0.8, 2.6)	0.860 (0.585, 1.263)	0.4342	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Role Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2783
≤60	156	87 (55.8)	69 (44.2)	1.6 (1.3, 2.4)	154	86 (55.8)	68 (44.2)	1.5 (0.9, 1.7)	0.869 (0.645, 1.172)	0.3316	
>60	95	46 (48.4)	49 (51.6)	1.4 (0.8, 1.8)	97	52 (53.6)	45 (46.4)	1.9 (1.3, 3.2)	1.170 (0.786, 1.741)	0.4549	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1444
<60	152	74 (48.7)	78 (51.3)	2.5 (1.7, 11.3)	151	71 (47.0)	80 (53.0)	2.1 (1.5, 4.1)	0.912 (0.657, 1.264)	0.5300	
≥60 - <65	36	18 (50.0)	18 (50.0)	1.3 (0.7, NE)	43	17 (39.5)	26 (60.5)	5.7 (2.0, NE)	1.706 (0.877, 3.319)	0.1210	
≥65	64	20 (31.3)	44 (68.8)	4.6 (2.0, NE)	59	29 (49.2)	30 (50.8)	2.0 (0.9, 5.5)	0.666 (0.376, 1.180)	0.1587	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1667
Male	120	50 (41.7)	70 (58.3)	3.2 (2.0, 18.9)	109	37 (33.9)	72 (66.1)	11.6 (2.1, NE)	1.199 (0.783, 1.835)	0.4031	
Female	132	62 (47.0)	70 (53.0)	2.3 (1.3, 11.8)	144	80 (55.6)	64 (44.4)	1.8 (1.3, 2.6)	0.822 (0.589, 1.147)	0.2100	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1960
White	150	64 (42.7)	86 (57.3)	2.6 (1.7, NE)	151	74 (49.0)	77 (51.0)	2.1 (1.5, 2.9)	0.831 (0.594, 1.163)	0.2443	
Non-white	102	48 (47.1)	54 (52.9)	2.9 (1.6, 8.9)	102	43 (42.2)	59 (57.8)	5.1 (1.6, 11.6)	1.147 (0.760, 1.732)	0.5213	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2200
North America	16	6 (37.5)	10 (62.5)	1.3 (0.7, NE)	16	7 (43.8)	9 (56.3)	2.1 (1.1, NE)	1.722 (0.575, 5.159)	0.3348	
Europe	150	64 (42.7)	86 (57.3)	2.6 (1.7, NE)	150	74 (49.3)	76 (50.7)	2.1 (1.4, 3.7)	0.790 (0.564, 1.105)	0.1469	
Asia/Other Regions	86	42 (48.8)	44 (51.2)	3.3 (1.6, 11.3)	87	36 (41.4)	51 (58.6)	2.7 (1.9, 8.2)	1.182 (0.757, 1.846)	0.4748	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1581
< 40x10^9/L	128	48 (37.5)	80 (62.5)	8.8 (2.5, NE)	125	63 (50.4)	62 (49.6)	2.6 (1.6, 5.5)	0.763 (0.524, 1.112)	0.1537	
≥ 40x10^9/L	124	64 (51.6)	60 (48.4)	2.0 (1.3, 3.2)	128	54 (42.2)	74 (57.8)	2.0 (1.5, 8.2)	1.118 (0.776, 1.610)	0.6005	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9083
Daunorubicin	116	50 (43.1)	66 (56.9)	2.7 (1.1, 11.8)	90	41 (45.6)	49 (54.4)	2.1 (1.5, 4.5)	0.958 (0.632, 1.453)	0.7649	
Idarubicin	136	62 (45.6)	74 (54.4)	2.9 (2.0, 11.8)	161	76 (47.2)	85 (52.8)	2.3 (1.6, 5.7)	0.901 (0.644, 1.261)	0.5374	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.0663
Favorable	12	7 (58.3)	5 (41.7)	0.7 (0.7, NE)	16	8 (50.0)	8 (50.0)	2.7 (1.4, NE)	2.032 (0.729, 5.664)	0.2104	
Intermediate	186	87 (46.8)	99 (53.2)	2.5 (1.6, 5.1)	180	76 (42.2)	104 (57.8)	2.6 (1.8, 5.7)	1.060 (0.779, 1.443)	0.7328	
Unfavorable	19	5 (26.3)	14 (73.7)	17.8 (1.3, NE)	26	15 (57.7)	11 (42.3)	1.6 (0.7, 5.1)	0.263 (0.084, 0.820)	0.0148	
Unknown	35	13 (37.1)	22 (62.9)	3.5 (2.0, NE)	30	17 (56.7)	13 (43.3)	2.6 (1.0, 5.7)	0.655 (0.317, 1.355)	0.2434	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3870
0 - Fully Active	82	40 (48.8)	42 (51.2)	2.6 (1.8, 11.8)	92	42 (45.7)	50 (54.3)	3.1 (2.0, 5.5)	1.101 (0.713, 1.698)	0.6767	
1 - Restricted in Physically Strenuous Activity	126	57 (45.2)	69 (54.8)	2.1 (1.3, 11.8)	126	60 (47.6)	66 (52.4)	1.9 (1.3, 5.7)	0.931 (0.648, 1.339)	0.6486	
2 - Ambulatory and Capable of All Selfcare	44	15 (34.1)	29 (65.9)	8.8 (1.7, NE)	34	15 (44.1)	19 (55.9)	1.6 (0.7, NE)	0.543 (0.252, 1.170)	0.1087	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5011
≥3 to ≤25%	88	35 (39.8)	53 (60.2)	4.6 (2.1, 24.3)	92	43 (46.7)	49 (53.3)	2.6 (1.6, 5.7)	0.832 (0.532, 1.302)	0.3891	
>25% to ≤50%	135	61 (45.2)	74 (54.8)	2.3 (1.3, 11.3)	128	62 (48.4)	66 (51.6)	2.3 (1.5, 3.1)	0.929 (0.651, 1.325)	0.6464	
>50%	28	16 (57.1)	12 (42.9)	2.0 (0.7, 8.9)	33	12 (36.4)	21 (63.6)	5.1 (1.3, NE)	1.302 (0.608, 2.787)	0.4776	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6902
Yes	130	62 (47.7)	68 (52.3)	2.5 (1.5, 8.9)	131	68 (51.9)	63 (48.1)	2.1 (1.5, 5.5)	0.968 (0.685, 1.367)	0.7923	
No	112	45 (40.2)	67 (59.8)	2.9 (2.0, 18.9)	111	44 (39.6)	67 (60.4)	2.3 (1.6, 5.7)	0.842 (0.555, 1.279)	0.4149	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Emotional Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6881
≤60	157	75 (47.8)	82 (52.2)	2.5 (1.7, 11.3)	154	71 (46.1)	83 (53.9)	2.1 (1.5, 4.1)	0.905 (0.653, 1.254)	0.5021	
>60	95	37 (38.9)	58 (61.1)	2.7 (1.3, 11.8)	99	46 (46.5)	53 (53.5)	2.6 (1.6, 5.7)	0.999 (0.648, 1.541)	0.9787	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3018
<60	152	66 (43.4)	86 (56.6)	3.2 (1.6, 24.3)	151	53 (35.1)	98 (64.9)	16.1 (2.5, NE)	1.270 (0.885, 1.824)	0.2004	
≥60 - <65	36	16 (44.4)	20 (55.6)	5.0 (0.7, NE)	43	13 (30.2)	30 (69.8)	25.5 (4.1, NE)	1.613 (0.774, 3.362)	0.2063	
≥65	64	17 (26.6)	47 (73.4)	NE (1.7, NE)	59	21 (35.6)	38 (64.4)	15.2 (1.1, NE)	0.788 (0.415, 1.496)	0.4584	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8184
Male	120	40 (33.3)	80 (66.7)	NE (1.7, NE)	109	30 (27.5)	79 (72.5)	NE (6.7, NE)	1.265 (0.787, 2.032)	0.3481	
Female	132	59 (44.7)	73 (55.3)	2.1 (1.6, 19.6)	144	57 (39.6)	87 (60.4)	6.1 (2.1, NE)	1.194 (0.829, 1.718)	0.3460	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5631
White	150	62 (41.3)	88 (58.7)	5.0 (1.7, NE)	151	51 (33.8)	100 (66.2)	16.1 (2.9, NE)	1.298 (0.896, 1.880)	0.1740	
Non-white	102	37 (36.3)	65 (63.7)	4.6 (1.6, NE)	102	36 (35.3)	66 (64.7)	25.5 (2.8, NE)	1.086 (0.686, 1.718)	0.7451	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2373
North America	16	7 (43.8)	9 (56.3)	1.6 (0.7, NE)	16	5 (31.3)	11 (68.8)	NE (1.7, NE)	3.050 (0.956, 9.733)	0.0481	
Europe	150	58 (38.7)	92 (61.3)	6.0 (1.8, NE)	150	47 (31.3)	103 (68.7)	NE (5.7, NE)	1.263 (0.859, 1.855)	0.2398	
Asia/Other Regions	86	34 (39.5)	52 (60.5)	3.8 (1.6, NE)	87	35 (40.2)	52 (59.8)	5.1 (1.6, NE)	0.979 (0.610, 1.571)	0.8934	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6984
< 40x10^9/L	128	46 (35.9)	82 (64.1)	19.6 (2.3, NE)	125	42 (33.6)	83 (66.4)	NE (5.1, NE)	1.260 (0.829, 1.915)	0.2836	
≥ 40x10^9/L	124	53 (42.7)	71 (57.3)	1.8 (1.4, NE)	128	45 (35.2)	83 (64.8)	11.5 (1.8, NE)	1.145 (0.769, 1.704)	0.5151	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8461
Daunorubicin	116	42 (36.2)	74 (63.8)	6.0 (1.6, NE)	90	32 (35.6)	58 (64.4)	6.7 (1.9, NE)	1.159 (0.731, 1.838)	0.5637	
Idarubicin	136	57 (41.9)	79 (58.1)	4.6 (1.6, NE)	161	55 (34.2)	106 (65.8)	25.5 (5.1, NE)	1.221 (0.843, 1.768)	0.2889	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4850
Favorable	12	6 (50.0)	6 (50.0)	1.6 (0.7, NE)	16	7 (43.8)	9 (56.3)	16.1 (1.6, NE)	1.687 (0.561, 5.072)	0.3674	
Intermediate	186	75 (40.3)	111 (59.7)	2.3 (1.6, NE)	180	54 (30.0)	126 (70.0)	NE (5.7, NE)	1.384 (0.975, 1.963)	0.0720	
Unfavorable	19	7 (36.8)	12 (63.2)	19.6 (0.7, NE)	26	14 (53.8)	12 (46.2)	1.3 (0.7, NE)	0.591 (0.212, 1.644)	0.3000	
Unknown	35	11 (31.4)	24 (68.6)	6.0 (4.6, NE)	30	11 (36.7)	19 (63.3)	15.2 (1.2, NE)	0.924 (0.399, 2.138)	0.8581	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5595
0 - Fully Active	82	31 (37.8)	51 (62.2)	19.6 (1.8, NE)	92	25 (27.2)	67 (72.8)	NE (15.2, NE)	1.471 (0.868, 2.493)	0.1504	
1 - Restricted in Physically Strenuous Activity	126	49 (38.9)	77 (61.1)	5.0 (1.6, NE)	126	48 (38.1)	78 (61.9)	6.7 (2.1, NE)	1.046 (0.702, 1.557)	0.8475	
2 - Ambulatory and Capable of All Selfcare	44	19 (43.2)	25 (56.8)	1.4 (0.8, NE)	34	14 (41.2)	20 (58.8)	5.7 (0.7, NE)	1.135 (0.568, 2.270)	0.7316	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3073
≥3 to ≤25%	88	28 (31.8)	60 (68.2)	24.3 (3.8, NE)	92	27 (29.3)	65 (70.7)	NE (4.1, NE)	1.272 (0.749, 2.159)	0.3969	
>25% to ≤50%	135	54 (40.0)	81 (60.0)	4.6 (1.6, NE)	128	49 (38.3)	79 (61.7)	11.5 (2.1, NE)	1.020 (0.693, 1.502)	0.9180	
>50%	28	17 (60.7)	11 (39.3)	1.4 (0.8, 2.9)	33	11 (33.3)	22 (66.7)	5.1 (1.6, NE)	2.134 (0.997, 4.568)	0.0463	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.8436
Yes	130	54 (41.5)	76 (58.5)	3.2 (1.6, NE)	131	48 (36.6)	83 (63.4)	16.1 (5.7, NE)	1.268 (0.859, 1.871)	0.2481	
No	112	42 (37.5)	70 (62.5)	5.1 (1.8, 24.3)	111	33 (29.7)	78 (70.3)	NE (1.6, NE)	1.192 (0.756, 1.882)	0.4425	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Cognitive Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4893
≤60	157	68 (43.3)	89 (56.7)	3.2 (1.6, 24.3)	154	53 (34.4)	101 (65.6)	16.1 (2.5, NE)	1.292 (0.902, 1.850)	0.1684	
>60	95	31 (32.6)	64 (67.4)	NE (1.6, NE)	99	34 (34.3)	65 (65.7)	15.2 (3.6, NE)	1.038 (0.637, 1.690)	0.8953	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9009
<60	151	85 (56.3)	66 (43.7)	1.9 (1.1, 4.3)	151	80 (53.0)	71 (47.0)	1.7 (1.5, 2.8)	0.976 (0.718, 1.326)	0.8186	
≥60 - <65	36	17 (47.2)	19 (52.8)	2.3 (0.8, 12.9)	43	21 (48.8)	22 (51.2)	3.2 (1.1, 9.6)	1.089 (0.574, 2.069)	0.8008	
≥65	64	23 (35.9)	41 (64.1)	2.6 (1.5, NE)	59	29 (49.2)	30 (50.8)	2.0 (1.2, 15.2)	0.870 (0.502, 1.507)	0.6104	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1447
Male	119	61 (51.3)	58 (48.7)	1.6 (0.8, 2.1)	109	50 (45.9)	59 (54.1)	2.5 (1.5, 5.7)	1.234 (0.848, 1.794)	0.2960	
Female	132	64 (48.5)	68 (51.5)	3.9 (1.7, 8.2)	144	80 (55.6)	64 (44.4)	1.7 (1.5, 2.6)	0.849 (0.610, 1.180)	0.3218	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3026
White	149	76 (51.0)	73 (49.0)	2.1 (1.3, 6.0)	151	82 (54.3)	69 (45.7)	1.7 (1.4, 2.6)	0.894 (0.653, 1.223)	0.4658	
Non-white	102	49 (48.0)	53 (52.0)	1.9 (1.3, 3.9)	102	48 (47.1)	54 (52.9)	2.6 (1.6, 6.9)	1.185 (0.794, 1.768)	0.4435	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4176
North America	16	6 (37.5)	10 (62.5)	2.0 (0.7, NE)	16	13 (81.3)	3 (18.8)	1.6 (0.7, 2.0)	0.761 (0.288, 2.013)	0.5744	
Europe	149	72 (48.3)	77 (51.7)	3.8 (1.4, 7.4)	150	76 (50.7)	74 (49.3)	1.9 (1.4, 3.2)	0.914 (0.662, 1.263)	0.5822	
Asia/Other Regions	86	47 (54.7)	39 (45.3)	1.7 (0.8, 2.9)	87	41 (47.1)	46 (52.9)	2.1 (1.6, 6.9)	1.259 (0.826, 1.920)	0.3166	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5390
< 40x10^9/L	127	59 (46.5)	68 (53.5)	2.1 (1.5, 6.0)	125	71 (56.8)	54 (43.2)	1.8 (1.6, 3.0)	0.915 (0.647, 1.293)	0.6040	
≥ 40x10^9/L	124	66 (53.2)	58 (46.8)	1.9 (0.8, 4.8)	128	59 (46.1)	69 (53.9)	1.9 (1.5, 3.4)	1.090 (0.766, 1.552)	0.6650	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.0111
Daunorubicin	116	55 (47.4)	61 (52.6)	5.6 (1.1, 8.2)	90	53 (58.9)	37 (41.1)	1.5 (0.8, 1.7)	0.630 (0.427, 0.931)	0.0170	
Idarubicin	135	70 (51.9)	65 (48.1)	1.7 (1.4, 2.6)	161	75 (46.6)	86 (53.4)	2.6 (1.7, 6.1)	1.264 (0.912, 1.751)	0.1705	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9522
Favorable	12	5 (41.7)	7 (58.3)	6.5 (0.7, NE)	16	11 (68.8)	5 (31.3)	2.5 (1.6, 15.6)	0.703 (0.240, 2.057)	0.5024	
Intermediate	185	98 (53.0)	87 (47.0)	1.8 (1.4, 2.6)	180	91 (50.6)	89 (49.4)	1.6 (1.3, 2.6)	1.001 (0.752, 1.332)	0.9690	
Unfavorable	19	8 (42.1)	11 (57.9)	1.3 (0.7, NE)	26	14 (53.8)	12 (46.2)	1.6 (0.7, 7.1)	1.099 (0.460, 2.626)	0.8125	
Unknown	35	14 (40.0)	21 (60.0)	8.2 (1.1, NE)	30	13 (43.3)	17 (56.7)	4.2 (1.5, NE)	1.039 (0.485, 2.226)	0.9286	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8908
0 - Fully Active	82	43 (52.4)	39 (47.6)	2.3 (1.5, 7.5)	92	50 (54.3)	42 (45.7)	2.0 (1.4, 3.7)	1.024 (0.681, 1.540)	0.9160	
1 - Restricted in Physically Strenuous Activity	126	62 (49.2)	64 (50.8)	2.1 (1.3, 6.5)	126	64 (50.8)	62 (49.2)	1.7 (1.4, 3.0)	0.957 (0.674, 1.358)	0.7754	
2 - Ambulatory and Capable of All Selfcare	43	20 (46.5)	23 (53.5)	1.5 (0.7, 6.5)	34	16 (47.1)	18 (52.9)	2.0 (1.4, 6.9)	1.022 (0.518, 2.018)	0.9995	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2746
≥3 to ≤25%	87	46 (52.9)	41 (47.1)	1.5 (1.1, 5.6)	92	49 (53.3)	43 (46.7)	2.8 (1.6, 6.6)	1.212 (0.809, 1.814)	0.3464	
>25% to ≤50%	135	65 (48.1)	70 (51.9)	2.3 (1.6, 6.0)	128	63 (49.2)	65 (50.8)	2.1 (1.4, 3.7)	1.007 (0.711, 1.425)	0.9683	
>50%	28	14 (50.0)	14 (50.0)	2.9 (0.8, NE)	33	18 (54.5)	15 (45.5)	1.6 (0.8, 1.7)	0.580 (0.279, 1.205)	0.1399	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1338
Yes	130	73 (56.2)	57 (43.8)	2.1 (1.4, 5.6)	131	82 (62.6)	49 (37.4)	1.6 (1.3, 2.1)	0.871 (0.634, 1.196)	0.3593	
No	111	49 (44.1)	62 (55.9)	1.7 (0.8, 2.8)	111	42 (37.8)	69 (62.2)	3.0 (1.8, 8.2)	1.275 (0.844, 1.927)	0.2436	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Functional Scales - Social Functioning

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8877
≤60	156	87 (55.8)	69 (44.2)	1.9 (1.3, 4.3)	154	80 (51.9)	74 (48.1)	1.7 (1.5, 2.8)	0.978 (0.721, 1.327)	0.8347	
>60	95	38 (40.0)	57 (60.0)	2.6 (1.4, 12.9)	99	50 (50.5)	49 (49.5)	2.1 (1.4, 5.7)	0.952 (0.624, 1.454)	0.8127	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6123
<60	151	109 (72.2)	42 (27.8)	0.7 (0.7, 0.8)	151	107 (70.9)	44 (29.1)	0.7 (0.7, 0.9)	0.984 (0.753, 1.285)	0.8426	
≥60 - <65	36	26 (72.2)	10 (27.8)	0.7 (0.7, 1.3)	42	28 (66.7)	14 (33.3)	1.1 (0.7, 2.0)	1.241 (0.725, 2.123)	0.4677	
≥65	64	34 (53.1)	30 (46.9)	1.5 (1.2, 1.9)	59	37 (62.7)	22 (37.3)	0.9 (0.7, 1.7)	0.847 (0.530, 1.353)	0.4726	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9361
Male	119	76 (63.9)	43 (36.1)	0.8 (0.7, 1.3)	108	68 (63.0)	40 (37.0)	0.9 (0.7, 1.5)	1.012 (0.729, 1.405)	0.9799	
Female	132	93 (70.5)	39 (29.5)	0.8 (0.7, 1.3)	144	104 (72.2)	40 (27.8)	0.8 (0.7, 1.0)	0.989 (0.747, 1.309)	0.9020	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6137
White	149	98 (65.8)	51 (34.2)	0.8 (0.7, 1.3)	151	102 (67.5)	49 (32.5)	0.8 (0.7, 1.1)	0.953 (0.722, 1.258)	0.6763	
Non-white	102	71 (69.6)	31 (30.4)	0.7 (0.7, 1.2)	101	70 (69.3)	31 (30.7)	0.8 (0.7, 1.3)	1.053 (0.756, 1.467)	0.8075	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8071
North America	16	10 (62.5)	6 (37.5)	1.3 (0.7, 2.3)	16	13 (81.3)	3 (18.8)	1.5 (0.7, 1.8)	0.765 (0.299, 1.959)	0.5341	
Europe	149	99 (66.4)	50 (33.6)	0.8 (0.7, 1.3)	149	101 (67.8)	48 (32.2)	0.8 (0.7, 1.1)	0.945 (0.716, 1.247)	0.6600	
Asia/Other Regions	86	60 (69.8)	26 (30.2)	0.7 (0.7, 1.4)	87	58 (66.7)	29 (33.3)	0.8 (0.7, 1.1)	1.059 (0.737, 1.522)	0.7969	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4197
< 40x10^9/L	128	83 (64.8)	45 (35.2)	0.8 (0.7, 1.5)	125	91 (72.8)	34 (27.2)	0.8 (0.7, 1.1)	0.925 (0.686, 1.247)	0.5732	
≥ 40x10^9/L	123	86 (69.9)	37 (30.1)	0.8 (0.7, 1.2)	127	81 (63.8)	46 (36.2)	0.8 (0.7, 1.3)	1.099 (0.811, 1.489)	0.5986	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3736
Daunorubicin	116	77 (66.4)	39 (33.6)	0.7 (0.7, 0.8)	90	57 (63.3)	33 (36.7)	0.9 (0.7, 1.4)	1.110 (0.785, 1.570)	0.6947	
Idarubicin	135	92 (68.1)	43 (31.9)	1.2 (0.7, 1.5)	160	114 (71.3)	46 (28.8)	0.8 (0.7, 0.9)	0.903 (0.686, 1.190)	0.4794	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5875
Favorable	12	9 (75.0)	3 (25.0)	0.7 (0.7, 1.8)	16	13 (81.3)	3 (18.8)	1.4 (0.7, 1.8)	1.255 (0.529, 2.975)	0.7043	
Intermediate	185	127 (68.6)	58 (31.4)	0.8 (0.7, 1.1)	179	119 (66.5)	60 (33.5)	0.8 (0.7, 0.9)	0.951 (0.740, 1.222)	0.6206	
Unfavorable	19	12 (63.2)	7 (36.8)	0.7 (0.7, 1.5)	26	17 (65.4)	9 (34.6)	0.7 (0.7, 2.3)	1.673 (0.786, 3.562)	0.1417	
Unknown	35	21 (60.0)	14 (40.0)	1.3 (0.7, 2.6)	30	22 (73.3)	8 (26.7)	0.9 (0.7, 2.6)	0.930 (0.506, 1.707)	0.7935	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7633
0 - Fully Active	82	59 (72.0)	23 (28.0)	0.8 (0.7, 1.7)	92	65 (70.7)	27 (29.3)	0.9 (0.7, 1.4)	1.011 (0.710, 1.439)	0.9944	
1 - Restricted in Physically Strenuous Activity	126	84 (66.7)	42 (33.3)	0.7 (0.7, 1.1)	125	85 (68.0)	40 (32.0)	0.8 (0.7, 1.0)	1.017 (0.752, 1.375)	0.9588	
2 - Ambulatory and Capable of All Selfcare	43	26 (60.5)	17 (39.5)	0.8 (0.7, 1.4)	34	22 (64.7)	12 (35.3)	0.7 (0.7, 1.5)	0.759 (0.423, 1.364)	0.3020	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6795
≥3 to ≤25%	88	58 (65.9)	30 (34.1)	0.7 (0.7, 1.1)	92	65 (70.7)	27 (29.3)	0.8 (0.7, 1.1)	1.083 (0.758, 1.548)	0.7165	
>25% to ≤50%	135	91 (67.4)	44 (32.6)	0.8 (0.7, 1.4)	127	88 (69.3)	39 (30.7)	0.8 (0.7, 1.0)	0.917 (0.683, 1.231)	0.5180	
>50%	27	19 (70.4)	8 (29.6)	0.8 (0.7, 1.7)	33	19 (57.6)	14 (42.4)	1.3 (0.7, 1.8)	1.173 (0.620, 2.216)	0.5855	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7969
Yes	129	88 (68.2)	41 (31.8)	0.8 (0.7, 1.4)	130	95 (73.1)	35 (26.9)	0.8 (0.7, 1.3)	0.977 (0.731, 1.306)	0.7797	
No	112	72 (64.3)	40 (35.7)	0.8 (0.7, 1.3)	111	68 (61.3)	43 (38.7)	0.7 (0.7, 1.1)	0.912 (0.653, 1.273)	0.5659	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales – Fatigue

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9715
≤60	156	112 (71.8)	44 (28.2)	0.7 (0.7, 0.8)	154	108 (70.1)	46 (29.9)	0.7 (0.7, 0.9)	0.984 (0.755, 1.282)	0.8590	
>60	95	57 (60.0)	38 (40.0)	1.3 (0.7, 1.7)	98	64 (65.3)	34 (34.7)	0.9 (0.8, 1.5)	0.968 (0.676, 1.385)	0.8122	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4915
<60	152	61 (40.1)	91 (59.9)	5.3 (1.8, NE)	151	65 (43.0)	86 (57.0)	2.4 (1.6, NE)	0.852 (0.601, 1.209)	0.3762	
≥60 - <65	36	13 (36.1)	23 (63.9)	12.4 (1.6, NE)	43	14 (32.6)	29 (67.4)	NE (1.5, NE)	1.061 (0.498, 2.257)	0.8700	
≥65	63	24 (38.1)	39 (61.9)	2.6 (1.6, NE)	59	22 (37.3)	37 (62.7)	2.6 (1.7, NE)	1.208 (0.677, 2.158)	0.5377	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1221
Male	119	33 (27.7)	86 (72.3)	NE (4.2, NE)	109	37 (33.9)	72 (66.1)	NE (2.4, NE)	0.748 (0.467, 1.196)	0.2314	
Female	132	65 (49.2)	67 (50.8)	1.8 (1.5, 2.6)	144	64 (44.4)	80 (55.6)	2.1 (1.6, NE)	1.167 (0.826, 1.648)	0.3883	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4373
White	149	55 (36.9)	94 (63.1)	NE (1.8, NE)	151	61 (40.4)	90 (59.6)	2.6 (2.0, NE)	0.880 (0.611, 1.268)	0.4861	
Non-white	102	43 (42.2)	59 (57.8)	2.5 (1.5, 9.3)	102	40 (39.2)	62 (60.8)	4.1 (1.6, NE)	1.097 (0.713, 1.687)	0.6545	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4497
North America	16	5 (31.3)	11 (68.8)	2.1 (0.7, NE)	16	7 (43.8)	9 (56.3)	2.0 (0.8, NE)	1.096 (0.347, 3.465)	0.8758	
Europe	149	55 (36.9)	94 (63.1)	NE (1.8, NE)	150	61 (40.7)	89 (59.3)	2.3 (1.8, NE)	0.835 (0.580, 1.203)	0.3374	
Asia/Other Regions	86	38 (44.2)	48 (55.8)	2.6 (1.3, 9.3)	87	33 (37.9)	54 (62.1)	4.3 (1.6, NE)	1.193 (0.748, 1.902)	0.4584	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2482
< 40x10^9/L	128	42 (32.8)	86 (67.2)	NE (2.6, NE)	125	52 (41.6)	73 (58.4)	2.7 (2.0, NE)	0.807 (0.537, 1.212)	0.3195	
≥ 40x10^9/L	123	56 (45.5)	67 (54.5)	2.0 (1.5, 9.3)	128	49 (38.3)	79 (61.7)	2.3 (1.7, NE)	1.119 (0.762, 1.642)	0.5870	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7456
Daunorubicin	116	51 (44.0)	65 (56.0)	1.8 (0.8, 5.3)	90	45 (50.0)	45 (50.0)	1.6 (0.8, 2.0)	0.871 (0.582, 1.304)	0.4664	
Idarubicin	135	47 (34.8)	88 (65.2)	NE (2.5, NE)	161	56 (34.8)	105 (65.2)	NE (2.6, NE)	0.939 (0.637, 1.384)	0.7802	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.1140
Favorable	12	7 (58.3)	5 (41.7)	1.5 (0.7, NE)	16	5 (31.3)	11 (68.8)	NE (0.7, NE)	2.738 (0.861, 8.703)	0.0690	
Intermediate	186	72 (38.7)	114 (61.3)	3.8 (1.9, NE)	180	73 (40.6)	107 (59.4)	2.3 (1.7, NE)	0.857 (0.618, 1.187)	0.3550	
Unfavorable	19	7 (36.8)	12 (63.2)	1.5 (0.7, NE)	26	7 (26.9)	19 (73.1)	NE (1.1, NE)	1.816 (0.636, 5.182)	0.2544	
Unknown	34	12 (35.3)	22 (64.7)	NE (0.7, NE)	30	15 (50.0)	15 (50.0)	2.1 (0.7, NE)	0.782 (0.366, 1.673)	0.5106	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.0227
0 - Fully Active	82	32 (39.0)	50 (61.0)	12.4 (1.8, NE)	92	41 (44.6)	51 (55.4)	2.1 (1.6, NE)	0.813 (0.512, 1.292)	0.3763	
1 - Restricted in Physically Strenuous Activity	125	49 (39.2)	76 (60.8)	2.6 (1.6, NE)	126	38 (30.2)	88 (69.8)	NE (2.6, NE)	1.369 (0.896, 2.092)	0.1331	
2 - Ambulatory and Capable of All Selfcare	44	17 (38.6)	27 (61.4)	1.8 (0.8, NE)	34	22 (64.7)	12 (35.3)	0.7 (0.7, 1.6)	0.481 (0.255, 0.908)	0.0209	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9166
≥3 to ≤25%	87	30 (34.5)	57 (65.5)	3.8 (1.5, NE)	92	38 (41.3)	54 (58.7)	2.1 (1.3, NE)	0.904 (0.560, 1.460)	0.6853	
>25% to ≤50%	135	54 (40.0)	81 (60.0)	4.2 (1.8, NE)	128	49 (38.3)	79 (61.7)	4.1 (2.1, NE)	1.000 (0.679, 1.473)	0.9942	
>50%	28	14 (50.0)	14 (50.0)	1.4 (0.7, NE)	33	14 (42.4)	19 (57.6)	1.7 (0.7, NE)	1.063 (0.506, 2.234)	0.8077	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6004
Yes	129	56 (43.4)	73 (56.6)	2.4 (1.6, NE)	131	58 (44.3)	73 (55.7)	2.6 (1.7, NE)	1.017 (0.705, 1.469)	0.9379	
No	112	39 (34.8)	73 (65.2)	5.3 (1.8, NE)	111	39 (35.1)	72 (64.9)	2.6 (2.1, NE)	0.859 (0.550, 1.340)	0.5093	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Nausea and Vomiting

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2401
≤60	157	62 (39.5)	95 (60.5)	5.3 (1.8, NE)	154	65 (42.2)	89 (57.8)	2.6 (1.6, NE)	0.851 (0.601, 1.206)	0.3717	
>60	94	36 (38.3)	58 (61.7)	2.6 (1.7, NE)	99	36 (36.4)	63 (63.6)	2.7 (2.0, NE)	1.177 (0.741, 1.869)	0.4971	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2157
<60	152	77 (50.7)	75 (49.3)	1.8 (1.2, 2.9)	151	74 (49.0)	77 (51.0)	1.5 (0.8, 2.4)	0.922 (0.670, 1.269)	0.6285	
≥60 - <65	36	18 (50.0)	18 (50.0)	0.8 (0.7, NE)	43	16 (37.2)	27 (62.8)	5.7 (1.6, NE)	1.825 (0.928, 3.589)	0.0775	
≥65	64	24 (37.5)	40 (62.5)	1.6 (1.2, NE)	59	25 (42.4)	34 (57.6)	1.6 (0.8, NE)	0.978 (0.558, 1.715)	0.9074	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7186
Male	120	51 (42.5)	69 (57.5)	1.8 (0.8, 8.0)	109	44 (40.4)	65 (59.6)	2.6 (1.5, NE)	1.094 (0.731, 1.638)	0.6761	
Female	132	68 (51.5)	64 (48.5)	1.6 (1.1, 2.5)	144	71 (49.3)	73 (50.7)	1.5 (0.8, 2.0)	1.007 (0.722, 1.405)	0.9598	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7896
White	150	72 (48.0)	78 (52.0)	1.4 (0.8, 3.2)	151	66 (43.7)	85 (56.3)	1.7 (0.8, NE)	1.082 (0.775, 1.512)	0.6312	
Non-white	102	47 (46.1)	55 (53.9)	1.9 (1.3, 7.4)	102	49 (48.0)	53 (52.0)	2.0 (1.3, 4.4)	0.993 (0.665, 1.482)	0.9608	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3483
North America	16	9 (56.3)	7 (43.8)	0.7 (0.7, 1.6)	16	9 (56.3)	7 (43.8)	1.7 (0.8, NE)	2.613 (1.011, 6.758)	0.0414	
Europe	150	68 (45.3)	82 (54.7)	1.4 (0.8, NE)	150	66 (44.0)	84 (56.0)	2.2 (0.8, 5.7)	0.979 (0.698, 1.375)	0.9180	
Asia/Other Regions	86	42 (48.8)	44 (51.2)	2.5 (1.3, 5.2)	87	40 (46.0)	47 (54.0)	1.6 (0.9, NE)	1.040 (0.674, 1.605)	0.8748	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4132
< 40x10^9/L	128	53 (41.4)	75 (58.6)	2.5 (1.4, NE)	125	58 (46.4)	67 (53.6)	1.8 (1.3, NE)	0.934 (0.643, 1.355)	0.7468	
≥ 40x10^9/L	124	66 (53.2)	58 (46.8)	1.3 (0.8, 2.5)	128	57 (44.5)	71 (55.5)	1.7 (0.8, 2.5)	1.155 (0.810, 1.646)	0.4467	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4367
Daunorubicin	116	49 (42.2)	67 (57.8)	1.8 (1.2, 8.2)	90	40 (44.4)	50 (55.6)	1.6 (0.8, NE)	0.934 (0.614, 1.421)	0.7350	
Idarubicin	136	70 (51.5)	66 (48.5)	1.5 (1.1, 2.5)	161	73 (45.3)	88 (54.7)	2.2 (1.0, 5.7)	1.144 (0.824, 1.587)	0.4059	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3413
Favorable	12	3 (25.0)	9 (75.0)	NE (0.7, NE)	16	11 (68.8)	5 (31.3)	1.5 (0.7, 2.5)	0.309 (0.085, 1.120)	0.0573	
Intermediate	186	93 (50.0)	93 (50.0)	1.4 (0.9, 1.9)	180	79 (43.9)	101 (56.1)	1.6 (0.8, 4.4)	1.093 (0.810, 1.475)	0.5563	
Unfavorable	19	8 (42.1)	11 (57.9)	1.5 (0.7, NE)	26	11 (42.3)	15 (57.7)	2.6 (0.7, NE)	1.256 (0.503, 3.133)	0.5980	
Unknown	35	15 (42.9)	20 (57.1)	3.3 (0.7, NE)	30	13 (43.3)	17 (56.7)	3.2 (1.3, NE)	1.221 (0.579, 2.573)	0.6247	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5674
0 - Fully Active	82	33 (40.2)	49 (59.8)	4.0 (1.8, NE)	92	40 (43.5)	52 (56.5)	2.0 (1.3, NE)	0.845 (0.533, 1.342)	0.4871	
1 - Restricted in Physically Strenuous Activity	126	61 (48.4)	65 (51.6)	1.6 (1.1, 2.9)	126	54 (42.9)	72 (57.1)	2.2 (1.0, NE)	1.161 (0.805, 1.675)	0.4142	
2 - Ambulatory and Capable of All Selfcare	44	25 (56.8)	19 (43.2)	0.8 (0.7, 1.2)	34	21 (61.8)	13 (38.2)	0.8 (0.7, 2.0)	1.010 (0.559, 1.826)	0.9604	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7013
≥3 to ≤25%	88	38 (43.2)	50 (56.8)	2.5 (1.2, 8.0)	92	40 (43.5)	52 (56.5)	1.6 (0.8, NE)	0.968 (0.621, 1.509)	0.8972	
>25% to ≤50%	135	65 (48.1)	70 (51.9)	1.6 (0.9, 2.9)	128	56 (43.8)	72 (56.3)	2.4 (1.3, 5.7)	1.170 (0.818, 1.673)	0.3968	
>50%	28	16 (57.1)	12 (42.9)	1.3 (0.7, NE)	33	19 (57.6)	14 (42.4)	1.5 (0.7, 2.2)	0.907 (0.466, 1.764)	0.7939	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3266
Yes	130	66 (50.8)	64 (49.2)	1.4 (1.2, 2.9)	131	71 (54.2)	60 (45.8)	1.5 (0.8, 2.2)	0.944 (0.675, 1.321)	0.7155	
No	112	49 (43.8)	63 (56.3)	1.8 (0.8, 4.0)	111	39 (35.1)	72 (64.9)	2.5 (1.3, NE)	1.203 (0.790, 1.833)	0.3685	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Symptom Scales - Pain

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2930
≤60	157	79 (50.3)	78 (49.7)	1.8 (1.2, 2.9)	154	74 (48.1)	80 (51.9)	1.5 (0.8, 2.4)	0.932 (0.679, 1.280)	0.6797	
>60	95	40 (42.1)	55 (57.9)	1.5 (0.8, 7.4)	99	41 (41.4)	58 (58.6)	2.6 (1.5, NE)	1.258 (0.814, 1.946)	0.3145	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5392
<60	152	56 (36.8)	96 (63.2)	NE (2.5, NE)	151	59 (39.1)	92 (60.9)	8.0 (1.8, NE)	0.876 (0.607, 1.263)	0.4445	
≥60 - <65	36	12 (33.3)	24 (66.7)	7.6 (0.8, NE)	43	17 (39.5)	26 (60.5)	4.1 (1.4, NE)	0.814 (0.387, 1.710)	0.5753	
≥65	64	19 (29.7)	45 (70.3)	NE (1.4, NE)	59	16 (27.1)	43 (72.9)	NE (1.5, NE)	1.292 (0.664, 2.512)	0.4491	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4018
Male	120	30 (25.0)	90 (75.0)	NE (NE, NE)	109	32 (29.4)	77 (70.6)	NE (5.7, NE)	0.835 (0.507, 1.375)	0.4484	
Female	132	57 (43.2)	75 (56.8)	2.5 (1.6, NE)	144	60 (41.7)	84 (58.3)	4.1 (1.7, NE)	1.067 (0.742, 1.533)	0.7325	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.0997
White	150	55 (36.7)	95 (63.3)	NE (1.8, NE)	151	48 (31.8)	103 (68.2)	NE (4.1, NE)	1.180 (0.801, 1.738)	0.4203	
Non-white	102	32 (31.4)	70 (68.6)	NE (2.5, NE)	102	44 (43.1)	58 (56.9)	1.9 (1.5, NE)	0.698 (0.442, 1.104)	0.1134	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9081
North America	16	6 (37.5)	10 (62.5)	1.8 (0.7, NE)	16	9 (56.3)	7 (43.8)	1.7 (0.8, NE)	1.102 (0.390, 3.111)	0.8722	
Europe	150	52 (34.7)	98 (65.3)	NE (2.1, NE)	150	50 (33.3)	100 (66.7)	NE (4.1, NE)	1.016 (0.689, 1.498)	0.9674	
Asia/Other Regions	86	29 (33.7)	57 (66.3)	NE (1.7, NE)	87	33 (37.9)	54 (62.1)	18.4 (1.3, NE)	0.882 (0.535, 1.455)	0.6065	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1205
< 40x10^9/L	128	36 (28.1)	92 (71.9)	NE (19.6, NE)	125	49 (39.2)	76 (60.8)	8.0 (1.8, NE)	0.740 (0.481, 1.139)	0.1627	
≥ 40x10^9/L	124	51 (41.1)	73 (58.9)	2.8 (1.6, NE)	128	43 (33.6)	85 (66.4)	18.4 (1.9, NE)	1.191 (0.794, 1.788)	0.4141	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2542
Daunorubicin	116	36 (31.0)	80 (69.0)	NE (2.9, NE)	90	35 (38.9)	55 (61.1)	3.4 (1.6, NE)	0.755 (0.473, 1.205)	0.2147	
Idarubicin	136	51 (37.5)	85 (62.5)	4.6 (1.7, NE)	161	56 (34.8)	105 (65.2)	NE (2.1, NE)	1.090 (0.746, 1.594)	0.6612	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7039
Favorable	12	3 (25.0)	9 (75.0)	NE (0.7, NE)	16	8 (50.0)	8 (50.0)	13.3 (1.0, NE)	0.639 (0.169, 2.410)	0.4863	
Intermediate	186	68 (36.6)	118 (63.4)	19.6 (1.8, NE)	180	65 (36.1)	115 (63.9)	5.7 (1.9, NE)	0.951 (0.677, 1.337)	0.7523	
Unfavorable	19	8 (42.1)	11 (57.9)	1.8 (0.7, NE)	26	9 (34.6)	17 (65.4)	NE (0.7, NE)	1.588 (0.612, 4.123)	0.3368	
Unknown	35	8 (22.9)	27 (77.1)	NE (2.6, NE)	30	9 (30.0)	21 (70.0)	NE (7.5, NE)	0.890 (0.343, 2.310)	0.8059	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2612
0 - Fully Active	82	25 (30.5)	57 (69.5)	NE (2.9, NE)	92	29 (31.5)	63 (68.5)	NE (8.0, NE)	0.957 (0.560, 1.635)	0.8589	
1 - Restricted in Physically Strenuous Activity	126	47 (37.3)	79 (62.7)	3.7 (1.7, NE)	126	44 (34.9)	82 (65.1)	NE (1.8, NE)	1.074 (0.712, 1.621)	0.7514	
2 - Ambulatory and Capable of All Selfcare	44	15 (34.1)	29 (65.9)	19.6 (0.8, NE)	34	19 (55.9)	15 (44.1)	1.5 (0.7, 2.0)	0.550 (0.276, 1.093)	0.0743	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.0322
≥3 to ≤25%	88	25 (28.4)	63 (71.6)	NE (2.8, NE)	92	40 (43.5)	52 (56.5)	1.9 (1.0, NE)	0.620 (0.375, 1.024)	0.0538	
>25% to ≤50%	135	51 (37.8)	84 (62.2)	2.9 (1.6, NE)	128	39 (30.5)	89 (69.5)	NE (5.7, NE)	1.411 (0.929, 2.141)	0.1125	
>50%	28	10 (35.7)	18 (64.3)	NE (1.3, NE)	33	13 (39.4)	20 (60.6)	1.7 (0.7, NE)	0.673 (0.294, 1.540)	0.3674	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9405
Yes	130	48 (36.9)	82 (63.1)	NE (2.1, NE)	131	54 (41.2)	77 (58.8)	7.5 (1.9, NE)	0.940 (0.637, 1.387)	0.7136	
No	112	36 (32.1)	76 (67.9)	NE (1.8, NE)	111	34 (30.6)	77 (69.4)	NE (1.7, NE)	0.964 (0.603, 1.541)	0.8764	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Dyspnea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5705
≤60	157	57 (36.3)	100 (63.7)	NE (2.5, NE)	154	59 (38.3)	95 (61.7)	8.0 (1.8, NE)	0.883 (0.613, 1.272)	0.4648	
>60	95	30 (31.6)	65 (68.4)	NE (1.6, NE)	99	33 (33.3)	66 (66.7)	NE (1.7, NE)	1.066 (0.650, 1.749)	0.7855	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1540
<60	152	79 (52.0)	73 (48.0)	2.3 (1.5, 4.4)	151	61 (40.4)	90 (59.6)	4.5 (1.7, NE)	1.343 (0.962, 1.876)	0.0797	
≥60 - <65	36	14 (38.9)	22 (61.1)	1.3 (0.7, NE)	43	20 (46.5)	23 (53.5)	3.1 (1.6, 11.8)	1.032 (0.520, 2.048)	0.9467	
≥65	64	21 (32.8)	43 (67.2)	3.5 (1.6, NE)	59	28 (47.5)	31 (52.5)	2.0 (1.3, 2.4)	0.699 (0.396, 1.232)	0.2126	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4649
Male	120	54 (45.0)	66 (55.0)	2.5 (1.5, 11.3)	109	40 (36.7)	69 (63.3)	3.2 (2.0, NE)	1.257 (0.835, 1.892)	0.2745	
Female	132	60 (45.5)	72 (54.5)	2.0 (1.5, 7.6)	144	69 (47.9)	75 (52.1)	2.0 (1.6, 7.8)	1.040 (0.736, 1.470)	0.8089	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9146
White	150	66 (44.0)	84 (56.0)	2.2 (1.3, 10.3)	151	64 (42.4)	87 (57.6)	2.4 (1.7, NE)	1.119 (0.794, 1.579)	0.5294	
Non-white	102	48 (47.1)	54 (52.9)	2.5 (1.6, 7.6)	102	45 (44.1)	57 (55.9)	3.1 (1.6, 8.7)	1.062 (0.704, 1.601)	0.7578	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9622
North America	16	7 (43.8)	9 (56.3)	2.6 (1.3, NE)	16	10 (62.5)	6 (37.5)	1.7 (0.7, 8.8)	1.026 (0.380, 2.771)	0.9604	
Europe	150	65 (43.3)	85 (56.7)	2.0 (1.5, 14.3)	150	61 (40.7)	89 (59.3)	2.6 (1.7, NE)	1.108 (0.782, 1.572)	0.5576	
Asia/Other Regions	86	42 (48.8)	44 (51.2)	2.5 (1.4, 10.6)	87	38 (43.7)	49 (56.3)	3.3 (1.7, 8.7)	1.116 (0.716, 1.739)	0.6271	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.8191
< 40x10^9/L	128	52 (40.6)	76 (59.4)	3.0 (1.6, 19.5)	125	53 (42.4)	72 (57.6)	3.1 (1.9, NE)	1.143 (0.780, 1.677)	0.4961	
≥ 40x10^9/L	124	62 (50.0)	62 (50.0)	2.1 (1.4, 3.3)	128	56 (43.8)	72 (56.3)	2.0 (1.7, 5.5)	1.074 (0.748, 1.541)	0.6853	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8526
Daunorubicin	116	50 (43.1)	66 (56.9)	2.3 (1.1, 10.3)	90	35 (38.9)	55 (61.1)	2.1 (1.6, NE)	1.172 (0.760, 1.807)	0.4845	
Idarubicin	136	64 (47.1)	72 (52.9)	2.5 (1.5, 10.6)	161	72 (44.7)	89 (55.3)	2.6 (1.9, 5.5)	1.105 (0.789, 1.548)	0.5383	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4106
Favorable	12	6 (50.0)	6 (50.0)	1.6 (0.7, NE)	16	8 (50.0)	8 (50.0)	8.8 (1.6, NE)	1.653 (0.566, 4.821)	0.3779	
Intermediate	186	89 (47.8)	97 (52.2)	2.2 (1.6, 3.5)	180	70 (38.9)	110 (61.1)	2.6 (1.7, NE)	1.232 (0.900, 1.684)	0.1862	
Unfavorable	19	8 (42.1)	11 (57.9)	1.3 (0.7, NE)	26	15 (57.7)	11 (42.3)	1.9 (0.7, 4.5)	0.964 (0.403, 2.305)	0.9936	
Unknown	35	11 (31.4)	24 (68.6)	17.1 (1.3, NE)	30	15 (50.0)	15 (50.0)	2.6 (0.8, NE)	0.654 (0.299, 1.429)	0.2955	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.0937
0 - Fully Active	82	36 (43.9)	46 (56.1)	7.6 (1.5, NE)	92	31 (33.7)	61 (66.3)	16.4 (2.6, NE)	1.603 (0.991, 2.594)	0.0526	
1 - Restricted in Physically Strenuous Activity	126	58 (46.0)	68 (54.0)	2.3 (1.6, 3.5)	126	58 (46.0)	68 (54.0)	2.1 (1.6, 3.3)	0.941 (0.653, 1.354)	0.7522	
2 - Ambulatory and Capable of All Selfcare	44	20 (45.5)	24 (54.5)	1.4 (0.8, 14.3)	34	20 (58.8)	14 (41.2)	1.6 (0.7, 2.0)	0.704 (0.372, 1.333)	0.2576	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1544
≥3 to ≤25%	88	40 (45.5)	48 (54.5)	1.8 (0.8, 14.3)	92	37 (40.2)	55 (59.8)	3.2 (1.6, NE)	1.325 (0.847, 2.073)	0.2224	
>25% to ≤50%	135	61 (45.2)	74 (54.8)	2.3 (1.6, 10.6)	128	53 (41.4)	75 (58.6)	2.6 (2.0, 8.8)	1.173 (0.811, 1.696)	0.3975	
>50%	28	13 (46.4)	15 (53.6)	2.8 (1.3, NE)	33	19 (57.6)	14 (42.4)	1.6 (0.7, 2.1)	0.622 (0.306, 1.262)	0.2134	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9184
Yes	130	65 (50.0)	65 (50.0)	1.8 (1.3, 7.6)	131	66 (50.4)	65 (49.6)	2.1 (1.6, 8.8)	1.125 (0.798, 1.585)	0.5177	
No	112	45 (40.2)	67 (59.8)	2.5 (1.7, 14.3)	111	38 (34.2)	73 (65.8)	2.6 (1.9, 16.4)	1.119 (0.725, 1.728)	0.5967	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Insomnia

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1028
≤60	157	80 (51.0)	77 (49.0)	2.3 (1.5, 4.4)	154	62 (40.3)	92 (59.7)	4.5 (1.7, 16.4)	1.323 (0.949, 1.843)	0.0942	
>60	95	34 (35.8)	61 (64.2)	3.3 (1.5, NE)	99	47 (47.5)	52 (52.5)	2.1 (1.7, 3.2)	0.844 (0.542, 1.312)	0.4446	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1349
<60	152	87 (57.2)	65 (42.8)	1.6 (0.9, 2.3)	151	83 (55.0)	68 (45.0)	1.5 (0.7, 1.9)	0.972 (0.719, 1.313)	0.8504	
≥60 - <65	36	23 (63.9)	13 (36.1)	0.8 (0.7, 1.6)	43	21 (48.8)	22 (51.2)	2.0 (0.8, 6.1)	1.598 (0.882, 2.894)	0.1314	
≥65	64	25 (39.1)	39 (60.9)	2.9 (1.5, 9.3)	59	32 (54.2)	27 (45.8)	1.4 (0.9, 2.0)	0.650 (0.384, 1.100)	0.1084	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3498
Male	120	61 (50.8)	59 (49.2)	1.5 (0.8, 2.2)	109	49 (45.0)	60 (55.0)	2.3 (0.8, 4.0)	1.139 (0.782, 1.659)	0.4937	
Female	132	74 (56.1)	58 (43.9)	2.0 (1.3, 2.6)	144	87 (60.4)	57 (39.6)	1.5 (0.9, 1.7)	0.893 (0.654, 1.219)	0.4709	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9809
White	150	78 (52.0)	72 (48.0)	1.6 (1.1, 2.5)	151	82 (54.3)	69 (45.7)	1.6 (0.9, 2.0)	0.964 (0.707, 1.315)	0.8006	
Non-white	102	57 (55.9)	45 (44.1)	1.8 (1.0, 2.5)	102	54 (52.9)	48 (47.1)	1.6 (0.7, 2.3)	0.962 (0.662, 1.399)	0.8457	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9666
North America	16	7 (43.8)	9 (56.3)	1.3 (0.7, NE)	16	12 (75.0)	4 (25.0)	1.7 (0.7, 3.1)	1.061 (0.391, 2.878)	0.9323	
Europe	150	78 (52.0)	72 (48.0)	1.6 (1.1, 2.5)	150	80 (53.3)	70 (46.7)	1.5 (0.8, 2.6)	0.947 (0.693, 1.293)	0.7356	
Asia/Other Regions	86	50 (58.1)	36 (41.9)	2.0 (0.8, 3.5)	87	44 (50.6)	43 (49.4)	1.6 (0.8, 2.0)	1.021 (0.679, 1.536)	0.9416	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.8354
< 40x10^9/L	128	62 (48.4)	66 (51.6)	2.0 (1.3, 3.8)	125	69 (55.2)	56 (44.8)	1.9 (1.3, 2.8)	0.946 (0.671, 1.333)	0.7377	
≥ 40x10^9/L	124	73 (58.9)	51 (41.1)	1.3 (0.8, 2.2)	128	67 (52.3)	61 (47.7)	1.5 (0.7, 1.7)	0.995 (0.713, 1.386)	0.9745	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2258
Daunorubicin	116	63 (54.3)	53 (45.7)	1.1 (0.7, 2.0)	90	47 (52.2)	43 (47.8)	1.6 (0.8, 2.3)	1.143 (0.783, 1.668)	0.5300	
Idarubicin	136	72 (52.9)	64 (47.1)	2.0 (1.5, 3.5)	161	89 (55.3)	72 (44.7)	1.5 (0.9, 1.9)	0.841 (0.616, 1.148)	0.2882	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.0013
Favorable	12	7 (58.3)	5 (41.7)	0.7 (0.6, NE)	16	6 (37.5)	10 (62.5)	8.7 (1.6, NE)	4.875 (1.373, 17.313)	0.0083	
Intermediate	186	100 (53.8)	86 (46.2)	1.7 (1.3, 2.5)	180	100 (55.6)	80 (44.4)	1.3 (0.8, 1.6)	0.816 (0.618, 1.078)	0.1502	
Unfavorable	19	12 (63.2)	7 (36.8)	0.7 (0.7, 1.5)	26	12 (46.2)	14 (53.8)	2.1 (0.7, NE)	2.989 (1.300, 6.872)	0.0059	
Unknown	35	16 (45.7)	19 (54.3)	3.0 (1.3, NE)	30	17 (56.7)	13 (43.3)	2.0 (0.9, NE)	0.836 (0.421, 1.659)	0.5911	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9593
0 - Fully Active	82	46 (56.1)	36 (43.9)	2.3 (1.0, 3.8)	92	52 (56.5)	40 (43.5)	1.6 (0.8, 2.0)	0.941 (0.632, 1.400)	0.7918	
1 - Restricted in Physically Strenuous Activity	126	67 (53.2)	59 (46.8)	1.5 (0.9, 2.5)	126	66 (52.4)	60 (47.6)	1.7 (1.0, 2.6)	1.016 (0.722, 1.428)	0.9502	
2 - Ambulatory and Capable of All Selfcare	44	22 (50.0)	22 (50.0)	1.5 (0.8, 2.0)	34	18 (52.9)	16 (47.1)	1.0 (0.7, 3.1)	0.944 (0.505, 1.763)	0.8251	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7940
≥3 to ≤25%	88	45 (51.1)	43 (48.9)	1.7 (0.8, 2.5)	92	51 (55.4)	41 (44.6)	1.6 (0.8, 2.8)	1.089 (0.729, 1.628)	0.7270	
>25% to ≤50%	135	74 (54.8)	61 (45.2)	1.8 (1.2, 2.6)	128	66 (51.6)	62 (48.4)	1.7 (0.8, 2.3)	0.962 (0.690, 1.342)	0.8300	
>50%	28	16 (57.1)	12 (42.9)	1.3 (0.7, 4.6)	33	19 (57.6)	14 (42.4)	1.5 (0.7, 3.1)	0.851 (0.437, 1.657)	0.6670	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9938
Yes	130	76 (58.5)	54 (41.5)	1.6 (1.2, 2.5)	131	83 (63.4)	48 (36.6)	1.5 (0.9, 1.8)	0.938 (0.687, 1.281)	0.6442	
No	112	53 (47.3)	59 (52.7)	2.0 (1.1, 2.6)	111	48 (43.2)	63 (56.8)	1.9 (0.7, 2.6)	0.948 (0.641, 1.402)	0.8158	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Appetite Loss

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8827
≤60	157	89 (56.7)	68 (43.3)	1.6 (0.8, 2.3)	154	83 (53.9)	71 (46.1)	1.5 (0.7, 1.9)	0.993 (0.736, 1.340)	0.9523	
>60	95	46 (48.4)	49 (51.6)	1.8 (1.2, 3.5)	99	53 (53.5)	46 (46.5)	1.7 (1.3, 2.1)	0.934 (0.628, 1.388)	0.7383	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8884
<60	152	52 (34.2)	100 (65.8)	NE (5.1, NE)	151	36 (23.8)	115 (76.2)	NE (NE, NE)	1.364 (0.892, 2.086)	0.1424	
≥60 - <65	36	9 (25.0)	27 (75.0)	NE (1.6, NE)	43	8 (18.6)	35 (81.4)	NE (5.7, NE)	1.518 (0.585, 3.936)	0.3944	
≥65	64	12 (18.8)	52 (81.3)	NE (NE, NE)	59	12 (20.3)	47 (79.7)	NE (NE, NE)	1.139 (0.512, 2.536)	0.7632	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.0090
Male	120	26 (21.7)	94 (78.3)	NE (NE, NE)	109	28 (25.7)	81 (74.3)	NE (NE, NE)	0.801 (0.470, 1.367)	0.4202	
Female	132	47 (35.6)	85 (64.4)	6.1 (2.4, NE)	144	28 (19.4)	116 (80.6)	NE (NE, NE)	2.050 (1.284, 3.274)	0.0022	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1625
White	150	43 (28.7)	107 (71.3)	NE (6.1, NE)	151	26 (17.2)	125 (82.8)	NE (NE, NE)	1.714 (1.053, 2.789)	0.0281	
Non-white	102	30 (29.4)	72 (70.6)	NE (2.5, NE)	102	30 (29.4)	72 (70.6)	NE (5.7, NE)	1.044 (0.629, 1.732)	0.8638	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6681
North America	16	5 (31.3)	11 (68.8)	2.1 (0.7, NE)	16	4 (25.0)	12 (75.0)	NE (1.7, NE)	2.055 (0.549, 7.689)	0.2735	
Europe	150	43 (28.7)	107 (71.3)	NE (5.7, NE)	150	29 (19.3)	121 (80.7)	NE (NE, NE)	1.489 (0.930, 2.386)	0.0968	
Asia/Other Regions	86	25 (29.1)	61 (70.9)	NE (2.8, NE)	87	23 (26.4)	64 (73.6)	NE (8.7, NE)	1.151 (0.653, 2.029)	0.6159	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0665
< 40x10^9/L	128	39 (30.5)	89 (69.5)	NE (3.8, NE)	125	25 (20.0)	100 (80.0)	NE (NE, NE)	1.871 (1.132, 3.093)	0.0131	
≥ 40x10^9/L	124	34 (27.4)	90 (72.6)	NE (6.1, NE)	128	31 (24.2)	97 (75.8)	NE (NE, NE)	0.979 (0.601, 1.594)	0.9361	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2917
Daunorubicin	116	34 (29.3)	82 (70.7)	NE (5.1, NE)	90	24 (26.7)	66 (73.3)	NE (NE, NE)	1.064 (0.631, 1.796)	0.8136	
Idarubicin	136	39 (28.7)	97 (71.3)	NE (5.7, NE)	161	32 (19.9)	129 (80.1)	NE (NE, NE)	1.537 (0.963, 2.453)	0.0687	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3583
Favorable	12	5 (41.7)	7 (58.3)	6.1 (1.6, NE)	16	1 (6.3)	15 (93.8)	NE (8.7, NE)	9.952 (1.151, 86.087)	0.0106	
Intermediate	186	52 (28.0)	134 (72.0)	NE (NE, NE)	180	40 (22.2)	140 (77.8)	NE (NE, NE)	1.201 (0.796, 1.815)	0.3847	
Unfavorable	19	4 (21.1)	15 (78.9)	NE (0.7, NE)	26	6 (23.1)	20 (76.9)	NE (2.2, NE)	1.119 (0.315, 3.979)	0.8524	
Unknown	35	12 (34.3)	23 (65.7)	NE (0.8, NE)	30	9 (30.0)	21 (70.0)	NE (3.4, NE)	1.372 (0.577, 3.262)	0.4832	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8057
0 - Fully Active	82	24 (29.3)	58 (70.7)	NE (5.1, NE)	92	20 (21.7)	72 (78.3)	NE (NE, NE)	1.338 (0.739, 2.422)	0.3325	
1 - Restricted in Physically Strenuous Activity	126	38 (30.2)	88 (69.8)	NE (2.8, NE)	126	28 (22.2)	98 (77.8)	NE (NE, NE)	1.447 (0.888, 2.358)	0.1363	
2 - Ambulatory and Capable of All Selfcare	44	11 (25.0)	33 (75.0)	NE (1.5, NE)	34	8 (23.5)	26 (76.5)	NE (5.7, NE)	1.032 (0.414, 2.568)	0.9450	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3176
≥3 to ≤25%	88	32 (36.4)	56 (63.6)	2.8 (1.6, NE)	92	21 (22.8)	71 (77.2)	NE (NE, NE)	1.924 (1.109, 3.339)	0.0178	
>25% to ≤50%	135	33 (24.4)	102 (75.6)	NE (NE, NE)	128	27 (21.1)	101 (78.9)	NE (NE, NE)	1.144 (0.688, 1.903)	0.6006	
>50%	28	8 (28.6)	20 (71.4)	NE (2.0, NE)	33	8 (24.2)	25 (75.8)	NE (2.2, NE)	0.999 (0.373, 2.672)	1.0000	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6745
Yes	130	37 (28.5)	93 (71.5)	NE (NE, NE)	131	32 (24.4)	99 (75.6)	NE (NE, NE)	1.256 (0.783, 2.017)	0.3507	
No	112	31 (27.7)	81 (72.3)	NE (3.8, NE)	111	20 (18.0)	91 (82.0)	NE (NE, NE)	1.462 (0.833, 2.565)	0.1789	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Constipation

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8612
≤60	157	52 (33.1)	105 (66.9)	NE (5.1, NE)	154	37 (24.0)	117 (76.0)	NE (NE, NE)	1.305 (0.856, 1.989)	0.2049	
>60	95	21 (22.1)	74 (77.9)	NE (NE, NE)	99	19 (19.2)	80 (80.8)	NE (NE, NE)	1.405 (0.755, 2.615)	0.2906	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7358
<60	152	64 (42.1)	88 (57.9)	2.6 (1.5, NE)	151	61 (40.4)	90 (59.6)	2.5 (1.5, NE)	0.934 (0.658, 1.327)	0.7222	
≥60 - <65	36	14 (38.9)	22 (61.1)	1.7 (0.7, NE)	43	20 (46.5)	23 (53.5)	2.0 (0.9, 5.7)	0.933 (0.470, 1.854)	0.8168	
≥65	64	21 (32.8)	43 (67.2)	8.1 (1.2, NE)	59	19 (32.2)	40 (67.8)	NE (1.7, NE)	1.226 (0.659, 2.281)	0.5197	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8312
Male	120	47 (39.2)	73 (60.8)	2.0 (1.4, NE)	109	43 (39.4)	66 (60.6)	2.6 (1.4, NE)	0.948 (0.627, 1.434)	0.7997	
Female	132	52 (39.4)	80 (60.6)	2.6 (1.5, NE)	144	57 (39.6)	87 (60.4)	2.5 (1.6, NE)	1.012 (0.694, 1.473)	0.9382	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8895
White	150	55 (36.7)	95 (63.3)	NE (1.7, NE)	151	54 (35.8)	97 (64.2)	NE (2.0, NE)	1.011 (0.694, 1.471)	0.9468	
Non-white	102	44 (43.1)	58 (56.9)	1.6 (1.1, 2.9)	102	46 (45.1)	56 (54.9)	1.7 (1.4, 2.6)	0.956 (0.632, 1.446)	0.8335	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5865
North America	16	7 (43.8)	9 (56.3)	1.3 (0.7, 2.0)	16	8 (50.0)	8 (50.0)	1.7 (0.8, NE)	2.028 (0.728, 5.651)	0.1738	
Europe	150	53 (35.3)	97 (64.7)	NE (1.9, NE)	150	52 (34.7)	98 (65.3)	NE (2.6, NE)	0.993 (0.677, 1.456)	0.9880	
Asia/Other Regions	86	39 (45.3)	47 (54.7)	1.6 (1.1, 2.9)	87	40 (46.0)	47 (54.0)	1.6 (0.8, 2.5)	0.897 (0.577, 1.396)	0.6115	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2229
< 40x10^9/L	128	40 (31.3)	88 (68.8)	NE (1.7, NE)	125	52 (41.6)	73 (58.4)	3.2 (1.6, NE)	0.810 (0.536, 1.223)	0.3120	
≥ 40x10^9/L	124	59 (47.6)	65 (52.4)	1.6 (1.4, 2.9)	128	48 (37.5)	80 (62.5)	2.0 (1.5, NE)	1.144 (0.781, 1.675)	0.4872	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4561
Daunorubicin	116	40 (34.5)	76 (65.5)	NE (1.6, NE)	90	34 (37.8)	56 (62.2)	2.5 (1.5, NE)	0.874 (0.553, 1.382)	0.5632	
Idarubicin	136	59 (43.4)	77 (56.6)	1.9 (1.2, NE)	161	65 (40.4)	96 (59.6)	2.6 (1.6, NE)	1.086 (0.763, 1.545)	0.6322	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6001
Favorable	12	2 (16.7)	10 (83.3)	NE (0.7, NE)	16	7 (43.8)	9 (56.3)	2.5 (0.7, NE)	0.456 (0.095, 2.196)	0.2911	
Intermediate	186	84 (45.2)	102 (54.8)	1.7 (1.2, 3.1)	180	73 (40.6)	107 (59.4)	1.8 (1.5, NE)	1.015 (0.742, 1.389)	0.9081	
Unfavorable	19	8 (42.1)	11 (57.9)	1.5 (0.7, NE)	26	12 (46.2)	14 (53.8)	1.6 (0.7, NE)	1.258 (0.513, 3.085)	0.5939	
Unknown	35	5 (14.3)	30 (85.7)	NE (NE, NE)	30	8 (26.7)	22 (73.3)	NE (3.2, NE)	0.658 (0.215, 2.011)	0.4493	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5324
0 - Fully Active	82	31 (37.8)	51 (62.2)	NE (1.5, NE)	92	32 (34.8)	60 (65.2)	NE (2.0, NE)	1.145 (0.699, 1.877)	0.5824	
1 - Restricted in Physically Strenuous Activity	126	49 (38.9)	77 (61.1)	2.9 (1.6, NE)	126	53 (42.1)	73 (57.9)	1.9 (1.1, NE)	0.824 (0.558, 1.216)	0.3371	
2 - Ambulatory and Capable of All Selfcare	44	19 (43.2)	25 (56.8)	1.4 (0.7, NE)	34	15 (44.1)	19 (55.9)	2.0 (0.7, NE)	1.138 (0.577, 2.244)	0.7511	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8877
≥3 to ≤25%	88	25 (28.4)	63 (71.6)	NE (1.6, NE)	92	31 (33.7)	61 (66.3)	NE (2.5, NE)	0.880 (0.519, 1.490)	0.6431	
>25% to ≤50%	135	58 (43.0)	77 (57.0)	1.7 (1.2, NE)	128	55 (43.0)	73 (57.0)	2.0 (1.4, NE)	1.007 (0.696, 1.457)	0.9762	
>50%	28	16 (57.1)	12 (42.9)	2.3 (0.8, 3.1)	33	14 (42.4)	19 (57.6)	1.7 (1.5, NE)	1.087 (0.529, 2.233)	0.7743	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7741
Yes	130	60 (46.2)	70 (53.8)	1.7 (1.2, NE)	131	59 (45.0)	72 (55.0)	2.1 (1.5, NE)	1.084 (0.757, 1.553)	0.6656	
No	112	38 (33.9)	74 (66.1)	NE (1.5, NE)	111	35 (31.5)	76 (68.5)	NE (1.6, NE)	0.993 (0.627, 1.573)	0.9849	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Diarrhea

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6470
≤60	157	65 (41.4)	92 (58.6)	2.6 (1.5, NE)	154	61 (39.6)	93 (60.4)	2.5 (1.5, NE)	0.940 (0.663, 1.333)	0.7432	
>60	95	34 (35.8)	61 (64.2)	3.1 (1.2, NE)	99	39 (39.4)	60 (60.6)	2.6 (1.6, NE)	1.066 (0.672, 1.689)	0.7938	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5845
<60	149	47 (31.5)	102 (68.5)	24.3 (8.8, NE)	151	41 (27.2)	110 (72.8)	NE (11.5, NE)	1.110 (0.730, 1.688)	0.6468	
≥60 - <65	36	7 (19.4)	29 (80.6)	NE (17.7, NE)	42	5 (11.9)	37 (88.1)	NE (NE, NE)	1.702 (0.538, 5.384)	0.3517	
≥65	63	12 (19.0)	51 (81.0)	NE (9.0, NE)	59	8 (13.6)	51 (86.4)	NE (NE, NE)	1.699 (0.694, 4.159)	0.2399	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.0332
Male	119	36 (30.3)	83 (69.7)	22.0 (4.5, NE)	109	18 (16.5)	91 (83.5)	NE (NE, NE)	1.994 (1.132, 3.512)	0.0149	
Female	129	30 (23.3)	99 (76.7)	NE (17.7, NE)	143	36 (25.2)	107 (74.8)	NE (28.0, NE)	0.898 (0.553, 1.458)	0.6437	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2810
White	147	34 (23.1)	113 (76.9)	NE (17.7, NE)	150	31 (20.7)	119 (79.3)	NE (28.0, NE)	1.081 (0.664, 1.759)	0.7536	
Non-white	101	32 (31.7)	69 (68.3)	9.9 (4.9, NE)	102	23 (22.5)	79 (77.5)	NE (12.8, NE)	1.592 (0.931, 2.721)	0.0927	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6394
North America	16	3 (18.8)	13 (81.3)	NE (1.6, NE)	16	3 (18.8)	13 (81.3)	NE (2.9, NE)	1.426 (0.286, 7.120)	0.6635	
Europe	146	32 (21.9)	114 (78.1)	NE (22.0, NE)	149	29 (19.5)	120 (80.5)	NE (28.0, NE)	1.091 (0.660, 1.804)	0.7325	
Asia/Other Regions	86	31 (36.0)	55 (64.0)	9.3 (3.8, NE)	87	22 (25.3)	65 (74.7)	NE (6.8, NE)	1.518 (0.879, 2.624)	0.1434	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6951
< 40x10^9/L	127	30 (23.6)	97 (76.4)	NE (9.4, NE)	125	29 (23.2)	96 (76.8)	NE (28.0, NE)	1.183 (0.710, 1.971)	0.5151	
≥ 40x10^9/L	121	36 (29.8)	85 (70.2)	NE (8.8, NE)	127	25 (19.7)	102 (80.3)	NE (NE, NE)	1.378 (0.827, 2.298)	0.2331	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6218
Daunorubicin	115	29 (25.2)	86 (74.8)	NE (9.4, NE)	89	20 (22.5)	69 (77.5)	NE (11.5, NE)	1.147 (0.649, 2.029)	0.6597	
Idarubicin	133	37 (27.8)	96 (72.2)	NE (9.3, NE)	161	33 (20.5)	128 (79.5)	NE (NE, NE)	1.395 (0.872, 2.231)	0.1610	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8575
Favorable	12	2 (16.7)	10 (83.3)	NE (1.4, NE)	16	4 (25.0)	12 (75.0)	NE (2.5, NE)	0.935 (0.171, 5.122)	0.9379	
Intermediate	182	55 (30.2)	127 (69.8)	22.0 (8.8, NE)	179	41 (22.9)	138 (77.1)	NE (28.0, NE)	1.307 (0.872, 1.959)	0.2021	
Unfavorable	19	3 (15.8)	16 (84.2)	NE (2.6, NE)	26	5 (19.2)	21 (80.8)	NE (6.8, NE)	0.808 (0.190, 3.434)	0.7718	
Unknown	35	6 (17.1)	29 (82.9)	NE (13.7, NE)	30	4 (13.3)	26 (86.7)	NE (NE, NE)	1.454 (0.409, 5.165)	0.5542	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2965
0 - Fully Active	81	19 (23.5)	62 (76.5)	NE (NE, NE)	91	21 (23.1)	70 (76.9)	NE (12.8, NE)	0.991 (0.533, 1.845)	0.9686	
1 - Restricted in Physically Strenuous Activity	124	37 (29.8)	87 (70.2)	22.0 (9.3, NE)	126	24 (19.0)	102 (81.0)	NE (NE, NE)	1.701 (1.017, 2.844)	0.0414	
2 - Ambulatory and Capable of All Selfcare	43	10 (23.3)	33 (76.7)	9.0 (4.4, NE)	34	9 (26.5)	25 (73.5)	7.8 (2.4, NE)	0.823 (0.333, 2.039)	0.6747	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8885
≥3 to ≤25%	87	24 (27.6)	63 (72.4)	NE (6.5, NE)	91	21 (23.1)	70 (76.9)	NE (28.0, NE)	1.437 (0.800, 2.582)	0.2246	
>25% to ≤50%	133	33 (24.8)	100 (75.2)	NE (9.9, NE)	128	26 (20.3)	102 (79.7)	NE (NE, NE)	1.192 (0.713, 1.993)	0.5134	
>50%	27	9 (33.3)	18 (66.7)	NE (2.3, NE)	33	7 (21.2)	26 (78.8)	6.8 (6.3, NE)	1.291 (0.478, 3.484)	0.6262	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1671
Yes	127	40 (31.5)	87 (68.5)	NE (9.0, NE)	131	29 (22.1)	102 (77.9)	NE (28.0, NE)	1.510 (0.936, 2.436)	0.0896	
No	111	22 (19.8)	89 (80.2)	NE (9.9, NE)	110	23 (20.9)	87 (79.1)	NE (NE, NE)	0.880 (0.490, 1.580)	0.6446	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 2.20.4 EORTC QLQ-C30 - First Improvement - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - PRO Intent to Treat Analysis Set

Common Symptoms - Financial Difficulties

	Quizartinib (N=254)				Placebo (N=255)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3454
≤60	154	48 (31.2)	106 (68.8)	24.3 (8.8, NE)	154	41 (26.6)	113 (73.4)	NE (11.5, NE)	1.117 (0.736, 1.695)	0.6228	
>60	94	18 (19.1)	76 (80.9)	NE (17.7, NE)	98	13 (13.3)	85 (86.7)	NE (NE, NE)	1.671 (0.818, 3.412)	0.1530	

N: number of subjects in analysis set; n: number of subjects in subgroup category with complete PRO baseline; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PRO: Patient Reported Outcome. A Minimal Clinically Important Difference of 10 is considered in this table.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 15NOV2023 – 13:11; Program name: .sas; Output name: DE_T_2_20_4_QLQC30_FI_SUB_PRO_ITT.rtf

Anhang 4-H7: Jegliche unerwünschter Ereignisse

Anhang 4-H7a: UE aller Schweregrade

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.1.2 Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7161
<60	159	159 (100)	0	0.3 (0.3, 0.4)	160	159 (99.4)	1 (0.6)	0.3 (0.1, 0.4)	0.977 (0.783, 1.218)	0.9144	
≥60 - <65	37	37 (100)	0	0.3 (0.1, 0.4)	43	42 (97.7)	1 (2.3)	0.4 (0.1, 0.6)	1.234 (0.792, 1.924)	0.3464	
≥65	69	68 (98.6)	1 (1.4)	0.3 (0.1, 0.4)	65	64 (98.5)	1 (1.5)	0.3 (0.3, 0.4)	1.037 (0.736, 1.461)	0.8299	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_1_2_TEAE_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.1.2 Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3442
Male	124	124 (100)	0	0.3 (0.3, 0.4)	120	119 (99.2)	1 (0.8)	0.3 (0.3, 0.4)	1.117 (0.868, 1.439)	0.3734	
Female	141	140 (99.3)	1 (0.7)	0.3 (0.3, 0.4)	148	146 (98.6)	2 (1.4)	0.3 (NE, NE)	0.944 (0.748, 1.191)	0.6558	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_1_2_TEAE_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.1.2 Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7942
White	157	157 (100)	0	0.3 (0.3, 0.4)	161	159 (98.8)	2 (1.2)	0.3 (0.3, 0.4)	1.000 (0.802, 1.248)	0.9387	
Non-white	108	107 (99.1)	1 (0.9)	0.3 (NE, NE)	107	106 (99.1)	1 (0.9)	0.3 (0.3, 0.4)	1.043 (0.796, 1.366)	0.7441	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_1_2_TEAE_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.1.2 Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0684
North America	16	16 (100)	0	0.3 (0.1, 0.4)	18	18 (100)	0	0.1 (NE, NE)	0.342 (0.158, 0.738)	0.0041	
Europe	161	161 (100)	0	0.3 (0.3, 0.4)	161	159 (98.8)	2 (1.2)	0.3 (0.3, 0.4)	1.016 (0.816, 1.266)	0.8697	
Asia/Other Regions	88	87 (98.9)	1 (1.1)	0.3 (NE, NE)	89	88 (98.9)	1 (1.1)	0.3 (0.3, 0.4)	1.107 (0.822, 1.491)	0.4987	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_1_2_TEAE_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.1.2 Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9355
< 40x10^9/L	132	132 (100)	0	0.4 (0.3, 0.4)	133	132 (99.2)	1 (0.8)	0.3 (0.3, 0.4)	1.028 (0.807, 1.309)	0.7898	
≥ 40x10^9/L	133	132 (99.2)	1 (0.8)	0.3 (0.1, 0.3)	135	133 (98.5)	2 (1.5)	0.3 (0.1, 0.3)	1.008 (0.791, 1.283)	0.9781	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_1_2_TEAE_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.1.2 Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9396
Daunorubicin	123	123 (100)	0	0.3 (0.3, 0.4)	94	94 (100)	0	0.4 (0.3, 0.4)	1.013 (0.772, 1.327)	0.9687	
Idarubicin	142	141 (99.3)	1 (0.7)	0.3 (0.3, 0.4)	171	168 (98.2)	3 (1.8)	0.3 (0.1, 0.3)	1.001 (0.799, 1.254)	0.9379	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_1_2_TEAE_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.1.2 Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.2859
Favorable	13	13 (100)	0	0.4 (0.3, 0.9)	19	19 (100)	0	0.3 (0.1, 0.4)	0.601 (0.291, 1.241)	0.2044	
Intermediate	195	194 (99.5)	1 (0.5)	0.3 (0.3, 0.4)	190	188 (98.9)	2 (1.1)	0.3 (0.3, 0.4)	1.047 (0.855, 1.280)	0.5950	
Unfavorable	19	19 (100)	0	0.1 (0.1, 0.3)	27	26 (96.3)	1 (3.7)	0.3 (0.1, 0.4)	1.509 (0.826, 2.754)	0.1713	
Unknown	38	38 (100)	0	0.3 (0.1, 0.4)	31	31 (100)	0	0.3 (0.1, 0.4)	0.971 (0.600, 1.573)	0.8223	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_1_2_TEAE_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.1.2 Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7530
0 - Fully Active	87	87 (100)	0	0.3 (0.1, 0.4)	97	97 (100)	0	0.3 (0.3, 0.4)	0.903 (0.673, 1.211)	0.4347	
1 - Restricted in Physically Strenuous Activity	133	132 (99.2)	1 (0.8)	0.3 (0.3, 0.4)	134	131 (97.8)	3 (2.2)	0.3 (0.3, 0.4)	1.062 (0.832, 1.355)	0.5631	
2 - Ambulatory and Capable of All Selfcare	45	45 (100)	0	0.1 (0.1, 0.3)	36	36 (100)	0	0.3 (0.1, 0.4)	1.046 (0.672, 1.628)	0.8814	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_1_2_TEAE_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.1.2 Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1962
≥3 to ≤25%	94	93 (98.9)	1 (1.1)	0.4 (0.3, 0.4)	98	96 (98.0)	2 (2.0)	0.3 (0.3, 0.4)	0.863 (0.648, 1.148)	0.3237	
>25% to ≤50%	141	141 (100)	0	0.3 (0.1, 0.3)	136	136 (100)	0	0.3 (0.3, 0.4)	1.052 (0.830, 1.333)	0.6601	
>50%	29	29 (100)	0	0.1 (0.1, 0.4)	34	33 (97.1)	1 (2.9)	0.4 (0.1, 0.6)	1.558 (0.918, 2.643)	0.0832	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_1_2_TEAE_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.1.2 Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6902
Yes	139	139 (100)	0	0.3 (0.3, 0.4)	137	136 (99.3)	1 (0.7)	0.3 (0.1, 0.4)	0.972 (0.767, 1.232)	0.8384	
No	116	115 (99.1)	1 (0.9)	0.3 (0.3, 0.4)	120	118 (98.3)	2 (1.7)	0.3 (0.3, 0.4)	1.034 (0.799, 1.339)	0.7727	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_1_2_TEAE_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.1.2 Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9166
≤60	164	164 (100)	0	0.3 (0.3, 0.4)	163	161 (98.8)	2 (1.2)	0.3 (0.3, 0.4)	1.011 (0.813, 1.258)	0.8396	
>60	101	100 (99.0)	1 (1.0)	0.3 (0.1, 0.4)	105	104 (99.0)	1 (1.0)	0.3 (0.3, 0.4)	1.035 (0.787, 1.363)	0.8233	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_1_2_TEAE_SUB_SAS.rtf

Anhang 4-H7b: SUE

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.2.2 Serious Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4285
<60	159	84 (52.8)	75 (47.2)	8.4 (3.3, 17.4)	160	64 (40.0)	96 (60.0)	11.2 (4.9, NE)	1.210 (0.873, 1.677)	0.2512	
≥60 - <65	37	19 (51.4)	18 (48.6)	4.6 (1.8, NE)	43	17 (39.5)	26 (60.5)	11.9 (4.4, NE)	1.268 (0.657, 2.447)	0.4771	
≥65	69	40 (58.0)	29 (42.0)	4.6 (1.5, 12.0)	65	42 (64.6)	23 (35.4)	2.7 (1.6, 6.0)	0.840 (0.543, 1.300)	0.4230	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_2_2_TEAESER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.2.2 Serious Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3236
Male	124	60 (48.4)	64 (51.6)	12.0 (3.3, 24.0)	120	53 (44.2)	67 (55.8)	7.1 (2.7, 28.6)	0.970 (0.669, 1.405)	0.8713	
Female	141	83 (58.9)	58 (41.1)	4.9 (2.0, 8.4)	148	70 (47.3)	78 (52.7)	6.9 (4.3, 11.2)	1.225 (0.890, 1.685)	0.2115	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_2_2_TEAESER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.2.2 Serious Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7804
White	157	89 (56.7)	68 (43.3)	4.6 (2.2, 12.2)	161	76 (47.2)	85 (52.8)	7.5 (2.7, 16.0)	1.087 (0.799, 1.479)	0.5910	
Non-white	108	54 (50.0)	54 (50.0)	6.7 (3.5, 19.0)	107	47 (43.9)	60 (56.1)	6.3 (4.9, 37.3)	1.135 (0.767, 1.680)	0.5267	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_2_2_TEAESER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.2.2 Serious Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6660
North America	16	8 (50.0)	8 (50.0)	2.5 (1.8, NE)	18	8 (44.4)	10 (55.6)	11.9 (2.4, NE)	1.640 (0.597, 4.506)	0.3330	
Europe	161	90 (55.9)	71 (44.1)	4.6 (2.1, 12.9)	161	78 (48.4)	83 (51.6)	6.3 (3.0, 10.7)	1.034 (0.762, 1.403)	0.8277	
Asia/Other Regions	88	45 (51.1)	43 (48.9)	6.7 (3.3, 12.7)	89	37 (41.6)	52 (58.4)	6.0 (4.3, NE)	1.158 (0.749, 1.791)	0.5131	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_2_2_TEAESER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.2.2 Serious Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6220
< 40x10^9/L	132	69 (52.3)	63 (47.7)	4.9 (2.3, 12.2)	133	61 (45.9)	72 (54.1)	7.5 (4.9, 28.6)	1.173 (0.830, 1.655)	0.3633	
≥ 40x10^9/L	133	74 (55.6)	59 (44.4)	6.3 (2.9, 15.4)	135	62 (45.9)	73 (54.1)	5.2 (3.2, 10.3)	1.037 (0.738, 1.459)	0.8334	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_2_2_TEAESER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.2.2 Serious Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2405
Daunorubicin	123	65 (52.8)	58 (47.2)	7.2 (2.6, 15.4)	94	35 (37.2)	59 (62.8)	10.7 (7.1, NE)	1.333 (0.883, 2.014)	0.1694	
Idarubicin	142	78 (54.9)	64 (45.1)	4.6 (2.3, 12.0)	171	87 (50.9)	84 (49.1)	4.4 (2.7, 9.2)	1.007 (0.741, 1.368)	0.9668	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_2_2_TEAESER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.2.2 Serious Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8257
Favorable	13	7 (53.8)	6 (46.2)	2.9 (1.7, NE)	19	8 (42.1)	11 (57.9)	10.1 (3.2, NE)	1.645 (0.594, 4.559)	0.3337	
Intermediate	195	98 (50.3)	97 (49.7)	8.9 (3.5, 17.4)	190	83 (43.7)	107 (56.3)	7.5 (4.9, 16.0)	1.039 (0.775, 1.394)	0.7978	
Unfavorable	19	11 (57.9)	8 (42.1)	3.3 (0.9, NE)	27	15 (55.6)	12 (44.4)	2.6 (1.1, 11.2)	1.015 (0.464, 2.220)	0.9559	
Unknown	38	27 (71.1)	11 (28.9)	2.6 (1.3, 8.4)	31	16 (51.6)	15 (48.4)	6.0 (1.2, NE)	1.288 (0.693, 2.396)	0.4221	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_2_2_TEAESER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.2.2 Serious Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6678
0 - Fully Active	87	43 (49.4)	44 (50.6)	12.0 (3.3, 31.5)	97	44 (45.4)	53 (54.6)	9.2 (2.7, NE)	0.943 (0.618, 1.438)	0.7863	
1 - Restricted in Physically Strenuous Activity	133	72 (54.1)	61 (45.9)	4.6 (2.3, 10.6)	134	62 (46.3)	72 (53.7)	6.3 (3.4, 16.0)	1.141 (0.812, 1.604)	0.4455	
2 - Ambulatory and Capable of All Selfcare	45	28 (62.2)	17 (37.8)	2.2 (1.6, 19.3)	36	17 (47.2)	19 (52.8)	4.4 (2.6, 10.7)	1.218 (0.660, 2.246)	0.5272	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_2_2_TEAESER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.2.2 Serious Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9226
≥3 to ≤25%	94	52 (55.3)	42 (44.7)	4.6 (2.2, 12.9)	98	49 (50.0)	49 (50.0)	5.2 (2.7, 11.9)	1.080 (0.730, 1.596)	0.7050	
>25% to ≤50%	141	77 (54.6)	64 (45.4)	6.7 (2.1, 12.2)	136	61 (44.9)	75 (55.1)	6.9 (4.4, 16.0)	1.162 (0.830, 1.627)	0.3816	
>50%	29	14 (48.3)	15 (51.7)	10.6 (2.9, NE)	34	13 (38.2)	21 (61.8)	7.5 (2.6, NE)	0.990 (0.461, 2.125)	0.9839	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_2_2_TEAESER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.2.2 Serious Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6357
Yes	139	80 (57.6)	59 (42.4)	6.7 (2.3, 15.0)	137	71 (51.8)	66 (48.2)	6.9 (4.4, 10.7)	1.012 (0.734, 1.396)	0.9430	
No	116	58 (50.0)	58 (50.0)	4.1 (2.5, 12.9)	120	48 (40.0)	72 (60.0)	6.3 (3.2, NE)	1.159 (0.790, 1.700)	0.4484	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_2_2_TEAESER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.2.2 Serious Treatment-emergent adverse events - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4054
≤60	164	87 (53.0)	77 (47.0)	7.2 (3.3, 17.4)	163	64 (39.3)	99 (60.7)	11.2 (5.0, NE)	1.233 (0.891, 1.704)	0.2042	
>60	101	56 (55.4)	45 (44.6)	4.6 (1.8, 8.9)	105	59 (56.2)	46 (43.8)	4.9 (2.7, 7.5)	0.976 (0.676, 1.407)	0.8841	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_2_2_TEAESER_SUB_SAS.rtf

Anhang 4-H7c: Schwere UE (CTCAE-Grad ≥ 3)

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.3.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥ 3) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6800
<60	159	145 (91.2)	14 (8.8)	0.4 (0.2, 0.7)	160	142 (88.8)	18 (11.3)	0.3 (0.2, 0.4)	0.888 (0.703, 1.121)	0.3156	
≥60 - <65	37	35 (94.6)	2 (5.4)	0.2 (0.1, 1.3)	43	39 (90.7)	4 (9.3)	0.3 (0.2, 1.0)	1.041 (0.658, 1.647)	0.8797	
≥65	69	64 (92.8)	5 (7.2)	0.3 (0.2, 0.5)	65	59 (90.8)	6 (9.2)	0.2 (0.2, 0.4)	0.890 (0.624, 1.270)	0.5096	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_3_2_TEAESEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.3.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥ 3) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2303
Male	124	112 (90.3)	12 (9.7)	0.3 (0.2, 0.6)	120	105 (87.5)	15 (12.5)	0.4 (0.3, 1.1)	1.047 (0.801, 1.369)	0.7518	
Female	141	132 (93.6)	9 (6.4)	0.4 (0.2, 0.5)	148	135 (91.2)	13 (8.8)	0.2 (0.2, 0.3)	0.826 (0.649, 1.051)	0.1183	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_3_2_TEAESEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.3.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥ 3) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2403
White	157	145 (92.4)	12 (7.6)	0.3 (0.2, 0.4)	161	148 (91.9)	13 (8.1)	0.3 (0.2, 0.3)	0.838 (0.664, 1.057)	0.1290	
Non-white	108	99 (91.7)	9 (8.3)	0.4 (0.2, 0.7)	107	92 (86.0)	15 (14.0)	0.3 (0.2, 0.5)	1.033 (0.777, 1.374)	0.8001	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_3_2_TEAESEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.3.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥ 3) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0371
North America	16	14 (87.5)	2 (12.5)	0.2 (0.1, 1.3)	18	18 (100)	0	0.1 (0.0, 0.2)	0.407 (0.194, 0.853)	0.0143	
Europe	161	148 (91.9)	13 (8.1)	0.3 (0.2, 0.4)	161	146 (90.7)	15 (9.3)	0.3 (0.2, 0.4)	0.919 (0.729, 1.157)	0.4534	
Asia/Other Regions	88	82 (93.2)	6 (6.8)	0.4 (0.3, 0.8)	89	76 (85.4)	13 (14.6)	0.3 (0.2, 1.1)	1.032 (0.754, 1.411)	0.8298	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_3_2_TEAESEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.3.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥ 3) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1489
< 40x10^9/L	132	118 (89.4)	14 (10.6)	0.3 (0.2, 0.6)	133	123 (92.5)	10 (7.5)	0.3 (0.2, 0.4)	0.771 (0.595, 0.999)	0.0442	
≥ 40x10^9/L	133	126 (94.7)	7 (5.3)	0.3 (0.2, 0.4)	135	117 (86.7)	18 (13.3)	0.3 (0.2, 0.3)	1.046 (0.813, 1.346)	0.7083	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_3_2_TEAESEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.3.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥ 3) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4944
Daunorubicin	123	112 (91.1)	11 (8.9)	0.4 (0.2, 0.7)	94	85 (90.4)	9 (9.6)	0.3 (0.2, 0.4)	0.813 (0.612, 1.081)	0.1505	
Idarubicin	142	132 (93.0)	10 (7.0)	0.3 (0.2, 0.4)	171	153 (89.5)	18 (10.5)	0.3 (0.2, 0.4)	0.954 (0.754, 1.205)	0.6833	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_3_2_TEAESEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.3.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥ 3) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.1441
Favorable	13	11 (84.6)	2 (15.4)	1.1 (0.2, 2.9)	19	18 (94.7)	1 (5.3)	0.4 (0.1, 1.6)	0.618 (0.284, 1.346)	0.2320	
Intermediate	195	177 (90.8)	18 (9.2)	0.3 (0.2, 0.5)	190	171 (90.0)	19 (10.0)	0.3 (0.2, 0.4)	0.901 (0.730, 1.113)	0.3339	
Unfavorable	19	19 (100)	0	0.3 (0.0, 2.3)	27	25 (92.6)	2 (7.4)	0.2 (0.1, 0.4)	0.635 (0.325, 1.242)	0.1679	
Unknown	38	37 (97.4)	1 (2.6)	0.2 (0.1, 0.4)	31	25 (80.6)	6 (19.4)	0.2 (0.1, 1.4)	1.396 (0.837, 2.328)	0.1853	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_3_2_TEAESEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.3.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥ 3) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6216
0 - Fully Active	87	79 (90.8)	8 (9.2)	0.5 (0.3, 1.0)	97	84 (86.6)	13 (13.4)	0.3 (0.2, 0.4)	0.827 (0.605, 1.129)	0.2368	
1 - Restricted in Physically Strenuous Activity	133	123 (92.5)	10 (7.5)	0.3 (0.2, 0.5)	134	122 (91.0)	12 (9.0)	0.3 (0.2, 0.5)	0.967 (0.752, 1.243)	0.7855	
2 - Ambulatory and Capable of All Selfcare	45	42 (93.3)	3 (6.7)	0.2 (0.1, 0.3)	36	34 (94.4)	2 (5.6)	0.2 (0.2, 0.3)	0.862 (0.541, 1.373)	0.5316	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_3_2_TEAESEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.3.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥ 3) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2898
≥3 to ≤25%	94	85 (90.4)	9 (9.6)	0.3 (0.2, 0.6)	98	89 (90.8)	9 (9.2)	0.2 (0.2, 0.3)	0.757 (0.557, 1.029)	0.0689	
>25% to ≤50%	141	130 (92.2)	11 (7.8)	0.3 (0.2, 0.4)	136	120 (88.2)	16 (11.8)	0.3 (0.2, 0.7)	1.029 (0.802, 1.319)	0.8172	
>50%	29	28 (96.6)	1 (3.4)	0.5 (0.1, 1.2)	34	31 (91.2)	3 (8.8)	0.3 (0.2, 0.4)	0.953 (0.564, 1.611)	0.8524	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_3_2_TEAESEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.3.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥ 3) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3885
Yes	139	133 (95.7)	6 (4.3)	0.2 (0.2, 0.4)	137	129 (94.2)	8 (5.8)	0.3 (0.2, 0.3)	0.867 (0.680, 1.107)	0.2515	
No	116	102 (87.9)	14 (12.1)	0.4 (0.3, 0.7)	120	101 (84.2)	19 (15.8)	0.3 (0.2, 0.6)	1.016 (0.771, 1.339)	0.8994	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_3_2_TEAESEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.3.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥ 3) - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9181
≤60	164	150 (91.5)	14 (8.5)	0.4 (0.2, 0.7)	163	143 (87.7)	20 (12.3)	0.3 (0.2, 0.4)	0.917 (0.728, 1.155)	0.4597	
>60	101	94 (93.1)	7 (6.9)	0.3 (0.2, 0.5)	105	97 (92.4)	8 (7.6)	0.2 (0.2, 0.3)	0.924 (0.695, 1.228)	0.5749	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_3_2_TEAESEV_SUB_SAS.rtf

Anhang 4-H7d: UE, die zum Therapieabbruch führten

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.4.2 Treatment-emergent adverse events associated with discontinuation of study treatment - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8860
<60	159	26 (16.4)	133 (83.6)	NE (NE, NE)	160	11 (6.9)	149 (93.1)	NE (NE, NE)	2.036 (1.004, 4.129)	0.0440	
≥60 - <65	37	8 (21.6)	29 (78.4)	NE (16.2, NE)	43	4 (9.3)	39 (90.7)	NE (20.2, NE)	2.191 (0.659, 7.288)	0.1898	
≥65	69	20 (29.0)	49 (71.0)	26.5 (13.2, NE)	65	8 (12.3)	57 (87.7)	NE (NE, NE)	2.599 (1.143, 5.911)	0.0180	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_4_2_TEAEDISC_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.4.2 Treatment-emergent adverse events associated with discontinuation of study treatment - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7259
Male	124	25 (20.2)	99 (79.8)	NE (NE, NE)	120	9 (7.5)	111 (92.5)	NE (NE, NE)	2.418 (1.127, 5.188)	0.0192	
Female	141	29 (20.6)	112 (79.4)	NE (NE, NE)	148	14 (9.5)	134 (90.5)	NE (NE, NE)	2.032 (1.073, 3.848)	0.0262	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_4_2_TEAEDISC_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.4.2 Treatment-emergent adverse events associated with discontinuation of study treatment - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9181
White	157	35 (22.3)	122 (77.7)	NE (NE, NE)	161	15 (9.3)	146 (90.7)	NE (NE, NE)	2.166 (1.181, 3.970)	0.0103	
Non-white	108	19 (17.6)	89 (82.4)	NE (NE, NE)	107	8 (7.5)	99 (92.5)	NE (NE, NE)	2.196 (0.961, 5.020)	0.0554	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_4_2_TEAEDISC_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.4.2 Treatment-emergent adverse events associated with discontinuation of study treatment - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5311
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	2 (11.1)	16 (88.9)	NE (10.3, NE)	0.648 (0.058, 7.221)	0.7184	
Europe	161	37 (23.0)	124 (77.0)	NE (NE, NE)	161	16 (9.9)	145 (90.1)	NE (NE, NE)	2.036 (1.131, 3.667)	0.0155	
Asia/Other Regions	88	16 (18.2)	72 (81.8)	NE (26.5, NE)	89	5 (5.6)	84 (94.4)	NE (NE, NE)	2.981 (1.091, 8.150)	0.0254	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_4_2_TEAEDISC_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)

Table 3.4.2 Treatment-emergent adverse events associated with discontinuation of study treatment - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2236
< 40x10^9/L	132	29 (22.0)	103 (78.0)	NE (NE, NE)	133	10 (7.5)	123 (92.5)	NE (NE, NE)	2.989 (1.456, 6.136)	0.0017	
≥ 40x10^9/L	133	25 (18.8)	108 (81.2)	NE (NE, NE)	135	13 (9.6)	122 (90.4)	NE (NE, NE)	1.626 (0.829, 3.189)	0.1526	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_4_2_TEAEDISC_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.4.2 Treatment-emergent adverse events associated with discontinuation of study treatment - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5359
Daunorubicin	123	21 (17.1)	102 (82.9)	NE (NE, NE)	94	8 (8.5)	86 (91.5)	NE (NE, NE)	1.809 (0.800, 4.091)	0.1484	
Idarubicin	142	33 (23.2)	109 (76.8)	NE (28.0, NE)	171	15 (8.8)	156 (91.2)	NE (NE, NE)	2.444 (1.326, 4.504)	0.0030	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_4_2_TEAEDISC_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.4.2 Treatment-emergent adverse events associated with discontinuation of study treatment - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9338
Favorable	13	2 (15.4)	11 (84.6)	NE (1.5, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	3.221 (0.292, 35.594)	0.3127	
Intermediate	195	37 (19.0)	158 (81.0)	NE (NE, NE)	190	15 (7.9)	175 (92.1)	NE (NE, NE)	2.133 (1.169, 3.890)	0.0115	
Unfavorable	19	4 (21.1)	15 (78.9)	NE (7.7, NE)	27	2 (7.4)	25 (92.6)	NE (11.3, NE)	2.350 (0.421, 13.104)	0.3163	
Unknown	38	11 (28.9)	27 (71.1)	NE (16.2, NE)	31	5 (16.1)	26 (83.9)	NE (19.9, NE)	1.761 (0.610, 5.087)	0.2858	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_4_2_TEAEDISC_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.4.2 Treatment-emergent adverse events associated with discontinuation of study treatment - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8628
0 - Fully Active	87	17 (19.5)	70 (80.5)	NE (28.0, NE)	97	9 (9.3)	88 (90.7)	NE (NE, NE)	1.847 (0.822, 4.150)	0.1316	
1 - Restricted in Physically Strenuous Activity	133	26 (19.5)	107 (80.5)	NE (NE, NE)	134	10 (7.5)	124 (92.5)	NE (NE, NE)	2.463 (1.187, 5.111)	0.0123	
2 - Ambulatory and Capable of All Selfcare	45	11 (24.4)	34 (75.6)	NE (13.2, NE)	36	4 (11.1)	32 (88.9)	NE (13.4, NE)	1.945 (0.613, 6.176)	0.2496	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_4_2_TEAEDISC_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.4.2 Treatment-emergent adverse events associated with discontinuation of study treatment - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8833
≥3 to ≤25%	94	18 (19.1)	76 (80.9)	NE (NE, NE)	98	8 (8.2)	90 (91.8)	NE (NE, NE)	2.305 (1.001, 5.304)	0.0430	
>25% to ≤50%	141	29 (20.6)	112 (79.4)	NE (NE, NE)	136	13 (9.6)	123 (90.4)	NE (NE, NE)	1.980 (1.028, 3.813)	0.0372	
>50%	29	7 (24.1)	22 (75.9)	NE (6.9, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	2.843 (0.582, 13.898)	0.1781	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_4_2_TEAEDISC_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.4.2 Treatment-emergent adverse events associated with discontinuation of study treatment - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9193
Yes	139	29 (20.9)	110 (79.1)	NE (NE, NE)	137	13 (9.5)	124 (90.5)	NE (NE, NE)	2.022 (1.050, 3.896)	0.0318	
No	116	23 (19.8)	93 (80.2)	NE (28.0, NE)	120	10 (8.3)	110 (91.7)	NE (NE, NE)	2.128 (1.011, 4.475)	0.0412	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_4_2_TEAEDISC_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.4.2 Treatment-emergent adverse events associated with discontinuation of study treatment - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8685
≤60	164	28 (17.1)	136 (82.9)	NE (NE, NE)	163	11 (6.7)	152 (93.3)	NE (NE, NE)	2.176 (1.081, 4.379)	0.0256	
>60	101	26 (25.7)	75 (74.3)	NE (16.2, NE)	105	12 (11.4)	93 (88.6)	NE (NE, NE)	2.367 (1.194, 4.695)	0.0110	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:27; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_4_2_TEAEDISC_SUB_SAS.rtf

Anhang 4-H8: Unerwünschte Ereignisse von besonderem Interesse

Anhang 4-H8a: UE von besonderem Interesse aller Schweregrade

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.5.2 Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

		Quizartinib (N=265)			Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											1.0000
<60	159	1 (0.6)	158 (99.4)	NE (NE, NE)	160	0	160 (100)	NE (NE, NE)	NE (0.000, NE)	0.3127	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.0341	
≥65	69	1 (1.4)	68 (98.6)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	0.498 (0.045, 5.496)	0.5615	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_5_2_AESI1_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)

Table 3.5.2 Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9567
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	2.769 (0.288, 26.637)	0.3568	
Female	141	3 (2.1)	138 (97.9)	NE (NE, NE)	148	1 (0.7)	147 (99.3)	NE (NE, NE)	3.096 (0.322, 29.783)	0.3021	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_5_2_AESI1_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.5.2 Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9998
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	2.932 (0.591, 14.544)	0.1671	
Non-white	108	0	108 (100)	NE (NE, NE)	107	0	107 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_5_2_AESI1_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.5.2 Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											1.0000
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	2.863 (0.577, 14.198)	0.1775	
Asia/Other Regions	88	0	88 (100)	NE (NE, NE)	89	0	89 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_5_2_AESI1_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.5.2 Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7189
< 40x10^9/L	132	2 (1.5)	130 (98.5)	NE (NE, NE)	133	1 (0.8)	132 (99.2)	NE (NE, NE)	2.061 (0.187, 22.737)	0.5462	
≥ 40x10^9/L	133	4 (3.0)	129 (97.0)	NE (NE, NE)	135	1 (0.7)	134 (99.3)	NE (NE, NE)	3.749 (0.418, 33.616)	0.2045	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_5_2_AESI1_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.5.2 Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4870
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	1 (1.1)	93 (98.9)	NE (NE, NE)	1.532 (0.139, 16.899)	0.7248	
Idarubicin	142	4 (2.8)	138 (97.2)	NE (NE, NE)	171	1 (0.6)	170 (99.4)	NE (NE, NE)	4.598 (0.514, 41.162)	0.1336	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_5_2_AESI1_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.5.2 Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9480
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	5 (2.6)	190 (97.4)	NE (NE, NE)	190	1 (0.5)	189 (99.5)	NE (NE, NE)	4.403 (0.514, 37.745)	0.1390	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.507 (0.094, 24.095)	0.7703	
Unknown	38	0	38 (100)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_5_2_AESI1_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.5.2 Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9714
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	0	97 (100)	NE (NE, NE)	NE (0.000, NE)	0.0652	
1 - Restricted in Physically Strenuous Activity	133	1 (0.8)	132 (99.2)	NE (NE, NE)	134	1 (0.7)	133 (99.3)	NE (NE, NE)	0.947 (0.059, 15.175)	0.9692	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	1.541 (0.140, 16.995)	0.7220	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_5_2_AESI1_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.5.2 Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											1.0000
≥3 to ≤25%	94	1 (1.1)	93 (98.9)	NE (NE, NE)	98	2 (2.0)	96 (98.0)	NE (NE, NE)	0.529 (0.048, 5.839)	0.5975	
>25% to ≤50%	141	4 (2.8)	137 (97.2)	NE (NE, NE)	136	0	136 (100)	NE (NE, NE)	NE (0.000, NE)	0.0492	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.3865	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_5_2_AESI1_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.5.2 Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9940
Yes	139	4 (2.9)	135 (97.1)	NE (NE, NE)	137	0	137 (100)	NE (NE, NE)	NE (0.000, NE)	0.0509	
No	116	2 (1.7)	114 (98.3)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	0.997 (0.140, 7.080)	0.9974	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_5_2_AESI1_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.5.2 Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9926
≤60	164	2 (1.2)	162 (98.8)	NE (NE, NE)	163	0	163 (100)	NE (NE, NE)	NE (0.000, NE)	0.1744	
>60	101	4 (4.0)	97 (96.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	2.115 (0.387, 11.551)	0.3755	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_5_2_AESI1_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.6.2 Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9999
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	7 (4.4)	153 (95.6)	NE (NE, NE)	0.676 (0.214, 2.132)	0.5014	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.2810	
≥65	69	0	69 (100)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	0.000 (0.000, NE)	0.1722	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_6_2_AESI2_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.6.2 Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1143
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.870 (0.342, 10.228)	0.4628	
Female	141	2 (1.4)	139 (98.6)	NE (NE, NE)	148	7 (4.7)	141 (95.3)	NE (NE, NE)	0.287 (0.060, 1.383)	0.0972	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_6_2_AESI2_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.6.2 Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7821
White	157	5 (3.2)	152 (96.8)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	0.697 (0.221, 2.200)	0.5360	
Non-white	108	1 (0.9)	107 (99.1)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	0.479 (0.043, 5.283)	0.5386	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_6_2_AESI2_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.6.2 Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7731
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	5 (3.1)	156 (96.9)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	0.775 (0.236, 2.542)	0.6727	
Asia/Other Regions	88	1 (1.1)	87 (98.9)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	0.329 (0.034, 3.162)	0.3108	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_6_2_AESI2_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.6.2 Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3491
< 40x10^9/L	132	1 (0.8)	131 (99.2)	NE (NE, NE)	133	4 (3.0)	129 (97.0)	NE (NE, NE)	0.260 (0.029, 2.324)	0.1938	
≥ 40x10^9/L	133	5 (3.8)	128 (96.2)	NE (NE, NE)	135	5 (3.7)	130 (96.3)	NE (NE, NE)	0.897 (0.259, 3.110)	0.8654	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_6_2_AESI2_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.6.2 Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9540
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	0.709 (0.100, 5.053)	0.7305	
Idarubicin	142	4 (2.8)	138 (97.2)	NE (NE, NE)	171	7 (4.1)	164 (95.9)	NE (NE, NE)	0.669 (0.196, 2.287)	0.5185	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_6_2_AESI2_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.6.2 Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9090
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (9.5, NE)	0.000 (0.000, NE)	0.5271	
Intermediate	195	5 (2.6)	190 (97.4)	NE (NE, NE)	190	4 (2.1)	186 (97.9)	NE (NE, NE)	1.173 (0.315, 4.370)	0.8123	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.000 (0.000, NE)	0.2437	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	0.410 (0.037, 4.561)	0.4540	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_6_2_AESI2_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.6.2 Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9866
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	0.789 (0.176, 3.529)	0.7561	
1 - Restricted in Physically Strenuous Activity	133	3 (2.3)	130 (97.7)	NE (NE, NE)	134	3 (2.2)	131 (97.8)	NE (NE, NE)	0.989 (0.199, 4.903)	0.9888	
2 - Ambulatory and Capable of All Selfcare	45	0	45 (100)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.000 (0.000, NE)	0.1242	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_6_2_AESI2_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.6.2 Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9881
≥3 to ≤25%	94	0	94 (100)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	0.000 (0.000, NE)	0.0506	
>25% to ≤50%	141	5 (3.5)	136 (96.5)	NE (NE, NE)	136	4 (2.9)	132 (97.1)	NE (NE, NE)	1.178 (0.316, 4.392)	0.8059	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	1.180 (0.074, 18.868)	0.9066	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_6_2_AESI2_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.6.2 Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6365
Yes	139	4 (2.9)	135 (97.1)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	0.778 (0.209, 2.901)	0.7078	
No	116	2 (1.7)	114 (98.3)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.471 (0.086, 2.576)	0.3741	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_6_2_AESI2_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.6.2 Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8893
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	7 (4.3)	156 (95.7)	NE (NE, NE)	0.664 (0.210, 2.095)	0.4823	
>60	101	1 (1.0)	100 (99.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	0.507 (0.046, 5.587)	0.5713	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_6_2_AESI2_SUB_SAS.rtf

Anhang 4-H8b: SUE von besonderem Interesse

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.7.2 Serious Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											NE
<60	159	0	159 (100)	NE (NE, NE)	160	0	160 (100)	NE (NE, NE)	NE (NE, NE)	NE	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (NE, NE)	NE	
≥65	69	0	69 (100)	NE (NE, NE)	65	0	65 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_7_2_AESI1SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.7.2 Serious Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											NE
Male	124	0	124 (100)	NE (NE, NE)	120	0	120 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Female	141	0	141 (100)	NE (NE, NE)	148	0	148 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_7_2_AESI1SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.7.2 Serious Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											NE
White	157	0	157 (100)	NE (NE, NE)	161	0	161 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Non-white	108	0	108 (100)	NE (NE, NE)	107	0	107 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_7_2_AESI1SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.7.2 Serious Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											NE
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	0	161 (100)	NE (NE, NE)	161	0	161 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Asia/Other Regions	88	0	88 (100)	NE (NE, NE)	89	0	89 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_7_2_AESI1SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.7.2 Serious Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											NE
< 40x10^9/L	132	0	132 (100)	NE (NE, NE)	133	0	133 (100)	NE (NE, NE)	NE (NE, NE)	NE	
≥ 40x10^9/L	133	0	133 (100)	NE (NE, NE)	135	0	135 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_7_2_AESI1SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.7.2 Serious Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											NE
Daunorubicin	123	0	123 (100)	NE (NE, NE)	94	0	94 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Idarubicin	142	0	142 (100)	NE (NE, NE)	171	0	171 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_7_2_AESI1SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.7.2 Serious Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											NE
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	0	195 (100)	NE (NE, NE)	190	0	190 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Unknown	38	0	38 (100)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_7_2_AESI1SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.7.2 Serious Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											NE
0 - Fully Active	87	0	87 (100)	NE (NE, NE)	97	0	97 (100)	NE (NE, NE)	NE (NE, NE)	NE	
1 - Restricted in Physically Strenuous Activity	133	0	133 (100)	NE (NE, NE)	134	0	134 (100)	NE (NE, NE)	NE (NE, NE)	NE	
2 - Ambulatory and Capable of All Selfcare	45	0	45 (100)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_7_2_AESI1SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.7.2 Serious Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											NE
≥3 to ≤25%	94	0	94 (100)	NE (NE, NE)	98	0	98 (100)	NE (NE, NE)	NE (NE, NE)	NE	
>25% to ≤50%	141	0	141 (100)	NE (NE, NE)	136	0	136 (100)	NE (NE, NE)	NE (NE, NE)	NE	
>50%	29	0	29 (100)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_7_2_AESI1SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.7.2 Serious Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											NE
Yes	139	0	139 (100)	NE (NE, NE)	137	0	137 (100)	NE (NE, NE)	NE (NE, NE)	NE	
No	116	0	116 (100)	NE (NE, NE)	120	0	120 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_7_2_AESI1SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.7.2 Serious Adverse events of special interest - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											NE
≤60	164	0	164 (100)	NE (NE, NE)	163	0	163 (100)	NE (NE, NE)	NE (NE, NE)	NE	
>60	101	0	101 (100)	NE (NE, NE)	105	0	105 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_7_2_AESI1SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.8.2 Serious Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											1.0000
<60	159	2 (1.3)	157 (98.7)	NE (NE, NE)	160	3 (1.9)	157 (98.1)	NE (NE, NE)	0.599 (0.100, 3.597)	0.5707	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (NE, NE)	NE	
≥65	69	0	69 (100)	NE (NE, NE)	65	0	65 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_8_2_AESI2SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.8.2 Serious Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7627
Male	124	1 (0.8)	123 (99.2)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	0.922 (0.058, 14.778)	0.9545	
Female	141	1 (0.7)	140 (99.3)	NE (NE, NE)	148	2 (1.4)	146 (98.6)	NE (NE, NE)	0.500 (0.045, 5.523)	0.5636	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_8_2_AESI2SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.8.2 Serious Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7089
White	157	1 (0.6)	156 (99.4)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	0.445 (0.040, 4.926)	0.4976	
Non-white	108	1 (0.9)	107 (99.1)	NE (NE, NE)	107	1 (0.9)	106 (99.1)	NE (NE, NE)	0.987 (0.062, 15.779)	0.9926	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_8_2_AESI2SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.8.2 Serious Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9302
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	1 (0.6)	160 (99.4)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	0.829 (0.052, 13.261)	0.8945	
Asia/Other Regions	88	1 (1.1)	87 (98.9)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	0.502 (0.045, 5.533)	0.5655	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_8_2_AESI2SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.8.2 Serious Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9954
< 40x10^9/L	132	0	132 (100)	NE (NE, NE)	133	2 (1.5)	131 (98.5)	NE (NE, NE)	0.000 (0.000, NE)	0.1613	
≥ 40x10^9/L	133	2 (1.5)	131 (98.5)	NE (NE, NE)	135	1 (0.7)	134 (99.3)	NE (NE, NE)	1.773 (0.160, 19.625)	0.6361	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_8_2_AESI2SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.8.2 Serious Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9025
Daunorubicin	123	1 (0.8)	122 (99.2)	NE (NE, NE)	94	1 (1.1)	93 (98.9)	NE (NE, NE)	0.654 (0.041, 10.528)	0.7629	
Idarubicin	142	1 (0.7)	141 (99.3)	NE (NE, NE)	171	2 (1.2)	169 (98.8)	NE (NE, NE)	0.589 (0.053, 6.508)	0.6625	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_8_2_AESI2SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.8.2 Serious Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (9.5, NE)	0.000 (0.000, NE)	0.5271	
Intermediate	195	1 (0.5)	194 (99.5)	NE (NE, NE)	190	0	190 (100)	NE (NE, NE)	NE (0.000, NE)	0.3428	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.000 (0.000, NE)	0.2437	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.3291	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_8_2_AESI2SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.8.2 Serious Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											1.0000
0 - Fully Active	87	2 (2.3)	85 (97.7)	NE (NE, NE)	97	1 (1.0)	96 (99.0)	NE (NE, NE)	2.100 (0.190, 23.173)	0.5356	
1 - Restricted in Physically Strenuous Activity	133	0	133 (100)	NE (NE, NE)	134	1 (0.7)	133 (99.3)	NE (NE, NE)	0.000 (0.000, NE)	0.3247	
2 - Ambulatory and Capable of All Selfcare	45	0	45 (100)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	0.000 (0.000, NE)	0.2801	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_8_2_AESI2SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.8.2 Serious Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											1.0000
≥3 to ≤25%	94	0	94 (100)	NE (NE, NE)	98	1 (1.0)	97 (99.0)	NE (NE, NE)	0.000 (0.000, NE)	0.3294	
>25% to ≤50%	141	2 (1.4)	139 (98.6)	NE (NE, NE)	136	1 (0.7)	135 (99.3)	NE (NE, NE)	1.911 (0.173, 21.101)	0.5906	
>50%	29	0	29 (100)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.000 (0.000, NE)	0.3570	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_8_2_AESI2SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.8.2 Serious Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7008
Yes	139	1 (0.7)	138 (99.3)	NE (NE, NE)	137	1 (0.7)	136 (99.3)	NE (NE, NE)	0.914 (0.057, 14.678)	0.9493	
No	116	1 (0.9)	115 (99.1)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	0.477 (0.043, 5.271)	0.5364	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_8_2_AESI2SER_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.8.2 Serious Adverse events of special interest - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9999
≤60	164	2 (1.2)	162 (98.8)	NE (NE, NE)	163	3 (1.8)	160 (98.2)	NE (NE, NE)	0.588 (0.098, 3.536)	0.5576	
>60	101	0	101 (100)	NE (NE, NE)	105	0	105 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_8_2_AESI2SER_SUB_SAS.rtf

Anhang 4-H8c: Schwere UE (CTCAE-Grad ≥ 3) von besonderem Interesse

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.9.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											1.0000
<60	159	1 (0.6)	158 (99.4)	NE (NE, NE)	160	0	160 (100)	NE (NE, NE)	NE (0.000, NE)	0.3127	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.0341	
≥65	69	1 (1.4)	68 (98.6)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	0.498 (0.045, 5.496)	0.5615	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_9_2_AESI1SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.9.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9567
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	2.769 (0.288, 26.637)	0.3568	
Female	141	3 (2.1)	138 (97.9)	NE (NE, NE)	148	1 (0.7)	147 (99.3)	NE (NE, NE)	3.096 (0.322, 29.783)	0.3021	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_9_2_AESI1SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.9.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9998
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	2.932 (0.591, 14.544)	0.1671	
Non-white	108	0	108 (100)	NE (NE, NE)	107	0	107 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_9_2_AESI1SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.9.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											1.0000
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	2.863 (0.577, 14.198)	0.1775	
Asia/Other Regions	88	0	88 (100)	NE (NE, NE)	89	0	89 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_9_2_AESI1SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.9.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7189
< 40x10^9/L	132	2 (1.5)	130 (98.5)	NE (NE, NE)	133	1 (0.8)	132 (99.2)	NE (NE, NE)	2.061 (0.187, 22.737)	0.5462	
≥ 40x10^9/L	133	4 (3.0)	129 (97.0)	NE (NE, NE)	135	1 (0.7)	134 (99.3)	NE (NE, NE)	3.749 (0.418, 33.616)	0.2045	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_9_2_AESI1SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.9.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4870
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	1 (1.1)	93 (98.9)	NE (NE, NE)	1.532 (0.139, 16.899)	0.7248	
Idarubicin	142	4 (2.8)	138 (97.2)	NE (NE, NE)	171	1 (0.6)	170 (99.4)	NE (NE, NE)	4.598 (0.514, 41.162)	0.1336	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_9_2_AESI1SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.9.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9480
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	5 (2.6)	190 (97.4)	NE (NE, NE)	190	1 (0.5)	189 (99.5)	NE (NE, NE)	4.403 (0.514, 37.745)	0.1390	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.507 (0.094, 24.095)	0.7703	
Unknown	38	0	38 (100)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_9_2_AESI1SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.9.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9714
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	0	97 (100)	NE (NE, NE)	NE (0.000, NE)	0.0652	
1 - Restricted in Physically Strenuous Activity	133	1 (0.8)	132 (99.2)	NE (NE, NE)	134	1 (0.7)	133 (99.3)	NE (NE, NE)	0.947 (0.059, 15.175)	0.9692	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	1.541 (0.140, 16.995)	0.7220	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_9_2_AESI1SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.9.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											1.0000
≥3 to ≤25%	94	1 (1.1)	93 (98.9)	NE (NE, NE)	98	2 (2.0)	96 (98.0)	NE (NE, NE)	0.529 (0.048, 5.839)	0.5975	
>25% to ≤50%	141	4 (2.8)	137 (97.2)	NE (NE, NE)	136	0	136 (100)	NE (NE, NE)	NE (0.000, NE)	0.0492	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.3865	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_9_2_AESI1SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.9.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9940
Yes	139	4 (2.9)	135 (97.1)	NE (NE, NE)	137	0	137 (100)	NE (NE, NE)	NE (0.000, NE)	0.0509	
No	116	2 (1.7)	114 (98.3)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	0.997 (0.140, 7.080)	0.9974	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_9_2_AESI1SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.9.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - QTcF prolongation ≥ Grade 3 - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9926
≤60	164	2 (1.2)	162 (98.8)	NE (NE, NE)	163	0	163 (100)	NE (NE, NE)	NE (0.000, NE)	0.1744	
>60	101	4 (4.0)	97 (96.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	2.115 (0.387, 11.551)	0.3755	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_9_2_AESI1SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.10.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											1.0000
<60	159	4 (2.5)	155 (97.5)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	0.634 (0.179, 2.249)	0.4768	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (NE, NE)	NE	
≥65	69	0	69 (100)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	0.000 (0.000, NE)	0.1722	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_10_2_AESI2SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.10.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1363
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.376 (0.229, 8.254)	0.7259	
Female	141	1 (0.7)	140 (99.3)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	0.166 (0.020, 1.381)	0.0584	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_10_2_AESI2SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.10.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

		Quizartinib (N=265)			Placebo (N=268)			Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9936
White	157	3 (1.9)	154 (98.1)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	0.480 (0.120, 1.924)	0.2893	
Non-white	108	1 (0.9)	107 (99.1)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	0.479 (0.043, 5.283)	0.5386	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_10_2_AESI2SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.10.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9071
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	3 (1.9)	158 (98.1)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	0.544 (0.130, 2.283)	0.3986	
Asia/Other Regions	88	1 (1.1)	87 (98.9)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	0.329 (0.034, 3.162)	0.3108	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_10_2_AESI2SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.10.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9931
< 40x10^9/L	132	0	132 (100)	NE (NE, NE)	133	4 (3.0)	129 (97.0)	NE (NE, NE)	0.000 (0.000, NE)	0.0489	
≥ 40x10^9/L	133	4 (3.0)	129 (97.0)	NE (NE, NE)	135	4 (3.0)	131 (97.0)	NE (NE, NE)	0.910 (0.227, 3.656)	0.8959	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_10_2_AESI2SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.10.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7276
Daunorubicin	123	1 (0.8)	122 (99.2)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	0.344 (0.031, 3.808)	0.3618	
Idarubicin	142	3 (2.1)	139 (97.9)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	0.582 (0.145, 2.327)	0.4377	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_10_2_AESI2SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.10.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9997
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (9.5, NE)	0.000 (0.000, NE)	0.5271	
Intermediate	195	3 (1.5)	192 (98.5)	NE (NE, NE)	190	4 (2.1)	186 (97.9)	NE (NE, NE)	0.693 (0.155, 3.103)	0.6302	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.000 (0.000, NE)	0.2437	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	0.787 (0.049, 12.739)	0.8657	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_10_2_AESI2SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.10.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6890
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	1.052 (0.212, 5.217)	0.9507	
1 - Restricted in Physically Strenuous Activity	133	1 (0.8)	132 (99.2)	NE (NE, NE)	134	3 (2.2)	131 (97.8)	NE (NE, NE)	0.322 (0.033, 3.098)	0.3008	
2 - Ambulatory and Capable of All Selfcare	45	0	45 (100)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.000 (0.000, NE)	0.1242	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_10_2_AESI2SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.10.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9999
≥3 to ≤25%	94	0	94 (100)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	0.000 (0.000, NE)	0.0506	
>25% to ≤50%	141	3 (2.1)	138 (97.9)	NE (NE, NE)	136	3 (2.2)	133 (97.8)	NE (NE, NE)	0.925 (0.186, 4.591)	0.9249	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	1.180 (0.074, 18.868)	0.9066	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_10_2_AESI2SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.10.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

		Quizartinib (N=265)			Placebo (N=268)			Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6432
Yes	139	3 (2.2)	136 (97.8)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	0.576 (0.137, 2.414)	0.4448	
No	116	1 (0.9)	115 (99.1)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	0.323 (0.033, 3.108)	0.3023	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_10_2_AESI2SEV_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.10.2 Severe Adverse events of special interest (CTCAE Grade ≥ 3) - Combined Elevations of Aminotransferases and Bilirubin - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (weeks) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9913
≤60	164	4 (2.4)	160 (97.6)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	0.623 (0.176, 2.213)	0.4610	
>60	101	0	101 (100)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	0.000 (0.000, NE)	0.1526	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. Only treatment-emergent adverse events of special interest are considered.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_1_1_1_OS_SUB_ITT.sas; Output name: DE_T_3_10_2_AESI2SEV_SUB_SAS.rtf

Anhang 4-H9: Unerwünschter Ereignisse nach SOC und PT

Anhang 4-H9a: UE aller Schweregrade nach SOC und PT

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2535
<60	159	129 (81.1)	30 (18.9)	0.3 (0.2, 0.6)	160	121 (75.6)	39 (24.4)	0.3 (0.2, 0.8)	1.070 (0.835, 1.372)	0.5464	
≥60 - <65	37	25 (67.6)	12 (32.4)	0.3 (0.2, 2.0)	43	36 (83.7)	7 (16.3)	0.3 (0.1, 1.2)	0.744 (0.445, 1.243)	0.2425	
≥65	69	61 (88.4)	8 (11.6)	0.2 (0.1, 0.3)	65	52 (80.0)	13 (20.0)	0.3 (0.2, 0.5)	1.297 (0.894, 1.884)	0.1706	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7198
Male	124	97 (78.2)	27 (21.8)	0.3 (0.2, 0.4)	120	94 (78.3)	26 (21.7)	0.3 (0.2, 0.8)	1.017 (0.766, 1.352)	0.9237	
Female	141	118 (83.7)	23 (16.3)	0.2 (0.2, 0.4)	148	115 (77.7)	33 (22.3)	0.2 (0.1, 0.4)	1.090 (0.843, 1.409)	0.4761	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6998
White	157	116 (73.9)	41 (26.1)	0.3 (0.2, 0.9)	161	115 (71.4)	46 (28.6)	0.2 (0.2, 0.6)	1.026 (0.792, 1.328)	0.8227	
Non-white	108	99 (91.7)	9 (8.3)	0.2 (0.2, 0.3)	107	94 (87.9)	13 (12.1)	0.3 (0.2, 0.6)	1.104 (0.831, 1.465)	0.4942	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0521
North America	16	15 (93.8)	1 (6.3)	0.2 (0.1, 1.4)	18	18 (100)	0	0.1 (0.1, 0.1)	0.345 (0.159, 0.747)	0.0050	
Europe	161	121 (75.2)	40 (24.8)	0.4 (0.2, 1.0)	161	114 (70.8)	47 (29.2)	0.3 (0.2, 0.9)	1.070 (0.829, 1.383)	0.5888	
Asia/Other Regions	88	79 (89.8)	9 (10.2)	0.2 (0.1, 0.3)	89	77 (86.5)	12 (13.5)	0.4 (0.2, 0.8)	1.225 (0.893, 1.679)	0.2118	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9222
< 40x10^9/L	132	102 (77.3)	30 (22.7)	0.4 (0.3, 0.9)	133	102 (76.7)	31 (23.3)	0.4 (0.3, 1.1)	1.080 (0.820, 1.422)	0.5662	
≥ 40x10^9/L	133	113 (85.0)	20 (15.0)	0.2 (0.1, 0.3)	135	107 (79.3)	28 (20.7)	0.2 (0.1, 0.3)	1.053 (0.808, 1.372)	0.7006	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7027
Daunorubicin	123	96 (78.0)	27 (22.0)	0.3 (0.2, 0.6)	94	72 (76.6)	22 (23.4)	0.4 (0.2, 1.1)	1.033 (0.761, 1.404)	0.8496	
Idarubicin	142	119 (83.8)	23 (16.2)	0.2 (0.2, 0.4)	171	134 (78.4)	37 (21.6)	0.3 (0.1, 0.4)	1.114 (0.870, 1.427)	0.3523	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5922
Favorable	13	11 (84.6)	2 (15.4)	0.2 (0.1, 0.9)	19	18 (94.7)	1 (5.3)	0.1 (0.1, 0.4)	0.745 (0.350, 1.586)	0.4674	
Intermediate	195	158 (81.0)	37 (19.0)	0.3 (0.2, 0.5)	190	145 (76.3)	45 (23.7)	0.3 (0.2, 0.5)	1.047 (0.836, 1.312)	0.6678	
Unfavorable	19	17 (89.5)	2 (10.5)	0.3 (0.1, 0.5)	27	22 (81.5)	5 (18.5)	0.4 (0.1, 1.2)	1.278 (0.670, 2.439)	0.4650	
Unknown	38	29 (76.3)	9 (23.7)	0.2 (0.1, 0.3)	31	23 (74.2)	8 (25.8)	0.4 (0.2, 3.0)	1.329 (0.766, 2.307)	0.3187	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8528
0 - Fully Active	87	70 (80.5)	17 (19.5)	0.4 (0.2, 1.0)	97	76 (78.4)	21 (21.6)	0.3 (0.1, 0.8)	1.011 (0.730, 1.401)	0.8966	
1 - Restricted in Physically Strenuous Activity	133	107 (80.5)	26 (19.5)	0.2 (0.2, 0.5)	134	101 (75.4)	33 (24.6)	0.4 (0.2, 0.9)	1.118 (0.852, 1.468)	0.4200	
2 - Ambulatory and Capable of All Selfcare	45	38 (84.4)	7 (15.6)	0.1 (0.1, 0.3)	36	31 (86.1)	5 (13.9)	0.2 (0.1, 0.4)	1.017 (0.633, 1.636)	0.9378	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1343
≥3 to ≤25%	94	72 (76.6)	22 (23.4)	0.4 (0.2, 0.6)	98	81 (82.7)	17 (17.3)	0.2 (0.1, 0.4)	0.832 (0.605, 1.143)	0.2788	
>25% to ≤50%	141	119 (84.4)	22 (15.6)	0.2 (0.2, 0.3)	136	107 (78.7)	29 (21.3)	0.3 (0.2, 0.8)	1.164 (0.896, 1.512)	0.2605	
>50%	29	24 (82.8)	5 (17.2)	0.2 (0.1, 1.1)	34	21 (61.8)	13 (38.2)	0.9 (0.1, NE)	1.535 (0.853, 2.760)	0.1479	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5726
Yes	139	114 (82.0)	25 (18.0)	0.2 (0.1, 0.8)	137	109 (79.6)	28 (20.4)	0.2 (0.1, 0.4)	0.991 (0.762, 1.288)	0.9492	
No	116	92 (79.3)	24 (20.7)	0.3 (0.2, 0.4)	120	91 (75.8)	29 (24.2)	0.3 (0.2, 0.8)	1.119 (0.837, 1.495)	0.4321	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8318
≤60	164	131 (79.9)	33 (20.1)	0.3 (0.2, 0.6)	163	123 (75.5)	40 (24.5)	0.3 (0.2, 0.8)	1.049 (0.820, 1.342)	0.6643	
>60	101	84 (83.2)	17 (16.8)	0.2 (0.1, 0.3)	105	86 (81.9)	19 (18.1)	0.3 (0.2, 0.4)	1.102 (0.815, 1.490)	0.5530	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0847
<60	159	50 (31.4)	109 (68.6)	NE (26.9, NE)	160	55 (34.4)	105 (65.6)	NE (9.3, NE)	0.808 (0.549, 1.187)	0.2781	
≥60 - <65	37	13 (35.1)	24 (64.9)	22.3 (2.6, NE)	43	16 (37.2)	27 (62.8)	7.5 (3.5, NE)	0.858 (0.411, 1.789)	0.6804	
≥65	69	35 (50.7)	34 (49.3)	6.7 (1.0, NE)	65	23 (35.4)	42 (64.6)	NE (5.9, NE)	1.668 (0.985, 2.825)	0.0549	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3057
Male	124	46 (37.1)	78 (62.9)	NE (13.2, NE)	120	37 (30.8)	83 (69.2)	NE (7.5, NE)	1.179 (0.764, 1.821)	0.4610	
Female	141	52 (36.9)	89 (63.1)	NE (14.0, NE)	148	57 (38.5)	91 (61.5)	NE (6.1, NE)	0.873 (0.599, 1.274)	0.4767	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8508
White	157	53 (33.8)	104 (66.2)	NE (19.4, NE)	161	51 (31.7)	110 (68.3)	NE (9.3, NE)	1.008 (0.685, 1.483)	0.9713	
Non-white	108	45 (41.7)	63 (58.3)	18.7 (6.7, NE)	107	43 (40.2)	64 (59.8)	NE (3.5, NE)	0.965 (0.635, 1.467)	0.8728	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3327
North America	16	7 (43.8)	9 (56.3)	7.7 (0.3, NE)	18	13 (72.2)	5 (27.8)	0.5 (0.1, 7.1)	0.547 (0.217, 1.379)	0.1924	
Europe	161	49 (30.4)	112 (69.6)	NE (NE, NE)	161	46 (28.6)	115 (71.4)	NE (11.4, NE)	1.011 (0.675, 1.514)	0.9663	
Asia/Other Regions	88	42 (47.7)	46 (52.3)	12.1 (2.1, NE)	89	35 (39.3)	54 (60.7)	NE (3.8, NE)	1.146 (0.730, 1.798)	0.5479	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0774
< 40x10^9/L	132	49 (37.1)	83 (62.9)	NE (12.1, NE)	133	39 (29.3)	94 (70.7)	NE (NE, NE)	1.321 (0.867, 2.013)	0.1915	
≥ 40x10^9/L	133	49 (36.8)	84 (63.2)	26.9 (13.3, NE)	135	55 (40.7)	80 (59.3)	9.3 (4.3, NE)	0.757 (0.512, 1.117)	0.1547	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8540
Daunorubicin	123	40 (32.5)	83 (67.5)	NE (22.3, NE)	94	26 (27.7)	68 (72.3)	NE (9.3, NE)	1.074 (0.653, 1.765)	0.7806	
Idarubicin	142	58 (40.8)	84 (59.2)	16.4 (9.3, NE)	171	67 (39.2)	104 (60.8)	NE (7.0, NE)	1.010 (0.710, 1.437)	0.9555	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9438
Favorable	13	4 (30.8)	9 (69.2)	NE (0.9, NE)	19	7 (36.8)	12 (63.2)	NE (0.6, NE)	0.833 (0.244, 2.846)	0.7678	
Intermediate	195	72 (36.9)	123 (63.1)	NE (13.3, NE)	190	64 (33.7)	126 (66.3)	NE (9.3, NE)	1.010 (0.720, 1.417)	0.9547	
Unfavorable	19	7 (36.8)	12 (63.2)	26.9 (0.9, NE)	27	12 (44.4)	15 (55.6)	6.1 (2.0, NE)	0.710 (0.273, 1.844)	0.4744	
Unknown	38	15 (39.5)	23 (60.5)	16.4 (2.1, NE)	31	11 (35.5)	20 (64.5)	NE (2.9, NE)	1.171 (0.537, 2.554)	0.6865	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7163
0 - Fully Active	87	26 (29.9)	61 (70.1)	NE (16.4, NE)	97	23 (23.7)	74 (76.3)	NE (NE, NE)	1.175 (0.670, 2.063)	0.5662	
1 - Restricted in Physically Strenuous Activity	133	53 (39.8)	80 (60.2)	22.3 (9.5, NE)	134	55 (41.0)	79 (59.0)	7.5 (4.4, NE)	0.913 (0.625, 1.332)	0.6325	
2 - Ambulatory and Capable of All Selfcare	45	19 (42.2)	26 (57.8)	19.4 (1.8, NE)	36	16 (44.4)	20 (55.6)	5.9 (1.3, NE)	0.805 (0.402, 1.609)	0.5189	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9863
≥3 to ≤25%	94	34 (36.2)	60 (63.8)	NE (13.2, NE)	98	34 (34.7)	64 (65.3)	NE (6.1, NE)	1.018 (0.632, 1.638)	0.9501	
>25% to ≤50%	141	54 (38.3)	87 (61.7)	NE (9.5, NE)	136	50 (36.8)	86 (63.2)	11.4 (7.0, NE)	0.977 (0.664, 1.438)	0.9095	
>50%	29	10 (34.5)	19 (65.5)	NE (9.3, NE)	34	10 (29.4)	24 (70.6)	NE (4.4, NE)	0.967 (0.392, 2.389)	0.9455	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0513
Yes	139	45 (32.4)	94 (67.6)	NE (19.4, NE)	137	52 (38.0)	85 (62.0)	NE (7.1, NE)	0.763 (0.511, 1.140)	0.1820	
No	116	50 (43.1)	66 (56.9)	13.2 (1.9, NE)	120	39 (32.5)	81 (67.5)	NE (6.1, NE)	1.351 (0.888, 2.054)	0.1552	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1108
≤60	164	52 (31.7)	112 (68.3)	NE (26.9, NE)	163	55 (33.7)	108 (66.3)	NE (9.3, NE)	0.830 (0.567, 1.215)	0.3380	
>60	101	46 (45.5)	55 (54.5)	16.4 (2.4, NE)	105	39 (37.1)	66 (62.9)	NE (5.9, NE)	1.305 (0.851, 2.000)	0.2232	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Nausea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0712
<60	159	50 (31.4)	109 (68.6)	NE (14.8, NE)	160	55 (34.4)	105 (65.6)	NE (11.0, NE)	0.804 (0.548, 1.180)	0.2661	
≥60 - <65	37	12 (32.4)	25 (67.6)	NE (1.9, NE)	43	6 (14.0)	37 (86.0)	NE (NE, NE)	2.682 (1.005, 7.159)	0.0404	
≥65	69	28 (40.6)	41 (59.4)	14.8 (3.3, NE)	65	23 (35.4)	42 (64.6)	NE (2.9, NE)	1.129 (0.650, 1.963)	0.6632	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Nausea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5452
Male	124	38 (30.6)	86 (69.4)	NE (14.9, NE)	120	36 (30.0)	84 (70.0)	NE (5.9, NE)	0.937 (0.593, 1.480)	0.7767	
Female	141	52 (36.9)	89 (63.1)	17.3 (8.1, NE)	148	48 (32.4)	100 (67.6)	NE (11.0, NE)	1.115 (0.753, 1.651)	0.5829	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Nausea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4151
White	157	50 (31.8)	107 (68.2)	NE (14.8, NE)	161	52 (32.3)	109 (67.7)	NE (11.0, NE)	0.944 (0.639, 1.393)	0.7669	
Non-white	108	40 (37.0)	68 (63.0)	15.5 (5.3, NE)	107	32 (29.9)	75 (70.1)	NE (6.0, NE)	1.190 (0.747, 1.895)	0.4602	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Nausea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6937
North America	16	6 (37.5)	10 (62.5)	14.8 (1.2, NE)	18	8 (44.4)	10 (55.6)	6.4 (0.4, NE)	0.848 (0.292, 2.463)	0.7617	
Europe	161	50 (31.1)	111 (68.9)	NE (17.3, NE)	161	49 (30.4)	112 (69.6)	NE (15.6, NE)	0.957 (0.645, 1.420)	0.8276	
Asia/Other Regions	88	34 (38.6)	54 (61.4)	15.5 (4.5, NE)	89	27 (30.3)	62 (69.7)	NE (5.3, NE)	1.228 (0.741, 2.037)	0.4241	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Nausea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3331
< 40x10^9/L	132	45 (34.1)	87 (65.9)	NE (10.9, NE)	133	48 (36.1)	85 (63.9)	NE (5.9, NE)	0.893 (0.594, 1.341)	0.5856	
≥ 40x10^9/L	133	45 (33.8)	88 (66.2)	NE (14.8, NE)	135	36 (26.7)	99 (73.3)	NE (NE, NE)	1.228 (0.792, 1.904)	0.3588	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Nausea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5396
Daunorubicin	123	37 (30.1)	86 (69.9)	NE (17.3, NE)	94	29 (30.9)	65 (69.1)	NE (6.0, NE)	0.913 (0.561, 1.488)	0.7166	
Idarubicin	142	53 (37.3)	89 (62.7)	15.5 (10.5, NE)	171	55 (32.2)	116 (67.8)	NE (NE, NE)	1.098 (0.753, 1.602)	0.6247	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Nausea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.2008
Favorable	13	6 (46.2)	7 (53.8)	4.5 (0.7, NE)	19	10 (52.6)	9 (47.4)	6.4 (0.2, NE)	1.049 (0.370, 2.970)	0.9409	
Intermediate	195	68 (34.9)	127 (65.1)	NE (14.8, NE)	190	50 (26.3)	140 (73.7)	NE (NE, NE)	1.280 (0.888, 1.845)	0.1847	
Unfavorable	19	7 (36.8)	12 (63.2)	8.1 (2.3, NE)	27	11 (40.7)	16 (59.3)	11.0 (1.8, NE)	0.851 (0.328, 2.210)	0.7426	
Unknown	38	9 (23.7)	29 (76.3)	NE (10.9, NE)	31	13 (41.9)	18 (58.1)	NE (1.5, NE)	0.498 (0.212, 1.168)	0.1020	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Nausea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4651
0 - Fully Active	87	29 (33.3)	58 (66.7)	NE (8.1, NE)	97	29 (29.9)	68 (70.1)	NE (NE, NE)	1.023 (0.611, 1.713)	0.9275	
1 - Restricted in Physically Strenuous Activity	133	44 (33.1)	89 (66.9)	NE (14.8, NE)	134	46 (34.3)	88 (65.7)	NE (6.0, NE)	0.909 (0.601, 1.375)	0.6519	
2 - Ambulatory and Capable of All Selfcare	45	17 (37.8)	28 (62.2)	17.3 (2.7, NE)	36	9 (25.0)	27 (75.0)	NE (5.9, NE)	1.578 (0.700, 3.558)	0.2676	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Nausea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5749
≥3 to ≤25%	94	27 (28.7)	67 (71.3)	NE (17.3, NE)	98	32 (32.7)	66 (67.3)	NE (11.0, NE)	0.866 (0.519, 1.446)	0.5798	
>25% to ≤50%	141	54 (38.3)	87 (61.7)	15.5 (8.1, NE)	136	46 (33.8)	90 (66.2)	NE (6.0, NE)	1.075 (0.725, 1.594)	0.7180	
>50%	29	9 (31.0)	20 (69.0)	10.9 (6.9, NE)	34	6 (17.6)	28 (82.4)	NE (NE, NE)	1.403 (0.494, 3.990)	0.5198	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Nausea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4068
Yes	139	47 (33.8)	92 (66.2)	NE (14.8, NE)	137	41 (29.9)	96 (70.1)	NE (NE, NE)	1.109 (0.729, 1.687)	0.6273	
No	116	37 (31.9)	79 (68.1)	NE (6.9, NE)	120	40 (33.3)	80 (66.7)	NE (5.3, NE)	0.853 (0.545, 1.335)	0.4850	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Nausea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0714
≤60	164	52 (31.7)	112 (68.3)	NE (14.8, NE)	163	55 (33.7)	108 (66.3)	NE (11.0, NE)	0.825 (0.564, 1.207)	0.3243	
>60	101	38 (37.6)	63 (62.4)	14.9 (8.1, NE)	105	29 (27.6)	76 (72.4)	NE (NE, NE)	1.462 (0.901, 2.371)	0.1217	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Vomiting

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6274
<60	159	38 (23.9)	121 (76.1)	NE (NE, NE)	160	33 (20.6)	127 (79.4)	NE (NE, NE)	1.034 (0.648, 1.650)	0.8862	
≥60 - <65	37	8 (21.6)	29 (78.4)	NE (NE, NE)	43	8 (18.6)	35 (81.4)	NE (37.3, NE)	1.295 (0.483, 3.472)	0.6121	
≥65	69	19 (27.5)	50 (72.5)	NE (10.9, NE)	65	12 (18.5)	53 (81.5)	NE (NE, NE)	1.604 (0.778, 3.304)	0.1953	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Vomiting

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6623
Male	124	20 (16.1)	104 (83.9)	NE (NE, NE)	120	16 (13.3)	104 (86.7)	NE (NE, NE)	1.100 (0.569, 2.127)	0.7741	
Female	141	45 (31.9)	96 (68.1)	NE (10.9, NE)	148	37 (25.0)	111 (75.0)	NE (37.3, NE)	1.312 (0.849, 2.027)	0.2196	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Vomiting

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3229
White	157	32 (20.4)	125 (79.6)	NE (NE, NE)	161	31 (19.3)	130 (80.7)	NE (NE, NE)	1.011 (0.616, 1.660)	0.9655	
Non-white	108	33 (30.6)	75 (69.4)	NE (8.7, NE)	107	22 (20.6)	85 (79.4)	NE (37.3, NE)	1.457 (0.849, 2.500)	0.1689	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Vomiting

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6640
North America	16	5 (31.3)	11 (68.8)	14.8 (1.9, NE)	18	6 (33.3)	12 (66.7)	NE (1.5, NE)	1.022 (0.311, 3.356)	0.9718	
Europe	161	29 (18.0)	132 (82.0)	NE (NE, NE)	161	26 (16.1)	135 (83.9)	NE (NE, NE)	1.071 (0.630, 1.822)	0.7999	
Asia/Other Regions	88	31 (35.2)	57 (64.8)	23.9 (7.0, NE)	89	21 (23.6)	68 (76.4)	NE (37.3, NE)	1.454 (0.835, 2.530)	0.1835	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Vomiting

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0117
< 40x10^9/L	132	33 (25.0)	99 (75.0)	NE (23.9, NE)	133	18 (13.5)	115 (86.5)	NE (NE, NE)	2.023 (1.139, 3.595)	0.0141	
≥ 40x10^9/L	133	32 (24.1)	101 (75.9)	NE (NE, NE)	135	35 (25.9)	100 (74.1)	NE (37.3, NE)	0.764 (0.471, 1.238)	0.2726	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Vomiting

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4733
Daunorubicin	123	26 (21.1)	97 (78.9)	NE (NE, NE)	94	18 (19.1)	76 (80.9)	NE (NE, NE)	0.989 (0.541, 1.809)	0.9715	
Idarubicin	142	39 (27.5)	103 (72.5)	NE (23.9, NE)	171	35 (20.5)	136 (79.5)	NE (37.3, NE)	1.331 (0.843, 2.101)	0.2178	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Vomiting

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3693
Favorable	13	3 (23.1)	10 (76.9)	NE (1.3, NE)	19	4 (21.1)	15 (78.9)	NE (NE, NE)	1.204 (0.268, 5.403)	0.8079	
Intermediate	195	50 (25.6)	145 (74.4)	NE (NE, NE)	190	38 (20.0)	152 (80.0)	NE (37.3, NE)	1.187 (0.778, 1.812)	0.4251	
Unfavorable	19	3 (15.8)	16 (84.2)	NE (4.3, NE)	27	8 (29.6)	19 (70.4)	NE (13.1, NE)	0.495 (0.131, 1.876)	0.2929	
Unknown	38	9 (23.7)	29 (76.3)	NE (11.6, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	2.571 (0.695, 9.513)	0.1428	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Vomiting

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4176
0 - Fully Active	87	24 (27.6)	63 (72.4)	NE (14.8, NE)	97	16 (16.5)	81 (83.5)	NE (NE, NE)	1.630 (0.865, 3.070)	0.1263	
1 - Restricted in Physically Strenuous Activity	133	29 (21.8)	104 (78.2)	NE (NE, NE)	134	27 (20.1)	107 (79.9)	NE (37.3, NE)	1.042 (0.617, 1.761)	0.8754	
2 - Ambulatory and Capable of All Selfcare	45	12 (26.7)	33 (73.3)	NE (9.0, NE)	36	10 (27.8)	26 (72.2)	NE (9.6, NE)	0.859 (0.369, 2.002)	0.7280	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Vomiting

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4482
≥3 to ≤25%	94	20 (21.3)	74 (78.7)	NE (NE, NE)	98	24 (24.5)	74 (75.5)	NE (NE, NE)	0.891 (0.492, 1.614)	0.7013	
>25% to ≤50%	141	41 (29.1)	100 (70.9)	NE (14.8, NE)	136	26 (19.1)	110 (80.9)	NE (37.3, NE)	1.471 (0.899, 2.407)	0.1214	
>50%	29	4 (13.8)	25 (86.2)	NE (9.0, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	1.070 (0.231, 4.948)	0.9307	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Vomiting

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4457
Yes	139	31 (22.3)	108 (77.7)	NE (NE, NE)	137	29 (21.2)	108 (78.8)	NE (37.3, NE)	1.010 (0.608, 1.678)	0.9675	
No	116	28 (24.1)	88 (75.9)	NE (12.2, NE)	120	21 (17.5)	99 (82.5)	NE (NE, NE)	1.330 (0.755, 2.344)	0.3220	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Vomiting

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3076
≤60	164	38 (23.2)	126 (76.8)	NE (NE, NE)	163	33 (20.2)	130 (79.8)	NE (NE, NE)	1.017 (0.637, 1.623)	0.9417	
>60	101	27 (26.7)	74 (73.3)	NE (NE, NE)	105	20 (19.0)	85 (81.0)	NE (37.3, NE)	1.519 (0.852, 2.710)	0.1542	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3921
<60	159	34 (21.4)	125 (78.6)	NE (NE, NE)	160	28 (17.5)	132 (82.5)	NE (NE, NE)	1.145 (0.693, 1.890)	0.5927	
≥60 - <65	37	5 (13.5)	32 (86.5)	NE (NE, NE)	43	10 (23.3)	33 (76.7)	NE (11.4, NE)	0.532 (0.181, 1.563)	0.2429	
≥65	69	18 (26.1)	51 (73.9)	NE (NE, NE)	65	18 (27.7)	47 (72.3)	NE (NE, NE)	0.983 (0.511, 1.889)	0.9556	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8044
Male	124	23 (18.5)	101 (81.5)	NE (NE, NE)	120	21 (17.5)	99 (82.5)	NE (NE, NE)	1.049 (0.580, 1.897)	0.8799	
Female	141	34 (24.1)	107 (75.9)	NE (NE, NE)	148	35 (23.6)	113 (76.4)	NE (NE, NE)	0.969 (0.604, 1.553)	0.9021	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1677
White	157	28 (17.8)	129 (82.2)	NE (NE, NE)	161	34 (21.1)	127 (78.9)	NE (NE, NE)	0.801 (0.485, 1.322)	0.3843	
Non-white	108	29 (26.9)	79 (73.1)	NE (17.3, NE)	107	22 (20.6)	85 (79.4)	NE (NE, NE)	1.335 (0.767, 2.324)	0.3051	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.1215
North America	16	4 (25.0)	12 (75.0)	NE (2.8, NE)	18	6 (33.3)	12 (66.7)	NE (0.2, NE)	0.704 (0.197, 2.507)	0.5867	
Europe	161	25 (15.5)	136 (84.5)	NE (NE, NE)	161	32 (19.9)	129 (80.1)	NE (NE, NE)	0.741 (0.438, 1.251)	0.2590	
Asia/Other Regions	88	28 (31.8)	60 (68.2)	NE (9.3, NE)	89	18 (20.2)	71 (79.8)	NE (NE, NE)	1.643 (0.909, 2.972)	0.0964	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7768
< 40x10^9/L	132	25 (18.9)	107 (81.1)	NE (NE, NE)	133	27 (20.3)	106 (79.7)	NE (NE, NE)	0.952 (0.552, 1.640)	0.8591	
≥ 40x10^9/L	133	32 (24.1)	101 (75.9)	NE (NE, NE)	135	29 (21.5)	106 (78.5)	NE (NE, NE)	1.035 (0.625, 1.714)	0.8927	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3035
Daunorubicin	123	27 (22.0)	96 (78.0)	NE (NE, NE)	94	15 (16.0)	79 (84.0)	NE (NE, NE)	1.349 (0.717, 2.537)	0.3524	
Idarubicin	142	30 (21.1)	112 (78.9)	NE (NE, NE)	171	40 (23.4)	131 (76.6)	NE (NE, NE)	0.874 (0.544, 1.403)	0.5782	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7065
Favorable	13	2 (15.4)	11 (84.6)	NE (1.8, NE)	19	5 (26.3)	14 (73.7)	NE (1.7, NE)	0.583 (0.113, 3.007)	0.5138	
Intermediate	195	42 (21.5)	153 (78.5)	NE (NE, NE)	190	40 (21.1)	150 (78.9)	NE (NE, NE)	0.959 (0.621, 1.479)	0.8480	
Unfavorable	19	6 (31.6)	13 (68.4)	NE (1.7, NE)	27	8 (29.6)	19 (70.4)	NE (1.3, NE)	1.103 (0.382, 3.180)	0.8534	
Unknown	38	7 (18.4)	31 (81.6)	NE (17.3, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	2.015 (0.521, 7.797)	0.3014	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7867
0 - Fully Active	87	19 (21.8)	68 (78.2)	NE (NE, NE)	97	18 (18.6)	79 (81.4)	NE (NE, NE)	1.157 (0.607, 2.204)	0.6543	
1 - Restricted in Physically Strenuous Activity	133	25 (18.8)	108 (81.2)	NE (NE, NE)	134	28 (20.9)	106 (79.1)	NE (NE, NE)	0.853 (0.497, 1.464)	0.5641	
2 - Ambulatory and Capable of All Selfcare	45	13 (28.9)	32 (71.1)	NE (6.2, NE)	36	10 (27.8)	26 (72.2)	NE (9.3, NE)	1.053 (0.461, 2.404)	0.9050	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1068
≥3 to ≤25%	94	17 (18.1)	77 (81.9)	NE (NE, NE)	98	27 (27.6)	71 (72.4)	NE (NE, NE)	0.622 (0.339, 1.141)	0.1224	
>25% to ≤50%	141	34 (24.1)	107 (75.9)	NE (NE, NE)	136	26 (19.1)	110 (80.9)	NE (NE, NE)	1.240 (0.743, 2.069)	0.4120	
>50%	29	6 (20.7)	23 (79.3)	NE (9.3, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	2.081 (0.517, 8.378)	0.2918	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5984
Yes	139	31 (22.3)	108 (77.7)	NE (NE, NE)	137	29 (21.2)	108 (78.8)	NE (NE, NE)	1.065 (0.641, 1.767)	0.8131	
No	116	25 (21.6)	91 (78.4)	NE (NE, NE)	120	27 (22.5)	93 (77.5)	NE (NE, NE)	0.882 (0.511, 1.521)	0.6575	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4332
≤60	164	35 (21.3)	129 (78.7)	NE (NE, NE)	163	29 (17.8)	134 (82.2)	NE (NE, NE)	1.122 (0.685, 1.838)	0.6426	
>60	101	22 (21.8)	79 (78.2)	NE (NE, NE)	105	27 (25.7)	78 (74.3)	NE (NE, NE)	0.852 (0.485, 1.496)	0.5748	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Constipation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5477
<60	159	30 (18.9)	129 (81.1)	NE (NE, NE)	160	38 (23.8)	122 (76.3)	NE (NE, NE)	0.700 (0.433, 1.132)	0.1440	
≥60 - <65	37	6 (16.2)	31 (83.8)	NE (NE, NE)	43	10 (23.3)	33 (76.7)	NE (7.0, NE)	0.534 (0.191, 1.488)	0.2228	
≥65	69	20 (29.0)	49 (71.0)	17.3 (3.9, NE)	65	21 (32.3)	44 (67.7)	27.8 (6.6, NE)	0.998 (0.539, 1.846)	0.9973	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Constipation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8095
Male	124	25 (20.2)	99 (79.8)	NE (NE, NE)	120	28 (23.3)	92 (76.7)	NE (16.5, NE)	0.791 (0.460, 1.358)	0.3943	
Female	141	31 (22.0)	110 (78.0)	NE (34.3, NE)	148	41 (27.7)	107 (72.3)	NE (27.8, NE)	0.714 (0.447, 1.140)	0.1565	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Constipation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8710
White	157	28 (17.8)	129 (82.2)	NE (NE, NE)	161	36 (22.4)	125 (77.6)	NE (NE, NE)	0.752 (0.459, 1.234)	0.2583	
Non-white	108	28 (25.9)	80 (74.1)	NE (24.4, NE)	107	33 (30.8)	74 (69.2)	NE (7.0, NE)	0.712 (0.430, 1.180)	0.1861	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Constipation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3202
North America	16	3 (18.8)	13 (81.3)	NE (7.2, NE)	18	8 (44.4)	10 (55.6)	16.5 (1.4, NE)	0.385 (0.101, 1.471)	0.1483	
Europe	161	27 (16.8)	134 (83.2)	NE (NE, NE)	161	38 (23.6)	123 (76.4)	NE (NE, NE)	0.659 (0.402, 1.080)	0.0954	
Asia/Other Regions	88	26 (29.5)	62 (70.5)	34.3 (17.3, NE)	89	23 (25.8)	66 (74.2)	NE (27.8, NE)	1.000 (0.570, 1.755)	0.9978	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Constipation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3384
< 40x10^9/L	132	26 (19.7)	106 (80.3)	NE (34.3, NE)	133	30 (22.6)	103 (77.4)	NE (NE, NE)	0.883 (0.522, 1.494)	0.6420	
≥ 40x10^9/L	133	30 (22.6)	103 (77.4)	NE (NE, NE)	135	39 (28.9)	96 (71.1)	NE (16.5, NE)	0.625 (0.387, 1.010)	0.0533	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Constipation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3902
Daunorubicin	123	25 (20.3)	98 (79.7)	NE (NE, NE)	94	26 (27.7)	68 (72.3)	NE (8.6, NE)	0.630 (0.363, 1.092)	0.0975	
Idarubicin	142	31 (21.8)	111 (78.2)	NE (34.3, NE)	171	41 (24.0)	130 (76.0)	NE (NE, NE)	0.849 (0.532, 1.355)	0.4929	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Constipation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5562
Favorable	13	2 (15.4)	11 (84.6)	NE (5.8, NE)	19	8 (42.1)	11 (57.9)	16.5 (1.4, NE)	0.277 (0.057, 1.353)	0.0930	
Intermediate	195	39 (20.0)	156 (80.0)	NE (NE, NE)	190	46 (24.2)	144 (75.8)	NE (NE, NE)	0.732 (0.477, 1.122)	0.1511	
Unfavorable	19	6 (31.6)	13 (68.4)	NE (1.6, NE)	27	7 (25.9)	20 (74.1)	NE (4.4, NE)	1.164 (0.388, 3.494)	0.7933	
Unknown	38	9 (23.7)	29 (76.3)	NE (NE, NE)	31	8 (25.8)	23 (74.2)	NE (NE, NE)	0.946 (0.365, 2.452)	0.9092	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Constipation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9548
0 - Fully Active	87	13 (14.9)	74 (85.1)	NE (NE, NE)	97	20 (20.6)	77 (79.4)	NE (NE, NE)	0.673 (0.334, 1.353)	0.2627	
1 - Restricted in Physically Strenuous Activity	133	34 (25.6)	99 (74.4)	NE (25.7, NE)	134	41 (30.6)	93 (69.4)	NE (16.5, NE)	0.755 (0.479, 1.190)	0.2244	
2 - Ambulatory and Capable of All Selfcare	45	9 (20.0)	36 (80.0)	NE (6.6, NE)	36	8 (22.2)	28 (77.8)	NE (4.4, NE)	0.727 (0.278, 1.902)	0.5161	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Constipation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2239
≥3 to ≤25%	94	16 (17.0)	78 (83.0)	NE (NE, NE)	98	31 (31.6)	67 (68.4)	NE (27.8, NE)	0.503 (0.275, 0.920)	0.0231	
>25% to ≤50%	141	36 (25.5)	105 (74.5)	NE (25.7, NE)	136	33 (24.3)	103 (75.7)	NE (NE, NE)	0.953 (0.594, 1.531)	0.8451	
>50%	29	4 (13.8)	25 (86.2)	NE (17.6, NE)	34	5 (14.7)	29 (85.3)	NE (6.6, NE)	0.671 (0.176, 2.563)	0.5572	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Constipation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4790
Yes	139	25 (18.0)	114 (82.0)	NE (NE, NE)	137	36 (26.3)	101 (73.7)	NE (27.8, NE)	0.587 (0.351, 0.979)	0.0390	
No	116	26 (22.4)	90 (77.6)	NE (25.7, NE)	120	31 (25.8)	89 (74.2)	NE (NE, NE)	0.800 (0.475, 1.348)	0.4025	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Constipation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4113
≤60	164	30 (18.3)	134 (81.7)	NE (NE, NE)	163	39 (23.9)	124 (76.1)	NE (NE, NE)	0.669 (0.415, 1.078)	0.0968	
>60	101	26 (25.7)	75 (74.3)	NE (10.8, NE)	105	30 (28.6)	75 (71.4)	NE (16.5, NE)	0.885 (0.523, 1.497)	0.6487	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2634
<60	159	24 (15.1)	135 (84.9)	NE (NE, NE)	160	22 (13.8)	138 (86.3)	NE (NE, NE)	1.063 (0.596, 1.897)	0.8331	
≥60 - <65	37	6 (16.2)	31 (83.8)	NE (NE, NE)	43	8 (18.6)	35 (81.4)	NE (NE, NE)	0.773 (0.267, 2.236)	0.6403	
≥65	69	16 (23.2)	53 (76.8)	NE (10.4, NE)	65	8 (12.3)	57 (87.7)	NE (NE, NE)	2.154 (0.921, 5.036)	0.0700	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6465
Male	124	17 (13.7)	107 (86.3)	NE (NE, NE)	120	15 (12.5)	105 (87.5)	NE (NE, NE)	1.085 (0.542, 2.174)	0.8166	
Female	141	29 (20.6)	112 (79.4)	NE (NE, NE)	148	23 (15.5)	125 (84.5)	NE (NE, NE)	1.305 (0.755, 2.256)	0.3354	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6272
White	157	23 (14.6)	134 (85.4)	NE (NE, NE)	161	21 (13.0)	140 (87.0)	NE (NE, NE)	1.087 (0.601, 1.966)	0.7800	
Non-white	108	23 (21.3)	85 (78.7)	NE (NE, NE)	107	17 (15.9)	90 (84.1)	NE (NE, NE)	1.357 (0.725, 2.540)	0.3371	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2317
North America	16	2 (12.5)	14 (87.5)	NE (NE, NE)	18	6 (33.3)	12 (66.7)	5.6 (0.2, NE)	0.324 (0.065, 1.609)	0.1454	
Europe	161	27 (16.8)	134 (83.2)	NE (NE, NE)	161	19 (11.8)	142 (88.2)	NE (NE, NE)	1.395 (0.775, 2.509)	0.2639	
Asia/Other Regions	88	17 (19.3)	71 (80.7)	NE (NE, NE)	89	13 (14.6)	76 (85.4)	NE (NE, NE)	1.357 (0.659, 2.795)	0.4069	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7620
< 40x10^9/L	132	22 (16.7)	110 (83.3)	NE (NE, NE)	133	20 (15.0)	113 (85.0)	NE (NE, NE)	1.133 (0.618, 2.076)	0.6822	
≥ 40x10^9/L	133	24 (18.0)	109 (82.0)	NE (NE, NE)	135	18 (13.3)	117 (86.7)	NE (NE, NE)	1.269 (0.688, 2.342)	0.4436	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6573
Daunorubicin	123	15 (12.2)	108 (87.8)	NE (NE, NE)	94	7 (7.4)	87 (92.6)	NE (NE, NE)	1.555 (0.633, 3.821)	0.3305	
Idarubicin	142	31 (21.8)	111 (78.2)	NE (NE, NE)	171	30 (17.5)	141 (82.5)	NE (NE, NE)	1.265 (0.765, 2.090)	0.3573	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9064
Favorable	13	0	13 (100)	NE (NE, NE)	19	6 (31.6)	13 (68.4)	NE (0.2, NE)	0.000 (0.000, NE)	0.0316	
Intermediate	195	35 (17.9)	160 (82.1)	NE (NE, NE)	190	25 (13.2)	165 (86.8)	NE (NE, NE)	1.324 (0.792, 2.213)	0.2809	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	3 (11.1)	24 (88.9)	NE (5.6, NE)	0.767 (0.123, 4.803)	0.7766	
Unknown	38	9 (23.7)	29 (76.3)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (NE, NE)	2.063 (0.634, 6.711)	0.2176	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3475
0 - Fully Active	87	10 (11.5)	77 (88.5)	NE (NE, NE)	97	14 (14.4)	83 (85.6)	NE (NE, NE)	0.753 (0.334, 1.695)	0.4950	
1 - Restricted in Physically Strenuous Activity	133	32 (24.1)	101 (75.9)	NE (NE, NE)	134	21 (15.7)	113 (84.3)	NE (NE, NE)	1.558 (0.898, 2.703)	0.1112	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	3 (8.3)	33 (91.7)	NE (9.7, NE)	1.014 (0.226, 4.547)	0.9852	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.0932
≥3 to ≤25%	94	11 (11.7)	83 (88.3)	NE (NE, NE)	98	16 (16.3)	82 (83.7)	NE (NE, NE)	0.676 (0.314, 1.457)	0.3183	
>25% to ≤50%	141	29 (20.6)	112 (79.4)	NE (NE, NE)	136	21 (15.4)	115 (84.6)	NE (NE, NE)	1.365 (0.778, 2.394)	0.2769	
>50%	29	6 (20.7)	23 (79.3)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	7.326 (0.882, 60.842)	0.0307	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6699
Yes	139	26 (18.7)	113 (81.3)	NE (NE, NE)	137	20 (14.6)	117 (85.4)	NE (NE, NE)	1.291 (0.720, 2.313)	0.3871	
No	116	18 (15.5)	98 (84.5)	NE (NE, NE)	120	17 (14.2)	103 (85.8)	NE (NE, NE)	1.044 (0.538, 2.026)	0.9002	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5165
≤60	164	25 (15.2)	139 (84.8)	NE (NE, NE)	163	22 (13.5)	141 (86.5)	NE (NE, NE)	1.094 (0.616, 1.941)	0.7570	
>60	101	21 (20.8)	80 (79.2)	NE (NE, NE)	105	16 (15.2)	89 (84.8)	NE (NE, NE)	1.418 (0.740, 2.718)	0.2878	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Dyspepsia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8535
<60	159	17 (10.7)	142 (89.3)	NE (NE, NE)	160	14 (8.8)	146 (91.3)	NE (NE, NE)	1.125 (0.554, 2.288)	0.7437	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	3 (7.0)	40 (93.0)	NE (21.4, NE)	1.354 (0.300, 6.121)	0.6959	
≥65	69	9 (13.0)	60 (87.0)	NE (NE, NE)	65	6 (9.2)	59 (90.8)	NE (NE, NE)	1.503 (0.535, 4.225)	0.4359	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Dyspepsia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5431
Male	124	15 (12.1)	109 (87.9)	NE (NE, NE)	120	9 (7.5)	111 (92.5)	NE (NE, NE)	1.529 (0.668, 3.498)	0.3110	
Female	141	15 (10.6)	126 (89.4)	NE (NE, NE)	148	14 (9.5)	134 (90.5)	NE (35.0, NE)	1.080 (0.520, 2.241)	0.8381	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Dyspepsia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2951
White	157	18 (11.5)	139 (88.5)	NE (NE, NE)	161	17 (10.6)	144 (89.4)	NE (NE, NE)	1.030 (0.530, 2.000)	0.9306	
Non-white	108	12 (11.1)	96 (88.9)	NE (NE, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	1.961 (0.735, 5.231)	0.1708	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Dyspepsia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3038
North America	16	3 (18.8)	13 (81.3)	22.0 (22.0, NE)	18	3 (16.7)	15 (83.3)	35.0 (4.8, NE)	1.591 (0.317, 7.979)	0.5689	
Europe	161	15 (9.3)	146 (90.7)	NE (NE, NE)	161	15 (9.3)	146 (90.7)	NE (NE, NE)	0.908 (0.443, 1.861)	0.7925	
Asia/Other Regions	88	12 (13.6)	76 (86.4)	NE (NE, NE)	89	5 (5.6)	84 (94.4)	NE (NE, NE)	2.504 (0.882, 7.112)	0.0745	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Dyspepsia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7450
< 40x10^9/L	132	13 (9.8)	119 (90.2)	NE (NE, NE)	133	12 (9.0)	121 (91.0)	NE (NE, NE)	1.121 (0.511, 2.458)	0.7766	
≥ 40x10^9/L	133	17 (12.8)	116 (87.2)	NE (NE, NE)	135	11 (8.1)	124 (91.9)	NE (NE, NE)	1.401 (0.655, 2.999)	0.3820	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Dyspepsia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.0379
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	8 (8.5)	86 (91.5)	NE (NE, NE)	0.507 (0.175, 1.469)	0.2027	
Idarubicin	142	24 (16.9)	118 (83.1)	NE (NE, NE)	171	15 (8.8)	156 (91.2)	NE (NE, NE)	1.926 (1.009, 3.675)	0.0431	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Dyspepsia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6834
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	2 (10.5)	17 (89.5)	NE (6.6, NE)	1.732 (0.108, 27.890)	0.6949	
Intermediate	195	24 (12.3)	171 (87.7)	NE (NE, NE)	190	14 (7.4)	176 (92.6)	NE (NE, NE)	1.552 (0.802, 3.004)	0.1885	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (2.2, NE)	27	3 (11.1)	24 (88.9)	23.2 (6.1, NE)	0.870 (0.137, 5.517)	0.8827	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (NE, NE)	0.662 (0.148, 2.959)	0.5858	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Dyspepsia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2785
0 - Fully Active	87	10 (11.5)	77 (88.5)	NE (NE, NE)	97	6 (6.2)	91 (93.8)	NE (NE, NE)	1.830 (0.665, 5.041)	0.2349	
1 - Restricted in Physically Strenuous Activity	133	13 (9.8)	120 (90.2)	NE (NE, NE)	134	15 (11.2)	119 (88.8)	NE (35.0, NE)	0.814 (0.387, 1.714)	0.5878	
2 - Ambulatory and Capable of All Selfcare	45	7 (15.6)	38 (84.4)	NE (20.8, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	2.436 (0.495, 11.995)	0.2589	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Dyspepsia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9574
≥3 to ≤25%	94	12 (12.8)	82 (87.2)	NE (NE, NE)	98	10 (10.2)	88 (89.8)	NE (NE, NE)	1.222 (0.528, 2.830)	0.6402	
>25% to ≤50%	141	16 (11.3)	125 (88.7)	NE (NE, NE)	136	12 (8.8)	124 (91.2)	NE (NE, NE)	1.283 (0.606, 2.716)	0.5143	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	1.898 (0.171, 21.061)	0.5957	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Dyspepsia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9503
Yes	139	17 (12.2)	122 (87.8)	NE (NE, NE)	137	13 (9.5)	124 (90.5)	NE (NE, NE)	1.248 (0.605, 2.575)	0.5477	
No	116	13 (11.2)	103 (88.8)	NE (NE, NE)	120	10 (8.3)	110 (91.7)	NE (NE, NE)	1.276 (0.559, 2.912)	0.5608	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Dyspepsia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6963
≤60	164	18 (11.0)	146 (89.0)	NE (NE, NE)	163	14 (8.6)	149 (91.4)	NE (NE, NE)	1.178 (0.585, 2.374)	0.6462	
>60	101	12 (11.9)	89 (88.1)	NE (NE, NE)	105	9 (8.6)	96 (91.4)	NE (35.0, NE)	1.414 (0.595, 3.358)	0.4302	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain upper

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7453
<60	159	19 (11.9)	140 (88.1)	NE (NE, NE)	160	18 (11.3)	142 (88.8)	NE (NE, NE)	0.994 (0.521, 1.895)	0.9859	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.776 (0.297, 10.634)	0.5235	
≥65	69	7 (10.1)	62 (89.9)	NE (NE, NE)	65	5 (7.7)	60 (92.3)	NE (NE, NE)	1.458 (0.462, 4.601)	0.5184	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain upper

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1118
Male	124	9 (7.3)	115 (92.7)	NE (NE, NE)	120	12 (10.0)	108 (90.0)	NE (NE, NE)	0.657 (0.276, 1.562)	0.3379	
Female	141	20 (14.2)	121 (85.8)	NE (NE, NE)	148	13 (8.8)	135 (91.2)	NE (NE, NE)	1.646 (0.819, 3.309)	0.1578	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain upper

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5194
White	157	16 (10.2)	141 (89.8)	NE (NE, NE)	161	16 (9.9)	145 (90.1)	NE (NE, NE)	0.979 (0.489, 1.960)	0.9531	
Non-white	108	13 (12.0)	95 (88.0)	NE (NE, NE)	107	9 (8.4)	98 (91.6)	NE (NE, NE)	1.415 (0.605, 3.310)	0.4217	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain upper

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6667
North America	16	1 (6.3)	15 (93.8)	NE (4.2, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	1.255 (0.078, 20.147)	0.8723	
Europe	161	17 (10.6)	144 (89.4)	NE (NE, NE)	161	17 (10.6)	144 (89.4)	NE (NE, NE)	0.935 (0.477, 1.833)	0.8470	
Asia/Other Regions	88	11 (12.5)	77 (87.5)	NE (NE, NE)	89	7 (7.9)	82 (92.1)	NE (NE, NE)	1.625 (0.630, 4.195)	0.3109	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain upper

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1748
< 40x10^9/L	132	8 (6.1)	124 (93.9)	NE (NE, NE)	133	12 (9.0)	121 (91.0)	NE (NE, NE)	0.688 (0.281, 1.683)	0.4091	
≥ 40x10^9/L	133	21 (15.8)	112 (84.2)	NE (NE, NE)	135	13 (9.6)	122 (90.4)	NE (NE, NE)	1.476 (0.738, 2.953)	0.2678	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain upper

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1919
Daunorubicin	123	15 (12.2)	108 (87.8)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	1.847 (0.716, 4.764)	0.1974	
Idarubicin	142	14 (9.9)	128 (90.1)	NE (NE, NE)	171	19 (11.1)	152 (88.9)	NE (NE, NE)	0.857 (0.430, 1.711)	0.6622	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain upper

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3756
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	23 (11.8)	172 (88.2)	NE (NE, NE)	190	14 (7.4)	176 (92.6)	NE (NE, NE)	1.505 (0.774, 2.928)	0.2241	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	5 (18.5)	22 (81.5)	NE (NE, NE)	0.312 (0.036, 2.667)	0.2602	
Unknown	38	5 (13.2)	33 (86.8)	NE (NE, NE)	31	6 (19.4)	25 (80.6)	NE (NE, NE)	0.741 (0.226, 2.433)	0.6201	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain upper

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8602
0 - Fully Active	87	8 (9.2)	79 (90.8)	NE (NE, NE)	97	9 (9.3)	88 (90.7)	NE (NE, NE)	0.954 (0.368, 2.473)	0.9242	
1 - Restricted in Physically Strenuous Activity	133	12 (9.0)	121 (91.0)	NE (NE, NE)	134	9 (6.7)	125 (93.3)	NE (NE, NE)	1.312 (0.553, 3.116)	0.5365	
2 - Ambulatory and Capable of All Selfcare	45	9 (20.0)	36 (80.0)	NE (10.5, NE)	36	7 (19.4)	29 (80.6)	NE (NE, NE)	0.986 (0.365, 2.665)	0.9764	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain upper

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3510
≥3 to ≤25%	94	10 (10.6)	84 (89.4)	NE (NE, NE)	98	11 (11.2)	87 (88.8)	NE (NE, NE)	0.962 (0.409, 2.266)	0.9305	
>25% to ≤50%	141	14 (9.9)	127 (90.1)	NE (NE, NE)	136	13 (9.6)	123 (90.4)	NE (NE, NE)	1.007 (0.473, 2.143)	0.9849	
>50%	29	5 (17.2)	24 (82.8)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	5.006 (0.582, 43.076)	0.1037	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain upper

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5439
Yes	139	17 (12.2)	122 (87.8)	NE (NE, NE)	137	12 (8.8)	125 (91.2)	NE (NE, NE)	1.371 (0.655, 2.874)	0.4014	
No	116	11 (9.5)	105 (90.5)	NE (NE, NE)	120	11 (9.2)	109 (90.8)	NE (NE, NE)	0.991 (0.430, 2.287)	0.9849	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Abdominal pain upper

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3959
≤60	164	19 (11.6)	145 (88.4)	NE (NE, NE)	163	18 (11.0)	145 (89.0)	NE (NE, NE)	0.977 (0.512, 1.864)	0.9457	
>60	101	10 (9.9)	91 (90.1)	NE (NE, NE)	105	7 (6.7)	98 (93.3)	NE (NE, NE)	1.596 (0.607, 4.196)	0.3404	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Haemorrhoids

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5487
<60	159	17 (10.7)	142 (89.3)	NE (NE, NE)	160	16 (10.0)	144 (90.0)	NE (NE, NE)	0.996 (0.502, 1.975)	0.9906	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	2.061 (0.185, 22.973)	0.5482	
≥65	69	6 (8.7)	63 (91.3)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	2.150 (0.536, 8.627)	0.2685	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Haemorrhoids

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1716
Male	124	8 (6.5)	116 (93.5)	NE (NE, NE)	120	10 (8.3)	110 (91.7)	NE (NE, NE)	0.750 (0.296, 1.902)	0.5426	
Female	141	17 (12.1)	124 (87.9)	NE (NE, NE)	148	10 (6.8)	138 (93.2)	NE (NE, NE)	1.745 (0.798, 3.815)	0.1577	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Haemorrhoids

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7184
White	157	11 (7.0)	146 (93.0)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	1.401 (0.563, 3.487)	0.4658	
Non-white	108	14 (13.0)	94 (87.0)	NE (NE, NE)	107	12 (11.2)	95 (88.8)	NE (NE, NE)	1.113 (0.515, 2.407)	0.7854	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Haemorrhoids

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6662
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.2888	
Europe	161	15 (9.3)	146 (90.7)	NE (NE, NE)	161	10 (6.2)	151 (93.8)	NE (NE, NE)	1.482 (0.665, 3.303)	0.3326	
Asia/Other Regions	88	9 (10.2)	79 (89.8)	NE (33.4, NE)	89	10 (11.2)	79 (88.8)	NE (NE, NE)	0.838 (0.340, 2.066)	0.7004	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Haemorrhoids

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1609
< 40x10^9/L	132	13 (9.8)	119 (90.2)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	2.005 (0.800, 5.027)	0.1300	
≥ 40x10^9/L	133	12 (9.0)	121 (91.0)	NE (NE, NE)	135	13 (9.6)	122 (90.4)	NE (NE, NE)	0.827 (0.376, 1.820)	0.6364	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Haemorrhoids

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6275
Daunorubicin	123	11 (8.9)	112 (91.1)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	1.642 (0.570, 4.731)	0.3531	
Idarubicin	142	14 (9.9)	128 (90.1)	NE (NE, NE)	171	14 (8.2)	157 (91.8)	NE (NE, NE)	1.175 (0.560, 2.469)	0.6698	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Haemorrhoids

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4992
Favorable	13	3 (23.1)	10 (76.9)	NE (1.2, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	5.048 (0.523, 48.751)	0.1200	
Intermediate	195	18 (9.2)	177 (90.8)	NE (NE, NE)	190	14 (7.4)	176 (92.6)	NE (NE, NE)	1.173 (0.583, 2.362)	0.6531	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.722 (0.065, 7.962)	0.7892	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	0.938 (0.189, 4.657)	0.9380	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Haemorrhoids

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1497
0 - Fully Active	87	6 (6.9)	81 (93.1)	NE (NE, NE)	97	7 (7.2)	90 (92.8)	NE (NE, NE)	0.930 (0.312, 2.768)	0.8955	
1 - Restricted in Physically Strenuous Activity	133	16 (12.0)	117 (88.0)	NE (NE, NE)	134	8 (6.0)	126 (94.0)	NE (NE, NE)	2.026 (0.867, 4.736)	0.0958	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (33.4, NE)	36	5 (13.9)	31 (86.1)	NE (NE, NE)	0.301 (0.058, 1.553)	0.1283	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Haemorrhoids

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3950
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	5 (5.1)	93 (94.9)	NE (NE, NE)	1.064 (0.308, 3.676)	0.9218	
>25% to ≤50%	141	19 (13.5)	122 (86.5)	NE (NE, NE)	136	12 (8.8)	124 (91.2)	NE (NE, NE)	1.519 (0.737, 3.133)	0.2543	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	0.368 (0.038, 3.538)	0.3669	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Haemorrhoids

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3982
Yes	139	15 (10.8)	124 (89.2)	NE (NE, NE)	137	14 (10.2)	123 (89.8)	NE (NE, NE)	1.018 (0.491, 2.112)	0.9604	
No	116	9 (7.8)	107 (92.2)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	1.866 (0.625, 5.567)	0.2559	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Haemorrhoids

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2377
≤60	164	17 (10.4)	147 (89.6)	NE (NE, NE)	163	16 (9.8)	147 (90.2)	NE (NE, NE)	0.978 (0.493, 1.939)	0.9483	
>60	101	8 (7.9)	93 (92.1)	NE (NE, NE)	105	4 (3.8)	101 (96.2)	NE (NE, NE)	2.219 (0.668, 7.371)	0.1819	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gingival bleeding

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7753
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	10 (6.3)	150 (93.8)	NE (NE, NE)	0.689 (0.262, 1.810)	0.4466	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.0613	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	1.304 (0.292, 5.825)	0.7278	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gingival bleeding

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7456
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	0.966 (0.339, 2.754)	0.9479	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	1.242 (0.417, 3.696)	0.6958	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gingival bleeding

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5751
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	0.872 (0.293, 2.595)	0.8049	
Non-white	108	8 (7.4)	100 (92.6)	NE (NE, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	1.349 (0.468, 3.888)	0.5778	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gingival bleeding

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5069
North America	16	2 (12.5)	14 (87.5)	NE (1.8, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	2.633 (0.237, 29.277)	0.4132	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	0.730 (0.253, 2.104)	0.5582	
Asia/Other Regions	88	6 (6.8)	82 (93.2)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	1.564 (0.441, 5.543)	0.4849	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gingival bleeding

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3826
< 40x10^9/L	132	4 (3.0)	128 (97.0)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	0.710 (0.200, 2.517)	0.5940	
≥ 40x10^9/L	133	10 (7.5)	123 (92.5)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	1.450 (0.552, 3.811)	0.4483	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gingival bleeding

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.0617
Daunorubicin	123	9 (7.3)	114 (92.7)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	3.538 (0.764, 16.376)	0.0843	
Idarubicin	142	5 (3.5)	137 (96.5)	NE (NE, NE)	171	10 (5.8)	161 (94.2)	NE (NE, NE)	0.599 (0.205, 1.752)	0.3441	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gingival bleeding

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7829
Favorable	13	0	13 (100)	NE (NE, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	0.000 (0.000, NE)	0.3162	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	4 (2.1)	186 (97.9)	NE (NE, NE)	2.207 (0.679, 7.166)	0.1763	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	3 (11.1)	24 (88.9)	NE (NE, NE)	1.037 (0.173, 6.213)	0.9775	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	0.839 (0.169, 4.158)	0.8294	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gingival bleeding

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2032
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	7 (7.2)	90 (92.8)	NE (NE, NE)	0.631 (0.185, 2.156)	0.4590	
1 - Restricted in Physically Strenuous Activity	133	8 (6.0)	125 (94.0)	NE (NE, NE)	134	3 (2.2)	131 (97.8)	NE (NE, NE)	2.697 (0.715, 10.168)	0.1270	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	3 (8.3)	33 (91.7)	NE (NE, NE)	0.541 (0.090, 3.240)	0.4949	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gingival bleeding

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6922
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	1.353 (0.363, 5.039)	0.6508	
>25% to ≤50%	141	6 (4.3)	135 (95.7)	NE (NE, NE)	136	9 (6.6)	127 (93.4)	NE (NE, NE)	0.644 (0.229, 1.811)	0.4007	
>50%	29	3 (10.3)	26 (89.7)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.0830	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gingival bleeding

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3217
Yes	139	9 (6.5)	130 (93.5)	NE (NE, NE)	137	6 (4.4)	131 (95.6)	NE (NE, NE)	1.529 (0.544, 4.296)	0.4167	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.670 (0.189, 2.376)	0.5328	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gingival bleeding

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1211
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	10 (6.1)	153 (93.9)	NE (NE, NE)	0.678 (0.258, 1.781)	0.4270	
>60	101	7 (6.9)	94 (93.1)	NE (NE, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	2.556 (0.661, 9.885)	0.1583	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gastrooesophageal reflux disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9775
<60	159	10 (6.3)	149 (93.7)	NE (NE, NE)	160	3 (1.9)	157 (98.1)	NE (NE, NE)	2.779 (0.762, 10.140)	0.1064	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.2791	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	1 (1.5)	64 (98.5)	NE (NE, NE)	2.248 (0.203, 24.926)	0.4977	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gastrooesophageal reflux disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9917
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	2.967 (0.613, 14.362)	0.1566	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	2 (1.4)	146 (98.6)	NE (NE, NE)	2.880 (0.580, 14.289)	0.1755	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gastrooesophageal reflux disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4744
White	157	4 (2.5)	153 (97.5)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	1.868 (0.340, 10.267)	0.4650	
Non-white	108	9 (8.3)	99 (91.7)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	4.145 (0.895, 19.203)	0.0484	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gastrooesophageal reflux disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8978
North America	16	3 (18.8)	13 (81.3)	NE (17.4, NE)	18	2 (11.1)	16 (88.9)	NE (NE, NE)	1.799 (0.300, 10.775)	0.5142	
Europe	161	2 (1.2)	159 (98.8)	NE (NE, NE)	161	0	161 (100)	NE (NE, NE)	NE (0.000, NE)	0.2445	
Asia/Other Regions	88	8 (9.1)	80 (90.9)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	3.711 (0.786, 17.513)	0.0757	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gastrooesophageal reflux disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7077
< 40x10^9/L	132	4 (3.0)	128 (97.0)	NE (NE, NE)	133	1 (0.8)	132 (99.2)	NE (NE, NE)	4.215 (0.471, 37.731)	0.1614	
≥ 40x10^9/L	133	9 (6.8)	124 (93.2)	NE (NE, NE)	135	3 (2.2)	132 (97.8)	NE (NE, NE)	2.503 (0.673, 9.309)	0.1571	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gastrooesophageal reflux disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9289
Daunorubicin	123	5 (4.1)	118 (95.9)	NE (NE, NE)	94	1 (1.1)	93 (98.9)	NE (NE, NE)	3.133 (0.365, 26.918)	0.2724	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	3 (1.8)	168 (98.2)	NE (NE, NE)	3.013 (0.798, 11.379)	0.0875	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gastrooesophageal reflux disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6866
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	0.000 (0.000, NE)	0.4142	
Intermediate	195	12 (6.2)	183 (93.8)	NE (NE, NE)	190	2 (1.1)	188 (98.9)	NE (NE, NE)	5.271 (1.178, 23.587)	0.0151	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (16.6, NE)	0.677 (0.042, 10.863)	0.7816	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gastrooesophageal reflux disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6685
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	1 (1.0)	96 (99.0)	NE (NE, NE)	4.691 (0.547, 40.208)	0.1201	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	3 (2.2)	131 (97.8)	NE (NE, NE)	1.558 (0.372, 6.532)	0.5408	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.1109	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gastrooesophageal reflux disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8261
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	2 (2.0)	96 (98.0)	NE (NE, NE)	1.946 (0.356, 10.647)	0.4342	
>25% to ≤50%	141	9 (6.4)	132 (93.6)	NE (NE, NE)	136	2 (1.5)	134 (98.5)	NE (NE, NE)	4.099 (0.885, 18.998)	0.0505	
>50%	29	0	29 (100)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gastrooesophageal reflux disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9309
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	2 (1.5)	135 (98.5)	NE (NE, NE)	3.277 (0.679, 15.814)	0.1177	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	2.733 (0.550, 13.567)	0.1999	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Gastrooesophageal reflux disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9266
≤60	164	10 (6.1)	154 (93.9)	NE (NE, NE)	163	3 (1.8)	160 (98.2)	NE (NE, NE)	2.736 (0.750, 9.984)	0.1124	
>60	101	3 (3.0)	98 (97.0)	NE (NE, NE)	105	1 (1.0)	104 (99.0)	NE (NE, NE)	3.352 (0.349, 32.234)	0.2666	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Proctalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9999
<60	159	10 (6.3)	149 (93.7)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	1.653 (0.601, 4.550)	0.3253	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	0.000 (0.000, NE)	0.3602	
≥65	69	0	69 (100)	NE (NE, NE)	65	1 (1.5)	64 (98.5)	NE (NE, NE)	0.000 (0.000, NE)	0.3336	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Proctalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4405
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.951 (0.307, 2.952)	0.9323	
Female	141	4 (2.8)	137 (97.2)	NE (NE, NE)	148	2 (1.4)	146 (98.6)	NE (NE, NE)	2.116 (0.388, 11.555)	0.3756	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Proctalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.0853
White	157	1 (0.6)	156 (99.4)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	0.260 (0.029, 2.323)	0.1938	
Non-white	108	9 (8.3)	99 (91.7)	NE (NE, NE)	107	4 (3.7)	103 (96.3)	NE (NE, NE)	2.266 (0.698, 7.358)	0.1614	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Proctalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3767
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	1.093 (0.068, 17.486)	0.9497	
Europe	161	1 (0.6)	160 (99.4)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	0.335 (0.035, 3.225)	0.3204	
Asia/Other Regions	88	8 (9.1)	80 (90.9)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	2.029 (0.611, 6.741)	0.2378	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Proctalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0966
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	1 (0.8)	132 (99.2)	NE (NE, NE)	5.338 (0.624, 45.704)	0.0863	
≥ 40x10^9/L	133	5 (3.8)	128 (96.2)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	0.666 (0.211, 2.103)	0.4862	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Proctalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7200
Daunorubicin	123	3 (2.4)	120 (97.6)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	1.160 (0.194, 6.940)	0.8710	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	5 (2.9)	166 (97.1)	NE (NE, NE)	1.679 (0.533, 5.292)	0.3701	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Proctalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	0	13 (100)	NE (NE, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	0.000 (0.000, NE)	0.2384	
Intermediate	195	5 (2.6)	190 (97.4)	NE (NE, NE)	190	6 (3.2)	184 (96.8)	NE (NE, NE)	0.786 (0.240, 2.577)	0.6896	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.0789	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.0900	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Proctalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9967
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	1.118 (0.226, 5.538)	0.8918	
1 - Restricted in Physically Strenuous Activity	133	6 (4.5)	127 (95.5)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	1.204 (0.367, 3.947)	0.7584	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.3634	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Proctalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5351
≥3 to ≤25%	94	2 (2.1)	92 (97.9)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	0.514 (0.094, 2.807)	0.4345	
>25% to ≤50%	141	7 (5.0)	134 (95.0)	NE (NE, NE)	136	4 (2.9)	132 (97.1)	NE (NE, NE)	1.732 (0.507, 5.916)	0.3754	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.2850	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Proctalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4875
Yes	139	3 (2.2)	136 (97.8)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	0.763 (0.171, 3.410)	0.7225	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	1.502 (0.423, 5.326)	0.5250	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Proctalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9891
≤60	164	10 (6.1)	154 (93.9)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	1.628 (0.591, 4.482)	0.3405	
>60	101	0	101 (100)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	0.000 (0.000, NE)	0.1770	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Mouth ulceration

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9999
<60	159	9 (5.7)	150 (94.3)	NE (NE, NE)	160	7 (4.4)	153 (95.6)	NE (NE, NE)	1.183 (0.440, 3.182)	0.7381	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	0.000 (0.000, NE)	0.3375	
≥65	69	0	69 (100)	NE (NE, NE)	65	4 (6.2)	61 (93.8)	NE (NE, NE)	0.000 (0.000, NE)	0.0423	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Mouth ulceration

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1021
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	8 (6.7)	112 (93.3)	NE (NE, NE)	0.333 (0.088, 1.257)	0.0882	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	4 (2.7)	144 (97.3)	NE (NE, NE)	1.547 (0.437, 5.485)	0.4956	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Mouth ulceration

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4160
White	157	3 (1.9)	154 (98.1)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	0.455 (0.113, 1.827)	0.2546	
Non-white	108	6 (5.6)	102 (94.4)	NE (NE, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	0.995 (0.321, 3.085)	0.9936	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Mouth ulceration

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8426
North America	16	0	16 (100)	NE (NE, NE)	18	2 (11.1)	16 (88.9)	NE (NE, NE)	0.000 (0.000, NE)	0.1762	
Europe	161	3 (1.9)	158 (98.1)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	1.323 (0.220, 7.959)	0.7590	
Asia/Other Regions	88	6 (6.8)	82 (93.2)	NE (NE, NE)	89	8 (9.0)	81 (91.0)	NE (NE, NE)	0.742 (0.257, 2.141)	0.5819	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Mouth ulceration

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9191
< 40x10^9/L	132	4 (3.0)	128 (97.0)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	0.671 (0.189, 2.378)	0.5342	
≥ 40x10^9/L	133	5 (3.8)	128 (96.2)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	0.734 (0.223, 2.414)	0.6087	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Mouth ulceration

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6869
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	0.551 (0.148, 2.057)	0.3690	
Idarubicin	142	5 (3.5)	137 (96.5)	NE (NE, NE)	171	7 (4.1)	164 (95.9)	NE (NE, NE)	0.819 (0.260, 2.585)	0.7341	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Mouth ulceration

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9548
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	1.498 (0.094, 23.970)	0.7738	
Intermediate	195	6 (3.1)	189 (96.9)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	0.779 (0.262, 2.322)	0.6551	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.000 (0.000, NE)	0.2530	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (27.0, NE)	0.804 (0.113, 5.739)	0.8278	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Mouth ulceration

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7237
0 - Fully Active	87	1 (1.1)	86 (98.9)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	0.358 (0.037, 3.442)	0.3528	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	7 (5.2)	127 (94.8)	NE (NE, NE)	0.690 (0.219, 2.176)	0.5253	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	1.112 (0.184, 6.723)	0.9081	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Mouth ulceration

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9161
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	6 (6.1)	92 (93.9)	NE (NE, NE)	0.517 (0.129, 2.069)	0.3443	
>25% to ≤50%	141	5 (3.5)	136 (96.5)	NE (NE, NE)	136	6 (4.4)	130 (95.6)	NE (NE, NE)	0.752 (0.229, 2.469)	0.6377	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.2850	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Mouth ulceration

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2791
Yes	139	6 (4.3)	133 (95.7)	NE (NE, NE)	137	6 (4.4)	131 (95.6)	NE (NE, NE)	0.950 (0.306, 2.949)	0.9295	
No	116	2 (1.7)	114 (98.3)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.322 (0.065, 1.597)	0.1439	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Mouth ulceration

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9874
≤60	164	9 (5.5)	155 (94.5)	NE (NE, NE)	163	7 (4.3)	156 (95.7)	NE (NE, NE)	1.164 (0.433, 3.134)	0.7616	
>60	101	0	101 (100)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	0.000 (0.000, NE)	0.0286	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Toothache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9924
<60	159	8 (5.0)	151 (95.0)	NE (NE, NE)	160	8 (5.0)	152 (95.0)	NE (NE, NE)	0.905 (0.339, 2.418)	0.8422	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	1.116 (0.070, 17.839)	0.9385	
≥65	69	0	69 (100)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	0.000 (0.000, NE)	0.1435	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Toothache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3775
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	1.129 (0.344, 3.704)	0.8411	
Female	141	3 (2.1)	138 (97.9)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	0.511 (0.128, 2.043)	0.3328	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Toothache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4425
White	157	5 (3.2)	152 (96.8)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	0.592 (0.193, 1.814)	0.3538	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	1.305 (0.292, 5.830)	0.7268	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Toothache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7078
North America	16	3 (18.8)	13 (81.3)	NE (2.3, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.0058	
Europe	161	2 (1.2)	159 (98.8)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	0.290 (0.058, 1.444)	0.1079	
Asia/Other Regions	88	4 (4.5)	84 (95.5)	NE (NE, NE)	89	5 (5.6)	84 (94.4)	NE (NE, NE)	0.792 (0.213, 2.949)	0.7274	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Toothache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9084
< 40x10^9/L	132	6 (4.5)	126 (95.5)	NE (NE, NE)	133	8 (6.0)	125 (94.0)	NE (NE, NE)	0.784 (0.272, 2.260)	0.6515	
≥ 40x10^9/L	133	3 (2.3)	130 (97.7)	NE (NE, NE)	135	3 (2.2)	132 (97.8)	NE (NE, NE)	0.867 (0.174, 4.327)	0.8624	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Toothache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1334
Daunorubicin	123	3 (2.4)	120 (97.6)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	0.353 (0.088, 1.416)	0.1247	
Idarubicin	142	6 (4.2)	136 (95.8)	NE (NE, NE)	171	5 (2.9)	166 (97.1)	NE (NE, NE)	1.384 (0.422, 4.542)	0.5901	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Toothache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6145
Favorable	13	2 (15.4)	11 (84.6)	NE (2.5, NE)	19	3 (15.8)	16 (84.2)	NE (6.4, NE)	1.371 (0.225, 8.340)	0.7308	
Intermediate	195	5 (2.6)	190 (97.4)	NE (NE, NE)	190	3 (1.6)	187 (98.4)	NE (NE, NE)	1.507 (0.359, 6.317)	0.5723	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (3.3, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.732 (0.066, 8.088)	0.7982	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	0.283 (0.029, 2.728)	0.2442	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Toothache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5407
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	1.294 (0.347, 4.827)	0.6999	
1 - Restricted in Physically Strenuous Activity	133	2 (1.5)	131 (98.5)	NE (NE, NE)	134	4 (3.0)	130 (97.0)	NE (NE, NE)	0.484 (0.089, 2.644)	0.3918	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	3 (8.3)	33 (91.7)	NE (NE, NE)	0.573 (0.096, 3.432)	0.5370	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Toothache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9782
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	7 (7.1)	91 (92.9)	NE (NE, NE)	0.740 (0.235, 2.334)	0.6066	
>25% to ≤50%	141	3 (2.1)	138 (97.9)	NE (NE, NE)	136	3 (2.2)	133 (97.8)	NE (NE, NE)	0.985 (0.199, 4.882)	0.9856	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.791 (0.049, 12.704)	0.8682	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Toothache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6054
Yes	139	3 (2.2)	136 (97.8)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	0.567 (0.135, 2.377)	0.4317	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.952 (0.307, 2.955)	0.9318	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Toothache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4662
≤60	164	8 (4.9)	156 (95.1)	NE (NE, NE)	163	8 (4.9)	155 (95.1)	NE (NE, NE)	0.887 (0.332, 2.371)	0.8115	
>60	101	1 (1.0)	100 (99.0)	NE (NE, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	0.355 (0.037, 3.409)	0.3479	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6698
<60	159	121 (76.1)	38 (23.9)	1.7 (1.2, 2.0)	160	114 (71.3)	46 (28.8)	1.4 (1.0, 2.2)	1.074 (0.831, 1.387)	0.5853	
≥60 - <65	37	27 (73.0)	10 (27.0)	1.8 (0.4, 2.3)	43	25 (58.1)	18 (41.9)	4.6 (1.1, 8.9)	1.380 (0.799, 2.385)	0.2508	
≥65	69	56 (81.2)	13 (18.8)	0.6 (0.3, 1.6)	65	49 (75.4)	16 (24.6)	1.5 (0.6, 2.4)	1.080 (0.731, 1.594)	0.7125	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8810
Male	124	94 (75.8)	30 (24.2)	1.1 (0.6, 1.7)	120	84 (70.0)	36 (30.0)	1.4 (0.6, 2.5)	1.157 (0.862, 1.553)	0.3317	
Female	141	110 (78.0)	31 (22.0)	1.7 (0.8, 2.0)	148	104 (70.3)	44 (29.7)	1.6 (1.2, 2.4)	1.130 (0.863, 1.478)	0.3708	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4201
White	157	121 (77.1)	36 (22.9)	1.4 (0.6, 1.7)	161	109 (67.7)	52 (32.3)	1.6 (1.2, 2.8)	1.216 (0.939, 1.576)	0.1390	
Non-white	108	83 (76.9)	25 (23.1)	1.6 (0.8, 2.0)	107	79 (73.8)	28 (26.2)	1.5 (0.7, 2.2)	1.039 (0.763, 1.416)	0.8115	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7204
North America	16	13 (81.3)	3 (18.8)	0.6 (0.2, 2.8)	18	16 (88.9)	2 (11.1)	1.4 (0.4, 2.6)	1.094 (0.515, 2.322)	0.8224	
Europe	161	126 (78.3)	35 (21.7)	1.2 (0.5, 1.7)	161	109 (67.7)	52 (32.3)	1.5 (1.2, 2.9)	1.222 (0.945, 1.579)	0.1239	
Asia/Other Regions	88	65 (73.9)	23 (26.1)	1.7 (0.8, 2.3)	89	63 (70.8)	26 (29.2)	1.7 (0.6, 2.4)	1.043 (0.736, 1.478)	0.8125	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6156
< 40x10^9/L	132	98 (74.2)	34 (25.8)	1.7 (1.0, 2.6)	133	95 (71.4)	38 (28.6)	1.5 (1.1, 2.8)	1.085 (0.818, 1.439)	0.5814	
≥ 40x10^9/L	133	106 (79.7)	27 (20.3)	1.1 (0.4, 1.6)	135	93 (68.9)	42 (31.1)	1.6 (1.0, 2.4)	1.215 (0.919, 1.607)	0.1677	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5968
Daunorubicin	123	95 (77.2)	28 (22.8)	1.7 (0.8, 2.0)	94	66 (70.2)	28 (29.8)	1.2 (0.5, 2.4)	1.035 (0.756, 1.418)	0.8321	
Idarubicin	142	109 (76.8)	33 (23.2)	1.2 (0.5, 1.8)	171	121 (70.8)	50 (29.2)	1.9 (1.2, 2.6)	1.170 (0.903, 1.515)	0.2389	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5181
Favorable	13	9 (69.2)	4 (30.8)	2.9 (0.3, NE)	19	11 (57.9)	8 (42.1)	4.9 (2.5, NE)	2.238 (0.899, 5.572)	0.0781	
Intermediate	195	149 (76.4)	46 (23.6)	1.4 (0.8, 1.7)	190	134 (70.5)	56 (29.5)	1.5 (1.0, 2.2)	1.052 (0.833, 1.330)	0.6765	
Unfavorable	19	15 (78.9)	4 (21.1)	1.4 (0.3, 2.8)	27	19 (70.4)	8 (29.6)	1.5 (0.2, 2.6)	1.013 (0.512, 2.005)	0.9663	
Unknown	38	31 (81.6)	7 (18.4)	1.2 (0.3, 2.0)	31	23 (74.2)	8 (25.8)	1.4 (0.3, 3.4)	1.286 (0.747, 2.214)	0.3494	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4410
0 - Fully Active	87	69 (79.3)	18 (20.7)	1.7 (0.9, 2.6)	97	70 (72.2)	27 (27.8)	1.5 (0.6, 3.3)	1.021 (0.731, 1.424)	0.9069	
1 - Restricted in Physically Strenuous Activity	133	96 (72.2)	37 (27.8)	1.6 (0.7, 2.0)	134	93 (69.4)	41 (30.6)	1.6 (1.2, 2.4)	1.110 (0.834, 1.477)	0.4785	
2 - Ambulatory and Capable of All Selfcare	45	39 (86.7)	6 (13.3)	0.5 (0.2, 1.4)	36	25 (69.4)	11 (30.6)	1.1 (0.3, 3.6)	1.620 (0.972, 2.700)	0.0624	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6081
≥3 to ≤25%	94	72 (76.6)	22 (23.4)	1.4 (0.5, 2.6)	98	70 (71.4)	28 (28.6)	1.6 (1.2, 2.6)	1.088 (0.782, 1.514)	0.6224	
>25% to ≤50%	141	110 (78.0)	31 (22.0)	1.3 (0.6, 1.7)	136	99 (72.8)	37 (27.2)	1.2 (0.6, 2.4)	1.091 (0.832, 1.432)	0.5219	
>50%	29	22 (75.9)	7 (24.1)	1.6 (0.5, 2.1)	34	19 (55.9)	15 (44.1)	3.4 (0.9, NE)	1.608 (0.858, 3.014)	0.1336	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1161
Yes	139	109 (78.4)	30 (21.6)	1.4 (0.8, 1.8)	137	101 (73.7)	36 (26.3)	1.6 (1.1, 2.5)	1.015 (0.773, 1.332)	0.9226	
No	116	89 (76.7)	27 (23.3)	1.3 (0.6, 2.0)	120	77 (64.2)	43 (35.8)	1.9 (1.2, 2.8)	1.397 (1.029, 1.896)	0.0319	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4324
≤60	164	124 (75.6)	40 (24.4)	1.7 (1.2, 2.0)	163	114 (69.9)	49 (30.1)	1.5 (1.0, 2.4)	1.070 (0.830, 1.380)	0.6002	
>60	101	80 (79.2)	21 (20.8)	0.7 (0.4, 1.6)	105	74 (70.5)	31 (29.5)	1.7 (0.9, 2.9)	1.240 (0.902, 1.705)	0.1904	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6962
<60	159	22 (13.8)	137 (86.2)	NE (NE, NE)	160	25 (15.6)	135 (84.4)	NE (NE, NE)	0.801 (0.451, 1.423)	0.4481	
≥60 - <65	37	5 (13.5)	32 (86.5)	NE (NE, NE)	43	6 (14.0)	37 (86.0)	NE (16.6, NE)	0.906 (0.276, 2.972)	0.8699	
≥65	69	12 (17.4)	57 (82.6)	NE (15.7, NE)	65	10 (15.4)	55 (84.6)	NE (NE, NE)	1.244 (0.536, 2.888)	0.6097	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3332
Male	124	20 (16.1)	104 (83.9)	NE (NE, NE)	120	16 (13.3)	104 (86.7)	NE (NE, NE)	1.162 (0.602, 2.244)	0.6546	
Female	141	19 (13.5)	122 (86.5)	NE (NE, NE)	148	25 (16.9)	123 (83.1)	NE (34.7, NE)	0.731 (0.402, 1.328)	0.3021	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9648
White	157	23 (14.6)	134 (85.4)	NE (NE, NE)	161	24 (14.9)	137 (85.1)	NE (NE, NE)	0.909 (0.512, 1.612)	0.7459	
Non-white	108	16 (14.8)	92 (85.2)	NE (NE, NE)	107	17 (15.9)	90 (84.1)	NE (NE, NE)	0.900 (0.455, 1.781)	0.7618	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2091
North America	16	4 (25.0)	12 (75.0)	NE (17.4, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	4.923 (0.550, 44.073)	0.1152	
Europe	161	20 (12.4)	141 (87.6)	NE (NE, NE)	161	24 (14.9)	137 (85.1)	NE (34.7, NE)	0.759 (0.418, 1.376)	0.3620	
Asia/Other Regions	88	15 (17.0)	73 (83.0)	NE (20.0, NE)	89	16 (18.0)	73 (82.0)	NE (NE, NE)	0.896 (0.443, 1.814)	0.7604	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9238
< 40x10^9/L	132	15 (11.4)	117 (88.6)	NE (NE, NE)	133	17 (12.8)	116 (87.2)	NE (NE, NE)	0.866 (0.432, 1.735)	0.6837	
≥ 40x10^9/L	133	24 (18.0)	109 (82.0)	NE (NE, NE)	135	24 (17.8)	111 (82.2)	NE (NE, NE)	0.932 (0.528, 1.644)	0.8105	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8895
Daunorubicin	123	18 (14.6)	105 (85.4)	NE (NE, NE)	94	13 (13.8)	81 (86.2)	NE (NE, NE)	0.954 (0.467, 1.952)	0.8984	
Idarubicin	142	21 (14.8)	121 (85.2)	NE (NE, NE)	171	27 (15.8)	144 (84.2)	NE (NE, NE)	0.895 (0.506, 1.584)	0.7025	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7258
Favorable	13	1 (7.7)	12 (92.3)	NE (5.5, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.1069	
Intermediate	195	30 (15.4)	165 (84.6)	NE (NE, NE)	190	27 (14.2)	163 (85.8)	NE (NE, NE)	0.975 (0.579, 1.643)	0.9258	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (20.0, NE)	27	4 (14.8)	23 (85.2)	NE (NE, NE)	0.262 (0.027, 2.508)	0.2172	
Unknown	38	7 (18.4)	31 (81.6)	NE (NE, NE)	31	9 (29.0)	22 (71.0)	34.7 (34.7, NE)	0.665 (0.247, 1.786)	0.4124	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7825
0 - Fully Active	87	8 (9.2)	79 (90.8)	NE (NE, NE)	97	11 (11.3)	86 (88.7)	NE (NE, NE)	0.707 (0.283, 1.761)	0.4539	
1 - Restricted in Physically Strenuous Activity	133	17 (12.8)	116 (87.2)	NE (NE, NE)	134	21 (15.7)	113 (84.3)	NE (NE, NE)	0.790 (0.417, 1.499)	0.4690	
2 - Ambulatory and Capable of All Selfcare	45	14 (31.1)	31 (68.9)	NE (19.3, NE)	36	9 (25.0)	27 (75.0)	NE (NE, NE)	1.163 (0.498, 2.716)	0.7263	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2442
≥3 to ≤25%	94	16 (17.0)	78 (83.0)	NE (NE, NE)	98	13 (13.3)	85 (86.7)	NE (34.7, NE)	1.295 (0.623, 2.694)	0.4873	
>25% to ≤50%	141	21 (14.9)	120 (85.1)	NE (NE, NE)	136	22 (16.2)	114 (83.8)	NE (NE, NE)	0.868 (0.477, 1.581)	0.6446	
>50%	29	2 (6.9)	27 (93.1)	NE (19.3, NE)	34	6 (17.6)	28 (82.4)	NE (NE, NE)	0.315 (0.062, 1.604)	0.1426	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1327
Yes	139	24 (17.3)	115 (82.7)	NE (NE, NE)	137	20 (14.6)	117 (85.4)	NE (NE, NE)	1.144 (0.632, 2.073)	0.6556	
No	116	10 (8.6)	106 (91.4)	NE (NE, NE)	120	17 (14.2)	103 (85.8)	NE (NE, NE)	0.553 (0.253, 1.210)	0.1326	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4082
≤60	164	22 (13.4)	142 (86.6)	NE (NE, NE)	163	25 (15.3)	138 (84.7)	NE (NE, NE)	0.788 (0.443, 1.400)	0.4149	
>60	101	17 (16.8)	84 (83.2)	NE (NE, NE)	105	16 (15.2)	89 (84.8)	NE (NE, NE)	1.134 (0.573, 2.246)	0.7172	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Upper respiratory tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1047
<60	159	18 (11.3)	141 (88.7)	NE (38.0, NE)	160	7 (4.4)	153 (95.6)	NE (NE, NE)	2.016 (0.839, 4.846)	0.1101	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (19.7, NE)	43	3 (7.0)	40 (93.0)	NE (18.2, NE)	0.597 (0.100, 3.582)	0.5687	
≥65	69	1 (1.4)	68 (98.6)	NE (30.1, NE)	65	5 (7.7)	60 (92.3)	NE (23.8, NE)	0.205 (0.024, 1.765)	0.1106	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Upper respiratory tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3586
Male	124	9 (7.3)	115 (92.7)	NE (38.0, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	1.813 (0.553, 5.940)	0.3189	
Female	141	12 (8.5)	129 (91.5)	NE (NE, NE)	148	11 (7.4)	137 (92.6)	NE (NE, NE)	0.918 (0.404, 2.085)	0.8384	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Upper respiratory tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4923
White	157	8 (5.1)	149 (94.9)	NE (38.0, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	0.935 (0.338, 2.588)	0.8976	
Non-white	108	13 (12.0)	95 (88.0)	NE (24.0, NE)	107	8 (7.5)	99 (92.5)	NE (NE, NE)	1.423 (0.589, 3.438)	0.4301	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Upper respiratory tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6371
North America	16	2 (12.5)	14 (87.5)	30.8 (23.6, NE)	18	1 (5.6)	17 (94.4)	NE (10.0, NE)	2.786 (0.249, 31.160)	0.3860	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	0.923 (0.281, 3.037)	0.8958	
Asia/Other Regions	88	13 (14.8)	75 (85.2)	30.1 (19.7, NE)	89	9 (10.1)	80 (89.9)	NE (22.3, NE)	1.264 (0.538, 2.965)	0.5900	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Upper respiratory tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5586
< 40x10^9/L	132	10 (7.6)	122 (92.4)	NE (38.0, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	1.377 (0.524, 3.623)	0.5145	
≥ 40x10^9/L	133	11 (8.3)	122 (91.7)	NE (NE, NE)	135	8 (5.9)	127 (94.1)	NE (NE, NE)	0.899 (0.360, 2.242)	0.8192	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Upper respiratory tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2248
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	0.623 (0.189, 2.048)	0.4312	
Idarubicin	142	15 (10.6)	127 (89.4)	NE (30.1, NE)	171	10 (5.8)	161 (94.2)	NE (NE, NE)	1.613 (0.723, 3.597)	0.2386	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Upper respiratory tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5093
Favorable	13	2 (15.4)	11 (84.6)	NE (11.1, NE)	19	1 (5.3)	18 (94.7)	NE (10.0, NE)	4.073 (0.367, 45.253)	0.2159	
Intermediate	195	16 (8.2)	179 (91.8)	NE (NE, NE)	190	11 (5.8)	179 (94.2)	NE (NE, NE)	1.105 (0.512, 2.384)	0.7989	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (12.7, NE)	27	3 (11.1)	24 (88.9)	NE (6.3, NE)	0.558 (0.084, 3.716)	0.5425	
Unknown	38	1 (2.6)	37 (97.4)	NE (22.1, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.4028	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Upper respiratory tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3404
0 - Fully Active	87	9 (10.3)	78 (89.7)	NE (38.0, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	2.027 (0.623, 6.590)	0.2306	
1 - Restricted in Physically Strenuous Activity	133	10 (7.5)	123 (92.5)	NE (NE, NE)	134	9 (6.7)	125 (93.3)	NE (NE, NE)	1.011 (0.410, 2.490)	0.9816	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (9.9, NE)	0.399 (0.052, 3.083)	0.3643	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Upper respiratory tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2392
≥3 to ≤25%	94	8 (8.5)	86 (91.5)	NE (38.0, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	2.111 (0.632, 7.056)	0.2145	
>25% to ≤50%	141	12 (8.5)	129 (91.5)	NE (30.1, NE)	136	9 (6.6)	127 (93.4)	NE (NE, NE)	1.025 (0.431, 2.439)	0.9546	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (6.3, NE)	0.219 (0.019, 2.472)	0.1795	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Upper respiratory tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1680
Yes	139	11 (7.9)	128 (92.1)	NE (NE, NE)	137	9 (6.6)	128 (93.4)	NE (NE, NE)	0.972 (0.402, 2.350)	0.9497	
No	116	10 (8.6)	106 (91.4)	NE (25.7, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	2.949 (0.807, 10.774)	0.0865	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Upper respiratory tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0425
≤60	164	18 (11.0)	146 (89.0)	NE (38.0, NE)	163	7 (4.3)	156 (95.7)	NE (NE, NE)	1.978 (0.823, 4.756)	0.1205	
>60	101	3 (3.0)	98 (97.0)	NE (30.1, NE)	105	8 (7.6)	97 (92.4)	NE (23.8, NE)	0.371 (0.098, 1.400)	0.1277	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral herpes

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1702
<60	159	13 (8.2)	146 (91.8)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	1.964 (0.744, 5.184)	0.1648	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.0597	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	6 (9.2)	59 (90.8)	NE (NE, NE)	0.322 (0.065, 1.596)	0.1436	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral herpes

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9209
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.241 (0.206, 7.466)	0.8131	
Female	141	15 (10.6)	126 (89.4)	NE (NE, NE)	148	10 (6.8)	138 (93.2)	NE (NE, NE)	1.525 (0.684, 3.397)	0.2992	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral herpes

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8799
White	157	13 (8.3)	144 (91.7)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	1.440 (0.615, 3.375)	0.3991	
Non-white	108	5 (4.6)	103 (95.4)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	1.497 (0.357, 6.274)	0.5785	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral herpes

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9044
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	14 (8.7)	147 (91.3)	NE (NE, NE)	161	10 (6.2)	151 (93.8)	NE (NE, NE)	1.280 (0.567, 2.890)	0.5510	
Asia/Other Regions	88	4 (4.5)	84 (95.5)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	1.913 (0.350, 10.467)	0.4465	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral herpes

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7555
< 40x10^9/L	132	9 (6.8)	123 (93.2)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	1.270 (0.473, 3.414)	0.6341	
≥ 40x10^9/L	133	9 (6.8)	124 (93.2)	NE (NE, NE)	135	5 (3.7)	130 (96.3)	NE (NE, NE)	1.700 (0.568, 5.085)	0.3370	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral herpes

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7694
Daunorubicin	123	9 (7.3)	114 (92.7)	NE (NE, NE)	94	4 (4.3)	90 (95.7)	NE (NE, NE)	1.587 (0.488, 5.165)	0.4385	
Idarubicin	142	9 (6.3)	133 (93.7)	NE (NE, NE)	171	8 (4.7)	163 (95.3)	NE (NE, NE)	1.284 (0.494, 3.332)	0.6076	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral herpes

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8846
Favorable	13	2 (15.4)	11 (84.6)	26.3 (26.3, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	2.220 (0.302, 16.334)	0.4226	
Intermediate	195	12 (6.2)	183 (93.8)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	1.503 (0.591, 3.825)	0.3893	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.2207	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	0.886 (0.179, 4.391)	0.8824	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral herpes

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9823
0 - Fully Active	87	9 (10.3)	78 (89.7)	NE (NE, NE)	97	6 (6.2)	91 (93.8)	NE (NE, NE)	1.587 (0.564, 4.464)	0.3776	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	1.347 (0.427, 4.251)	0.6095	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	1.674 (0.152, 18.470)	0.6707	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral herpes

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4835
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	6 (6.1)	92 (93.9)	NE (NE, NE)	0.673 (0.190, 2.389)	0.5379	
>25% to ≤50%	141	12 (8.5)	129 (91.5)	NE (NE, NE)	136	6 (4.4)	130 (95.6)	NE (NE, NE)	1.841 (0.690, 4.911)	0.2156	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.1224	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral herpes

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1749
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	8 (5.8)	129 (94.2)	NE (NE, NE)	0.847 (0.307, 2.338)	0.7468	
No	116	10 (8.6)	106 (91.4)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	2.373 (0.743, 7.578)	0.1325	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral herpes

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3231
≤60	164	13 (7.9)	151 (92.1)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	1.930 (0.731, 5.096)	0.1764	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	6 (5.7)	99 (94.3)	NE (NE, NE)	0.869 (0.265, 2.850)	0.8147	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Conjunctivitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9999
<60	159	11 (6.9)	148 (93.1)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	1.772 (0.655, 4.796)	0.2529	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	0.000 (0.000, NE)	0.1456	
≥65	69	5 (7.2)	64 (92.8)	NE (28.1, NE)	65	0	65 (100)	NE (NE, NE)	NE (0.000, NE)	0.0178	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Conjunctivitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6156
Male	124	8 (6.5)	116 (93.5)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	2.530 (0.671, 9.542)	0.1557	
Female	141	8 (5.7)	133 (94.3)	NE (NE, NE)	148	5 (3.4)	143 (96.6)	NE (NE, NE)	1.522 (0.497, 4.664)	0.4591	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Conjunctivitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4967
White	157	12 (7.6)	145 (92.4)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	2.341 (0.823, 6.657)	0.1003	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	1.250 (0.280, 5.591)	0.7697	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Conjunctivitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5105
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.2888	
Europe	161	14 (8.7)	147 (91.3)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	2.118 (0.812, 5.524)	0.1161	
Asia/Other Regions	88	1 (1.1)	87 (98.9)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	0.498 (0.045, 5.487)	0.5608	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Conjunctivitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1030
< 40x10^9/L	132	9 (6.8)	123 (93.2)	NE (NE, NE)	133	2 (1.5)	131 (98.5)	NE (NE, NE)	4.759 (1.028, 22.037)	0.0276	
≥ 40x10^9/L	133	7 (5.3)	126 (94.7)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	1.026 (0.343, 3.066)	0.9627	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Conjunctivitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1413
Daunorubicin	123	11 (8.9)	112 (91.1)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	3.975 (0.880, 17.962)	0.0526	
Idarubicin	142	5 (3.5)	137 (96.5)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	0.937 (0.285, 3.075)	0.9139	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Conjunctivitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9130
Favorable	13	1 (7.7)	12 (92.3)	NE (1.5, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.1797	
Intermediate	195	12 (6.2)	183 (93.8)	NE (NE, NE)	190	6 (3.2)	184 (96.8)	NE (NE, NE)	1.717 (0.643, 4.581)	0.2741	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.843 (0.076, 9.309)	0.8889	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.1738	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Conjunctivitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9702
0 - Fully Active	87	6 (6.9)	81 (93.1)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	1.506 (0.424, 5.358)	0.5240	
1 - Restricted in Physically Strenuous Activity	133	8 (6.0)	125 (94.0)	NE (NE, NE)	134	4 (3.0)	130 (97.0)	NE (NE, NE)	1.939 (0.583, 6.445)	0.2705	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.1774	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Conjunctivitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9988
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	1.752 (0.418, 7.335)	0.4369	
>25% to ≤50%	141	10 (7.1)	131 (92.9)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	1.843 (0.628, 5.405)	0.2576	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.2850	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Conjunctivitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0596
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	7 (5.1)	130 (94.9)	NE (NE, NE)	0.956 (0.335, 2.732)	0.9336	
No	116	9 (7.8)	107 (92.2)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	8.596 (1.088, 67.900)	0.0141	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Conjunctivitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5952
≤60	164	11 (6.7)	153 (93.3)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	1.734 (0.641, 4.693)	0.2718	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	2.632 (0.510, 13.593)	0.2300	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3644
<60	159	9 (5.7)	150 (94.3)	NE (NE, NE)	160	2 (1.3)	158 (98.8)	NE (NE, NE)	4.339 (0.937, 20.094)	0.0405	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	4.385 (0.488, 39.370)	0.1494	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	0.965 (0.195, 4.784)	0.9630	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7245
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	3.361 (0.698, 16.186)	0.1086	
Female	141	9 (6.4)	132 (93.6)	NE (NE, NE)	148	4 (2.7)	144 (97.3)	NE (NE, NE)	2.336 (0.719, 7.589)	0.1456	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3574
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	5.960 (0.717, 49.538)	0.0600	
Non-white	108	10 (9.3)	98 (90.7)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	1.998 (0.683, 5.846)	0.1975	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8259
North America	16	2 (12.5)	14 (87.5)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	2.258 (0.205, 24.901)	0.4905	
Europe	161	5 (3.1)	156 (96.9)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	4.691 (0.548, 40.188)	0.1200	
Asia/Other Regions	88	9 (10.2)	79 (89.8)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	2.257 (0.695, 7.334)	0.1641	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0137
< 40x10^9/L	132	1 (0.8)	131 (99.2)	NE (NE, NE)	133	4 (3.0)	129 (97.0)	NE (NE, NE)	0.257 (0.029, 2.300)	0.1900	
≥ 40x10^9/L	133	15 (11.3)	118 (88.7)	NE (NE, NE)	135	2 (1.5)	133 (98.5)	NE (NE, NE)	7.239 (1.654, 31.678)	0.0021	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9881
Daunorubicin	123	7 (5.7)	116 (94.3)	NE (NE, NE)	94	0	94 (100)	NE (NE, NE)	NE (0.000, NE)	0.0208	
Idarubicin	142	9 (6.3)	133 (93.7)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	1.786 (0.635, 5.020)	0.2648	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.2207	
Intermediate	195	11 (5.6)	184 (94.4)	NE (NE, NE)	190	6 (3.2)	184 (96.8)	NE (NE, NE)	1.667 (0.616, 4.514)	0.3090	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (4.3, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.0909	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.1796	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5430
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	1 (1.0)	96 (99.0)	NE (NE, NE)	5.307 (0.620, 45.441)	0.0879	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	1.409 (0.447, 4.441)	0.5561	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.0617	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7072
≥3 to ≤25%	94	7 (7.4)	87 (92.6)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	1.926 (0.564, 6.580)	0.2871	
>25% to ≤50%	141	9 (6.4)	132 (93.6)	NE (NE, NE)	136	2 (1.5)	134 (98.5)	NE (NE, NE)	4.282 (0.925, 19.832)	0.0426	
>50%	29	0	29 (100)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3647
Yes	139	10 (7.2)	129 (92.8)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	1.984 (0.678, 5.808)	0.2022	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	6.018 (0.725, 49.976)	0.0582	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2858
≤60	164	10 (6.1)	154 (93.9)	NE (NE, NE)	163	2 (1.2)	161 (98.8)	NE (NE, NE)	4.747 (1.040, 21.679)	0.0265	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	4 (3.8)	101 (96.2)	NE (NE, NE)	1.620 (0.457, 5.742)	0.4512	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6940
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	16 (10.0)	144 (90.0)	NE (NE, NE)	0.400 (0.164, 0.973)	0.0364	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	0.538 (0.098, 2.945)	0.4674	
≥65	69	6 (8.7)	63 (91.3)	NE (NE, NE)	65	8 (12.3)	57 (87.7)	NE (NE, NE)	0.735 (0.255, 2.120)	0.5678	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7510
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	12 (10.0)	108 (90.0)	NE (NE, NE)	0.451 (0.169, 1.204)	0.1027	
Female	141	9 (6.4)	132 (93.6)	NE (NE, NE)	148	16 (10.8)	132 (89.2)	NE (NE, NE)	0.563 (0.249, 1.274)	0.1619	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2822
White	157	11 (7.0)	146 (93.0)	NE (NE, NE)	161	16 (9.9)	145 (90.1)	NE (NE, NE)	0.690 (0.320, 1.486)	0.3395	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	12 (11.2)	95 (88.8)	NE (NE, NE)	0.308 (0.099, 0.957)	0.0311	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9131
North America	16	0	16 (100)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	0.000 (0.000, NE)	0.3458	
Europe	161	11 (6.8)	150 (93.2)	NE (NE, NE)	161	18 (11.2)	143 (88.8)	NE (NE, NE)	0.576 (0.272, 1.221)	0.1450	
Asia/Other Regions	88	4 (4.5)	84 (95.5)	NE (NE, NE)	89	9 (10.1)	80 (89.9)	NE (NE, NE)	0.416 (0.128, 1.352)	0.1319	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1487
< 40x10^9/L	132	10 (7.6)	122 (92.4)	NE (NE, NE)	133	13 (9.8)	120 (90.2)	NE (NE, NE)	0.780 (0.342, 1.780)	0.5545	
≥ 40x10^9/L	133	5 (3.8)	128 (96.2)	NE (NE, NE)	135	15 (11.1)	120 (88.9)	NE (NE, NE)	0.293 (0.106, 0.809)	0.0118	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5015
Daunorubicin	123	8 (6.5)	115 (93.5)	NE (NE, NE)	94	9 (9.6)	85 (90.4)	NE (NE, NE)	0.654 (0.252, 1.696)	0.3782	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	19 (11.1)	152 (88.9)	NE (NE, NE)	0.414 (0.174, 0.985)	0.0396	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7122
Favorable	13	1 (7.7)	12 (92.3)	NE (1.8, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	0.926 (0.083, 10.298)	0.9500	
Intermediate	195	10 (5.1)	185 (94.9)	NE (NE, NE)	190	14 (7.4)	176 (92.6)	NE (NE, NE)	0.652 (0.290, 1.470)	0.2995	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	7 (25.9)	20 (74.1)	NE (3.4, NE)	0.186 (0.023, 1.511)	0.0777	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	5 (16.1)	26 (83.9)	NE (NE, NE)	0.482 (0.115, 2.018)	0.3089	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5688
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	9 (9.3)	88 (90.7)	NE (NE, NE)	0.470 (0.145, 1.527)	0.1982	
1 - Restricted in Physically Strenuous Activity	133	9 (6.8)	124 (93.2)	NE (NE, NE)	134	13 (9.7)	121 (90.3)	NE (NE, NE)	0.659 (0.281, 1.541)	0.3332	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	6 (16.7)	30 (83.3)	NE (5.2, NE)	0.261 (0.052, 1.303)	0.0784	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9426
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	6 (6.1)	92 (93.9)	NE (NE, NE)	0.518 (0.129, 2.070)	0.3427	
>25% to ≤50%	141	12 (8.5)	129 (91.5)	NE (NE, NE)	136	16 (11.8)	120 (88.2)	NE (NE, NE)	0.684 (0.324, 1.448)	0.3194	
>50%	29	0	29 (100)	NE (NE, NE)	34	6 (17.6)	28 (82.4)	NE (NE, NE)	0.000 (0.000, NE)	0.0108	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9199
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	14 (10.2)	123 (89.8)	NE (NE, NE)	0.467 (0.188, 1.157)	0.0922	
No	116	7 (6.0)	109 (94.0)	NE (NE, NE)	120	13 (10.8)	107 (89.2)	NE (NE, NE)	0.529 (0.211, 1.326)	0.1667	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6470
≤60	164	8 (4.9)	156 (95.1)	NE (NE, NE)	163	16 (9.8)	147 (90.2)	NE (NE, NE)	0.451 (0.193, 1.055)	0.0593	
>60	101	7 (6.9)	94 (93.1)	NE (NE, NE)	105	12 (11.4)	93 (88.6)	NE (NE, NE)	0.606 (0.239, 1.540)	0.2880	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Folliculitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											1.0000
<60	159	11 (6.9)	148 (93.1)	NE (NE, NE)	160	4 (2.5)	156 (97.5)	NE (NE, NE)	2.564 (0.815, 8.065)	0.0950	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (NE, NE)	NE	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	0	65 (100)	NE (NE, NE)	NE (0.000, NE)	0.0748	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Folliculitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3413
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	2.233 (0.577, 8.638)	0.2318	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	1 (0.7)	147 (99.3)	NE (NE, NE)	6.807 (0.837, 55.362)	0.0375	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Folliculitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5258
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	5.941 (0.714, 49.400)	0.0608	
Non-white	108	8 (7.4)	100 (92.6)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	2.605 (0.691, 9.822)	0.1421	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Folliculitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9359
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	5 (3.1)	156 (96.9)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	4.718 (0.550, 40.441)	0.1186	
Asia/Other Regions	88	9 (10.2)	79 (89.8)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	2.940 (0.795, 10.872)	0.0899	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Folliculitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6073
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	1 (0.8)	132 (99.2)	NE (NE, NE)	5.214 (0.609, 44.648)	0.0922	
≥ 40x10^9/L	133	9 (6.8)	124 (93.2)	NE (NE, NE)	135	3 (2.2)	132 (97.8)	NE (NE, NE)	2.698 (0.729, 9.991)	0.1219	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Folliculitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9895
Daunorubicin	123	8 (6.5)	115 (93.5)	NE (NE, NE)	94	0	94 (100)	NE (NE, NE)	NE (0.000, NE)	0.0190	
Idarubicin	142	6 (4.2)	136 (95.8)	NE (NE, NE)	171	4 (2.3)	167 (97.7)	NE (NE, NE)	1.808 (0.510, 6.408)	0.3522	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Folliculitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	11 (5.6)	184 (94.4)	NE (NE, NE)	190	4 (2.1)	186 (97.9)	NE (NE, NE)	2.440 (0.776, 7.676)	0.1150	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (5.0, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.2689	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.1836	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Folliculitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9948
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	2.779 (0.539, 14.329)	0.2022	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	2 (1.5)	132 (98.5)	NE (NE, NE)	2.276 (0.441, 11.755)	0.3127	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.0881	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Folliculitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9999
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	0	98 (100)	NE (NE, NE)	NE (0.000, NE)	0.0202	
>25% to ≤50%	141	8 (5.7)	133 (94.3)	NE (NE, NE)	136	4 (2.9)	132 (97.1)	NE (NE, NE)	1.866 (0.561, 6.207)	0.3014	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.2789	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Folliculitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7868
Yes	139	8 (5.8)	131 (94.2)	NE (NE, NE)	137	2 (1.5)	135 (98.5)	NE (NE, NE)	3.897 (0.827, 18.365)	0.0636	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	2.935 (0.592, 14.557)	0.1672	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Folliculitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9897
≤60	164	11 (6.7)	153 (93.3)	NE (NE, NE)	163	4 (2.5)	159 (97.5)	NE (NE, NE)	2.519 (0.801, 7.923)	0.1019	
>60	101	3 (3.0)	98 (97.0)	NE (NE, NE)	105	0	105 (100)	NE (NE, NE)	NE (0.000, NE)	0.0724	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8474
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	5 (3.1)	155 (96.9)	NE (NE, NE)	0.978 (0.283, 3.381)	0.9719	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.1285	
≥65	69	5 (7.2)	64 (92.8)	NE (26.5, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	1.696 (0.405, 7.101)	0.4644	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7665
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.842 (0.337, 10.071)	0.4740	
Female	141	8 (5.7)	133 (94.3)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	1.406 (0.488, 4.053)	0.5261	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8597
White	157	7 (4.5)	150 (95.5)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	1.423 (0.451, 4.486)	0.5450	
Non-white	108	5 (4.6)	103 (95.4)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	1.601 (0.382, 6.708)	0.5157	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6253
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.2888	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	0.970 (0.313, 3.009)	0.9571	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	2.481 (0.481, 12.791)	0.2612	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0222
< 40x10^9/L	132	8 (6.1)	124 (93.9)	NE (NE, NE)	133	1 (0.8)	132 (99.2)	NE (NE, NE)	8.774 (1.097, 70.188)	0.0134	
≥ 40x10^9/L	133	4 (3.0)	129 (97.0)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	0.511 (0.149, 1.754)	0.2772	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9898
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	0	94 (100)	NE (NE, NE)	NE (0.000, NE)	0.2153	
Idarubicin	142	10 (7.0)	132 (93.0)	NE (NE, NE)	171	8 (4.7)	163 (95.3)	NE (NE, NE)	1.472 (0.580, 3.732)	0.4127	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9991
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	6 (3.2)	184 (96.8)	NE (NE, NE)	1.428 (0.508, 4.012)	0.4977	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (4.3, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.414 (0.088, 22.637)	0.8055	
Unknown	38	2 (5.3)	36 (94.7)	NE (26.5, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	1.551 (0.138, 17.481)	0.7206	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6453
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	1.448 (0.240, 8.729)	0.6844	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	1.010 (0.292, 3.489)	0.9874	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	3.287 (0.367, 29.432)	0.2594	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9992
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	1.429 (0.320, 6.388)	0.6386	
>25% to ≤50%	141	8 (5.7)	133 (94.3)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	1.527 (0.499, 4.671)	0.4548	
>50%	29	0	29 (100)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4545
Yes	139	8 (5.8)	131 (94.2)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	1.949 (0.586, 6.479)	0.2679	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.983 (0.246, 3.934)	0.9812	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4875
≤60	164	6 (3.7)	158 (96.3)	NE (NE, NE)	163	5 (3.1)	158 (96.9)	NE (NE, NE)	1.155 (0.352, 3.786)	0.8117	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	2.198 (0.550, 8.795)	0.2529	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Nasopharyngitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											1.0000
<60	159	9 (5.7)	150 (94.3)	NE (NE, NE)	160	7 (4.4)	153 (95.6)	NE (NE, NE)	0.991 (0.368, 2.669)	0.9864	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (27.3, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.2733	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	0	65 (100)	NE (NE, NE)	NE (0.000, NE)	0.1385	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Nasopharyngitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2746
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	0.901 (0.274, 2.959)	0.8639	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	2 (1.4)	146 (98.6)	NE (NE, NE)	2.722 (0.548, 13.508)	0.2018	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Nasopharyngitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7917
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	1.289 (0.421, 3.950)	0.6562	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	1.845 (0.337, 10.090)	0.4728	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Nasopharyngitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9285
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	8 (5.0)	153 (95.0)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	1.619 (0.487, 5.387)	0.4273	
Asia/Other Regions	88	4 (4.5)	84 (95.5)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	1.226 (0.274, 5.493)	0.7898	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Nasopharyngitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3216
< 40x10^9/L	132	7 (5.3)	125 (94.7)	NE (38.6, NE)	133	3 (2.3)	130 (97.7)	NE (NE, NE)	2.282 (0.590, 8.824)	0.2187	
≥ 40x10^9/L	133	5 (3.8)	128 (96.2)	NE (NE, NE)	135	4 (3.0)	131 (97.0)	NE (NE, NE)	0.930 (0.248, 3.488)	0.9150	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Nasopharyngitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8554
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	3 (3.2)	91 (96.8)	NE (NE, NE)	1.177 (0.293, 4.721)	0.8180	
Idarubicin	142	6 (4.2)	136 (95.8)	NE (NE, NE)	171	4 (2.3)	167 (97.7)	NE (NE, NE)	1.448 (0.407, 5.149)	0.5654	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Nasopharyngitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	0	13 (100)	NE (NE, NE)	19	3 (15.8)	16 (84.2)	NE (6.4, NE)	0.000 (0.000, NE)	0.2162	
Intermediate	195	11 (5.6)	184 (94.4)	NE (NE, NE)	190	4 (2.1)	186 (97.9)	NE (NE, NE)	2.181 (0.694, 6.858)	0.1714	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.4201	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Nasopharyngitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7455
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (38.6, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	1.540 (0.367, 6.455)	0.5517	
1 - Restricted in Physically Strenuous Activity	133	6 (4.5)	127 (95.5)	NE (NE, NE)	134	3 (2.2)	131 (97.8)	NE (NE, NE)	1.780 (0.445, 7.124)	0.4083	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	0.492 (0.028, 8.712)	0.6225	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Nasopharyngitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6578
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (38.6, NE)	98	5 (5.1)	93 (94.9)	NE (NE, NE)	0.929 (0.269, 3.212)	0.9077	
>25% to ≤50%	141	6 (4.3)	135 (95.7)	NE (NE, NE)	136	2 (1.5)	134 (98.5)	NE (NE, NE)	2.613 (0.527, 12.972)	0.2222	
>50%	29	1 (3.4)	28 (96.6)	NE (11.2, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.5271	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Nasopharyngitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.8133
Yes	139	8 (5.8)	131 (94.2)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	1.363 (0.445, 4.175)	0.5859	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.716 (0.314, 9.388)	0.5282	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Nasopharyngitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9924
≤60	164	9 (5.5)	155 (94.5)	NE (NE, NE)	163	7 (4.3)	156 (95.7)	NE (NE, NE)	0.975 (0.362, 2.624)	0.9596	
>60	101	3 (3.0)	98 (97.0)	NE (27.3, NE)	105	0	105 (100)	NE (NE, NE)	NE (0.000, NE)	0.0634	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral candidiasis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4421
<60	159	9 (5.7)	150 (94.3)	NE (NE, NE)	160	3 (1.9)	157 (98.1)	NE (NE, NE)	2.890 (0.781, 10.696)	0.0961	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	3 (7.0)	40 (93.0)	NE (NE, NE)	0.523 (0.085, 3.206)	0.4765	
≥65	69	0	69 (100)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	0.000 (0.000, NE)	0.0832	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral candidiasis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3881
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	1.852 (0.462, 7.432)	0.3765	
Female	141	5 (3.5)	136 (96.5)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	0.800 (0.243, 2.631)	0.7127	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral candidiasis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1928
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	1.912 (0.574, 6.372)	0.2834	
Non-white	108	3 (2.8)	105 (97.2)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	0.560 (0.134, 2.347)	0.4212	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral candidiasis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6289
North America	16	3 (18.8)	13 (81.3)	11.4 (10.3, NE)	18	3 (16.7)	15 (83.3)	NE (5.4, NE)	1.372 (0.273, 6.904)	0.6999	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	1.940 (0.484, 7.770)	0.3405	
Asia/Other Regions	88	2 (2.3)	86 (97.7)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	0.671 (0.112, 4.017)	0.6602	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral candidiasis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1940
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	0.709 (0.225, 2.234)	0.5546	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	2 (1.5)	133 (98.5)	NE (NE, NE)	2.862 (0.575, 14.238)	0.1794	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral candidiasis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4088
Daunorubicin	123	3 (2.4)	120 (97.6)	NE (NE, NE)	94	3 (3.2)	91 (96.8)	NE (NE, NE)	0.717 (0.144, 3.562)	0.6832	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	1.521 (0.527, 4.393)	0.4347	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral candidiasis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9782
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (8.4, NE)	1.936 (0.118, 31.668)	0.6372	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	8 (4.2)	182 (95.8)	NE (NE, NE)	0.975 (0.375, 2.538)	0.9589	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.3534	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral candidiasis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.0920
0 - Fully Active	87	7 (8.0)	80 (92.0)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	3.608 (0.749, 17.391)	0.0871	
1 - Restricted in Physically Strenuous Activity	133	2 (1.5)	131 (98.5)	NE (NE, NE)	134	6 (4.5)	128 (95.5)	NE (NE, NE)	0.315 (0.063, 1.565)	0.1360	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	1.676 (0.152, 18.480)	0.6699	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral candidiasis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6998
≥3 to ≤25%	94	2 (2.1)	92 (97.9)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	0.528 (0.097, 2.884)	0.4540	
>25% to ≤50%	141	7 (5.0)	134 (95.0)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	1.196 (0.378, 3.785)	0.7609	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.1479	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral candidiasis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3655
Yes	139	8 (5.8)	131 (94.2)	NE (NE, NE)	137	8 (5.8)	129 (94.2)	NE (NE, NE)	0.935 (0.350, 2.498)	0.8933	
No	116	3 (2.6)	113 (97.4)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	2.935 (0.305, 28.224)	0.3282	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Oral candidiasis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0451
≤60	164	9 (5.5)	155 (94.5)	NE (NE, NE)	163	3 (1.8)	160 (98.2)	NE (NE, NE)	2.850 (0.770, 10.547)	0.1010	
>60	101	2 (2.0)	99 (98.0)	NE (NE, NE)	105	6 (5.7)	99 (94.3)	NE (NE, NE)	0.320 (0.064, 1.592)	0.1427	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Urinary tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3987
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	5 (3.1)	155 (96.9)	NE (NE, NE)	0.908 (0.263, 3.142)	0.8795	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	0.407 (0.036, 4.561)	0.4516	
≥65	69	5 (7.2)	64 (92.8)	NE (26.5, NE)	65	2 (3.1)	63 (96.9)	NE (29.3, NE)	2.903 (0.561, 15.007)	0.1831	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Urinary tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9916
Male	124	0	124 (100)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	0.000 (0.000, NE)	0.0562	
Female	141	11 (7.8)	130 (92.2)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	1.783 (0.659, 4.827)	0.2483	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Urinary tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4745
White	157	7 (4.5)	150 (95.5)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	0.862 (0.302, 2.465)	0.7821	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	1.907 (0.349, 10.435)	0.4487	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Urinary tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2897
North America	16	1 (6.3)	15 (93.8)	NE (12.1, NE)	18	3 (16.7)	15 (83.3)	NE (4.0, NE)	0.471 (0.049, 4.544)	0.5050	
Europe	161	5 (3.1)	156 (96.9)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	0.826 (0.239, 2.861)	0.7631	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	1 (1.1)	88 (98.9)	NE (NE, NE)	5.145 (0.601, 44.038)	0.0953	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Urinary tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3909
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	3 (2.3)	130 (97.7)	NE (NE, NE)	1.748 (0.417, 7.323)	0.4387	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	0.756 (0.243, 2.355)	0.6288	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Urinary tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8912
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	4 (4.3)	90 (95.7)	NE (NE, NE)	0.967 (0.272, 3.442)	0.9588	
Idarubicin	142	5 (3.5)	137 (96.5)	NE (NE, NE)	171	5 (2.9)	166 (97.1)	NE (NE, NE)	1.102 (0.319, 3.814)	0.8780	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Urinary tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9976
Favorable	13	0	13 (100)	NE (NE, NE)	19	3 (15.8)	16 (84.2)	NE (29.3, NE)	0.000 (0.000, NE)	0.3480	
Intermediate	195	7 (3.6)	188 (96.4)	NE (NE, NE)	190	5 (2.6)	185 (97.4)	NE (NE, NE)	1.169 (0.370, 3.694)	0.7894	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (9.7, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.0753	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	1.701 (0.153, 18.870)	0.6615	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Urinary tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5825
0 - Fully Active	87	6 (6.9)	81 (93.1)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	1.564 (0.441, 5.544)	0.4853	
1 - Restricted in Physically Strenuous Activity	133	3 (2.3)	130 (97.7)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	0.541 (0.129, 2.265)	0.3927	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.1740	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Urinary tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2525
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	5 (5.1)	93 (94.9)	NE (NE, NE)	0.618 (0.148, 2.585)	0.5054	
>25% to ≤50%	141	8 (5.7)	133 (94.3)	NE (NE, NE)	136	2 (1.5)	134 (98.5)	NE (NE, NE)	3.565 (0.756, 16.820)	0.0863	
>50%	29	0	29 (100)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.000 (0.000, NE)	0.1197	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Urinary tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1660
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	1.534 (0.448, 5.256)	0.4927	
No	116	2 (1.7)	114 (98.3)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	0.354 (0.069, 1.830)	0.1955	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Urinary tract infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4707
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	5 (3.1)	158 (96.9)	NE (NE, NE)	0.891 (0.257, 3.081)	0.8550	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	4 (3.8)	101 (96.2)	NE (NE, NE)	1.592 (0.448, 5.658)	0.4687	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sinusitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9256
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	4 (2.5)	156 (97.5)	NE (NE, NE)	1.717 (0.502, 5.873)	0.3820	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.1243	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	1.197 (0.168, 8.523)	0.8571	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sinusitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1948
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.884 (0.220, 3.544)	0.8617	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	2 (1.4)	146 (98.6)	NE (NE, NE)	3.710 (0.770, 17.866)	0.0794	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sinusitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3256
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	2.701 (0.716, 10.193)	0.1263	
Non-white	108	3 (2.8)	105 (97.2)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	0.946 (0.191, 4.689)	0.9470	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sinusitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7044
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (7.7, NE)	1.403 (0.086, 22.815)	0.8110	
Europe	161	8 (5.0)	153 (95.0)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	2.649 (0.702, 9.990)	0.1346	
Asia/Other Regions	88	2 (2.3)	86 (97.7)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	0.991 (0.140, 7.037)	0.9926	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sinusitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9916
< 40x10^9/L	132	7 (5.3)	125 (94.7)	NE (NE, NE)	133	4 (3.0)	129 (97.0)	NE (NE, NE)	1.829 (0.535, 6.251)	0.3273	
≥ 40x10^9/L	133	4 (3.0)	129 (97.0)	NE (NE, NE)	135	2 (1.5)	133 (98.5)	NE (NE, NE)	1.836 (0.335, 10.066)	0.4771	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sinusitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4874
Daunorubicin	123	5 (4.1)	118 (95.9)	NE (NE, NE)	94	3 (3.2)	91 (96.8)	NE (NE, NE)	1.204 (0.287, 5.052)	0.7986	
Idarubicin	142	6 (4.2)	136 (95.8)	NE (NE, NE)	171	3 (1.8)	168 (98.2)	NE (NE, NE)	2.382 (0.595, 9.537)	0.2057	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sinusitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (7.7, NE)	0.000 (0.000, NE)	0.4795	
Intermediate	195	7 (3.6)	188 (96.4)	NE (NE, NE)	190	4 (2.1)	186 (97.9)	NE (NE, NE)	1.638 (0.479, 5.603)	0.4268	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (2.7, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.1923	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.1026	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sinusitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7292
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	1 (1.0)	96 (99.0)	NE (NE, NE)	3.209 (0.333, 30.884)	0.2858	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	4 (3.0)	130 (97.0)	NE (NE, NE)	1.740 (0.509, 5.947)	0.3709	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	0.836 (0.052, 13.358)	0.8987	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sinusitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2529
≥3 to ≤25%	94	1 (1.1)	93 (98.9)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	0.344 (0.036, 3.311)	0.3331	
>25% to ≤50%	141	10 (7.1)	131 (92.9)	NE (NE, NE)	136	3 (2.2)	133 (97.8)	NE (NE, NE)	3.200 (0.880, 11.634)	0.0616	
>50%	29	0	29 (100)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sinusitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2172
Yes	139	5 (3.6)	134 (96.4)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	1.227 (0.329, 4.577)	0.7608	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	5.878 (0.708, 48.834)	0.0625	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sinusitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7672
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	4 (2.5)	159 (97.5)	NE (NE, NE)	1.695 (0.496, 5.796)	0.3942	
>60	101	4 (4.0)	97 (96.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	2.271 (0.415, 12.412)	0.3306	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Cellulitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9148
<60	159	6 (3.8)	153 (96.2)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	0.921 (0.296, 2.864)	0.8873	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	0.000 (0.000, NE)	0.1900	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	1.401 (0.313, 6.265)	0.6572	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Cellulitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5910
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	1.294 (0.290, 5.784)	0.7349	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	8 (5.4)	140 (94.6)	NE (NE, NE)	0.743 (0.257, 2.143)	0.5815	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Cellulitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5594
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	0.728 (0.252, 2.102)	0.5562	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	1.258 (0.281, 5.630)	0.7636	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Cellulitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8624
North America	16	1 (6.3)	15 (93.8)	NE (2.8, NE)	18	2 (11.1)	16 (88.9)	NE (NE, NE)	0.826 (0.073, 9.349)	0.8770	
Europe	161	4 (2.5)	157 (97.5)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	0.742 (0.199, 2.770)	0.6566	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	1.242 (0.333, 4.627)	0.7462	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Cellulitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0983
< 40x10^9/L	132	7 (5.3)	125 (94.7)	NE (NE, NE)	133	4 (3.0)	129 (97.0)	NE (NE, NE)	1.834 (0.537, 6.267)	0.3252	
≥ 40x10^9/L	133	3 (2.3)	130 (97.7)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	0.408 (0.105, 1.583)	0.1804	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Cellulitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2092
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	0.467 (0.132, 1.660)	0.2285	
Idarubicin	142	6 (4.2)	136 (95.8)	NE (NE, NE)	171	5 (2.9)	166 (97.1)	NE (NE, NE)	1.443 (0.440, 4.732)	0.5425	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Cellulitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7148
Favorable	13	1 (7.7)	12 (92.3)	NE (25.8, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	1.732 (0.108, 27.890)	0.6949	
Intermediate	195	6 (3.1)	189 (96.9)	NE (NE, NE)	190	8 (4.2)	182 (95.8)	NE (NE, NE)	0.717 (0.249, 2.066)	0.5359	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (2.8, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	2.914 (0.262, 32.372)	0.3618	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	0.829 (0.052, 13.348)	0.8948	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Cellulitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7545
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	1.054 (0.263, 4.216)	0.9395	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	0.993 (0.287, 3.431)	0.9906	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.405 (0.037, 4.466)	0.4451	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Cellulitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5009
≥3 to ≤25%	94	2 (2.1)	92 (97.9)	NE (NE, NE)	98	5 (5.1)	93 (94.9)	NE (NE, NE)	0.409 (0.079, 2.111)	0.2702	
>25% to ≤50%	141	6 (4.3)	135 (95.7)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	1.106 (0.337, 3.629)	0.8680	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	2.285 (0.207, 25.197)	0.4877	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Cellulitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5343
Yes	139	6 (4.3)	133 (95.7)	NE (NE, NE)	137	8 (5.8)	129 (94.2)	NE (NE, NE)	0.749 (0.260, 2.159)	0.5922	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	1.173 (0.262, 5.256)	0.8348	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Cellulitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9483
≤60	164	6 (3.7)	158 (96.3)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	0.906 (0.291, 2.817)	0.8644	
>60	101	4 (4.0)	97 (96.0)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	0.858 (0.230, 3.194)	0.8187	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Herpes zoster

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4687
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	1 (0.6)	159 (99.4)	NE (NE, NE)	5.341 (0.655, 43.522)	0.0796	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	0.829 (0.052, 13.258)	0.8945	
≥65	69	2 (2.9)	67 (97.1)	NE (32.5, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	0.975 (0.137, 6.947)	0.9800	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Herpes zoster

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1091
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	0.740 (0.148, 3.685)	0.7118	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	1 (0.7)	147 (99.3)	NE (NE, NE)	6.525 (0.802, 53.089)	0.0433	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Herpes zoster

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7673
White	157	2 (1.3)	155 (98.7)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	1.471 (0.133, 16.231)	0.7512	
Non-white	108	8 (7.4)	100 (92.6)	NE (33.0, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	2.461 (0.652, 9.282)	0.1691	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Herpes zoster

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9936
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	3 (1.9)	158 (98.1)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	2.349 (0.244, 22.635)	0.4464	
Asia/Other Regions	88	7 (8.0)	81 (92.0)	NE (33.0, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	2.044 (0.527, 7.932)	0.2909	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Herpes zoster

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6401
< 40x10^9/L	132	3 (2.3)	129 (97.7)	NE (NE, NE)	133	2 (1.5)	131 (98.5)	NE (NE, NE)	1.415 (0.236, 8.481)	0.7028	
≥ 40x10^9/L	133	7 (5.3)	126 (94.7)	NE (NE, NE)	135	2 (1.5)	133 (98.5)	NE (NE, NE)	2.548 (0.527, 12.310)	0.2279	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Herpes zoster

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9920
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	0	94 (100)	NE (NE, NE)	NE (0.000, NE)	0.3050	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	4 (2.3)	167 (97.7)	NE (NE, NE)	1.959 (0.588, 6.526)	0.2646	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Herpes zoster

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	8 (4.1)	187 (95.9)	NE (NE, NE)	190	4 (2.1)	186 (97.9)	NE (NE, NE)	1.511 (0.454, 5.027)	0.4979	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.1651	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Herpes zoster

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8397
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	1 (1.0)	96 (99.0)	NE (NE, NE)	2.628 (0.272, 25.417)	0.3862	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	2 (1.5)	132 (98.5)	NE (NE, NE)	2.335 (0.452, 12.069)	0.2976	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (9.6, NE)	0.819 (0.074, 9.135)	0.8712	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Herpes zoster

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											1.0000
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	1.222 (0.328, 4.557)	0.7647	
>25% to ≤50%	141	4 (2.8)	137 (97.2)	NE (NE, NE)	136	0	136 (100)	NE (NE, NE)	NE (0.000, NE)	0.0598	
>50%	29	1 (3.4)	28 (96.6)	NE (10.6, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.5271	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Herpes zoster

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.8296
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	3 (2.2)	134 (97.8)	NE (NE, NE)	1.951 (0.503, 7.558)	0.3246	
No	116	3 (2.6)	113 (97.4)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	2.582 (0.268, 24.882)	0.3946	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Herpes zoster

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2366
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	1 (0.6)	162 (99.4)	NE (NE, NE)	5.236 (0.642, 42.676)	0.0841	
>60	101	3 (3.0)	98 (97.0)	NE (32.5, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	1.038 (0.209, 5.162)	0.9634	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8414
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	5 (3.1)	155 (96.9)	NE (NE, NE)	0.961 (0.278, 3.323)	0.9498	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	3 (7.0)	40 (93.0)	NE (NE, NE)	0.000 (0.000, NE)	0.1039	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	4 (6.2)	61 (93.8)	NE (NE, NE)	0.522 (0.096, 2.851)	0.4449	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3671
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.927 (0.232, 3.713)	0.9151	
Female	141	3 (2.1)	138 (97.9)	NE (NE, NE)	148	8 (5.4)	140 (94.6)	NE (NE, NE)	0.373 (0.099, 1.408)	0.1301	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5531
White	157	5 (3.2)	152 (96.8)	NE (NE, NE)	161	10 (6.2)	151 (93.8)	NE (NE, NE)	0.483 (0.165, 1.413)	0.1744	
Non-white	108	2 (1.9)	106 (98.1)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	0.963 (0.136, 6.843)	0.9703	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9999
North America	16	0	16 (100)	NE (NE, NE)	18	5 (27.8)	13 (72.2)	NE (5.1, NE)	0.000 (0.000, NE)	0.0526	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	0.816 (0.274, 2.431)	0.7156	
Asia/Other Regions	88	1 (1.1)	87 (98.9)	NE (NE, NE)	89	0	89 (100)	NE (NE, NE)	NE (0.000, NE)	0.3117	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6848
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	8 (6.0)	125 (94.0)	NE (NE, NE)	0.667 (0.218, 2.039)	0.4744	
≥ 40x10^9/L	133	2 (1.5)	131 (98.5)	NE (NE, NE)	135	4 (3.0)	131 (97.0)	NE (NE, NE)	0.452 (0.082, 2.479)	0.3483	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4812
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	4 (4.3)	90 (95.7)	NE (NE, NE)	0.370 (0.068, 2.023)	0.2320	
Idarubicin	142	5 (3.5)	137 (96.5)	NE (NE, NE)	171	8 (4.7)	163 (95.3)	NE (NE, NE)	0.727 (0.238, 2.225)	0.5753	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9362
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	1.770 (0.109, 28.654)	0.6839	
Intermediate	195	6 (3.1)	189 (96.9)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	0.779 (0.261, 2.321)	0.6533	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (5.1, NE)	0.000 (0.000, NE)	0.1900	
Unknown	38	0	38 (100)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	0.000 (0.000, NE)	0.1396	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5792
0 - Fully Active	87	1 (1.1)	86 (98.9)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	0.250 (0.028, 2.241)	0.1802	
1 - Restricted in Physically Strenuous Activity	133	6 (4.5)	127 (95.5)	NE (NE, NE)	134	6 (4.5)	128 (95.5)	NE (NE, NE)	0.985 (0.317, 3.055)	0.9797	
2 - Ambulatory and Capable of All Selfcare	45	0	45 (100)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.000 (0.000, NE)	0.1159	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7211
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	6 (6.1)	92 (93.9)	NE (NE, NE)	0.711 (0.201, 2.519)	0.5949	
>25% to ≤50%	141	2 (1.4)	139 (98.6)	NE (NE, NE)	136	6 (4.4)	130 (95.6)	NE (NE, NE)	0.303 (0.061, 1.503)	0.1212	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.2850	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3760
Yes	139	2 (1.4)	137 (98.6)	NE (NE, NE)	137	6 (4.4)	131 (95.6)	NE (NE, NE)	0.316 (0.064, 1.569)	0.1370	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.794 (0.242, 2.606)	0.7041	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal infection

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2644
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	5 (3.1)	158 (96.9)	NE (NE, NE)	0.942 (0.272, 3.258)	0.9250	
>60	101	2 (2.0)	99 (98.0)	NE (NE, NE)	105	7 (6.7)	98 (93.3)	NE (NE, NE)	0.296 (0.061, 1.424)	0.1063	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3255
<60	159	1 (0.6)	158 (99.4)	NE (NE, NE)	160	5 (3.1)	155 (96.9)	NE (NE, NE)	0.186 (0.022, 1.598)	0.0858	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	3 (7.0)	40 (93.0)	NE (NE, NE)	0.000 (0.000, NE)	0.0761	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	1.542 (0.258, 9.232)	0.6324	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8238
Male	124	2 (1.6)	122 (98.4)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.451 (0.082, 2.466)	0.3454	
Female	141	2 (1.4)	139 (98.6)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	0.335 (0.068, 1.662)	0.1599	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1451
White	157	1 (0.6)	156 (99.4)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	0.130 (0.016, 1.057)	0.0242	
Non-white	108	3 (2.8)	105 (97.2)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	0.972 (0.196, 4.814)	0.9718	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6181
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.2850	
Europe	161	2 (1.2)	159 (98.8)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	0.199 (0.043, 0.922)	0.0219	
Asia/Other Regions	88	1 (1.1)	87 (98.9)	NE (NE, NE)	89	1 (1.1)	88 (98.9)	NE (NE, NE)	0.949 (0.059, 15.184)	0.9707	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7051
< 40x10^9/L	132	1 (0.8)	131 (99.2)	NE (NE, NE)	133	4 (3.0)	129 (97.0)	NE (NE, NE)	0.262 (0.029, 2.348)	0.1979	
≥ 40x10^9/L	133	3 (2.3)	130 (97.7)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	0.452 (0.113, 1.812)	0.2497	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9924
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	4 (4.3)	90 (95.7)	NE (NE, NE)	0.702 (0.175, 2.810)	0.6148	
Idarubicin	142	0	142 (100)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	0.000 (0.000, NE)	0.0225	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	4 (2.1)	191 (97.9)	NE (NE, NE)	190	4 (2.1)	186 (97.9)	NE (NE, NE)	0.880 (0.219, 3.529)	0.8571	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.000 (0.000, NE)	0.2569	
Unknown	38	0	38 (100)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (NE, NE)	0.000 (0.000, NE)	0.0335	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8486
0 - Fully Active	87	1 (1.1)	86 (98.9)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	0.346 (0.036, 3.325)	0.3352	
1 - Restricted in Physically Strenuous Activity	133	2 (1.5)	131 (98.5)	NE (NE, NE)	134	6 (4.5)	128 (95.5)	NE (NE, NE)	0.312 (0.063, 1.545)	0.1310	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	0.861 (0.054, 13.765)	0.9154	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8553
≥3 to ≤25%	94	1 (1.1)	93 (98.9)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	0.264 (0.029, 2.363)	0.2002	
>25% to ≤50%	141	3 (2.1)	138 (97.9)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	0.543 (0.130, 2.274)	0.3958	
>50%	29	0	29 (100)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.000 (0.000, NE)	0.2278	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5794
Yes	139	3 (2.2)	136 (97.8)	NE (NE, NE)	137	6 (4.4)	131 (95.6)	NE (NE, NE)	0.476 (0.119, 1.905)	0.2827	
No	116	1 (0.9)	115 (99.1)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.226 (0.025, 2.023)	0.1455	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Staphylococcal sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3344
≤60	164	1 (0.6)	163 (99.4)	NE (NE, NE)	163	5 (3.1)	158 (96.9)	NE (NE, NE)	0.184 (0.021, 1.573)	0.0822	
>60	101	3 (3.0)	98 (97.0)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	0.630 (0.151, 2.638)	0.5238	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9728
<60	159	105 (66.0)	54 (34.0)	1.6 (1.3, 2.2)	160	98 (61.3)	62 (38.8)	1.5 (1.1, 3.3)	0.990 (0.751, 1.306)	0.9515	
≥60 - <65	37	27 (73.0)	10 (27.0)	1.1 (0.2, 2.5)	43	31 (72.1)	12 (27.9)	1.3 (0.5, 2.4)	1.062 (0.628, 1.795)	0.8392	
≥65	69	45 (65.2)	24 (34.8)	1.5 (0.8, 2.6)	65	44 (67.7)	21 (32.3)	2.0 (1.2, 3.3)	0.990 (0.653, 1.502)	0.9685	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6835
Male	124	83 (66.9)	41 (33.1)	1.5 (1.1, 2.0)	120	81 (67.5)	39 (32.5)	1.5 (1.0, 2.4)	0.943 (0.694, 1.283)	0.7102	
Female	141	94 (66.7)	47 (33.3)	1.6 (1.2, 2.5)	148	92 (62.2)	56 (37.8)	1.8 (1.3, 2.7)	1.026 (0.769, 1.370)	0.8690	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5979
White	157	104 (66.2)	53 (33.8)	1.6 (1.1, 2.1)	161	106 (65.8)	55 (34.2)	1.5 (0.9, 2.0)	0.932 (0.710, 1.225)	0.6128	
Non-white	108	73 (67.6)	35 (32.4)	1.6 (1.1, 2.4)	107	67 (62.6)	40 (37.4)	2.1 (1.3, 3.7)	1.039 (0.744, 1.451)	0.8203	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0512
North America	16	11 (68.8)	5 (31.3)	1.2 (0.2, NE)	18	15 (83.3)	3 (16.7)	0.8 (0.2, 1.5)	0.746 (0.342, 1.626)	0.4627	
Europe	161	101 (62.7)	60 (37.3)	1.7 (1.3, 2.8)	161	106 (65.8)	55 (34.2)	1.5 (0.9, 2.0)	0.830 (0.630, 1.093)	0.1856	
Asia/Other Regions	88	65 (73.9)	23 (26.1)	1.3 (0.6, 2.0)	89	52 (58.4)	37 (41.6)	2.4 (1.5, 5.9)	1.398 (0.969, 2.016)	0.0717	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6342
< 40x10^9/L	132	86 (65.2)	46 (34.8)	1.6 (1.0, 2.1)	133	84 (63.2)	49 (36.8)	2.0 (1.2, 3.7)	1.023 (0.755, 1.386)	0.8877	
≥ 40x10^9/L	133	91 (68.4)	42 (31.6)	1.6 (1.2, 2.2)	135	89 (65.9)	46 (34.1)	1.5 (1.1, 2.1)	0.939 (0.700, 1.259)	0.6754	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2378
Daunorubicin	123	81 (65.9)	42 (34.1)	2.0 (1.6, 2.8)	94	61 (64.9)	33 (35.1)	1.5 (1.1, 2.2)	0.836 (0.598, 1.170)	0.2915	
Idarubicin	142	96 (67.6)	46 (32.4)	1.3 (0.7, 1.6)	171	109 (63.7)	62 (36.3)	1.8 (1.2, 2.7)	1.121 (0.851, 1.475)	0.4137	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4852
Favorable	13	7 (53.8)	6 (46.2)	3.8 (0.1, NE)	19	17 (89.5)	2 (10.5)	1.2 (0.1, 4.9)	0.602 (0.248, 1.458)	0.2603	
Intermediate	195	129 (66.2)	66 (33.8)	1.6 (1.2, 2.0)	190	115 (60.5)	75 (39.5)	2.0 (1.3, 3.3)	1.069 (0.831, 1.376)	0.6073	
Unfavorable	19	12 (63.2)	7 (36.8)	1.1 (0.1, NE)	27	18 (66.7)	9 (33.3)	1.7 (0.4, 8.7)	0.854 (0.399, 1.826)	0.6648	
Unknown	38	29 (76.3)	9 (23.7)	1.6 (0.4, 2.2)	31	23 (74.2)	8 (25.8)	1.3 (0.2, 2.0)	0.853 (0.492, 1.479)	0.5667	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4108
0 - Fully Active	87	60 (69.0)	27 (31.0)	1.5 (0.8, 2.1)	97	62 (63.9)	35 (36.1)	1.7 (1.2, 6.5)	1.105 (0.774, 1.578)	0.5834	
1 - Restricted in Physically Strenuous Activity	133	91 (68.4)	42 (31.6)	1.6 (1.1, 2.2)	134	85 (63.4)	49 (36.6)	2.0 (1.2, 3.3)	1.001 (0.743, 1.347)	0.9933	
2 - Ambulatory and Capable of All Selfcare	45	26 (57.8)	19 (42.2)	2.0 (0.5, 16.2)	36	25 (69.4)	11 (30.6)	1.3 (0.4, 2.1)	0.724 (0.415, 1.262)	0.2577	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2369
≥3 to ≤25%	94	61 (64.9)	33 (35.1)	1.7 (1.2, 3.8)	98	59 (60.2)	39 (39.8)	2.0 (1.1, 11.8)	0.990 (0.690, 1.421)	0.9593	
>25% to ≤50%	141	93 (66.0)	48 (34.0)	1.6 (1.0, 2.2)	136	94 (69.1)	42 (30.9)	1.4 (1.0, 2.0)	0.870 (0.652, 1.160)	0.3423	
>50%	29	23 (79.3)	6 (20.7)	1.1 (0.3, 1.7)	34	20 (58.8)	14 (41.2)	4.0 (0.8, 6.8)	1.631 (0.892, 2.980)	0.1091	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6547
Yes	139	91 (65.5)	48 (34.5)	1.6 (1.1, 2.2)	137	92 (67.2)	45 (32.8)	1.6 (1.2, 2.4)	0.957 (0.715, 1.281)	0.7645	
No	116	79 (68.1)	37 (31.9)	1.5 (0.9, 2.0)	120	75 (62.5)	45 (37.5)	1.5 (1.1, 2.4)	1.034 (0.753, 1.421)	0.8317	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9379
≤60	164	109 (66.5)	55 (33.5)	1.6 (1.3, 2.2)	163	98 (60.1)	65 (39.9)	1.6 (1.2, 5.0)	1.020 (0.775, 1.341)	0.8838	
>60	101	68 (67.3)	33 (32.7)	1.4 (0.8, 2.1)	105	75 (71.4)	30 (28.6)	1.5 (1.2, 2.4)	0.965 (0.694, 1.341)	0.8262	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3879
<60	159	65 (40.9)	94 (59.1)	32.7 (6.5, NE)	160	63 (39.4)	97 (60.6)	NE (5.0, NE)	0.953 (0.674, 1.350)	0.7912	
≥60 - <65	37	20 (54.1)	17 (45.9)	2.0 (1.6, NE)	43	16 (37.2)	27 (62.8)	NE (2.3, NE)	1.523 (0.788, 2.943)	0.2109	
≥65	69	27 (39.1)	42 (60.9)	13.2 (2.1, NE)	65	30 (46.2)	35 (53.8)	4.0 (2.0, NE)	0.935 (0.556, 1.573)	0.7941	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5153
Male	124	52 (41.9)	72 (58.1)	28.2 (2.1, NE)	120	51 (42.5)	69 (57.5)	6.8 (2.4, NE)	0.927 (0.630, 1.366)	0.6973	
Female	141	60 (42.6)	81 (57.4)	20.1 (3.0, NE)	148	58 (39.2)	90 (60.8)	9.4 (4.7, NE)	1.097 (0.764, 1.574)	0.6147	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9942
White	157	71 (45.2)	86 (54.8)	6.3 (2.1, NE)	161	70 (43.5)	91 (56.5)	6.5 (2.7, NE)	1.019 (0.732, 1.418)	0.9157	
Non-white	108	41 (38.0)	67 (62.0)	30.7 (13.2, NE)	107	39 (36.4)	68 (63.6)	14.3 (5.2, NE)	1.015 (0.654, 1.574)	0.9487	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6257
North America	16	2 (12.5)	14 (87.5)	NE (1.5, NE)	18	3 (16.7)	15 (83.3)	NE (6.5, NE)	0.865 (0.143, 5.219)	0.8742	
Europe	161	73 (45.3)	88 (54.7)	6.5 (2.2, NE)	161	75 (46.6)	86 (53.4)	5.0 (2.0, NE)	0.905 (0.655, 1.250)	0.5420	
Asia/Other Regions	88	37 (42.0)	51 (58.0)	20.1 (3.0, NE)	89	31 (34.8)	58 (65.2)	NE (4.0, NE)	1.212 (0.751, 1.956)	0.4318	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4567
< 40x10^9/L	132	58 (43.9)	74 (56.1)	20.1 (2.1, NE)	133	55 (41.4)	78 (58.6)	7.0 (5.0, NE)	1.110 (0.767, 1.606)	0.5827	
≥ 40x10^9/L	133	54 (40.6)	79 (59.4)	NE (3.5, NE)	135	54 (40.0)	81 (60.0)	9.4 (2.3, NE)	0.932 (0.638, 1.360)	0.7154	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7757
Daunorubicin	123	47 (38.2)	76 (61.8)	28.2 (8.9, NE)	94	33 (35.1)	61 (64.9)	NE (5.0, NE)	1.013 (0.648, 1.581)	0.9580	
Idarubicin	142	65 (45.8)	77 (54.2)	6.3 (2.1, NE)	171	73 (42.7)	98 (57.3)	6.5 (3.3, NE)	1.116 (0.798, 1.559)	0.5252	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3542
Favorable	13	7 (53.8)	6 (46.2)	3.6 (0.5, NE)	19	8 (42.1)	11 (57.9)	NE (1.2, NE)	1.559 (0.557, 4.360)	0.3942	
Intermediate	195	76 (39.0)	119 (61.0)	32.7 (8.9, NE)	190	73 (38.4)	117 (61.6)	14.3 (4.7, NE)	0.954 (0.691, 1.316)	0.7712	
Unfavorable	19	10 (52.6)	9 (47.4)	2.0 (0.1, NE)	27	10 (37.0)	17 (63.0)	6.5 (2.1, NE)	1.709 (0.700, 4.171)	0.2243	
Unknown	38	19 (50.0)	19 (50.0)	6.5 (1.3, NE)	31	18 (58.1)	13 (41.9)	2.0 (0.8, NE)	0.774 (0.405, 1.479)	0.4330	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6011
0 - Fully Active	87	41 (47.1)	46 (52.9)	8.9 (2.0, NE)	97	41 (42.3)	56 (57.7)	7.0 (2.3, NE)	1.106 (0.717, 1.706)	0.6524	
1 - Restricted in Physically Strenuous Activity	133	57 (42.9)	76 (57.1)	28.2 (2.8, NE)	134	54 (40.3)	80 (59.7)	6.8 (4.7, NE)	1.047 (0.722, 1.520)	0.8079	
2 - Ambulatory and Capable of All Selfcare	45	14 (31.1)	31 (68.9)	NE (6.5, NE)	36	14 (38.9)	22 (61.1)	NE (1.4, NE)	0.696 (0.327, 1.483)	0.3440	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1392
≥3 to ≤25%	94	42 (44.7)	52 (55.3)	13.2 (2.8, NE)	98	31 (31.6)	67 (68.4)	NE (6.5, NE)	1.405 (0.883, 2.235)	0.1502	
>25% to ≤50%	141	56 (39.7)	85 (60.3)	NE (2.6, NE)	136	65 (47.8)	71 (52.2)	2.7 (1.8, 14.3)	0.803 (0.561, 1.148)	0.2250	
>50%	29	14 (48.3)	15 (51.7)	NE (1.2, NE)	34	13 (38.2)	21 (61.8)	6.5 (4.0, NE)	1.205 (0.565, 2.570)	0.6340	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7552
Yes	139	60 (43.2)	79 (56.8)	20.1 (3.0, NE)	137	57 (41.6)	80 (58.4)	9.4 (4.0, NE)	1.078 (0.750, 1.549)	0.6857	
No	116	49 (42.2)	67 (57.8)	28.2 (2.2, NE)	120	47 (39.2)	73 (60.8)	6.5 (2.4, NE)	0.985 (0.659, 1.472)	0.9388	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6838
≤60	164	68 (41.5)	96 (58.5)	32.7 (6.5, NE)	163	63 (38.7)	100 (61.3)	NE (5.2, NE)	0.991 (0.703, 1.397)	0.9607	
>60	101	44 (43.6)	57 (56.4)	6.3 (1.9, NE)	105	46 (43.8)	59 (56.2)	6.5 (2.4, NE)	1.084 (0.717, 1.640)	0.7091	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Oedema peripheral

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9326
<60	159	17 (10.7)	142 (89.3)	NE (NE, NE)	160	21 (13.1)	139 (86.9)	NE (NE, NE)	0.680 (0.357, 1.294)	0.2376	
≥60 - <65	37	6 (16.2)	31 (83.8)	NE (22.1, NE)	43	8 (18.6)	35 (81.4)	NE (10.1, NE)	0.694 (0.238, 2.024)	0.5002	
≥65	69	7 (10.1)	62 (89.9)	NE (NE, NE)	65	8 (12.3)	57 (87.7)	NE (NE, NE)	0.823 (0.298, 2.271)	0.7081	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Oedema peripheral

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5139
Male	124	15 (12.1)	109 (87.9)	NE (NE, NE)	120	15 (12.5)	105 (87.5)	NE (NE, NE)	0.824 (0.401, 1.694)	0.5997	
Female	141	15 (10.6)	126 (89.4)	NE (NE, NE)	148	22 (14.9)	126 (85.1)	NE (NE, NE)	0.616 (0.319, 1.189)	0.1455	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Oedema peripheral

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4702
White	157	15 (9.6)	142 (90.4)	NE (NE, NE)	161	22 (13.7)	139 (86.3)	NE (NE, NE)	0.623 (0.322, 1.204)	0.1563	
Non-white	108	15 (13.9)	93 (86.1)	NE (NE, NE)	107	15 (14.0)	92 (86.0)	NE (NE, NE)	0.822 (0.401, 1.686)	0.5903	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Oedema peripheral

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.1425
North America	16	1 (6.3)	15 (93.8)	NE (17.9, NE)	18	7 (38.9)	11 (61.1)	11.9 (0.5, NE)	0.138 (0.017, 1.123)	0.0305	
Europe	161	13 (8.1)	148 (91.9)	NE (NE, NE)	161	18 (11.2)	143 (88.8)	NE (NE, NE)	0.633 (0.309, 1.297)	0.2074	
Asia/Other Regions	88	16 (18.2)	72 (81.8)	NE (NE, NE)	89	12 (13.5)	77 (86.5)	NE (NE, NE)	1.134 (0.535, 2.404)	0.7443	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Oedema peripheral

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7525
< 40x10^9/L	132	13 (9.8)	119 (90.2)	NE (NE, NE)	133	16 (12.0)	117 (88.0)	NE (NE, NE)	0.759 (0.365, 1.581)	0.4612	
≥ 40x10^9/L	133	17 (12.8)	116 (87.2)	NE (NE, NE)	135	21 (15.6)	114 (84.4)	NE (NE, NE)	0.654 (0.343, 1.247)	0.1939	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Oedema peripheral

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6151
Daunorubicin	123	15 (12.2)	108 (87.8)	NE (NE, NE)	94	12 (12.8)	82 (87.2)	NE (NE, NE)	0.792 (0.369, 1.700)	0.5502	
Idarubicin	142	15 (10.6)	127 (89.4)	NE (NE, NE)	171	25 (14.6)	146 (85.4)	NE (NE, NE)	0.624 (0.328, 1.186)	0.1459	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Oedema peripheral

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7796
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	3 (15.8)	16 (84.2)	NE (10.3, NE)	0.517 (0.053, 5.015)	0.5682	
Intermediate	195	24 (12.3)	171 (87.7)	NE (NE, NE)	190	24 (12.6)	166 (87.4)	NE (NE, NE)	0.825 (0.467, 1.458)	0.5086	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	8 (29.6)	19 (70.4)	NE (3.3, NE)	0.000 (0.000, NE)	0.0098	
Unknown	38	5 (13.2)	33 (86.8)	NE (22.1, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	1.791 (0.346, 9.277)	0.4811	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Oedema peripheral

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.0731
0 - Fully Active	87	11 (12.6)	76 (87.4)	NE (NE, NE)	97	7 (7.2)	90 (92.8)	NE (NE, NE)	1.622 (0.628, 4.191)	0.3130	
1 - Restricted in Physically Strenuous Activity	133	16 (12.0)	117 (88.0)	NE (NE, NE)	134	23 (17.2)	111 (82.8)	NE (NE, NE)	0.573 (0.302, 1.089)	0.0855	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	7 (19.4)	29 (80.6)	NE (7.8, NE)	0.280 (0.071, 1.102)	0.0534	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Oedema peripheral

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5135
≥3 to ≤25%	94	8 (8.5)	86 (91.5)	NE (NE, NE)	98	15 (15.3)	83 (84.7)	NE (NE, NE)	0.496 (0.210, 1.173)	0.1039	
>25% to ≤50%	141	19 (13.5)	122 (86.5)	NE (NE, NE)	136	20 (14.7)	116 (85.3)	NE (NE, NE)	0.798 (0.425, 1.500)	0.4844	
>50%	29	3 (10.3)	26 (89.7)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	1.264 (0.202, 7.909)	0.8021	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Oedema peripheral

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5045
Yes	139	17 (12.2)	122 (87.8)	NE (NE, NE)	137	23 (16.8)	114 (83.2)	NE (NE, NE)	0.628 (0.334, 1.178)	0.1439	
No	116	12 (10.3)	104 (89.7)	NE (NE, NE)	120	12 (10.0)	108 (90.0)	NE (NE, NE)	0.899 (0.403, 2.008)	0.7959	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Oedema peripheral

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8956
≤60	164	18 (11.0)	146 (89.0)	NE (NE, NE)	163	21 (12.9)	142 (87.1)	NE (NE, NE)	0.709 (0.376, 1.336)	0.2856	
>60	101	12 (11.9)	89 (88.1)	NE (23.2, NE)	105	16 (15.2)	89 (84.8)	NE (NE, NE)	0.730 (0.345, 1.545)	0.4098	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Fatigue

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5501
<60	159	15 (9.4)	144 (90.6)	NE (NE, NE)	160	14 (8.8)	146 (91.3)	NE (NE, NE)	0.894 (0.429, 1.860)	0.7645	
≥60 - <65	37	7 (18.9)	30 (81.1)	NE (NE, NE)	43	4 (9.3)	39 (90.7)	NE (30.2, NE)	2.051 (0.599, 7.027)	0.2427	
≥65	69	7 (10.1)	62 (89.9)	NE (NE, NE)	65	5 (7.7)	60 (92.3)	NE (NE, NE)	1.365 (0.433, 4.302)	0.5937	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Fatigue

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6095
Male	124	14 (11.3)	110 (88.7)	NE (NE, NE)	120	9 (7.5)	111 (92.5)	NE (NE, NE)	1.403 (0.606, 3.248)	0.4275	
Female	141	15 (10.6)	126 (89.4)	NE (NE, NE)	148	14 (9.5)	134 (90.5)	NE (NE, NE)	0.996 (0.479, 2.070)	0.9919	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Fatigue

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2200
White	157	17 (10.8)	140 (89.2)	NE (NE, NE)	161	17 (10.6)	144 (89.4)	NE (NE, NE)	0.891 (0.453, 1.752)	0.7383	
Non-white	108	12 (11.1)	96 (88.9)	NE (NE, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	1.915 (0.718, 5.106)	0.1862	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Fatigue

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8040
North America	16	5 (31.3)	11 (68.8)	NE (1.4, NE)	18	6 (33.3)	12 (66.7)	30.2 (3.0, NE)	1.511 (0.448, 5.092)	0.5030	
Europe	161	15 (9.3)	146 (90.7)	NE (NE, NE)	161	12 (7.5)	149 (92.5)	NE (NE, NE)	1.063 (0.496, 2.281)	0.8740	
Asia/Other Regions	88	9 (10.2)	79 (89.8)	NE (NE, NE)	89	5 (5.6)	84 (94.4)	NE (NE, NE)	1.699 (0.568, 5.077)	0.3361	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Fatigue

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2992
< 40x10^9/L	132	15 (11.4)	117 (88.6)	NE (NE, NE)	133	10 (7.5)	123 (92.5)	NE (NE, NE)	1.543 (0.693, 3.438)	0.2842	
≥ 40x10^9/L	133	14 (10.5)	119 (89.5)	NE (NE, NE)	135	13 (9.6)	122 (90.4)	NE (NE, NE)	0.878 (0.410, 1.881)	0.7368	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Fatigue

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4337
Daunorubicin	123	14 (11.4)	109 (88.6)	NE (NE, NE)	94	10 (10.6)	84 (89.4)	NE (30.2, NE)	0.857 (0.377, 1.946)	0.7109	
Idarubicin	142	15 (10.6)	127 (89.4)	NE (NE, NE)	171	12 (7.0)	159 (93.0)	NE (NE, NE)	1.424 (0.666, 3.045)	0.3605	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Fatigue

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4620
Favorable	13	0	13 (100)	NE (NE, NE)	19	5 (26.3)	14 (73.7)	NE (6.6, NE)	0.000 (0.000, NE)	0.0894	
Intermediate	195	26 (13.3)	169 (86.7)	NE (NE, NE)	190	14 (7.4)	176 (92.6)	NE (NE, NE)	1.613 (0.841, 3.095)	0.1464	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (8.4, NE)	27	1 (3.7)	26 (96.3)	NE (11.8, NE)	2.742 (0.248, 30.274)	0.3907	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (17.0, NE)	0.278 (0.029, 2.693)	0.2379	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Fatigue

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5482
0 - Fully Active	87	9 (10.3)	78 (89.7)	NE (NE, NE)	97	9 (9.3)	88 (90.7)	NE (NE, NE)	1.004 (0.398, 2.533)	0.9930	
1 - Restricted in Physically Strenuous Activity	133	13 (9.8)	120 (90.2)	NE (NE, NE)	134	12 (9.0)	122 (91.0)	NE (NE, NE)	0.975 (0.444, 2.143)	0.9492	
2 - Ambulatory and Capable of All Selfcare	45	7 (15.6)	38 (84.4)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	2.902 (0.600, 14.039)	0.1646	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Fatigue

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9002
≥3 to ≤25%	94	10 (10.6)	84 (89.4)	NE (NE, NE)	98	10 (10.2)	88 (89.8)	NE (NE, NE)	1.010 (0.420, 2.432)	0.9799	
>25% to ≤50%	141	18 (12.8)	123 (87.2)	NE (NE, NE)	136	12 (8.8)	124 (91.2)	NE (NE, NE)	1.295 (0.622, 2.696)	0.4880	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	1.140 (0.071, 18.227)	0.9265	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Fatigue

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6358
Yes	139	19 (13.7)	120 (86.3)	NE (NE, NE)	137	16 (11.7)	121 (88.3)	NE (NE, NE)	1.055 (0.541, 2.056)	0.8748	
No	116	10 (8.6)	106 (91.4)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	1.399 (0.532, 3.682)	0.4947	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Fatigue

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2679
≤60	164	15 (9.1)	149 (90.9)	NE (NE, NE)	163	14 (8.6)	149 (91.4)	NE (NE, NE)	0.877 (0.421, 1.827)	0.7263	
>60	101	14 (13.9)	87 (86.1)	NE (NE, NE)	105	9 (8.6)	96 (91.4)	NE (30.2, NE)	1.670 (0.722, 3.860)	0.2255	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Asthenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0486
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	14 (8.8)	146 (91.3)	NE (NE, NE)	0.335 (0.121, 0.931)	0.0277	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	3 (7.0)	40 (93.0)	NE (NE, NE)	1.037 (0.207, 5.183)	0.9648	
≥65	69	8 (11.6)	61 (88.4)	NE (NE, NE)	65	4 (6.2)	61 (93.8)	NE (NE, NE)	2.308 (0.693, 7.687)	0.1610	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Asthenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2182
Male	124	8 (6.5)	116 (93.5)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	1.206 (0.418, 3.483)	0.7284	
Female	141	8 (5.7)	133 (94.3)	NE (NE, NE)	148	15 (10.1)	133 (89.9)	NE (NE, NE)	0.516 (0.218, 1.218)	0.1244	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Asthenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5811
White	157	10 (6.4)	147 (93.6)	NE (NE, NE)	161	15 (9.3)	146 (90.7)	NE (NE, NE)	0.638 (0.286, 1.421)	0.2674	
Non-white	108	6 (5.6)	102 (94.4)	NE (NE, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	0.909 (0.293, 2.822)	0.8689	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Asthenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5734
North America	16	1 (6.3)	15 (93.8)	NE (2.2, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.1824	
Europe	161	10 (6.2)	151 (93.8)	NE (NE, NE)	161	17 (10.6)	144 (89.4)	NE (NE, NE)	0.527 (0.241, 1.154)	0.1037	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	1.120 (0.300, 4.186)	0.8659	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Asthenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4464
< 40x10^9/L	132	9 (6.8)	123 (93.2)	NE (NE, NE)	133	10 (7.5)	123 (92.5)	NE (NE, NE)	0.910 (0.369, 2.241)	0.8371	
≥ 40x10^9/L	133	7 (5.3)	126 (94.7)	NE (NE, NE)	135	11 (8.1)	124 (91.9)	NE (NE, NE)	0.554 (0.214, 1.435)	0.2177	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Asthenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9242
Daunorubicin	123	7 (5.7)	116 (94.3)	NE (NE, NE)	94	7 (7.4)	87 (92.6)	NE (NE, NE)	0.689 (0.241, 1.970)	0.4845	
Idarubicin	142	9 (6.3)	133 (93.7)	NE (NE, NE)	171	14 (8.2)	157 (91.8)	NE (NE, NE)	0.730 (0.316, 1.688)	0.4599	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Asthenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8610
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	0.000 (0.000, NE)	0.4081	
Intermediate	195	14 (7.2)	181 (92.8)	NE (NE, NE)	190	14 (7.4)	176 (92.6)	NE (NE, NE)	0.879 (0.418, 1.846)	0.7343	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.000 (0.000, NE)	0.2400	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (NE, NE)	0.372 (0.068, 2.037)	0.2353	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Asthenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9883
0 - Fully Active	87	8 (9.2)	79 (90.8)	NE (NE, NE)	97	11 (11.3)	86 (88.7)	NE (NE, NE)	0.745 (0.299, 1.856)	0.5270	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	10 (7.5)	124 (92.5)	NE (NE, NE)	0.663 (0.252, 1.743)	0.4013	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.5930	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Asthenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6850
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	7 (7.1)	91 (92.9)	NE (NE, NE)	0.592 (0.173, 2.025)	0.3981	
>25% to ≤50%	141	10 (7.1)	131 (92.9)	NE (NE, NE)	136	13 (9.6)	123 (90.4)	NE (NE, NE)	0.690 (0.302, 1.576)	0.3771	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (6.8, NE)	1.931 (0.172, 21.723)	0.5878	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Asthenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5198
Yes	139	10 (7.2)	129 (92.8)	NE (NE, NE)	137	11 (8.0)	126 (92.0)	NE (NE, NE)	0.847 (0.359, 1.998)	0.7043	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	10 (8.3)	110 (91.7)	NE (NE, NE)	0.568 (0.206, 1.564)	0.2674	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Asthenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0138
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	14 (8.6)	149 (91.4)	NE (NE, NE)	0.330 (0.119, 0.918)	0.0255	
>60	101	11 (10.9)	90 (89.1)	NE (NE, NE)	105	7 (6.7)	98 (93.3)	NE (NE, NE)	1.757 (0.680, 4.542)	0.2383	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Non-cardiac chest pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7594
<60	159	9 (5.7)	150 (94.3)	NE (NE, NE)	160	3 (1.9)	157 (98.1)	NE (NE, NE)	2.806 (0.758, 10.388)	0.1065	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	1.203 (0.075, 19.237)	0.8958	
≥65	69	4 (5.8)	65 (94.2)	NE (26.1, NE)	65	1 (1.5)	64 (98.5)	NE (NE, NE)	4.213 (0.471, 37.709)	0.1617	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Non-cardiac chest pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4184
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	5.352 (0.644, 44.505)	0.0818	
Female	141	8 (5.7)	133 (94.3)	NE (NE, NE)	148	4 (2.7)	144 (97.3)	NE (NE, NE)	2.103 (0.633, 6.989)	0.2143	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Non-cardiac chest pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7288
White	157	10 (6.4)	147 (93.6)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	2.449 (0.767, 7.823)	0.1182	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	1 (0.9)	106 (99.1)	NE (NE, NE)	3.726 (0.416, 33.402)	0.2072	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Non-cardiac chest pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6839
North America	16	3 (18.8)	13 (81.3)	NE (2.3, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	4.175 (0.432, 40.378)	0.1803	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	1.819 (0.454, 7.293)	0.3912	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	1 (1.1)	88 (98.9)	NE (NE, NE)	5.040 (0.589, 43.146)	0.1004	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Non-cardiac chest pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9876
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	2 (1.5)	131 (98.5)	NE (NE, NE)	2.539 (0.492, 13.105)	0.2487	
≥ 40x10^9/L	133	9 (6.8)	124 (93.2)	NE (NE, NE)	135	3 (2.2)	132 (97.8)	NE (NE, NE)	2.681 (0.725, 9.924)	0.1242	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Non-cardiac chest pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1150
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	0.749 (0.105, 5.315)	0.7715	
Idarubicin	142	12 (8.5)	130 (91.5)	NE (NE, NE)	171	3 (1.8)	168 (98.2)	NE (NE, NE)	4.633 (1.306, 16.433)	0.0090	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Non-cardiac chest pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9664
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	3 (1.6)	187 (98.4)	NE (NE, NE)	2.757 (0.745, 10.200)	0.1129	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (6.1, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.299 (0.081, 20.918)	0.8532	
Unknown	38	4 (10.5)	34 (89.5)	NE (26.1, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	3.298 (0.364, 29.851)	0.2610	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Non-cardiac chest pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9636
0 - Fully Active	87	6 (6.9)	81 (93.1)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	3.073 (0.619, 15.265)	0.1484	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	2 (1.5)	132 (98.5)	NE (NE, NE)	2.460 (0.477, 12.692)	0.2661	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	2.360 (0.243, 22.880)	0.4453	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Non-cardiac chest pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9999
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	0	98 (100)	NE (NE, NE)	NE (0.000, NE)	0.0736	
>25% to ≤50%	141	8 (5.7)	133 (94.3)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	1.484 (0.485, 4.542)	0.4863	
>50%	29	3 (10.3)	26 (89.7)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.0898	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Non-cardiac chest pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6947
Yes	139	10 (7.2)	129 (92.8)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	2.397 (0.751, 7.657)	0.1278	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	3.811 (0.425, 34.163)	0.1984	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Non-cardiac chest pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9858
≤60	164	9 (5.5)	155 (94.5)	NE (NE, NE)	163	3 (1.8)	160 (98.2)	NE (NE, NE)	2.758 (0.745, 10.210)	0.1130	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	2.778 (0.539, 14.326)	0.2025	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6993
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	3 (1.9)	157 (98.1)	NE (NE, NE)	2.248 (0.580, 8.707)	0.2286	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (37.3, NE)	1.326 (0.082, 21.305)	0.8418	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	4 (6.2)	61 (93.8)	NE (NE, NE)	0.985 (0.246, 3.938)	0.9824	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9378
Male	124	5 (4.0)	119 (96.0)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	1.573 (0.376, 6.586)	0.5317	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	5 (3.4)	143 (96.6)	NE (NE, NE)	1.426 (0.452, 4.496)	0.5426	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9815
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	1.444 (0.406, 5.127)	0.5681	
Non-white	108	6 (5.6)	102 (94.4)	NE (NE, NE)	107	4 (3.7)	103 (96.3)	NE (37.3, NE)	1.438 (0.405, 5.110)	0.5719	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9989
North America	16	0	16 (100)	NE (NE, NE)	18	2 (11.1)	16 (88.9)	NE (NE, NE)	0.000 (0.000, NE)	0.3230	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	1.876 (0.468, 7.516)	0.3662	
Asia/Other Regions	88	6 (6.8)	82 (93.2)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (37.3, NE)	1.970 (0.492, 7.893)	0.3291	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1115
< 40x10^9/L	132	7 (5.3)	125 (94.7)	NE (NE, NE)	133	2 (1.5)	131 (98.5)	NE (NE, NE)	3.782 (0.785, 18.216)	0.0746	
≥ 40x10^9/L	133	5 (3.8)	128 (96.2)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	0.749 (0.228, 2.461)	0.6331	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7446
Daunorubicin	123	5 (4.1)	118 (95.9)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	1.922 (0.373, 9.906)	0.4272	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	1.329 (0.446, 3.959)	0.6087	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9985
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.2267	
Intermediate	195	8 (4.1)	187 (95.9)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	1.052 (0.381, 2.905)	0.9216	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (6.1, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.225 (0.076, 19.862)	0.8864	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.1764	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1338
0 - Fully Active	87	7 (8.0)	80 (92.0)	NE (NE, NE)	97	1 (1.0)	96 (99.0)	NE (NE, NE)	7.647 (0.941, 62.177)	0.0246	
1 - Restricted in Physically Strenuous Activity	133	4 (3.0)	129 (97.0)	NE (NE, NE)	134	6 (4.5)	128 (95.5)	NE (37.3, NE)	0.658 (0.186, 2.334)	0.5141	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	0.749 (0.047, 11.986)	0.8377	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8251
≥3 to ≤25%	94	6 (6.4)	88 (93.6)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	1.652 (0.466, 5.857)	0.4319	
>25% to ≤50%	141	4 (2.8)	137 (97.2)	NE (NE, NE)	136	4 (2.9)	132 (97.1)	NE (NE, NE)	0.864 (0.216, 3.466)	0.8369	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.1485	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7006
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	1.701 (0.498, 5.816)	0.3912	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	1.207 (0.324, 4.502)	0.7790	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4353
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	3 (1.8)	160 (98.2)	NE (NE, NE)	2.212 (0.571, 8.568)	0.2384	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (37.3, NE)	1.048 (0.303, 3.620)	0.9413	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Catheter site pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7307
<60	159	6 (3.8)	153 (96.2)	NE (NE, NE)	160	4 (2.5)	156 (97.5)	NE (NE, NE)	1.502 (0.424, 5.322)	0.5264	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	2.315 (0.210, 25.531)	0.4805	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	1 (1.5)	64 (98.5)	NE (NE, NE)	4.045 (0.452, 36.197)	0.1758	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Catheter site pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8036
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	2.288 (0.592, 8.847)	0.2172	
Female	141	5 (3.5)	136 (96.5)	NE (NE, NE)	148	3 (2.0)	145 (98.0)	NE (NE, NE)	1.795 (0.429, 7.513)	0.4164	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Catheter site pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7784
White	157	7 (4.5)	150 (95.5)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	1.855 (0.543, 6.337)	0.3164	
Non-white	108	5 (4.6)	103 (95.4)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	2.487 (0.483, 12.821)	0.2597	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Catheter site pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4368
North America	16	4 (25.0)	12 (75.0)	NE (1.6, NE)	18	2 (11.1)	16 (88.9)	NE (NE, NE)	2.995 (0.537, 16.703)	0.1902	
Europe	161	3 (1.9)	158 (98.1)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	1.016 (0.205, 5.036)	0.9842	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	1 (1.1)	88 (98.9)	NE (NE, NE)	5.098 (0.596, 43.633)	0.0977	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Catheter site pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9915
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	0	133 (100)	NE (NE, NE)	NE (0.000, NE)	0.0199	
≥ 40x10^9/L	133	7 (5.3)	126 (94.7)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	1.134 (0.381, 3.375)	0.8233	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Catheter site pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4131
Daunorubicin	123	5 (4.1)	118 (95.9)	NE (NE, NE)	94	3 (3.2)	91 (96.8)	NE (NE, NE)	1.264 (0.302, 5.290)	0.7489	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	3 (1.8)	168 (98.2)	NE (NE, NE)	2.886 (0.746, 11.163)	0.1077	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Catheter site pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6970
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	0.000 (0.000, NE)	0.4561	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	2 (1.1)	188 (98.9)	NE (NE, NE)	4.355 (0.941, 20.160)	0.0397	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.792 (0.072, 8.733)	0.8483	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	1.772 (0.161, 19.548)	0.6410	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Catheter site pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8620
0 - Fully Active	87	2 (2.3)	85 (97.7)	NE (NE, NE)	97	0	97 (100)	NE (NE, NE)	NE (0.000, NE)	0.1393	
1 - Restricted in Physically Strenuous Activity	133	6 (4.5)	127 (95.5)	NE (NE, NE)	134	3 (2.2)	131 (97.8)	NE (NE, NE)	2.035 (0.509, 8.136)	0.3054	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	3 (8.3)	33 (91.7)	NE (NE, NE)	1.137 (0.254, 5.085)	0.8663	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Catheter site pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8254
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	1.468 (0.329, 6.562)	0.6129	
>25% to ≤50%	141	6 (4.3)	135 (95.7)	NE (NE, NE)	136	2 (1.5)	134 (98.5)	NE (NE, NE)	2.974 (0.600, 14.737)	0.1609	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	2.198 (0.198, 24.385)	0.5104	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Catheter site pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1865
Yes	139	6 (4.3)	133 (95.7)	NE (NE, NE)	137	1 (0.7)	136 (99.3)	NE (NE, NE)	6.240 (0.752, 51.814)	0.0520	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	1.208 (0.368, 3.957)	0.7564	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Catheter site pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6484
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	4 (2.5)	159 (97.5)	NE (NE, NE)	1.720 (0.503, 5.876)	0.3814	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	2.718 (0.527, 14.009)	0.2131	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Chills

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8706
<60	159	6 (3.8)	153 (96.2)	NE (NE, NE)	160	9 (5.6)	151 (94.4)	NE (NE, NE)	0.650 (0.231, 1.827)	0.4104	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (20.5, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.097 (0.154, 7.802)	0.9263	
≥65	69	0	69 (100)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	0.000 (0.000, NE)	0.0864	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Chills

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3571
Male	124	1 (0.8)	123 (99.2)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.241 (0.027, 2.157)	0.1668	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	10 (6.8)	138 (93.2)	NE (NE, NE)	0.707 (0.269, 1.858)	0.4797	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Chills

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2490
White	157	7 (4.5)	150 (95.5)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	0.764 (0.284, 2.056)	0.5940	
Non-white	108	1 (0.9)	107 (99.1)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	0.197 (0.023, 1.682)	0.0980	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Chills

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7638
North America	16	0	16 (100)	NE (NE, NE)	18	3 (16.7)	15 (83.3)	NE (NE, NE)	0.000 (0.000, NE)	0.0926	
Europe	161	7 (4.3)	154 (95.7)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	0.820 (0.297, 2.267)	0.7013	
Asia/Other Regions	88	1 (1.1)	87 (98.9)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	0.336 (0.035, 3.234)	0.3217	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Chills

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0952
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	4 (3.0)	129 (97.0)	NE (NE, NE)	1.291 (0.346, 4.814)	0.7028	
≥ 40x10^9/L	133	3 (2.3)	130 (97.7)	NE (NE, NE)	135	10 (7.4)	125 (92.6)	NE (NE, NE)	0.282 (0.077, 1.025)	0.0401	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Chills

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9858
Daunorubicin	123	0	123 (100)	NE (NE, NE)	94	7 (7.4)	87 (92.6)	NE (NE, NE)	0.000 (0.000, NE)	0.0021	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	1.578 (0.547, 4.552)	0.3944	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Chills

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3910
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	0.000 (0.000, NE)	0.4268	
Intermediate	195	3 (1.5)	192 (98.5)	NE (NE, NE)	190	10 (5.3)	180 (94.7)	NE (NE, NE)	0.275 (0.076, 1.000)	0.0359	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Unknown	38	5 (13.2)	33 (86.8)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	1.573 (0.376, 6.585)	0.5318	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Chills

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9922
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	6 (6.2)	91 (93.8)	NE (NE, NE)	0.529 (0.132, 2.116)	0.3597	
1 - Restricted in Physically Strenuous Activity	133	3 (2.3)	130 (97.7)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	0.581 (0.139, 2.431)	0.4512	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	3 (8.3)	33 (91.7)	NE (NE, NE)	0.630 (0.105, 3.771)	0.6092	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Chills

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7718
≥3 to ≤25%	94	1 (1.1)	93 (98.9)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	0.356 (0.037, 3.419)	0.3494	
>25% to ≤50%	141	5 (3.5)	136 (96.5)	NE (NE, NE)	136	9 (6.6)	127 (93.4)	NE (NE, NE)	0.515 (0.172, 1.537)	0.2258	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.943 (0.132, 6.743)	0.9538	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Chills

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5704
Yes	139	6 (4.3)	133 (95.7)	NE (NE, NE)	137	11 (8.0)	126 (92.0)	NE (NE, NE)	0.518 (0.191, 1.402)	0.1878	
No	116	2 (1.7)	114 (98.3)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.037 (0.146, 7.364)	0.9708	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Chills

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7293
≤60	164	6 (3.7)	158 (96.3)	NE (NE, NE)	163	9 (5.5)	154 (94.5)	NE (NE, NE)	0.641 (0.228, 1.802)	0.3952	
>60	101	2 (2.0)	99 (98.0)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	0.449 (0.087, 2.317)	0.3262	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9404
<60	159	104 (65.4)	55 (34.6)	2.1 (1.6, 4.2)	160	88 (55.0)	72 (45.0)	2.3 (1.5, 4.1)	1.094 (0.823, 1.454)	0.5304	
≥60 - <65	37	26 (70.3)	11 (29.7)	1.9 (1.1, 5.4)	43	23 (53.5)	20 (46.5)	1.6 (0.9, NE)	1.183 (0.673, 2.077)	0.5530	
≥65	69	38 (55.1)	31 (44.9)	2.0 (1.5, 9.7)	65	32 (49.2)	33 (50.8)	2.7 (1.5, NE)	1.069 (0.667, 1.712)	0.7669	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1676
Male	124	77 (62.1)	47 (37.9)	2.0 (1.6, 2.6)	120	55 (45.8)	65 (54.2)	3.9 (1.6, NE)	1.331 (0.940, 1.882)	0.1052	
Female	141	91 (64.5)	50 (35.5)	2.2 (1.6, 5.9)	148	88 (59.5)	60 (40.5)	1.6 (1.2, 3.0)	0.960 (0.715, 1.287)	0.7957	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5595
White	157	104 (66.2)	53 (33.8)	1.9 (1.6, 2.5)	161	92 (57.1)	69 (42.9)	1.6 (1.3, 3.0)	1.042 (0.786, 1.381)	0.7659	
Non-white	108	64 (59.3)	44 (40.7)	4.5 (1.6, 7.5)	107	51 (47.7)	56 (52.3)	4.1 (1.6, NE)	1.179 (0.815, 1.704)	0.3752	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.1827
North America	16	10 (62.5)	6 (37.5)	1.7 (0.2, NE)	18	14 (77.8)	4 (22.2)	0.3 (0.1, 3.0)	0.652 (0.287, 1.485)	0.3211	
Europe	161	102 (63.4)	59 (36.6)	2.0 (1.6, 5.3)	161	87 (54.0)	74 (46.0)	2.5 (1.5, 6.2)	1.050 (0.788, 1.400)	0.7339	
Asia/Other Regions	88	56 (63.6)	32 (36.4)	2.1 (1.5, 6.0)	89	42 (47.2)	47 (52.8)	4.0 (1.6, NE)	1.341 (0.898, 2.002)	0.1482	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3644
< 40x10^9/L	132	82 (62.1)	50 (37.9)	2.0 (1.5, 5.8)	133	77 (57.9)	56 (42.1)	1.7 (1.3, 4.0)	0.988 (0.723, 1.351)	0.9440	
≥ 40x10^9/L	133	86 (64.7)	47 (35.3)	2.1 (1.6, 5.3)	135	66 (48.9)	69 (51.1)	2.9 (1.6, 10.3)	1.205 (0.873, 1.661)	0.2514	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6664
Daunorubicin	123	82 (66.7)	41 (33.3)	1.8 (1.4, 2.9)	94	52 (55.3)	42 (44.7)	1.6 (1.2, 5.2)	1.127 (0.795, 1.596)	0.4965	
Idarubicin	142	86 (60.6)	56 (39.4)	2.5 (1.7, 6.5)	171	89 (52.0)	82 (48.0)	2.7 (1.6, 6.2)	1.034 (0.768, 1.392)	0.8207	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.2985
Favorable	13	8 (61.5)	5 (38.5)	1.7 (0.7, NE)	19	16 (84.2)	3 (15.8)	0.5 (0.2, 1.6)	0.511 (0.218, 1.199)	0.1227	
Intermediate	195	120 (61.5)	75 (38.5)	2.1 (1.7, 4.5)	190	98 (51.6)	92 (48.4)	2.7 (1.6, 6.2)	1.089 (0.834, 1.422)	0.5250	
Unfavorable	19	12 (63.2)	7 (36.8)	2.5 (0.1, NE)	27	15 (55.6)	12 (44.4)	2.9 (0.6, NE)	1.116 (0.517, 2.409)	0.8052	
Unknown	38	28 (73.7)	10 (26.3)	1.6 (0.4, 8.6)	31	14 (45.2)	17 (54.8)	NE (1.2, NE)	1.670 (0.876, 3.184)	0.1110	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1923
0 - Fully Active	87	51 (58.6)	36 (41.4)	2.6 (1.8, 8.2)	97	56 (57.7)	41 (42.3)	2.3 (1.2, 5.2)	0.861 (0.588, 1.260)	0.4428	
1 - Restricted in Physically Strenuous Activity	133	88 (66.2)	45 (33.8)	1.9 (1.6, 5.3)	134	65 (48.5)	69 (51.5)	2.9 (1.6, NE)	1.312 (0.952, 1.810)	0.0942	
2 - Ambulatory and Capable of All Selfcare	45	29 (64.4)	16 (35.6)	2.1 (0.9, 6.7)	36	21 (58.3)	15 (41.7)	1.6 (0.9, 7.1)	1.075 (0.612, 1.888)	0.8055	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.0938
≥3 to ≤25%	94	59 (62.8)	35 (37.2)	2.1 (1.6, 6.4)	98	60 (61.2)	38 (38.8)	1.5 (1.0, 2.1)	0.772 (0.536, 1.113)	0.1676	
>25% to ≤50%	141	88 (62.4)	53 (37.6)	1.9 (1.6, 4.2)	136	67 (49.3)	69 (50.7)	3.6 (1.7, NE)	1.332 (0.969, 1.831)	0.0753	
>50%	29	20 (69.0)	9 (31.0)	2.2 (1.6, 6.7)	34	16 (47.1)	18 (52.9)	3.1 (0.5, NE)	1.203 (0.622, 2.328)	0.5779	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4603
Yes	139	86 (61.9)	53 (38.1)	2.9 (1.6, 6.7)	137	79 (57.7)	58 (42.3)	2.3 (1.6, 5.2)	0.986 (0.726, 1.339)	0.9403	
No	116	75 (64.7)	41 (35.3)	1.9 (1.6, 2.5)	120	61 (50.8)	59 (49.2)	2.0 (1.2, 4.1)	1.177 (0.839, 1.652)	0.3438	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7176
≤60	164	108 (65.9)	56 (34.1)	2.1 (1.6, 3.7)	163	88 (54.0)	75 (46.0)	2.5 (1.6, 5.2)	1.135 (0.856, 1.504)	0.3768	
>60	101	60 (59.4)	41 (40.6)	2.0 (1.6, 5.9)	105	55 (52.4)	50 (47.6)	1.8 (1.4, 7.1)	1.047 (0.726, 1.512)	0.7959	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8020
<60	159	72 (45.3)	87 (54.7)	4.2 (2.2, NE)	160	71 (44.4)	89 (55.6)	4.1 (2.7, NE)	0.975 (0.702, 1.354)	0.8829	
≥60 - <65	37	18 (48.6)	19 (51.4)	2.9 (1.6, NE)	43	16 (37.2)	27 (62.8)	NE (1.5, NE)	1.240 (0.632, 2.434)	0.5238	
≥65	69	27 (39.1)	42 (60.9)	18.9 (1.7, NE)	65	26 (40.0)	39 (60.0)	NE (1.6, NE)	0.965 (0.563, 1.654)	0.9015	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.0924
Male	124	56 (45.2)	68 (54.8)	3.9 (2.1, NE)	120	42 (35.0)	78 (65.0)	NE (4.1, NE)	1.302 (0.872, 1.943)	0.1940	
Female	141	61 (43.3)	80 (56.7)	5.5 (2.2, NE)	148	71 (48.0)	77 (52.0)	3.4 (1.7, NE)	0.827 (0.587, 1.165)	0.2782	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6229
White	157	74 (47.1)	83 (52.9)	2.8 (1.9, NE)	161	74 (46.0)	87 (54.0)	3.1 (1.6, NE)	0.965 (0.699, 1.332)	0.8339	
Non-white	108	43 (39.8)	65 (60.2)	18.9 (3.4, NE)	107	39 (36.4)	68 (63.6)	NE (4.1, NE)	1.091 (0.707, 1.683)	0.6927	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5432
North America	16	8 (50.0)	8 (50.0)	2.2 (0.2, NE)	18	11 (61.1)	7 (38.9)	1.0 (0.1, NE)	0.712 (0.286, 1.775)	0.4782	
Europe	161	68 (42.2)	93 (57.8)	NE (2.0, NE)	161	67 (41.6)	94 (58.4)	9.0 (2.7, NE)	0.965 (0.688, 1.352)	0.8357	
Asia/Other Regions	88	41 (46.6)	47 (53.4)	4.5 (2.1, NE)	89	35 (39.3)	54 (60.7)	NE (3.4, NE)	1.206 (0.768, 1.894)	0.4137	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0300
< 40x10^9/L	132	54 (40.9)	78 (59.1)	NE (2.6, NE)	133	68 (51.1)	65 (48.9)	3.4 (1.6, 9.0)	0.766 (0.536, 1.095)	0.1408	
≥ 40x10^9/L	133	63 (47.4)	70 (52.6)	3.7 (2.1, NE)	135	45 (33.3)	90 (66.7)	NE (4.1, NE)	1.356 (0.924, 1.988)	0.1165	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7135
Daunorubicin	123	60 (48.8)	63 (51.2)	3.5 (1.7, 18.9)	94	44 (46.8)	50 (53.2)	3.7 (1.6, NE)	1.016 (0.689, 1.501)	0.9328	
Idarubicin	142	57 (40.1)	85 (59.9)	NE (2.5, NE)	171	68 (39.8)	103 (60.2)	NE (3.6, NE)	0.947 (0.666, 1.347)	0.7646	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.1506
Favorable	13	5 (38.5)	8 (61.5)	NE (0.7, NE)	19	13 (68.4)	6 (31.6)	1.2 (0.2, NE)	0.427 (0.152, 1.201)	0.0976	
Intermediate	195	83 (42.6)	112 (57.4)	5.5 (2.8, NE)	190	79 (41.6)	111 (58.4)	9.0 (3.0, NE)	0.945 (0.694, 1.287)	0.7243	
Unfavorable	19	11 (57.9)	8 (42.1)	2.5 (0.1, NE)	27	9 (33.3)	18 (66.7)	NE (2.1, NE)	2.034 (0.842, 4.913)	0.1114	
Unknown	38	18 (47.4)	20 (52.6)	2.0 (1.2, NE)	31	12 (38.7)	19 (61.3)	NE (1.5, NE)	1.267 (0.609, 2.634)	0.5168	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4327
0 - Fully Active	87	38 (43.7)	49 (56.3)	NE (2.1, NE)	97	47 (48.5)	50 (51.5)	3.6 (1.8, NE)	0.818 (0.533, 1.255)	0.3561	
1 - Restricted in Physically Strenuous Activity	133	61 (45.9)	72 (54.1)	3.9 (2.0, NE)	134	52 (38.8)	82 (61.2)	NE (3.7, NE)	1.138 (0.786, 1.647)	0.4896	
2 - Ambulatory and Capable of All Selfcare	45	18 (40.0)	27 (60.0)	2.2 (1.6, NE)	36	13 (36.1)	23 (63.9)	7.1 (1.5, NE)	1.264 (0.618, 2.587)	0.5150	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.0231
≥3 to ≤25%	94	34 (36.2)	60 (63.8)	NE (2.6, NE)	98	49 (50.0)	49 (50.0)	2.1 (1.5, NE)	0.633 (0.408, 0.981)	0.0391	
>25% to ≤50%	141	69 (48.9)	72 (51.1)	3.5 (1.9, 18.9)	136	52 (38.2)	84 (61.8)	NE (3.6, NE)	1.355 (0.945, 1.942)	0.0960	
>50%	29	14 (48.3)	15 (51.7)	NE (1.6, NE)	34	12 (35.3)	22 (64.7)	4.0 (2.7, NE)	1.177 (0.543, 2.548)	0.6822	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3621
Yes	139	56 (40.3)	83 (59.7)	NE (2.9, NE)	137	60 (43.8)	77 (56.2)	9.0 (2.7, NE)	0.894 (0.621, 1.287)	0.5499	
No	116	60 (51.7)	56 (48.3)	2.1 (1.7, 4.2)	120	51 (42.5)	69 (57.5)	NE (1.5, NE)	1.148 (0.790, 1.669)	0.4653	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8524
≤60	164	76 (46.3)	88 (53.7)	3.9 (2.1, NE)	163	71 (43.6)	92 (56.4)	5.2 (3.0, NE)	1.025 (0.741, 1.416)	0.8820	
>60	101	41 (40.6)	60 (59.4)	18.9 (1.9, NE)	105	42 (40.0)	63 (60.0)	NE (1.8, NE)	0.975 (0.634, 1.500)	0.9154	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7166
<60	159	33 (20.8)	126 (79.2)	NE (22.5, NE)	160	17 (10.6)	143 (89.4)	NE (NE, NE)	1.672 (0.930, 3.006)	0.0824	
≥60 - <65	37	9 (24.3)	28 (75.7)	17.5 (13.2, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	2.619 (0.785, 8.741)	0.1055	
≥65	69	12 (17.4)	57 (82.6)	24.6 (11.6, NE)	65	6 (9.2)	59 (90.8)	NE (21.3, NE)	2.739 (1.009, 7.433)	0.0400	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1808
Male	124	22 (17.7)	102 (82.3)	NE (20.5, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	3.178 (1.287, 7.847)	0.0081	
Female	141	32 (22.7)	109 (77.3)	28.5 (17.2, NE)	148	21 (14.2)	127 (85.8)	NE (38.7, NE)	1.576 (0.908, 2.738)	0.1037	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2806
White	157	36 (22.9)	121 (77.1)	28.5 (17.5, NE)	161	21 (13.0)	140 (87.0)	NE (38.7, NE)	1.632 (0.952, 2.799)	0.0722	
Non-white	108	18 (16.7)	90 (83.3)	NE (22.6, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	2.766 (1.097, 6.977)	0.0246	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2522
North America	16	2 (12.5)	14 (87.5)	NE (10.5, NE)	18	2 (11.1)	16 (88.9)	NE (NE, NE)	1.355 (0.190, 9.682)	0.7609	
Europe	161	36 (22.4)	125 (77.6)	28.5 (18.3, NE)	161	21 (13.0)	140 (87.0)	NE (38.7, NE)	1.497 (0.873, 2.568)	0.1396	
Asia/Other Regions	88	16 (18.2)	72 (81.8)	NE (14.5, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	3.806 (1.267, 11.426)	0.0105	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6064
< 40x10^9/L	132	32 (24.2)	100 (75.8)	38.8 (13.7, NE)	133	16 (12.0)	117 (88.0)	NE (38.7, NE)	2.121 (1.163, 3.868)	0.0121	
≥ 40x10^9/L	133	22 (16.5)	111 (83.5)	31.5 (22.6, NE)	135	11 (8.1)	124 (91.9)	NE (NE, NE)	1.661 (0.803, 3.433)	0.1666	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1740
Daunorubicin	123	21 (17.1)	102 (82.9)	38.8 (18.3, NE)	94	11 (11.7)	83 (88.3)	NE (38.7, NE)	1.316 (0.632, 2.740)	0.4613	
Idarubicin	142	33 (23.2)	109 (76.8)	31.5 (17.5, NE)	171	15 (8.8)	156 (91.2)	NE (NE, NE)	2.499 (1.357, 4.604)	0.0023	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7030
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	42 (21.5)	153 (78.5)	28.5 (17.2, NE)	190	19 (10.0)	171 (90.0)	NE (NE, NE)	1.949 (1.132, 3.356)	0.0142	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (18.3, NE)	27	3 (11.1)	24 (88.9)	NE (NE, NE)	0.789 (0.120, 5.186)	0.8052	
Unknown	38	10 (26.3)	28 (73.7)	26.8 (11.5, NE)	31	5 (16.1)	26 (83.9)	NE (17.1, NE)	1.588 (0.540, 4.670)	0.3968	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1065
0 - Fully Active	87	16 (18.4)	71 (81.6)	NE (20.5, NE)	97	13 (13.4)	84 (86.6)	NE (38.7, NE)	1.169 (0.561, 2.436)	0.6763	
1 - Restricted in Physically Strenuous Activity	133	27 (20.3)	106 (79.7)	28.5 (22.5, NE)	134	8 (6.0)	126 (94.0)	NE (NE, NE)	3.536 (1.601, 7.811)	0.0009	
2 - Ambulatory and Capable of All Selfcare	45	11 (24.4)	34 (75.6)	17.1 (9.2, NE)	36	6 (16.7)	30 (83.3)	NE (NE, NE)	1.188 (0.435, 3.247)	0.7414	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5419
≥3 to ≤25%	94	19 (20.2)	75 (79.8)	38.8 (17.5, NE)	98	14 (14.3)	84 (85.7)	NE (38.7, NE)	1.420 (0.711, 2.834)	0.3177	
>25% to ≤50%	141	27 (19.1)	114 (80.9)	NE (22.5, NE)	136	10 (7.4)	126 (92.6)	NE (NE, NE)	2.437 (1.178, 5.042)	0.0130	
>50%	29	8 (27.6)	21 (72.4)	14.3 (7.6, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	1.766 (0.461, 6.768)	0.4054	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3166
Yes	139	31 (22.3)	108 (77.7)	38.8 (17.2, NE)	137	19 (13.9)	118 (86.1)	NE (NE, NE)	1.529 (0.863, 2.708)	0.1436	
No	116	22 (19.0)	94 (81.0)	28.5 (18.3, NE)	120	8 (6.7)	112 (93.3)	NE (38.7, NE)	2.574 (1.144, 5.792)	0.0178	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4519
≤60	164	34 (20.7)	130 (79.3)	NE (22.5, NE)	163	17 (10.4)	146 (89.6)	NE (NE, NE)	1.688 (0.942, 3.026)	0.0751	
>60	101	20 (19.8)	81 (80.2)	24.6 (13.5, 38.8)	105	10 (9.5)	95 (90.5)	NE (NE, NE)	2.540 (1.177, 5.479)	0.0140	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9499
<60	159	19 (11.9)	140 (88.1)	NE (NE, NE)	160	17 (10.6)	143 (89.4)	NE (NE, NE)	0.932 (0.483, 1.797)	0.8335	
≥60 - <65	37	5 (13.5)	32 (86.5)	NE (12.2, NE)	43	5 (11.6)	38 (88.4)	NE (NE, NE)	0.913 (0.262, 3.180)	0.8861	
≥65	69	6 (8.7)	63 (91.3)	NE (NE, NE)	65	8 (12.3)	57 (87.7)	NE (17.8, NE)	0.767 (0.266, 2.212)	0.6228	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5748
Male	124	11 (8.9)	113 (91.1)	NE (NE, NE)	120	12 (10.0)	108 (90.0)	NE (NE, NE)	0.751 (0.330, 1.708)	0.4947	
Female	141	19 (13.5)	122 (86.5)	NE (NE, NE)	148	18 (12.2)	130 (87.8)	NE (NE, NE)	0.969 (0.508, 1.849)	0.9254	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7964
White	157	21 (13.4)	136 (86.6)	NE (NE, NE)	161	20 (12.4)	141 (87.6)	NE (NE, NE)	0.894 (0.484, 1.654)	0.7230	
Non-white	108	9 (8.3)	99 (91.7)	NE (NE, NE)	107	10 (9.3)	97 (90.7)	NE (NE, NE)	0.796 (0.323, 1.960)	0.6182	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4826
North America	16	0	16 (100)	NE (NE, NE)	18	5 (27.8)	13 (72.2)	NE (1.6, NE)	0.000 (0.000, NE)	0.0443	
Europe	161	20 (12.4)	141 (87.6)	NE (NE, NE)	161	20 (12.4)	141 (87.6)	NE (NE, NE)	0.818 (0.439, 1.524)	0.5265	
Asia/Other Regions	88	10 (11.4)	78 (88.6)	NE (NE, NE)	89	5 (5.6)	84 (94.4)	NE (NE, NE)	1.783 (0.608, 5.227)	0.2856	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7185
< 40x10^9/L	132	15 (11.4)	117 (88.6)	NE (NE, NE)	133	18 (13.5)	115 (86.5)	NE (NE, NE)	0.808 (0.407, 1.604)	0.5411	
≥ 40x10^9/L	133	15 (11.3)	118 (88.7)	NE (NE, NE)	135	12 (8.9)	123 (91.1)	NE (NE, NE)	0.968 (0.451, 2.075)	0.9337	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3312
Daunorubicin	123	15 (12.2)	108 (87.8)	NE (NE, NE)	94	8 (8.5)	86 (91.5)	NE (NE, NE)	1.227 (0.519, 2.901)	0.6399	
Idarubicin	142	15 (10.6)	127 (89.4)	NE (NE, NE)	171	21 (12.3)	150 (87.7)	NE (NE, NE)	0.725 (0.373, 1.409)	0.3408	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9664
Favorable	13	0	13 (100)	NE (NE, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	0.000 (0.000, NE)	0.2595	
Intermediate	195	21 (10.8)	174 (89.2)	NE (NE, NE)	190	21 (11.1)	169 (88.9)	NE (NE, NE)	0.804 (0.439, 1.475)	0.4808	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (5.2, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	1.266 (0.176, 9.115)	0.8141	
Unknown	38	7 (18.4)	31 (81.6)	NE (13.7, NE)	31	5 (16.1)	26 (83.9)	NE (17.8, NE)	1.058 (0.334, 3.351)	0.9230	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1514
0 - Fully Active	87	6 (6.9)	81 (93.1)	NE (NE, NE)	97	14 (14.4)	83 (85.6)	NE (NE, NE)	0.394 (0.151, 1.028)	0.0486	
1 - Restricted in Physically Strenuous Activity	133	16 (12.0)	117 (88.0)	NE (NE, NE)	134	12 (9.0)	122 (91.0)	NE (NE, NE)	1.171 (0.553, 2.479)	0.6804	
2 - Ambulatory and Capable of All Selfcare	45	8 (17.8)	37 (82.2)	NE (10.6, NE)	36	4 (11.1)	32 (88.9)	NE (NE, NE)	1.288 (0.384, 4.327)	0.6803	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9793
≥3 to ≤25%	94	10 (10.6)	84 (89.4)	NE (NE, NE)	98	11 (11.2)	87 (88.8)	NE (NE, NE)	0.905 (0.384, 2.131)	0.8183	
>25% to ≤50%	141	14 (9.9)	127 (90.1)	NE (NE, NE)	136	14 (10.3)	122 (89.7)	NE (NE, NE)	0.804 (0.382, 1.691)	0.5638	
>50%	29	5 (17.2)	24 (82.8)	NE (6.7, NE)	34	5 (14.7)	29 (85.3)	NE (NE, NE)	0.816 (0.230, 2.901)	0.7534	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0232
Yes	139	17 (12.2)	122 (87.8)	NE (NE, NE)	137	25 (18.2)	112 (81.8)	NE (NE, NE)	0.570 (0.307, 1.058)	0.0710	
No	116	11 (9.5)	105 (90.5)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	2.561 (0.814, 8.051)	0.0953	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6737
≤60	164	20 (12.2)	144 (87.8)	NE (NE, NE)	163	17 (10.4)	146 (89.6)	NE (NE, NE)	0.967 (0.505, 1.851)	0.9204	
>60	101	10 (9.9)	91 (90.1)	NE (NE, NE)	105	13 (12.4)	92 (87.6)	NE (NE, NE)	0.750 (0.329, 1.713)	0.4938	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9180
<60	159	18 (11.3)	141 (88.7)	NE (NE, NE)	160	14 (8.8)	146 (91.3)	NE (NE, NE)	1.058 (0.524, 2.134)	0.8752	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	5 (11.6)	38 (88.4)	NE (NE, NE)	0.845 (0.225, 3.177)	0.8023	
≥65	69	7 (10.1)	62 (89.9)	NE (NE, NE)	65	0	65 (100)	NE (NE, NE)	NE (0.000, NE)	0.0064	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4912
Male	124	12 (9.7)	112 (90.3)	NE (NE, NE)	120	9 (7.5)	111 (92.5)	NE (NE, NE)	1.097 (0.460, 2.616)	0.8347	
Female	141	17 (12.1)	124 (87.9)	NE (NE, NE)	148	10 (6.8)	138 (93.2)	NE (NE, NE)	1.668 (0.763, 3.644)	0.1950	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5164
White	157	18 (11.5)	139 (88.5)	NE (NE, NE)	161	10 (6.2)	151 (93.8)	NE (NE, NE)	1.618 (0.745, 3.514)	0.2193	
Non-white	108	11 (10.2)	97 (89.8)	NE (NE, NE)	107	9 (8.4)	98 (91.6)	NE (NE, NE)	1.120 (0.464, 2.706)	0.8003	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4150
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	4 (22.2)	14 (77.8)	NE (3.0, NE)	0.340 (0.037, 3.103)	0.3167	
Europe	161	18 (11.2)	143 (88.8)	NE (NE, NE)	161	10 (6.2)	151 (93.8)	NE (NE, NE)	1.527 (0.703, 3.317)	0.2816	
Asia/Other Regions	88	10 (11.4)	78 (88.6)	NE (NE, NE)	89	5 (5.6)	84 (94.4)	NE (NE, NE)	1.886 (0.644, 5.527)	0.2395	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0618
< 40x10^9/L	132	17 (12.9)	115 (87.1)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	2.505 (1.038, 6.045)	0.0344	
≥ 40x10^9/L	133	12 (9.0)	121 (91.0)	NE (NE, NE)	135	12 (8.9)	123 (91.1)	NE (NE, NE)	0.801 (0.358, 1.793)	0.5885	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4854
Daunorubicin	123	14 (11.4)	109 (88.6)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	1.897 (0.682, 5.278)	0.2122	
Idarubicin	142	15 (10.6)	127 (89.4)	NE (NE, NE)	171	13 (7.6)	158 (92.4)	NE (NE, NE)	1.221 (0.580, 2.572)	0.5975	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6653
Favorable	13	1 (7.7)	12 (92.3)	NE (27.5, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	0.911 (0.082, 10.179)	0.9397	
Intermediate	195	23 (11.8)	172 (88.2)	NE (NE, NE)	190	11 (5.8)	179 (94.2)	NE (NE, NE)	1.755 (0.854, 3.607)	0.1209	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (5.2, NE)	27	3 (11.1)	24 (88.9)	NE (NE, NE)	0.947 (0.158, 5.688)	0.9526	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	0.806 (0.161, 4.022)	0.7874	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5019
0 - Fully Active	87	10 (11.5)	77 (88.5)	NE (NE, NE)	97	6 (6.2)	91 (93.8)	NE (NE, NE)	1.656 (0.600, 4.565)	0.3250	
1 - Restricted in Physically Strenuous Activity	133	15 (11.3)	118 (88.7)	NE (NE, NE)	134	9 (6.7)	125 (93.3)	NE (NE, NE)	1.516 (0.663, 3.469)	0.3206	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	4 (11.1)	32 (88.9)	NE (NE, NE)	0.641 (0.156, 2.640)	0.5314	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2213
≥3 to ≤25%	94	13 (13.8)	81 (86.2)	NE (NE, NE)	98	10 (10.2)	88 (89.8)	NE (NE, NE)	1.354 (0.593, 3.088)	0.4700	
>25% to ≤50%	141	15 (10.6)	126 (89.4)	NE (NE, NE)	136	6 (4.4)	130 (95.6)	NE (NE, NE)	2.074 (0.803, 5.359)	0.1238	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	0.367 (0.038, 3.541)	0.3664	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1083
Yes	139	15 (10.8)	124 (89.2)	NE (NE, NE)	137	14 (10.2)	123 (89.8)	NE (NE, NE)	0.956 (0.461, 1.985)	0.9052	
No	116	12 (10.3)	104 (89.7)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	2.765 (0.891, 8.583)	0.0664	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3158
≤60	164	19 (11.6)	145 (88.4)	NE (NE, NE)	163	14 (8.6)	149 (91.4)	NE (NE, NE)	1.107 (0.553, 2.215)	0.7746	
>60	101	10 (9.9)	91 (90.1)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	2.081 (0.711, 6.092)	0.1715	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3222
<60	159	94 (59.1)	65 (40.9)	2.5 (1.6, 9.6)	160	91 (56.9)	69 (43.1)	1.8 (0.8, 4.8)	0.948 (0.710, 1.265)	0.7254	
≥60 - <65	37	24 (64.9)	13 (35.1)	1.5 (0.2, 7.3)	43	26 (60.5)	17 (39.5)	2.1 (0.4, 7.9)	1.151 (0.660, 2.007)	0.6263	
≥65	69	47 (68.1)	22 (31.9)	0.9 (0.3, 2.2)	65	36 (55.4)	29 (44.6)	4.9 (0.6, 21.0)	1.437 (0.929, 2.224)	0.0994	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3762
Male	124	82 (66.1)	42 (33.9)	1.6 (0.5, 2.6)	120	69 (57.5)	51 (42.5)	2.1 (0.5, 6.8)	1.174 (0.852, 1.617)	0.3249	
Female	141	83 (58.9)	58 (41.1)	2.5 (1.3, 7.3)	148	84 (56.8)	64 (43.2)	1.8 (0.7, 6.1)	0.965 (0.712, 1.307)	0.8285	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8044
White	157	92 (58.6)	65 (41.4)	2.8 (1.0, 8.8)	161	86 (53.4)	75 (46.6)	2.6 (1.0, 7.1)	1.086 (0.809, 1.458)	0.5763	
Non-white	108	73 (67.6)	35 (32.4)	1.6 (0.5, 2.2)	107	67 (62.6)	40 (37.4)	1.1 (0.5, 4.8)	1.030 (0.739, 1.435)	0.8626	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.1807
North America	16	13 (81.3)	3 (18.8)	1.1 (0.2, 2.2)	18	18 (100)	0	0.2 (0.1, 0.3)	0.639 (0.303, 1.347)	0.2460	
Europe	161	89 (55.3)	72 (44.7)	4.9 (1.6, 10.1)	161	81 (50.3)	80 (49.7)	6.6 (1.6, 10.1)	1.097 (0.812, 1.484)	0.5455	
Asia/Other Regions	88	63 (71.6)	25 (28.4)	1.5 (0.5, 2.0)	89	54 (60.7)	35 (39.3)	1.1 (0.5, 3.1)	1.165 (0.809, 1.678)	0.4080	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9105
< 40x10^9/L	132	75 (56.8)	57 (43.2)	2.5 (1.0, 10.1)	133	75 (56.4)	58 (43.6)	4.8 (1.1, 7.1)	1.041 (0.756, 1.434)	0.8098	
≥ 40x10^9/L	133	90 (67.7)	43 (32.3)	1.6 (0.5, 3.1)	135	78 (57.8)	57 (42.2)	1.1 (0.5, 3.0)	1.074 (0.793, 1.456)	0.6339	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6343
Daunorubicin	123	80 (65.0)	43 (35.0)	1.7 (0.9, 2.8)	94	52 (55.3)	42 (44.7)	2.6 (0.4, 6.6)	1.108 (0.781, 1.572)	0.5557	
Idarubicin	142	85 (59.9)	57 (40.1)	2.2 (0.8, 9.4)	171	100 (58.5)	71 (41.5)	1.8 (0.7, 5.3)	0.997 (0.746, 1.331)	0.9775	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5673
Favorable	13	6 (46.2)	7 (53.8)	2.2 (0.9, NE)	19	11 (57.9)	8 (42.1)	4.7 (0.2, NE)	0.769 (0.282, 2.093)	0.6041	
Intermediate	195	123 (63.1)	72 (36.9)	1.8 (0.8, 3.3)	190	108 (56.8)	82 (43.2)	2.2 (0.9, 6.1)	1.092 (0.843, 1.414)	0.4968	
Unfavorable	19	15 (78.9)	4 (21.1)	0.4 (0.1, 2.6)	27	16 (59.3)	11 (40.7)	1.1 (0.5, NE)	1.647 (0.812, 3.341)	0.1647	
Unknown	38	21 (55.3)	17 (44.7)	9.6 (1.5, 12.2)	31	17 (54.8)	14 (45.2)	1.6 (0.3, NE)	0.923 (0.487, 1.751)	0.8051	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2324
0 - Fully Active	87	46 (52.9)	41 (47.1)	5.2 (2.2, 11.6)	97	41 (42.3)	56 (57.7)	10.1 (4.7, NE)	1.171 (0.768, 1.784)	0.4568	
1 - Restricted in Physically Strenuous Activity	133	88 (66.2)	45 (33.8)	1.2 (0.5, 2.3)	134	83 (61.9)	51 (38.1)	1.3 (0.6, 3.0)	1.089 (0.807, 1.471)	0.5797	
2 - Ambulatory and Capable of All Selfcare	45	31 (68.9)	14 (31.1)	0.4 (0.2, 2.7)	36	29 (80.6)	7 (19.4)	0.3 (0.2, 0.5)	0.726 (0.435, 1.212)	0.2111	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.0241
≥3 to ≤25%	94	56 (59.6)	38 (40.4)	2.2 (0.8, 10.9)	98	55 (56.1)	43 (43.9)	2.2 (1.1, 7.3)	1.069 (0.736, 1.553)	0.7288	
>25% to ≤50%	141	95 (67.4)	46 (32.6)	1.4 (0.5, 2.0)	136	75 (55.1)	61 (44.9)	2.2 (0.6, 7.9)	1.237 (0.914, 1.675)	0.1638	
>50%	29	13 (44.8)	16 (55.2)	9.1 (2.3, NE)	34	23 (67.6)	11 (32.4)	0.7 (0.3, 5.3)	0.332 (0.152, 0.725)	0.0037	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.8165
Yes	139	89 (64.0)	50 (36.0)	1.7 (0.5, 5.2)	137	87 (63.5)	50 (36.5)	1.6 (0.6, 4.8)	1.032 (0.767, 1.387)	0.8338	
No	116	67 (57.8)	49 (42.2)	2.2 (1.6, 10.1)	120	58 (48.3)	62 (51.7)	3.1 (1.1, NE)	1.083 (0.761, 1.539)	0.6537	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1676
≤60	164	96 (58.5)	68 (41.5)	2.5 (1.6, 9.6)	163	92 (56.4)	71 (43.6)	1.8 (0.9, 4.8)	0.947 (0.711, 1.262)	0.7181	
>60	101	69 (68.3)	32 (31.7)	1.0 (0.4, 2.2)	105	61 (58.1)	44 (41.9)	2.1 (0.6, 7.3)	1.304 (0.923, 1.840)	0.1286	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9491
<60	159	55 (34.6)	104 (65.4)	NE (18.4, NE)	160	57 (35.6)	103 (64.4)	NE (5.1, NE)	0.914 (0.630, 1.324)	0.6311	
≥60 - <65	37	14 (37.8)	23 (62.2)	NE (2.7, NE)	43	15 (34.9)	28 (65.1)	NE (1.1, NE)	1.097 (0.529, 2.274)	0.8028	
≥65	69	24 (34.8)	45 (65.2)	NE (4.6, NE)	65	24 (36.9)	41 (63.1)	NE (3.3, NE)	0.993 (0.564, 1.750)	0.9835	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4396
Male	124	45 (36.3)	79 (63.7)	NE (16.9, NE)	120	41 (34.2)	79 (65.8)	NE (NE, NE)	1.083 (0.709, 1.654)	0.7207	
Female	141	48 (34.0)	93 (66.0)	NE (18.4, NE)	148	55 (37.2)	93 (62.8)	NE (4.7, NE)	0.852 (0.579, 1.256)	0.4211	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4089
White	157	47 (29.9)	110 (70.1)	NE (NE, NE)	161	55 (34.2)	106 (65.8)	NE (6.8, NE)	0.843 (0.571, 1.244)	0.3874	
Non-white	108	46 (42.6)	62 (57.4)	NE (2.2, NE)	107	41 (38.3)	66 (61.7)	NE (3.7, NE)	1.087 (0.713, 1.656)	0.6986	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6837
North America	16	8 (50.0)	8 (50.0)	3.0 (0.6, NE)	18	7 (38.9)	11 (61.1)	NE (0.3, NE)	1.463 (0.522, 4.099)	0.4595	
Europe	161	46 (28.6)	115 (71.4)	NE (NE, NE)	161	51 (31.7)	110 (68.3)	NE (NE, NE)	0.866 (0.581, 1.291)	0.4797	
Asia/Other Regions	88	39 (44.3)	49 (55.7)	17.1 (1.9, NE)	89	38 (42.7)	51 (57.3)	NE (2.3, NE)	1.026 (0.656, 1.603)	0.9159	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9010
< 40x10^9/L	132	40 (30.3)	92 (69.7)	NE (17.1, NE)	133	44 (33.1)	89 (66.9)	NE (NE, NE)	0.924 (0.602, 1.417)	0.7179	
≥ 40x10^9/L	133	53 (39.8)	80 (60.2)	NE (3.3, NE)	135	52 (38.5)	83 (61.5)	NE (3.7, NE)	0.963 (0.657, 1.413)	0.8453	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7203
Daunorubicin	123	44 (35.8)	79 (64.2)	NE (18.4, NE)	94	32 (34.0)	62 (66.0)	NE (4.7, NE)	1.017 (0.645, 1.604)	0.9444	
Idarubicin	142	49 (34.5)	93 (65.5)	NE (17.1, NE)	171	63 (36.8)	108 (63.2)	NE (6.8, NE)	0.905 (0.623, 1.314)	0.5954	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.2887
Favorable	13	4 (30.8)	9 (69.2)	NE (1.9, NE)	19	6 (31.6)	13 (68.4)	NE (3.4, NE)	1.163 (0.325, 4.159)	0.8167	
Intermediate	195	71 (36.4)	124 (63.6)	NE (18.4, NE)	190	70 (36.8)	120 (63.2)	NE (7.1, NE)	0.954 (0.686, 1.328)	0.7825	
Unfavorable	19	9 (47.4)	10 (52.6)	16.9 (0.4, NE)	27	7 (25.9)	20 (74.1)	NE (5.3, NE)	1.875 (0.688, 5.113)	0.2148	
Unknown	38	9 (23.7)	29 (76.3)	NE (NE, NE)	31	12 (38.7)	19 (61.3)	NE (1.5, NE)	0.573 (0.241, 1.360)	0.2020	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9839
0 - Fully Active	87	21 (24.1)	66 (75.9)	NE (NE, NE)	97	24 (24.7)	73 (75.3)	NE (NE, NE)	0.904 (0.503, 1.624)	0.7333	
1 - Restricted in Physically Strenuous Activity	133	50 (37.6)	83 (62.4)	NE (12.1, NE)	134	53 (39.6)	81 (60.4)	NE (3.7, NE)	0.930 (0.632, 1.369)	0.7122	
2 - Ambulatory and Capable of All Selfcare	45	22 (48.9)	23 (51.1)	2.7 (0.4, NE)	36	19 (52.8)	17 (47.2)	0.9 (0.3, NE)	0.869 (0.469, 1.612)	0.6490	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5589
≥3 to ≤25%	94	34 (36.2)	60 (63.8)	NE (16.9, NE)	98	33 (33.7)	65 (66.3)	NE (4.7, NE)	1.087 (0.673, 1.756)	0.7361	
>25% to ≤50%	141	51 (36.2)	90 (63.8)	NE (4.6, NE)	136	50 (36.8)	86 (63.2)	NE (7.1, NE)	0.945 (0.640, 1.396)	0.7781	
>50%	29	8 (27.6)	21 (72.4)	NE (NE, NE)	34	13 (38.2)	21 (61.8)	6.8 (2.3, NE)	0.615 (0.253, 1.493)	0.2777	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5371
Yes	139	50 (36.0)	89 (64.0)	NE (NE, NE)	137	49 (35.8)	88 (64.2)	NE (7.1, NE)	1.040 (0.701, 1.542)	0.8473	
No	116	38 (32.8)	78 (67.2)	NE (16.9, NE)	120	42 (35.0)	78 (65.0)	NE (5.3, NE)	0.842 (0.543, 1.307)	0.4430	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8113
≤60	164	57 (34.8)	107 (65.2)	NE (18.4, NE)	163	58 (35.6)	105 (64.4)	NE (5.1, NE)	0.921 (0.639, 1.328)	0.6571	
>60	101	36 (35.6)	65 (64.4)	NE (4.6, NE)	105	38 (36.2)	67 (63.8)	NE (7.1, NE)	1.006 (0.637, 1.586)	0.9757	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2544
<60	159	20 (12.6)	139 (87.4)	NE (NE, NE)	160	21 (13.1)	139 (86.9)	NE (NE, NE)	0.887 (0.480, 1.640)	0.6993	
≥60 - <65	37	7 (18.9)	30 (81.1)	NE (NE, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	1.879 (0.548, 6.437)	0.3042	
≥65	69	19 (27.5)	50 (72.5)	NE (8.7, NE)	65	11 (16.9)	54 (83.1)	NE (NE, NE)	1.841 (0.875, 3.870)	0.1022	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2048
Male	124	24 (19.4)	100 (80.6)	NE (NE, NE)	120	13 (10.8)	107 (89.2)	NE (NE, NE)	1.725 (0.878, 3.391)	0.1081	
Female	141	22 (15.6)	119 (84.4)	NE (NE, NE)	148	23 (15.5)	125 (84.5)	NE (NE, NE)	0.990 (0.551, 1.777)	0.9712	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2401
White	157	20 (12.7)	137 (87.3)	NE (NE, NE)	161	20 (12.4)	141 (87.6)	NE (NE, NE)	0.968 (0.520, 1.804)	0.9157	
Non-white	108	26 (24.1)	82 (75.9)	NE (NE, NE)	107	16 (15.0)	91 (85.0)	NE (NE, NE)	1.645 (0.882, 3.067)	0.1132	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2905
North America	16	4 (25.0)	12 (75.0)	14.8 (7.8, NE)	18	7 (38.9)	11 (61.1)	NE (1.0, NE)	0.583 (0.170, 2.004)	0.3864	
Europe	161	19 (11.8)	142 (88.2)	NE (NE, NE)	161	16 (9.9)	145 (90.1)	NE (NE, NE)	1.113 (0.571, 2.168)	0.7546	
Asia/Other Regions	88	23 (26.1)	65 (73.9)	NE (NE, NE)	89	13 (14.6)	76 (85.4)	NE (NE, NE)	1.850 (0.937, 3.652)	0.0717	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2598
< 40x10^9/L	132	21 (15.9)	111 (84.1)	NE (NE, NE)	133	13 (9.8)	120 (90.2)	NE (NE, NE)	1.680 (0.841, 3.355)	0.1377	
≥ 40x10^9/L	133	25 (18.8)	108 (81.2)	NE (NE, NE)	135	23 (17.0)	112 (83.0)	NE (NE, NE)	1.007 (0.570, 1.778)	0.9828	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5020
Daunorubicin	123	19 (15.4)	104 (84.6)	NE (NE, NE)	94	13 (13.8)	81 (86.2)	NE (NE, NE)	1.037 (0.511, 2.103)	0.9227	
Idarubicin	142	27 (19.0)	115 (81.0)	NE (NE, NE)	171	23 (13.5)	148 (86.5)	NE (NE, NE)	1.412 (0.809, 2.463)	0.2225	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7890
Favorable	13	0	13 (100)	NE (NE, NE)	19	5 (26.3)	14 (73.7)	NE (14.1, NE)	0.000 (0.000, NE)	0.0545	
Intermediate	195	37 (19.0)	158 (81.0)	NE (NE, NE)	190	21 (11.1)	169 (88.9)	NE (NE, NE)	1.661 (0.972, 2.839)	0.0609	
Unfavorable	19	5 (26.3)	14 (73.7)	NE (0.5, NE)	27	6 (22.2)	21 (77.8)	NE (NE, NE)	1.418 (0.432, 4.652)	0.5630	
Unknown	38	4 (10.5)	34 (89.5)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (NE, NE)	0.801 (0.200, 3.212)	0.7537	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2258
0 - Fully Active	87	13 (14.9)	74 (85.1)	NE (NE, NE)	97	7 (7.2)	90 (92.8)	NE (NE, NE)	1.957 (0.780, 4.908)	0.1448	
1 - Restricted in Physically Strenuous Activity	133	22 (16.5)	111 (83.5)	NE (NE, NE)	134	24 (17.9)	110 (82.1)	NE (NE, NE)	0.885 (0.496, 1.580)	0.6781	
2 - Ambulatory and Capable of All Selfcare	45	11 (24.4)	34 (75.6)	NE (18.1, NE)	36	5 (13.9)	31 (86.1)	NE (13.6, NE)	1.775 (0.609, 5.173)	0.2868	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1067
≥3 to ≤25%	94	18 (19.1)	76 (80.9)	NE (NE, NE)	98	14 (14.3)	84 (85.7)	NE (NE, NE)	1.329 (0.661, 2.674)	0.4244	
>25% to ≤50%	141	27 (19.1)	114 (80.9)	NE (NE, NE)	136	16 (11.8)	120 (88.2)	NE (NE, NE)	1.657 (0.893, 3.076)	0.1060	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	6 (17.6)	28 (82.4)	13.6 (13.6, NE)	0.126 (0.014, 1.130)	0.0338	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.8177
Yes	139	29 (20.9)	110 (79.1)	NE (NE, NE)	137	22 (16.1)	115 (83.9)	NE (NE, NE)	1.269 (0.729, 2.211)	0.3985	
No	116	15 (12.9)	101 (87.1)	NE (NE, NE)	120	13 (10.8)	107 (89.2)	NE (NE, NE)	1.142 (0.543, 2.401)	0.7253	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0767
≤60	164	20 (12.2)	144 (87.8)	NE (NE, NE)	163	21 (12.9)	142 (87.1)	NE (NE, NE)	0.873 (0.472, 1.614)	0.6628	
>60	101	26 (25.7)	75 (74.3)	NE (14.8, NE)	105	15 (14.3)	90 (85.7)	NE (NE, NE)	1.934 (1.024, 3.652)	0.0383	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypomagnesaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7751
<60	159	21 (13.2)	138 (86.8)	NE (NE, NE)	160	20 (12.5)	140 (87.5)	NE (NE, NE)	0.944 (0.511, 1.745)	0.8558	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	3 (7.0)	40 (93.0)	NE (NE, NE)	1.460 (0.326, 6.530)	0.6188	
≥65	69	5 (7.2)	64 (92.8)	NE (NE, NE)	65	7 (10.8)	58 (89.2)	NE (NE, NE)	0.712 (0.226, 2.245)	0.5602	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypomagnesaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5081
Male	124	15 (12.1)	109 (87.9)	NE (NE, NE)	120	12 (10.0)	108 (90.0)	NE (NE, NE)	1.161 (0.543, 2.482)	0.7006	
Female	141	15 (10.6)	126 (89.4)	NE (NE, NE)	148	18 (12.2)	130 (87.8)	NE (NE, NE)	0.812 (0.409, 1.613)	0.5521	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypomagnesaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6239
White	157	19 (12.1)	138 (87.9)	NE (NE, NE)	161	21 (13.0)	140 (87.0)	NE (NE, NE)	0.867 (0.466, 1.614)	0.6510	
Non-white	108	11 (10.2)	97 (89.8)	NE (NE, NE)	107	9 (8.4)	98 (91.6)	NE (NE, NE)	1.146 (0.475, 2.768)	0.7595	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypomagnesaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3028
North America	16	4 (25.0)	12 (75.0)	NE (2.0, NE)	18	3 (16.7)	15 (83.3)	NE (NE, NE)	1.572 (0.350, 7.054)	0.5518	
Europe	161	13 (8.1)	148 (91.9)	NE (NE, NE)	161	18 (11.2)	143 (88.8)	NE (NE, NE)	0.662 (0.324, 1.352)	0.2534	
Asia/Other Regions	88	13 (14.8)	75 (85.2)	NE (NE, NE)	89	9 (10.1)	80 (89.9)	NE (NE, NE)	1.356 (0.579, 3.176)	0.4807	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypomagnesaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1504
< 40x10^9/L	132	15 (11.4)	117 (88.6)	NE (NE, NE)	133	11 (8.3)	122 (91.7)	NE (NE, NE)	1.442 (0.662, 3.141)	0.3536	
≥ 40x10^9/L	133	15 (11.3)	118 (88.7)	NE (NE, NE)	135	19 (14.1)	116 (85.9)	NE (NE, NE)	0.673 (0.341, 1.328)	0.2503	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypomagnesaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6362
Daunorubicin	123	14 (11.4)	109 (88.6)	NE (NE, NE)	94	9 (9.6)	85 (90.4)	NE (NE, NE)	1.118 (0.484, 2.587)	0.7947	
Idarubicin	142	16 (11.3)	126 (88.7)	NE (NE, NE)	171	21 (12.3)	150 (87.7)	NE (NE, NE)	0.860 (0.448, 1.649)	0.6498	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypomagnesaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8307
Favorable	13	2 (15.4)	11 (84.6)	NE (2.0, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	1.746 (0.243, 12.533)	0.5748	
Intermediate	195	20 (10.3)	175 (89.7)	NE (NE, NE)	190	21 (11.1)	169 (88.9)	NE (NE, NE)	0.831 (0.450, 1.536)	0.5572	
Unfavorable	19	3 (15.8)	16 (84.2)	NE (25.8, NE)	27	3 (11.1)	24 (88.9)	NE (NE, NE)	1.166 (0.216, 6.299)	0.8585	
Unknown	38	5 (13.2)	33 (86.8)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (NE, NE)	1.054 (0.282, 3.942)	0.9374	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypomagnesaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.0555
0 - Fully Active	87	11 (12.6)	76 (87.4)	NE (NE, NE)	97	9 (9.3)	88 (90.7)	NE (NE, NE)	1.218 (0.504, 2.943)	0.6612	
1 - Restricted in Physically Strenuous Activity	133	17 (12.8)	116 (87.2)	NE (NE, NE)	134	13 (9.7)	121 (90.3)	NE (NE, NE)	1.291 (0.627, 2.658)	0.4876	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	8 (22.2)	28 (77.8)	NE (NE, NE)	0.182 (0.038, 0.861)	0.0160	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypomagnesaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1246
≥3 to ≤25%	94	10 (10.6)	84 (89.4)	NE (NE, NE)	98	11 (11.2)	87 (88.8)	NE (NE, NE)	0.945 (0.401, 2.225)	0.8967	
>25% to ≤50%	141	18 (12.8)	123 (87.2)	NE (NE, NE)	136	12 (8.8)	124 (91.2)	NE (NE, NE)	1.403 (0.676, 2.915)	0.3616	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	7 (20.6)	27 (79.4)	NE (4.6, NE)	0.227 (0.045, 1.132)	0.0503	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypomagnesaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2672
Yes	139	13 (9.4)	126 (90.6)	NE (NE, NE)	137	17 (12.4)	120 (87.6)	NE (NE, NE)	0.699 (0.339, 1.441)	0.3301	
No	116	16 (13.8)	100 (86.2)	NE (NE, NE)	120	12 (10.0)	108 (90.0)	NE (NE, NE)	1.306 (0.618, 2.761)	0.4844	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypomagnesaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8137
≤60	164	22 (13.4)	142 (86.6)	NE (NE, NE)	163	20 (12.3)	143 (87.7)	NE (NE, NE)	0.976 (0.532, 1.792)	0.9397	
>60	101	8 (7.9)	93 (92.1)	NE (NE, NE)	105	10 (9.5)	95 (90.5)	NE (NE, NE)	0.848 (0.335, 2.148)	0.7273	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6055
<60	159	15 (9.4)	144 (90.6)	NE (NE, NE)	160	15 (9.4)	145 (90.6)	NE (NE, NE)	0.962 (0.470, 1.969)	0.9187	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	0.884 (0.198, 3.951)	0.8713	
≥65	69	9 (13.0)	60 (87.0)	NE (26.8, NE)	65	5 (7.7)	60 (92.3)	NE (NE, NE)	1.793 (0.601, 5.353)	0.2878	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1181
Male	124	14 (11.3)	110 (88.7)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	1.931 (0.779, 4.787)	0.1481	
Female	141	13 (9.2)	128 (90.8)	NE (NE, NE)	148	17 (11.5)	131 (88.5)	NE (NE, NE)	0.779 (0.378, 1.604)	0.4996	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4624
White	157	14 (8.9)	143 (91.1)	NE (NE, NE)	161	15 (9.3)	146 (90.7)	NE (NE, NE)	0.944 (0.456, 1.957)	0.8796	
Non-white	108	13 (12.0)	95 (88.0)	NE (NE, NE)	107	9 (8.4)	98 (91.6)	NE (NE, NE)	1.430 (0.611, 3.345)	0.4076	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0919
North America	16	4 (25.0)	12 (75.0)	NE (1.3, NE)	18	10 (55.6)	8 (44.4)	2.6 (0.2, NE)	0.392 (0.123, 1.253)	0.1012	
Europe	161	13 (8.1)	148 (91.9)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	1.833 (0.730, 4.598)	0.1895	
Asia/Other Regions	88	10 (11.4)	78 (88.6)	NE (NE, NE)	89	7 (7.9)	82 (92.1)	NE (NE, NE)	1.440 (0.548, 3.787)	0.4557	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5315
< 40x10^9/L	132	12 (9.1)	120 (90.9)	NE (NE, NE)	133	13 (9.8)	120 (90.2)	NE (NE, NE)	0.941 (0.429, 2.062)	0.8795	
≥ 40x10^9/L	133	15 (11.3)	118 (88.7)	NE (NE, NE)	135	11 (8.1)	124 (91.9)	NE (NE, NE)	1.332 (0.611, 2.905)	0.4694	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2299
Daunorubicin	123	10 (8.1)	113 (91.9)	NE (NE, NE)	94	10 (10.6)	84 (89.4)	NE (NE, NE)	0.746 (0.310, 1.792)	0.5116	
Idarubicin	142	17 (12.0)	125 (88.0)	NE (NE, NE)	171	14 (8.2)	157 (91.8)	NE (NE, NE)	1.460 (0.720, 2.964)	0.2908	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9943
Favorable	13	0	13 (100)	NE (NE, NE)	19	4 (21.1)	15 (78.9)	NE (NE, NE)	0.000 (0.000, NE)	0.0838	
Intermediate	195	22 (11.3)	173 (88.7)	NE (NE, NE)	190	16 (8.4)	174 (91.6)	NE (NE, NE)	1.322 (0.694, 2.518)	0.3945	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.543 (0.097, 24.683)	0.7571	
Unknown	38	4 (10.5)	34 (89.5)	NE (26.8, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	0.997 (0.222, 4.470)	0.9970	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9584
0 - Fully Active	87	7 (8.0)	80 (92.0)	NE (NE, NE)	97	7 (7.2)	90 (92.8)	NE (NE, NE)	1.097 (0.385, 3.128)	0.8616	
1 - Restricted in Physically Strenuous Activity	133	15 (11.3)	118 (88.7)	NE (NE, NE)	134	14 (10.4)	120 (89.6)	NE (NE, NE)	1.059 (0.511, 2.195)	0.8759	
2 - Ambulatory and Capable of All Selfcare	45	5 (11.1)	40 (88.9)	NE (NE, NE)	36	3 (8.3)	33 (91.7)	NE (NE, NE)	1.378 (0.329, 5.765)	0.6615	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4202
≥3 to ≤25%	94	9 (9.6)	85 (90.4)	NE (NE, NE)	98	7 (7.1)	91 (92.9)	NE (NE, NE)	1.349 (0.502, 3.624)	0.5513	
>25% to ≤50%	141	16 (11.3)	125 (88.7)	NE (NE, NE)	136	12 (8.8)	124 (91.2)	NE (NE, NE)	1.292 (0.611, 2.732)	0.4997	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	5 (14.7)	29 (85.3)	NE (NE, NE)	0.428 (0.083, 2.214)	0.2989	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6688
Yes	139	17 (12.2)	122 (87.8)	NE (NE, NE)	137	16 (11.7)	121 (88.3)	NE (NE, NE)	1.036 (0.523, 2.052)	0.9177	
No	116	8 (6.9)	108 (93.1)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	1.376 (0.477, 3.967)	0.5521	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6718
≤60	164	16 (9.8)	148 (90.2)	NE (NE, NE)	163	15 (9.2)	148 (90.8)	NE (NE, NE)	1.016 (0.502, 2.057)	0.9615	
>60	101	11 (10.9)	90 (89.1)	NE (NE, NE)	105	9 (8.6)	96 (91.4)	NE (NE, NE)	1.314 (0.545, 3.172)	0.5417	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypocalcaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0380
<60	159	12 (7.5)	147 (92.5)	NE (NE, NE)	160	20 (12.5)	140 (87.5)	NE (NE, NE)	0.583 (0.285, 1.193)	0.1352	
≥60 - <65	37	8 (21.6)	29 (78.4)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	10.216 (1.277, 81.706)	0.0066	
≥65	69	6 (8.7)	63 (91.3)	NE (NE, NE)	65	8 (12.3)	57 (87.7)	NE (NE, NE)	0.735 (0.255, 2.119)	0.5620	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypocalcaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2127
Male	124	9 (7.3)	115 (92.7)	NE (NE, NE)	120	14 (11.7)	106 (88.3)	NE (NE, NE)	0.610 (0.264, 1.410)	0.2428	
Female	141	17 (12.1)	124 (87.9)	NE (NE, NE)	148	15 (10.1)	133 (89.9)	NE (NE, NE)	1.208 (0.603, 2.420)	0.5937	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypocalcaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7026
White	157	17 (10.8)	140 (89.2)	NE (NE, NE)	161	18 (11.2)	143 (88.8)	NE (NE, NE)	0.977 (0.503, 1.896)	0.9441	
Non-white	108	9 (8.3)	99 (91.7)	NE (NE, NE)	107	11 (10.3)	96 (89.7)	NE (NE, NE)	0.792 (0.328, 1.910)	0.6033	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypocalcaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4262
North America	16	3 (18.8)	13 (81.3)	NE (2.2, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	3.891 (0.400, 37.834)	0.2046	
Europe	161	14 (8.7)	147 (91.3)	NE (NE, NE)	161	18 (11.2)	143 (88.8)	NE (NE, NE)	0.770 (0.383, 1.549)	0.4614	
Asia/Other Regions	88	9 (10.2)	79 (89.8)	NE (NE, NE)	89	10 (11.2)	79 (88.8)	NE (NE, NE)	0.894 (0.363, 2.201)	0.8093	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypocalcaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0551
< 40x10^9/L	132	15 (11.4)	117 (88.6)	NE (NE, NE)	133	10 (7.5)	123 (92.5)	NE (NE, NE)	1.624 (0.729, 3.616)	0.2308	
≥ 40x10^9/L	133	11 (8.3)	122 (91.7)	NE (NE, NE)	135	19 (14.1)	116 (85.9)	NE (NE, NE)	0.561 (0.267, 1.180)	0.1217	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypocalcaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8225
Daunorubicin	123	8 (6.5)	115 (93.5)	NE (NE, NE)	94	7 (7.4)	87 (92.6)	NE (NE, NE)	0.867 (0.314, 2.391)	0.7859	
Idarubicin	142	18 (12.7)	124 (87.3)	NE (NE, NE)	171	22 (12.9)	149 (87.1)	NE (NE, NE)	0.987 (0.529, 1.840)	0.9671	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypocalcaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7685
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	3 (15.8)	16 (84.2)	NE (NE, NE)	0.479 (0.050, 4.613)	0.5150	
Intermediate	195	16 (8.2)	179 (91.8)	NE (NE, NE)	190	15 (7.9)	175 (92.1)	NE (NE, NE)	1.029 (0.509, 2.082)	0.9369	
Unfavorable	19	4 (21.1)	15 (78.9)	NE (NE, NE)	27	4 (14.8)	23 (85.2)	NE (NE, NE)	1.557 (0.389, 6.233)	0.5279	
Unknown	38	5 (13.2)	33 (86.8)	NE (NE, NE)	31	6 (19.4)	25 (80.6)	NE (NE, NE)	0.683 (0.208, 2.237)	0.5256	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypocalcaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1582
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	10 (10.3)	87 (89.7)	NE (NE, NE)	0.430 (0.135, 1.371)	0.1418	
1 - Restricted in Physically Strenuous Activity	133	17 (12.8)	116 (87.2)	NE (NE, NE)	134	12 (9.0)	122 (91.0)	NE (NE, NE)	1.440 (0.688, 3.015)	0.3310	
2 - Ambulatory and Capable of All Selfcare	45	5 (11.1)	40 (88.9)	NE (NE, NE)	36	7 (19.4)	29 (80.6)	NE (NE, NE)	0.584 (0.185, 1.842)	0.3498	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypocalcaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7431
≥3 to ≤25%	94	11 (11.7)	83 (88.3)	NE (NE, NE)	98	11 (11.2)	87 (88.8)	NE (NE, NE)	1.087 (0.471, 2.508)	0.8437	
>25% to ≤50%	141	12 (8.5)	129 (91.5)	NE (NE, NE)	136	14 (10.3)	122 (89.7)	NE (NE, NE)	0.821 (0.380, 1.775)	0.6139	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	4 (11.8)	30 (88.2)	NE (NE, NE)	0.562 (0.103, 3.067)	0.4980	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypocalcaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9928
Yes	139	12 (8.6)	127 (91.4)	NE (NE, NE)	137	12 (8.8)	125 (91.2)	NE (NE, NE)	1.003 (0.451, 2.234)	0.9931	
No	116	11 (9.5)	105 (90.5)	NE (NE, NE)	120	11 (9.2)	109 (90.8)	NE (NE, NE)	1.011 (0.438, 2.331)	0.9820	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypocalcaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0918
≤60	164	13 (7.9)	151 (92.1)	NE (NE, NE)	163	20 (12.3)	143 (87.7)	NE (NE, NE)	0.623 (0.310, 1.253)	0.1810	
>60	101	13 (12.9)	88 (87.1)	NE (NE, NE)	105	9 (8.6)	96 (91.4)	NE (NE, NE)	1.598 (0.683, 3.739)	0.2775	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypoalbuminaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9038
<60	159	13 (8.2)	146 (91.8)	NE (NE, NE)	160	12 (7.5)	148 (92.5)	NE (NE, NE)	1.101 (0.502, 2.413)	0.8093	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	1.124 (0.280, 4.506)	0.8695	
≥65	69	6 (8.7)	63 (91.3)	NE (NE, NE)	65	7 (10.8)	58 (89.2)	NE (36.7, NE)	0.833 (0.280, 2.479)	0.7436	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypoalbuminaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2616
Male	124	14 (11.3)	110 (88.7)	NE (NE, NE)	120	10 (8.3)	110 (91.7)	NE (NE, NE)	1.400 (0.621, 3.154)	0.4153	
Female	141	9 (6.4)	132 (93.6)	NE (NE, NE)	148	13 (8.8)	135 (91.2)	NE (NE, NE)	0.724 (0.309, 1.693)	0.4549	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypoalbuminaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1590
White	157	10 (6.4)	147 (93.6)	NE (NE, NE)	161	15 (9.3)	146 (90.7)	NE (NE, NE)	0.697 (0.313, 1.553)	0.3752	
Non-white	108	13 (12.0)	95 (88.0)	NE (NE, NE)	107	8 (7.5)	99 (92.5)	NE (NE, NE)	1.622 (0.672, 3.915)	0.2773	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypoalbuminaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5896
North America	16	0	16 (100)	NE (NE, NE)	18	2 (11.1)	16 (88.9)	36.7 (36.7, NE)	0.000 (0.000, NE)	0.1695	
Europe	161	13 (8.1)	148 (91.9)	NE (NE, NE)	161	15 (9.3)	146 (90.7)	NE (NE, NE)	0.875 (0.416, 1.841)	0.7253	
Asia/Other Regions	88	10 (11.4)	78 (88.6)	NE (NE, NE)	89	6 (6.7)	83 (93.3)	NE (NE, NE)	1.700 (0.618, 4.676)	0.3001	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypoalbuminaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1173
< 40x10^9/L	132	12 (9.1)	120 (90.9)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	1.793 (0.706, 4.555)	0.2125	
≥ 40x10^9/L	133	11 (8.3)	122 (91.7)	NE (NE, NE)	135	16 (11.9)	119 (88.1)	NE (NE, NE)	0.676 (0.313, 1.459)	0.3166	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypoalbuminaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1298
Daunorubicin	123	15 (12.2)	108 (87.8)	NE (NE, NE)	94	7 (7.4)	87 (92.6)	NE (NE, NE)	1.669 (0.681, 4.094)	0.2575	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	15 (8.8)	156 (91.2)	NE (NE, NE)	0.632 (0.268, 1.492)	0.2908	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypoalbuminaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3479
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	3 (15.8)	16 (84.2)	NE (36.7, NE)	0.784 (0.071, 8.650)	0.8420	
Intermediate	195	18 (9.2)	177 (90.8)	NE (NE, NE)	190	12 (6.3)	178 (93.7)	NE (NE, NE)	1.465 (0.706, 3.043)	0.3030	
Unfavorable	19	3 (15.8)	16 (84.2)	NE (2.6, NE)	27	4 (14.8)	23 (85.2)	NE (NE, NE)	1.164 (0.260, 5.205)	0.8360	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (NE, NE)	0.200 (0.022, 1.787)	0.1084	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypoalbuminaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8524
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	6 (6.2)	91 (93.8)	NE (NE, NE)	0.743 (0.210, 2.635)	0.6429	
1 - Restricted in Physically Strenuous Activity	133	13 (9.8)	120 (90.2)	NE (NE, NE)	134	12 (9.0)	122 (91.0)	NE (NE, NE)	1.124 (0.513, 2.466)	0.7694	
2 - Ambulatory and Capable of All Selfcare	45	6 (13.3)	39 (86.7)	NE (NE, NE)	36	5 (13.9)	31 (86.1)	NE (NE, NE)	0.999 (0.305, 3.276)	0.9919	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypoalbuminaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.0935
≥3 to ≤25%	94	12 (12.8)	82 (87.2)	NE (NE, NE)	98	6 (6.1)	92 (93.9)	NE (NE, NE)	2.225 (0.835, 5.929)	0.1009	
>25% to ≤50%	141	10 (7.1)	131 (92.9)	NE (NE, NE)	136	12 (8.8)	124 (91.2)	NE (NE, NE)	0.795 (0.343, 1.840)	0.5905	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	5 (14.7)	29 (85.3)	NE (NE, NE)	0.227 (0.027, 1.943)	0.1386	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypoalbuminaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4560
Yes	139	14 (10.1)	125 (89.9)	NE (NE, NE)	137	16 (11.7)	121 (88.3)	NE (NE, NE)	0.879 (0.429, 1.800)	0.7218	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	1.536 (0.433, 5.445)	0.5029	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypoalbuminaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6411
≤60	164	14 (8.5)	150 (91.5)	NE (NE, NE)	163	12 (7.4)	151 (92.6)	NE (NE, NE)	1.173 (0.543, 2.537)	0.6828	
>60	101	9 (8.9)	92 (91.1)	NE (NE, NE)	105	11 (10.5)	94 (89.5)	NE (NE, NE)	0.881 (0.365, 2.126)	0.7794	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyperglycaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5263
<60	159	6 (3.8)	153 (96.2)	NE (NE, NE)	160	4 (2.5)	156 (97.5)	NE (NE, NE)	1.345 (0.378, 4.783)	0.6459	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (16.2, NE)	0.533 (0.048, 5.906)	0.6025	
≥65	69	5 (7.2)	64 (92.8)	NE (NE, NE)	65	9 (13.8)	56 (86.2)	NE (NE, NE)	0.543 (0.182, 1.619)	0.2655	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyperglycaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4109
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	1.060 (0.356, 3.163)	0.9169	
Female	141	5 (3.5)	136 (96.5)	NE (NE, NE)	148	9 (6.1)	139 (93.9)	NE (NE, NE)	0.554 (0.185, 1.656)	0.2838	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyperglycaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5530
White	157	5 (3.2)	152 (96.8)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	0.589 (0.192, 1.806)	0.3492	
Non-white	108	7 (6.5)	101 (93.5)	NE (NE, NE)	107	7 (6.5)	100 (93.5)	NE (NE, NE)	0.968 (0.339, 2.763)	0.9520	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyperglycaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7406
North America	16	0	16 (100)	NE (NE, NE)	18	4 (22.2)	14 (77.8)	NE (9.1, NE)	0.000 (0.000, NE)	0.1106	
Europe	161	7 (4.3)	154 (95.7)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	0.824 (0.298, 2.280)	0.7095	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	1.640 (0.391, 6.876)	0.4955	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyperglycaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9739
< 40x10^9/L	132	6 (4.5)	126 (95.5)	NE (NE, NE)	133	8 (6.0)	125 (94.0)	NE (NE, NE)	0.738 (0.256, 2.128)	0.5727	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	0.785 (0.263, 2.344)	0.6625	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyperglycaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8766
Daunorubicin	123	5 (4.1)	118 (95.9)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	0.689 (0.199, 2.386)	0.5539	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	10 (5.8)	161 (94.2)	NE (NE, NE)	0.810 (0.308, 2.132)	0.6689	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyperglycaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7452
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (9.1, NE)	0.000 (0.000, NE)	0.4795	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	8 (4.2)	182 (95.8)	NE (NE, NE)	1.039 (0.400, 2.699)	0.9373	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (2.6, NE)	27	3 (11.1)	24 (88.9)	NE (12.7, NE)	0.746 (0.119, 4.670)	0.7539	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	0.253 (0.026, 2.448)	0.2005	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyperglycaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7888
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	0.755 (0.168, 3.382)	0.7122	
1 - Restricted in Physically Strenuous Activity	133	8 (6.0)	125 (94.0)	NE (NE, NE)	134	9 (6.7)	125 (93.3)	NE (NE, NE)	0.860 (0.331, 2.231)	0.7552	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.433 (0.039, 4.779)	0.4818	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyperglycaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5004
≥3 to ≤25%	94	2 (2.1)	92 (97.9)	NE (NE, NE)	98	6 (6.1)	92 (93.9)	NE (NE, NE)	0.336 (0.068, 1.668)	0.1612	
>25% to ≤50%	141	9 (6.4)	132 (93.6)	NE (NE, NE)	136	8 (5.9)	128 (94.1)	NE (NE, NE)	1.007 (0.388, 2.617)	0.9873	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.806 (0.050, 12.928)	0.8787	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyperglycaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2857
Yes	139	4 (2.9)	135 (97.1)	NE (NE, NE)	137	8 (5.8)	129 (94.2)	NE (NE, NE)	0.465 (0.140, 1.549)	0.2016	
No	116	7 (6.0)	109 (94.0)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	1.118 (0.375, 3.330)	0.8402	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyperglycaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1412
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	4 (2.5)	159 (97.5)	NE (NE, NE)	1.567 (0.457, 5.371)	0.4711	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	11 (10.5)	94 (89.5)	NE (NE, NE)	0.471 (0.164, 1.356)	0.1529	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyponatraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5011
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	10 (6.3)	150 (93.8)	NE (NE, NE)	0.472 (0.161, 1.382)	0.1609	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	2.390 (0.217, 26.355)	0.4630	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	4 (6.2)	61 (93.8)	NE (NE, NE)	0.733 (0.164, 3.275)	0.6829	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyponatraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.0724
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	11 (9.2)	109 (90.8)	NE (NE, NE)	0.328 (0.104, 1.032)	0.0449	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	4 (2.7)	144 (97.3)	NE (NE, NE)	1.561 (0.440, 5.536)	0.4867	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyponatraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6839
White	157	4 (2.5)	153 (97.5)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	0.806 (0.216, 3.003)	0.7462	
Non-white	108	6 (5.6)	102 (94.4)	NE (NE, NE)	107	10 (9.3)	97 (90.7)	NE (NE, NE)	0.564 (0.205, 1.552)	0.2604	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyponatraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9623
North America	16	1 (6.3)	15 (93.8)	NE (4.1, NE)	18	2 (11.1)	16 (88.9)	NE (NE, NE)	0.617 (0.055, 6.863)	0.6917	
Europe	161	3 (1.9)	158 (98.1)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	0.593 (0.142, 2.484)	0.4692	
Asia/Other Regions	88	6 (6.8)	82 (93.2)	NE (NE, NE)	89	8 (9.0)	81 (91.0)	NE (NE, NE)	0.720 (0.249, 2.077)	0.5412	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyponatraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6404
< 40x10^9/L	132	4 (3.0)	128 (97.0)	NE (NE, NE)	133	5 (3.8)	128 (96.2)	NE (NE, NE)	0.824 (0.221, 3.068)	0.7714	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	10 (7.4)	125 (92.6)	NE (NE, NE)	0.531 (0.192, 1.467)	0.2148	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyponatraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3607
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	7 (7.4)	87 (92.6)	NE (NE, NE)	0.428 (0.125, 1.463)	0.1628	
Idarubicin	142	6 (4.2)	136 (95.8)	NE (NE, NE)	171	8 (4.7)	163 (95.3)	NE (NE, NE)	0.864 (0.299, 2.494)	0.7867	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyponatraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6077
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	0.000 (0.000, NE)	0.4268	
Intermediate	195	5 (2.6)	190 (97.4)	NE (NE, NE)	190	10 (5.3)	180 (94.7)	NE (NE, NE)	0.473 (0.162, 1.384)	0.1617	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.502 (0.094, 24.044)	0.7721	
Unknown	38	4 (10.5)	34 (89.5)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	1.640 (0.299, 9.007)	0.5653	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyponatraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7429
0 - Fully Active	87	2 (2.3)	85 (97.7)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	1.127 (0.159, 8.002)	0.9048	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	10 (7.5)	124 (92.5)	NE (NE, NE)	0.474 (0.162, 1.389)	0.1637	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	3 (8.3)	33 (91.7)	NE (NE, NE)	0.772 (0.155, 3.835)	0.7512	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyponatraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4547
≥3 to ≤25%	94	1 (1.1)	93 (98.9)	NE (NE, NE)	98	5 (5.1)	93 (94.9)	NE (NE, NE)	0.209 (0.024, 1.789)	0.1142	
>25% to ≤50%	141	7 (5.0)	134 (95.0)	NE (NE, NE)	136	7 (5.1)	129 (94.9)	NE (NE, NE)	0.935 (0.327, 2.668)	0.8989	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	0.723 (0.120, 4.348)	0.7220	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyponatraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6439
Yes	139	5 (3.6)	134 (96.4)	NE (NE, NE)	137	6 (4.4)	131 (95.6)	NE (NE, NE)	0.825 (0.252, 2.702)	0.7488	
No	116	2 (1.7)	114 (98.3)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.490 (0.090, 2.679)	0.4006	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hyponatraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9533
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	10 (6.1)	153 (93.9)	NE (NE, NE)	0.661 (0.251, 1.737)	0.3975	
>60	101	3 (3.0)	98 (97.0)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	0.621 (0.148, 2.600)	0.5107	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5391
<60	159	91 (57.2)	68 (42.8)	1.8 (1.0, 4.8)	160	95 (59.4)	65 (40.6)	2.1 (1.2, 3.5)	0.955 (0.716, 1.274)	0.7542	
≥60 - <65	37	23 (62.2)	14 (37.8)	2.1 (0.4, 9.7)	43	29 (67.4)	14 (32.6)	0.9 (0.2, 2.0)	0.744 (0.426, 1.299)	0.2945	
≥65	69	38 (55.1)	31 (44.9)	1.7 (0.9, 3.3)	65	34 (52.3)	31 (47.7)	2.7 (0.6, NE)	1.124 (0.707, 1.788)	0.6145	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1926
Male	124	63 (50.8)	61 (49.2)	3.3 (1.7, 9.5)	120	68 (56.7)	52 (43.3)	2.0 (1.1, 4.7)	0.812 (0.576, 1.144)	0.2374	
Female	141	89 (63.1)	52 (36.9)	1.3 (0.6, 1.9)	148	90 (60.8)	58 (39.2)	1.6 (1.1, 2.7)	1.096 (0.817, 1.469)	0.5369	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6445
White	157	79 (50.3)	78 (49.7)	2.3 (1.7, 23.6)	161	85 (52.8)	76 (47.2)	4.2 (1.6, 7.0)	0.910 (0.670, 1.237)	0.5587	
Non-white	108	73 (67.6)	35 (32.4)	1.1 (0.6, 2.0)	107	73 (68.2)	34 (31.8)	1.2 (0.6, 1.8)	1.001 (0.723, 1.385)	0.9962	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3408
North America	16	9 (56.3)	7 (43.8)	9.7 (0.1, NE)	18	17 (94.4)	1 (5.6)	0.4 (0.2, 1.4)	0.526 (0.233, 1.184)	0.1180	
Europe	161	83 (51.6)	78 (48.4)	2.6 (1.7, 9.5)	161	79 (49.1)	82 (50.9)	4.6 (1.6, 19.9)	1.008 (0.740, 1.371)	0.9500	
Asia/Other Regions	88	60 (68.2)	28 (31.8)	0.7 (0.3, 1.8)	89	62 (69.7)	27 (30.3)	1.1 (0.5, 2.0)	1.036 (0.725, 1.479)	0.8521	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5889
< 40x10^9/L	132	74 (56.1)	58 (43.9)	1.8 (0.9, 6.5)	133	76 (57.1)	57 (42.9)	2.7 (1.2, 5.2)	1.002 (0.728, 1.381)	0.9904	
≥ 40x10^9/L	133	78 (58.6)	55 (41.4)	1.9 (1.1, 3.3)	135	82 (60.7)	53 (39.3)	1.5 (0.8, 2.3)	0.897 (0.657, 1.223)	0.4968	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2562
Daunorubicin	123	69 (56.1)	54 (43.9)	2.1 (1.6, 6.5)	94	58 (61.7)	36 (38.3)	1.5 (0.9, 3.3)	0.800 (0.564, 1.136)	0.2124	
Idarubicin	142	83 (58.5)	59 (41.5)	1.3 (0.8, 2.5)	171	99 (57.9)	72 (42.1)	1.8 (1.1, 4.2)	1.051 (0.785, 1.407)	0.7286	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5733
Favorable	13	8 (61.5)	5 (38.5)	0.8 (0.4, NE)	19	13 (68.4)	6 (31.6)	2.4 (0.4, 14.3)	1.197 (0.489, 2.927)	0.6980	
Intermediate	195	118 (60.5)	77 (39.5)	1.7 (0.9, 2.1)	190	113 (59.5)	77 (40.5)	1.5 (1.1, 2.7)	1.006 (0.777, 1.302)	0.9579	
Unfavorable	19	6 (31.6)	13 (68.4)	NE (0.9, NE)	27	14 (51.9)	13 (48.1)	5.2 (0.3, NE)	0.529 (0.200, 1.398)	0.1901	
Unknown	38	20 (52.6)	18 (47.4)	3.3 (1.2, 23.6)	31	18 (58.1)	13 (41.9)	1.6 (0.2, NE)	0.848 (0.444, 1.621)	0.6274	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9507
0 - Fully Active	87	47 (54.0)	40 (46.0)	2.1 (1.1, 22.7)	97	55 (56.7)	42 (43.3)	2.4 (1.2, 4.7)	0.962 (0.652, 1.421)	0.8418	
1 - Restricted in Physically Strenuous Activity	133	78 (58.6)	55 (41.4)	1.8 (1.2, 3.7)	134	79 (59.0)	55 (41.0)	1.8 (1.1, 4.8)	0.950 (0.694, 1.299)	0.7529	
2 - Ambulatory and Capable of All Selfcare	45	27 (60.0)	18 (40.0)	0.7 (0.3, 8.8)	36	23 (63.9)	13 (36.1)	1.1 (0.3, 3.4)	0.891 (0.510, 1.557)	0.6895	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9269
≥3 to ≤25%	94	53 (56.4)	41 (43.6)	2.1 (1.1, 8.8)	98	59 (60.2)	39 (39.8)	1.8 (1.1, 4.8)	0.916 (0.632, 1.328)	0.6428	
>25% to ≤50%	141	85 (60.3)	56 (39.7)	1.6 (0.7, 2.1)	136	85 (62.5)	51 (37.5)	1.2 (0.6, 2.6)	0.959 (0.710, 1.296)	0.7960	
>50%	29	14 (48.3)	15 (51.7)	3.7 (0.8, NE)	34	14 (41.2)	20 (58.8)	5.4 (1.4, NE)	1.177 (0.560, 2.471)	0.6619	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9571
Yes	139	79 (56.8)	60 (43.2)	1.8 (1.2, 6.5)	137	81 (59.1)	56 (40.9)	1.5 (1.0, 5.3)	0.958 (0.703, 1.307)	0.7893	
No	116	71 (61.2)	45 (38.8)	1.6 (0.8, 2.5)	120	73 (60.8)	47 (39.2)	1.6 (1.1, 2.8)	0.966 (0.697, 1.339)	0.8427	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9085
≤60	164	94 (57.3)	70 (42.7)	1.9 (1.0, 4.8)	163	97 (59.5)	66 (40.5)	1.8 (1.1, 3.4)	0.947 (0.713, 1.258)	0.7062	
>60	101	58 (57.4)	43 (42.6)	1.8 (1.2, 3.3)	105	61 (58.1)	44 (41.9)	1.6 (0.6, 4.7)	0.975 (0.680, 1.397)	0.8956	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3860
<60	159	47 (29.6)	112 (70.4)	NE (36.7, NE)	160	37 (23.1)	123 (76.9)	NE (NE, NE)	1.259 (0.818, 1.938)	0.2941	
≥60 - <65	37	10 (27.0)	27 (73.0)	NE (9.2, NE)	43	14 (32.6)	29 (67.4)	NE (5.5, NE)	0.722 (0.320, 1.632)	0.4306	
≥65	69	12 (17.4)	57 (82.6)	NE (NE, NE)	65	15 (23.1)	50 (76.9)	NE (11.7, NE)	0.788 (0.369, 1.685)	0.5401	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1188
Male	124	26 (21.0)	98 (79.0)	NE (NE, NE)	120	31 (25.8)	89 (74.2)	NE (29.0, NE)	0.751 (0.445, 1.266)	0.2819	
Female	141	43 (30.5)	98 (69.5)	NE (36.7, NE)	148	35 (23.6)	113 (76.4)	NE (NE, NE)	1.310 (0.838, 2.048)	0.2335	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4798
White	157	34 (21.7)	123 (78.3)	NE (36.7, NE)	161	36 (22.4)	125 (77.6)	NE (NE, NE)	0.903 (0.564, 1.444)	0.6704	
Non-white	108	35 (32.4)	73 (67.6)	NE (NE, NE)	107	30 (28.0)	77 (72.0)	NE (29.0, NE)	1.177 (0.722, 1.917)	0.5109	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9550
North America	16	2 (12.5)	14 (87.5)	NE (15.2, NE)	18	2 (11.1)	16 (88.9)	NE (11.7, NE)	1.602 (0.223, 11.497)	0.6365	
Europe	161	36 (22.4)	125 (77.6)	NE (36.7, NE)	161	34 (21.1)	127 (78.9)	NE (NE, NE)	1.000 (0.625, 1.599)	0.9982	
Asia/Other Regions	88	31 (35.2)	57 (64.8)	NE (2.5, NE)	89	30 (33.7)	59 (66.3)	29.0 (5.2, NE)	1.057 (0.639, 1.746)	0.8265	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9065
< 40x10^9/L	132	29 (22.0)	103 (78.0)	NE (NE, NE)	133	29 (21.8)	104 (78.2)	NE (NE, NE)	0.999 (0.596, 1.672)	0.9947	
≥ 40x10^9/L	133	40 (30.1)	93 (69.9)	NE (36.7, NE)	135	37 (27.4)	98 (72.6)	NE (29.0, NE)	1.048 (0.670, 1.639)	0.8366	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9698
Daunorubicin	123	33 (26.8)	90 (73.2)	NE (36.7, NE)	94	24 (25.5)	70 (74.5)	NE (NE, NE)	1.018 (0.601, 1.723)	0.9466	
Idarubicin	142	36 (25.4)	106 (74.6)	NE (NE, NE)	171	42 (24.6)	129 (75.4)	NE (29.0, NE)	1.011 (0.648, 1.579)	0.9609	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.0724
Favorable	13	7 (53.8)	6 (46.2)	1.6 (0.4, NE)	19	6 (31.6)	13 (68.4)	NE (4.1, NE)	2.647 (0.863, 8.121)	0.0781	
Intermediate	195	54 (27.7)	141 (72.3)	NE (36.7, NE)	190	44 (23.2)	146 (76.8)	NE (NE, NE)	1.180 (0.792, 1.757)	0.4143	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (15.2, NE)	27	10 (37.0)	17 (63.0)	11.7 (3.2, NE)	0.099 (0.013, 0.783)	0.0073	
Unknown	38	7 (18.4)	31 (81.6)	NE (NE, NE)	31	6 (19.4)	25 (80.6)	NE (NE, NE)	0.902 (0.302, 2.690)	0.8600	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4662
0 - Fully Active	87	24 (27.6)	63 (72.4)	NE (NE, NE)	97	20 (20.6)	77 (79.4)	NE (NE, NE)	1.384 (0.764, 2.508)	0.2836	
1 - Restricted in Physically Strenuous Activity	133	32 (24.1)	101 (75.9)	NE (36.7, NE)	134	33 (24.6)	101 (75.4)	NE (29.0, NE)	0.926 (0.570, 1.507)	0.7609	
2 - Ambulatory and Capable of All Selfcare	45	13 (28.9)	32 (71.1)	NE (2.5, NE)	36	12 (33.3)	24 (66.7)	NE (1.3, NE)	0.788 (0.357, 1.740)	0.5568	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5995
≥3 to ≤25%	94	27 (28.7)	67 (71.3)	36.7 (36.7, NE)	98	28 (28.6)	70 (71.4)	NE (29.0, NE)	0.958 (0.564, 1.627)	0.8777	
>25% to ≤50%	141	35 (24.8)	106 (75.2)	NE (NE, NE)	136	34 (25.0)	102 (75.0)	NE (NE, NE)	1.000 (0.624, 1.604)	0.9987	
>50%	29	7 (24.1)	22 (75.9)	NE (9.2, NE)	34	4 (11.8)	30 (88.2)	NE (NE, NE)	1.768 (0.509, 6.143)	0.3645	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5173
Yes	139	38 (27.3)	101 (72.7)	NE (NE, NE)	137	34 (24.8)	103 (75.2)	NE (NE, NE)	1.132 (0.712, 1.798)	0.6003	
No	116	29 (25.0)	87 (75.0)	NE (36.7, NE)	120	30 (25.0)	90 (75.0)	NE (29.0, NE)	0.899 (0.540, 1.499)	0.6882	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2048
≤60	164	48 (29.3)	116 (70.7)	NE (36.7, NE)	163	38 (23.3)	125 (76.7)	NE (NE, NE)	1.230 (0.803, 1.883)	0.3404	
>60	101	21 (20.8)	80 (79.2)	NE (NE, NE)	105	28 (26.7)	77 (73.3)	NE (18.1, NE)	0.760 (0.431, 1.338)	0.3395	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Pruritus

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0113
<60	159	20 (12.6)	139 (87.4)	NE (NE, NE)	160	24 (15.0)	136 (85.0)	NE (NE, NE)	0.746 (0.412, 1.352)	0.3336	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	11 (25.6)	32 (74.4)	NE (9.1, NE)	0.234 (0.065, 0.851)	0.0168	
≥65	69	12 (17.4)	57 (82.6)	NE (19.7, NE)	65	5 (7.7)	60 (92.3)	NE (NE, NE)	2.745 (0.963, 7.829)	0.0492	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Pruritus

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6214
Male	124	15 (12.1)	109 (87.9)	NE (NE, NE)	120	18 (15.0)	102 (85.0)	NE (NE, NE)	0.735 (0.370, 1.461)	0.3777	
Female	141	20 (14.2)	121 (85.8)	NE (NE, NE)	148	22 (14.9)	126 (85.1)	NE (NE, NE)	0.917 (0.500, 1.681)	0.7795	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Pruritus

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1274
White	157	11 (7.0)	146 (93.0)	NE (NE, NE)	161	19 (11.8)	142 (88.2)	NE (NE, NE)	0.561 (0.267, 1.180)	0.1221	
Non-white	108	24 (22.2)	84 (77.8)	NE (21.2, NE)	107	21 (19.6)	86 (80.4)	NE (NE, NE)	1.119 (0.623, 2.011)	0.7044	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Pruritus

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0359
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	5 (27.8)	13 (72.2)	NE (6.1, NE)	0.218 (0.025, 1.868)	0.1245	
Europe	161	10 (6.2)	151 (93.8)	NE (NE, NE)	161	19 (11.8)	142 (88.2)	NE (NE, NE)	0.495 (0.230, 1.065)	0.0662	
Asia/Other Regions	88	24 (27.3)	64 (72.7)	NE (19.7, NE)	89	16 (18.0)	73 (82.0)	NE (NE, NE)	1.515 (0.804, 2.854)	0.1946	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Pruritus

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0292
< 40x10^9/L	132	21 (15.9)	111 (84.1)	NE (NE, NE)	133	17 (12.8)	116 (87.2)	NE (NE, NE)	1.398 (0.737, 2.651)	0.3039	
≥ 40x10^9/L	133	14 (10.5)	119 (89.5)	NE (NE, NE)	135	23 (17.0)	112 (83.0)	NE (NE, NE)	0.518 (0.266, 1.011)	0.0498	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Pruritus

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2864
Daunorubicin	123	14 (11.4)	109 (88.6)	NE (NE, NE)	94	16 (17.0)	78 (83.0)	NE (NE, NE)	0.626 (0.305, 1.283)	0.1979	
Idarubicin	142	21 (14.8)	121 (85.2)	NE (NE, NE)	171	24 (14.0)	147 (86.0)	NE (NE, NE)	0.995 (0.554, 1.789)	0.9873	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Pruritus

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5664
Favorable	13	2 (15.4)	11 (84.6)	NE (4.4, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	3.861 (0.336, 44.430)	0.2462	
Intermediate	195	26 (13.3)	169 (86.7)	NE (NE, NE)	190	28 (14.7)	162 (85.3)	NE (NE, NE)	0.819 (0.480, 1.399)	0.4649	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	5 (18.5)	22 (81.5)	NE (6.1, NE)	0.533 (0.103, 2.747)	0.4442	
Unknown	38	5 (13.2)	33 (86.8)	NE (NE, NE)	31	6 (19.4)	25 (80.6)	NE (8.7, NE)	0.653 (0.199, 2.149)	0.4802	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Pruritus

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3519
0 - Fully Active	87	10 (11.5)	77 (88.5)	NE (NE, NE)	97	8 (8.2)	89 (91.8)	NE (NE, NE)	1.387 (0.547, 3.516)	0.4911	
1 - Restricted in Physically Strenuous Activity	133	17 (12.8)	116 (87.2)	NE (NE, NE)	134	22 (16.4)	112 (83.6)	NE (NE, NE)	0.689 (0.365, 1.298)	0.2460	
2 - Ambulatory and Capable of All Selfcare	45	8 (17.8)	37 (82.2)	NE (23.5, NE)	36	10 (27.8)	26 (72.2)	NE (3.4, NE)	0.596 (0.234, 1.516)	0.2729	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Pruritus

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2325
≥3 to ≤25%	94	16 (17.0)	78 (83.0)	NE (NE, NE)	98	12 (12.2)	86 (87.8)	NE (NE, NE)	1.471 (0.696, 3.111)	0.3106	
>25% to ≤50%	141	19 (13.5)	122 (86.5)	NE (NE, NE)	136	26 (19.1)	110 (80.9)	NE (NE, NE)	0.648 (0.358, 1.172)	0.1484	
>50%	29	0	29 (100)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.000 (0.000, NE)	0.1464	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Pruritus

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3037
Yes	139	19 (13.7)	120 (86.3)	NE (NE, NE)	137	17 (12.4)	120 (87.6)	NE (NE, NE)	1.070 (0.556, 2.060)	0.8403	
No	116	16 (13.8)	100 (86.2)	NE (NE, NE)	120	22 (18.3)	98 (81.7)	NE (NE, NE)	0.662 (0.347, 1.263)	0.2077	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Pruritus

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3626
≤60	164	20 (12.2)	144 (87.8)	NE (NE, NE)	163	25 (15.3)	138 (84.7)	NE (NE, NE)	0.703 (0.390, 1.268)	0.2409	
>60	101	15 (14.9)	86 (85.1)	NE (NE, NE)	105	15 (14.3)	90 (85.7)	NE (NE, NE)	1.061 (0.519, 2.172)	0.8724	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Alopecia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8095
<60	159	10 (6.3)	149 (93.7)	NE (NE, NE)	160	4 (2.5)	156 (97.5)	NE (NE, NE)	2.493 (0.781, 7.961)	0.1104	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (20.3, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.114 (0.157, 7.917)	0.9141	
≥65	69	6 (8.7)	63 (91.3)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	1.980 (0.495, 7.920)	0.3241	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Alopecia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2618
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	5.921 (0.713, 49.169)	0.0612	
Female	141	12 (8.5)	129 (91.5)	NE (NE, NE)	148	8 (5.4)	140 (94.6)	NE (NE, NE)	1.565 (0.639, 3.830)	0.3220	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Alopecia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7937
White	157	7 (4.5)	150 (95.5)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	1.738 (0.508, 5.947)	0.3728	
Non-white	108	11 (10.2)	97 (89.8)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	2.252 (0.782, 6.482)	0.1214	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Alopecia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2372
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	4 (22.2)	14 (77.8)	NE (NE, NE)	0.298 (0.033, 2.678)	0.2513	
Europe	161	5 (3.1)	156 (96.9)	NE (NE, NE)	161	0	161 (100)	NE (NE, NE)	NE (0.000, NE)	0.0392	
Asia/Other Regions	88	12 (13.6)	76 (86.4)	NE (NE, NE)	89	5 (5.6)	84 (94.4)	NE (NE, NE)	2.543 (0.896, 7.219)	0.0688	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Alopecia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7168
< 40x10^9/L	132	7 (5.3)	125 (94.7)	NE (NE, NE)	133	3 (2.3)	130 (97.7)	NE (NE, NE)	2.403 (0.621, 9.291)	0.1892	
≥ 40x10^9/L	133	11 (8.3)	122 (91.7)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	1.789 (0.660, 4.847)	0.2453	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Alopecia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1582
Daunorubicin	123	9 (7.3)	114 (92.7)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	1.087 (0.386, 3.060)	0.8717	
Idarubicin	142	9 (6.3)	133 (93.7)	NE (NE, NE)	171	3 (1.8)	168 (98.2)	NE (NE, NE)	3.759 (1.018, 13.885)	0.0328	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Alopecia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9418
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	0.000 (0.000, NE)	0.4561	
Intermediate	195	15 (7.7)	180 (92.3)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	2.073 (0.845, 5.086)	0.1033	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.0789	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	0.859 (0.054, 13.748)	0.9144	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Alopecia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6875
0 - Fully Active	87	6 (6.9)	81 (93.1)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	2.244 (0.561, 8.976)	0.2402	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	1.424 (0.452, 4.490)	0.5426	
2 - Ambulatory and Capable of All Selfcare	45	5 (11.1)	40 (88.9)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	4.360 (0.509, 37.359)	0.1422	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Alopecia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9962
≥3 to ≤25%	94	7 (7.4)	87 (92.6)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	1.872 (0.548, 6.398)	0.3085	
>25% to ≤50%	141	9 (6.4)	132 (93.6)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	1.784 (0.598, 5.324)	0.2920	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.1783	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Alopecia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3862
Yes	139	9 (6.5)	130 (93.5)	NE (NE, NE)	137	6 (4.4)	131 (95.6)	NE (NE, NE)	1.493 (0.531, 4.197)	0.4427	
No	116	9 (7.8)	107 (92.2)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	3.084 (0.834, 11.397)	0.0752	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Alopecia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5003
≤60	164	11 (6.7)	153 (93.3)	NE (NE, NE)	163	4 (2.5)	159 (97.5)	NE (NE, NE)	2.716 (0.864, 8.542)	0.0749	
>60	101	7 (6.9)	94 (93.1)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	1.530 (0.485, 4.827)	0.4636	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Erythema

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5697
<60	159	12 (7.5)	147 (92.5)	NE (NE, NE)	160	10 (6.3)	150 (93.8)	NE (NE, NE)	1.090 (0.470, 2.528)	0.8412	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	3.144 (0.326, 30.360)	0.2964	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (27.5, NE)	0.699 (0.117, 4.189)	0.6937	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Erythema

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6365
Male	124	10 (8.1)	114 (91.9)	NE (NE, NE)	120	9 (7.5)	111 (92.5)	NE (NE, NE)	0.985 (0.399, 2.431)	0.9744	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	5 (3.4)	143 (96.6)	NE (NE, NE)	1.445 (0.458, 4.558)	0.5274	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Erythema

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7557
White	157	10 (6.4)	147 (93.6)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	1.081 (0.438, 2.664)	0.8667	
Non-white	108	7 (6.5)	101 (93.5)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	1.346 (0.427, 4.245)	0.6107	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Erythema

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7487
North America	16	1 (6.3)	15 (93.8)	NE (18.0, NE)	18	1 (5.6)	17 (94.4)	NE (9.5, NE)	1.323 (0.081, 21.732)	0.8442	
Europe	161	13 (8.1)	148 (91.9)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	1.390 (0.594, 3.253)	0.4464	
Asia/Other Regions	88	3 (3.4)	85 (96.6)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	0.720 (0.161, 3.221)	0.6663	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Erythema

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4324
< 40x10^9/L	132	10 (7.6)	122 (92.4)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	1.493 (0.568, 3.924)	0.4135	
≥ 40x10^9/L	133	7 (5.3)	126 (94.7)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	0.848 (0.296, 2.425)	0.7578	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Erythema

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1113
Daunorubicin	123	9 (7.3)	114 (92.7)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	3.149 (0.679, 14.600)	0.1220	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	12 (7.0)	159 (93.0)	NE (NE, NE)	0.771 (0.315, 1.888)	0.5681	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Erythema

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9768
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (9.5, NE)	0.000 (0.000, NE)	0.5271	
Intermediate	195	13 (6.7)	182 (93.3)	NE (NE, NE)	190	12 (6.3)	178 (93.7)	NE (NE, NE)	0.956 (0.436, 2.097)	0.9096	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (18.0, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.1561	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	1.749 (0.158, 19.298)	0.6440	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Erythema

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9683
0 - Fully Active	87	7 (8.0)	80 (92.0)	NE (NE, NE)	97	6 (6.2)	91 (93.8)	NE (NE, NE)	1.241 (0.417, 3.695)	0.6979	
1 - Restricted in Physically Strenuous Activity	133	8 (6.0)	125 (94.0)	NE (NE, NE)	134	7 (5.2)	127 (94.8)	NE (NE, NE)	1.087 (0.394, 3.001)	0.8720	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	1.521 (0.135, 17.121)	0.7322	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Erythema

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1734
≥3 to ≤25%	94	11 (11.7)	83 (88.3)	NE (NE, NE)	98	5 (5.1)	93 (94.9)	NE (NE, NE)	2.442 (0.848, 7.031)	0.0871	
>25% to ≤50%	141	6 (4.3)	135 (95.7)	NE (NE, NE)	136	9 (6.6)	127 (93.4)	NE (NE, NE)	0.607 (0.216, 1.709)	0.3399	
>50%	29	0	29 (100)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Erythema

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5836
Yes	139	10 (7.2)	129 (92.8)	NE (NE, NE)	137	7 (5.1)	130 (94.9)	NE (NE, NE)	1.387 (0.527, 3.650)	0.5053	
No	116	7 (6.0)	109 (94.0)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	0.933 (0.327, 2.664)	0.8955	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Erythema

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7358
≤60	164	12 (7.3)	152 (92.7)	NE (NE, NE)	163	10 (6.1)	153 (93.9)	NE (NE, NE)	1.072 (0.462, 2.486)	0.8718	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	4 (3.8)	101 (96.2)	NE (NE, NE)	1.412 (0.378, 5.268)	0.6060	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Urticaria

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2222
<60	159	11 (6.9)	148 (93.1)	NE (NE, NE)	160	5 (3.1)	155 (96.9)	NE (NE, NE)	2.145 (0.744, 6.187)	0.1482	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	0.272 (0.030, 2.439)	0.2128	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	2.151 (0.393, 11.765)	0.3655	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Urticaria

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5732
Male	124	8 (6.5)	116 (93.5)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	1.969 (0.593, 6.538)	0.2601	
Female	141	8 (5.7)	133 (94.3)	NE (NE, NE)	148	7 (4.7)	141 (95.3)	NE (NE, NE)	1.196 (0.434, 3.301)	0.7288	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Urticaria

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9759
White	157	3 (1.9)	154 (98.1)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	1.585 (0.265, 9.485)	0.6117	
Non-white	108	13 (12.0)	95 (88.0)	NE (NE, NE)	107	9 (8.4)	98 (91.6)	NE (NE, NE)	1.460 (0.624, 3.416)	0.3811	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Urticaria

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6915
North America	16	0	16 (100)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	0.000 (0.000, NE)	0.3496	
Europe	161	4 (2.5)	157 (97.5)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	3.682 (0.409, 33.119)	0.2131	
Asia/Other Regions	88	12 (13.6)	76 (86.4)	NE (NE, NE)	89	9 (10.1)	80 (89.9)	NE (NE, NE)	1.377 (0.580, 3.269)	0.4673	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Urticaria

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4468
< 40x10^9/L	132	9 (6.8)	123 (93.2)	NE (NE, NE)	133	5 (3.8)	128 (96.2)	NE (NE, NE)	1.928 (0.646, 5.760)	0.2315	
≥ 40x10^9/L	133	7 (5.3)	126 (94.7)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	1.133 (0.380, 3.373)	0.8222	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Urticaria

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4757
Daunorubicin	123	7 (5.7)	116 (94.3)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	1.014 (0.321, 3.203)	0.9806	
Idarubicin	142	9 (6.3)	133 (93.7)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	1.828 (0.651, 5.138)	0.2451	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Urticaria

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7946
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	0.000 (0.000, NE)	0.4561	
Intermediate	195	14 (7.2)	181 (92.8)	NE (NE, NE)	190	8 (4.2)	182 (95.8)	NE (NE, NE)	1.664 (0.698, 3.970)	0.2457	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.1967	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (10.1, NE)	0.351 (0.032, 3.886)	0.3723	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Urticaria

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8905
0 - Fully Active	87	6 (6.9)	81 (93.1)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	1.651 (0.466, 5.851)	0.4327	
1 - Restricted in Physically Strenuous Activity	133	9 (6.8)	124 (93.2)	NE (NE, NE)	134	6 (4.5)	128 (95.5)	NE (NE, NE)	1.491 (0.530, 4.194)	0.4457	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	0.874 (0.055, 13.996)	0.9239	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Urticaria

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3372
≥3 to ≤25%	94	8 (8.5)	86 (91.5)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	2.901 (0.769, 10.946)	0.0996	
>25% to ≤50%	141	7 (5.0)	134 (95.0)	NE (NE, NE)	136	8 (5.9)	128 (94.1)	NE (NE, NE)	0.846 (0.307, 2.335)	0.7469	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.2850	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Urticaria

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4838
Yes	139	8 (5.8)	131 (94.2)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	1.987 (0.598, 6.604)	0.2532	
No	116	8 (6.9)	108 (93.1)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	1.164 (0.422, 3.210)	0.7713	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Urticaria

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3523
≤60	164	12 (7.3)	152 (92.7)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	1.914 (0.717, 5.110)	0.1874	
>60	101	4 (4.0)	97 (96.0)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	0.875 (0.235, 3.260)	0.8426	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash erythematous

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8010
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	0	160 (100)	NE (NE, NE)	NE (0.000, NE)	0.0238	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.122 (0.158, 7.963)	0.9089	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	1 (1.5)	64 (98.5)	NE (NE, NE)	3.153 (0.328, 30.319)	0.2937	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash erythematous

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6632
Male	124	5 (4.0)	119 (96.0)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	4.782 (0.559, 40.938)	0.1144	
Female	141	5 (3.5)	136 (96.5)	NE (NE, NE)	148	2 (1.4)	146 (98.6)	NE (NE, NE)	2.644 (0.513, 13.630)	0.2268	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash erythematous

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1448
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	8.300 (1.038, 66.395)	0.0169	
Non-white	108	2 (1.9)	106 (98.1)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	1.006 (0.142, 7.141)	0.9956	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash erythematous

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6225
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	1.093 (0.068, 17.486)	0.9497	
Europe	161	7 (4.3)	154 (95.7)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	6.647 (0.817, 54.045)	0.0405	
Asia/Other Regions	88	2 (2.3)	86 (97.7)	NE (NE, NE)	89	1 (1.1)	88 (98.9)	NE (NE, NE)	2.046 (0.186, 22.566)	0.5503	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash erythematous

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9901
< 40x10^9/L	132	3 (2.3)	129 (97.7)	NE (NE, NE)	133	0	133 (100)	NE (NE, NE)	NE (0.000, NE)	0.0749	
≥ 40x10^9/L	133	7 (5.3)	126 (94.7)	NE (NE, NE)	135	3 (2.2)	132 (97.8)	NE (NE, NE)	2.224 (0.575, 8.606)	0.2343	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash erythematous

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1498
Daunorubicin	123	3 (2.4)	120 (97.6)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	1.136 (0.190, 6.799)	0.8887	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	1 (0.6)	170 (99.4)	NE (NE, NE)	8.463 (1.041, 68.803)	0.0164	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash erythematous

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	2 (1.1)	188 (98.9)	NE (NE, NE)	4.220 (0.911, 19.541)	0.0450	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	0.000 (0.000, NE)	0.4386	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.3340	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash erythematous

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9998
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	1.630 (0.272, 9.757)	0.5887	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	0	134 (100)	NE (NE, NE)	NE (0.000, NE)	0.0270	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	1.597 (0.145, 17.610)	0.6997	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash erythematous

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9380
≥3 to ≤25%	94	1 (1.1)	93 (98.9)	NE (NE, NE)	98	0	98 (100)	NE (NE, NE)	NE (0.000, NE)	0.2888	
>25% to ≤50%	141	7 (5.0)	134 (95.0)	NE (NE, NE)	136	2 (1.5)	134 (98.5)	NE (NE, NE)	3.384 (0.703, 16.296)	0.1060	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	2.305 (0.209, 25.424)	0.4827	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash erythematous

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6212
Yes	139	8 (5.8)	131 (94.2)	NE (NE, NE)	137	2 (1.5)	135 (98.5)	NE (NE, NE)	4.058 (0.862, 19.110)	0.0549	
No	116	2 (1.7)	114 (98.3)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	2.020 (0.183, 22.285)	0.5578	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash erythematous

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6690
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	1 (0.6)	162 (99.4)	NE (NE, NE)	5.009 (0.585, 42.875)	0.1020	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	2.749 (0.533, 14.171)	0.2075	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Petechiae

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7988
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	0.839 (0.256, 2.751)	0.7713	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.123 (0.158, 7.979)	0.9081	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	4 (6.2)	61 (93.8)	NE (NE, NE)	0.499 (0.091, 2.725)	0.4130	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Petechiae

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.0280
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	2.278 (0.589, 8.812)	0.2196	
Female	141	2 (1.4)	139 (98.6)	NE (NE, NE)	148	9 (6.1)	139 (93.9)	NE (NE, NE)	0.234 (0.051, 1.084)	0.0430	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Petechiae

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3278
White	157	7 (4.5)	150 (95.5)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	1.025 (0.359, 2.924)	0.9635	
Non-white	108	2 (1.9)	106 (98.1)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	0.391 (0.076, 2.018)	0.2450	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Petechiae

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5544
North America	16	0	16 (100)	NE (NE, NE)	18	3 (16.7)	15 (83.3)	NE (NE, NE)	0.000 (0.000, NE)	0.1378	
Europe	161	8 (5.0)	153 (95.0)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	1.333 (0.462, 3.845)	0.5930	
Asia/Other Regions	88	1 (1.1)	87 (98.9)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	0.345 (0.036, 3.318)	0.3343	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Petechiae

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4879
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	5 (3.8)	128 (96.2)	NE (NE, NE)	1.042 (0.302, 3.598)	0.9476	
≥ 40x10^9/L	133	4 (3.0)	129 (97.0)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	0.559 (0.163, 1.911)	0.3466	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Petechiae

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2990
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	4 (4.3)	90 (95.7)	NE (NE, NE)	0.373 (0.068, 2.037)	0.2357	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	8 (4.7)	163 (95.3)	NE (NE, NE)	1.068 (0.387, 2.945)	0.8989	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Petechiae

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7497
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	8 (4.1)	187 (95.9)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	1.103 (0.400, 3.043)	0.8501	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.000 (0.000, NE)	0.2641	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	0.280 (0.029, 2.688)	0.2398	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Petechiae

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6297
0 - Fully Active	87	1 (1.1)	86 (98.9)	NE (NE, NE)	97	5 (5.2)	92 (94.8)	NE (NE, NE)	0.210 (0.024, 1.796)	0.1154	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	7 (5.2)	127 (94.8)	NE (NE, NE)	0.719 (0.228, 2.266)	0.5725	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.1130	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Petechiae

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7049
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	7 (7.1)	91 (92.9)	NE (NE, NE)	0.446 (0.115, 1.726)	0.2299	
>25% to ≤50%	141	5 (3.5)	136 (96.5)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	0.989 (0.286, 3.418)	0.9865	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.2789	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Petechiae

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2992
Yes	139	4 (2.9)	135 (97.1)	NE (NE, NE)	137	8 (5.8)	129 (94.2)	NE (NE, NE)	0.492 (0.148, 1.636)	0.2375	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	1.302 (0.349, 4.847)	0.6935	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Petechiae

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8702
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	0.826 (0.252, 2.708)	0.7513	
>60	101	4 (4.0)	97 (96.0)	NE (NE, NE)	105	6 (5.7)	99 (94.3)	NE (NE, NE)	0.716 (0.202, 2.538)	0.6035	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash maculo-papular

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3717
<60	159	3 (1.9)	156 (98.1)	NE (NE, NE)	160	8 (5.0)	152 (95.0)	NE (NE, NE)	0.353 (0.094, 1.334)	0.1088	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (16.1, NE)	43	3 (7.0)	40 (93.0)	NE (NE, NE)	1.272 (0.283, 5.717)	0.7529	
≥65	69	1 (1.4)	68 (98.6)	NE (NE, NE)	65	1 (1.5)	64 (98.5)	NE (NE, NE)	0.971 (0.061, 15.522)	0.9832	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash maculo-papular

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1446
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.815 (0.331, 9.946)	0.4860	
Female	141	4 (2.8)	137 (97.2)	NE (NE, NE)	148	10 (6.8)	138 (93.2)	NE (NE, NE)	0.389 (0.122, 1.241)	0.0982	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash maculo-papular

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2491
White	157	4 (2.5)	153 (97.5)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	0.423 (0.130, 1.378)	0.1414	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	1.254 (0.280, 5.607)	0.7667	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash maculo-papular

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2982
North America	16	2 (12.5)	14 (87.5)	NE (9.7, NE)	18	7 (38.9)	11 (61.1)	NE (1.3, NE)	0.290 (0.060, 1.400)	0.1018	
Europe	161	4 (2.5)	157 (97.5)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	1.831 (0.334, 10.041)	0.4796	
Asia/Other Regions	88	2 (2.3)	86 (97.7)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	0.629 (0.105, 3.774)	0.6093	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash maculo-papular

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4305
< 40x10^9/L	132	3 (2.3)	129 (97.7)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	0.436 (0.113, 1.686)	0.2157	
≥ 40x10^9/L	133	5 (3.8)	128 (96.2)	NE (NE, NE)	135	5 (3.7)	130 (96.3)	NE (NE, NE)	0.859 (0.247, 2.982)	0.8114	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash maculo-papular

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6045
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	0.464 (0.131, 1.646)	0.2232	
Idarubicin	142	4 (2.8)	138 (97.2)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	0.744 (0.209, 2.644)	0.6471	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash maculo-papular

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9570
Favorable	13	0	13 (100)	NE (NE, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	0.000 (0.000, NE)	0.2451	
Intermediate	195	6 (3.1)	189 (96.9)	NE (NE, NE)	190	9 (4.7)	181 (95.3)	NE (NE, NE)	0.586 (0.208, 1.650)	0.3061	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (4.6, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.354 (0.084, 21.726)	0.8299	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.4054	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash maculo-papular

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9219
0 - Fully Active	87	2 (2.3)	85 (97.7)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	0.539 (0.099, 2.946)	0.4687	
1 - Restricted in Physically Strenuous Activity	133	6 (4.5)	127 (95.5)	NE (NE, NE)	134	7 (5.2)	127 (94.8)	NE (NE, NE)	0.787 (0.264, 2.345)	0.6676	
2 - Ambulatory and Capable of All Selfcare	45	0	45 (100)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	0.000 (0.000, NE)	0.3031	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash maculo-papular

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9487
≥3 to ≤25%	94	2 (2.1)	92 (97.9)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	0.519 (0.095, 2.834)	0.4415	
>25% to ≤50%	141	4 (2.8)	137 (97.2)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	0.729 (0.195, 2.720)	0.6357	
>50%	29	2 (6.9)	27 (93.1)	NE (16.1, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	0.512 (0.080, 3.273)	0.4727	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash maculo-papular

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0239
Yes	139	2 (1.4)	137 (98.6)	NE (NE, NE)	137	8 (5.8)	129 (94.2)	NE (NE, NE)	0.228 (0.048, 1.075)	0.0412	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	2.894 (0.584, 14.345)	0.1729	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Rash maculo-papular

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3584
≤60	164	4 (2.4)	160 (97.6)	NE (NE, NE)	163	8 (4.9)	155 (95.1)	NE (NE, NE)	0.460 (0.138, 1.530)	0.1943	
>60	101	4 (4.0)	97 (96.0)	NE (NE, NE)	105	4 (3.8)	101 (96.2)	NE (NE, NE)	1.031 (0.258, 4.125)	0.9653	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Dry skin

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7236
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	5 (3.1)	155 (96.9)	NE (NE, NE)	0.907 (0.262, 3.141)	0.8771	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	3 (7.0)	40 (93.0)	NE (14.1, NE)	0.324 (0.033, 3.139)	0.3058	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	1.029 (0.145, 7.312)	0.9769	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Dry skin

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9577
Male	124	5 (4.0)	119 (96.0)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.740 (0.225, 2.434)	0.6194	
Female	141	3 (2.1)	138 (97.9)	NE (NE, NE)	148	4 (2.7)	144 (97.3)	NE (NE, NE)	0.736 (0.165, 3.291)	0.6870	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Dry skin

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7245
White	157	3 (1.9)	154 (98.1)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	0.862 (0.173, 4.292)	0.8565	
Non-white	108	5 (4.6)	103 (95.4)	NE (NE, NE)	107	7 (6.5)	100 (93.5)	NE (NE, NE)	0.682 (0.216, 2.149)	0.5102	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Dry skin

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7101
North America	16	2 (12.5)	14 (87.5)	NE (10.6, NE)	18	2 (11.1)	16 (88.9)	NE (4.8, NE)	1.656 (0.230, 11.917)	0.6126	
Europe	161	1 (0.6)	160 (99.4)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	0.509 (0.046, 5.612)	0.5738	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	6 (6.7)	83 (93.3)	NE (NE, NE)	0.799 (0.244, 2.622)	0.7104	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Dry skin

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1976
< 40x10^9/L	132	2 (1.5)	130 (98.5)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	0.344 (0.069, 1.705)	0.1709	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	4 (3.0)	131 (97.0)	NE (NE, NE)	1.315 (0.369, 4.690)	0.6714	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Dry skin

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5240
Daunorubicin	123	3 (2.4)	120 (97.6)	NE (NE, NE)	94	4 (4.3)	90 (95.7)	NE (NE, NE)	0.555 (0.124, 2.480)	0.4342	
Idarubicin	142	5 (3.5)	137 (96.5)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	0.913 (0.278, 2.998)	0.8801	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Dry skin

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9910
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (10.1, NE)	0.000 (0.000, NE)	0.5271	
Intermediate	195	7 (3.6)	188 (96.4)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	0.897 (0.314, 2.563)	0.8389	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (4.4, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.354 (0.085, 21.649)	0.8297	
Unknown	38	0	38 (100)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	0.000 (0.000, NE)	0.3006	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Dry skin

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7952
0 - Fully Active	87	2 (2.3)	85 (97.7)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	1.060 (0.149, 7.538)	0.9532	
1 - Restricted in Physically Strenuous Activity	133	4 (3.0)	129 (97.0)	NE (NE, NE)	134	8 (6.0)	126 (94.0)	NE (NE, NE)	0.459 (0.138, 1.528)	0.1934	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.1890	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Dry skin

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9761
≥3 to ≤25%	94	0	94 (100)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	0.000 (0.000, NE)	0.0510	
>25% to ≤50%	141	7 (5.0)	134 (95.0)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	1.259 (0.399, 3.975)	0.6942	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.983 (0.061, 15.845)	0.9906	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Dry skin

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3475
Yes	139	5 (3.6)	134 (96.4)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	1.211 (0.324, 4.525)	0.7755	
No	116	3 (2.6)	113 (97.4)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.455 (0.114, 1.823)	0.2540	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Dry skin

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7350
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	5 (3.1)	158 (96.9)	NE (NE, NE)	0.891 (0.257, 3.088)	0.8558	
>60	101	3 (3.0)	98 (97.0)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	0.627 (0.150, 2.625)	0.5190	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1506
<60	159	86 (54.1)	73 (45.9)	6.2 (3.0, 9.5)	160	70 (43.8)	90 (56.3)	6.9 (4.0, NE)	1.164 (0.849, 1.597)	0.3431	
≥60 - <65	37	19 (51.4)	18 (48.6)	6.0 (0.3, NE)	43	15 (34.9)	28 (65.1)	31.2 (9.6, NE)	1.707 (0.866, 3.367)	0.1218	
≥65	69	35 (50.7)	34 (49.3)	2.9 (1.6, 8.0)	65	20 (30.8)	45 (69.2)	NE (6.1, NE)	2.165 (1.248, 3.756)	0.0050	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5527
Male	124	71 (57.3)	53 (42.7)	3.0 (1.8, 8.0)	120	47 (39.2)	73 (60.8)	9.2 (4.0, NE)	1.532 (1.060, 2.216)	0.0226	
Female	141	69 (48.9)	72 (51.1)	7.1 (2.7, 10.8)	148	58 (39.2)	90 (60.8)	11.2 (6.1, NE)	1.315 (0.927, 1.864)	0.1220	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9290
White	157	79 (50.3)	78 (49.7)	6.0 (2.3, 11.9)	161	60 (37.3)	101 (62.7)	9.6 (6.3, NE)	1.435 (1.025, 2.009)	0.0345	
Non-white	108	61 (56.5)	47 (43.5)	3.4 (1.9, 8.0)	107	45 (42.1)	62 (57.9)	11.2 (3.1, NE)	1.410 (0.959, 2.075)	0.0791	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5876
North America	16	11 (68.8)	5 (31.3)	1.3 (0.3, NE)	18	13 (72.2)	5 (27.8)	0.6 (0.1, 6.3)	0.980 (0.429, 2.239)	0.9678	
Europe	161	79 (49.1)	82 (50.9)	8.0 (3.6, 15.2)	161	53 (32.9)	108 (67.1)	NE (9.0, NE)	1.571 (1.109, 2.226)	0.0104	
Asia/Other Regions	88	50 (56.8)	38 (43.2)	3.0 (1.7, 7.6)	89	39 (43.8)	50 (56.2)	6.9 (2.7, NE)	1.369 (0.900, 2.081)	0.1416	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7543
< 40x10^9/L	132	70 (53.0)	62 (47.0)	7.0 (2.4, 8.6)	133	54 (40.6)	79 (59.4)	9.6 (6.6, NE)	1.480 (1.037, 2.112)	0.0296	
≥ 40x10^9/L	133	70 (52.6)	63 (47.4)	3.2 (1.9, 15.9)	135	51 (37.8)	84 (62.2)	NE (4.2, NE)	1.383 (0.964, 1.985)	0.0758	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis – DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1353
Daunorubicin	123	59 (48.0)	64 (52.0)	8.3 (2.7, 15.9)	94	39 (41.5)	55 (58.5)	9.0 (5.5, NE)	1.127 (0.752, 1.691)	0.5488	
Idarubicin	142	81 (57.0)	61 (43.0)	3.4 (1.9, 7.2)	171	65 (38.0)	106 (62.0)	12.6 (6.1, NE)	1.675 (1.209, 2.322)	0.0018	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9865
Favorable	13	6 (46.2)	7 (53.8)	NE (0.2, NE)	19	8 (42.1)	11 (57.9)	6.6 (1.4, NE)	1.261 (0.437, 3.644)	0.6676	
Intermediate	195	107 (54.9)	88 (45.1)	4.5 (2.4, 8.3)	190	74 (38.9)	116 (61.1)	9.6 (6.0, NE)	1.482 (1.101, 1.993)	0.0089	
Unfavorable	19	11 (57.9)	8 (42.1)	4.0 (0.8, 15.9)	27	12 (44.4)	15 (55.6)	11.2 (0.5, NE)	1.206 (0.531, 2.738)	0.6460	
Unknown	38	16 (42.1)	22 (57.9)	NE (1.7, NE)	31	10 (32.3)	21 (67.7)	17.0 (5.5, NE)	1.597 (0.722, 3.532)	0.2436	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2422
0 - Fully Active	87	49 (56.3)	38 (43.7)	3.4 (1.8, 8.3)	97	33 (34.0)	64 (66.0)	NE (7.1, NE)	1.899 (1.221, 2.954)	0.0039	
1 - Restricted in Physically Strenuous Activity	133	66 (49.6)	67 (50.4)	7.1 (2.7, 11.9)	134	58 (43.3)	76 (56.7)	6.9 (5.5, NE)	1.163 (0.817, 1.655)	0.4107	
2 - Ambulatory and Capable of All Selfcare	45	25 (55.6)	20 (44.4)	5.8 (1.6, 10.3)	36	14 (38.9)	22 (61.1)	NE (1.2, NE)	1.335 (0.690, 2.584)	0.3707	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.0243
≥3 to ≤25%	94	51 (54.3)	43 (45.7)	3.0 (1.8, 11.0)	98	37 (37.8)	61 (62.2)	11.2 (6.1, NE)	1.756 (1.148, 2.684)	0.0086	
>25% to ≤50%	141	78 (55.3)	63 (44.7)	3.6 (1.9, 7.6)	136	52 (38.2)	84 (61.8)	17.0 (6.0, NE)	1.523 (1.072, 2.163)	0.0179	
>50%	29	11 (37.9)	18 (62.1)	10.3 (4.3, NE)	34	16 (47.1)	18 (52.9)	1.8 (0.7, NE)	0.505 (0.228, 1.117)	0.0870	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2605
Yes	139	72 (51.8)	67 (48.2)	7.0 (3.0, 10.3)	137	59 (43.1)	78 (56.9)	9.6 (5.8, NE)	1.320 (0.935, 1.863)	0.1137	
No	116	61 (52.6)	55 (47.4)	3.2 (1.9, 11.0)	120	36 (30.0)	84 (70.0)	NE (6.1, NE)	1.797 (1.190, 2.715)	0.0046	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0812
≤60	164	88 (53.7)	76 (46.3)	7.0 (3.0, 9.5)	163	70 (42.9)	93 (57.1)	6.9 (4.2, NE)	1.182 (0.863, 1.619)	0.2957	
>60	101	52 (51.5)	49 (48.5)	4.3 (1.6, 8.3)	105	35 (33.3)	70 (66.7)	31.2 (9.2, NE)	1.907 (1.242, 2.929)	0.0028	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3782
<60	159	29 (18.2)	130 (81.8)	NE (NE, NE)	160	22 (13.8)	138 (86.3)	NE (NE, NE)	1.216 (0.697, 2.122)	0.4892	
≥60 - <65	37	5 (13.5)	32 (86.5)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	2.584 (0.498, 13.419)	0.2415	
≥65	69	8 (11.6)	61 (88.4)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	2.918 (0.774, 11.008)	0.0974	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3933
Male	124	25 (20.2)	99 (79.8)	NE (NE, NE)	120	13 (10.8)	107 (89.2)	NE (NE, NE)	1.824 (0.933, 3.568)	0.0746	
Female	141	17 (12.1)	124 (87.9)	NE (NE, NE)	148	14 (9.5)	134 (90.5)	NE (NE, NE)	1.228 (0.604, 2.496)	0.5691	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3036
White	157	22 (14.0)	135 (86.0)	NE (NE, NE)	161	11 (6.8)	150 (93.2)	NE (NE, NE)	1.935 (0.937, 3.998)	0.0695	
Non-white	108	20 (18.5)	88 (81.5)	NE (NE, NE)	107	16 (15.0)	91 (85.0)	NE (NE, NE)	1.201 (0.622, 2.320)	0.5843	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2708
North America	16	4 (25.0)	12 (75.0)	17.4 (1.6, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.0131	
Europe	161	19 (11.8)	142 (88.2)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	2.162 (0.944, 4.949)	0.0614	
Asia/Other Regions	88	19 (21.6)	69 (78.4)	NE (NE, NE)	89	19 (21.3)	70 (78.7)	NE (17.0, NE)	0.962 (0.509, 1.821)	0.9073	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6789
< 40x10^9/L	132	22 (16.7)	110 (83.3)	NE (NE, NE)	133	14 (10.5)	119 (89.5)	NE (NE, NE)	1.665 (0.851, 3.257)	0.1323	
≥ 40x10^9/L	133	20 (15.0)	113 (85.0)	NE (NE, NE)	135	13 (9.6)	122 (90.4)	NE (NE, NE)	1.402 (0.696, 2.823)	0.3421	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8385
Daunorubicin	123	13 (10.6)	110 (89.4)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	1.577 (0.598, 4.158)	0.3524	
Idarubicin	142	29 (20.4)	113 (79.6)	NE (NE, NE)	171	20 (11.7)	151 (88.3)	NE (NE, NE)	1.727 (0.976, 3.054)	0.0573	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4232
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	3 (15.8)	16 (84.2)	NE (NE, NE)	0.560 (0.058, 5.393)	0.6108	
Intermediate	195	33 (16.9)	162 (83.1)	NE (NE, NE)	190	16 (8.4)	174 (91.6)	NE (NE, NE)	1.912 (1.052, 3.475)	0.0305	
Unfavorable	19	5 (26.3)	14 (73.7)	15.9 (13.1, NE)	27	4 (14.8)	23 (85.2)	NE (NE, NE)	1.509 (0.395, 5.762)	0.5450	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (8.8, NE)	0.549 (0.122, 2.478)	0.4292	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3743
0 - Fully Active	87	16 (18.4)	71 (81.6)	NE (20.7, NE)	97	8 (8.2)	89 (91.8)	NE (NE, NE)	2.108 (0.901, 4.930)	0.0780	
1 - Restricted in Physically Strenuous Activity	133	19 (14.3)	114 (85.7)	NE (NE, NE)	134	13 (9.7)	121 (90.3)	NE (NE, NE)	1.460 (0.721, 2.959)	0.2907	
2 - Ambulatory and Capable of All Selfcare	45	7 (15.6)	38 (84.4)	NE (8.2, NE)	36	6 (16.7)	30 (83.3)	NE (NE, NE)	0.860 (0.287, 2.574)	0.7871	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4979
≥3 to ≤25%	94	16 (17.0)	78 (83.0)	NE (NE, NE)	98	8 (8.2)	90 (91.8)	NE (NE, NE)	2.318 (0.992, 5.420)	0.0457	
>25% to ≤50%	141	21 (14.9)	120 (85.1)	NE (NE, NE)	136	15 (11.0)	121 (89.0)	NE (NE, NE)	1.245 (0.641, 2.419)	0.5169	
>50%	29	5 (17.2)	24 (82.8)	NE (15.9, NE)	34	4 (11.8)	30 (88.2)	NE (NE, NE)	0.891 (0.224, 3.540)	0.8701	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5705
Yes	139	21 (15.1)	118 (84.9)	NE (NE, NE)	137	10 (7.3)	127 (92.7)	NE (NE, NE)	2.058 (0.968, 4.375)	0.0554	
No	116	19 (16.4)	97 (83.6)	NE (NE, NE)	120	12 (10.0)	108 (90.0)	NE (NE, NE)	1.518 (0.736, 3.130)	0.2546	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2071
≤60	164	30 (18.3)	134 (81.7)	NE (NE, NE)	163	22 (13.5)	141 (86.5)	NE (NE, NE)	1.235 (0.711, 2.145)	0.4529	
>60	101	12 (11.9)	89 (88.1)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	2.633 (0.927, 7.481)	0.0589	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Electrocardiogram QT prolonged

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3882
<60	159	15 (9.4)	144 (90.6)	NE (NE, NE)	160	5 (3.1)	155 (96.9)	NE (NE, NE)	2.967 (1.077, 8.174)	0.0272	
≥60 - <65	37	10 (27.0)	27 (73.0)	NE (12.3, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	11.674 (1.492, 91.310)	0.0029	
≥65	69	11 (15.9)	58 (84.1)	NE (22.9, NE)	65	5 (7.7)	60 (92.3)	NE (NE, NE)	2.490 (0.862, 7.188)	0.0808	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Electrocardiogram QT prolonged

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7067
Male	124	13 (10.5)	111 (89.5)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	4.351 (1.240, 15.269)	0.0121	
Female	141	23 (16.3)	118 (83.7)	NE (NE, NE)	148	8 (5.4)	140 (94.6)	NE (NE, NE)	3.063 (1.370, 6.850)	0.0041	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Electrocardiogram QT prolonged

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8224
White	157	21 (13.4)	136 (86.6)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	3.582 (1.445, 8.880)	0.0032	
Non-white	108	15 (13.9)	93 (86.1)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	3.059 (1.112, 8.418)	0.0224	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Electrocardiogram QT prolonged

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5680
North America	16	5 (31.3)	11 (68.8)	NE (0.9, NE)	18	1 (5.6)	17 (94.4)	NE (6.2, NE)	6.845 (0.797, 58.778)	0.0425	
Europe	161	18 (11.2)	143 (88.8)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	2.556 (1.067, 6.123)	0.0286	
Asia/Other Regions	88	13 (14.8)	75 (85.2)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	4.562 (1.299, 16.012)	0.0093	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Electrocardiogram QT prolonged

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1282
< 40x10^9/L	132	16 (12.1)	116 (87.9)	NE (NE, NE)	133	8 (6.0)	125 (94.0)	NE (NE, NE)	2.116 (0.905, 4.945)	0.0761	
≥ 40x10^9/L	133	20 (15.0)	113 (85.0)	NE (NE, NE)	135	3 (2.2)	132 (97.8)	NE (NE, NE)	6.642 (1.972, 22.371)	0.0004	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Electrocardiogram QT prolonged

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1910
Daunorubicin	123	16 (13.0)	107 (87.0)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	2.029 (0.794, 5.189)	0.1300	
Idarubicin	142	20 (14.1)	122 (85.9)	NE (NE, NE)	171	5 (2.9)	166 (97.1)	NE (NE, NE)	4.893 (1.836, 13.042)	0.0004	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Electrocardiogram QT prolonged

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7446
Favorable	13	2 (15.4)	11 (84.6)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.0811	
Intermediate	195	26 (13.3)	169 (86.7)	NE (NE, NE)	190	6 (3.2)	184 (96.8)	NE (NE, NE)	4.166 (1.714, 10.126)	0.0006	
Unfavorable	19	3 (15.8)	16 (84.2)	NE (7.2, NE)	27	3 (11.1)	24 (88.9)	NE (6.2, NE)	1.538 (0.310, 7.631)	0.5958	
Unknown	38	5 (13.2)	33 (86.8)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	4.225 (0.492, 36.298)	0.1531	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Electrocardiogram QT prolonged

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8054
0 - Fully Active	87	15 (17.2)	72 (82.8)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	4.314 (1.431, 13.002)	0.0046	
1 - Restricted in Physically Strenuous Activity	133	15 (11.3)	118 (88.7)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	3.090 (1.123, 8.503)	0.0212	
2 - Ambulatory and Capable of All Selfcare	45	6 (13.3)	39 (86.7)	NE (20.0, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	2.127 (0.422, 10.708)	0.3483	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Electrocardiogram QT prolonged

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2887
≥3 to ≤25%	94	10 (10.6)	84 (89.4)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	2.764 (0.867, 8.816)	0.0730	
>25% to ≤50%	141	22 (15.6)	119 (84.4)	NE (NE, NE)	136	4 (2.9)	132 (97.1)	NE (NE, NE)	5.524 (1.903, 16.033)	0.0004	
>50%	29	4 (13.8)	25 (86.2)	NE (20.0, NE)	34	3 (8.8)	31 (91.2)	NE (9.7, NE)	0.951 (0.204, 4.437)	0.9495	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Electrocardiogram QT prolonged

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6947
Yes	139	20 (14.4)	119 (85.6)	NE (NE, NE)	137	6 (4.4)	131 (95.6)	NE (NE, NE)	3.408 (1.368, 8.488)	0.0050	
No	116	14 (12.1)	102 (87.9)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	4.695 (1.348, 16.351)	0.0074	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Electrocardiogram QT prolonged

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7406
≤60	164	16 (9.8)	148 (90.2)	NE (NE, NE)	163	5 (3.1)	158 (96.9)	NE (NE, NE)	3.109 (1.137, 8.496)	0.0197	
>60	101	20 (19.8)	81 (80.2)	NE (22.9, NE)	105	6 (5.7)	99 (94.3)	NE (NE, NE)	3.801 (1.526, 9.467)	0.0020	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Aspartate aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1525
<60	159	17 (10.7)	142 (89.3)	NE (NE, NE)	160	16 (10.0)	144 (90.0)	NE (NE, NE)	0.950 (0.478, 1.887)	0.8820	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	2.063 (0.375, 11.337)	0.3947	
≥65	69	7 (10.1)	62 (89.9)	NE (NE, NE)	65	1 (1.5)	64 (98.5)	NE (NE, NE)	7.512 (0.924, 61.093)	0.0262	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Aspartate aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9209
Male	124	15 (12.1)	109 (87.9)	NE (NE, NE)	120	10 (8.3)	110 (91.7)	NE (NE, NE)	1.354 (0.607, 3.018)	0.4569	
Female	141	13 (9.2)	128 (90.8)	NE (NE, NE)	148	9 (6.1)	139 (93.9)	NE (NE, NE)	1.478 (0.631, 3.463)	0.3660	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Aspartate aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.0383
White	157	14 (8.9)	143 (91.1)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	3.401 (1.117, 10.355)	0.0220	
Non-white	108	14 (13.0)	94 (87.0)	NE (NE, NE)	107	15 (14.0)	92 (86.0)	NE (NE, NE)	0.856 (0.413, 1.775)	0.6753	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Aspartate aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0970
North America	16	3 (18.8)	13 (81.3)	NE (1.6, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.0408	
Europe	161	12 (7.5)	149 (92.5)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	3.716 (1.046, 13.199)	0.0295	
Asia/Other Regions	88	13 (14.8)	75 (85.2)	NE (NE, NE)	89	16 (18.0)	73 (82.0)	NE (NE, NE)	0.757 (0.364, 1.577)	0.4559	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Aspartate aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6338
< 40x10^9/L	132	14 (10.6)	118 (89.4)	NE (NE, NE)	133	9 (6.8)	124 (93.2)	NE (NE, NE)	1.621 (0.701, 3.751)	0.2543	
≥ 40x10^9/L	133	14 (10.5)	119 (89.5)	NE (NE, NE)	135	10 (7.4)	125 (92.6)	NE (NE, NE)	1.245 (0.551, 2.813)	0.5962	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Aspartate aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8657
Daunorubicin	123	11 (8.9)	112 (91.1)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	1.594 (0.553, 4.594)	0.3836	
Idarubicin	142	17 (12.0)	125 (88.0)	NE (NE, NE)	171	14 (8.2)	157 (91.8)	NE (NE, NE)	1.395 (0.686, 2.834)	0.3553	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Aspartate aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3875
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	0.773 (0.070, 8.527)	0.8329	
Intermediate	195	23 (11.8)	172 (88.2)	NE (NE, NE)	190	10 (5.3)	180 (94.7)	NE (NE, NE)	2.075 (0.987, 4.363)	0.0489	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	4 (14.8)	23 (85.2)	NE (NE, NE)	0.773 (0.142, 4.221)	0.7655	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (8.8, NE)	0.469 (0.077, 2.839)	0.3987	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Aspartate aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3113
0 - Fully Active	87	10 (11.5)	77 (88.5)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	2.383 (0.745, 7.626)	0.1313	
1 - Restricted in Physically Strenuous Activity	133	13 (9.8)	120 (90.2)	NE (NE, NE)	134	10 (7.5)	124 (92.5)	NE (NE, NE)	1.313 (0.576, 2.996)	0.5170	
2 - Ambulatory and Capable of All Selfcare	45	5 (11.1)	40 (88.9)	NE (NE, NE)	36	5 (13.9)	31 (86.1)	NE (NE, NE)	0.741 (0.214, 2.571)	0.6355	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Aspartate aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2419
≥3 to ≤25%	94	11 (11.7)	83 (88.3)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	3.008 (0.957, 9.461)	0.0478	
>25% to ≤50%	141	16 (11.3)	125 (88.7)	NE (NE, NE)	136	13 (9.6)	123 (90.4)	NE (NE, NE)	1.105 (0.531, 2.299)	0.7883	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.495 (0.045, 5.492)	0.5586	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Aspartate aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1152
Yes	139	14 (10.1)	125 (89.9)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	3.425 (1.126, 10.420)	0.0211	
No	116	12 (10.3)	104 (89.7)	NE (NE, NE)	120	10 (8.3)	110 (91.7)	NE (NE, NE)	1.083 (0.466, 2.517)	0.8513	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Aspartate aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0491
≤60	164	17 (10.4)	147 (89.6)	NE (NE, NE)	163	16 (9.8)	147 (90.2)	NE (NE, NE)	0.934 (0.470, 1.856)	0.8442	
>60	101	11 (10.9)	90 (89.1)	NE (NE, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	4.021 (1.121, 14.423)	0.0208	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7176
<60	159	21 (13.2)	138 (86.8)	NE (NE, NE)	160	8 (5.0)	152 (95.0)	NE (NE, NE)	2.238 (0.990, 5.061)	0.0468	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (25.7, NE)	43	2 (4.7)	41 (95.3)	NE (31.2, NE)	1.146 (0.161, 8.148)	0.8917	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	2.087 (0.382, 11.399)	0.3852	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6013
Male	124	12 (9.7)	112 (90.3)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	1.797 (0.673, 4.798)	0.2351	
Female	141	15 (10.6)	126 (89.4)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	2.415 (0.937, 6.227)	0.0596	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4315
White	157	10 (6.4)	147 (93.6)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	1.565 (0.568, 4.313)	0.3824	
Non-white	108	17 (15.7)	91 (84.3)	NE (25.7, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	2.666 (1.050, 6.768)	0.0318	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.1031
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	5 (27.8)	13 (72.2)	31.2 (6.3, NE)	0.227 (0.026, 1.954)	0.1403	
Europe	161	11 (6.8)	150 (93.2)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	4.931 (1.092, 22.265)	0.0214	
Asia/Other Regions	88	15 (17.0)	73 (83.0)	NE (15.2, NE)	89	5 (5.6)	84 (94.4)	NE (NE, NE)	2.677 (0.970, 7.383)	0.0479	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5693
< 40x10^9/L	132	14 (10.6)	118 (89.4)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	2.536 (0.974, 6.602)	0.0481	
≥ 40x10^9/L	133	13 (9.8)	120 (90.2)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	1.687 (0.639, 4.456)	0.2859	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4590
Daunorubicin	123	11 (8.9)	112 (91.1)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (31.2, NE)	3.914 (0.866, 17.686)	0.0555	
Idarubicin	142	16 (11.3)	126 (88.7)	NE (NE, NE)	171	9 (5.3)	162 (94.7)	NE (NE, NE)	1.967 (0.869, 4.453)	0.0983	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5777
Favorable	13	2 (15.4)	11 (84.6)	NE (1.7, NE)	19	4 (21.1)	15 (78.9)	NE (6.3, NE)	0.852 (0.156, 4.668)	0.8538	
Intermediate	195	18 (9.2)	177 (90.8)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	2.225 (0.928, 5.334)	0.0656	
Unfavorable	19	4 (21.1)	15 (78.9)	NE (5.3, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	5.447 (0.607, 48.868)	0.0891	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.1330	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6964
0 - Fully Active	87	9 (10.3)	78 (89.7)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	3.023 (0.818, 11.176)	0.0811	
1 - Restricted in Physically Strenuous Activity	133	15 (11.3)	118 (88.7)	NE (NE, NE)	134	9 (6.7)	125 (93.3)	NE (NE, NE)	1.591 (0.696, 3.638)	0.2667	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.1762	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9826
≥3 to ≤25%	94	13 (13.8)	81 (86.2)	NE (NE, NE)	98	5 (5.1)	93 (94.9)	NE (NE, NE)	2.892 (1.031, 8.116)	0.0345	
>25% to ≤50%	141	14 (9.9)	127 (90.1)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	2.385 (0.858, 6.630)	0.0858	
>50%	29	0	29 (100)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.000 (0.000, NE)	0.1815	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4081
Yes	139	14 (10.1)	125 (89.9)	NE (NE, NE)	137	7 (5.1)	130 (94.9)	NE (NE, NE)	1.790 (0.721, 4.440)	0.2028	
No	116	11 (9.5)	105 (90.5)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	3.470 (0.967, 12.449)	0.0420	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6694
≤60	164	21 (12.8)	143 (87.2)	NE (NE, NE)	163	8 (4.9)	155 (95.1)	NE (NE, NE)	2.194 (0.971, 4.962)	0.0528	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	4 (3.8)	101 (96.2)	NE (31.2, NE)	1.669 (0.470, 5.924)	0.4232	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7288
<60	159	19 (11.9)	140 (88.1)	NE (NE, NE)	160	19 (11.9)	141 (88.1)	NE (NE, NE)	0.934 (0.494, 1.766)	0.8340	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.1210	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	6 (9.2)	59 (90.8)	NE (28.1, NE)	0.476 (0.119, 1.911)	0.2847	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9861
Male	124	12 (9.7)	112 (90.3)	NE (NE, NE)	120	12 (10.0)	108 (90.0)	NE (NE, NE)	0.912 (0.409, 2.034)	0.8226	
Female	141	12 (8.5)	129 (91.5)	NE (NE, NE)	148	13 (8.8)	135 (91.2)	NE (NE, NE)	0.915 (0.417, 2.007)	0.8249	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2338
White	157	17 (10.8)	140 (89.2)	NE (NE, NE)	161	14 (8.7)	147 (91.3)	NE (NE, NE)	1.189 (0.585, 2.418)	0.6311	
Non-white	108	7 (6.5)	101 (93.5)	NE (NE, NE)	107	11 (10.3)	96 (89.7)	NE (NE, NE)	0.580 (0.225, 1.498)	0.2546	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6263
North America	16	1 (6.3)	15 (93.8)	NE (1.9, NE)	18	3 (16.7)	15 (83.3)	NE (6.1, NE)	0.671 (0.070, 6.466)	0.7284	
Europe	161	14 (8.7)	147 (91.3)	NE (NE, NE)	161	11 (6.8)	150 (93.2)	NE (NE, NE)	1.218 (0.552, 2.687)	0.6248	
Asia/Other Regions	88	9 (10.2)	79 (89.8)	NE (NE, NE)	89	11 (12.4)	78 (87.6)	NE (NE, NE)	0.749 (0.310, 1.811)	0.5192	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5942
< 40x10^9/L	132	10 (7.6)	122 (92.4)	NE (NE, NE)	133	13 (9.8)	120 (90.2)	NE (NE, NE)	0.776 (0.340, 1.771)	0.5467	
≥ 40x10^9/L	133	14 (10.5)	119 (89.5)	NE (NE, NE)	135	12 (8.9)	123 (91.1)	NE (NE, NE)	1.049 (0.484, 2.275)	0.9022	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4429
Daunorubicin	123	11 (8.9)	112 (91.1)	NE (NE, NE)	94	11 (11.7)	83 (88.3)	NE (NE, NE)	0.697 (0.302, 1.611)	0.3976	
Idarubicin	142	13 (9.2)	129 (90.8)	NE (NE, NE)	171	14 (8.2)	157 (91.8)	NE (NE, NE)	1.055 (0.495, 2.249)	0.8893	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6723
Favorable	13	2 (15.4)	11 (84.6)	NE (NE, NE)	19	2 (10.5)	17 (89.5)	NE (28.1, NE)	1.795 (0.250, 12.877)	0.5550	
Intermediate	195	18 (9.2)	177 (90.8)	NE (NE, NE)	190	17 (8.9)	173 (91.1)	NE (NE, NE)	0.922 (0.474, 1.791)	0.8104	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	4 (14.8)	23 (85.2)	NE (NE, NE)	0.362 (0.040, 3.241)	0.3433	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	1.284 (0.214, 7.725)	0.7840	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9139
0 - Fully Active	87	9 (10.3)	78 (89.7)	NE (NE, NE)	97	9 (9.3)	88 (90.7)	NE (NE, NE)	1.016 (0.402, 2.564)	0.9737	
1 - Restricted in Physically Strenuous Activity	133	11 (8.3)	122 (91.7)	NE (NE, NE)	134	12 (9.0)	122 (91.0)	NE (NE, NE)	0.880 (0.388, 1.998)	0.7603	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	4 (11.1)	32 (88.9)	NE (NE, NE)	0.732 (0.180, 2.971)	0.6617	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6647
≥3 to ≤25%	94	9 (9.6)	85 (90.4)	NE (NE, NE)	98	8 (8.2)	90 (91.8)	NE (NE, NE)	1.192 (0.459, 3.093)	0.7179	
>25% to ≤50%	141	12 (8.5)	129 (91.5)	NE (NE, NE)	136	12 (8.8)	124 (91.2)	NE (NE, NE)	0.895 (0.401, 1.996)	0.7868	
>50%	29	3 (10.3)	26 (89.7)	NE (13.5, NE)	34	5 (14.7)	29 (85.3)	NE (NE, NE)	0.512 (0.118, 2.220)	0.3651	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6472
Yes	139	12 (8.6)	127 (91.4)	NE (NE, NE)	137	11 (8.0)	126 (92.0)	NE (NE, NE)	1.018 (0.448, 2.314)	0.9653	
No	116	10 (8.6)	106 (91.4)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	1.359 (0.517, 3.576)	0.5326	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9642
≤60	164	19 (11.6)	145 (88.4)	NE (NE, NE)	163	19 (11.7)	144 (88.3)	NE (NE, NE)	0.918 (0.485, 1.736)	0.7930	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	6 (5.7)	99 (94.3)	NE (NE, NE)	0.857 (0.261, 2.812)	0.7993	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8899
<60	159	12 (7.5)	147 (92.5)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	1.686 (0.630, 4.510)	0.2928	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.188 (0.167, 8.437)	0.8628	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	0	65 (100)	NE (NE, NE)	NE (0.000, NE)	0.0394	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6203
Male	124	10 (8.1)	114 (91.9)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	1.745 (0.595, 5.120)	0.3041	
Female	141	8 (5.7)	133 (94.3)	NE (NE, NE)	148	3 (2.0)	145 (98.0)	NE (NE, NE)	2.661 (0.705, 10.041)	0.1329	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5416
White	157	9 (5.7)	148 (94.3)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	2.834 (0.766, 10.486)	0.1028	
Non-white	108	9 (8.3)	99 (91.7)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	1.665 (0.557, 4.976)	0.3563	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8408
North America	16	2 (12.5)	14 (87.5)	NE (1.9, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.0815	
Europe	161	10 (6.2)	151 (93.8)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	2.265 (0.709, 7.230)	0.1560	
Asia/Other Regions	88	6 (6.8)	82 (93.2)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	1.386 (0.389, 4.932)	0.6127	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2576
< 40x10^9/L	132	10 (7.6)	122 (92.4)	NE (NE, NE)	133	3 (2.3)	130 (97.7)	NE (NE, NE)	3.500 (0.963, 12.724)	0.0424	
≥ 40x10^9/L	133	8 (6.0)	125 (94.0)	NE (NE, NE)	135	5 (3.7)	130 (96.3)	NE (NE, NE)	1.318 (0.429, 4.051)	0.6283	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6055
Daunorubicin	123	7 (5.7)	116 (94.3)	NE (NE, NE)	94	3 (3.2)	91 (96.8)	NE (NE, NE)	1.717 (0.443, 6.652)	0.4289	
Idarubicin	142	11 (7.7)	131 (92.3)	NE (NE, NE)	171	5 (2.9)	166 (97.1)	NE (NE, NE)	2.430 (0.844, 7.002)	0.0892	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8234
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	16 (8.2)	179 (91.8)	NE (NE, NE)	190	6 (3.2)	184 (96.8)	NE (NE, NE)	2.331 (0.911, 5.964)	0.0692	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (5.7, NE)	27	2 (7.4)	25 (92.6)	NE (11.2, NE)	0.654 (0.059, 7.236)	0.7270	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.3664	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3332
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	0.975 (0.243, 3.910)	0.9711	
1 - Restricted in Physically Strenuous Activity	133	12 (9.0)	121 (91.0)	NE (NE, NE)	134	3 (2.2)	131 (97.8)	NE (NE, NE)	3.899 (1.100, 13.822)	0.0230	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	1.301 (0.113, 14.941)	0.8322	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8112
≥3 to ≤25%	94	7 (7.4)	87 (92.6)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	1.886 (0.552, 6.446)	0.3033	
>25% to ≤50%	141	11 (7.8)	130 (92.2)	NE (NE, NE)	136	3 (2.2)	133 (97.8)	NE (NE, NE)	3.237 (0.902, 11.624)	0.0567	
>50%	29	0	29 (100)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.000 (0.000, NE)	0.3557	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1826
Yes	139	8 (5.8)	131 (94.2)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	1.487 (0.486, 4.555)	0.4839	
No	116	8 (6.9)	108 (93.1)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	7.390 (0.923, 59.183)	0.0270	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4971
≤60	164	12 (7.3)	152 (92.7)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	1.657 (0.619, 4.433)	0.3096	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	3.246 (0.655, 16.090)	0.1268	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1301
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	12 (7.5)	148 (92.5)	NE (NE, NE)	0.545 (0.214, 1.388)	0.1967	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.1224	
≥65	69	7 (10.1)	62 (89.9)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	3.494 (0.726, 16.825)	0.0965	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9024
Male	124	8 (6.5)	116 (93.5)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	1.115 (0.404, 3.077)	0.8362	
Female	141	8 (5.7)	133 (94.3)	NE (NE, NE)	148	7 (4.7)	141 (95.3)	NE (NE, NE)	1.202 (0.436, 3.317)	0.7206	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6547
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	1.345 (0.466, 3.882)	0.5822	
Non-white	108	8 (7.4)	100 (92.6)	NE (NE, NE)	107	8 (7.5)	99 (92.5)	NE (NE, NE)	0.993 (0.373, 2.646)	0.9889	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6504
North America	16	1 (6.3)	15 (93.8)	NE (1.9, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.1824	
Europe	161	9 (5.6)	152 (94.4)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	1.455 (0.517, 4.095)	0.4750	
Asia/Other Regions	88	6 (6.8)	82 (93.2)	NE (NE, NE)	89	8 (9.0)	81 (91.0)	NE (NE, NE)	0.750 (0.260, 2.163)	0.5934	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1816
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	8 (6.0)	125 (94.0)	NE (NE, NE)	0.638 (0.209, 1.951)	0.4276	
≥ 40x10^9/L	133	11 (8.3)	122 (91.7)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	1.860 (0.687, 5.032)	0.2145	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7608
Daunorubicin	123	8 (6.5)	115 (93.5)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	0.980 (0.340, 2.828)	0.9715	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	8 (4.7)	163 (95.3)	NE (NE, NE)	1.229 (0.461, 3.276)	0.6799	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7534
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.2267	
Intermediate	195	13 (6.7)	182 (93.3)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	1.791 (0.714, 4.492)	0.2073	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	4 (14.8)	23 (85.2)	NE (NE, NE)	0.000 (0.000, NE)	0.0926	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	0.609 (0.101, 3.660)	0.5843	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6544
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	5 (5.2)	92 (94.8)	NE (NE, NE)	0.638 (0.152, 2.672)	0.5350	
1 - Restricted in Physically Strenuous Activity	133	10 (7.5)	123 (92.5)	NE (NE, NE)	134	7 (5.2)	127 (94.8)	NE (NE, NE)	1.437 (0.547, 3.779)	0.4598	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	1.302 (0.218, 7.796)	0.7735	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6078
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	2 (2.0)	96 (98.0)	NE (NE, NE)	2.697 (0.523, 13.901)	0.2174	
>25% to ≤50%	141	11 (7.8)	130 (92.2)	NE (NE, NE)	136	10 (7.4)	126 (92.6)	NE (NE, NE)	1.064 (0.452, 2.506)	0.8862	
>50%	29	0	29 (100)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.000 (0.000, NE)	0.1857	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3627
Yes	139	11 (7.9)	128 (92.1)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	2.249 (0.781, 6.473)	0.1226	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.996 (0.249, 3.987)	0.9971	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0324
≤60	164	8 (4.9)	156 (95.1)	NE (NE, NE)	163	12 (7.4)	151 (92.6)	NE (NE, NE)	0.621 (0.253, 1.522)	0.2935	
>60	101	8 (7.9)	93 (92.1)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	4.397 (0.933, 20.710)	0.0406	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood alkaline phosphatase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8935
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	11 (6.9)	149 (93.1)	NE (NE, NE)	0.592 (0.229, 1.532)	0.2752	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.1261	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	0.975 (0.137, 6.926)	0.9801	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood alkaline phosphatase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8764
Male	124	5 (4.0)	119 (96.0)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.793 (0.242, 2.602)	0.7020	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	7 (4.7)	141 (95.3)	NE (NE, NE)	0.858 (0.288, 2.556)	0.7821	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood alkaline phosphatase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1941
White	157	7 (4.5)	150 (95.5)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	1.413 (0.448, 4.459)	0.5535	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	8 (7.5)	99 (92.5)	NE (NE, NE)	0.468 (0.141, 1.556)	0.2049	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood alkaline phosphatase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5598
North America	16	1 (6.3)	15 (93.8)	NE (1.9, NE)	18	2 (11.1)	16 (88.9)	NE (NE, NE)	0.612 (0.055, 6.797)	0.6863	
Europe	161	5 (3.1)	156 (96.9)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	1.543 (0.367, 6.483)	0.5506	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	8 (9.0)	81 (91.0)	NE (NE, NE)	0.606 (0.198, 1.857)	0.3767	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood alkaline phosphatase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5659
< 40x10^9/L	132	6 (4.5)	126 (95.5)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	1.041 (0.335, 3.232)	0.9443	
≥ 40x10^9/L	133	5 (3.8)	128 (96.2)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	0.655 (0.207, 2.074)	0.4697	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood alkaline phosphatase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7862
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	4 (4.3)	90 (95.7)	NE (NE, NE)	0.712 (0.177, 2.854)	0.6295	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	9 (5.3)	162 (94.7)	NE (NE, NE)	0.924 (0.344, 2.484)	0.8744	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood alkaline phosphatase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7100
Favorable	13	2 (15.4)	11 (84.6)	NE (1.5, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	1.576 (0.222, 11.203)	0.6468	
Intermediate	195	8 (4.1)	187 (95.9)	NE (NE, NE)	190	6 (3.2)	184 (96.8)	NE (NE, NE)	1.220 (0.422, 3.521)	0.7133	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	4 (14.8)	23 (85.2)	NE (NE, NE)	0.375 (0.042, 3.352)	0.3607	
Unknown	38	0	38 (100)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (17.0, NE)	0.000 (0.000, NE)	0.2294	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood alkaline phosphatase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2832
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	1.458 (0.243, 8.758)	0.6782	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	7 (5.2)	127 (94.8)	NE (NE, NE)	1.008 (0.353, 2.874)	0.9896	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	4 (11.1)	32 (88.9)	NE (NE, NE)	0.197 (0.022, 1.760)	0.1058	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood alkaline phosphatase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2540
≥3 to ≤25%	94	8 (8.5)	86 (91.5)	NE (NE, NE)	98	5 (5.1)	93 (94.9)	NE (NE, NE)	1.745 (0.571, 5.334)	0.3225	
>25% to ≤50%	141	3 (2.1)	138 (97.9)	NE (NE, NE)	136	7 (5.1)	129 (94.9)	NE (NE, NE)	0.385 (0.099, 1.492)	0.1517	
>50%	29	0	29 (100)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.000 (0.000, NE)	0.3496	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood alkaline phosphatase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4125
Yes	139	4 (2.9)	135 (97.1)	NE (NE, NE)	137	2 (1.5)	135 (98.5)	NE (NE, NE)	1.963 (0.359, 10.745)	0.4279	
No	116	7 (6.0)	109 (94.0)	NE (NE, NE)	120	8 (6.7)	112 (93.3)	NE (NE, NE)	0.829 (0.300, 2.291)	0.7190	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood alkaline phosphatase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1906
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	11 (6.7)	152 (93.3)	NE (NE, NE)	0.583 (0.225, 1.510)	0.2618	
>60	101	4 (4.0)	97 (96.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	2.104 (0.385, 11.501)	0.3798	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Weight decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7227
<60	159	6 (3.8)	153 (96.2)	NE (NE, NE)	160	8 (5.0)	152 (95.0)	NE (NE, NE)	0.684 (0.236, 1.983)	0.4817	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.177 (0.166, 8.359)	0.8703	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	1.611 (0.269, 9.651)	0.5984	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Weight decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1027
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	11 (9.2)	109 (90.8)	NE (NE, NE)	0.558 (0.215, 1.447)	0.2243	
Female	141	4 (2.8)	137 (97.2)	NE (NE, NE)	148	1 (0.7)	147 (99.3)	NE (NE, NE)	4.092 (0.457, 36.666)	0.1720	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Weight decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2687
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	1.395 (0.392, 4.968)	0.6060	
Non-white	108	5 (4.6)	103 (95.4)	NE (NE, NE)	107	8 (7.5)	99 (92.5)	NE (NE, NE)	0.592 (0.193, 1.810)	0.3525	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Weight decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5412
North America	16	1 (6.3)	15 (93.8)	NE (19.1, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	1.500 (0.091, 24.680)	0.7752	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	1.435 (0.404, 5.099)	0.5750	
Asia/Other Regions	88	4 (4.5)	84 (95.5)	NE (NE, NE)	89	7 (7.9)	82 (92.1)	NE (NE, NE)	0.539 (0.157, 1.849)	0.3181	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Weight decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9127
< 40x10^9/L	132	4 (3.0)	128 (97.0)	NE (NE, NE)	133	5 (3.8)	128 (96.2)	NE (NE, NE)	0.819 (0.220, 3.052)	0.7654	
≥ 40x10^9/L	133	7 (5.3)	126 (94.7)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	0.931 (0.325, 2.665)	0.8945	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Weight decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6306
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	4 (4.3)	90 (95.7)	NE (NE, NE)	1.132 (0.319, 4.019)	0.8476	
Idarubicin	142	5 (3.5)	137 (96.5)	NE (NE, NE)	171	8 (4.7)	163 (95.3)	NE (NE, NE)	0.696 (0.227, 2.132)	0.5234	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Weight decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9992
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.2267	
Intermediate	195	7 (3.6)	188 (96.4)	NE (NE, NE)	190	8 (4.2)	182 (95.8)	NE (NE, NE)	0.797 (0.288, 2.206)	0.6629	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.727 (0.066, 8.022)	0.7941	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	0.730 (0.102, 5.218)	0.7528	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Weight decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9181
0 - Fully Active	87	2 (2.3)	85 (97.7)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	1.036 (0.145, 7.384)	0.9717	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	10 (7.5)	124 (92.5)	NE (NE, NE)	0.661 (0.251, 1.741)	0.3994	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.1965	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Weight decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9626
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	1.389 (0.310, 6.216)	0.6658	
>25% to ≤50%	141	7 (5.0)	134 (95.0)	NE (NE, NE)	136	6 (4.4)	130 (95.6)	NE (NE, NE)	1.060 (0.355, 3.163)	0.9164	
>50%	29	0	29 (100)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (5.6, NE)	0.000 (0.000, NE)	0.0650	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Weight decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6090
Yes	139	4 (2.9)	135 (97.1)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	0.918 (0.228, 3.687)	0.9037	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	1.634 (0.390, 6.851)	0.4975	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Weight decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4274
≤60	164	6 (3.7)	158 (96.3)	NE (NE, NE)	163	8 (4.9)	155 (95.1)	NE (NE, NE)	0.676 (0.233, 1.959)	0.4674	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	4 (3.8)	101 (96.2)	NE (NE, NE)	1.344 (0.361, 5.010)	0.6586	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3949
<60	159	77 (48.4)	82 (51.6)	8.3 (3.6, 18.9)	160	62 (38.8)	98 (61.3)	NE (7.1, NE)	1.150 (0.823, 1.608)	0.4063	
≥60 - <65	37	17 (45.9)	20 (54.1)	11.4 (1.8, NE)	43	24 (55.8)	19 (44.2)	4.9 (1.4, 8.2)	0.656 (0.348, 1.236)	0.1880	
≥65	69	29 (42.0)	40 (58.0)	11.1 (1.3, NE)	65	29 (44.6)	36 (55.4)	9.2 (2.1, NE)	0.960 (0.574, 1.607)	0.8800	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8371
Male	124	64 (51.6)	60 (48.4)	3.7 (1.8, 18.3)	120	55 (45.8)	65 (54.2)	7.1 (2.6, NE)	1.046 (0.729, 1.502)	0.8010	
Female	141	59 (41.8)	82 (58.2)	13.5 (6.7, 31.7)	148	60 (40.5)	88 (59.5)	15.0 (5.6, NE)	0.976 (0.681, 1.398)	0.8970	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3350
White	157	65 (41.4)	92 (58.6)	11.4 (7.2, NE)	161	67 (41.6)	94 (58.4)	9.7 (5.0, NE)	0.902 (0.641, 1.270)	0.5545	
Non-white	108	58 (53.7)	50 (46.3)	3.9 (1.8, 13.5)	107	48 (44.9)	59 (55.1)	8.2 (3.9, NE)	1.170 (0.798, 1.716)	0.4142	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0993
North America	16	9 (56.3)	7 (43.8)	1.8 (0.8, NE)	18	15 (83.3)	3 (16.7)	0.6 (0.2, 2.1)	0.487 (0.206, 1.153)	0.0963	
Europe	161	63 (39.1)	98 (60.9)	18.9 (10.8, NE)	161	61 (37.9)	100 (62.1)	15.0 (7.1, NE)	0.941 (0.661, 1.339)	0.7350	
Asia/Other Regions	88	51 (58.0)	37 (42.0)	3.5 (1.8, 8.1)	89	39 (43.8)	50 (56.2)	9.0 (4.0, NE)	1.369 (0.902, 2.078)	0.1365	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5101
< 40x10^9/L	132	55 (41.7)	77 (58.3)	11.2 (5.6, NE)	133	57 (42.9)	76 (57.1)	9.2 (5.6, NE)	0.926 (0.639, 1.341)	0.6856	
≥ 40x10^9/L	133	68 (51.1)	65 (48.9)	7.2 (2.2, 18.9)	135	58 (43.0)	77 (57.0)	11.5 (2.9, NE)	1.107 (0.780, 1.573)	0.5615	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9220
Daunorubicin	123	58 (47.2)	65 (52.8)	9.3 (2.3, 30.7)	94	40 (42.6)	54 (57.4)	9.7 (2.9, NE)	1.002 (0.669, 1.502)	0.9927	
Idarubicin	142	65 (45.8)	77 (54.2)	11.1 (3.6, 31.7)	171	73 (42.7)	98 (57.3)	9.0 (5.6, NE)	1.029 (0.737, 1.438)	0.8588	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.2549
Favorable	13	4 (30.8)	9 (69.2)	NE (1.1, NE)	19	11 (57.9)	8 (42.1)	6.8 (1.2, NE)	0.524 (0.167, 1.647)	0.2538	
Intermediate	195	92 (47.2)	103 (52.8)	10.8 (3.6, 18.9)	190	78 (41.1)	112 (58.9)	9.0 (5.0, NE)	1.036 (0.765, 1.401)	0.8142	
Unfavorable	19	7 (36.8)	12 (63.2)	NE (0.6, NE)	27	14 (51.9)	13 (48.1)	5.6 (0.4, NE)	0.616 (0.246, 1.541)	0.2954	
Unknown	38	20 (52.6)	18 (47.4)	3.6 (0.8, NE)	31	12 (38.7)	19 (61.3)	NE (2.6, NE)	1.570 (0.766, 3.217)	0.2121	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5202
0 - Fully Active	87	37 (42.5)	50 (57.5)	11.4 (3.7, NE)	97	34 (35.1)	63 (64.9)	26.6 (9.2, NE)	1.216 (0.763, 1.939)	0.4103	
1 - Restricted in Physically Strenuous Activity	133	60 (45.1)	73 (54.9)	10.8 (3.6, NE)	134	61 (45.5)	73 (54.5)	6.3 (2.9, NE)	0.873 (0.611, 1.248)	0.4636	
2 - Ambulatory and Capable of All Selfcare	45	26 (57.8)	19 (42.2)	1.8 (0.4, 18.9)	36	20 (55.6)	16 (44.4)	1.3 (0.4, NE)	0.918 (0.509, 1.658)	0.7805	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1014
≥3 to ≤25%	94	41 (43.6)	53 (56.4)	11.2 (5.6, NE)	98	46 (46.9)	52 (53.1)	9.0 (2.9, NE)	0.820 (0.538, 1.250)	0.3587	
>25% to ≤50%	141	68 (48.2)	73 (51.8)	4.5 (2.1, NE)	136	63 (46.3)	73 (53.7)	8.2 (2.7, NE)	1.034 (0.734, 1.457)	0.8476	
>50%	29	14 (48.3)	15 (51.7)	18.9 (1.6, NE)	34	6 (17.6)	28 (82.4)	NE (5.6, NE)	2.404 (0.915, 6.319)	0.0670	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1919
Yes	139	61 (43.9)	78 (56.1)	18.3 (5.6, NE)	137	62 (45.3)	75 (54.7)	9.0 (4.9, NE)	0.849 (0.596, 1.211)	0.3691	
No	116	56 (48.3)	60 (51.7)	8.3 (2.9, 16.3)	120	49 (40.8)	71 (59.2)	15.0 (3.3, NE)	1.202 (0.819, 1.765)	0.3437	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3501
≤60	164	78 (47.6)	86 (52.4)	8.8 (3.6, 18.9)	163	63 (38.7)	100 (61.3)	NE (7.1, NE)	1.124 (0.806, 1.568)	0.4826	
>60	101	45 (44.6)	56 (55.4)	11.1 (2.2, NE)	105	52 (49.5)	53 (50.5)	6.8 (2.9, 9.7)	0.866 (0.581, 1.293)	0.4809	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Cough

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3505
<60	159	36 (22.6)	123 (77.4)	NE (27.1, NE)	160	25 (15.6)	135 (84.4)	NE (NE, NE)	1.283 (0.769, 2.141)	0.3376	
≥60 - <65	37	6 (16.2)	31 (83.8)	NE (11.4, NE)	43	10 (23.3)	33 (76.7)	NE (8.2, NE)	0.527 (0.190, 1.460)	0.2103	
≥65	69	8 (11.6)	61 (88.4)	NE (NE, NE)	65	9 (13.8)	56 (86.2)	NE (11.7, NE)	0.878 (0.339, 2.278)	0.7892	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Cough

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4046
Male	124	23 (18.5)	101 (81.5)	NE (20.1, NE)	120	22 (18.3)	98 (81.7)	NE (NE, NE)	0.853 (0.474, 1.536)	0.5953	
Female	141	27 (19.1)	114 (80.9)	NE (32.7, NE)	148	22 (14.9)	126 (85.1)	NE (NE, NE)	1.195 (0.680, 2.100)	0.5352	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Cough

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3091
White	157	26 (16.6)	131 (83.4)	NE (32.7, NE)	161	27 (16.8)	134 (83.2)	NE (NE, NE)	0.850 (0.495, 1.459)	0.5550	
Non-white	108	24 (22.2)	84 (77.8)	NE (30.7, NE)	107	17 (15.9)	90 (84.1)	NE (NE, NE)	1.337 (0.718, 2.491)	0.3579	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Cough

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3222
North America	16	3 (18.8)	13 (81.3)	18.5 (2.7, NE)	18	8 (44.4)	10 (55.6)	11.7 (2.3, NE)	0.468 (0.123, 1.777)	0.2538	
Europe	161	24 (14.9)	137 (85.1)	NE (32.7, NE)	161	21 (13.0)	140 (87.0)	NE (NE, NE)	0.971 (0.539, 1.747)	0.9199	
Asia/Other Regions	88	23 (26.1)	65 (73.9)	NE (20.1, NE)	89	15 (16.9)	74 (83.1)	NE (NE, NE)	1.480 (0.771, 2.841)	0.2346	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Cough

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5246
< 40x10^9/L	132	18 (13.6)	114 (86.4)	NE (32.7, NE)	133	21 (15.8)	112 (84.2)	NE (NE, NE)	0.857 (0.457, 1.610)	0.6307	
≥ 40x10^9/L	133	32 (24.1)	101 (75.9)	NE (18.9, NE)	135	23 (17.0)	112 (83.0)	NE (NE, NE)	1.132 (0.660, 1.941)	0.6508	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Cough

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4157
Daunorubicin	123	24 (19.5)	99 (80.5)	NE (30.7, NE)	94	12 (12.8)	82 (87.2)	NE (NE, NE)	1.357 (0.678, 2.718)	0.3864	
Idarubicin	142	26 (18.3)	116 (81.7)	NE (27.1, NE)	171	30 (17.5)	141 (82.5)	NE (NE, NE)	0.942 (0.556, 1.594)	0.8231	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Cough

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.1321
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	6 (31.6)	13 (68.4)	NE (2.3, NE)	0.254 (0.031, 2.114)	0.1711	
Intermediate	195	41 (21.0)	154 (79.0)	NE (30.7, NE)	190	26 (13.7)	164 (86.3)	NE (NE, NE)	1.330 (0.812, 2.179)	0.2552	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (18.5, NE)	27	7 (25.9)	20 (74.1)	15.0 (5.6, NE)	0.128 (0.015, 1.073)	0.0277	
Unknown	38	7 (18.4)	31 (81.6)	NE (6.7, NE)	31	5 (16.1)	26 (83.9)	NE (11.5, NE)	1.188 (0.377, 3.746)	0.7689	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Cough

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4212
0 - Fully Active	87	17 (19.5)	70 (80.5)	NE (27.1, NE)	97	12 (12.4)	85 (87.6)	NE (NE, NE)	1.438 (0.686, 3.014)	0.3332	
1 - Restricted in Physically Strenuous Activity	133	21 (15.8)	112 (84.2)	NE (32.7, NE)	134	24 (17.9)	110 (82.1)	NE (18.5, NE)	0.776 (0.432, 1.397)	0.3973	
2 - Ambulatory and Capable of All Selfcare	45	12 (26.7)	33 (73.3)	NE (6.4, NE)	36	8 (22.2)	28 (77.8)	NE (NE, NE)	0.930 (0.372, 2.326)	0.8819	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Cough

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3852
≥3 to ≤25%	94	18 (19.1)	76 (80.9)	NE (20.1, NE)	98	19 (19.4)	79 (80.6)	NE (NE, NE)	0.971 (0.509, 1.853)	0.9277	
>25% to ≤50%	141	27 (19.1)	114 (80.9)	NE (NE, NE)	136	24 (17.6)	112 (82.4)	NE (NE, NE)	0.987 (0.569, 1.713)	0.9633	
>50%	29	5 (17.2)	24 (82.8)	NE (10.8, NE)	34	1 (2.9)	33 (97.1)	NE (5.6, NE)	3.976 (0.453, 34.888)	0.1805	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Cough

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4367
Yes	139	26 (18.7)	113 (81.3)	NE (NE, NE)	137	26 (19.0)	111 (81.0)	NE (NE, NE)	0.871 (0.505, 1.502)	0.6204	
No	116	23 (19.8)	93 (80.2)	30.7 (20.1, NE)	120	18 (15.0)	102 (85.0)	NE (NE, NE)	1.234 (0.665, 2.289)	0.5060	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Cough

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2292
≤60	164	36 (22.0)	128 (78.0)	NE (27.1, NE)	163	25 (15.3)	138 (84.7)	NE (NE, NE)	1.259 (0.755, 2.100)	0.3761	
>60	101	14 (13.9)	87 (86.1)	NE (NE, NE)	105	19 (18.1)	86 (81.9)	NE (15.9, NE)	0.724 (0.362, 1.445)	0.3568	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Epistaxis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7005
<60	159	22 (13.8)	137 (86.2)	NE (NE, NE)	160	18 (11.3)	142 (88.8)	NE (NE, NE)	1.195 (0.641, 2.229)	0.5724	
≥60 - <65	37	8 (21.6)	29 (78.4)	NE (NE, NE)	43	5 (11.6)	38 (88.4)	NE (NE, NE)	1.898 (0.621, 5.806)	0.2524	
≥65	69	10 (14.5)	59 (85.5)	NE (26.1, NE)	65	6 (9.2)	59 (90.8)	NE (NE, NE)	1.716 (0.623, 4.727)	0.2897	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Epistaxis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6450
Male	124	21 (16.9)	103 (83.1)	NE (NE, NE)	120	16 (13.3)	104 (86.7)	NE (NE, NE)	1.252 (0.653, 2.400)	0.4972	
Female	141	19 (13.5)	122 (86.5)	NE (NE, NE)	148	13 (8.8)	135 (91.2)	NE (NE, NE)	1.532 (0.756, 3.102)	0.2321	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Epistaxis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8149
White	157	23 (14.6)	134 (85.4)	NE (NE, NE)	161	18 (11.2)	143 (88.8)	NE (NE, NE)	1.319 (0.712, 2.445)	0.3787	
Non-white	108	17 (15.7)	91 (84.3)	NE (NE, NE)	107	11 (10.3)	96 (89.7)	NE (NE, NE)	1.472 (0.689, 3.143)	0.3116	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Epistaxis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6380
North America	16	3 (18.8)	13 (81.3)	NE (1.7, NE)	18	3 (16.7)	15 (83.3)	NE (6.4, NE)	1.965 (0.379, 10.184)	0.4137	
Europe	161	20 (12.4)	141 (87.6)	NE (NE, NE)	161	17 (10.6)	144 (89.4)	NE (NE, NE)	1.158 (0.606, 2.210)	0.6576	
Asia/Other Regions	88	17 (19.3)	71 (80.7)	NE (NE, NE)	89	9 (10.1)	80 (89.9)	NE (NE, NE)	1.889 (0.842, 4.239)	0.1159	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Epistaxis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4096
< 40x10^9/L	132	16 (12.1)	116 (87.9)	NE (NE, NE)	133	15 (11.3)	118 (88.7)	NE (NE, NE)	1.107 (0.547, 2.240)	0.7753	
≥ 40x10^9/L	133	24 (18.0)	109 (82.0)	NE (NE, NE)	135	14 (10.4)	121 (89.6)	NE (NE, NE)	1.633 (0.844, 3.160)	0.1401	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Epistaxis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2584
Daunorubicin	123	22 (17.9)	101 (82.1)	NE (NE, NE)	94	9 (9.6)	85 (90.4)	NE (NE, NE)	1.882 (0.866, 4.089)	0.1043	
Idarubicin	142	18 (12.7)	124 (87.3)	NE (NE, NE)	171	20 (11.7)	151 (88.3)	NE (NE, NE)	1.057 (0.559, 1.998)	0.8610	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Epistaxis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4247
Favorable	13	3 (23.1)	10 (76.9)	NE (1.1, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	4.733 (0.492, 45.528)	0.1403	
Intermediate	195	28 (14.4)	167 (85.6)	NE (NE, NE)	190	20 (10.5)	170 (89.5)	NE (NE, NE)	1.309 (0.737, 2.324)	0.3562	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	5 (18.5)	22 (81.5)	NE (6.4, NE)	0.581 (0.113, 2.995)	0.5137	
Unknown	38	7 (18.4)	31 (81.6)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	1.957 (0.505, 7.577)	0.3164	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Epistaxis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1349
0 - Fully Active	87	10 (11.5)	77 (88.5)	NE (NE, NE)	97	12 (12.4)	85 (87.6)	NE (NE, NE)	0.932 (0.403, 2.157)	0.8696	
1 - Restricted in Physically Strenuous Activity	133	23 (17.3)	110 (82.7)	NE (NE, NE)	134	10 (7.5)	124 (92.5)	NE (NE, NE)	2.299 (1.094, 4.830)	0.0233	
2 - Ambulatory and Capable of All Selfcare	45	7 (15.6)	38 (84.4)	NE (NE, NE)	36	7 (19.4)	29 (80.6)	NE (NE, NE)	0.792 (0.278, 2.259)	0.6623	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Epistaxis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6696
≥3 to ≤25%	94	13 (13.8)	81 (86.2)	NE (NE, NE)	98	12 (12.2)	86 (87.8)	NE (NE, NE)	1.130 (0.516, 2.478)	0.7577	
>25% to ≤50%	141	24 (17.0)	117 (83.0)	NE (NE, NE)	136	16 (11.8)	120 (88.2)	NE (NE, NE)	1.455 (0.773, 2.739)	0.2412	
>50%	29	3 (10.3)	26 (89.7)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (5.4, NE)	2.777 (0.287, 26.826)	0.3570	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Epistaxis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6948
Yes	139	21 (15.1)	118 (84.9)	NE (NE, NE)	137	14 (10.2)	123 (89.8)	NE (NE, NE)	1.493 (0.759, 2.938)	0.2412	
No	116	17 (14.7)	99 (85.3)	NE (NE, NE)	120	14 (11.7)	106 (88.3)	NE (NE, NE)	1.240 (0.611, 2.516)	0.5482	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Epistaxis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3692
≤60	164	22 (13.4)	142 (86.6)	NE (NE, NE)	163	18 (11.0)	145 (89.0)	NE (NE, NE)	1.175 (0.630, 2.193)	0.6081	
>60	101	18 (17.8)	83 (82.2)	NE (26.1, NE)	105	11 (10.5)	94 (89.5)	NE (NE, NE)	1.831 (0.865, 3.880)	0.1086	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Oropharyngeal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3633
<60	159	22 (13.8)	137 (86.2)	NE (NE, NE)	160	11 (6.9)	149 (93.1)	NE (NE, NE)	1.829 (0.886, 3.776)	0.0972	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	0.530 (0.096, 2.916)	0.4581	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	1.060 (0.214, 5.263)	0.9427	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Oropharyngeal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7563
Male	124	10 (8.1)	114 (91.9)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	1.362 (0.518, 3.580)	0.5289	
Female	141	17 (12.1)	124 (87.9)	NE (NE, NE)	148	11 (7.4)	137 (92.6)	NE (NE, NE)	1.513 (0.708, 3.231)	0.2819	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Oropharyngeal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7709
White	157	14 (8.9)	143 (91.1)	NE (NE, NE)	161	10 (6.2)	151 (93.8)	NE (NE, NE)	1.374 (0.610, 3.096)	0.4415	
Non-white	108	13 (12.0)	95 (88.0)	NE (31.7, NE)	107	8 (7.5)	99 (92.5)	NE (NE, NE)	1.570 (0.650, 3.790)	0.3113	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Oropharyngeal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2373
North America	16	1 (6.3)	15 (93.8)	NE (38.0, NE)	18	4 (22.2)	14 (77.8)	NE (3.4, NE)	0.331 (0.037, 2.994)	0.3015	
Europe	161	12 (7.5)	149 (92.5)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	1.439 (0.588, 3.524)	0.4231	
Asia/Other Regions	88	14 (15.9)	74 (84.1)	NE (31.7, NE)	89	6 (6.7)	83 (93.3)	NE (NE, NE)	2.309 (0.886, 6.019)	0.0776	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Oropharyngeal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6114
< 40x10^9/L	132	13 (9.8)	119 (90.2)	NE (NE, NE)	133	8 (6.0)	125 (94.0)	NE (NE, NE)	1.674 (0.694, 4.040)	0.2462	
≥ 40x10^9/L	133	14 (10.5)	119 (89.5)	NE (NE, NE)	135	10 (7.4)	125 (92.6)	NE (NE, NE)	1.251 (0.555, 2.823)	0.5878	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Oropharyngeal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3071
Daunorubicin	123	11 (8.9)	112 (91.1)	NE (NE, NE)	94	8 (8.5)	86 (91.5)	NE (35.4, NE)	1.003 (0.403, 2.496)	0.9954	
Idarubicin	142	16 (11.3)	126 (88.7)	NE (NE, NE)	171	10 (5.8)	161 (94.2)	NE (NE, NE)	1.799 (0.815, 3.968)	0.1400	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Oropharyngeal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9993
Favorable	13	1 (7.7)	12 (92.3)	NE (4.4, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.0943	
Intermediate	195	20 (10.3)	175 (89.7)	NE (NE, NE)	190	17 (8.9)	173 (91.1)	NE (NE, NE)	1.023 (0.535, 1.956)	0.9432	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (38.0, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	0.577 (0.028, 11.808)	0.7194	
Unknown	38	5 (13.2)	33 (86.8)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.0387	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Oropharyngeal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7538
0 - Fully Active	87	6 (6.9)	81 (93.1)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	2.066 (0.516, 8.283)	0.2950	
1 - Restricted in Physically Strenuous Activity	133	13 (9.8)	120 (90.2)	NE (NE, NE)	134	11 (8.2)	123 (91.8)	NE (NE, NE)	1.091 (0.489, 2.438)	0.8306	
2 - Ambulatory and Capable of All Selfcare	45	8 (17.8)	37 (82.2)	NE (31.7, NE)	36	4 (11.1)	32 (88.9)	35.4 (35.4, NE)	1.573 (0.471, 5.255)	0.4581	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Oropharyngeal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6252
≥3 to ≤25%	94	9 (9.6)	85 (90.4)	NE (38.0, NE)	98	10 (10.2)	88 (89.8)	NE (NE, NE)	0.928 (0.376, 2.288)	0.8720	
>25% to ≤50%	141	15 (10.6)	126 (89.4)	NE (NE, NE)	136	8 (5.9)	128 (94.1)	NE (NE, NE)	1.721 (0.729, 4.062)	0.2100	
>50%	29	3 (10.3)	26 (89.7)	NE (31.7, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.1570	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Oropharyngeal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3757
Yes	139	14 (10.1)	125 (89.9)	NE (NE, NE)	137	12 (8.8)	125 (91.2)	NE (NE, NE)	1.085 (0.501, 2.348)	0.8354	
No	116	12 (10.3)	104 (89.7)	NE (38.0, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	1.932 (0.725, 5.152)	0.1800	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Oropharyngeal pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2139
≤60	164	22 (13.4)	142 (86.6)	NE (NE, NE)	163	11 (6.7)	152 (93.3)	NE (NE, NE)	1.792 (0.868, 3.700)	0.1094	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	7 (6.7)	98 (93.3)	NE (NE, NE)	0.745 (0.236, 2.350)	0.6146	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Dyspnoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3546
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	11 (6.9)	149 (93.1)	NE (NE, NE)	0.388 (0.134, 1.125)	0.0710	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	5 (11.6)	38 (88.4)	37.3 (12.2, NE)	0.583 (0.138, 2.457)	0.4568	
≥65	69	6 (8.7)	63 (91.3)	NE (NE, NE)	65	5 (7.7)	60 (92.3)	NE (NE, NE)	1.184 (0.361, 3.880)	0.7804	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Dyspnoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4382
Male	124	8 (6.5)	116 (93.5)	NE (NE, NE)	120	14 (11.7)	106 (88.3)	NE (NE, NE)	0.498 (0.208, 1.191)	0.1098	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	7 (4.7)	141 (95.3)	NE (NE, NE)	0.768 (0.257, 2.291)	0.6352	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Dyspnoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.0367
White	157	11 (7.0)	146 (93.0)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	1.114 (0.460, 2.699)	0.8089	
Non-white	108	3 (2.8)	105 (97.2)	NE (NE, NE)	107	12 (11.2)	95 (88.8)	NE (37.3, NE)	0.215 (0.060, 0.764)	0.0090	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Dyspnoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0757
North America	16	2 (12.5)	14 (87.5)	NE (NE, NE)	18	3 (16.7)	15 (83.3)	NE (6.8, NE)	0.917 (0.152, 5.525)	0.9242	
Europe	161	10 (6.2)	151 (93.8)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	1.239 (0.470, 3.268)	0.6630	
Asia/Other Regions	88	2 (2.3)	86 (97.7)	NE (NE, NE)	89	11 (12.4)	78 (87.6)	NE (37.3, NE)	0.164 (0.036, 0.742)	0.0074	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Dyspnoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4531
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	11 (8.3)	122 (91.7)	NE (NE, NE)	0.443 (0.154, 1.277)	0.1213	
≥ 40x10^9/L	133	9 (6.8)	124 (93.2)	NE (NE, NE)	135	10 (7.4)	125 (92.6)	NE (37.3, NE)	0.734 (0.296, 1.819)	0.5019	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Dyspnoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5698
Daunorubicin	123	5 (4.1)	118 (95.9)	NE (NE, NE)	94	7 (7.4)	87 (92.6)	NE (NE, NE)	0.480 (0.152, 1.521)	0.2031	
Idarubicin	142	9 (6.3)	133 (93.7)	NE (NE, NE)	171	14 (8.2)	157 (91.8)	NE (NE, NE)	0.682 (0.294, 1.581)	0.3691	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Dyspnoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9224
Favorable	13	0	13 (100)	NE (NE, NE)	19	3 (15.8)	16 (84.2)	NE (6.8, NE)	0.000 (0.000, NE)	0.2044	
Intermediate	195	10 (5.1)	185 (94.9)	NE (NE, NE)	190	14 (7.4)	176 (92.6)	NE (NE, NE)	0.616 (0.273, 1.390)	0.2384	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (8.4, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.633 (0.057, 7.032)	0.7069	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (9.0, NE)	1.274 (0.211, 7.678)	0.7913	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Dyspnoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6465
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	5 (5.2)	92 (94.8)	NE (NE, NE)	0.770 (0.206, 2.885)	0.6976	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	14 (10.4)	120 (89.6)	NE (37.3, NE)	0.444 (0.179, 1.103)	0.0724	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.989 (0.158, 6.182)	0.9906	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Dyspnoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4372
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	9 (9.2)	89 (90.8)	NE (NE, NE)	0.336 (0.091, 1.241)	0.0857	
>25% to ≤50%	141	9 (6.4)	132 (93.6)	NE (NE, NE)	136	11 (8.1)	125 (91.9)	NE (37.3, NE)	0.673 (0.277, 1.633)	0.3786	
>50%	29	2 (6.9)	27 (93.1)	NE (18.9, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	1.479 (0.129, 16.998)	0.7520	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Dyspnoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.8769
Yes	139	8 (5.8)	131 (94.2)	NE (NE, NE)	137	10 (7.3)	127 (92.7)	NE (NE, NE)	0.699 (0.275, 1.776)	0.4498	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	9 (7.5)	111 (92.5)	NE (NE, NE)	0.630 (0.224, 1.775)	0.3770	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Dyspnoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1876
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	11 (6.7)	152 (93.3)	NE (NE, NE)	0.382 (0.132, 1.108)	0.0662	
>60	101	9 (8.9)	92 (91.1)	NE (NE, NE)	105	10 (9.5)	95 (90.5)	NE (37.3, NE)	0.907 (0.368, 2.235)	0.8311	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Pleural effusion

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9998
<60	159	4 (2.5)	155 (97.5)	NE (NE, NE)	160	3 (1.9)	157 (98.1)	NE (NE, NE)	1.289 (0.287, 5.778)	0.7397	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	3 (7.0)	40 (93.0)	NE (NE, NE)	0.000 (0.000, NE)	0.0673	
≥65	69	6 (8.7)	63 (91.3)	NE (NE, NE)	65	5 (7.7)	60 (92.3)	NE (NE, NE)	1.242 (0.379, 4.072)	0.7216	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Pleural effusion

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8834
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.989 (0.319, 3.068)	0.9853	
Female	141	4 (2.8)	137 (97.2)	NE (NE, NE)	148	5 (3.4)	143 (96.6)	NE (NE, NE)	0.785 (0.211, 2.929)	0.7185	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Pleural effusion

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1136
White	157	2 (1.3)	155 (98.7)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	0.324 (0.065, 1.610)	0.1469	
Non-white	108	8 (7.4)	100 (92.6)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	1.580 (0.517, 4.833)	0.4177	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Pleural effusion

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5949
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	2 (11.1)	16 (88.9)	NE (13.0, NE)	0.625 (0.056, 6.961)	0.6996	
Europe	161	4 (2.5)	157 (97.5)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	0.649 (0.183, 2.304)	0.5007	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	1.650 (0.394, 6.914)	0.4873	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Pleural effusion

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1524
< 40x10^9/L	132	3 (2.3)	129 (97.7)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	0.441 (0.114, 1.706)	0.2226	
≥ 40x10^9/L	133	7 (5.3)	126 (94.7)	NE (NE, NE)	135	4 (3.0)	131 (97.0)	NE (NE, NE)	1.753 (0.512, 6.002)	0.3658	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Pleural effusion

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.0235
Daunorubicin	123	3 (2.4)	120 (97.6)	NE (NE, NE)	94	7 (7.4)	87 (92.6)	NE (NE, NE)	0.287 (0.074, 1.113)	0.0546	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	3 (1.8)	168 (98.2)	NE (NE, NE)	2.920 (0.755, 11.293)	0.1032	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Pleural effusion

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9815
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	7 (3.6)	188 (96.4)	NE (NE, NE)	190	8 (4.2)	182 (95.8)	NE (NE, NE)	0.789 (0.285, 2.180)	0.6474	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	0.000 (0.000, NE)	0.4142	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	1.273 (0.213, 7.620)	0.7911	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Pleural effusion

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6056
0 - Fully Active	87	1 (1.1)	86 (98.9)	NE (NE, NE)	97	0	97 (100)	NE (NE, NE)	NE (0.000, NE)	0.2879	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	9 (6.7)	125 (93.3)	NE (NE, NE)	0.553 (0.185, 1.651)	0.2819	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (9.7, NE)	1.439 (0.261, 7.948)	0.6746	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Pleural effusion

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9783
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	0.787 (0.176, 3.521)	0.7551	
>25% to ≤50%	141	5 (3.5)	136 (96.5)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	0.957 (0.277, 3.310)	0.9460	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	1.049 (0.146, 7.525)	0.9621	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Pleural effusion

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5897
Yes	139	6 (4.3)	133 (95.7)	NE (NE, NE)	137	6 (4.4)	131 (95.6)	NE (NE, NE)	0.948 (0.305, 2.945)	0.9273	
No	116	3 (2.6)	113 (97.4)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	0.609 (0.146, 2.550)	0.4932	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Pleural effusion

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6428
≤60	164	4 (2.4)	160 (97.6)	NE (NE, NE)	163	3 (1.8)	160 (98.2)	NE (NE, NE)	1.272 (0.284, 5.703)	0.7527	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	8 (7.6)	97 (92.4)	NE (NE, NE)	0.814 (0.282, 2.347)	0.7027	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Rhinorrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8248
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	3 (1.9)	157 (98.1)	NE (NE, NE)	2.109 (0.543, 8.195)	0.2702	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	0.000 (0.000, NE)	0.2943	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	1.133 (0.226, 5.686)	0.8795	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Rhinorrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4379
Male	124	5 (4.0)	119 (96.0)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	2.348 (0.455, 12.110)	0.2932	
Female	141	5 (3.5)	136 (96.5)	NE (NE, NE)	148	5 (3.4)	143 (96.6)	NE (NE, NE)	0.989 (0.285, 3.424)	0.9855	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Rhinorrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3366
White	157	1 (0.6)	156 (99.4)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	0.466 (0.042, 5.180)	0.5243	
Non-white	108	9 (8.3)	99 (91.7)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	1.749 (0.586, 5.222)	0.3103	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Rhinorrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9949
North America	16	0	16 (100)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	0.000 (0.000, NE)	0.4533	
Europe	161	2 (1.2)	159 (98.8)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	1.828 (0.165, 20.255)	0.6179	
Asia/Other Regions	88	8 (9.1)	80 (90.9)	NE (NE, NE)	89	5 (5.6)	84 (94.4)	NE (NE, NE)	1.618 (0.529, 4.946)	0.3945	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Rhinorrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7003
< 40x10^9/L	132	3 (2.3)	129 (97.7)	NE (NE, NE)	133	3 (2.3)	130 (97.7)	NE (NE, NE)	1.017 (0.205, 5.043)	0.9840	
≥ 40x10^9/L	133	7 (5.3)	126 (94.7)	NE (NE, NE)	135	4 (3.0)	131 (97.0)	NE (NE, NE)	1.563 (0.456, 5.354)	0.4739	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Rhinorrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1332
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	3 (3.2)	91 (96.8)	NE (NE, NE)	0.446 (0.074, 2.700)	0.3670	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	4 (2.3)	167 (97.7)	NE (NE, NE)	2.378 (0.715, 7.903)	0.1448	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Rhinorrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	8 (4.1)	187 (95.9)	NE (NE, NE)	190	4 (2.1)	186 (97.9)	NE (NE, NE)	1.720 (0.517, 5.729)	0.3710	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.000 (0.000, NE)	0.2546	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	1.704 (0.154, 18.815)	0.6597	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Rhinorrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3832
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	2.684 (0.520, 13.848)	0.2197	
1 - Restricted in Physically Strenuous Activity	133	4 (3.0)	129 (97.0)	NE (NE, NE)	134	3 (2.2)	131 (97.8)	NE (NE, NE)	1.323 (0.296, 5.912)	0.7136	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.222 (0.016, 2.995)	0.2296	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Rhinorrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9614
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	1.005 (0.202, 4.993)	0.9951	
>25% to ≤50%	141	6 (4.3)	135 (95.7)	NE (NE, NE)	136	4 (2.9)	132 (97.1)	NE (NE, NE)	1.402 (0.395, 4.978)	0.5996	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.2705	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Rhinorrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6372
Yes	139	6 (4.3)	133 (95.7)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	1.156 (0.352, 3.794)	0.8105	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.912 (0.349, 10.471)	0.4469	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Rhinorrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3748
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	3 (1.8)	160 (98.2)	NE (NE, NE)	2.073 (0.533, 8.055)	0.2820	
>60	101	3 (3.0)	98 (97.0)	NE (NE, NE)	105	4 (3.8)	101 (96.2)	NE (NE, NE)	0.848 (0.189, 3.793)	0.8287	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4938
<60	159	66 (41.5)	93 (58.5)	24.0 (3.3, NE)	160	54 (33.8)	106 (66.3)	40.8 (8.9, NE)	1.230 (0.858, 1.763)	0.2601	
≥60 - <65	37	13 (35.1)	24 (64.9)	22.4 (2.4, NE)	43	16 (37.2)	27 (62.8)	4.8 (2.6, NE)	0.808 (0.386, 1.694)	0.5699	
≥65	69	24 (34.8)	45 (65.2)	12.3 (4.0, NE)	65	27 (41.5)	38 (58.5)	11.1 (4.5, 27.5)	0.855 (0.493, 1.483)	0.5744	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3052
Male	124	39 (31.5)	85 (68.5)	NE (13.2, NE)	120	29 (24.2)	91 (75.8)	NE (25.4, NE)	1.333 (0.824, 2.158)	0.2408	
Female	141	64 (45.4)	77 (54.6)	8.5 (3.0, 24.0)	148	68 (45.9)	80 (54.1)	6.0 (3.3, 18.3)	0.951 (0.676, 1.338)	0.7749	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.0247
White	157	49 (31.2)	108 (68.8)	NE (22.4, NE)	161	58 (36.0)	103 (64.0)	18.3 (6.0, NE)	0.806 (0.551, 1.181)	0.2668	
Non-white	108	54 (50.0)	54 (50.0)	3.8 (2.0, 11.8)	107	39 (36.4)	68 (63.6)	17.0 (4.8, NE)	1.527 (1.011, 2.307)	0.0423	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0216
North America	16	7 (43.8)	9 (56.3)	8.5 (1.1, NE)	18	13 (72.2)	5 (27.8)	1.6 (0.2, 4.7)	0.516 (0.204, 1.303)	0.1543	
Europe	161	50 (31.1)	111 (68.9)	NE (22.4, NE)	161	52 (32.3)	109 (67.7)	18.3 (8.9, NE)	0.893 (0.605, 1.319)	0.5685	
Asia/Other Regions	88	46 (52.3)	42 (47.7)	3.7 (1.8, 11.8)	89	32 (36.0)	57 (64.0)	27.5 (4.5, NE)	1.728 (1.098, 2.719)	0.0168	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5565
< 40x10^9/L	132	56 (42.4)	76 (57.6)	12.3 (3.0, NE)	133	51 (38.3)	82 (61.7)	11.3 (7.2, 27.5)	1.116 (0.763, 1.633)	0.5683	
≥ 40x10^9/L	133	47 (35.3)	86 (64.7)	NE (5.4, NE)	135	46 (34.1)	89 (65.9)	40.8 (4.3, NE)	0.979 (0.651, 1.472)	0.9186	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.0398
Daunorubicin	123	39 (31.7)	84 (68.3)	NE (22.4, NE)	94	34 (36.2)	60 (63.8)	NE (4.0, NE)	0.761 (0.479, 1.207)	0.2456	
Idarubicin	142	64 (45.1)	78 (54.9)	8.5 (2.5, 24.0)	171	63 (36.8)	108 (63.2)	17.0 (7.2, NE)	1.327 (0.937, 1.881)	0.1104	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4018
Favorable	13	3 (23.1)	10 (76.9)	NE (0.7, NE)	19	10 (52.6)	9 (47.4)	4.0 (0.9, NE)	0.413 (0.113, 1.502)	0.1639	
Intermediate	195	78 (40.0)	117 (60.0)	22.4 (5.4, NE)	190	63 (33.2)	127 (66.8)	27.5 (7.2, NE)	1.152 (0.826, 1.606)	0.4029	
Unfavorable	19	6 (31.6)	13 (68.4)	NE (1.3, NE)	27	12 (44.4)	15 (55.6)	8.9 (3.3, NE)	0.819 (0.307, 2.187)	0.6854	
Unknown	38	16 (42.1)	22 (57.9)	4.0 (2.3, NE)	31	12 (38.7)	19 (61.3)	17.0 (3.1, NE)	1.249 (0.590, 2.644)	0.5685	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9164
0 - Fully Active	87	34 (39.1)	53 (60.9)	12.0 (3.8, NE)	97	35 (36.1)	62 (63.9)	18.3 (4.5, NE)	1.021 (0.636, 1.638)	0.9313	
1 - Restricted in Physically Strenuous Activity	133	52 (39.1)	81 (60.9)	22.4 (3.3, NE)	134	49 (36.6)	85 (63.4)	17.0 (5.7, NE)	1.042 (0.705, 1.539)	0.8353	
2 - Ambulatory and Capable of All Selfcare	45	17 (37.8)	28 (62.2)	24.0 (1.2, NE)	36	13 (36.1)	23 (63.9)	8.9 (4.3, NE)	1.256 (0.599, 2.633)	0.5453	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9048
≥3 to ≤25%	94	40 (42.6)	54 (57.4)	12.3 (2.0, NE)	98	39 (39.8)	59 (60.2)	11.3 (6.0, NE)	1.086 (0.698, 1.690)	0.7132	
>25% to ≤50%	141	51 (36.2)	90 (63.8)	NE (5.8, NE)	136	48 (35.3)	88 (64.7)	NE (4.5, NE)	1.011 (0.681, 1.501)	0.9529	
>50%	29	12 (41.4)	17 (58.6)	24.0 (2.3, NE)	34	10 (29.4)	24 (70.6)	40.8 (4.5, NE)	1.427 (0.598, 3.407)	0.4290	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7748
Yes	139	57 (41.0)	82 (59.0)	22.4 (3.3, NE)	137	54 (39.4)	83 (60.6)	25.4 (4.5, NE)	1.009 (0.695, 1.464)	0.9602	
No	116	43 (37.1)	73 (62.9)	NE (4.8, NE)	120	41 (34.2)	79 (65.8)	9.0 (4.7, NE)	1.092 (0.712, 1.676)	0.6890	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2599
≤60	164	67 (40.9)	97 (59.1)	24.0 (3.7, NE)	163	54 (33.1)	109 (66.9)	40.8 (8.9, NE)	1.223 (0.855, 1.752)	0.2706	
>60	101	36 (35.6)	65 (64.4)	22.4 (4.0, NE)	105	43 (41.0)	62 (59.0)	9.0 (4.5, 27.5)	0.858 (0.551, 1.337)	0.4966	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Headache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7001
<60	159	48 (30.2)	111 (69.8)	NE (NE, NE)	160	31 (19.4)	129 (80.6)	NE (40.8, NE)	1.573 (1.001, 2.472)	0.0472	
≥60 - <65	37	10 (27.0)	27 (73.0)	NE (3.0, NE)	43	8 (18.6)	35 (81.4)	NE (NE, NE)	1.402 (0.552, 3.561)	0.4754	
≥65	69	15 (21.7)	54 (78.3)	NE (12.0, NE)	65	14 (21.5)	51 (78.5)	NE (18.3, NE)	1.086 (0.524, 2.252)	0.8292	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Headache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8729
Male	124	26 (21.0)	98 (79.0)	NE (NE, NE)	120	17 (14.2)	103 (85.8)	NE (NE, NE)	1.519 (0.824, 2.799)	0.1780	
Female	141	47 (33.3)	94 (66.7)	NE (12.0, NE)	148	36 (24.3)	112 (75.7)	40.8 (40.8, NE)	1.388 (0.899, 2.143)	0.1369	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Headache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1155
White	157	35 (22.3)	122 (77.7)	NE (NE, NE)	161	32 (19.9)	129 (80.1)	NE (NE, NE)	1.105 (0.684, 1.786)	0.6845	
Non-white	108	38 (35.2)	70 (64.8)	24.0 (4.0, NE)	107	21 (19.6)	86 (80.4)	40.8 (40.8, NE)	1.930 (1.132, 3.290)	0.0139	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Headache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0745
North America	16	3 (18.8)	13 (81.3)	NE (1.8, NE)	18	7 (38.9)	11 (61.1)	4.7 (1.1, NE)	0.452 (0.117, 1.755)	0.2403	
Europe	161	36 (22.4)	125 (77.6)	NE (NE, NE)	161	28 (17.4)	133 (82.6)	NE (NE, NE)	1.236 (0.753, 2.027)	0.4017	
Asia/Other Regions	88	34 (38.6)	54 (61.4)	24.0 (3.7, NE)	89	18 (20.2)	71 (79.8)	40.8 (40.8, NE)	2.229 (1.255, 3.959)	0.0050	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Headache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.8007
< 40x10^9/L	132	38 (28.8)	94 (71.2)	NE (22.4, NE)	133	28 (21.1)	105 (78.9)	NE (25.4, NE)	1.465 (0.898, 2.388)	0.1236	
≥ 40x10^9/L	133	35 (26.3)	98 (73.7)	NE (NE, NE)	135	25 (18.5)	110 (81.5)	NE (40.8, NE)	1.343 (0.803, 2.247)	0.2593	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Headache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2479
Daunorubicin	123	28 (22.8)	95 (77.2)	NE (NE, NE)	94	18 (19.1)	76 (80.9)	NE (NE, NE)	1.099 (0.607, 1.991)	0.7541	
Idarubicin	142	45 (31.7)	97 (68.3)	NE (12.0, NE)	171	35 (20.5)	136 (79.5)	40.8 (40.8, NE)	1.664 (1.069, 2.590)	0.0226	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Headache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7090
Favorable	13	3 (23.1)	10 (76.9)	NE (0.7, NE)	19	6 (31.6)	13 (68.4)	NE (2.9, NE)	0.822 (0.205, 3.305)	0.7827	
Intermediate	195	51 (26.2)	144 (73.8)	NE (NE, NE)	190	36 (18.9)	154 (81.1)	40.8 (40.8, NE)	1.335 (0.871, 2.046)	0.1829	
Unfavorable	19	5 (26.3)	14 (73.7)	NE (3.8, NE)	27	5 (18.5)	22 (81.5)	NE (4.7, NE)	1.538 (0.444, 5.324)	0.4936	
Unknown	38	14 (36.8)	24 (63.2)	4.0 (3.0, NE)	31	6 (19.4)	25 (80.6)	NE (NE, NE)	2.228 (0.855, 5.807)	0.0938	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Headache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7179
0 - Fully Active	87	23 (26.4)	64 (73.6)	NE (NE, NE)	97	20 (20.6)	77 (79.4)	NE (18.3, NE)	1.254 (0.688, 2.284)	0.4597	
1 - Restricted in Physically Strenuous Activity	133	36 (27.1)	97 (72.9)	NE (22.4, NE)	134	26 (19.4)	108 (80.6)	NE (NE, NE)	1.381 (0.834, 2.287)	0.2080	
2 - Ambulatory and Capable of All Selfcare	45	14 (31.1)	31 (68.9)	NE (2.3, NE)	36	7 (19.4)	29 (80.6)	40.8 (40.8, NE)	2.131 (0.817, 5.560)	0.1134	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Headache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5331
≥3 to ≤25%	94	30 (31.9)	64 (68.1)	NE (4.0, NE)	98	24 (24.5)	74 (75.5)	NE (25.4, NE)	1.334 (0.780, 2.284)	0.2910	
>25% to ≤50%	141	32 (22.7)	109 (77.3)	NE (NE, NE)	136	24 (17.6)	112 (82.4)	NE (NE, NE)	1.308 (0.770, 2.221)	0.3193	
>50%	29	11 (37.9)	18 (62.1)	24.0 (2.3, NE)	34	5 (14.7)	29 (85.3)	40.8 (4.5, NE)	3.057 (0.968, 9.659)	0.0460	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Headache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9759
Yes	139	41 (29.5)	98 (70.5)	NE (24.0, NE)	137	30 (21.9)	107 (78.1)	40.8 (40.8, NE)	1.355 (0.846, 2.172)	0.2043	
No	116	30 (25.9)	86 (74.1)	NE (12.0, NE)	120	23 (19.2)	97 (80.8)	NE (NE, NE)	1.362 (0.791, 2.345)	0.2629	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Headache

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5746
≤60	164	48 (29.3)	116 (70.7)	NE (NE, NE)	163	31 (19.0)	132 (81.0)	NE (40.8, NE)	1.541 (0.981, 2.422)	0.0583	
>60	101	25 (24.8)	76 (75.2)	NE (12.3, NE)	105	22 (21.0)	83 (79.0)	NE (25.4, NE)	1.237 (0.697, 2.196)	0.4673	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Dizziness

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5190
<60	159	11 (6.9)	148 (93.1)	NE (NE, NE)	160	11 (6.9)	149 (93.1)	NE (NE, NE)	0.936 (0.405, 2.163)	0.8770	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (17.8, NE)	43	4 (9.3)	39 (90.7)	NE (10.4, NE)	0.200 (0.022, 1.798)	0.1110	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	4 (6.2)	61 (93.8)	NE (NE, NE)	1.066 (0.266, 4.267)	0.9277	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Dizziness

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5728
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	1.096 (0.334, 3.599)	0.8795	
Female	141	10 (7.1)	131 (92.9)	NE (NE, NE)	148	14 (9.5)	134 (90.5)	NE (NE, NE)	0.683 (0.303, 1.540)	0.3557	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Dizziness

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3645
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	10 (6.2)	151 (93.8)	NE (NE, NE)	0.538 (0.195, 1.487)	0.2247	
Non-white	108	10 (9.3)	98 (90.7)	NE (NE, NE)	107	9 (8.4)	98 (91.6)	NE (NE, NE)	1.041 (0.422, 2.563)	0.9299	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Dizziness

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3494
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	6 (33.3)	12 (66.7)	12.0 (4.5, NE)	0.181 (0.021, 1.546)	0.0818	
Europe	161	5 (3.1)	156 (96.9)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	0.890 (0.256, 3.091)	0.8546	
Asia/Other Regions	88	10 (11.4)	78 (88.6)	NE (NE, NE)	89	8 (9.0)	81 (91.0)	NE (NE, NE)	1.207 (0.476, 3.060)	0.6906	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Dizziness

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9262
< 40x10^9/L	132	10 (7.6)	122 (92.4)	NE (NE, NE)	133	13 (9.8)	120 (90.2)	NE (NE, NE)	0.777 (0.340, 1.773)	0.5476	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	0.867 (0.278, 2.702)	0.8078	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Dizziness

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7310
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	4 (4.3)	90 (95.7)	NE (NE, NE)	0.701 (0.175, 2.811)	0.6144	
Idarubicin	142	12 (8.5)	130 (91.5)	NE (NE, NE)	171	15 (8.8)	156 (91.2)	NE (NE, NE)	0.881 (0.411, 1.886)	0.7448	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Dizziness

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7494
Favorable	13	0	13 (100)	NE (NE, NE)	19	4 (21.1)	15 (78.9)	NE (10.4, NE)	0.000 (0.000, NE)	0.1348	
Intermediate	195	14 (7.2)	181 (92.8)	NE (NE, NE)	190	10 (5.3)	180 (94.7)	NE (NE, NE)	1.264 (0.561, 2.848)	0.5709	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	3 (11.1)	24 (88.9)	NE (12.0, NE)	0.442 (0.046, 4.282)	0.4694	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (9.0, NE)	0.317 (0.029, 3.507)	0.3229	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Dizziness

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7775
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	5 (5.2)	92 (94.8)	NE (NE, NE)	1.080 (0.313, 3.731)	0.9035	
1 - Restricted in Physically Strenuous Activity	133	9 (6.8)	124 (93.2)	NE (NE, NE)	134	14 (10.4)	120 (89.6)	NE (NE, NE)	0.569 (0.246, 1.317)	0.1824	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.2672	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Dizziness

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4953
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	10 (10.2)	88 (89.8)	NE (NE, NE)	0.505 (0.172, 1.479)	0.2036	
>25% to ≤50%	141	9 (6.4)	132 (93.6)	NE (NE, NE)	136	8 (5.9)	128 (94.1)	NE (NE, NE)	1.031 (0.397, 2.681)	0.9494	
>50%	29	2 (6.9)	27 (93.1)	NE (17.8, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	1.468 (0.126, 17.109)	0.7578	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Dizziness

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3560
Yes	139	11 (7.9)	128 (92.1)	NE (NE, NE)	137	9 (6.6)	128 (93.4)	NE (NE, NE)	1.155 (0.477, 2.794)	0.7492	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	8 (6.7)	112 (93.3)	NE (NE, NE)	0.563 (0.184, 1.724)	0.3074	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Dizziness

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7531
≤60	164	11 (6.7)	153 (93.3)	NE (NE, NE)	163	11 (6.7)	152 (93.3)	NE (NE, NE)	0.917 (0.397, 2.121)	0.8409	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	8 (7.6)	97 (92.4)	NE (NE, NE)	0.652 (0.213, 1.998)	0.4506	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0254
<60	159	63 (39.6)	96 (60.4)	13.4 (8.0, NE)	160	61 (38.1)	99 (61.9)	11.0 (4.9, NE)	0.990 (0.696, 1.408)	0.9546	
≥60 - <65	37	7 (18.9)	30 (81.1)	34.3 (23.2, NE)	43	19 (44.2)	24 (55.8)	5.8 (4.5, NE)	0.184 (0.067, 0.510)	0.0003	
≥65	69	21 (30.4)	48 (69.6)	13.0 (8.9, NE)	65	28 (43.1)	37 (56.9)	5.5 (3.4, 9.4)	0.581 (0.327, 1.031)	0.0598	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3062
Male	124	39 (31.5)	85 (68.5)	23.2 (12.2, NE)	120	49 (40.8)	71 (59.2)	5.4 (3.7, NE)	0.642 (0.420, 0.981)	0.0386	
Female	141	52 (36.9)	89 (63.1)	20.6 (10.7, NE)	148	59 (39.9)	89 (60.1)	7.8 (5.6, 35.0)	0.843 (0.580, 1.226)	0.3707	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1584
White	157	43 (27.4)	114 (72.6)	34.3 (23.2, NE)	161	60 (37.3)	101 (62.7)	7.9 (4.9, NE)	0.628 (0.423, 0.932)	0.0196	
Non-white	108	48 (44.4)	60 (55.6)	10.7 (5.5, 21.5)	107	48 (44.9)	59 (55.1)	5.8 (3.8, 29.0)	0.917 (0.613, 1.369)	0.6723	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5490
North America	16	8 (50.0)	8 (50.0)	2.3 (0.7, NE)	18	10 (55.6)	8 (44.4)	5.5 (1.4, NE)	1.103 (0.431, 2.826)	0.8408	
Europe	161	42 (26.1)	119 (73.9)	34.3 (23.2, NE)	161	53 (32.9)	108 (67.1)	11.0 (6.4, NE)	0.670 (0.446, 1.006)	0.0515	
Asia/Other Regions	88	41 (46.6)	47 (53.4)	10.7 (4.8, 20.6)	89	45 (50.6)	44 (49.4)	3.8 (2.4, 28.3)	0.834 (0.544, 1.276)	0.4029	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4173
< 40x10^9/L	132	44 (33.3)	88 (66.7)	21.5 (13.0, NE)	133	51 (38.3)	82 (61.7)	7.9 (5.5, 29.0)	0.825 (0.550, 1.237)	0.3523	
≥ 40x10^9/L	133	47 (35.3)	86 (64.7)	22.0 (10.7, NE)	135	57 (42.2)	78 (57.8)	5.6 (3.8, 35.0)	0.668 (0.453, 0.986)	0.0406	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)			Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8058
Daunorubicin	123	42 (34.1)	81 (65.9)	34.3 (8.9, NE)	94	34 (36.2)	60 (63.8)	8.6 (4.9, NE)	0.821 (0.521, 1.294)	0.3921	
Idarubicin	142	49 (34.5)	93 (65.5)	20.6 (12.2, 27.9)	171	73 (42.7)	98 (57.3)	5.8 (4.5, 28.3)	0.738 (0.513, 1.062)	0.1009	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4276
Favorable	13	2 (15.4)	11 (84.6)	NE (5.5, NE)	19	11 (57.9)	8 (42.1)	4.0 (1.4, NE)	0.251 (0.056, 1.135)	0.0515	
Intermediate	195	68 (34.9)	127 (65.1)	21.5 (10.7, 31.4)	190	72 (37.9)	118 (62.1)	7.8 (5.2, 35.0)	0.796 (0.571, 1.110)	0.1772	
Unfavorable	19	7 (36.8)	12 (63.2)	19.4 (2.0, NE)	27	12 (44.4)	15 (55.6)	7.5 (2.0, NE)	0.736 (0.283, 1.916)	0.5257	
Unknown	38	14 (36.8)	24 (63.2)	34.3 (5.6, NE)	31	13 (41.9)	18 (58.1)	6.6 (3.5, NE)	0.825 (0.379, 1.797)	0.6319	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2017
0 - Fully Active	87	31 (35.6)	56 (64.4)	22.0 (8.9, NE)	97	32 (33.0)	65 (67.0)	NE (6.4, NE)	1.049 (0.640, 1.719)	0.8500	
1 - Restricted in Physically Strenuous Activity	133	45 (33.8)	88 (66.2)	27.9 (13.0, NE)	134	61 (45.5)	73 (54.5)	5.2 (3.7, 6.6)	0.562 (0.380, 0.832)	0.0036	
2 - Ambulatory and Capable of All Selfcare	45	15 (33.3)	30 (66.7)	10.7 (4.7, NE)	36	14 (38.9)	22 (61.1)	7.8 (1.9, NE)	0.825 (0.396, 1.722)	0.6048	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8824
≥3 to ≤25%	94	32 (34.0)	62 (66.0)	23.2 (10.7, NE)	98	42 (42.9)	56 (57.1)	6.5 (4.0, 23.5)	0.674 (0.425, 1.070)	0.0930	
>25% to ≤50%	141	50 (35.5)	91 (64.5)	20.6 (8.9, NE)	136	56 (41.2)	80 (58.8)	6.4 (4.4, 29.0)	0.802 (0.546, 1.176)	0.2580	
>50%	29	9 (31.0)	20 (69.0)	NE (4.5, NE)	34	10 (29.4)	24 (70.6)	35.0 (5.2, NE)	0.919 (0.359, 2.352)	0.8566	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4008
Yes	139	49 (35.3)	90 (64.7)	23.2 (13.0, NE)	137	63 (46.0)	74 (54.0)	6.5 (4.9, 23.5)	0.633 (0.434, 0.923)	0.0164	
No	116	39 (33.6)	77 (66.4)	19.4 (6.7, NE)	120	44 (36.7)	76 (63.3)	6.4 (3.7, NE)	0.824 (0.534, 1.269)	0.3788	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0186
≤60	164	64 (39.0)	100 (61.0)	19.4 (8.0, NE)	163	61 (37.4)	102 (62.6)	11.0 (4.9, NE)	0.984 (0.692, 1.398)	0.9280	
>60	101	27 (26.7)	74 (73.3)	31.4 (13.0, NE)	105	47 (44.8)	58 (55.2)	5.6 (4.5, 7.9)	0.412 (0.252, 0.676)	0.0003	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Arthralgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7394
<60	159	23 (14.5)	136 (85.5)	NE (NE, NE)	160	18 (11.3)	142 (88.8)	NE (NE, NE)	1.092 (0.589, 2.027)	0.7798	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	8 (18.6)	35 (81.4)	30.2 (10.1, NE)	0.000 (0.000, NE)	0.0012	
≥65	69	6 (8.7)	63 (91.3)	NE (NE, NE)	65	9 (13.8)	56 (86.2)	NE (NE, NE)	0.666 (0.237, 1.871)	0.4364	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Arthralgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2883
Male	124	17 (13.7)	107 (86.3)	NE (35.0, NE)	120	15 (12.5)	105 (87.5)	NE (28.3, NE)	0.943 (0.470, 1.893)	0.8696	
Female	141	12 (8.5)	129 (91.5)	NE (NE, NE)	148	20 (13.5)	128 (86.5)	NE (NE, NE)	0.561 (0.274, 1.148)	0.1081	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Arthralgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6685
White	157	16 (10.2)	141 (89.8)	NE (NE, NE)	161	21 (13.0)	140 (87.0)	NE (NE, NE)	0.686 (0.357, 1.317)	0.2540	
Non-white	108	13 (12.0)	95 (88.0)	NE (NE, NE)	107	14 (13.1)	93 (86.9)	NE (28.3, NE)	0.810 (0.380, 1.725)	0.5836	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Arthralgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7126
North America	16	2 (12.5)	14 (87.5)	19.2 (19.2, NE)	18	3 (16.7)	15 (83.3)	NE (5.5, NE)	1.228 (0.198, 7.610)	0.8248	
Europe	161	16 (9.9)	145 (90.1)	NE (NE, NE)	161	21 (13.0)	140 (87.0)	NE (NE, NE)	0.639 (0.333, 1.228)	0.1744	
Asia/Other Regions	88	11 (12.5)	77 (87.5)	NE (NE, NE)	89	11 (12.4)	78 (87.6)	NE (28.3, NE)	0.884 (0.382, 2.043)	0.7735	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Arthralgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3218
< 40x10^9/L	132	14 (10.6)	118 (89.4)	NE (NE, NE)	133	15 (11.3)	118 (88.7)	NE (NE, NE)	0.943 (0.455, 1.955)	0.8748	
≥ 40x10^9/L	133	15 (11.3)	118 (88.7)	NE (35.0, NE)	135	20 (14.8)	115 (85.2)	NE (26.5, NE)	0.556 (0.284, 1.091)	0.0833	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Arthralgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8903
Daunorubicin	123	14 (11.4)	109 (88.6)	NE (NE, NE)	94	12 (12.8)	82 (87.2)	NE (30.2, NE)	0.762 (0.352, 1.653)	0.4896	
Idarubicin	142	15 (10.6)	127 (89.4)	NE (NE, NE)	171	23 (13.5)	148 (86.5)	NE (NE, NE)	0.685 (0.357, 1.314)	0.2516	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Arthralgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8072
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	3 (15.8)	16 (84.2)	NE (NE, NE)	0.537 (0.056, 5.180)	0.5850	
Intermediate	195	25 (12.8)	170 (87.2)	NE (NE, NE)	190	22 (11.6)	168 (88.4)	NE (NE, NE)	0.941 (0.530, 1.671)	0.8350	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	5 (18.5)	22 (81.5)	22.5 (22.5, NE)	0.000 (0.000, NE)	0.0289	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	5 (16.1)	26 (83.9)	NE (12.5, NE)	0.432 (0.102, 1.825)	0.2406	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Arthralgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8871
0 - Fully Active	87	8 (9.2)	79 (90.8)	NE (NE, NE)	97	12 (12.4)	85 (87.6)	NE (NE, NE)	0.670 (0.274, 1.642)	0.3782	
1 - Restricted in Physically Strenuous Activity	133	15 (11.3)	118 (88.7)	NE (NE, NE)	134	19 (14.2)	115 (85.8)	NE (28.3, NE)	0.706 (0.358, 1.390)	0.3103	
2 - Ambulatory and Capable of All Selfcare	45	6 (13.3)	39 (86.7)	NE (20.7, NE)	36	4 (11.1)	32 (88.9)	NE (NE, NE)	0.902 (0.250, 3.259)	0.8753	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Arthralgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9925
≥3 to ≤25%	94	12 (12.8)	82 (87.2)	NE (35.0, NE)	98	16 (16.3)	82 (83.7)	NE (30.2, NE)	0.721 (0.341, 1.525)	0.3897	
>25% to ≤50%	141	15 (10.6)	126 (89.4)	NE (NE, NE)	136	17 (12.5)	119 (87.5)	NE (28.3, NE)	0.756 (0.377, 1.516)	0.4286	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.841 (0.118, 5.988)	0.8622	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Arthralgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6175
Yes	139	13 (9.4)	126 (90.6)	NE (NE, NE)	137	19 (13.9)	118 (86.1)	NE (NE, NE)	0.600 (0.296, 1.217)	0.1516	
No	116	15 (12.9)	101 (87.1)	NE (35.0, NE)	120	16 (13.3)	104 (86.7)	NE (22.5, NE)	0.791 (0.390, 1.606)	0.5159	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Arthralgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0460
≤60	164	23 (14.0)	141 (86.0)	NE (NE, NE)	163	18 (11.0)	145 (89.0)	NE (NE, NE)	1.069 (0.576, 1.985)	0.8323	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	17 (16.2)	88 (83.8)	NE (28.3, NE)	0.344 (0.136, 0.874)	0.0187	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Back pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1254
<60	159	14 (8.8)	145 (91.2)	NE (NE, NE)	160	13 (8.1)	147 (91.9)	NE (NE, NE)	1.009 (0.473, 2.151)	0.9814	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	4 (9.3)	39 (90.7)	NE (10.8, NE)	0.721 (0.159, 3.266)	0.6695	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	11 (16.9)	54 (83.1)	NE (34.0, NE)	0.170 (0.038, 0.766)	0.0088	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Back pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7958
Male	124	10 (8.1)	114 (91.9)	NE (NE, NE)	120	15 (12.5)	105 (87.5)	NE (NE, NE)	0.619 (0.278, 1.380)	0.2368	
Female	141	9 (6.4)	132 (93.6)	NE (NE, NE)	148	13 (8.8)	135 (91.2)	NE (NE, NE)	0.644 (0.275, 1.509)	0.3072	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Back pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2007
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	17 (10.6)	144 (89.4)	NE (NE, NE)	0.440 (0.189, 1.022)	0.0496	
Non-white	108	11 (10.2)	97 (89.8)	NE (NE, NE)	107	11 (10.3)	96 (89.7)	NE (NE, NE)	0.929 (0.402, 2.147)	0.8649	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Back pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7303
North America	16	1 (6.3)	15 (93.8)	NE (12.1, NE)	18	3 (16.7)	15 (83.3)	NE (7.9, NE)	0.557 (0.057, 5.486)	0.6113	
Europe	161	8 (5.0)	153 (95.0)	NE (NE, NE)	161	14 (8.7)	147 (91.3)	NE (NE, NE)	0.527 (0.221, 1.259)	0.1424	
Asia/Other Regions	88	10 (11.4)	78 (88.6)	NE (NE, NE)	89	11 (12.4)	78 (87.6)	NE (NE, NE)	0.822 (0.348, 1.941)	0.6556	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Back pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.8073
< 40x10^9/L	132	6 (4.5)	126 (95.5)	NE (NE, NE)	133	11 (8.3)	122 (91.7)	NE (NE, NE)	0.572 (0.211, 1.548)	0.2657	
≥ 40x10^9/L	133	13 (9.8)	120 (90.2)	NE (NE, NE)	135	17 (12.6)	118 (87.4)	NE (34.0, NE)	0.633 (0.306, 1.307)	0.2124	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Back pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4530
Daunorubicin	123	7 (5.7)	116 (94.3)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	0.965 (0.305, 3.054)	0.9524	
Idarubicin	142	12 (8.5)	130 (91.5)	NE (NE, NE)	171	23 (13.5)	148 (86.5)	NE (NE, NE)	0.580 (0.288, 1.168)	0.1221	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Back pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8493
Favorable	13	0	13 (100)	NE (NE, NE)	19	3 (15.8)	16 (84.2)	NE (7.9, NE)	0.000 (0.000, NE)	0.3472	
Intermediate	195	13 (6.7)	182 (93.3)	NE (NE, NE)	190	18 (9.5)	172 (90.5)	NE (NE, NE)	0.622 (0.304, 1.273)	0.1895	
Unfavorable	19	3 (15.8)	16 (84.2)	NE (4.8, NE)	27	3 (11.1)	24 (88.9)	NE (4.4, NE)	1.215 (0.238, 6.214)	0.8149	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (NE, NE)	0.603 (0.134, 2.718)	0.5061	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Back pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1228
0 - Fully Active	87	9 (10.3)	78 (89.7)	NE (NE, NE)	97	8 (8.2)	89 (91.8)	NE (NE, NE)	1.185 (0.457, 3.075)	0.7272	
1 - Restricted in Physically Strenuous Activity	133	6 (4.5)	127 (95.5)	NE (NE, NE)	134	17 (12.7)	117 (87.3)	NE (34.0, NE)	0.317 (0.125, 0.807)	0.0110	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	3 (8.3)	33 (91.7)	NE (NE, NE)	1.008 (0.220, 4.620)	0.9917	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Back pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7563
≥3 to ≤25%	94	7 (7.4)	87 (92.6)	NE (NE, NE)	98	8 (8.2)	90 (91.8)	NE (NE, NE)	0.858 (0.310, 2.371)	0.7670	
>25% to ≤50%	141	11 (7.8)	130 (92.2)	NE (NE, NE)	136	18 (13.2)	118 (86.8)	NE (34.0, NE)	0.546 (0.257, 1.158)	0.1091	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.471 (0.042, 5.222)	0.5297	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Back pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3327
Yes	139	12 (8.6)	127 (91.4)	NE (NE, NE)	137	21 (15.3)	116 (84.7)	NE (NE, NE)	0.499 (0.245, 1.017)	0.0513	
No	116	7 (6.0)	109 (94.0)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	1.011 (0.354, 2.885)	0.9850	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Back pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0415
≤60	164	15 (9.1)	149 (90.9)	NE (NE, NE)	163	13 (8.0)	150 (92.0)	NE (NE, NE)	1.065 (0.506, 2.243)	0.8674	
>60	101	4 (4.0)	97 (96.0)	NE (NE, NE)	105	15 (14.3)	90 (85.7)	NE (34.0, NE)	0.251 (0.083, 0.758)	0.0081	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Pain in extremity

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3563
<60	159	12 (7.5)	147 (92.5)	NE (NE, NE)	160	17 (10.6)	143 (89.4)	NE (NE, NE)	0.613 (0.292, 1.287)	0.1923	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (31.4, NE)	43	3 (7.0)	40 (93.0)	NE (29.1, NE)	0.376 (0.039, 3.619)	0.3784	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (29.4, NE)	1.907 (0.349, 10.421)	0.4484	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Pain in extremity

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3553
Male	124	8 (6.5)	116 (93.5)	NE (NE, NE)	120	13 (10.8)	107 (89.2)	NE (NE, NE)	0.512 (0.211, 1.239)	0.1306	
Female	141	9 (6.4)	132 (93.6)	NE (NE, NE)	148	9 (6.1)	139 (93.9)	NE (NE, NE)	0.930 (0.368, 2.348)	0.8776	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Pain in extremity

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.0311
White	157	5 (3.2)	152 (96.8)	NE (NE, NE)	161	14 (8.7)	147 (91.3)	NE (NE, NE)	0.309 (0.111, 0.861)	0.0176	
Non-white	108	12 (11.1)	96 (88.9)	NE (NE, NE)	107	8 (7.5)	99 (92.5)	NE (NE, NE)	1.409 (0.576, 3.451)	0.4505	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Pain in extremity

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2705
North America	16	1 (6.3)	15 (93.8)	NE (12.1, NE)	18	4 (22.2)	14 (77.8)	29.4 (29.1, NE)	0.439 (0.047, 4.099)	0.4588	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	11 (6.8)	150 (93.2)	NE (NE, NE)	0.450 (0.166, 1.221)	0.1077	
Asia/Other Regions	88	10 (11.4)	78 (88.6)	NE (NE, NE)	89	7 (7.9)	82 (92.1)	NE (NE, NE)	1.342 (0.509, 3.534)	0.5506	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Pain in extremity

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2987
< 40x10^9/L	132	9 (6.8)	123 (93.2)	NE (NE, NE)	133	9 (6.8)	124 (93.2)	NE (NE, NE)	0.978 (0.388, 2.468)	0.9631	
≥ 40x10^9/L	133	8 (6.0)	125 (94.0)	NE (NE, NE)	135	13 (9.6)	122 (90.4)	NE (35.0, NE)	0.498 (0.206, 1.207)	0.1159	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Pain in extremity

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8809
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	0.689 (0.222, 2.142)	0.5182	
Idarubicin	142	11 (7.7)	131 (92.3)	NE (NE, NE)	171	16 (9.4)	155 (90.6)	NE (NE, NE)	0.715 (0.331, 1.545)	0.3919	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Pain in extremity

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8496
Favorable	13	1 (7.7)	12 (92.3)	NE (5.5, NE)	19	3 (15.8)	16 (84.2)	NE (29.1, NE)	1.037 (0.101, 10.602)	0.9756	
Intermediate	195	13 (6.7)	182 (93.3)	NE (NE, NE)	190	10 (5.3)	180 (94.7)	NE (NE, NE)	1.121 (0.491, 2.562)	0.7853	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	5 (18.5)	22 (81.5)	NE (5.2, NE)	0.000 (0.000, NE)	0.0475	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (26.5, NE)	0.523 (0.115, 2.382)	0.3972	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Pain in extremity

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8953
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	0.763 (0.170, 3.413)	0.7222	
1 - Restricted in Physically Strenuous Activity	133	9 (6.8)	124 (93.2)	NE (NE, NE)	134	14 (10.4)	120 (89.6)	NE (NE, NE)	0.578 (0.250, 1.338)	0.1950	
2 - Ambulatory and Capable of All Selfcare	45	5 (11.1)	40 (88.9)	NE (23.7, NE)	36	4 (11.1)	32 (88.9)	NE (35.0, NE)	0.884 (0.235, 3.324)	0.8551	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Pain in extremity

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.0777
≥3 to ≤25%	94	8 (8.5)	86 (91.5)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	2.042 (0.615, 6.785)	0.2335	
>25% to ≤50%	141	7 (5.0)	134 (95.0)	NE (NE, NE)	136	13 (9.6)	123 (90.4)	NE (NE, NE)	0.464 (0.185, 1.166)	0.0945	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	5 (14.7)	29 (85.3)	35.0 (NE, NE)	0.414 (0.080, 2.139)	0.2771	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Pain in extremity

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3239
Yes	139	8 (5.8)	131 (94.2)	NE (NE, NE)	137	14 (10.2)	123 (89.8)	NE (35.0, NE)	0.472 (0.197, 1.130)	0.0846	
No	116	8 (6.9)	108 (93.1)	NE (NE, NE)	120	8 (6.7)	112 (93.3)	NE (NE, NE)	0.908 (0.340, 2.423)	0.8479	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Pain in extremity

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4487
≤60	164	12 (7.3)	152 (92.7)	NE (NE, NE)	163	17 (10.4)	146 (89.6)	NE (NE, NE)	0.602 (0.287, 1.264)	0.1756	
>60	101	5 (5.0)	96 (95.0)	NE (31.4, NE)	105	5 (4.8)	100 (95.2)	NE (29.4, NE)	0.990 (0.286, 3.425)	0.9878	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Myalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4555
<60	159	11 (6.9)	148 (93.1)	NE (NE, NE)	160	10 (6.3)	150 (93.8)	NE (NE, NE)	0.969 (0.411, 2.288)	0.9433	
≥60 - <65	37	4 (10.8)	33 (89.2)	43.0 (23.2, NE)	43	3 (7.0)	40 (93.0)	NE (NE, NE)	1.092 (0.220, 5.424)	0.9148	
≥65	69	1 (1.4)	68 (98.6)	NE (NE, NE)	65	4 (6.2)	61 (93.8)	NE (NE, NE)	0.259 (0.029, 2.319)	0.1931	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Myalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6632
Male	124	5 (4.0)	119 (96.0)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.674 (0.205, 2.218)	0.5138	
Female	141	11 (7.8)	130 (92.2)	NE (43.0, NE)	148	11 (7.4)	137 (92.6)	NE (NE, NE)	0.996 (0.431, 2.301)	0.9923	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Myalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5264
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	10 (6.2)	151 (93.8)	NE (NE, NE)	0.699 (0.275, 1.779)	0.4505	
Non-white	108	8 (7.4)	100 (92.6)	43.0 (43.0, NE)	107	7 (6.5)	100 (93.5)	NE (NE, NE)	1.105 (0.401, 3.050)	0.8452	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Myalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4575
North America	16	2 (12.5)	14 (87.5)	NE (2.0, NE)	18	2 (11.1)	16 (88.9)	NE (4.9, NE)	1.561 (0.212, 11.480)	0.6592	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	0.539 (0.191, 1.522)	0.2360	
Asia/Other Regions	88	8 (9.1)	80 (90.9)	NE (43.0, NE)	89	6 (6.7)	83 (93.3)	NE (NE, NE)	1.273 (0.441, 3.679)	0.6536	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Myalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4458
< 40x10^9/L	132	10 (7.6)	122 (92.4)	NE (43.0, NE)	133	9 (6.8)	124 (93.2)	NE (NE, NE)	1.070 (0.430, 2.661)	0.8850	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	8 (5.9)	127 (94.1)	NE (NE, NE)	0.611 (0.211, 1.769)	0.3588	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Myalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5806
Daunorubicin	123	5 (4.1)	118 (95.9)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	0.624 (0.180, 2.167)	0.4542	
Idarubicin	142	11 (7.7)	131 (92.3)	NE (43.0, NE)	171	12 (7.0)	159 (93.0)	NE (NE, NE)	1.029 (0.451, 2.344)	0.9465	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Myalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8118
Favorable	13	1 (7.7)	12 (92.3)	NE (15.7, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	0.849 (0.075, 9.591)	0.8949	
Intermediate	195	12 (6.2)	183 (93.8)	NE (43.0, NE)	190	12 (6.3)	178 (93.7)	NE (NE, NE)	0.852 (0.382, 1.900)	0.6949	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	22.5 (7.5, NE)	0.000 (0.000, NE)	0.0784	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (17.3, NE)	2.736 (0.284, 26.372)	0.3642	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Myalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1867
0 - Fully Active	87	8 (9.2)	79 (90.8)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	2.127 (0.640, 7.069)	0.2072	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	43.0 (NE, NE)	134	13 (9.7)	121 (90.3)	NE (NE, NE)	0.419 (0.159, 1.104)	0.0695	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.4945	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Myalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9794
≥3 to ≤25%	94	7 (7.4)	87 (92.6)	NE (43.0, NE)	98	7 (7.1)	91 (92.9)	NE (NE, NE)	0.884 (0.306, 2.555)	0.8202	
>25% to ≤50%	141	9 (6.4)	132 (93.6)	NE (NE, NE)	136	10 (7.4)	126 (92.6)	NE (NE, NE)	0.856 (0.348, 2.111)	0.7360	
>50%	29	0	29 (100)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Myalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9998
Yes	139	9 (6.5)	130 (93.5)	NE (43.0, NE)	137	11 (8.0)	126 (92.0)	NE (NE, NE)	0.774 (0.320, 1.870)	0.5678	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.749 (0.228, 2.457)	0.6326	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Myalgia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7812
≤60	164	11 (6.7)	153 (93.3)	NE (NE, NE)	163	10 (6.1)	153 (93.9)	NE (NE, NE)	0.949 (0.402, 2.242)	0.9059	
>60	101	5 (5.0)	96 (95.0)	43.0 (43.0, NE)	105	7 (6.7)	98 (93.3)	NE (NE, NE)	0.726 (0.229, 2.302)	0.5844	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Muscle spasms

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3811
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	2 (1.3)	158 (98.8)	NE (NE, NE)	2.648 (0.547, 12.807)	0.2083	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	0.000 (0.000, NE)	0.1686	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	5 (7.7)	60 (92.3)	NE (27.9, NE)	0.585 (0.139, 2.453)	0.4577	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Muscle spasms

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2901
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	1.521 (0.379, 6.097)	0.5513	
Female	141	4 (2.8)	137 (97.2)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	0.587 (0.165, 2.088)	0.4049	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Muscle spasms

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9874
White	157	4 (2.5)	153 (97.5)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	0.355 (0.109, 1.159)	0.0732	
Non-white	108	6 (5.6)	102 (94.4)	NE (NE, NE)	107	0	107 (100)	NE (NE, NE)	NE (0.000, NE)	0.0192	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Muscle spasms

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8272
North America	16	2 (12.5)	14 (87.5)	23.8 (23.8, NE)	18	4 (22.2)	14 (77.8)	NE (16.0, NE)	0.653 (0.118, 3.604)	0.6224	
Europe	161	7 (4.3)	154 (95.7)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	1.259 (0.367, 4.321)	0.7136	
Asia/Other Regions	88	1 (1.1)	87 (98.9)	NE (NE, NE)	89	1 (1.1)	88 (98.9)	NE (NE, NE)	0.904 (0.056, 14.593)	0.9435	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Muscle spasms

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3129
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	0.649 (0.206, 2.050)	0.4582	
≥ 40x10^9/L	133	5 (3.8)	128 (96.2)	NE (NE, NE)	135	2 (1.5)	133 (98.5)	NE (NE, NE)	1.931 (0.372, 10.036)	0.4256	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Muscle spasms

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7901
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	3 (3.2)	91 (96.8)	NE (NE, NE)	0.797 (0.177, 3.590)	0.7671	
Idarubicin	142	6 (4.2)	136 (95.8)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	0.976 (0.314, 3.033)	0.9668	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Muscle spasms

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9529
Favorable	13	0	13 (100)	NE (NE, NE)	19	2 (10.5)	17 (89.5)	NE (16.0, NE)	0.000 (0.000, NE)	0.2692	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	4 (2.1)	186 (97.9)	NE (NE, NE)	1.777 (0.546, 5.785)	0.3332	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (11.0, NE)	0.000 (0.000, NE)	0.2260	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	0.791 (0.049, 12.884)	0.8686	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Muscle spasms

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3833
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	2.327 (0.450, 12.028)	0.2995	
1 - Restricted in Physically Strenuous Activity	133	4 (3.0)	129 (97.0)	NE (NE, NE)	134	6 (4.5)	128 (95.5)	NE (NE, NE)	0.584 (0.164, 2.075)	0.4001	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (7.8, NE)	0.328 (0.020, 5.477)	0.4160	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Muscle spasms

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9231
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	5 (5.1)	93 (94.9)	NE (NE, NE)	0.783 (0.210, 2.922)	0.7154	
>25% to ≤50%	141	6 (4.3)	135 (95.7)	NE (NE, NE)	136	4 (2.9)	132 (97.1)	NE (NE, NE)	1.144 (0.321, 4.074)	0.8349	
>50%	29	0	29 (100)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Muscle spasms

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3943
Yes	139	6 (4.3)	133 (95.7)	NE (NE, NE)	137	7 (5.1)	130 (94.9)	NE (NE, NE)	0.683 (0.229, 2.037)	0.4913	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.784 (0.326, 9.764)	0.4987	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Muscle spasms

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0878
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	2 (1.2)	161 (98.8)	NE (NE, NE)	2.595 (0.536, 12.555)	0.2186	
>60	101	3 (3.0)	98 (97.0)	NE (NE, NE)	105	7 (6.7)	98 (93.3)	NE (NE, NE)	0.436 (0.112, 1.690)	0.2165	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Neck pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9993
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	8 (5.0)	152 (95.0)	NE (NE, NE)	0.532 (0.174, 1.634)	0.2631	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	0.463 (0.042, 5.125)	0.5176	
≥65	69	0	69 (100)	NE (NE, NE)	65	1 (1.5)	64 (98.5)	NE (NE, NE)	0.000 (0.000, NE)	0.3134	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Neck pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3364
Male	124	2 (1.6)	122 (98.4)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.278 (0.056, 1.382)	0.0946	
Female	141	4 (2.8)	137 (97.2)	NE (NE, NE)	148	5 (3.4)	143 (96.6)	NE (NE, NE)	0.785 (0.210, 2.931)	0.7182	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Neck pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1254
White	157	4 (2.5)	153 (97.5)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	1.246 (0.278, 5.581)	0.7734	
Non-white	108	2 (1.9)	106 (98.1)	NE (NE, NE)	107	8 (7.5)	99 (92.5)	NE (NE, NE)	0.231 (0.049, 1.091)	0.0436	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Neck pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2254
North America	16	2 (12.5)	14 (87.5)	NE (2.9, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	2.902 (0.253, 33.295)	0.3720	
Europe	161	2 (1.2)	159 (98.8)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	0.620 (0.103, 3.720)	0.5978	
Asia/Other Regions	88	2 (2.3)	86 (97.7)	NE (NE, NE)	89	7 (7.9)	82 (92.1)	NE (NE, NE)	0.247 (0.051, 1.194)	0.0598	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Neck pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1851
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	0.859 (0.262, 2.816)	0.8016	
≥ 40x10^9/L	133	1 (0.8)	132 (99.2)	NE (NE, NE)	135	5 (3.7)	130 (96.3)	NE (NE, NE)	0.147 (0.017, 1.266)	0.0435	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Neck pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2051
Daunorubicin	123	1 (0.8)	122 (99.2)	NE (NE, NE)	94	4 (4.3)	90 (95.7)	NE (NE, NE)	0.181 (0.020, 1.617)	0.0848	
Idarubicin	142	5 (3.5)	137 (96.5)	NE (NE, NE)	171	7 (4.1)	164 (95.9)	NE (NE, NE)	0.791 (0.251, 2.496)	0.6885	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Neck pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9867
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	5 (2.6)	190 (97.4)	NE (NE, NE)	190	9 (4.7)	181 (95.3)	NE (NE, NE)	0.467 (0.156, 1.396)	0.1630	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	0.000 (0.000, NE)	0.4292	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (29.0, NE)	0.671 (0.041, 11.051)	0.7787	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Neck pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4854
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	1.064 (0.215, 5.273)	0.9380	
1 - Restricted in Physically Strenuous Activity	133	2 (1.5)	131 (98.5)	NE (NE, NE)	134	7 (5.2)	127 (94.8)	NE (NE, NE)	0.269 (0.056, 1.296)	0.0791	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (5.4, NE)	0.485 (0.030, 7.856)	0.6030	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Neck pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7044
≥3 to ≤25%	94	1 (1.1)	93 (98.9)	NE (NE, NE)	98	5 (5.1)	93 (94.9)	NE (NE, NE)	0.203 (0.024, 1.738)	0.1064	
>25% to ≤50%	141	4 (2.8)	137 (97.2)	NE (NE, NE)	136	6 (4.4)	130 (95.6)	NE (NE, NE)	0.606 (0.171, 2.152)	0.4337	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.5465	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Neck pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5959
Yes	139	3 (2.2)	136 (97.8)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	0.670 (0.149, 3.002)	0.5986	
No	116	3 (2.6)	113 (97.4)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	0.389 (0.100, 1.505)	0.1553	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Neck pain

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7608
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	8 (4.9)	155 (95.1)	NE (NE, NE)	0.523 (0.170, 1.604)	0.2490	
>60	101	1 (1.0)	100 (99.0)	NE (NE, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	0.354 (0.037, 3.406)	0.3464	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3867
<60	159	42 (26.4)	117 (73.6)	NE (NE, NE)	160	33 (20.6)	127 (79.4)	NE (NE, NE)	1.232 (0.780, 1.945)	0.3687	
≥60 - <65	37	12 (32.4)	25 (67.6)	NE (3.9, NE)	43	15 (34.9)	28 (65.1)	35.9 (5.0, NE)	0.966 (0.450, 2.074)	0.9307	
≥65	69	17 (24.6)	52 (75.4)	NE (16.5, NE)	65	22 (33.8)	43 (66.2)	NE (4.9, NE)	0.708 (0.375, 1.336)	0.2831	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5549
Male	124	34 (27.4)	90 (72.6)	NE (28.3, NE)	120	35 (29.2)	85 (70.8)	NE (7.7, NE)	0.900 (0.561, 1.444)	0.6633	
Female	141	37 (26.2)	104 (73.8)	NE (31.1, NE)	148	35 (23.6)	113 (76.4)	NE (NE, NE)	1.086 (0.684, 1.725)	0.7254	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5593
White	157	44 (28.0)	113 (72.0)	NE (28.3, NE)	161	41 (25.5)	120 (74.5)	NE (NE, NE)	1.084 (0.708, 1.660)	0.7112	
Non-white	108	27 (25.0)	81 (75.0)	NE (31.1, NE)	107	29 (27.1)	78 (72.9)	NE (17.5, NE)	0.885 (0.524, 1.495)	0.6481	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9571
North America	16	8 (50.0)	8 (50.0)	10.5 (0.8, NE)	18	11 (61.1)	7 (38.9)	1.6 (0.9, NE)	0.889 (0.355, 2.227)	0.8135	
Europe	161	43 (26.7)	118 (73.3)	NE (28.3, NE)	161	41 (25.5)	120 (74.5)	NE (NE, NE)	1.021 (0.665, 1.567)	0.9253	
Asia/Other Regions	88	20 (22.7)	68 (77.3)	NE (31.1, NE)	89	18 (20.2)	71 (79.8)	NE (35.9, NE)	1.090 (0.576, 2.062)	0.7911	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4805
< 40x10^9/L	132	36 (27.3)	96 (72.7)	NE (NE, NE)	133	34 (25.6)	99 (74.4)	NE (35.9, NE)	1.120 (0.701, 1.790)	0.6329	
≥ 40x10^9/L	133	35 (26.3)	98 (73.7)	NE (28.3, NE)	135	36 (26.7)	99 (73.3)	NE (NE, NE)	0.892 (0.559, 1.422)	0.6304	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7575
Daunorubicin	123	35 (28.5)	88 (71.5)	NE (28.3, NE)	94	24 (25.5)	70 (74.5)	NE (8.4, NE)	1.037 (0.615, 1.746)	0.8920	
Idarubicin	142	36 (25.4)	106 (74.6)	NE (31.1, NE)	171	46 (26.9)	125 (73.1)	NE (35.9, NE)	0.927 (0.599, 1.434)	0.7328	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9033
Favorable	13	2 (15.4)	11 (84.6)	28.3 (NE, NE)	19	5 (26.3)	14 (73.7)	NE (9.8, NE)	0.715 (0.137, 3.735)	0.6892	
Intermediate	195	55 (28.2)	140 (71.8)	NE (31.1, NE)	190	49 (25.8)	141 (74.2)	NE (35.9, NE)	1.031 (0.701, 1.515)	0.8777	
Unfavorable	19	4 (21.1)	15 (78.9)	NE (3.2, NE)	27	7 (25.9)	20 (74.1)	NE (NE, NE)	0.690 (0.201, 2.370)	0.5535	
Unknown	38	10 (26.3)	28 (73.7)	NE (16.5, NE)	31	9 (29.0)	22 (71.0)	NE (5.7, NE)	1.024 (0.415, 2.525)	0.9617	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1489
0 - Fully Active	87	21 (24.1)	66 (75.9)	NE (28.3, NE)	97	15 (15.5)	82 (84.5)	NE (NE, NE)	1.514 (0.780, 2.941)	0.2173	
1 - Restricted in Physically Strenuous Activity	133	38 (28.6)	95 (71.4)	NE (15.4, NE)	134	40 (29.9)	94 (70.1)	NE (17.5, NE)	0.910 (0.583, 1.419)	0.6759	
2 - Ambulatory and Capable of All Selfcare	45	12 (26.7)	33 (73.3)	NE (1.8, NE)	36	15 (41.7)	21 (58.3)	NE (1.7, NE)	0.593 (0.277, 1.271)	0.1754	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4065
≥3 to ≤25%	94	29 (30.9)	65 (69.1)	NE (7.0, NE)	98	25 (25.5)	73 (74.5)	NE (NE, NE)	1.318 (0.772, 2.250)	0.3111	
>25% to ≤50%	141	32 (22.7)	109 (77.3)	NE (31.1, NE)	136	35 (25.7)	101 (74.3)	NE (35.9, NE)	0.806 (0.498, 1.303)	0.3775	
>50%	29	10 (34.5)	19 (65.5)	NE (3.4, NE)	34	10 (29.4)	24 (70.6)	8.4 (5.0, NE)	0.987 (0.407, 2.392)	0.9773	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3540
Yes	139	41 (29.5)	98 (70.5)	NE (28.3, NE)	137	36 (26.3)	101 (73.7)	NE (NE, NE)	1.151 (0.735, 1.802)	0.5387	
No	116	30 (25.9)	86 (74.1)	NE (15.4, NE)	120	33 (27.5)	87 (72.5)	NE (17.5, NE)	0.841 (0.513, 1.380)	0.4938	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1981
≤60	164	43 (26.2)	121 (73.8)	NE (NE, NE)	163	33 (20.2)	130 (79.8)	NE (NE, NE)	1.239 (0.786, 1.951)	0.3538	
>60	101	28 (27.7)	73 (72.3)	NE (16.5, NE)	105	37 (35.2)	68 (64.8)	35.9 (5.7, NE)	0.789 (0.483, 1.289)	0.3416	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5244
<60	159	16 (10.1)	143 (89.9)	NE (NE, NE)	160	13 (8.1)	147 (91.9)	NE (NE, NE)	1.140 (0.547, 2.374)	0.7261	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	6 (14.0)	37 (86.0)	NE (27.5, NE)	0.521 (0.130, 2.099)	0.3511	
≥65	69	10 (14.5)	59 (85.5)	NE (NE, NE)	65	14 (21.5)	51 (78.5)	NE (NE, NE)	0.695 (0.309, 1.565)	0.3759	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1336
Male	124	19 (15.3)	105 (84.7)	NE (NE, NE)	120	15 (12.5)	105 (87.5)	NE (NE, NE)	1.185 (0.602, 2.334)	0.6229	
Female	141	10 (7.1)	131 (92.9)	NE (NE, NE)	148	18 (12.2)	130 (87.8)	NE (NE, NE)	0.544 (0.251, 1.181)	0.1178	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3206
White	157	19 (12.1)	138 (87.9)	NE (NE, NE)	161	18 (11.2)	143 (88.8)	NE (NE, NE)	1.051 (0.551, 2.006)	0.8803	
Non-white	108	10 (9.3)	98 (90.7)	NE (NE, NE)	107	15 (14.0)	92 (86.0)	NE (NE, NE)	0.612 (0.275, 1.364)	0.2256	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9348
North America	16	2 (12.5)	14 (87.5)	NE (NE, NE)	18	3 (16.7)	15 (83.3)	NE (27.5, NE)	1.057 (0.168, 6.648)	0.9533	
Europe	161	21 (13.0)	140 (87.0)	NE (NE, NE)	161	22 (13.7)	139 (86.3)	NE (NE, NE)	0.898 (0.493, 1.635)	0.7238	
Asia/Other Regions	88	6 (6.8)	82 (93.2)	NE (NE, NE)	89	8 (9.0)	81 (91.0)	NE (NE, NE)	0.676 (0.234, 1.952)	0.4660	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5575
< 40x10^9/L	132	16 (12.1)	116 (87.9)	NE (NE, NE)	133	17 (12.8)	116 (87.2)	NE (NE, NE)	0.973 (0.492, 1.927)	0.9401	
≥ 40x10^9/L	133	13 (9.8)	120 (90.2)	NE (NE, NE)	135	16 (11.9)	119 (88.1)	NE (NE, NE)	0.698 (0.335, 1.456)	0.3352	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9637
Daunorubicin	123	13 (10.6)	110 (89.4)	NE (NE, NE)	94	11 (11.7)	83 (88.3)	NE (27.5, NE)	0.794 (0.354, 1.780)	0.5740	
Idarubicin	142	16 (11.3)	126 (88.7)	NE (NE, NE)	171	22 (12.9)	149 (87.1)	NE (NE, NE)	0.854 (0.449, 1.627)	0.6327	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9999
Favorable	13	1 (7.7)	12 (92.3)	28.3 (NE, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	1.432 (0.122, 16.793)	0.7738	
Intermediate	195	20 (10.3)	175 (89.7)	NE (NE, NE)	190	21 (11.1)	169 (88.9)	NE (NE, NE)	0.852 (0.461, 1.573)	0.6084	
Unfavorable	19	4 (21.1)	15 (78.9)	NE (3.2, NE)	27	6 (22.2)	21 (77.8)	NE (NE, NE)	0.813 (0.228, 2.900)	0.7495	
Unknown	38	4 (10.5)	34 (89.5)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (NE, NE)	0.833 (0.208, 3.336)	0.7963	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1637
0 - Fully Active	87	10 (11.5)	77 (88.5)	NE (NE, NE)	97	6 (6.2)	91 (93.8)	NE (NE, NE)	1.732 (0.628, 4.775)	0.2828	
1 - Restricted in Physically Strenuous Activity	133	13 (9.8)	120 (90.2)	NE (NE, NE)	134	22 (16.4)	112 (83.6)	NE (NE, NE)	0.555 (0.279, 1.103)	0.0886	
2 - Ambulatory and Capable of All Selfcare	45	6 (13.3)	39 (86.7)	NE (NE, NE)	36	5 (13.9)	31 (86.1)	NE (NE, NE)	1.004 (0.306, 3.291)	0.9918	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6033
≥3 to ≤25%	94	11 (11.7)	83 (88.3)	NE (NE, NE)	98	14 (14.3)	84 (85.7)	NE (NE, NE)	0.854 (0.388, 1.882)	0.6942	
>25% to ≤50%	141	15 (10.6)	126 (89.4)	NE (NE, NE)	136	13 (9.6)	123 (90.4)	NE (NE, NE)	1.038 (0.493, 2.186)	0.9211	
>50%	29	3 (10.3)	26 (89.7)	NE (NE, NE)	34	6 (17.6)	28 (82.4)	NE (6.9, NE)	0.444 (0.110, 1.788)	0.2408	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3548
Yes	139	17 (12.2)	122 (87.8)	NE (NE, NE)	137	16 (11.7)	121 (88.3)	NE (NE, NE)	1.020 (0.515, 2.021)	0.9554	
No	116	12 (10.3)	104 (89.7)	NE (NE, NE)	120	17 (14.2)	103 (85.8)	NE (NE, NE)	0.652 (0.311, 1.366)	0.2541	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3286
≤60	164	16 (9.8)	148 (90.2)	NE (NE, NE)	163	13 (8.0)	150 (92.0)	NE (NE, NE)	1.118 (0.537, 2.328)	0.7646	
>60	101	13 (12.9)	88 (87.1)	NE (NE, NE)	105	20 (19.0)	85 (81.0)	NE (NE, NE)	0.680 (0.338, 1.367)	0.2754	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypotension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5629
<60	159	12 (7.5)	147 (92.5)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	1.932 (0.724, 5.156)	0.1808	
≥60 - <65	37	5 (13.5)	32 (86.5)	NE (NE, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	1.390 (0.372, 5.195)	0.6195	
≥65	69	6 (8.7)	63 (91.3)	NE (26.5, NE)	65	7 (10.8)	58 (89.2)	NE (NE, NE)	0.840 (0.282, 2.500)	0.7528	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypotension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4981
Male	124	9 (7.3)	115 (92.7)	NE (NE, NE)	120	8 (6.7)	112 (93.3)	NE (NE, NE)	1.058 (0.408, 2.747)	0.9060	
Female	141	14 (9.9)	127 (90.1)	NE (NE, NE)	148	9 (6.1)	139 (93.9)	NE (NE, NE)	1.589 (0.687, 3.675)	0.2745	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypotension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6860
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	1.113 (0.402, 3.077)	0.8366	
Non-white	108	15 (13.9)	93 (86.1)	NE (NE, NE)	107	10 (9.3)	97 (90.7)	NE (NE, NE)	1.474 (0.662, 3.282)	0.3390	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypotension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5856
North America	16	4 (25.0)	12 (75.0)	NE (10.5, NE)	18	4 (22.2)	14 (77.8)	NE (1.4, NE)	1.248 (0.312, 4.996)	0.7541	
Europe	161	7 (4.3)	154 (95.7)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	0.948 (0.331, 2.710)	0.9200	
Asia/Other Regions	88	12 (13.6)	76 (86.4)	NE (31.1, NE)	89	6 (6.7)	83 (93.3)	NE (NE, NE)	2.003 (0.751, 5.342)	0.1569	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypotension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2005
< 40x10^9/L	132	12 (9.1)	120 (90.9)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	2.141 (0.803, 5.708)	0.1190	
≥ 40x10^9/L	133	11 (8.3)	122 (91.7)	NE (NE, NE)	135	11 (8.1)	124 (91.9)	NE (NE, NE)	0.906 (0.391, 2.098)	0.8190	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypotension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6388
Daunorubicin	123	9 (7.3)	114 (92.7)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	1.127 (0.400, 3.172)	0.8208	
Idarubicin	142	14 (9.9)	128 (90.1)	NE (NE, NE)	171	11 (6.4)	160 (93.6)	NE (NE, NE)	1.469 (0.666, 3.240)	0.3375	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypotension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6413
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	3 (15.8)	16 (84.2)	NE (NE, NE)	0.503 (0.052, 4.839)	0.5443	
Intermediate	195	17 (8.7)	178 (91.3)	NE (NE, NE)	190	11 (5.8)	179 (94.2)	NE (NE, NE)	1.416 (0.662, 3.026)	0.3672	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.000 (0.000, NE)	0.2519	
Unknown	38	5 (13.2)	33 (86.8)	NE (26.5, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	4.113 (0.477, 35.427)	0.1631	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypotension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.0929
0 - Fully Active	87	8 (9.2)	79 (90.8)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	2.734 (0.724, 10.328)	0.1222	
1 - Restricted in Physically Strenuous Activity	133	12 (9.0)	121 (91.0)	NE (NE, NE)	134	8 (6.0)	126 (94.0)	NE (NE, NE)	1.517 (0.620, 3.713)	0.3583	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	6 (16.7)	30 (83.3)	NE (NE, NE)	0.339 (0.083, 1.390)	0.1165	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypotension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8542
≥3 to ≤25%	94	7 (7.4)	87 (92.6)	NE (NE, NE)	98	6 (6.1)	92 (93.9)	NE (NE, NE)	1.249 (0.420, 3.719)	0.6883	
>25% to ≤50%	141	13 (9.2)	128 (90.8)	NE (NE, NE)	136	8 (5.9)	128 (94.1)	NE (NE, NE)	1.521 (0.629, 3.676)	0.3479	
>50%	29	3 (10.3)	26 (89.7)	NE (19.3, NE)	34	3 (8.8)	31 (91.2)	NE (8.4, NE)	0.699 (0.132, 3.716)	0.6734	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypotension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.8821
Yes	139	13 (9.4)	126 (90.6)	NE (NE, NE)	137	10 (7.3)	127 (92.7)	NE (NE, NE)	1.243 (0.544, 2.839)	0.6047	
No	116	10 (8.6)	106 (91.4)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	1.425 (0.542, 3.746)	0.4707	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypotension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2673
≤60	164	13 (7.9)	151 (92.1)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	2.065 (0.784, 5.442)	0.1338	
>60	101	10 (9.9)	91 (90.1)	NE (31.1, NE)	105	11 (10.5)	94 (89.5)	NE (NE, NE)	0.963 (0.409, 2.269)	0.9325	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Phlebitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4404
<60	159	1 (0.6)	158 (99.4)	NE (NE, NE)	160	7 (4.4)	153 (95.6)	NE (NE, NE)	0.140 (0.017, 1.139)	0.0317	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	1.193 (0.075, 19.079)	0.9004	
≥65	69	1 (1.4)	68 (98.6)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	0.537 (0.049, 5.932)	0.6059	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Phlebitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3648
Male	124	1 (0.8)	123 (99.2)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.146 (0.017, 1.214)	0.0389	
Female	141	2 (1.4)	139 (98.6)	NE (NE, NE)	148	4 (2.7)	144 (97.3)	NE (NE, NE)	0.534 (0.098, 2.913)	0.4608	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Phlebitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3528
White	157	2 (1.3)	155 (98.7)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	0.226 (0.049, 1.045)	0.0372	
Non-white	108	1 (0.9)	107 (99.1)	NE (NE, NE)	107	1 (0.9)	106 (99.1)	NE (NE, NE)	0.919 (0.057, 14.715)	0.9526	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Phlebitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8797
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	2 (1.2)	159 (98.8)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	0.244 (0.052, 1.150)	0.0531	
Asia/Other Regions	88	1 (1.1)	87 (98.9)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	0.464 (0.042, 5.128)	0.5212	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Phlebitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4843
< 40x10^9/L	132	1 (0.8)	131 (99.2)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	0.180 (0.022, 1.494)	0.0734	
≥ 40x10^9/L	133	2 (1.5)	131 (98.5)	NE (NE, NE)	135	4 (3.0)	131 (97.0)	NE (NE, NE)	0.444 (0.081, 2.436)	0.3369	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Phlebitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8738
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	0.305 (0.059, 1.570)	0.1319	
Idarubicin	142	1 (0.7)	141 (99.3)	NE (NE, NE)	171	5 (2.9)	166 (97.1)	NE (NE, NE)	0.227 (0.026, 1.943)	0.1386	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Phlebitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9551
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	2 (1.0)	193 (99.0)	NE (NE, NE)	190	5 (2.6)	185 (97.4)	NE (NE, NE)	0.387 (0.075, 1.993)	0.2387	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	5 (16.1)	26 (83.9)	NE (NE, NE)	0.159 (0.018, 1.369)	0.0555	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Phlebitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7189
0 - Fully Active	87	1 (1.1)	86 (98.9)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	0.253 (0.028, 2.273)	0.1854	
1 - Restricted in Physically Strenuous Activity	133	1 (0.8)	132 (99.2)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	0.200 (0.023, 1.716)	0.1031	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	0.933 (0.058, 14.915)	0.9608	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Phlebitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6872
≥3 to ≤25%	94	2 (2.1)	92 (97.9)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	0.518 (0.095, 2.838)	0.4404	
>25% to ≤50%	141	1 (0.7)	140 (99.3)	NE (NE, NE)	136	6 (4.4)	130 (95.6)	NE (NE, NE)	0.160 (0.019, 1.325)	0.0514	
>50%	29	0	29 (100)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Phlebitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4069
Yes	139	2 (1.4)	137 (98.6)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	0.482 (0.088, 2.640)	0.3900	
No	116	1 (0.9)	115 (99.1)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.161 (0.019, 1.339)	0.0530	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Phlebitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2165
≤60	164	1 (0.6)	163 (99.4)	NE (NE, NE)	163	7 (4.3)	156 (95.7)	NE (NE, NE)	0.138 (0.017, 1.122)	0.0301	
>60	101	2 (2.0)	99 (98.0)	NE (NE, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	0.746 (0.125, 4.466)	0.7472	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6987
<60	159	35 (22.0)	124 (78.0)	NE (NE, NE)	160	36 (22.5)	124 (77.5)	NE (NE, NE)	0.926 (0.581, 1.476)	0.7476	
≥60 - <65	37	8 (21.6)	29 (78.4)	NE (16.3, NE)	43	12 (27.9)	31 (72.1)	37.3 (5.5, NE)	0.616 (0.250, 1.516)	0.2866	
≥65	69	17 (24.6)	52 (75.4)	NE (13.1, NE)	65	23 (35.4)	42 (64.6)	23.5 (4.9, NE)	0.699 (0.373, 1.309)	0.2609	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6527
Male	124	29 (23.4)	95 (76.6)	NE (NE, NE)	120	35 (29.2)	85 (70.8)	NE (10.2, NE)	0.739 (0.451, 1.211)	0.2296	
Female	141	31 (22.0)	110 (78.0)	NE (NE, NE)	148	36 (24.3)	112 (75.7)	NE (25.3, NE)	0.856 (0.529, 1.385)	0.5242	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5995
White	157	32 (20.4)	125 (79.6)	NE (NE, NE)	161	42 (26.1)	119 (73.9)	NE (22.8, NE)	0.745 (0.470, 1.181)	0.2081	
Non-white	108	28 (25.9)	80 (74.1)	NE (18.0, NE)	107	29 (27.1)	78 (72.9)	NE (37.3, NE)	0.900 (0.535, 1.513)	0.6898	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8256
North America	16	9 (56.3)	7 (43.8)	2.3 (0.3, NE)	18	14 (77.8)	4 (22.2)	1.8 (0.3, 5.5)	1.254 (0.486, 3.235)	0.6207	
Europe	161	28 (17.4)	133 (82.6)	NE (NE, NE)	161	34 (21.1)	127 (78.9)	NE (25.3, NE)	0.765 (0.463, 1.263)	0.2927	
Asia/Other Regions	88	23 (26.1)	65 (73.9)	NE (13.1, NE)	89	23 (25.8)	66 (74.2)	NE (37.3, NE)	0.970 (0.544, 1.729)	0.9149	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6405
< 40x10^9/L	132	26 (19.7)	106 (80.3)	NE (NE, NE)	133	31 (23.3)	102 (76.7)	NE (25.3, NE)	0.872 (0.517, 1.468)	0.6038	
≥ 40x10^9/L	133	34 (25.6)	99 (74.4)	NE (NE, NE)	135	40 (29.6)	95 (70.4)	37.3 (10.2, NE)	0.744 (0.469, 1.179)	0.2038	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1421
Daunorubicin	123	19 (15.4)	104 (84.6)	NE (NE, NE)	94	22 (23.4)	72 (76.6)	NE (25.3, NE)	0.579 (0.312, 1.073)	0.0789	
Idarubicin	142	41 (28.9)	101 (71.1)	NE (16.3, NE)	171	49 (28.7)	122 (71.3)	NE (22.8, NE)	0.999 (0.659, 1.512)	0.9939	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4801
Favorable	13	0	13 (100)	NE (NE, NE)	19	6 (31.6)	13 (68.4)	NE (4.9, NE)	0.000 (0.000, NE)	0.0579	
Intermediate	195	49 (25.1)	146 (74.9)	NE (NE, NE)	190	50 (26.3)	140 (73.7)	NE (25.3, NE)	0.885 (0.596, 1.313)	0.5432	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	9 (33.3)	18 (66.7)	6.6 (5.7, NE)	0.298 (0.064, 1.387)	0.1017	
Unknown	38	9 (23.7)	29 (76.3)	NE (13.1, NE)	31	6 (19.4)	25 (80.6)	NE (10.8, NE)	1.244 (0.442, 3.501)	0.6812	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.0481
0 - Fully Active	87	22 (25.3)	65 (74.7)	NE (13.1, NE)	97	20 (20.6)	77 (79.4)	NE (25.3, NE)	1.277 (0.697, 2.341)	0.4281	
1 - Restricted in Physically Strenuous Activity	133	26 (19.5)	107 (80.5)	NE (NE, NE)	134	43 (32.1)	91 (67.9)	37.3 (6.6, NE)	0.510 (0.312, 0.832)	0.0060	
2 - Ambulatory and Capable of All Selfcare	45	12 (26.7)	33 (73.3)	NE (9.1, NE)	36	8 (22.2)	28 (77.8)	NE (NE, NE)	1.229 (0.502, 3.009)	0.6519	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2341
≥3 to ≤25%	94	19 (20.2)	75 (79.8)	NE (NE, NE)	98	27 (27.6)	71 (72.4)	NE (13.1, NE)	0.703 (0.391, 1.266)	0.2366	
>25% to ≤50%	141	32 (22.7)	109 (77.3)	NE (NE, NE)	136	39 (28.7)	97 (71.3)	NE (22.8, NE)	0.728 (0.456, 1.163)	0.1829	
>50%	29	9 (31.0)	20 (69.0)	NE (16.3, NE)	34	5 (14.7)	29 (85.3)	NE (NE, NE)	1.950 (0.651, 5.842)	0.2170	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0730
Yes	139	30 (21.6)	109 (78.4)	NE (NE, NE)	137	43 (31.4)	94 (68.6)	37.3 (22.8, NE)	0.620 (0.389, 0.990)	0.0432	
No	116	29 (25.0)	87 (75.0)	NE (18.0, NE)	120	25 (20.8)	95 (79.2)	NE (25.3, NE)	1.201 (0.703, 2.051)	0.5031	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4920
≤60	164	35 (21.3)	129 (78.7)	NE (NE, NE)	163	36 (22.1)	127 (77.9)	NE (NE, NE)	0.909 (0.571, 1.449)	0.6892	
>60	101	25 (24.8)	76 (75.2)	NE (16.3, NE)	105	35 (33.3)	70 (66.7)	23.5 (6.5, NE)	0.695 (0.416, 1.162)	0.1622	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6266
<60	159	8 (5.0)	151 (95.0)	NE (NE, NE)	160	14 (8.8)	146 (91.3)	NE (NE, NE)	0.563 (0.236, 1.342)	0.1886	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	3 (7.0)	40 (93.0)	NE (NE, NE)	0.000 (0.000, NE)	0.0956	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	1.499 (0.250, 8.977)	0.6552	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3243
Male	124	8 (6.5)	116 (93.5)	NE (NE, NE)	120	10 (8.3)	110 (91.7)	NE (NE, NE)	0.775 (0.306, 1.965)	0.5910	
Female	141	3 (2.1)	138 (97.9)	NE (NE, NE)	148	9 (6.1)	139 (93.9)	NE (NE, NE)	0.345 (0.093, 1.274)	0.0946	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3719
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	11 (6.8)	150 (93.2)	NE (NE, NE)	0.751 (0.302, 1.867)	0.5359	
Non-white	108	3 (2.8)	105 (97.2)	NE (NE, NE)	107	8 (7.5)	99 (92.5)	NE (NE, NE)	0.363 (0.096, 1.370)	0.1191	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9509
North America	16	0	16 (100)	NE (NE, NE)	18	5 (27.8)	13 (72.2)	NE (0.3, NE)	0.000 (0.000, NE)	0.0248	
Europe	161	7 (4.3)	154 (95.7)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	0.867 (0.314, 2.391)	0.7820	
Asia/Other Regions	88	4 (4.5)	84 (95.5)	NE (NE, NE)	89	6 (6.7)	83 (93.3)	NE (NE, NE)	0.676 (0.191, 2.395)	0.5414	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6202
< 40x10^9/L	132	4 (3.0)	128 (97.0)	NE (NE, NE)	133	9 (6.8)	124 (93.2)	NE (NE, NE)	0.459 (0.141, 1.490)	0.1837	
≥ 40x10^9/L	133	7 (5.3)	126 (94.7)	NE (NE, NE)	135	10 (7.4)	125 (92.6)	NE (NE, NE)	0.676 (0.257, 1.777)	0.4244	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6470
Daunorubicin	123	5 (4.1)	118 (95.9)	NE (NE, NE)	94	8 (8.5)	86 (91.5)	NE (NE, NE)	0.463 (0.151, 1.416)	0.1667	
Idarubicin	142	6 (4.2)	136 (95.8)	NE (NE, NE)	171	11 (6.4)	160 (93.6)	NE (NE, NE)	0.655 (0.242, 1.770)	0.4003	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9937
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	0.000 (0.000, NE)	0.4561	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	14 (7.4)	176 (92.6)	NE (NE, NE)	0.602 (0.261, 1.392)	0.2305	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	3 (11.1)	24 (88.9)	NE (NE, NE)	0.518 (0.054, 4.998)	0.5624	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	0.897 (0.056, 14.404)	0.9391	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6833
0 - Fully Active	87	1 (1.1)	86 (98.9)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	0.278 (0.031, 2.488)	0.2207	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	10 (7.5)	124 (92.5)	NE (NE, NE)	0.495 (0.169, 1.447)	0.1896	
2 - Ambulatory and Capable of All Selfcare	45	5 (11.1)	40 (88.9)	NE (NE, NE)	36	5 (13.9)	31 (86.1)	NE (NE, NE)	0.802 (0.232, 2.771)	0.7263	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2151
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	6 (6.1)	92 (93.9)	NE (NE, NE)	0.534 (0.134, 2.135)	0.3670	
>25% to ≤50%	141	4 (2.8)	137 (97.2)	NE (NE, NE)	136	11 (8.1)	125 (91.9)	NE (NE, NE)	0.346 (0.110, 1.088)	0.0572	
>50%	29	4 (13.8)	25 (86.2)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	2.134 (0.390, 11.684)	0.3707	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0718
Yes	139	3 (2.2)	136 (97.8)	NE (NE, NE)	137	11 (8.0)	126 (92.0)	NE (NE, NE)	0.265 (0.074, 0.949)	0.0283	
No	116	8 (6.9)	108 (93.1)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	1.184 (0.429, 3.264)	0.7439	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8660
≤60	164	8 (4.9)	156 (95.1)	NE (NE, NE)	163	14 (8.6)	149 (91.4)	NE (NE, NE)	0.554 (0.232, 1.321)	0.1764	
>60	101	3 (3.0)	98 (97.0)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	0.629 (0.150, 2.631)	0.5216	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Allergic transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6669
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	8 (5.0)	152 (95.0)	NE (NE, NE)	0.619 (0.202, 1.893)	0.3957	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	1.057 (0.066, 16.954)	0.9687	
≥65	69	1 (1.4)	68 (98.6)	NE (NE, NE)	65	4 (6.2)	61 (93.8)	NE (NE, NE)	0.246 (0.028, 2.202)	0.1741	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Allergic transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5563
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	0.396 (0.102, 1.534)	0.1645	
Female	141	4 (2.8)	137 (97.2)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	0.705 (0.199, 2.498)	0.5858	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Allergic transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8903
White	157	3 (1.9)	154 (98.1)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	0.511 (0.128, 2.043)	0.3330	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	7 (6.5)	100 (93.5)	NE (NE, NE)	0.568 (0.166, 1.941)	0.3601	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Allergic transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9083
North America	16	1 (6.3)	15 (93.8)	NE (2.9, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.1069	
Europe	161	3 (1.9)	158 (98.1)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	0.592 (0.141, 2.481)	0.4685	
Asia/Other Regions	88	3 (3.4)	85 (96.6)	NE (NE, NE)	89	8 (9.0)	81 (91.0)	NE (NE, NE)	0.372 (0.099, 1.404)	0.1284	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Allergic transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3068
< 40x10^9/L	132	3 (2.3)	129 (97.7)	NE (NE, NE)	133	3 (2.3)	130 (97.7)	NE (NE, NE)	1.064 (0.215, 5.274)	0.9395	
≥ 40x10^9/L	133	4 (3.0)	129 (97.0)	NE (NE, NE)	135	10 (7.4)	125 (92.6)	NE (NE, NE)	0.380 (0.119, 1.215)	0.0898	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Allergic transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7633
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	0.585 (0.157, 2.179)	0.4182	
Idarubicin	142	3 (2.1)	139 (97.9)	NE (NE, NE)	171	8 (4.7)	163 (95.3)	NE (NE, NE)	0.442 (0.117, 1.667)	0.2150	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Allergic transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9991
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	6 (3.1)	189 (96.9)	NE (NE, NE)	190	11 (5.8)	179 (94.2)	NE (NE, NE)	0.505 (0.187, 1.367)	0.1703	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	0.417 (0.038, 4.607)	0.4617	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Allergic transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7070
0 - Fully Active	87	1 (1.1)	86 (98.9)	NE (NE, NE)	97	5 (5.2)	92 (94.8)	NE (NE, NE)	0.211 (0.025, 1.810)	0.1175	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	8 (6.0)	126 (94.0)	NE (NE, NE)	0.614 (0.201, 1.878)	0.3877	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.3576	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Allergic transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8555
≥3 to ≤25%	94	2 (2.1)	92 (97.9)	NE (NE, NE)	98	5 (5.1)	93 (94.9)	NE (NE, NE)	0.417 (0.081, 2.148)	0.2801	
>25% to ≤50%	141	4 (2.8)	137 (97.2)	NE (NE, NE)	136	7 (5.1)	129 (94.9)	NE (NE, NE)	0.537 (0.157, 1.835)	0.3128	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	1.021 (0.063, 16.430)	0.9884	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Allergic transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1597
Yes	139	2 (1.4)	137 (98.6)	NE (NE, NE)	137	7 (5.1)	130 (94.9)	NE (NE, NE)	0.283 (0.059, 1.360)	0.0923	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	1.253 (0.336, 4.668)	0.7363	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Injury, poisoning and procedural complications; PT: Allergic transfusion reaction

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7242
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	8 (4.9)	155 (95.1)	NE (NE, NE)	0.610 (0.200, 1.867)	0.3817	
>60	101	2 (2.0)	99 (98.0)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	0.423 (0.082, 2.182)	0.2896	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2991
<60	159	36 (22.6)	123 (77.4)	NE (NE, NE)	160	33 (20.6)	127 (79.4)	NE (NE, NE)	1.044 (0.650, 1.677)	0.8608	
≥60 - <65	37	9 (24.3)	28 (75.7)	NE (6.6, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	2.620 (0.805, 8.528)	0.0965	
≥65	69	12 (17.4)	57 (82.6)	NE (NE, NE)	65	13 (20.0)	52 (80.0)	NE (NE, NE)	0.930 (0.424, 2.039)	0.8552	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3188
Male	124	31 (25.0)	93 (75.0)	NE (NE, NE)	120	22 (18.3)	98 (81.7)	NE (NE, NE)	1.425 (0.825, 2.461)	0.2018	
Female	141	26 (18.4)	115 (81.6)	NE (NE, NE)	148	28 (18.9)	120 (81.1)	NE (NE, NE)	0.918 (0.537, 1.567)	0.7522	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8214
White	157	28 (17.8)	129 (82.2)	NE (NE, NE)	161	26 (16.1)	135 (83.9)	NE (NE, NE)	1.112 (0.651, 1.899)	0.7013	
Non-white	108	29 (26.9)	79 (73.1)	NE (25.4, NE)	107	24 (22.4)	83 (77.6)	NE (NE, NE)	1.181 (0.687, 2.030)	0.5454	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8793
North America	16	6 (37.5)	10 (62.5)	NE (0.2, NE)	18	7 (38.9)	11 (61.1)	7.0 (1.4, NE)	1.153 (0.383, 3.474)	0.8078	
Europe	161	25 (15.5)	136 (84.5)	NE (NE, NE)	161	19 (11.8)	142 (88.2)	NE (NE, NE)	1.332 (0.733, 2.420)	0.3480	
Asia/Other Regions	88	26 (29.5)	62 (70.5)	NE (10.5, NE)	89	24 (27.0)	65 (73.0)	NE (9.5, NE)	1.038 (0.595, 1.811)	0.8940	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0684
< 40x10^9/L	132	19 (14.4)	113 (85.6)	NE (NE, NE)	133	26 (19.5)	107 (80.5)	NE (NE, NE)	0.733 (0.405, 1.326)	0.2998	
≥ 40x10^9/L	133	38 (28.6)	95 (71.4)	NE (NE, NE)	135	24 (17.8)	111 (82.2)	NE (NE, NE)	1.579 (0.946, 2.636)	0.0781	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1145
Daunorubicin	123	24 (19.5)	99 (80.5)	NE (NE, NE)	94	22 (23.4)	72 (76.6)	NE (10.0, NE)	0.809 (0.453, 1.447)	0.4722	
Idarubicin	142	33 (23.2)	109 (76.8)	NE (NE, NE)	171	27 (15.8)	144 (84.2)	NE (NE, NE)	1.469 (0.883, 2.444)	0.1364	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.1604
Favorable	13	0	13 (100)	NE (NE, NE)	19	6 (31.6)	13 (68.4)	NE (7.0, NE)	0.000 (0.000, NE)	0.0466	
Intermediate	195	47 (24.1)	148 (75.9)	NE (NE, NE)	190	29 (15.3)	161 (84.7)	NE (NE, NE)	1.598 (1.006, 2.541)	0.0453	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	9 (33.3)	18 (66.7)	8.7 (2.1, NE)	0.131 (0.016, 1.044)	0.0244	
Unknown	38	9 (23.7)	29 (76.3)	NE (6.3, NE)	31	5 (16.1)	26 (83.9)	NE (5.7, NE)	1.405 (0.466, 4.235)	0.5440	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5820
0 - Fully Active	87	15 (17.2)	72 (82.8)	NE (NE, NE)	97	16 (16.5)	81 (83.5)	NE (NE, NE)	1.047 (0.517, 2.118)	0.9005	
1 - Restricted in Physically Strenuous Activity	133	29 (21.8)	104 (78.2)	NE (NE, NE)	134	28 (20.9)	106 (79.1)	NE (NE, NE)	1.007 (0.598, 1.695)	0.9814	
2 - Ambulatory and Capable of All Selfcare	45	13 (28.9)	32 (71.1)	NE (2.5, NE)	36	6 (16.7)	30 (83.3)	NE (8.7, NE)	1.824 (0.690, 4.826)	0.2186	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7889
≥3 to ≤25%	94	17 (18.1)	77 (81.9)	NE (NE, NE)	98	16 (16.3)	82 (83.7)	NE (NE, NE)	1.125 (0.568, 2.227)	0.7358	
>25% to ≤50%	141	33 (23.4)	108 (76.6)	NE (NE, NE)	136	26 (19.1)	110 (80.9)	NE (NE, NE)	1.257 (0.751, 2.104)	0.3859	
>50%	29	7 (24.1)	22 (75.9)	NE (8.9, NE)	34	8 (23.5)	26 (76.5)	9.5 (9.5, NE)	0.782 (0.276, 2.218)	0.6424	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7132
Yes	139	31 (22.3)	108 (77.7)	NE (NE, NE)	137	28 (20.4)	109 (79.6)	NE (NE, NE)	1.104 (0.662, 1.842)	0.7057	
No	116	24 (20.7)	92 (79.3)	NE (NE, NE)	120	19 (15.8)	101 (84.2)	NE (NE, NE)	1.295 (0.709, 2.365)	0.4003	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6534
≤60	164	37 (22.6)	127 (77.4)	NE (NE, NE)	163	33 (20.2)	130 (79.8)	NE (NE, NE)	1.059 (0.661, 1.696)	0.8119	
>60	101	20 (19.8)	81 (80.2)	NE (NE, NE)	105	17 (16.2)	88 (83.8)	NE (NE, NE)	1.287 (0.674, 2.458)	0.4443	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Insomnia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4771
<60	159	24 (15.1)	135 (84.9)	NE (NE, NE)	160	20 (12.5)	140 (87.5)	NE (NE, NE)	1.142 (0.630, 2.071)	0.6625	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	4.316 (0.479, 38.858)	0.1553	
≥65	69	9 (13.0)	60 (87.0)	NE (NE, NE)	65	9 (13.8)	56 (86.2)	NE (NE, NE)	1.021 (0.405, 2.574)	0.9657	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Insomnia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3198
Male	124	21 (16.9)	103 (83.1)	NE (NE, NE)	120	13 (10.8)	107 (89.2)	NE (NE, NE)	1.579 (0.790, 3.157)	0.1930	
Female	141	16 (11.3)	125 (88.7)	NE (NE, NE)	148	17 (11.5)	131 (88.5)	NE (NE, NE)	0.941 (0.475, 1.865)	0.8615	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Insomnia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4307
White	157	15 (9.6)	142 (90.4)	NE (NE, NE)	161	15 (9.3)	146 (90.7)	NE (NE, NE)	0.999 (0.487, 2.048)	0.9934	
Non-white	108	22 (20.4)	86 (79.6)	NE (NE, NE)	107	15 (14.0)	92 (86.0)	NE (NE, NE)	1.456 (0.755, 2.807)	0.2593	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Insomnia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6919
North America	16	5 (31.3)	11 (68.8)	NE (0.6, NE)	18	4 (22.2)	14 (77.8)	NE (7.0, NE)	1.505 (0.403, 5.619)	0.5453	
Europe	161	11 (6.8)	150 (93.2)	NE (NE, NE)	161	11 (6.8)	150 (93.2)	NE (NE, NE)	0.993 (0.430, 2.293)	0.9819	
Asia/Other Regions	88	21 (23.9)	67 (76.1)	NE (25.4, NE)	89	15 (16.9)	74 (83.1)	NE (NE, NE)	1.379 (0.710, 2.680)	0.3403	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Insomnia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0558
< 40x10^9/L	132	14 (10.6)	118 (89.4)	NE (NE, NE)	133	19 (14.3)	114 (85.7)	NE (NE, NE)	0.750 (0.376, 1.497)	0.4109	
≥ 40x10^9/L	133	23 (17.3)	110 (82.7)	NE (NE, NE)	135	11 (8.1)	124 (91.9)	NE (NE, NE)	2.026 (0.985, 4.165)	0.0501	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Insomnia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1454
Daunorubicin	123	14 (11.4)	109 (88.6)	NE (NE, NE)	94	13 (13.8)	81 (86.2)	NE (NE, NE)	0.786 (0.368, 1.678)	0.5287	
Idarubicin	142	23 (16.2)	119 (83.8)	NE (NE, NE)	171	17 (9.9)	154 (90.1)	NE (NE, NE)	1.614 (0.862, 3.022)	0.1312	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Insomnia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.2615
Favorable	13	0	13 (100)	NE (NE, NE)	19	4 (21.1)	15 (78.9)	NE (7.0, NE)	0.000 (0.000, NE)	0.1116	
Intermediate	195	29 (14.9)	166 (85.1)	NE (NE, NE)	190	15 (7.9)	175 (92.1)	NE (NE, NE)	1.883 (1.009, 3.514)	0.0433	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	6 (22.2)	21 (77.8)	NE (5.8, NE)	0.221 (0.026, 1.845)	0.1264	
Unknown	38	7 (18.4)	31 (81.6)	NE (25.4, NE)	31	5 (16.1)	26 (83.9)	NE (5.7, NE)	1.008 (0.315, 3.221)	0.9899	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Insomnia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1065
0 - Fully Active	87	10 (11.5)	77 (88.5)	NE (NE, NE)	97	9 (9.3)	88 (90.7)	NE (NE, NE)	1.197 (0.486, 2.949)	0.6958	
1 - Restricted in Physically Strenuous Activity	133	17 (12.8)	116 (87.2)	NE (NE, NE)	134	20 (14.9)	114 (85.1)	NE (NE, NE)	0.825 (0.431, 1.577)	0.5551	
2 - Ambulatory and Capable of All Selfcare	45	10 (22.2)	35 (77.8)	NE (3.3, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	9.559 (1.222, 74.793)	0.0085	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Insomnia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7635
≥3 to ≤25%	94	9 (9.6)	85 (90.4)	NE (NE, NE)	98	10 (10.2)	88 (89.8)	NE (NE, NE)	0.951 (0.386, 2.342)	0.9126	
>25% to ≤50%	141	25 (17.7)	116 (82.3)	NE (NE, NE)	136	17 (12.5)	119 (87.5)	NE (NE, NE)	1.398 (0.754, 2.594)	0.2863	
>50%	29	3 (10.3)	26 (89.7)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	1.118 (0.225, 5.554)	0.8914	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Insomnia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.8191
Yes	139	19 (13.7)	120 (86.3)	NE (NE, NE)	137	16 (11.7)	121 (88.3)	NE (NE, NE)	1.186 (0.609, 2.308)	0.6162	
No	116	16 (13.8)	100 (86.2)	NE (NE, NE)	120	12 (10.0)	108 (90.0)	NE (NE, NE)	1.337 (0.632, 2.829)	0.4470	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Insomnia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8643
≤60	164	25 (15.2)	139 (84.8)	NE (NE, NE)	163	20 (12.3)	143 (87.7)	NE (NE, NE)	1.178 (0.653, 2.124)	0.5879	
>60	101	12 (11.9)	89 (88.1)	NE (NE, NE)	105	10 (9.5)	95 (90.5)	NE (NE, NE)	1.289 (0.557, 2.984)	0.5529	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Anxiety

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9990
<60	159	12 (7.5)	147 (92.5)	NE (NE, NE)	160	7 (4.4)	153 (95.6)	NE (NE, NE)	1.661 (0.654, 4.222)	0.2814	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.611 (0.268, 9.693)	0.5993	
≥65	69	0	69 (100)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	0.000 (0.000, NE)	0.0883	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Anxiety

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2076
Male	124	9 (7.3)	115 (92.7)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	2.157 (0.664, 7.004)	0.1900	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	8 (5.4)	140 (94.6)	NE (NE, NE)	0.769 (0.267, 2.220)	0.6267	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Anxiety

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4116
White	157	13 (8.3)	144 (91.7)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	1.481 (0.633, 3.468)	0.3630	
Non-white	108	2 (1.9)	106 (98.1)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	0.627 (0.105, 3.753)	0.6056	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Anxiety

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6870
North America	16	4 (25.0)	12 (75.0)	NE (2.6, NE)	18	3 (16.7)	15 (83.3)	NE (10.0, NE)	2.583 (0.540, 12.353)	0.2198	
Europe	161	8 (5.0)	153 (95.0)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	1.121 (0.406, 3.092)	0.8260	
Asia/Other Regions	88	3 (3.4)	85 (96.6)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	1.363 (0.227, 8.183)	0.7337	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Anxiety

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1359
< 40x10^9/L	132	2 (1.5)	130 (98.5)	NE (NE, NE)	133	5 (3.8)	128 (96.2)	NE (NE, NE)	0.432 (0.084, 2.227)	0.3015	
≥ 40x10^9/L	133	13 (9.8)	120 (90.2)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	1.791 (0.714, 4.495)	0.2081	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Anxiety

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2168
Daunorubicin	123	5 (4.1)	118 (95.9)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	0.738 (0.213, 2.556)	0.6307	
Idarubicin	142	10 (7.0)	132 (93.0)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	2.002 (0.727, 5.510)	0.1706	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Anxiety

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9670
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	0.000 (0.000, NE)	0.4081	
Intermediate	195	12 (6.2)	183 (93.8)	NE (NE, NE)	190	8 (4.2)	182 (95.8)	NE (NE, NE)	1.394 (0.569, 3.414)	0.4660	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.854 (0.077, 9.431)	0.8974	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	1.784 (0.162, 19.687)	0.6319	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Anxiety

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7161
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	6 (6.2)	91 (93.8)	NE (NE, NE)	0.914 (0.279, 2.995)	0.8813	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	1.372 (0.435, 4.326)	0.5878	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	2.250 (0.232, 21.847)	0.4709	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Anxiety

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5891
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	1.794 (0.429, 7.508)	0.4171	
>25% to ≤50%	141	6 (4.3)	135 (95.7)	NE (NE, NE)	136	7 (5.1)	129 (94.9)	NE (NE, NE)	0.846 (0.284, 2.516)	0.7616	
>50%	29	4 (13.8)	25 (86.2)	NE (8.9, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	1.875 (0.333, 10.570)	0.4687	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Anxiety

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5809
Yes	139	9 (6.5)	130 (93.5)	NE (NE, NE)	137	6 (4.4)	131 (95.6)	NE (NE, NE)	1.487 (0.529, 4.182)	0.4493	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.989 (0.319, 3.069)	0.9852	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Psychiatric disorders; PT: Anxiety

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2908
≤60	164	12 (7.3)	152 (92.7)	NE (NE, NE)	163	7 (4.3)	156 (95.7)	NE (NE, NE)	1.630 (0.641, 4.144)	0.3001	
>60	101	3 (3.0)	98 (97.0)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	0.636 (0.152, 2.663)	0.5318	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2370
<60	159	32 (20.1)	127 (79.9)	NE (34.9, NE)	160	19 (11.9)	141 (88.1)	NE (NE, NE)	1.518 (0.859, 2.681)	0.1470	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	7 (16.3)	36 (83.7)	NE (9.7, NE)	0.580 (0.169, 1.992)	0.3803	
≥65	69	13 (18.8)	56 (81.2)	NE (23.7, NE)	65	15 (23.1)	50 (76.9)	NE (26.0, NE)	0.830 (0.394, 1.746)	0.6243	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1075
Male	124	19 (15.3)	105 (84.7)	NE (34.9, NE)	120	21 (17.5)	99 (82.5)	NE (NE, NE)	0.772 (0.414, 1.439)	0.4164	
Female	141	30 (21.3)	111 (78.7)	NE (24.2, NE)	148	20 (13.5)	128 (86.5)	NE (NE, NE)	1.523 (0.865, 2.683)	0.1421	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.0936
White	157	22 (14.0)	135 (86.0)	NE (NE, NE)	161	24 (14.9)	137 (85.1)	NE (NE, NE)	0.805 (0.450, 1.440)	0.4648	
Non-white	108	27 (25.0)	81 (75.0)	NE (21.7, NE)	107	17 (15.9)	90 (84.1)	NE (NE, NE)	1.646 (0.897, 3.021)	0.1033	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6760
North America	16	5 (31.3)	11 (68.8)	34.9 (1.9, NE)	18	7 (38.9)	11 (61.1)	20.0 (1.8, NE)	0.844 (0.267, 2.668)	0.7719	
Europe	161	22 (13.7)	139 (86.3)	NE (NE, NE)	161	18 (11.2)	143 (88.8)	NE (NE, NE)	1.091 (0.584, 2.037)	0.7829	
Asia/Other Regions	88	22 (25.0)	66 (75.0)	NE (15.7, NE)	89	16 (18.0)	73 (82.0)	NE (NE, NE)	1.357 (0.712, 2.587)	0.3514	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2618
< 40x10^9/L	132	20 (15.2)	112 (84.8)	NE (NE, NE)	133	23 (17.3)	110 (82.7)	NE (NE, NE)	0.864 (0.474, 1.573)	0.6339	
≥ 40x10^9/L	133	29 (21.8)	104 (78.2)	NE (34.9, NE)	135	18 (13.3)	117 (86.7)	NE (NE, NE)	1.435 (0.795, 2.588)	0.2266	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1447
Daunorubicin	123	18 (14.6)	105 (85.4)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	2.114 (0.838, 5.332)	0.1048	
Idarubicin	142	31 (21.8)	111 (78.2)	NE (23.7, NE)	171	35 (20.5)	136 (79.5)	NE (NE, NE)	0.983 (0.606, 1.595)	0.9471	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.5472
Favorable	13	2 (15.4)	11 (84.6)	NE (4.0, NE)	19	3 (15.8)	16 (84.2)	NE (NE, NE)	1.149 (0.190, 6.936)	0.8797	
Intermediate	195	38 (19.5)	157 (80.5)	NE (34.9, NE)	190	33 (17.4)	157 (82.6)	NE (NE, NE)	0.998 (0.626, 1.593)	0.9962	
Unfavorable	19	3 (15.8)	16 (84.2)	NE (11.1, NE)	27	4 (14.8)	23 (85.2)	NE (NE, NE)	1.094 (0.244, 4.915)	0.9062	
Unknown	38	6 (15.8)	32 (84.2)	NE (21.7, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	5.348 (0.643, 44.516)	0.0815	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1091
0 - Fully Active	87	17 (19.5)	70 (80.5)	NE (23.7, NE)	97	11 (11.3)	86 (88.7)	NE (NE, NE)	1.664 (0.779, 3.553)	0.1836	
1 - Restricted in Physically Strenuous Activity	133	21 (15.8)	112 (84.2)	NE (NE, NE)	134	26 (19.4)	108 (80.6)	NE (NE, NE)	0.718 (0.404, 1.277)	0.2589	
2 - Ambulatory and Capable of All Selfcare	45	11 (24.4)	34 (75.6)	NE (12.7, NE)	36	4 (11.1)	32 (88.9)	NE (9.7, NE)	2.020 (0.635, 6.423)	0.2255	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6876
≥3 to ≤25%	94	16 (17.0)	78 (83.0)	NE (NE, NE)	98	16 (16.3)	82 (83.7)	NE (NE, NE)	1.058 (0.529, 2.117)	0.8723	
>25% to ≤50%	141	30 (21.3)	111 (78.7)	NE (23.7, NE)	136	21 (15.4)	115 (84.6)	NE (NE, NE)	1.253 (0.716, 2.190)	0.4262	
>50%	29	3 (10.3)	26 (89.7)	NE (NE, NE)	34	4 (11.8)	30 (88.2)	NE (NE, NE)	0.696 (0.151, 3.197)	0.6392	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7335
Yes	139	29 (20.9)	110 (79.1)	NE (NE, NE)	137	25 (18.2)	112 (81.8)	NE (NE, NE)	1.058 (0.619, 1.809)	0.8318	
No	116	18 (15.5)	98 (84.5)	NE (23.7, NE)	120	14 (11.7)	106 (88.3)	NE (NE, NE)	1.188 (0.590, 2.390)	0.6281	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0842
≤60	164	33 (20.1)	131 (79.9)	NE (34.9, NE)	163	19 (11.7)	144 (88.3)	NE (NE, NE)	1.534 (0.871, 2.700)	0.1348	
>60	101	16 (15.8)	85 (84.2)	NE (23.7, NE)	105	22 (21.0)	83 (79.0)	NE (26.0, NE)	0.748 (0.393, 1.425)	0.3766	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Acute kidney injury

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5943
<60	159	9 (5.7)	150 (94.3)	NE (NE, NE)	160	4 (2.5)	156 (97.5)	NE (NE, NE)	2.045 (0.628, 6.659)	0.2252	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (21.9, NE)	0.504 (0.045, 5.627)	0.5704	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	1.354 (0.303, 6.051)	0.6901	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Acute kidney injury

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9952
Male	124	5 (4.0)	119 (96.0)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	1.659 (0.396, 6.942)	0.4836	
Female	141	9 (6.4)	132 (93.6)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	1.486 (0.528, 4.183)	0.4499	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Acute kidney injury

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1953
White	157	4 (2.5)	153 (97.5)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	0.793 (0.212, 2.963)	0.7301	
Non-white	108	10 (9.3)	98 (90.7)	NE (NE, NE)	107	4 (3.7)	103 (96.3)	NE (NE, NE)	2.439 (0.764, 7.780)	0.1192	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Acute kidney injury

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9412
North America	16	2 (12.5)	14 (87.5)	NE (NE, NE)	18	2 (11.1)	16 (88.9)	NE (21.9, NE)	1.524 (0.211, 11.021)	0.6740	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	1.484 (0.418, 5.266)	0.5376	
Asia/Other Regions	88	6 (6.8)	82 (93.2)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	1.817 (0.453, 7.287)	0.3927	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Acute kidney injury

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3289
< 40x10^9/L	132	6 (4.5)	126 (95.5)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	1.010 (0.326, 3.135)	0.9858	
≥ 40x10^9/L	133	8 (6.0)	125 (94.0)	NE (NE, NE)	135	3 (2.2)	132 (97.8)	NE (NE, NE)	2.624 (0.696, 9.899)	0.1389	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Acute kidney injury

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9306
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	3 (3.2)	91 (96.8)	NE (NE, NE)	1.419 (0.354, 5.689)	0.6199	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	1.573 (0.545, 4.541)	0.3984	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Acute kidney injury

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9472
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	12 (6.2)	183 (93.8)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	1.547 (0.608, 3.937)	0.3554	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.827 (0.075, 9.140)	0.8770	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.3534	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Acute kidney injury

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7274
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	1.077 (0.217, 5.340)	0.9272	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	1.307 (0.414, 4.126)	0.6475	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	3.374 (0.377, 30.199)	0.2478	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Acute kidney injury

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4680
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	1.319 (0.354, 4.917)	0.6791	
>25% to ≤50%	141	8 (5.7)	133 (94.3)	NE (NE, NE)	136	3 (2.2)	133 (97.8)	NE (NE, NE)	2.460 (0.651, 9.292)	0.1699	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.494 (0.045, 5.481)	0.5580	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Acute kidney injury

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2005
Yes	139	10 (7.2)	129 (92.8)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	2.427 (0.760, 7.751)	0.1217	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	0.768 (0.206, 2.863)	0.6934	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Acute kidney injury

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4479
≤60	164	9 (5.5)	155 (94.5)	NE (NE, NE)	163	4 (2.5)	159 (97.5)	NE (NE, NE)	2.007 (0.616, 6.537)	0.2380	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	5 (4.8)	100 (95.2)	NE (NE, NE)	1.100 (0.318, 3.800)	0.8803	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8113
<60	159	27 (17.0)	132 (83.0)	NE (NE, NE)	160	27 (16.9)	133 (83.1)	NE (NE, NE)	0.886 (0.519, 1.513)	0.6582	
≥60 - <65	37	6 (16.2)	31 (83.8)	NE (9.2, NE)	43	6 (14.0)	37 (86.0)	NE (9.9, NE)	0.844 (0.268, 2.658)	0.7724	
≥65	69	13 (18.8)	56 (81.2)	NE (28.9, NE)	65	18 (27.7)	47 (72.3)	NE (5.9, NE)	0.679 (0.332, 1.391)	0.2860	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5969
Male	124	18 (14.5)	106 (85.5)	NE (NE, NE)	120	21 (17.5)	99 (82.5)	NE (21.7, NE)	0.723 (0.384, 1.360)	0.3119	
Female	141	28 (19.9)	113 (80.1)	NE (28.9, NE)	148	30 (20.3)	118 (79.7)	NE (19.0, NE)	0.898 (0.536, 1.505)	0.6816	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5536
White	157	24 (15.3)	133 (84.7)	NE (NE, NE)	161	29 (18.0)	132 (82.0)	NE (NE, NE)	0.757 (0.440, 1.304)	0.3140	
Non-white	108	22 (20.4)	86 (79.6)	NE (19.2, NE)	107	22 (20.6)	85 (79.4)	NE (21.7, NE)	0.925 (0.512, 1.672)	0.7976	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2244
North America	16	2 (12.5)	14 (87.5)	NE (7.8, NE)	18	7 (38.9)	11 (61.1)	5.6 (2.1, NE)	0.231 (0.046, 1.155)	0.0545	
Europe	161	25 (15.5)	136 (84.5)	NE (NE, NE)	161	28 (17.4)	133 (82.6)	NE (NE, NE)	0.779 (0.453, 1.339)	0.3654	
Asia/Other Regions	88	19 (21.6)	69 (78.4)	NE (NE, NE)	89	16 (18.0)	73 (82.0)	NE (21.7, NE)	1.176 (0.604, 2.288)	0.6332	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.8211
< 40x10^9/L	132	25 (18.9)	107 (81.1)	NE (28.9, NE)	133	31 (23.3)	102 (76.7)	NE (13.8, NE)	0.796 (0.470, 1.350)	0.3965	
≥ 40x10^9/L	133	21 (15.8)	112 (84.2)	NE (NE, NE)	135	20 (14.8)	115 (85.2)	NE (21.7, NE)	0.879 (0.475, 1.628)	0.6807	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4526
Daunorubicin	123	16 (13.0)	107 (87.0)	NE (NE, NE)	94	15 (16.0)	79 (84.0)	NE (13.0, NE)	0.661 (0.325, 1.344)	0.2490	
Idarubicin	142	30 (21.1)	112 (78.9)	NE (28.9, NE)	171	36 (21.1)	135 (78.9)	NE (33.1, NE)	0.942 (0.580, 1.530)	0.8079	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8981
Favorable	13	2 (15.4)	11 (84.6)	NE (1.8, NE)	19	4 (21.1)	15 (78.9)	NE (4.6, NE)	1.061 (0.190, 5.923)	0.9461	
Intermediate	195	36 (18.5)	159 (81.5)	NE (NE, NE)	190	35 (18.4)	155 (81.6)	NE (21.7, NE)	0.862 (0.540, 1.375)	0.5319	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (4.7, NE)	27	5 (18.5)	22 (81.5)	NE (5.4, NE)	0.544 (0.105, 2.816)	0.4639	
Unknown	38	6 (15.8)	32 (84.2)	NE (26.1, NE)	31	6 (19.4)	25 (80.6)	NE (6.0, NE)	0.793 (0.253, 2.486)	0.6901	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5884
0 - Fully Active	87	16 (18.4)	71 (81.6)	NE (28.9, NE)	97	17 (17.5)	80 (82.5)	NE (NE, NE)	0.994 (0.502, 1.969)	0.9866	
1 - Restricted in Physically Strenuous Activity	133	26 (19.5)	107 (80.5)	NE (NE, NE)	134	29 (21.6)	105 (78.4)	NE (21.7, NE)	0.820 (0.482, 1.394)	0.4623	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	5 (13.9)	31 (86.1)	NE (19.0, NE)	0.419 (0.107, 1.644)	0.2003	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2287
≥3 to ≤25%	94	17 (18.1)	77 (81.9)	NE (NE, NE)	98	26 (26.5)	72 (73.5)	NE (13.8, NE)	0.628 (0.341, 1.158)	0.1332	
>25% to ≤50%	141	28 (19.9)	113 (80.1)	NE (28.9, NE)	136	22 (16.2)	114 (83.8)	NE (NE, NE)	1.145 (0.654, 2.006)	0.6346	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (13.0, NE)	0.214 (0.021, 2.182)	0.1577	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5788
Yes	139	26 (18.7)	113 (81.3)	NE (NE, NE)	137	29 (21.2)	108 (78.8)	NE (19.0, NE)	0.785 (0.461, 1.335)	0.3689	
No	116	20 (17.2)	96 (82.8)	NE (28.0, NE)	120	19 (15.8)	101 (84.2)	NE (21.7, NE)	1.006 (0.536, 1.886)	0.9855	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7768
≤60	164	27 (16.5)	137 (83.5)	NE (NE, NE)	163	27 (16.6)	136 (83.4)	NE (NE, NE)	0.869 (0.509, 1.485)	0.6086	
>60	101	19 (18.8)	82 (81.2)	NE (28.9, NE)	105	24 (22.9)	81 (77.1)	NE (13.0, NE)	0.770 (0.421, 1.409)	0.3952	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Dry eye

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9739
<60	159	12 (7.5)	147 (92.5)	NE (NE, NE)	160	7 (4.4)	153 (95.6)	NE (NE, NE)	1.512 (0.594, 3.849)	0.3829	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (12.8, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.539 (0.280, 8.465)	0.6176	
≥65	69	6 (8.7)	63 (91.3)	NE (28.9, NE)	65	4 (6.2)	61 (93.8)	NE (NE, NE)	1.587 (0.448, 5.625)	0.4709	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Dry eye

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4773
Male	124	8 (6.5)	116 (93.5)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	2.416 (0.640, 9.116)	0.1789	
Female	141	14 (9.9)	127 (90.1)	NE (NE, NE)	148	10 (6.8)	138 (93.2)	NE (NE, NE)	1.321 (0.586, 2.978)	0.5008	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Dry eye

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8038
White	157	11 (7.0)	146 (93.0)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	1.438 (0.556, 3.720)	0.4513	
Non-white	108	11 (10.2)	97 (89.8)	NE (NE, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	1.697 (0.627, 4.591)	0.2923	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Dry eye

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.1421
North America	16	2 (12.5)	14 (87.5)	NE (7.8, NE)	18	3 (16.7)	15 (83.3)	NE (NE, NE)	0.754 (0.123, 4.621)	0.7596	
Europe	161	9 (5.6)	152 (94.4)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	1.006 (0.387, 2.612)	0.9905	
Asia/Other Regions	88	11 (12.5)	77 (87.5)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	5.245 (1.162, 23.676)	0.0160	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Dry eye

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6399
< 40x10^9/L	132	14 (10.6)	118 (89.4)	NE (NE, NE)	133	10 (7.5)	123 (92.5)	NE (NE, NE)	1.476 (0.655, 3.326)	0.3443	
≥ 40x10^9/L	133	8 (6.0)	125 (94.0)	NE (NE, NE)	135	3 (2.2)	132 (97.8)	NE (NE, NE)	2.179 (0.576, 8.244)	0.2398	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Dry eye

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.0155
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	7 (7.4)	87 (92.6)	NE (NE, NE)	0.518 (0.173, 1.548)	0.2305	
Idarubicin	142	16 (11.3)	126 (88.7)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	3.141 (1.228, 8.031)	0.0117	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Dry eye

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8741
Favorable	13	1 (7.7)	12 (92.3)	NE (1.8, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	2.245 (0.138, 36.501)	0.5596	
Intermediate	195	17 (8.7)	178 (91.3)	NE (NE, NE)	190	9 (4.7)	181 (95.3)	NE (NE, NE)	1.596 (0.710, 3.585)	0.2536	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (4.7, NE)	27	2 (7.4)	25 (92.6)	NE (7.1, NE)	0.608 (0.055, 6.704)	0.6811	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	2.748 (0.286, 26.457)	0.3614	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Dry eye

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8481
0 - Fully Active	87	10 (11.5)	77 (88.5)	NE (NE, NE)	97	7 (7.2)	90 (92.8)	NE (NE, NE)	1.469 (0.559, 3.861)	0.4328	
1 - Restricted in Physically Strenuous Activity	133	12 (9.0)	121 (91.0)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	2.278 (0.802, 6.473)	0.1121	
2 - Ambulatory and Capable of All Selfcare	45	0	45 (100)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (9.6, NE)	0.000 (0.000, NE)	0.1573	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Dry eye

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4378
≥3 to ≤25%	94	10 (10.6)	84 (89.4)	NE (NE, NE)	98	8 (8.2)	90 (91.8)	NE (NE, NE)	1.308 (0.516, 3.315)	0.5707	
>25% to ≤50%	141	12 (8.5)	129 (91.5)	NE (NE, NE)	136	3 (2.2)	133 (97.8)	NE (NE, NE)	3.593 (1.013, 12.746)	0.0343	
>50%	29	0	29 (100)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (13.0, NE)	0.000 (0.000, NE)	0.0391	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Dry eye

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6174
Yes	139	10 (7.2)	129 (92.8)	NE (NE, NE)	137	7 (5.1)	130 (94.9)	NE (NE, NE)	1.344 (0.511, 3.535)	0.5481	
No	116	12 (10.3)	104 (89.7)	NE (28.9, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	1.865 (0.699, 4.974)	0.2060	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Eye disorders; PT: Dry eye

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7881
≤60	164	12 (7.3)	152 (92.7)	NE (NE, NE)	163	7 (4.3)	156 (95.7)	NE (NE, NE)	1.485 (0.583, 3.781)	0.4042	
>60	101	10 (9.9)	91 (90.1)	NE (28.9, NE)	105	6 (5.7)	99 (94.3)	NE (NE, NE)	1.756 (0.638, 4.836)	0.2695	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1802
<60	159	20 (12.6)	139 (87.4)	NE (NE, NE)	160	23 (14.4)	137 (85.6)	NE (NE, NE)	0.803 (0.440, 1.465)	0.4746	
≥60 - <65	37	8 (21.6)	29 (78.4)	NE (26.7, NE)	43	5 (11.6)	38 (88.4)	NE (14.9, NE)	1.729 (0.563, 5.315)	0.3347	
≥65	69	10 (14.5)	59 (85.5)	NE (NE, NE)	65	19 (29.2)	46 (70.8)	NE (9.7, NE)	0.492 (0.229, 1.058)	0.0639	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4096
Male	124	16 (12.9)	108 (87.1)	NE (NE, NE)	120	23 (19.2)	97 (80.8)	NE (28.6, NE)	0.621 (0.328, 1.177)	0.1403	
Female	141	22 (15.6)	119 (84.4)	NE (NE, NE)	148	24 (16.2)	124 (83.8)	NE (NE, NE)	0.920 (0.515, 1.641)	0.7772	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9879
White	157	22 (14.0)	135 (86.0)	NE (NE, NE)	161	28 (17.4)	133 (82.6)	NE (NE, NE)	0.754 (0.431, 1.320)	0.3205	
Non-white	108	16 (14.8)	92 (85.2)	NE (NE, NE)	107	19 (17.8)	88 (82.2)	NE (NE, NE)	0.782 (0.402, 1.521)	0.4679	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3815
North America	16	6 (37.5)	10 (62.5)	NE (1.2, NE)	18	8 (44.4)	10 (55.6)	7.0 (0.7, NE)	0.874 (0.302, 2.526)	0.8074	
Europe	161	25 (15.5)	136 (84.5)	NE (NE, NE)	161	25 (15.5)	136 (84.5)	NE (NE, NE)	0.930 (0.533, 1.621)	0.7960	
Asia/Other Regions	88	7 (8.0)	81 (92.0)	NE (NE, NE)	89	14 (15.7)	75 (84.3)	NE (NE, NE)	0.461 (0.186, 1.144)	0.0868	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6924
< 40x10^9/L	132	16 (12.1)	116 (87.9)	NE (NE, NE)	133	23 (17.3)	110 (82.7)	NE (NE, NE)	0.690 (0.364, 1.306)	0.2516	
≥ 40x10^9/L	133	22 (16.5)	111 (83.5)	NE (NE, NE)	135	24 (17.8)	111 (82.2)	NE (NE, NE)	0.823 (0.460, 1.472)	0.5117	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2668
Daunorubicin	123	21 (17.1)	102 (82.9)	NE (NE, NE)	94	15 (16.0)	79 (84.0)	NE (28.6, NE)	1.022 (0.526, 1.984)	0.9492	
Idarubicin	142	17 (12.0)	125 (88.0)	NE (NE, NE)	171	31 (18.1)	140 (81.9)	NE (NE, NE)	0.606 (0.335, 1.096)	0.0938	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6726
Favorable	13	2 (15.4)	11 (84.6)	NE (1.8, NE)	19	5 (26.3)	14 (73.7)	NE (7.0, NE)	0.686 (0.132, 3.561)	0.6521	
Intermediate	195	29 (14.9)	166 (85.1)	NE (NE, NE)	190	30 (15.8)	160 (84.2)	NE (NE, NE)	0.876 (0.525, 1.460)	0.6122	
Unfavorable	19	4 (21.1)	15 (78.9)	NE (1.8, NE)	27	6 (22.2)	21 (77.8)	NE (3.3, NE)	1.106 (0.311, 3.932)	0.8759	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	6 (19.4)	25 (80.6)	NE (NE, NE)	0.411 (0.103, 1.644)	0.1954	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9292
0 - Fully Active	87	9 (10.3)	78 (89.7)	NE (NE, NE)	97	14 (14.4)	83 (85.6)	NE (NE, NE)	0.682 (0.295, 1.577)	0.3673	
1 - Restricted in Physically Strenuous Activity	133	21 (15.8)	112 (84.2)	NE (NE, NE)	134	26 (19.4)	108 (80.6)	NE (NE, NE)	0.762 (0.429, 1.355)	0.3535	
2 - Ambulatory and Capable of All Selfcare	45	8 (17.8)	37 (82.2)	NE (25.1, NE)	36	7 (19.4)	29 (80.6)	NE (9.7, NE)	0.847 (0.303, 2.363)	0.7504	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8519
≥3 to ≤25%	94	11 (11.7)	83 (88.3)	NE (NE, NE)	98	17 (17.3)	81 (82.7)	NE (NE, NE)	0.656 (0.307, 1.402)	0.2736	
>25% to ≤50%	141	23 (16.3)	118 (83.7)	NE (NE, NE)	136	26 (19.1)	110 (80.9)	NE (NE, NE)	0.807 (0.460, 1.416)	0.4538	
>50%	29	4 (13.8)	25 (86.2)	NE (NE, NE)	34	4 (11.8)	30 (88.2)	NE (5.3, NE)	1.031 (0.257, 4.135)	0.9656	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7017
Yes	139	20 (14.4)	119 (85.6)	NE (NE, NE)	137	23 (16.8)	114 (83.2)	NE (NE, NE)	0.811 (0.445, 1.479)	0.4939	
No	116	17 (14.7)	99 (85.3)	NE (NE, NE)	120	23 (19.2)	97 (80.8)	NE (NE, NE)	0.696 (0.372, 1.305)	0.2560	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6342
≤60	164	22 (13.4)	142 (86.6)	NE (NE, NE)	163	23 (14.1)	140 (85.9)	NE (NE, NE)	0.863 (0.480, 1.552)	0.6239	
>60	101	16 (15.8)	85 (84.2)	NE (NE, NE)	105	24 (22.9)	81 (77.1)	NE (14.9, NE)	0.683 (0.363, 1.286)	0.2341	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Sinus tachycardia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5632
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	0.810 (0.247, 2.657)	0.7269	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	1.793 (0.161, 19.971)	0.6302	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	2.020 (0.370, 11.030)	0.4089	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Sinus tachycardia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.0365
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	6.285 (0.771, 51.206)	0.0492	
Female	141	4 (2.8)	137 (97.2)	NE (NE, NE)	148	8 (5.4)	140 (94.6)	NE (NE, NE)	0.508 (0.153, 1.690)	0.2605	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Sinus tachycardia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7814
White	157	9 (5.7)	148 (94.3)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	1.242 (0.461, 3.343)	0.6678	
Non-white	108	2 (1.9)	106 (98.1)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	0.985 (0.139, 6.992)	0.9878	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Sinus tachycardia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.1832
North America	16	2 (12.5)	14 (87.5)	NE (NE, NE)	18	5 (27.8)	13 (72.2)	10.1 (7.0, NE)	0.523 (0.101, 2.716)	0.4327	
Europe	161	9 (5.6)	152 (94.4)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	4.385 (0.946, 20.322)	0.0390	
Asia/Other Regions	88	0	88 (100)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	0.000 (0.000, NE)	0.1364	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Sinus tachycardia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7591
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	5 (3.8)	128 (96.2)	NE (NE, NE)	1.010 (0.292, 3.493)	0.9875	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	4 (3.0)	131 (97.0)	NE (NE, NE)	1.437 (0.404, 5.108)	0.5740	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Sinus tachycardia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3360
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	2.214 (0.446, 11.003)	0.3189	
Idarubicin	142	5 (3.5)	137 (96.5)	NE (NE, NE)	171	7 (4.1)	164 (95.9)	NE (NE, NE)	0.805 (0.255, 2.541)	0.7104	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Sinus tachycardia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8384
Favorable	13	2 (15.4)	11 (84.6)	NE (1.8, NE)	19	3 (15.8)	16 (84.2)	NE (10.1, NE)	1.186 (0.197, 7.143)	0.8524	
Intermediate	195	7 (3.6)	188 (96.4)	NE (NE, NE)	190	3 (1.6)	187 (98.4)	NE (NE, NE)	2.116 (0.546, 8.200)	0.2670	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.696 (0.063, 7.691)	0.7665	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	0.937 (0.059, 15.008)	0.9636	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Sinus tachycardia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9799
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	1.660 (0.277, 9.934)	0.5743	
1 - Restricted in Physically Strenuous Activity	133	8 (6.0)	125 (94.0)	NE (NE, NE)	134	6 (4.5)	128 (95.5)	NE (NE, NE)	1.255 (0.435, 3.626)	0.6746	
2 - Ambulatory and Capable of All Selfcare	45	0	45 (100)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	0.000 (0.000, NE)	0.3066	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Sinus tachycardia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8326
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	1.424 (0.318, 6.369)	0.6418	
>25% to ≤50%	141	5 (3.5)	136 (96.5)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	0.890 (0.257, 3.088)	0.8550	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	2.149 (0.194, 23.780)	0.5226	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Sinus tachycardia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6551
Yes	139	5 (3.6)	134 (96.4)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	0.947 (0.273, 3.278)	0.9309	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	1.446 (0.408, 5.131)	0.5656	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Sinus tachycardia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2636
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	0.796 (0.243, 2.612)	0.7057	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	2.043 (0.510, 8.182)	0.3031	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Atrial fibrillation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0998
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	1 (0.6)	159 (99.4)	NE (NE, NE)	4.924 (0.575, 42.158)	0.1065	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.186 (0.167, 8.420)	0.8644	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	7 (10.8)	58 (89.2)	NE (NE, NE)	0.275 (0.057, 1.324)	0.0846	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Atrial fibrillation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.0956
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	0.412 (0.107, 1.595)	0.1847	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	3 (2.0)	145 (98.0)	NE (NE, NE)	2.064 (0.516, 8.255)	0.2952	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Atrial fibrillation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7242
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	1.015 (0.327, 3.151)	0.9793	
Non-white	108	3 (2.8)	105 (97.2)	NE (NE, NE)	107	4 (3.7)	103 (96.3)	NE (NE, NE)	0.733 (0.164, 3.277)	0.6836	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Atrial fibrillation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9999
North America	16	1 (6.3)	15 (93.8)	NE (2.2, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.1824	
Europe	161	8 (5.0)	153 (95.0)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	0.977 (0.367, 2.606)	0.9635	
Asia/Other Regions	88	0	88 (100)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	0.000 (0.000, NE)	0.1645	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Atrial fibrillation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2762
< 40x10^9/L	132	3 (2.3)	129 (97.7)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	0.513 (0.128, 2.052)	0.3366	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	4 (3.0)	131 (97.0)	NE (NE, NE)	1.482 (0.418, 5.256)	0.5396	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Atrial fibrillation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9639
Daunorubicin	123	5 (4.1)	118 (95.9)	NE (NE, NE)	94	4 (4.3)	90 (95.7)	NE (NE, NE)	0.931 (0.250, 3.469)	0.9157	
Idarubicin	142	4 (2.8)	138 (97.2)	NE (NE, NE)	171	5 (2.9)	166 (97.1)	NE (NE, NE)	0.960 (0.257, 3.576)	0.9509	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Atrial fibrillation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9733
Favorable	13	2 (15.4)	11 (84.6)	NE (1.9, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.0624	
Intermediate	195	5 (2.6)	190 (97.4)	NE (NE, NE)	190	6 (3.2)	184 (96.8)	NE (NE, NE)	0.779 (0.237, 2.556)	0.6791	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.757 (0.069, 8.347)	0.8192	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	0.406 (0.037, 4.474)	0.4461	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Atrial fibrillation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3342
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	2.222 (0.407, 12.132)	0.3438	
1 - Restricted in Physically Strenuous Activity	133	4 (3.0)	129 (97.0)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	0.774 (0.208, 2.884)	0.7014	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	3 (8.3)	33 (91.7)	NE (NE, NE)	0.275 (0.029, 2.642)	0.2310	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Atrial fibrillation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6406
≥3 to ≤25%	94	2 (2.1)	92 (97.9)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	0.528 (0.097, 2.885)	0.4538	
>25% to ≤50%	141	5 (3.5)	136 (96.5)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	0.946 (0.273, 3.274)	0.9306	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	1.859 (0.168, 20.588)	0.6077	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Atrial fibrillation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7902
Yes	139	5 (3.6)	134 (96.4)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	1.000 (0.289, 3.456)	0.9997	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	0.798 (0.214, 2.974)	0.7362	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Atrial fibrillation

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0271
≤60	164	6 (3.7)	158 (96.3)	NE (NE, NE)	163	1 (0.6)	162 (99.4)	NE (NE, NE)	5.839 (0.703, 48.494)	0.0637	
>60	101	3 (3.0)	98 (97.0)	NE (NE, NE)	105	9 (8.6)	96 (91.4)	NE (NE, NE)	0.346 (0.094, 1.279)	0.0956	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7853
<60	159	25 (15.7)	134 (84.3)	NE (NE, NE)	160	13 (8.1)	147 (91.9)	NE (NE, NE)	1.483 (0.758, 2.905)	0.2465	
≥60 - <65	37	5 (13.5)	32 (86.5)	NE (15.8, NE)	43	4 (9.3)	39 (90.7)	NE (11.9, NE)	1.146 (0.306, 4.284)	0.8395	
≥65	69	7 (10.1)	62 (89.9)	NE (27.4, NE)	65	7 (10.8)	58 (89.2)	NE (34.9, NE)	0.995 (0.349, 2.840)	0.9929	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6822
Male	124	17 (13.7)	107 (86.3)	NE (NE, NE)	120	9 (7.5)	111 (92.5)	NE (34.9, NE)	1.514 (0.674, 3.403)	0.3116	
Female	141	20 (14.2)	121 (85.8)	NE (27.4, NE)	148	15 (10.1)	133 (89.9)	NE (NE, NE)	1.184 (0.606, 2.315)	0.6205	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4638
White	157	22 (14.0)	135 (86.0)	NE (NE, NE)	161	16 (9.9)	145 (90.1)	NE (NE, NE)	1.141 (0.598, 2.178)	0.6881	
Non-white	108	15 (13.9)	93 (86.1)	NE (23.9, NE)	107	8 (7.5)	99 (92.5)	NE (NE, NE)	1.654 (0.701, 3.903)	0.2461	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2557
North America	16	4 (25.0)	12 (75.0)	8.7 (3.0, NE)	18	3 (16.7)	15 (83.3)	NE (11.9, NE)	11.326 (1.212, 105.805)	0.0089	
Europe	161	21 (13.0)	140 (87.0)	NE (NE, NE)	161	12 (7.5)	149 (92.5)	NE (NE, NE)	1.411 (0.692, 2.874)	0.3408	
Asia/Other Regions	88	12 (13.6)	76 (86.4)	NE (18.1, NE)	89	9 (10.1)	80 (89.9)	NE (NE, NE)	1.036 (0.435, 2.464)	0.9369	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.8176
< 40x10^9/L	132	18 (13.6)	114 (86.4)	NE (NE, NE)	133	13 (9.8)	120 (90.2)	NE (NE, NE)	1.383 (0.677, 2.826)	0.3709	
≥ 40x10^9/L	133	19 (14.3)	114 (85.7)	NE (NE, NE)	135	11 (8.1)	124 (91.9)	NE (34.9, NE)	1.245 (0.591, 2.626)	0.5634	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6792
Daunorubicin	123	19 (15.4)	104 (84.6)	NE (20.2, NE)	94	8 (8.5)	86 (91.5)	NE (NE, NE)	1.364 (0.595, 3.123)	0.4614	
Idarubicin	142	18 (12.7)	124 (87.3)	NE (NE, NE)	171	16 (9.4)	155 (90.6)	NE (NE, NE)	1.148 (0.585, 2.254)	0.6872	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7575
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (34.9, NE)	NE (NE, NE)	NE	
Intermediate	195	27 (13.8)	168 (86.2)	NE (NE, NE)	190	19 (10.0)	171 (90.0)	NE (NE, NE)	1.070 (0.594, 1.927)	0.8209	
Unfavorable	19	3 (15.8)	16 (84.2)	NE (4.1, NE)	27	2 (7.4)	25 (92.6)	NE (8.0, NE)	1.905 (0.316, 11.479)	0.4742	
Unknown	38	7 (18.4)	31 (81.6)	NE (18.1, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	2.341 (0.484, 11.317)	0.2760	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2179
0 - Fully Active	87	12 (13.8)	75 (86.2)	NE (27.4, NE)	97	5 (5.2)	92 (94.8)	NE (NE, NE)	2.367 (0.833, 6.724)	0.0953	
1 - Restricted in Physically Strenuous Activity	133	22 (16.5)	111 (83.5)	NE (20.2, NE)	134	16 (11.9)	118 (88.1)	NE (34.9, NE)	1.160 (0.609, 2.211)	0.6508	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	3 (8.3)	33 (91.7)	NE (5.6, NE)	0.583 (0.110, 3.084)	0.5211	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7975
≥3 to ≤25%	94	11 (11.7)	83 (88.3)	NE (NE, NE)	98	10 (10.2)	88 (89.8)	NE (NE, NE)	1.038 (0.440, 2.448)	0.9313	
>25% to ≤50%	141	22 (15.6)	119 (84.4)	NE (23.9, NE)	136	12 (8.8)	124 (91.2)	NE (NE, NE)	1.520 (0.752, 3.076)	0.2404	
>50%	29	4 (13.8)	25 (86.2)	NE (10.9, NE)	34	2 (5.9)	32 (94.1)	NE (6.8, NE)	0.902 (0.155, 5.248)	0.9090	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3413
Yes	139	21 (15.1)	118 (84.9)	NE (NE, NE)	137	11 (8.0)	126 (92.0)	NE (NE, NE)	1.601 (0.771, 3.326)	0.2030	
No	116	15 (12.9)	101 (87.1)	NE (12.2, NE)	120	13 (10.8)	107 (89.2)	NE (NE, NE)	0.958 (0.455, 2.017)	0.9123	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5676
≤60	164	25 (15.2)	139 (84.8)	NE (NE, NE)	163	13 (8.0)	150 (92.0)	NE (NE, NE)	1.454 (0.743, 2.848)	0.2713	
>60	101	12 (11.9)	89 (88.1)	NE (27.4, NE)	105	11 (10.5)	94 (89.5)	NE (34.9, NE)	1.093 (0.481, 2.480)	0.8314	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Graft versus host disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5154
<60	159	8 (5.0)	151 (95.0)	NE (NE, NE)	160	3 (1.9)	157 (98.1)	NE (NE, NE)	1.908 (0.506, 7.193)	0.3310	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (11.9, NE)	0.389 (0.035, 4.300)	0.4245	
≥65	69	1 (1.4)	68 (98.6)	NE (NE, NE)	65	0	65 (100)	NE (NE, NE)	NE (0.000, NE)	0.3049	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Graft versus host disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8200
Male	124	5 (4.0)	119 (96.0)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.829 (0.355, 9.429)	0.4635	
Female	141	5 (3.5)	136 (96.5)	NE (NE, NE)	148	3 (2.0)	145 (98.0)	NE (NE, NE)	1.390 (0.332, 5.818)	0.6505	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Graft versus host disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4864
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	2.349 (0.474, 11.641)	0.2810	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	1.084 (0.242, 4.843)	0.9159	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Graft versus host disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6521
North America	16	2 (12.5)	14 (87.5)	NE (8.7, NE)	18	1 (5.6)	17 (94.4)	NE (11.9, NE)	4.918 (0.436, 55.432)	0.1551	
Europe	161	3 (1.9)	158 (98.1)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	1.140 (0.190, 6.825)	0.8857	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	1.832 (0.355, 9.446)	0.4621	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Graft versus host disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6808
< 40x10^9/L	132	6 (4.5)	126 (95.5)	NE (NE, NE)	133	3 (2.3)	130 (97.7)	NE (NE, NE)	1.958 (0.489, 7.834)	0.3328	
≥ 40x10^9/L	133	4 (3.0)	129 (97.0)	NE (NE, NE)	135	2 (1.5)	133 (98.5)	NE (NE, NE)	1.241 (0.227, 6.777)	0.8025	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Graft versus host disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3552
Daunorubicin	123	3 (2.4)	120 (97.6)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	0.788 (0.132, 4.719)	0.7940	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	3 (1.8)	168 (98.2)	NE (NE, NE)	2.298 (0.594, 8.887)	0.2141	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Graft versus host disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	6 (3.1)	189 (96.9)	NE (NE, NE)	190	5 (2.6)	185 (97.4)	NE (NE, NE)	0.855 (0.261, 2.803)	0.7961	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (8.1, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.2888	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.1732	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Graft versus host disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4777
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	1 (1.0)	96 (99.0)	NE (NE, NE)	4.683 (0.547, 40.091)	0.1203	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	4 (3.0)	130 (97.0)	NE (NE, NE)	1.005 (0.270, 3.743)	0.9938	
2 - Ambulatory and Capable of All Selfcare	45	0	45 (100)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Graft versus host disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5318
≥3 to ≤25%	94	2 (2.1)	92 (97.9)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	0.662 (0.110, 3.963)	0.6488	
>25% to ≤50%	141	7 (5.0)	134 (95.0)	NE (NE, NE)	136	2 (1.5)	134 (98.5)	NE (NE, NE)	2.572 (0.534, 12.384)	0.2216	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.5465	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Graft versus host disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2388
Yes	139	5 (3.6)	134 (96.4)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	0.942 (0.253, 3.510)	0.9290	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	4.119 (0.480, 35.317)	0.1612	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Graft versus host disease

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5760
≤60	164	8 (4.9)	156 (95.1)	NE (NE, NE)	163	3 (1.8)	160 (98.2)	NE (NE, NE)	1.879 (0.498, 7.083)	0.3431	
>60	101	2 (2.0)	99 (98.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	0.949 (0.134, 6.738)	0.9581	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Reproductive system and breast disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6848
<60	159	24 (15.1)	135 (84.9)	NE (NE, NE)	160	16 (10.0)	144 (90.0)	NE (NE, NE)	1.392 (0.738, 2.626)	0.3054	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (33.3, NE)	43	3 (7.0)	40 (93.0)	NE (22.3, NE)	1.153 (0.232, 5.718)	0.8618	
≥65	69	9 (13.0)	60 (87.0)	NE (15.7, NE)	65	4 (6.2)	61 (93.8)	NE (NE, NE)	2.320 (0.714, 7.542)	0.1495	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Reproductive system and breast disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4710
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	2.546 (0.512, 12.656)	0.2364	
Female	141	30 (21.3)	111 (78.7)	NE (33.3, NE)	148	21 (14.2)	127 (85.8)	NE (NE, NE)	1.490 (0.852, 2.605)	0.1583	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Reproductive system and breast disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9754
White	157	17 (10.8)	140 (89.2)	NE (NE, NE)	161	11 (6.8)	150 (93.2)	NE (NE, NE)	1.565 (0.732, 3.346)	0.2433	
Non-white	108	19 (17.6)	89 (82.4)	NE (NE, NE)	107	12 (11.2)	95 (88.8)	NE (NE, NE)	1.538 (0.746, 3.169)	0.2388	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Reproductive system and breast disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.1901
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	5 (27.8)	13 (72.2)	NE (22.3, NE)	0.255 (0.030, 2.195)	0.1798	
Europe	161	17 (10.6)	144 (89.4)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	1.819 (0.809, 4.088)	0.1418	
Asia/Other Regions	88	18 (20.5)	70 (79.5)	NE (15.9, NE)	89	9 (10.1)	80 (89.9)	NE (NE, NE)	2.000 (0.898, 4.455)	0.0837	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Reproductive system and breast disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4698
< 40x10^9/L	132	15 (11.4)	117 (88.6)	NE (NE, NE)	133	12 (9.0)	121 (91.0)	NE (NE, NE)	1.220 (0.570, 2.610)	0.6076	
≥ 40x10^9/L	133	21 (15.8)	112 (84.2)	NE (NE, NE)	135	11 (8.1)	124 (91.9)	NE (NE, NE)	1.842 (0.887, 3.827)	0.0961	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Reproductive system and breast disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8859
Daunorubicin	123	16 (13.0)	107 (87.0)	NE (33.3, NE)	94	8 (8.5)	86 (91.5)	NE (NE, NE)	1.395 (0.595, 3.269)	0.4419	
Idarubicin	142	20 (14.1)	122 (85.9)	NE (NE, NE)	171	15 (8.8)	156 (91.2)	NE (NE, NE)	1.572 (0.804, 3.072)	0.1815	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Reproductive system and breast disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8834
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	1.596 (0.100, 25.516)	0.7388	
Intermediate	195	29 (14.9)	166 (85.1)	NE (NE, NE)	190	17 (8.9)	173 (91.1)	NE (NE, NE)	1.575 (0.865, 2.868)	0.1340	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.771 (0.070, 8.513)	0.8317	
Unknown	38	5 (13.2)	33 (86.8)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	1.279 (0.304, 5.385)	0.7359	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Reproductive system and breast disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1551
0 - Fully Active	87	11 (12.6)	76 (87.4)	NE (NE, NE)	97	9 (9.3)	88 (90.7)	NE (NE, NE)	1.259 (0.521, 3.041)	0.6085	
1 - Restricted in Physically Strenuous Activity	133	21 (15.8)	112 (84.2)	NE (33.3, NE)	134	9 (6.7)	125 (93.3)	NE (NE, NE)	2.405 (1.101, 5.252)	0.0228	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (21.8, NE)	36	5 (13.9)	31 (86.1)	NE (4.4, NE)	0.528 (0.134, 2.078)	0.3536	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Reproductive system and breast disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5081
≥3 to ≤25%	94	10 (10.6)	84 (89.4)	NE (NE, NE)	98	10 (10.2)	88 (89.8)	NE (NE, NE)	1.024 (0.426, 2.462)	0.9572	
>25% to ≤50%	141	21 (14.9)	120 (85.1)	NE (NE, NE)	136	11 (8.1)	125 (91.9)	NE (NE, NE)	1.790 (0.862, 3.716)	0.1126	
>50%	29	5 (17.2)	24 (82.8)	NE (7.5, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	2.354 (0.446, 12.439)	0.3000	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Reproductive system and breast disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6553
Yes	139	24 (17.3)	115 (82.7)	NE (NE, NE)	137	17 (12.4)	120 (87.6)	NE (NE, NE)	1.332 (0.715, 2.482)	0.3641	
No	116	9 (7.8)	107 (92.2)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	1.812 (0.607, 5.412)	0.2797	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Reproductive system and breast disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5501
≤60	164	24 (14.6)	140 (85.4)	NE (NE, NE)	163	16 (9.8)	147 (90.2)	NE (NE, NE)	1.368 (0.725, 2.582)	0.3314	
>60	101	12 (11.9)	89 (88.1)	NE (33.3, NE)	105	7 (6.7)	98 (93.3)	NE (NE, NE)	1.944 (0.765, 4.942)	0.1547	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8220
<60	159	22 (13.8)	137 (86.2)	NE (NE, NE)	160	18 (11.3)	142 (88.8)	NE (NE, NE)	1.133 (0.607, 2.115)	0.6943	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (19.9, NE)	43	3 (7.0)	40 (93.0)	NE (6.8, NE)	0.941 (0.188, 4.710)	0.9408	
≥65	69	6 (8.7)	63 (91.3)	NE (NE, NE)	65	8 (12.3)	57 (87.7)	NE (NE, NE)	0.756 (0.262, 2.180)	0.6054	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4188
Male	124	13 (10.5)	111 (89.5)	NE (NE, NE)	120	14 (11.7)	106 (88.3)	NE (NE, NE)	0.825 (0.387, 1.761)	0.6194	
Female	141	18 (12.8)	123 (87.2)	NE (NE, NE)	148	15 (10.1)	133 (89.9)	NE (NE, NE)	1.232 (0.620, 2.445)	0.5510	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5221
White	157	15 (9.6)	142 (90.4)	NE (NE, NE)	161	12 (7.5)	149 (92.5)	NE (NE, NE)	1.252 (0.585, 2.678)	0.5627	
Non-white	108	16 (14.8)	92 (85.2)	NE (NE, NE)	107	17 (15.9)	90 (84.1)	NE (NE, NE)	0.860 (0.434, 1.704)	0.6640	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9356
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	2 (11.1)	16 (88.9)	NE (NE, NE)	0.565 (0.051, 6.226)	0.6319	
Europe	161	18 (11.2)	143 (88.8)	NE (NE, NE)	161	16 (9.9)	145 (90.1)	NE (NE, NE)	1.072 (0.546, 2.105)	0.8414	
Asia/Other Regions	88	12 (13.6)	76 (86.4)	NE (NE, NE)	89	11 (12.4)	78 (87.6)	NE (NE, NE)	0.987 (0.434, 2.242)	0.9745	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2140
< 40x10^9/L	132	12 (9.1)	120 (90.9)	NE (NE, NE)	133	8 (6.0)	125 (94.0)	NE (NE, NE)	1.556 (0.636, 3.809)	0.3292	
≥ 40x10^9/L	133	19 (14.3)	114 (85.7)	NE (NE, NE)	135	21 (15.6)	114 (84.4)	NE (NE, NE)	0.791 (0.424, 1.476)	0.4603	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6366
Daunorubicin	123	15 (12.2)	108 (87.8)	NE (NE, NE)	94	9 (9.6)	85 (90.4)	NE (NE, NE)	1.202 (0.525, 2.753)	0.6627	
Idarubicin	142	16 (11.3)	126 (88.7)	NE (NE, NE)	171	20 (11.7)	151 (88.3)	NE (NE, NE)	0.908 (0.470, 1.754)	0.7742	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9434
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	1.481 (0.093, 23.673)	0.7800	
Intermediate	195	23 (11.8)	172 (88.2)	NE (NE, NE)	190	22 (11.6)	168 (88.4)	NE (NE, NE)	0.930 (0.517, 1.671)	0.8078	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	3 (11.1)	24 (88.9)	NE (8.7, NE)	0.982 (0.164, 5.888)	0.9845	
Unknown	38	5 (13.2)	33 (86.8)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	1.343 (0.320, 5.638)	0.6857	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8472
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	1.380 (0.370, 5.142)	0.6295	
1 - Restricted in Physically Strenuous Activity	133	19 (14.3)	114 (85.7)	NE (NE, NE)	134	20 (14.9)	114 (85.1)	NE (NE, NE)	0.879 (0.469, 1.650)	0.6875	
2 - Ambulatory and Capable of All Selfcare	45	7 (15.6)	38 (84.4)	NE (NE, NE)	36	5 (13.9)	31 (86.1)	NE (8.3, NE)	1.117 (0.353, 3.535)	0.8504	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5421
≥3 to ≤25%	94	9 (9.6)	85 (90.4)	NE (NE, NE)	98	13 (13.3)	85 (86.7)	NE (NE, NE)	0.728 (0.311, 1.704)	0.4629	
>25% to ≤50%	141	20 (14.2)	121 (85.8)	NE (NE, NE)	136	15 (11.0)	121 (89.0)	NE (NE, NE)	1.183 (0.604, 2.317)	0.6237	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	2.337 (0.212, 25.772)	0.4752	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6287
Yes	139	15 (10.8)	124 (89.2)	NE (NE, NE)	137	16 (11.7)	121 (88.3)	NE (NE, NE)	0.876 (0.432, 1.775)	0.7119	
No	116	13 (11.2)	103 (88.8)	NE (NE, NE)	120	11 (9.2)	109 (90.8)	NE (NE, NE)	1.172 (0.525, 2.617)	0.6981	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6549
≤60	164	22 (13.4)	142 (86.6)	NE (NE, NE)	163	18 (11.0)	145 (89.0)	NE (NE, NE)	1.116 (0.598, 2.083)	0.7308	
>60	101	9 (8.9)	92 (91.1)	NE (NE, NE)	105	11 (10.5)	94 (89.5)	NE (NE, NE)	0.877 (0.363, 2.118)	0.7718	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Ear and labyrinth disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3621
<60	159	6 (3.8)	153 (96.2)	NE (NE, NE)	160	3 (1.9)	157 (98.1)	NE (NE, NE)	1.977 (0.494, 7.908)	0.3259	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	4.375 (0.487, 39.286)	0.1500	
≥65	69	6 (8.7)	63 (91.3)	NE (22.2, NE)	65	7 (10.8)	58 (89.2)	NE (27.5, NE)	0.893 (0.299, 2.670)	0.8392	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Ear and labyrinth disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5274
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	0.900 (0.181, 4.472)	0.8979	
Female	141	13 (9.2)	128 (90.8)	NE (NE, NE)	148	8 (5.4)	140 (94.6)	NE (NE, NE)	1.688 (0.699, 4.075)	0.2390	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Ear and labyrinth disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6949
White	157	12 (7.6)	145 (92.4)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	1.298 (0.546, 3.086)	0.5540	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	1.891 (0.346, 10.336)	0.4545	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Ear and labyrinth disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7264
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	2 (11.1)	16 (88.9)	NE (27.5, NE)	0.841 (0.074, 9.502)	0.8882	
Europe	161	12 (7.5)	149 (92.5)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	1.427 (0.583, 3.496)	0.4345	
Asia/Other Regions	88	3 (3.4)	85 (96.6)	NE (NE, NE)	89	1 (1.1)	88 (98.9)	NE (NE, NE)	2.957 (0.308, 28.430)	0.3244	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Ear and labyrinth disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.7051
< 40x10^9/L	132	7 (5.3)	125 (94.7)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	1.230 (0.413, 3.660)	0.7096	
≥ 40x10^9/L	133	9 (6.8)	124 (93.2)	NE (NE, NE)	135	5 (3.7)	130 (96.3)	NE (NE, NE)	1.527 (0.509, 4.582)	0.4464	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Ear and labyrinth disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5218
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	1 (1.1)	93 (98.9)	NE (NE, NE)	3.132 (0.350, 28.021)	0.2813	
Idarubicin	142	12 (8.5)	130 (91.5)	NE (NE, NE)	171	10 (5.8)	161 (94.2)	NE (NE, NE)	1.355 (0.585, 3.141)	0.4780	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Ear and labyrinth disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8792
Favorable	13	1 (7.7)	12 (92.3)	NE (2.0, NE)	19	2 (10.5)	17 (89.5)	NE (27.5, NE)	1.182 (0.106, 13.194)	0.8919	
Intermediate	195	11 (5.6)	184 (94.4)	NE (NE, NE)	190	5 (2.6)	185 (97.4)	NE (NE, NE)	1.988 (0.690, 5.727)	0.1942	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	3 (11.1)	24 (88.9)	NE (NE, NE)	1.039 (0.174, 6.221)	0.9663	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	1.567 (0.142, 17.345)	0.7118	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Ear and labyrinth disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6770
0 - Fully Active	87	8 (9.2)	79 (90.8)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	2.935 (0.778, 11.071)	0.0952	
1 - Restricted in Physically Strenuous Activity	133	8 (6.0)	125 (94.0)	NE (NE, NE)	134	6 (4.5)	128 (95.5)	NE (NE, NE)	1.313 (0.455, 3.789)	0.6127	
2 - Ambulatory and Capable of All Selfcare	45	0	45 (100)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.000 (0.000, NE)	0.1248	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Ear and labyrinth disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8225
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	2 (2.0)	96 (98.0)	NE (NE, NE)	2.132 (0.390, 11.649)	0.3711	
>25% to ≤50%	141	11 (7.8)	130 (92.2)	NE (NE, NE)	136	8 (5.9)	128 (94.1)	NE (NE, NE)	1.258 (0.505, 3.135)	0.6208	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	1.193 (0.075, 19.078)	0.9005	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Ear and labyrinth disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9023
Yes	139	10 (7.2)	129 (92.8)	NE (NE, NE)	137	6 (4.4)	131 (95.6)	NE (NE, NE)	1.573 (0.571, 4.336)	0.3770	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	1.485 (0.419, 5.267)	0.5375	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.11.2 Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Ear and labyrinth disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5223
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	3 (1.8)	160 (98.2)	NE (NE, NE)	2.269 (0.587, 8.777)	0.2221	
>60	101	9 (8.9)	92 (91.1)	NE (NE, NE)	105	8 (7.6)	97 (92.4)	NE (NE, NE)	1.239 (0.477, 3.218)	0.6591	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:02; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_11_2_TEAESOCPT_SUB_SAS.rtf

Anhang 4-H9b: SUE nach SOC und PT

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

		Quizartinib (N=265)				Placebo (N=268)			Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6243
<60	159	46 (28.9)	113 (71.1)	NE (30.2, NE)	160	37 (23.1)	123 (76.9)	NE (NE, NE)	1.117 (0.724, 1.725)	0.6148	
≥60 - <65	37	9 (24.3)	28 (75.7)	NE (NE, NE)	43	9 (20.9)	34 (79.1)	NE (4.9, NE)	1.006 (0.396, 2.553)	0.9898	
≥65	69	21 (30.4)	48 (69.6)	26.5 (15.7, NE)	65	25 (38.5)	40 (61.5)	10.2 (4.5, NE)	0.759 (0.424, 1.356)	0.3492	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3221
Male	124	31 (25.0)	93 (75.0)	NE (26.5, NE)	120	32 (26.7)	88 (73.3)	NE (6.9, NE)	0.814 (0.495, 1.337)	0.4132	
Female	141	45 (31.9)	96 (68.1)	31.5 (19.3, NE)	148	39 (26.4)	109 (73.6)	NE (NE, NE)	1.139 (0.741, 1.750)	0.5516	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4878
White	157	49 (31.2)	108 (68.8)	NE (30.2, NE)	161	42 (26.1)	119 (73.9)	NE (16.7, NE)	1.090 (0.721, 1.649)	0.6804	
Non-white	108	27 (25.0)	81 (75.0)	33.0 (24.0, NE)	107	29 (27.1)	78 (72.9)	NE (6.9, NE)	0.843 (0.499, 1.426)	0.5255	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9391
North America	16	2 (12.5)	14 (87.5)	NE (NE, NE)	18	4 (22.2)	14 (77.8)	NE (6.5, NE)	0.712 (0.128, 3.952)	0.6960	
Europe	161	50 (31.1)	111 (68.9)	NE (30.2, NE)	161	45 (28.0)	116 (72.0)	NE (9.2, NE)	0.993 (0.663, 1.488)	0.9721	
Asia/Other Regions	88	24 (27.3)	64 (72.7)	33.0 (19.0, NE)	89	22 (24.7)	67 (75.3)	NE (NE, NE)	0.980 (0.548, 1.751)	0.9449	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4685
< 40x10^9/L	132	36 (27.3)	96 (72.7)	NE (31.5, NE)	133	33 (24.8)	100 (75.2)	NE (NE, NE)	1.115 (0.695, 1.789)	0.6521	
≥ 40x10^9/L	133	40 (30.1)	93 (69.9)	33.0 (24.0, NE)	135	38 (28.1)	97 (71.9)	NE (6.9, NE)	0.843 (0.539, 1.320)	0.4550	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2117
Daunorubicin	123	33 (26.8)	90 (73.2)	NE (30.2, NE)	94	17 (18.1)	77 (81.9)	NE (NE, NE)	1.350 (0.751, 2.428)	0.3159	
Idarubicin	142	43 (30.3)	99 (69.7)	NE (24.0, NE)	171	53 (31.0)	118 (69.0)	NE (6.9, NE)	0.876 (0.585, 1.312)	0.5209	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.1789
Favorable	13	5 (38.5)	8 (61.5)	NE (1.8, NE)	19	5 (26.3)	14 (73.7)	NE (4.6, NE)	1.928 (0.555, 6.697)	0.2978	
Intermediate	195	54 (27.7)	141 (72.3)	NE (30.2, NE)	190	44 (23.2)	146 (76.8)	NE (16.7, NE)	1.045 (0.701, 1.558)	0.8299	
Unfavorable	19	3 (15.8)	16 (84.2)	NE (6.1, NE)	27	11 (40.7)	16 (59.3)	6.5 (1.6, NE)	0.271 (0.073, 1.006)	0.0383	
Unknown	38	14 (36.8)	24 (63.2)	26.5 (3.5, NE)	31	10 (32.3)	21 (67.7)	NE (4.5, NE)	1.175 (0.521, 2.648)	0.6963	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8580
0 - Fully Active	87	21 (24.1)	66 (75.9)	NE (31.5, NE)	97	23 (23.7)	74 (76.3)	NE (NE, NE)	0.880 (0.486, 1.594)	0.6731	
1 - Restricted in Physically Strenuous Activity	133	38 (28.6)	95 (71.4)	NE (19.0, NE)	134	38 (28.4)	96 (71.6)	NE (6.9, NE)	0.954 (0.608, 1.496)	0.8384	
2 - Ambulatory and Capable of All Selfcare	45	17 (37.8)	28 (62.2)	20.0 (5.9, NE)	36	10 (27.8)	26 (72.2)	10.7 (4.4, NE)	1.031 (0.462, 2.300)	0.9423	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7209
≥3 to ≤25%	94	28 (29.8)	66 (70.2)	NE (24.0, NE)	98	27 (27.6)	71 (72.4)	NE (16.7, NE)	1.074 (0.633, 1.824)	0.7946	
>25% to ≤50%	141	39 (27.7)	102 (72.3)	NE (30.2, NE)	136	38 (27.9)	98 (72.1)	NE (9.3, NE)	0.877 (0.560, 1.373)	0.5640	
>50%	29	9 (31.0)	20 (69.0)	NE (6.9, NE)	34	6 (17.6)	28 (82.4)	NE (NE, NE)	1.323 (0.465, 3.768)	0.5988	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2714
Yes	139	43 (30.9)	96 (69.1)	NE (26.5, NE)	137	35 (25.5)	102 (74.5)	NE (16.7, NE)	1.128 (0.721, 1.765)	0.5977	
No	116	29 (25.0)	87 (75.0)	31.5 (24.0, NE)	120	33 (27.5)	87 (72.5)	NE (6.3, NE)	0.773 (0.468, 1.276)	0.3132	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2490
≤60	164	49 (29.9)	115 (70.1)	NE (24.0, NE)	163	37 (22.7)	126 (77.3)	NE (NE, NE)	1.176 (0.766, 1.806)	0.4568	
>60	101	27 (26.7)	74 (73.3)	31.5 (20.0, NE)	105	34 (32.4)	71 (67.6)	16.7 (6.5, NE)	0.775 (0.467, 1.286)	0.3211	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9123
<60	159	10 (6.3)	149 (93.7)	NE (NE, NE)	160	7 (4.4)	153 (95.6)	NE (NE, NE)	1.241 (0.470, 3.274)	0.6623	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.166 (0.164, 8.274)	0.8781	
≥65	69	5 (7.2)	64 (92.8)	NE (20.0, NE)	65	6 (9.2)	59 (90.8)	NE (NE, NE)	0.897 (0.272, 2.954)	0.8576	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6101
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	0.878 (0.307, 2.508)	0.8085	
Female	141	10 (7.1)	131 (92.9)	NE (NE, NE)	148	8 (5.4)	140 (94.6)	NE (NE, NE)	1.207 (0.476, 3.061)	0.6911	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9967
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	1.073 (0.388, 2.967)	0.8912	
Non-white	108	9 (8.3)	99 (91.7)	NE (NE, NE)	107	8 (7.5)	99 (92.5)	NE (NE, NE)	1.039 (0.400, 2.697)	0.9370	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7107
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	8 (5.0)	153 (95.0)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	0.798 (0.307, 2.076)	0.6446	
Asia/Other Regions	88	9 (10.2)	79 (89.8)	NE (NE, NE)	89	6 (6.7)	83 (93.3)	NE (NE, NE)	1.378 (0.489, 3.882)	0.5428	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6147
< 40x10^9/L	132	8 (6.1)	124 (93.9)	NE (NE, NE)	133	9 (6.8)	124 (93.2)	NE (NE, NE)	0.880 (0.339, 2.283)	0.7928	
≥ 40x10^9/L	133	9 (6.8)	124 (93.2)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	1.280 (0.453, 3.617)	0.6392	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.1540
Daunorubicin	123	8 (6.5)	115 (93.5)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	2.645 (0.560, 12.497)	0.2018	
Idarubicin	142	9 (6.3)	133 (93.7)	NE (NE, NE)	171	13 (7.6)	158 (92.4)	NE (NE, NE)	0.762 (0.325, 1.787)	0.5312	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8590
Favorable	13	1 (7.7)	12 (92.3)	NE (5.5, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.1069	
Intermediate	195	11 (5.6)	184 (94.4)	NE (NE, NE)	190	8 (4.2)	182 (95.8)	NE (NE, NE)	1.133 (0.454, 2.824)	0.7884	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (20.0, NE)	27	3 (11.1)	24 (88.9)	NE (NE, NE)	0.333 (0.032, 3.502)	0.3413	
Unknown	38	4 (10.5)	34 (89.5)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	1.123 (0.251, 5.037)	0.8793	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7228
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	5 (5.2)	92 (94.8)	NE (NE, NE)	0.627 (0.150, 2.628)	0.5193	
1 - Restricted in Physically Strenuous Activity	133	8 (6.0)	125 (94.0)	NE (NE, NE)	134	7 (5.2)	127 (94.8)	NE (NE, NE)	1.042 (0.377, 2.878)	0.9362	
2 - Ambulatory and Capable of All Selfcare	45	6 (13.3)	39 (86.7)	NE (20.0, NE)	36	3 (8.3)	33 (91.7)	NE (NE, NE)	1.273 (0.307, 5.270)	0.7386	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1628
≥3 to ≤25%	94	9 (9.6)	85 (90.4)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	2.351 (0.724, 7.638)	0.1425	
>25% to ≤50%	141	7 (5.0)	134 (95.0)	NE (NE, NE)	136	8 (5.9)	128 (94.1)	NE (NE, NE)	0.757 (0.274, 2.094)	0.5906	
>50%	29	1 (3.4)	28 (96.6)	NE (19.3, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	0.279 (0.027, 2.859)	0.2554	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1727
Yes	139	9 (6.5)	130 (93.5)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	1.641 (0.549, 4.908)	0.3705	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	8 (6.7)	112 (93.3)	NE (NE, NE)	0.586 (0.191, 1.795)	0.3443	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7213
≤60	164	10 (6.1)	154 (93.9)	NE (NE, NE)	163	7 (4.3)	156 (95.7)	NE (NE, NE)	1.219 (0.462, 3.217)	0.6886	
>60	101	7 (6.9)	94 (93.1)	NE (NE, NE)	105	8 (7.6)	97 (92.4)	NE (NE, NE)	0.931 (0.337, 2.572)	0.8898	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7390
<60	159	4 (2.5)	155 (97.5)	NE (NE, NE)	160	5 (3.1)	155 (96.9)	NE (NE, NE)	0.796 (0.214, 2.966)	0.7334	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.1285	
≥65	69	5 (7.2)	64 (92.8)	NE (26.5, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	1.696 (0.405, 7.101)	0.4644	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6694
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.842 (0.337, 10.071)	0.4740	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	1.242 (0.417, 3.695)	0.6965	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9432
White	157	7 (4.5)	150 (95.5)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	1.423 (0.451, 4.486)	0.5450	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	1.277 (0.285, 5.712)	0.7489	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7675
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.2888	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	0.970 (0.313, 3.009)	0.9571	
Asia/Other Regions	88	4 (4.5)	84 (95.5)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	2.005 (0.367, 10.946)	0.4126	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0308
< 40x10^9/L	132	7 (5.3)	125 (94.7)	NE (NE, NE)	133	1 (0.8)	132 (99.2)	NE (NE, NE)	7.748 (0.953, 63.014)	0.0235	
≥ 40x10^9/L	133	4 (3.0)	129 (97.0)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	0.511 (0.149, 1.754)	0.2772	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9899
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	0	94 (100)	NE (NE, NE)	NE (0.000, NE)	0.2153	
Idarubicin	142	9 (6.3)	133 (93.7)	NE (NE, NE)	171	8 (4.7)	163 (95.3)	NE (NE, NE)	1.335 (0.515, 3.463)	0.5510	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9991
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	6 (3.2)	184 (96.8)	NE (NE, NE)	1.428 (0.508, 4.012)	0.4977	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	0.000 (0.000, NE)	0.4142	
Unknown	38	2 (5.3)	36 (94.7)	NE (26.5, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	1.551 (0.138, 17.481)	0.7206	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6354
0 - Fully Active	87	2 (2.3)	85 (97.7)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	0.953 (0.133, 6.837)	0.9618	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	1.010 (0.292, 3.489)	0.9874	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	3.287 (0.367, 29.432)	0.2594	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9963
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	1.429 (0.320, 6.388)	0.6386	
>25% to ≤50%	141	7 (5.0)	134 (95.0)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	1.361 (0.432, 4.290)	0.5971	
>50%	29	0	29 (100)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5503
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	1.720 (0.503, 5.884)	0.3819	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.983 (0.246, 3.934)	0.9812	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3826
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	5 (3.1)	158 (96.9)	NE (NE, NE)	0.978 (0.283, 3.381)	0.9724	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	2.198 (0.550, 8.795)	0.2529	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8693
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	7 (4.4)	153 (95.6)	NE (NE, NE)	0.691 (0.219, 2.177)	0.5253	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.057 (0.148, 7.550)	0.9561	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	5 (7.7)	60 (92.3)	NE (NE, NE)	0.596 (0.142, 2.494)	0.4732	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8114
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.627 (0.177, 2.225)	0.4663	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	8 (5.4)	140 (94.6)	NE (NE, NE)	0.769 (0.267, 2.218)	0.6267	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2301
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	1.037 (0.389, 2.763)	0.9420	
Non-white	108	2 (1.9)	106 (98.1)	NE (NE, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	0.317 (0.064, 1.573)	0.1382	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8959
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	8 (5.0)	153 (95.0)	NE (NE, NE)	161	10 (6.2)	151 (93.8)	NE (NE, NE)	0.772 (0.304, 1.957)	0.5846	
Asia/Other Regions	88	2 (2.3)	86 (97.7)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	0.492 (0.090, 2.689)	0.4036	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4517
< 40x10^9/L	132	7 (5.3)	125 (94.7)	NE (NE, NE)	133	8 (6.0)	125 (94.0)	NE (NE, NE)	0.908 (0.329, 2.504)	0.8514	
≥ 40x10^9/L	133	3 (2.3)	130 (97.7)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	0.455 (0.113, 1.823)	0.2543	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8324
Daunorubicin	123	5 (4.1)	118 (95.9)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	0.632 (0.193, 2.070)	0.4442	
Idarubicin	142	5 (3.5)	137 (96.5)	NE (NE, NE)	171	8 (4.7)	163 (95.3)	NE (NE, NE)	0.724 (0.237, 2.213)	0.5693	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9405
Favorable	13	1 (7.7)	12 (92.3)	NE (1.8, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	1.641 (0.103, 26.241)	0.7236	
Intermediate	195	5 (2.6)	190 (97.4)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	0.653 (0.207, 2.061)	0.4643	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.745 (0.068, 8.221)	0.8097	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (NE, NE)	0.624 (0.140, 2.787)	0.5360	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7043
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	5 (5.2)	92 (94.8)	NE (NE, NE)	0.659 (0.157, 2.757)	0.5645	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	1.378 (0.437, 4.342)	0.5819	
2 - Ambulatory and Capable of All Selfcare	45	0	45 (100)	NE (NE, NE)	36	4 (11.1)	32 (88.9)	NE (5.2, NE)	0.000 (0.000, NE)	0.0197	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9942
≥3 to ≤25%	94	2 (2.1)	92 (97.9)	NE (NE, NE)	98	2 (2.0)	96 (98.0)	NE (NE, NE)	1.072 (0.151, 7.612)	0.9444	
>25% to ≤50%	141	8 (5.7)	133 (94.3)	NE (NE, NE)	136	8 (5.9)	128 (94.1)	NE (NE, NE)	0.931 (0.349, 2.484)	0.8880	
>50%	29	0	29 (100)	NE (NE, NE)	34	4 (11.8)	30 (88.2)	NE (NE, NE)	0.000 (0.000, NE)	0.0478	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5421
Yes	139	5 (3.6)	134 (96.4)	NE (NE, NE)	137	6 (4.4)	131 (95.6)	NE (NE, NE)	0.809 (0.247, 2.653)	0.7266	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	8 (6.7)	112 (93.3)	NE (NE, NE)	0.499 (0.150, 1.656)	0.2461	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7378
≤60	164	6 (3.7)	158 (96.3)	NE (NE, NE)	163	7 (4.3)	156 (95.7)	NE (NE, NE)	0.820 (0.275, 2.440)	0.7200	
>60	101	4 (4.0)	97 (96.0)	NE (NE, NE)	105	7 (6.7)	98 (93.3)	NE (NE, NE)	0.601 (0.176, 2.055)	0.4127	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4546
<60	159	21 (13.2)	138 (86.8)	NE (NE, NE)	160	20 (12.5)	140 (87.5)	NE (NE, NE)	0.968 (0.524, 1.788)	0.9179	
≥60 - <65	37	5 (13.5)	32 (86.5)	NE (31.5, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	2.773 (0.537, 14.320)	0.2038	
≥65	69	12 (17.4)	57 (82.6)	NE (NE, NE)	65	10 (15.4)	55 (84.6)	NE (NE, NE)	1.353 (0.584, 3.135)	0.4801	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2590
Male	124	19 (15.3)	105 (84.7)	NE (NE, NE)	120	11 (9.2)	109 (90.8)	NE (NE, NE)	1.642 (0.781, 3.451)	0.1863	
Female	141	19 (13.5)	122 (86.5)	NE (NE, NE)	148	21 (14.2)	127 (85.8)	NE (NE, NE)	0.909 (0.488, 1.693)	0.7630	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3700
White	157	29 (18.5)	128 (81.5)	NE (NE, NE)	161	27 (16.8)	134 (83.2)	NE (NE, NE)	1.042 (0.616, 1.761)	0.8794	
Non-white	108	9 (8.3)	99 (91.7)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	1.776 (0.595, 5.302)	0.2964	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9281
North America	16	2 (12.5)	14 (87.5)	NE (2.2, NE)	18	2 (11.1)	16 (88.9)	NE (NE, NE)	2.343 (0.322, 17.035)	0.3867	
Europe	161	23 (14.3)	138 (85.7)	NE (NE, NE)	161	18 (11.2)	143 (88.8)	NE (NE, NE)	1.185 (0.639, 2.200)	0.5900	
Asia/Other Regions	88	13 (14.8)	75 (85.2)	NE (NE, NE)	89	12 (13.5)	77 (86.5)	NE (NE, NE)	1.064 (0.485, 2.333)	0.8777	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4983
< 40x10^9/L	132	18 (13.6)	114 (86.4)	NE (NE, NE)	133	19 (14.3)	114 (85.7)	NE (NE, NE)	1.014 (0.532, 1.933)	0.9663	
≥ 40x10^9/L	133	20 (15.0)	113 (85.0)	NE (NE, NE)	135	13 (9.6)	122 (90.4)	NE (NE, NE)	1.400 (0.695, 2.820)	0.3450	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6459
Daunorubicin	123	14 (11.4)	109 (88.6)	NE (NE, NE)	94	7 (7.4)	87 (92.6)	NE (NE, NE)	1.515 (0.611, 3.757)	0.3669	
Idarubicin	142	24 (16.9)	118 (83.1)	NE (NE, NE)	171	24 (14.0)	147 (86.0)	NE (NE, NE)	1.163 (0.660, 2.049)	0.6019	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.3993
Favorable	13	1 (7.7)	12 (92.3)	NE (1.7, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	1.597 (0.100, 25.565)	0.7385	
Intermediate	195	25 (12.8)	170 (87.2)	NE (NE, NE)	190	22 (11.6)	168 (88.4)	NE (NE, NE)	1.044 (0.588, 1.852)	0.8840	
Unfavorable	19	6 (31.6)	13 (68.4)	NE (2.5, NE)	27	3 (11.1)	24 (88.9)	NE (NE, NE)	3.338 (0.834, 13.362)	0.0706	
Unknown	38	6 (15.8)	32 (84.2)	NE (31.5, NE)	31	6 (19.4)	25 (80.6)	NE (6.0, NE)	0.690 (0.221, 2.158)	0.5222	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1369
0 - Fully Active	87	10 (11.5)	77 (88.5)	NE (NE, NE)	97	16 (16.5)	81 (83.5)	NE (NE, NE)	0.642 (0.291, 1.416)	0.2676	
1 - Restricted in Physically Strenuous Activity	133	22 (16.5)	111 (83.5)	NE (NE, NE)	134	14 (10.4)	120 (89.6)	NE (NE, NE)	1.553 (0.794, 3.038)	0.1945	
2 - Ambulatory and Capable of All Selfcare	45	6 (13.3)	39 (86.7)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	2.585 (0.521, 12.814)	0.2275	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4109
≥3 to ≤25%	94	12 (12.8)	82 (87.2)	NE (NE, NE)	98	15 (15.3)	83 (84.7)	NE (NE, NE)	0.826 (0.386, 1.765)	0.6198	
>25% to ≤50%	141	21 (14.9)	120 (85.1)	NE (NE, NE)	136	15 (11.0)	121 (89.0)	NE (NE, NE)	1.344 (0.692, 2.608)	0.3816	
>50%	29	5 (17.2)	24 (82.8)	NE (31.5, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	2.240 (0.427, 11.768)	0.3282	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.8667
Yes	139	22 (15.8)	117 (84.2)	NE (NE, NE)	137	20 (14.6)	117 (85.4)	NE (NE, NE)	1.091 (0.595, 2.001)	0.7774	
No	116	13 (11.2)	103 (88.8)	NE (NE, NE)	120	12 (10.0)	108 (90.0)	NE (NE, NE)	0.999 (0.455, 2.191)	0.9974	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2588
≤60	164	21 (12.8)	143 (87.2)	NE (NE, NE)	163	20 (12.3)	143 (87.7)	NE (NE, NE)	0.951 (0.515, 1.757)	0.8732	
>60	101	17 (16.8)	84 (83.2)	NE (31.5, NE)	105	12 (11.4)	93 (88.6)	NE (NE, NE)	1.638 (0.782, 3.430)	0.1876	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.3613
<60	159	16 (10.1)	143 (89.9)	NE (NE, NE)	160	15 (9.4)	145 (90.6)	NE (NE, NE)	1.010 (0.499, 2.044)	0.9774	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	4.370 (0.487, 39.191)	0.1501	
≥65	69	9 (13.0)	60 (87.0)	NE (NE, NE)	65	6 (9.2)	59 (90.8)	NE (NE, NE)	1.678 (0.596, 4.723)	0.3234	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9770
Male	124	14 (11.3)	110 (88.7)	NE (NE, NE)	120	10 (8.3)	110 (91.7)	NE (NE, NE)	1.312 (0.583, 2.954)	0.5107	
Female	141	15 (10.6)	126 (89.4)	NE (NE, NE)	148	12 (8.1)	136 (91.9)	NE (NE, NE)	1.322 (0.619, 2.825)	0.4714	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9884
White	157	25 (15.9)	132 (84.1)	NE (NE, NE)	161	19 (11.8)	142 (88.2)	NE (NE, NE)	1.317 (0.725, 2.392)	0.3654	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	1.337 (0.299, 5.974)	0.7038	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3520
North America	16	2 (12.5)	14 (87.5)	NE (2.2, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	3.939 (0.357, 43.513)	0.2270	
Europe	161	19 (11.8)	142 (88.2)	NE (NE, NE)	161	11 (6.8)	150 (93.2)	NE (NE, NE)	1.658 (0.789, 3.487)	0.1779	
Asia/Other Regions	88	8 (9.1)	80 (90.9)	NE (NE, NE)	89	10 (11.2)	79 (88.8)	NE (NE, NE)	0.795 (0.314, 2.015)	0.6271	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3948
< 40x10^9/L	132	14 (10.6)	118 (89.4)	NE (NE, NE)	133	14 (10.5)	119 (89.5)	NE (NE, NE)	1.079 (0.514, 2.264)	0.8406	
≥ 40x10^9/L	133	15 (11.3)	118 (88.7)	NE (NE, NE)	135	8 (5.9)	127 (94.1)	NE (NE, NE)	1.779 (0.754, 4.201)	0.1825	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2393
Daunorubicin	123	11 (8.9)	112 (91.1)	NE (NE, NE)	94	3 (3.2)	91 (96.8)	NE (NE, NE)	2.857 (0.797, 10.240)	0.0918	
Idarubicin	142	18 (12.7)	124 (87.3)	NE (NE, NE)	171	18 (10.5)	153 (89.5)	NE (NE, NE)	1.185 (0.616, 2.278)	0.6104	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6854
Favorable	13	1 (7.7)	12 (92.3)	NE (1.7, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	1.597 (0.100, 25.565)	0.7385	
Intermediate	195	20 (10.3)	175 (89.7)	NE (NE, NE)	190	15 (7.9)	175 (92.1)	NE (NE, NE)	1.234 (0.631, 2.411)	0.5391	
Unfavorable	19	5 (26.3)	14 (73.7)	NE (2.5, NE)	27	3 (11.1)	24 (88.9)	NE (NE, NE)	2.795 (0.667, 11.713)	0.1419	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	0.767 (0.155, 3.805)	0.7448	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5863
0 - Fully Active	87	10 (11.5)	77 (88.5)	NE (NE, NE)	97	11 (11.3)	86 (88.7)	NE (NE, NE)	0.959 (0.407, 2.258)	0.9226	
1 - Restricted in Physically Strenuous Activity	133	14 (10.5)	119 (89.5)	NE (NE, NE)	134	9 (6.7)	125 (93.3)	NE (NE, NE)	1.545 (0.669, 3.571)	0.3051	
2 - Ambulatory and Capable of All Selfcare	45	5 (11.1)	40 (88.9)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	2.158 (0.418, 11.132)	0.3462	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.4112
≥3 to ≤25%	94	9 (9.6)	85 (90.4)	NE (NE, NE)	98	11 (11.2)	87 (88.8)	NE (NE, NE)	0.856 (0.355, 2.065)	0.7284	
>25% to ≤50%	141	17 (12.1)	124 (87.9)	NE (NE, NE)	136	10 (7.4)	126 (92.6)	NE (NE, NE)	1.661 (0.760, 3.629)	0.1986	
>50%	29	3 (10.3)	26 (89.7)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	2.716 (0.283, 26.115)	0.3672	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1124
Yes	139	19 (13.7)	120 (86.3)	NE (NE, NE)	137	10 (7.3)	127 (92.7)	NE (NE, NE)	1.943 (0.904, 4.180)	0.0833	
No	116	10 (8.6)	106 (91.4)	NE (NE, NE)	120	12 (10.0)	108 (90.0)	NE (NE, NE)	0.779 (0.336, 1.803)	0.5585	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1797
≤60	164	16 (9.8)	148 (90.2)	NE (NE, NE)	163	15 (9.2)	148 (90.8)	NE (NE, NE)	0.993 (0.491, 2.009)	0.9842	
>60	101	13 (12.9)	88 (87.1)	NE (NE, NE)	105	7 (6.7)	98 (93.3)	NE (NE, NE)	2.147 (0.856, 5.383)	0.0959	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8570
<60	159	13 (8.2)	146 (91.8)	NE (NE, NE)	160	7 (4.4)	153 (95.6)	NE (NE, NE)	1.736 (0.692, 4.357)	0.2338	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	1.164 (0.073, 18.616)	0.9142	
≥65	69	8 (11.6)	61 (88.4)	NE (23.7, NE)	65	7 (10.8)	58 (89.2)	NE (NE, NE)	1.176 (0.426, 3.246)	0.7541	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9203
Male	124	10 (8.1)	114 (91.9)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	1.459 (0.529, 4.026)	0.4628	
Female	141	12 (8.5)	129 (91.5)	NE (NE, NE)	148	9 (6.1)	139 (93.9)	NE (NE, NE)	1.326 (0.558, 3.151)	0.5211	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.0046
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	13 (8.1)	148 (91.9)	NE (NE, NE)	0.565 (0.233, 1.366)	0.1986	
Non-white	108	14 (13.0)	94 (87.0)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	6.856 (1.558, 30.177)	0.0031	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3196
North America	16	0	16 (100)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	0.000 (0.000, NE)	0.4533	
Europe	161	12 (7.5)	149 (92.5)	NE (NE, NE)	161	11 (6.8)	150 (93.2)	NE (NE, NE)	0.997 (0.439, 2.264)	0.9947	
Asia/Other Regions	88	10 (11.4)	78 (88.6)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	3.160 (0.868, 11.502)	0.0653	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4692
< 40x10^9/L	132	8 (6.1)	124 (93.9)	NE (NE, NE)	133	8 (6.0)	125 (94.0)	NE (NE, NE)	1.042 (0.391, 2.779)	0.9348	
≥ 40x10^9/L	133	14 (10.5)	119 (89.5)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	1.730 (0.695, 4.305)	0.2328	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4140
Daunorubicin	123	13 (10.6)	110 (89.4)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	1.796 (0.639, 5.051)	0.2596	
Idarubicin	142	9 (6.3)	133 (93.7)	NE (NE, NE)	171	10 (5.8)	161 (94.2)	NE (NE, NE)	1.011 (0.410, 2.492)	0.9805	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9594
Favorable	13	2 (15.4)	11 (84.6)	NE (1.8, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.0715	
Intermediate	195	14 (7.2)	181 (92.8)	NE (NE, NE)	190	11 (5.8)	179 (94.2)	NE (NE, NE)	1.100 (0.498, 2.426)	0.8128	
Unfavorable	19	3 (15.8)	16 (84.2)	NE (3.3, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	1.861 (0.300, 11.543)	0.4984	
Unknown	38	3 (7.9)	35 (92.1)	NE (23.7, NE)	31	2 (6.5)	29 (93.5)	NE (7.5, NE)	1.244 (0.207, 7.477)	0.8109	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7753
0 - Fully Active	87	7 (8.0)	80 (92.0)	NE (NE, NE)	97	6 (6.2)	91 (93.8)	NE (NE, NE)	1.205 (0.404, 3.591)	0.7376	
1 - Restricted in Physically Strenuous Activity	133	11 (8.3)	122 (91.7)	NE (NE, NE)	134	8 (6.0)	126 (94.0)	NE (NE, NE)	1.310 (0.526, 3.258)	0.5600	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	2.419 (0.262, 22.288)	0.4219	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2971
≥3 to ≤25%	94	9 (9.6)	85 (90.4)	NE (NE, NE)	98	6 (6.1)	92 (93.9)	NE (NE, NE)	1.601 (0.570, 4.498)	0.3677	
>25% to ≤50%	141	12 (8.5)	129 (91.5)	NE (NE, NE)	136	6 (4.4)	130 (95.6)	NE (NE, NE)	1.800 (0.674, 4.806)	0.2340	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (7.5, NE)	0.231 (0.024, 2.255)	0.1703	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5432
Yes	139	16 (11.5)	123 (88.5)	NE (NE, NE)	137	10 (7.3)	127 (92.7)	NE (NE, NE)	1.472 (0.667, 3.249)	0.3355	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	0.929 (0.268, 3.215)	0.9076	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6421
≤60	164	13 (7.9)	151 (92.1)	NE (NE, NE)	163	7 (4.3)	156 (95.7)	NE (NE, NE)	1.700 (0.678, 4.266)	0.2527	
>60	101	9 (8.9)	92 (91.1)	NE (NE, NE)	105	8 (7.6)	97 (92.4)	NE (NE, NE)	1.158 (0.446, 3.005)	0.7625	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4347
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	3 (1.9)	157 (98.1)	NE (NE, NE)	2.060 (0.531, 7.992)	0.2858	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	0.535 (0.098, 2.929)	0.4633	
≥65	69	5 (7.2)	64 (92.8)	NE (NE, NE)	65	5 (7.7)	60 (92.3)	NE (NE, NE)	0.992 (0.287, 3.427)	0.9826	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7697
Male	124	9 (7.3)	115 (92.7)	NE (NE, NE)	120	8 (6.7)	112 (93.3)	NE (NE, NE)	0.949 (0.365, 2.469)	0.9130	
Female	141	5 (3.5)	136 (96.5)	NE (NE, NE)	148	4 (2.7)	144 (97.3)	NE (NE, NE)	1.257 (0.337, 4.687)	0.7330	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9893
White	157	7 (4.5)	150 (95.5)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	1.094 (0.366, 3.265)	0.8720	
Non-white	108	7 (6.5)	101 (93.5)	NE (NE, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	1.054 (0.353, 3.140)	0.9282	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4745
North America	16	1 (6.3)	15 (93.8)	NE (1.8, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.1824	
Europe	161	8 (5.0)	153 (95.0)	NE (NE, NE)	161	10 (6.2)	151 (93.8)	NE (NE, NE)	0.724 (0.285, 1.839)	0.4945	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	2.254 (0.436, 11.654)	0.3209	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1899
< 40x10^9/L	132	4 (3.0)	128 (97.0)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	0.584 (0.171, 1.996)	0.3853	
≥ 40x10^9/L	133	10 (7.5)	123 (92.5)	NE (NE, NE)	135	5 (3.7)	130 (96.3)	NE (NE, NE)	1.697 (0.577, 4.991)	0.3320	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2497
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	0.687 (0.221, 2.136)	0.5140	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	5 (2.9)	166 (97.1)	NE (NE, NE)	1.784 (0.582, 5.469)	0.3050	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8028
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	8 (4.1)	187 (95.9)	NE (NE, NE)	190	9 (4.7)	181 (95.3)	NE (NE, NE)	0.756 (0.291, 1.963)	0.5638	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.543 (0.097, 24.683)	0.7571	
Unknown	38	5 (13.2)	33 (86.8)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	1.935 (0.374, 10.013)	0.4262	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7652
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	1.009 (0.203, 5.007)	0.9914	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	1.301 (0.412, 4.104)	0.6530	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	4 (11.1)	32 (88.9)	NE (13.4, NE)	0.736 (0.180, 3.000)	0.6675	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9826
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	1.032 (0.208, 5.118)	0.9690	
>25% to ≤50%	141	11 (7.8)	130 (92.2)	NE (NE, NE)	136	8 (5.9)	128 (94.1)	NE (NE, NE)	1.242 (0.499, 3.094)	0.6405	
>50%	29	0	29 (100)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.000 (0.000, NE)	0.3642	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1454
Yes	139	4 (2.9)	135 (97.1)	NE (NE, NE)	137	7 (5.1)	130 (94.9)	NE (NE, NE)	0.515 (0.150, 1.766)	0.2823	
No	116	9 (7.8)	107 (92.2)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	1.727 (0.579, 5.158)	0.3213	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2778
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	3 (1.8)	160 (98.2)	NE (NE, NE)	2.026 (0.522, 7.862)	0.2974	
>60	101	7 (6.9)	94 (93.1)	NE (NE, NE)	105	9 (8.6)	96 (91.4)	NE (NE, NE)	0.800 (0.298, 2.150)	0.6544	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8324
<60	159	6 (3.8)	153 (96.2)	NE (NE, NE)	160	3 (1.9)	157 (98.1)	NE (NE, NE)	1.906 (0.476, 7.633)	0.3540	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.461 (0.243, 8.804)	0.6770	
≥65	69	5 (7.2)	64 (92.8)	NE (26.1, NE)	65	5 (7.7)	60 (92.3)	NE (NE, NE)	1.037 (0.300, 3.589)	0.9537	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2541
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	0.876 (0.307, 2.502)	0.8053	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	3 (2.0)	145 (98.0)	NE (NE, NE)	2.362 (0.610, 9.139)	0.1992	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1858
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	2.607 (0.691, 9.837)	0.1418	
Non-white	108	6 (5.6)	102 (94.4)	NE (NE, NE)	107	7 (6.5)	100 (93.5)	NE (NE, NE)	0.765 (0.257, 2.280)	0.6301	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6337
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	7 (4.3)	154 (95.7)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	0.921 (0.323, 2.630)	0.8784	
Asia/Other Regions	88	7 (8.0)	81 (92.0)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	2.151 (0.555, 8.333)	0.2557	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6677
< 40x10^9/L	132	6 (4.5)	126 (95.5)	NE (NE, NE)	133	4 (3.0)	129 (97.0)	NE (NE, NE)	1.590 (0.449, 5.636)	0.4685	
≥ 40x10^9/L	133	8 (6.0)	125 (94.0)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	1.088 (0.375, 3.153)	0.8761	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5230
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	1 (1.1)	93 (98.9)	NE (NE, NE)	3.052 (0.341, 27.316)	0.2934	
Idarubicin	142	10 (7.0)	132 (93.0)	NE (NE, NE)	171	9 (5.3)	162 (94.7)	NE (NE, NE)	1.258 (0.511, 3.099)	0.6169	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4665
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	6 (3.1)	189 (96.9)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	0.730 (0.245, 2.177)	0.5706	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (11.2, NE)	1.501 (0.211, 10.659)	0.6825	
Unknown	38	6 (15.8)	32 (84.2)	NE (26.1, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	4.936 (0.591, 41.190)	0.1014	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3113
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	1 (1.0)	96 (99.0)	NE (NE, NE)	4.194 (0.467, 37.674)	0.1643	
1 - Restricted in Physically Strenuous Activity	133	9 (6.8)	124 (93.2)	NE (NE, NE)	134	7 (5.2)	127 (94.8)	NE (NE, NE)	1.170 (0.435, 3.145)	0.7554	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.424 (0.038, 4.681)	0.4707	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1957
≥3 to ≤25%	94	6 (6.4)	88 (93.6)	NE (NE, NE)	98	1 (1.0)	97 (99.0)	NE (NE, NE)	6.421 (0.773, 53.326)	0.0476	
>25% to ≤50%	141	5 (3.5)	136 (96.5)	NE (NE, NE)	136	6 (4.4)	130 (95.6)	NE (NE, NE)	0.733 (0.223, 2.410)	0.6081	
>50%	29	3 (10.3)	26 (89.7)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (6.8, NE)	0.868 (0.174, 4.324)	0.8627	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0785
Yes	139	6 (4.3)	133 (95.7)	NE (NE, NE)	137	8 (5.8)	129 (94.2)	NE (NE, NE)	0.690 (0.239, 1.993)	0.4905	
No	116	8 (6.9)	108 (93.1)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	3.836 (0.814, 18.077)	0.0672	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6825
≤60	164	6 (3.7)	158 (96.3)	NE (NE, NE)	163	3 (1.8)	160 (98.2)	NE (NE, NE)	1.875 (0.468, 7.510)	0.3667	
>60	101	8 (7.9)	93 (92.1)	NE (NE, NE)	105	7 (6.7)	98 (93.3)	NE (NE, NE)	1.237 (0.448, 3.414)	0.6816	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9581
<60	159	8 (5.0)	151 (95.0)	NE (NE, NE)	160	5 (3.1)	155 (96.9)	NE (NE, NE)	1.471 (0.480, 4.509)	0.4966	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	0.000 (0.000, NE)	0.3602	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	1 (1.5)	64 (98.5)	NE (26.7, NE)	2.340 (0.211, 25.896)	0.4753	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9786
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.413 (0.236, 8.465)	0.7040	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	5 (3.4)	143 (96.6)	NE (NE, NE)	1.385 (0.439, 4.367)	0.5771	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1964
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	2.902 (0.585, 14.404)	0.1721	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	0.723 (0.194, 2.701)	0.6284	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5946
North America	16	0	16 (100)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (5.1, NE)	0.000 (0.000, NE)	0.4292	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	2.720 (0.548, 13.500)	0.2020	
Asia/Other Regions	88	4 (4.5)	84 (95.5)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	0.983 (0.246, 3.931)	0.9806	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5013
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	5 (3.8)	128 (96.2)	NE (NE, NE)	1.025 (0.296, 3.541)	0.9694	
≥ 40x10^9/L	133	5 (3.8)	128 (96.2)	NE (NE, NE)	135	2 (1.5)	133 (98.5)	NE (NE, NE)	2.346 (0.455, 12.106)	0.2938	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9747
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	1.467 (0.268, 8.013)	0.6566	
Idarubicin	142	6 (4.2)	136 (95.8)	NE (NE, NE)	171	5 (2.9)	166 (97.1)	NE (NE, NE)	1.339 (0.408, 4.396)	0.6297	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.7598
Favorable	13	1 (7.7)	12 (92.3)	NE (1.8, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	1.597 (0.100, 25.565)	0.7385	
Intermediate	195	6 (3.1)	189 (96.9)	NE (NE, NE)	190	3 (1.6)	187 (98.4)	NE (NE, NE)	1.717 (0.429, 6.877)	0.4393	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (6.2, NE)	27	3 (11.1)	24 (88.9)	NE (11.2, NE)	0.432 (0.045, 4.176)	0.4554	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.1965	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7951
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	2.073 (0.379, 11.342)	0.3901	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	4 (3.0)	130 (97.0)	NE (NE, NE)	1.191 (0.319, 4.439)	0.7946	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	0.837 (0.052, 13.391)	0.9000	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1258
≥3 to ≤25%	94	1 (1.1)	93 (98.9)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	0.247 (0.028, 2.210)	0.1753	
>25% to ≤50%	141	9 (6.4)	132 (93.6)	NE (NE, NE)	136	2 (1.5)	134 (98.5)	NE (NE, NE)	4.278 (0.924, 19.818)	0.0426	
>50%	29	0	29 (100)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.000 (0.000, NE)	0.3570	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.8918
Yes	139	5 (3.6)	134 (96.4)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	1.169 (0.313, 4.368)	0.8158	
No	116	3 (2.6)	113 (97.4)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.346 (0.224, 8.098)	0.7446	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8202
≤60	164	8 (4.9)	156 (95.1)	NE (NE, NE)	163	5 (3.1)	158 (96.9)	NE (NE, NE)	1.446 (0.472, 4.432)	0.5163	
>60	101	2 (2.0)	99 (98.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	1.130 (0.159, 8.052)	0.9031	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8679
<60	159	4 (2.5)	155 (97.5)	NE (NE, NE)	160	4 (2.5)	156 (97.5)	NE (NE, NE)	0.887 (0.221, 3.565)	0.8657	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.683 (0.281, 10.075)	0.5643	
≥65	69	0	69 (100)	NE (NE, NE)	65	4 (6.2)	61 (93.8)	NE (NE, NE)	0.000 (0.000, NE)	0.0454	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2176
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	0.365 (0.094, 1.417)	0.1289	
Female	141	4 (2.8)	137 (97.2)	NE (NE, NE)	148	3 (2.0)	145 (98.0)	NE (NE, NE)	1.358 (0.304, 6.076)	0.6876	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.1279
White	157	3 (1.9)	154 (98.1)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	0.343 (0.091, 1.298)	0.0984	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	1.947 (0.356, 10.637)	0.4330	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3992
North America	16	2 (12.5)	14 (87.5)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (10.1, NE)	2.680 (0.240, 29.866)	0.4047	
Europe	161	4 (2.5)	157 (97.5)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	0.438 (0.131, 1.461)	0.1666	
Asia/Other Regions	88	1 (1.1)	87 (98.9)	NE (NE, NE)	89	1 (1.1)	88 (98.9)	NE (NE, NE)	1.023 (0.064, 16.356)	0.9871	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4387
< 40x10^9/L	132	2 (1.5)	130 (98.5)	NE (NE, NE)	133	5 (3.8)	128 (96.2)	NE (NE, NE)	0.403 (0.078, 2.080)	0.2613	
≥ 40x10^9/L	133	5 (3.8)	128 (96.2)	NE (NE, NE)	135	5 (3.7)	130 (96.3)	NE (NE, NE)	0.872 (0.251, 3.035)	0.8306	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9555
Daunorubicin	123	3 (2.4)	120 (97.6)	NE (NE, NE)	94	3 (3.2)	91 (96.8)	NE (NE, NE)	0.678 (0.136, 3.373)	0.6328	
Idarubicin	142	4 (2.8)	138 (97.2)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	0.758 (0.214, 2.693)	0.6679	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9622
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (10.1, NE)	0.000 (0.000, NE)	0.5271	
Intermediate	195	4 (2.1)	191 (97.9)	NE (NE, NE)	190	6 (3.2)	184 (96.8)	NE (NE, NE)	0.581 (0.163, 2.064)	0.3955	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.643 (0.102, 26.346)	0.7230	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	0.824 (0.116, 5.856)	0.8467	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3653
0 - Fully Active	87	2 (2.3)	85 (97.7)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	0.704 (0.118, 4.222)	0.7000	
1 - Restricted in Physically Strenuous Activity	133	1 (0.8)	132 (99.2)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	0.182 (0.021, 1.563)	0.0808	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	1.660 (0.304, 9.065)	0.5542	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6871
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	6 (6.1)	92 (93.9)	NE (NE, NE)	0.514 (0.129, 2.058)	0.3384	
>25% to ≤50%	141	4 (2.8)	137 (97.2)	NE (NE, NE)	136	3 (2.2)	133 (97.8)	NE (NE, NE)	1.159 (0.259, 5.195)	0.8471	
>50%	29	0	29 (100)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.000 (0.000, NE)	0.3557	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9669
Yes	139	3 (2.2)	136 (97.8)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	0.532 (0.126, 2.238)	0.3815	
No	116	3 (2.6)	113 (97.4)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	0.561 (0.134, 2.348)	0.4203	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.12.2 Serious Treatment-emergent adverse events by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6110
≤60	164	4 (2.4)	160 (97.6)	NE (NE, NE)	163	4 (2.5)	159 (97.5)	NE (NE, NE)	0.871 (0.216, 3.502)	0.8457	
>60	101	3 (3.0)	98 (97.0)	NE (NE, NE)	105	6 (5.7)	99 (94.3)	NE (NE, NE)	0.522 (0.131, 2.091)	0.3505	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:28; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_12_2_TEAESERSOCPT_SUB_SAS.rtf

Anhang 4-H9c: Schwere UE (CTCAE-Grad ≥ 3) nach SOC und PT

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9216
<60	159	96 (60.4)	63 (39.6)	2.2 (1.7, 5.5)	160	79 (49.4)	81 (50.6)	3.7 (1.7, 10.3)	1.171 (0.869, 1.578)	0.2991	
≥60 - <65	37	23 (62.2)	14 (37.8)	2.0 (1.7, 5.9)	43	22 (51.2)	21 (48.8)	2.9 (0.9, NE)	1.013 (0.564, 1.822)	0.9538	
≥65	69	36 (52.2)	33 (47.8)	5.7 (1.5, 10.1)	65	30 (46.2)	35 (53.8)	3.6 (1.6, NE)	1.122 (0.690, 1.824)	0.6294	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.2260
Male	124	68 (54.8)	56 (45.2)	2.1 (1.7, 6.5)	120	48 (40.0)	72 (60.0)	7.1 (2.9, NE)	1.366 (0.943, 1.979)	0.0971	
Female	141	87 (61.7)	54 (38.3)	2.3 (1.7, 5.9)	148	83 (56.1)	65 (43.9)	1.8 (1.3, 4.0)	1.001 (0.741, 1.353)	0.9819	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2109
White	157	95 (60.5)	62 (39.5)	2.0 (1.7, 3.5)	161	87 (54.0)	74 (46.0)	2.2 (1.5, 4.0)	1.011 (0.755, 1.353)	0.9387	
Non-white	108	60 (55.6)	48 (44.4)	5.5 (1.9, 8.2)	107	44 (41.1)	63 (58.9)	7.1 (3.6, NE)	1.351 (0.916, 1.995)	0.1262	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0779
North America	16	10 (62.5)	6 (37.5)	1.8 (0.2, NE)	18	14 (77.8)	4 (22.2)	0.3 (0.1, 3.0)	0.672 (0.295, 1.530)	0.3545	
Europe	161	93 (57.8)	68 (42.2)	2.3 (1.7, 6.4)	161	82 (50.9)	79 (49.1)	2.7 (1.6, 7.7)	1.011 (0.750, 1.362)	0.9429	
Asia/Other Regions	88	52 (59.1)	36 (40.9)	2.2 (1.6, 6.5)	89	35 (39.3)	54 (60.7)	NE (3.7, NE)	1.586 (1.033, 2.435)	0.0332	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1958
< 40x10^9/L	132	76 (57.6)	56 (42.4)	2.5 (1.6, 5.9)	133	74 (55.6)	59 (44.4)	2.1 (1.4, 5.2)	0.970 (0.703, 1.338)	0.8548	
≥ 40x10^9/L	133	79 (59.4)	54 (40.6)	2.2 (1.9, 6.0)	135	57 (42.2)	78 (57.8)	7.7 (2.7, NE)	1.314 (0.934, 1.848)	0.1146	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5712
Daunorubicin	123	78 (63.4)	45 (36.6)	1.9 (1.6, 3.7)	94	49 (52.1)	45 (47.9)	2.7 (1.4, 9.0)	1.167 (0.816, 1.669)	0.3955	
Idarubicin	142	77 (54.2)	65 (45.8)	4.5 (2.0, 7.8)	171	81 (47.4)	90 (52.6)	4.0 (2.1, NE)	1.040 (0.761, 1.422)	0.8029	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.2705
Favorable	13	6 (46.2)	7 (53.8)	1.8 (0.7, NE)	19	14 (73.7)	5 (26.3)	1.2 (0.2, 3.1)	0.477 (0.183, 1.244)	0.1249	
Intermediate	195	111 (56.9)	84 (43.1)	2.2 (1.9, 5.8)	190	92 (48.4)	98 (51.6)	3.6 (1.7, 7.7)	1.075 (0.815, 1.418)	0.6029	
Unfavorable	19	12 (63.2)	7 (36.8)	2.5 (0.1, NE)	27	11 (40.7)	16 (59.3)	4.0 (1.7, NE)	1.699 (0.746, 3.867)	0.2096	
Unknown	38	26 (68.4)	12 (31.6)	1.7 (0.8, 8.6)	31	14 (45.2)	17 (54.8)	NE (1.2, NE)	1.502 (0.782, 2.886)	0.2133	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.3130
0 - Fully Active	87	47 (54.0)	40 (46.0)	3.5 (1.8, 11.6)	97	51 (52.6)	46 (47.4)	3.0 (1.4, 10.3)	0.907 (0.609, 1.349)	0.6335	
1 - Restricted in Physically Strenuous Activity	133	84 (63.2)	49 (36.8)	2.0 (1.6, 5.5)	134	63 (47.0)	71 (53.0)	3.7 (1.6, NE)	1.296 (0.934, 1.798)	0.1178	
2 - Ambulatory and Capable of All Selfcare	45	24 (53.3)	21 (46.7)	2.2 (1.2, 11.5)	36	17 (47.2)	19 (52.8)	7.1 (0.9, NE)	1.138 (0.611, 2.120)	0.6836	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.1031
≥3 to ≤25%	94	51 (54.3)	43 (45.7)	2.6 (1.7, 9.5)	98	54 (55.1)	44 (44.9)	1.6 (1.4, 5.2)	0.795 (0.539, 1.170)	0.2467	
>25% to ≤50%	141	83 (58.9)	58 (41.1)	2.0 (1.7, 4.5)	136	61 (44.9)	75 (55.1)	7.1 (2.5, NE)	1.387 (0.997, 1.931)	0.0509	
>50%	29	20 (69.0)	9 (31.0)	2.2 (1.6, 7.6)	34	16 (47.1)	18 (52.9)	3.1 (0.7, NE)	1.213 (0.627, 2.347)	0.5706	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1542
Yes	139	78 (56.1)	61 (43.9)	4.5 (2.0, 8.6)	137	76 (55.5)	61 (44.5)	2.7 (1.6, 6.2)	0.936 (0.682, 1.284)	0.6868	
No	116	72 (62.1)	44 (37.9)	1.8 (1.6, 2.5)	120	53 (44.2)	67 (55.8)	4.1 (1.5, NE)	1.343 (0.941, 1.916)	0.1025	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5807
≤60	164	99 (60.4)	65 (39.6)	2.2 (1.8, 5.5)	163	79 (48.5)	84 (51.5)	3.7 (2.1, 10.3)	1.194 (0.888, 1.606)	0.2397	
>60	101	56 (55.4)	45 (44.6)	2.1 (1.6, 5.9)	105	52 (49.5)	53 (50.5)	2.7 (1.5, NE)	1.037 (0.710, 1.514)	0.8393	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9445
<60	159	72 (45.3)	87 (54.7)	4.2 (2.2, NE)	160	68 (42.5)	92 (57.5)	5.2 (3.0, NE)	1.024 (0.735, 1.427)	0.8849	
≥60 - <65	37	17 (45.9)	20 (54.1)	2.9 (1.9, NE)	43	16 (37.2)	27 (62.8)	NE (1.5, NE)	1.125 (0.568, 2.228)	0.7280	
≥65	69	27 (39.1)	42 (60.9)	18.9 (1.7, NE)	65	26 (40.0)	39 (60.0)	NE (1.6, NE)	0.965 (0.563, 1.654)	0.9015	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.0816
Male	124	55 (44.4)	69 (55.6)	3.9 (2.1, NE)	120	40 (33.3)	80 (66.7)	NE (7.1, NE)	1.340 (0.891, 2.014)	0.1570	
Female	141	61 (43.3)	80 (56.7)	5.5 (2.2, NE)	148	70 (47.3)	78 (52.7)	3.4 (1.8, NE)	0.834 (0.592, 1.176)	0.3025	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4616
White	157	73 (46.5)	84 (53.5)	2.9 (2.0, NE)	161	73 (45.3)	88 (54.7)	3.1 (1.7, NE)	0.955 (0.690, 1.322)	0.7864	
Non-white	108	43 (39.8)	65 (60.2)	18.9 (3.4, NE)	107	37 (34.6)	70 (65.4)	NE (5.2, NE)	1.156 (0.745, 1.794)	0.5151	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4263
North America	16	8 (50.0)	8 (50.0)	2.2 (0.2, NE)	18	11 (61.1)	7 (38.9)	1.0 (0.1, NE)	0.712 (0.286, 1.775)	0.4782	
Europe	161	67 (41.6)	94 (58.4)	NE (2.1, NE)	161	66 (41.0)	95 (59.0)	9.0 (2.7, NE)	0.956 (0.680, 1.343)	0.7933	
Asia/Other Regions	88	41 (46.6)	47 (53.4)	4.5 (2.1, NE)	89	33 (37.1)	56 (62.9)	NE (3.7, NE)	1.289 (0.815, 2.038)	0.2768	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0192
< 40x10^9/L	132	53 (40.2)	79 (59.8)	NE (2.8, NE)	133	67 (50.4)	66 (49.6)	3.4 (1.6, NE)	0.760 (0.530, 1.090)	0.1328	
≥ 40x10^9/L	133	63 (47.4)	70 (52.6)	3.7 (2.1, NE)	135	43 (31.9)	92 (68.1)	NE (NE, NE)	1.416 (0.961, 2.087)	0.0762	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5720
Daunorubicin	123	60 (48.8)	63 (51.2)	3.5 (1.7, 18.9)	94	42 (44.7)	52 (55.3)	3.7 (1.6, NE)	1.064 (0.717, 1.580)	0.7542	
Idarubicin	142	56 (39.4)	86 (60.6)	NE (2.6, NE)	171	67 (39.2)	104 (60.8)	NE (3.6, NE)	0.940 (0.659, 1.341)	0.7333	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.1682
Favorable	13	5 (38.5)	8 (61.5)	NE (0.7, NE)	19	13 (68.4)	6 (31.6)	1.2 (0.2, NE)	0.427 (0.152, 1.201)	0.0976	
Intermediate	195	82 (42.1)	113 (57.9)	5.7 (2.8, NE)	190	76 (40.0)	114 (60.0)	9.0 (3.0, NE)	0.970 (0.710, 1.326)	0.8534	
Unfavorable	19	11 (57.9)	8 (42.1)	2.5 (0.1, NE)	27	9 (33.3)	18 (66.7)	NE (2.1, NE)	2.034 (0.842, 4.913)	0.1114	
Unknown	38	18 (47.4)	20 (52.6)	2.3 (1.2, NE)	31	12 (38.7)	19 (61.3)	NE (1.5, NE)	1.243 (0.598, 2.583)	0.5517	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6046
0 - Fully Active	87	38 (43.7)	49 (56.3)	NE (2.1, NE)	97	45 (46.4)	52 (53.6)	5.2 (2.3, NE)	0.861 (0.559, 1.327)	0.4964	
1 - Restricted in Physically Strenuous Activity	133	61 (45.9)	72 (54.1)	3.9 (2.0, NE)	134	52 (38.8)	82 (61.2)	NE (3.7, NE)	1.129 (0.780, 1.635)	0.5150	
2 - Ambulatory and Capable of All Selfcare	45	17 (37.8)	28 (62.2)	NE (1.6, NE)	36	13 (36.1)	23 (63.9)	7.1 (1.5, NE)	1.162 (0.563, 2.398)	0.6775	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany) Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.0129
≥3 to ≤25%	94	33 (35.1)	61 (64.9)	NE (2.6, NE)	98	48 (49.0)	50 (51.0)	2.7 (1.5, NE)	0.616 (0.395, 0.961)	0.0310	
>25% to ≤50%	141	69 (48.9)	72 (51.1)	3.5 (1.9, 18.9)	136	50 (36.8)	86 (63.2)	NE (3.7, NE)	1.416 (0.984, 2.038)	0.0592	
>50%	29	14 (48.3)	15 (51.7)	NE (1.6, NE)	34	12 (35.3)	22 (64.7)	4.0 (2.7, NE)	1.177 (0.543, 2.548)	0.6822	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1992
Yes	139	55 (39.6)	84 (60.4)	NE (3.5, NE)	137	60 (43.8)	77 (56.2)	9.0 (2.7, NE)	0.866 (0.601, 1.249)	0.4454	
No	116	60 (51.7)	56 (48.3)	2.1 (1.7, 4.2)	120	48 (40.0)	72 (60.0)	NE (1.6, NE)	1.234 (0.844, 1.805)	0.2758	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Febrile neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7467
≤60	164	75 (45.7)	89 (54.3)	4.2 (2.2, NE)	163	68 (41.7)	95 (58.3)	5.2 (3.0, NE)	1.055 (0.759, 1.465)	0.7489	
>60	101	41 (40.6)	60 (59.4)	18.9 (2.0, NE)	105	42 (40.0)	63 (60.0)	NE (1.8, NE)	0.967 (0.629, 1.488)	0.8858	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5303
<60	159	28 (17.6)	131 (82.4)	NE (NE, NE)	160	15 (9.4)	145 (90.6)	NE (NE, NE)	1.600 (0.853, 3.001)	0.1391	
≥60 - <65	37	8 (21.6)	29 (78.4)	31.5 (13.2, NE)	43	3 (7.0)	40 (93.0)	NE (NE, NE)	2.947 (0.760, 11.430)	0.1031	
≥65	69	12 (17.4)	57 (82.6)	24.6 (11.6, NE)	65	5 (7.7)	60 (92.3)	NE (NE, NE)	3.216 (1.110, 9.317)	0.0235	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.1163
Male	124	19 (15.3)	105 (84.7)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	4.117 (1.399, 12.116)	0.0053	
Female	141	29 (20.6)	112 (79.4)	31.5 (17.2, NE)	148	19 (12.8)	129 (87.2)	NE (38.7, NE)	1.549 (0.867, 2.767)	0.1364	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4052
White	157	31 (19.7)	126 (80.3)	38.8 (24.6, NE)	161	17 (10.6)	144 (89.4)	NE (38.7, NE)	1.715 (0.948, 3.102)	0.0711	
Non-white	108	17 (15.7)	91 (84.3)	NE (NE, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	2.575 (1.014, 6.537)	0.0391	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2667
North America	16	2 (12.5)	14 (87.5)	NE (10.5, NE)	18	2 (11.1)	16 (88.9)	NE (NE, NE)	1.355 (0.190, 9.682)	0.7609	
Europe	161	32 (19.9)	129 (80.1)	38.8 (24.6, NE)	161	18 (11.2)	143 (88.8)	NE (38.7, NE)	1.529 (0.857, 2.729)	0.1474	
Asia/Other Regions	88	14 (15.9)	74 (84.1)	NE (14.9, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	4.202 (1.206, 14.641)	0.0143	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5420
< 40x10^9/L	132	30 (22.7)	102 (77.3)	38.8 (13.7, NE)	133	14 (10.5)	119 (89.5)	NE (38.7, NE)	2.254 (1.195, 4.255)	0.0099	
≥ 40x10^9/L	133	18 (13.5)	115 (86.5)	NE (28.5, NE)	135	9 (6.7)	126 (93.3)	NE (NE, NE)	1.609 (0.721, 3.591)	0.2413	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3483
Daunorubicin	123	19 (15.4)	104 (84.6)	38.8 (28.5, NE)	94	9 (9.6)	85 (90.4)	NE (38.7, NE)	1.440 (0.649, 3.198)	0.3671	
Idarubicin	142	29 (20.4)	113 (79.6)	NE (24.6, NE)	171	14 (8.2)	157 (91.8)	NE (NE, NE)	2.315 (1.223, 4.384)	0.0079	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9521
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	37 (19.0)	158 (81.0)	NE (24.6, NE)	190	17 (8.9)	173 (91.1)	NE (NE, NE)	1.875 (1.055, 3.334)	0.0296	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (18.3, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	1.124 (0.143, 8.864)	0.9117	
Unknown	38	9 (23.7)	29 (76.3)	31.5 (11.5, NE)	31	4 (12.9)	27 (87.1)	NE (17.1, NE)	1.704 (0.522, 5.562)	0.3714	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1004
0 - Fully Active	87	15 (17.2)	72 (82.8)	NE (24.6, NE)	97	13 (13.4)	84 (86.6)	NE (38.7, NE)	1.085 (0.515, 2.287)	0.8290	
1 - Restricted in Physically Strenuous Activity	133	25 (18.8)	108 (81.2)	31.5 (26.8, NE)	134	7 (5.2)	127 (94.8)	NE (NE, NE)	3.575 (1.542, 8.289)	0.0015	
2 - Ambulatory and Capable of All Selfcare	45	8 (17.8)	37 (82.2)	NE (9.5, NE)	36	3 (8.3)	33 (91.7)	NE (NE, NE)	1.795 (0.471, 6.845)	0.3848	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5856
≥3 to ≤25%	94	17 (18.1)	77 (81.9)	38.8 (26.8, NE)	98	12 (12.2)	86 (87.8)	NE (38.7, NE)	1.468 (0.701, 3.076)	0.3062	
>25% to ≤50%	141	25 (17.7)	116 (82.3)	NE (18.3, NE)	136	9 (6.6)	127 (93.4)	NE (NE, NE)	2.461 (1.147, 5.279)	0.0168	
>50%	29	6 (20.7)	23 (79.3)	31.5 (7.6, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	1.872 (0.369, 9.485)	0.4422	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2883
Yes	139	27 (19.4)	112 (80.6)	NE (26.8, NE)	137	16 (11.7)	121 (88.3)	NE (NE, NE)	1.564 (0.842, 2.906)	0.1539	
No	116	21 (18.1)	95 (81.9)	NE (18.3, NE)	120	7 (5.8)	113 (94.2)	NE (38.7, NE)	2.777 (1.179, 6.545)	0.0148	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Neutropenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2186
≤60	164	28 (17.1)	136 (82.9)	NE (NE, NE)	163	15 (9.2)	148 (90.8)	NE (NE, NE)	1.570 (0.837, 2.945)	0.1560	
>60	101	20 (19.8)	81 (80.2)	24.6 (13.5, 38.8)	105	8 (7.6)	97 (92.4)	NE (NE, NE)	3.165 (1.380, 7.258)	0.0042	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9762
<60	159	13 (8.2)	146 (91.8)	NE (NE, NE)	160	16 (10.0)	144 (90.0)	NE (NE, NE)	0.689 (0.330, 1.438)	0.3185	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	5 (11.6)	38 (88.4)	NE (NE, NE)	0.745 (0.198, 2.800)	0.6615	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	5 (7.7)	60 (92.3)	NE (NE, NE)	0.808 (0.217, 3.011)	0.7504	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8638
Male	124	9 (7.3)	115 (92.7)	NE (NE, NE)	120	11 (9.2)	109 (90.8)	NE (NE, NE)	0.685 (0.283, 1.659)	0.4005	
Female	141	12 (8.5)	129 (91.5)	NE (NE, NE)	148	15 (10.1)	133 (89.9)	NE (NE, NE)	0.747 (0.349, 1.600)	0.4525	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6446
White	157	15 (9.6)	142 (90.4)	NE (NE, NE)	161	17 (10.6)	144 (89.4)	NE (NE, NE)	0.770 (0.383, 1.547)	0.4614	
Non-white	108	6 (5.6)	102 (94.4)	NE (NE, NE)	107	9 (8.4)	98 (91.6)	NE (NE, NE)	0.595 (0.212, 1.675)	0.3200	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7444
North America	16	0	16 (100)	NE (NE, NE)	18	5 (27.8)	13 (72.2)	NE (1.6, NE)	0.000 (0.000, NE)	0.0443	
Europe	161	14 (8.7)	147 (91.3)	NE (NE, NE)	161	16 (9.9)	145 (90.1)	NE (NE, NE)	0.737 (0.359, 1.516)	0.4058	
Asia/Other Regions	88	7 (8.0)	81 (92.0)	NE (NE, NE)	89	5 (5.6)	84 (94.4)	NE (NE, NE)	1.247 (0.394, 3.941)	0.7080	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5806
< 40x10^9/L	132	12 (9.1)	120 (90.9)	NE (NE, NE)	133	14 (10.5)	119 (89.5)	NE (NE, NE)	0.838 (0.387, 1.815)	0.6537	
≥ 40x10^9/L	133	9 (6.8)	124 (93.2)	NE (NE, NE)	135	12 (8.9)	123 (91.1)	NE (NE, NE)	0.603 (0.253, 1.437)	0.2488	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5309
Daunorubicin	123	10 (8.1)	113 (91.9)	NE (NE, NE)	94	7 (7.4)	87 (92.6)	NE (NE, NE)	0.956 (0.363, 2.519)	0.9279	
Idarubicin	142	11 (7.7)	131 (92.3)	NE (NE, NE)	171	18 (10.5)	153 (89.5)	NE (NE, NE)	0.641 (0.302, 1.360)	0.2429	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9995
Favorable	13	0	13 (100)	NE (NE, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	0.000 (0.000, NE)	0.2595	
Intermediate	195	16 (8.2)	179 (91.8)	NE (NE, NE)	190	18 (9.5)	172 (90.5)	NE (NE, NE)	0.734 (0.374, 1.442)	0.3678	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (6.4, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.647 (0.057, 7.303)	0.7228	
Unknown	38	4 (10.5)	34 (89.5)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (NE, NE)	0.775 (0.192, 3.122)	0.7189	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2298
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	12 (12.4)	85 (87.6)	NE (NE, NE)	0.317 (0.102, 0.986)	0.0363	
1 - Restricted in Physically Strenuous Activity	133	11 (8.3)	122 (91.7)	NE (NE, NE)	134	10 (7.5)	124 (92.5)	NE (NE, NE)	0.987 (0.418, 2.329)	0.9751	
2 - Ambulatory and Capable of All Selfcare	45	6 (13.3)	39 (86.7)	NE (17.1, NE)	36	4 (11.1)	32 (88.9)	NE (NE, NE)	0.922 (0.253, 3.364)	0.9027	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8493
≥3 to ≤25%	94	8 (8.5)	86 (91.5)	NE (NE, NE)	98	10 (10.2)	88 (89.8)	NE (NE, NE)	0.794 (0.313, 2.014)	0.6263	
>25% to ≤50%	141	9 (6.4)	132 (93.6)	NE (NE, NE)	136	11 (8.1)	125 (91.9)	NE (NE, NE)	0.691 (0.285, 1.673)	0.4088	
>50%	29	3 (10.3)	26 (89.7)	NE (11.5, NE)	34	5 (14.7)	29 (85.3)	NE (NE, NE)	0.540 (0.125, 2.334)	0.4030	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0213
Yes	139	10 (7.2)	129 (92.8)	NE (NE, NE)	137	21 (15.3)	116 (84.7)	NE (NE, NE)	0.415 (0.195, 0.884)	0.0186	
No	116	9 (7.8)	107 (92.2)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	2.090 (0.643, 6.796)	0.2100	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Thrombocytopenia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9606
≤60	164	14 (8.5)	150 (91.5)	NE (NE, NE)	163	16 (9.8)	147 (90.2)	NE (NE, NE)	0.732 (0.356, 1.507)	0.3958	
>60	101	7 (6.9)	94 (93.1)	NE (NE, NE)	105	10 (9.5)	95 (90.5)	NE (NE, NE)	0.692 (0.263, 1.820)	0.4534	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9998
<60	159	9 (5.7)	150 (94.3)	NE (NE, NE)	160	10 (6.3)	150 (93.8)	NE (NE, NE)	0.782 (0.316, 1.932)	0.5921	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	0.760 (0.169, 3.421)	0.7198	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	0	65 (100)	NE (NE, NE)	NE (0.000, NE)	0.0836	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4863
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	0.740 (0.248, 2.212)	0.5874	
Female	141	9 (6.4)	132 (93.6)	NE (NE, NE)	148	7 (4.7)	141 (95.3)	NE (NE, NE)	1.260 (0.469, 3.389)	0.6462	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5765
White	157	10 (6.4)	147 (93.6)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	1.145 (0.451, 2.910)	0.7759	
Non-white	108	5 (4.6)	103 (95.4)	NE (NE, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	0.780 (0.238, 2.559)	0.6808	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5426
North America	16	1 (6.3)	15 (93.8)	NE (1.8, NE)	18	3 (16.7)	15 (83.3)	NE (3.0, NE)	0.547 (0.056, 5.363)	0.5990	
Europe	161	8 (5.0)	153 (95.0)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	0.871 (0.326, 2.328)	0.7838	
Asia/Other Regions	88	6 (6.8)	82 (93.2)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	2.019 (0.504, 8.080)	0.3108	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9664
< 40x10^9/L	132	7 (5.3)	125 (94.7)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	1.037 (0.363, 2.958)	0.9465	
≥ 40x10^9/L	133	8 (6.0)	125 (94.0)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	0.954 (0.344, 2.650)	0.9278	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2244
Daunorubicin	123	7 (5.7)	116 (94.3)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	2.321 (0.480, 11.210)	0.2808	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	11 (6.4)	160 (93.6)	NE (NE, NE)	0.819 (0.329, 2.038)	0.6666	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8323
Favorable	13	0	13 (100)	NE (NE, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	0.000 (0.000, NE)	0.2595	
Intermediate	195	12 (6.2)	183 (93.8)	NE (NE, NE)	190	8 (4.2)	182 (95.8)	NE (NE, NE)	1.259 (0.513, 3.088)	0.6143	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.502 (0.094, 24.044)	0.7721	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	0.588 (0.098, 3.519)	0.5505	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7557
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	6 (6.2)	91 (93.8)	NE (NE, NE)	0.836 (0.254, 2.748)	0.7679	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	7 (5.2)	127 (94.8)	NE (NE, NE)	0.928 (0.325, 2.650)	0.8888	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	2.011 (0.200, 20.243)	0.5484	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9017
≥3 to ≤25%	94	7 (7.4)	87 (92.6)	NE (NE, NE)	98	8 (8.2)	90 (91.8)	NE (NE, NE)	0.895 (0.324, 2.472)	0.8309	
>25% to ≤50%	141	7 (5.0)	134 (95.0)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	1.211 (0.383, 3.832)	0.7449	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	1.193 (0.075, 19.078)	0.9005	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0636
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	11 (8.0)	126 (92.0)	NE (NE, NE)	0.582 (0.225, 1.506)	0.2592	
No	116	7 (6.0)	109 (94.0)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	3.214 (0.667, 15.491)	0.1239	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Blood and lymphatic system disorders; PT: Anaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3550
≤60	164	9 (5.5)	155 (94.5)	NE (NE, NE)	163	10 (6.1)	153 (93.9)	NE (NE, NE)	0.767 (0.310, 1.896)	0.5638	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	4 (3.8)	101 (96.2)	NE (NE, NE)	1.578 (0.445, 5.598)	0.4758	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6174
<60	159	81 (50.9)	78 (49.1)	5.5 (2.8, 17.4)	160	81 (50.6)	79 (49.4)	4.5 (2.4, 5.8)	0.877 (0.644, 1.194)	0.4106	
≥60 - <65	37	18 (48.6)	19 (51.4)	4.4 (1.8, NE)	43	18 (41.9)	25 (58.1)	6.3 (4.0, NE)	1.127 (0.585, 2.170)	0.7294	
≥65	69	41 (59.4)	28 (40.6)	2.3 (1.1, 15.7)	65	36 (55.4)	29 (44.6)	3.1 (1.4, 6.9)	1.079 (0.688, 1.691)	0.7403	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7956
Male	124	66 (53.2)	58 (46.8)	3.9 (1.8, 12.9)	120	63 (52.5)	57 (47.5)	4.0 (2.5, 5.4)	0.929 (0.658, 1.313)	0.6764	
Female	141	74 (52.5)	67 (47.5)	4.3 (2.2, 19.3)	148	72 (48.6)	76 (51.4)	4.7 (3.2, 16.7)	1.004 (0.726, 1.389)	0.9733	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7606
White	157	83 (52.9)	74 (47.1)	3.3 (2.0, 17.4)	161	80 (49.7)	81 (50.3)	4.5 (3.1, 6.9)	0.998 (0.734, 1.357)	0.9959	
Non-white	108	57 (52.8)	51 (47.2)	4.6 (2.0, 19.0)	107	55 (51.4)	52 (48.6)	4.4 (2.2, 6.3)	0.923 (0.637, 1.338)	0.6765	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9799
North America	16	9 (56.3)	7 (43.8)	2.8 (0.3, NE)	18	11 (61.1)	7 (38.9)	3.2 (0.4, NE)	0.985 (0.406, 2.390)	0.9870	
Europe	161	85 (52.8)	76 (47.2)	3.3 (2.1, 12.9)	161	81 (50.3)	80 (49.7)	4.5 (3.3, 5.5)	0.978 (0.721, 1.326)	0.8919	
Asia/Other Regions	88	46 (52.3)	42 (47.7)	7.7 (2.0, 26.0)	89	43 (48.3)	46 (51.7)	3.6 (1.9, NE)	0.965 (0.636, 1.463)	0.8720	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.8893
< 40x10^9/L	132	63 (47.7)	69 (52.3)	6.1 (2.8, 26.0)	133	64 (48.1)	69 (51.9)	5.1 (3.9, NE)	0.940 (0.664, 1.332)	0.7284	
≥ 40x10^9/L	133	77 (57.9)	56 (42.1)	2.8 (1.7, 7.7)	135	71 (52.6)	64 (47.4)	3.5 (1.9, 4.7)	0.986 (0.714, 1.363)	0.9427	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7333
Daunorubicin	123	62 (50.4)	61 (49.6)	3.4 (2.1, 26.0)	94	45 (47.9)	49 (52.1)	4.7 (1.5, NE)	0.926 (0.631, 1.360)	0.6996	
Idarubicin	142	78 (54.9)	64 (45.1)	4.3 (2.0, 15.7)	171	89 (52.0)	82 (48.0)	3.9 (3.0, 5.8)	0.991 (0.731, 1.344)	0.9522	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)			Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.0912
Favorable	13	8 (61.5)	5 (38.5)	2.9 (0.3, 26.0)	19	7 (36.8)	12 (63.2)	NE (4.6, NE)	2.723 (0.971, 7.635)	0.0497	
Intermediate	195	101 (51.8)	94 (48.2)	4.0 (2.2, 17.4)	190	94 (49.5)	96 (50.5)	4.0 (2.7, 5.1)	0.918 (0.692, 1.216)	0.5536	
Unfavorable	19	8 (42.1)	11 (57.9)	6.1 (2.6, NE)	27	17 (63.0)	10 (37.0)	5.4 (0.2, 6.3)	0.532 (0.229, 1.235)	0.1358	
Unknown	38	23 (60.5)	15 (39.5)	2.8 (0.6, 26.5)	31	16 (51.6)	15 (48.4)	4.5 (0.8, NE)	1.269 (0.669, 2.405)	0.4502	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7519
0 - Fully Active	87	45 (51.7)	42 (48.3)	6.1 (2.8, 26.5)	97	49 (50.5)	48 (49.5)	4.6 (3.1, 16.7)	0.841 (0.560, 1.263)	0.4097	
1 - Restricted in Physically Strenuous Activity	133	70 (52.6)	63 (47.4)	3.3 (2.0, 15.7)	134	66 (49.3)	68 (50.7)	4.7 (2.7, 10.2)	1.049 (0.749, 1.468)	0.7785	
2 - Ambulatory and Capable of All Selfcare	45	25 (55.6)	20 (44.4)	1.8 (0.3, NE)	36	20 (55.6)	16 (44.4)	2.6 (0.4, NE)	0.970 (0.536, 1.756)	0.9072	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6341
≥3 to ≤25%	94	46 (48.9)	48 (51.1)	5.5 (1.8, NE)	98	44 (44.9)	54 (55.1)	5.3 (3.5, NE)	1.122 (0.742, 1.697)	0.5900	
>25% to ≤50%	141	77 (54.6)	64 (45.4)	3.9 (2.1, 9.9)	136	74 (54.4)	62 (45.6)	3.6 (2.2, 5.1)	0.868 (0.631, 1.196)	0.3931	
>50%	29	17 (58.6)	12 (41.4)	2.6 (0.8, NE)	34	17 (50.0)	17 (50.0)	4.7 (1.0, NE)	1.047 (0.534, 2.054)	0.8860	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1712
Yes	139	74 (53.2)	65 (46.8)	4.4 (2.0, 26.5)	137	76 (55.5)	61 (44.5)	4.0 (2.5, 5.3)	0.859 (0.623, 1.184)	0.3529	
No	116	60 (51.7)	56 (48.3)	3.4 (2.0, 7.7)	120	50 (41.7)	70 (58.3)	6.3 (3.2, NE)	1.211 (0.832, 1.763)	0.3158	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3684
≤60	164	84 (51.2)	80 (48.8)	4.9 (2.6, 17.4)	163	81 (49.7)	82 (50.3)	4.6 (2.7, 5.8)	0.894 (0.658, 1.213)	0.4792	
>60	101	56 (55.4)	45 (44.6)	3.3 (1.6, 15.7)	105	54 (51.4)	51 (48.6)	4.5 (2.6, 10.2)	1.115 (0.767, 1.621)	0.5758	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7517
<60	159	18 (11.3)	141 (88.7)	NE (NE, NE)	160	20 (12.5)	140 (87.5)	NE (NE, NE)	0.821 (0.433, 1.557)	0.5465	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	5 (11.6)	38 (88.4)	NE (NE, NE)	0.665 (0.159, 2.785)	0.5745	
≥65	69	10 (14.5)	59 (85.5)	NE (15.7, NE)	65	9 (13.8)	56 (86.2)	NE (NE, NE)	1.131 (0.459, 2.785)	0.7887	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4818
Male	124	16 (12.9)	108 (87.1)	NE (NE, NE)	120	14 (11.7)	106 (88.3)	NE (NE, NE)	1.050 (0.512, 2.153)	0.8936	
Female	141	15 (10.6)	126 (89.4)	NE (NE, NE)	148	20 (13.5)	128 (86.5)	NE (NE, NE)	0.737 (0.377, 1.441)	0.3720	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9321
White	157	18 (11.5)	139 (88.5)	NE (NE, NE)	161	20 (12.4)	141 (87.6)	NE (NE, NE)	0.849 (0.449, 1.608)	0.6180	
Non-white	108	13 (12.0)	95 (88.0)	NE (NE, NE)	107	14 (13.1)	93 (86.9)	NE (NE, NE)	0.899 (0.422, 1.912)	0.7802	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5440
North America	16	2 (12.5)	14 (87.5)	NE (17.4, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	2.435 (0.220, 26.885)	0.4531	
Europe	161	16 (9.9)	145 (90.1)	NE (NE, NE)	161	20 (12.4)	141 (87.6)	NE (NE, NE)	0.732 (0.379, 1.415)	0.3514	
Asia/Other Regions	88	13 (14.8)	75 (85.2)	NE (NE, NE)	89	13 (14.6)	76 (85.4)	NE (NE, NE)	0.968 (0.448, 2.089)	0.9323	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5597
< 40x10^9/L	132	11 (8.3)	121 (91.7)	NE (NE, NE)	133	15 (11.3)	118 (88.7)	NE (NE, NE)	0.716 (0.329, 1.559)	0.3971	
≥ 40x10^9/L	133	20 (15.0)	113 (85.0)	NE (NE, NE)	135	19 (14.1)	116 (85.9)	NE (NE, NE)	0.989 (0.527, 1.855)	0.9748	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9721
Daunorubicin	123	14 (11.4)	109 (88.6)	NE (NE, NE)	94	11 (11.7)	83 (88.3)	NE (NE, NE)	0.883 (0.400, 1.948)	0.7580	
Idarubicin	142	17 (12.0)	125 (88.0)	NE (NE, NE)	171	22 (12.9)	149 (87.1)	NE (NE, NE)	0.894 (0.475, 1.685)	0.7289	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	1 (7.7)	12 (92.3)	NE (5.5, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.1069	
Intermediate	195	24 (12.3)	171 (87.7)	NE (NE, NE)	190	24 (12.6)	166 (87.4)	NE (NE, NE)	0.868 (0.492, 1.530)	0.6257	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	3 (11.1)	24 (88.9)	NE (NE, NE)	0.000 (0.000, NE)	0.1571	
Unknown	38	6 (15.8)	32 (84.2)	NE (NE, NE)	31	6 (19.4)	25 (80.6)	NE (NE, NE)	0.892 (0.287, 2.769)	0.8402	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8808
0 - Fully Active	87	7 (8.0)	80 (92.0)	NE (NE, NE)	97	9 (9.3)	88 (90.7)	NE (NE, NE)	0.780 (0.290, 2.099)	0.6215	
1 - Restricted in Physically Strenuous Activity	133	13 (9.8)	120 (90.2)	NE (NE, NE)	134	17 (12.7)	117 (87.3)	NE (NE, NE)	0.736 (0.357, 1.516)	0.4036	
2 - Ambulatory and Capable of All Selfcare	45	11 (24.4)	34 (75.6)	NE (19.3, NE)	36	8 (22.2)	28 (77.8)	NE (NE, NE)	1.059 (0.422, 2.655)	0.8992	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2297
≥3 to ≤25%	94	12 (12.8)	82 (87.2)	NE (NE, NE)	98	9 (9.2)	89 (90.8)	NE (NE, NE)	1.412 (0.595, 3.353)	0.4316	
>25% to ≤50%	141	17 (12.1)	124 (87.9)	NE (NE, NE)	136	19 (14.0)	117 (86.0)	NE (NE, NE)	0.822 (0.427, 1.583)	0.5571	
>50%	29	2 (6.9)	27 (93.1)	NE (19.3, NE)	34	6 (17.6)	28 (82.4)	NE (NE, NE)	0.315 (0.062, 1.604)	0.1426	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3587
Yes	139	18 (12.9)	121 (87.1)	NE (NE, NE)	137	18 (13.1)	119 (86.9)	NE (NE, NE)	0.954 (0.496, 1.834)	0.8876	
No	116	8 (6.9)	108 (93.1)	NE (NE, NE)	120	13 (10.8)	107 (89.2)	NE (NE, NE)	0.577 (0.239, 1.394)	0.2164	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Pneumonia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6847
≤60	164	18 (11.0)	146 (89.0)	NE (NE, NE)	163	20 (12.3)	143 (87.7)	NE (NE, NE)	0.809 (0.427, 1.532)	0.5151	
>60	101	13 (12.9)	88 (87.1)	NE (NE, NE)	105	14 (13.3)	91 (86.7)	NE (NE, NE)	0.969 (0.455, 2.062)	0.9354	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6583
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	15 (9.4)	145 (90.6)	NE (NE, NE)	0.429 (0.175, 1.054)	0.0573	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	0.538 (0.098, 2.945)	0.4674	
≥65	69	6 (8.7)	63 (91.3)	NE (NE, NE)	65	7 (10.8)	58 (89.2)	NE (NE, NE)	0.833 (0.280, 2.478)	0.7411	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7826
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	11 (9.2)	109 (90.8)	NE (NE, NE)	0.499 (0.184, 1.352)	0.1633	
Female	141	9 (6.4)	132 (93.6)	NE (NE, NE)	148	15 (10.1)	133 (89.9)	NE (NE, NE)	0.602 (0.264, 1.377)	0.2246	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4207
White	157	11 (7.0)	146 (93.0)	NE (NE, NE)	161	16 (9.9)	145 (90.1)	NE (NE, NE)	0.690 (0.320, 1.486)	0.3395	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	10 (9.3)	97 (90.7)	NE (NE, NE)	0.375 (0.118, 1.197)	0.0849	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9976
North America	16	0	16 (100)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	0.000 (0.000, NE)	0.3458	
Europe	161	11 (6.8)	150 (93.2)	NE (NE, NE)	161	18 (11.2)	143 (88.8)	NE (NE, NE)	0.576 (0.272, 1.221)	0.1450	
Asia/Other Regions	88	4 (4.5)	84 (95.5)	NE (NE, NE)	89	7 (7.9)	82 (92.1)	NE (NE, NE)	0.550 (0.161, 1.880)	0.3332	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.1515
< 40x10^9/L	132	10 (7.6)	122 (92.4)	NE (NE, NE)	133	12 (9.0)	121 (91.0)	NE (NE, NE)	0.848 (0.366, 1.962)	0.6991	
≥ 40x10^9/L	133	5 (3.8)	128 (96.2)	NE (NE, NE)	135	14 (10.4)	121 (89.6)	NE (NE, NE)	0.319 (0.115, 0.888)	0.0212	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4489
Daunorubicin	123	8 (6.5)	115 (93.5)	NE (NE, NE)	94	8 (8.5)	86 (91.5)	NE (NE, NE)	0.749 (0.281, 1.997)	0.5627	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	18 (10.5)	153 (89.5)	NE (NE, NE)	0.439 (0.183, 1.053)	0.0580	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8050
Favorable	13	1 (7.7)	12 (92.3)	NE (1.8, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	0.926 (0.083, 10.298)	0.9500	
Intermediate	195	10 (5.1)	185 (94.9)	NE (NE, NE)	190	14 (7.4)	176 (92.6)	NE (NE, NE)	0.652 (0.290, 1.470)	0.2995	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	6 (22.2)	21 (77.8)	NE (5.8, NE)	0.223 (0.027, 1.854)	0.1283	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (NE, NE)	0.624 (0.140, 2.787)	0.5360	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5823
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	7 (7.2)	90 (92.8)	NE (NE, NE)	0.623 (0.182, 2.130)	0.4465	
1 - Restricted in Physically Strenuous Activity	133	9 (6.8)	124 (93.2)	NE (NE, NE)	134	13 (9.7)	121 (90.3)	NE (NE, NE)	0.659 (0.281, 1.541)	0.3332	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	6 (16.7)	30 (83.3)	NE (5.2, NE)	0.261 (0.052, 1.303)	0.0784	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9136
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	6 (6.1)	92 (93.9)	NE (NE, NE)	0.518 (0.129, 2.070)	0.3427	
>25% to ≤50%	141	12 (8.5)	129 (91.5)	NE (NE, NE)	136	15 (11.0)	121 (89.0)	NE (NE, NE)	0.735 (0.344, 1.572)	0.4267	
>50%	29	0	29 (100)	NE (NE, NE)	34	5 (14.7)	29 (85.3)	NE (NE, NE)	0.000 (0.000, NE)	0.0227	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9914
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	13 (9.5)	124 (90.5)	NE (NE, NE)	0.507 (0.202, 1.271)	0.1398	
No	116	7 (6.0)	109 (94.0)	NE (NE, NE)	120	13 (10.8)	107 (89.2)	NE (NE, NE)	0.529 (0.211, 1.326)	0.1667	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Sepsis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6366
≤60	164	8 (4.9)	156 (95.1)	NE (NE, NE)	163	15 (9.2)	148 (90.8)	NE (NE, NE)	0.485 (0.205, 1.144)	0.0911	
>60	101	7 (6.9)	94 (93.1)	NE (NE, NE)	105	11 (10.5)	94 (89.5)	NE (NE, NE)	0.664 (0.257, 1.712)	0.3936	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8474
<60	159	5 (3.1)	154 (96.9)	NE (NE, NE)	160	5 (3.1)	155 (96.9)	NE (NE, NE)	0.978 (0.283, 3.381)	0.9719	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.1285	
≥65	69	5 (7.2)	64 (92.8)	NE (26.5, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	1.696 (0.405, 7.101)	0.4644	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7665
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.842 (0.337, 10.071)	0.4740	
Female	141	8 (5.7)	133 (94.3)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	1.406 (0.488, 4.053)	0.5261	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8597
White	157	7 (4.5)	150 (95.5)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	1.423 (0.451, 4.486)	0.5450	
Non-white	108	5 (4.6)	103 (95.4)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	1.601 (0.382, 6.708)	0.5157	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6253
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.2888	
Europe	161	6 (3.7)	155 (96.3)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	0.970 (0.313, 3.009)	0.9571	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	2.481 (0.481, 12.791)	0.2612	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0222
< 40x10^9/L	132	8 (6.1)	124 (93.9)	NE (NE, NE)	133	1 (0.8)	132 (99.2)	NE (NE, NE)	8.774 (1.097, 70.188)	0.0134	
≥ 40x10^9/L	133	4 (3.0)	129 (97.0)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	0.511 (0.149, 1.754)	0.2772	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9898
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	0	94 (100)	NE (NE, NE)	NE (0.000, NE)	0.2153	
Idarubicin	142	10 (7.0)	132 (93.0)	NE (NE, NE)	171	8 (4.7)	163 (95.3)	NE (NE, NE)	1.472 (0.580, 3.732)	0.4127	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9991
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	6 (3.2)	184 (96.8)	NE (NE, NE)	1.428 (0.508, 4.012)	0.4977	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (4.3, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.414 (0.088, 22.637)	0.8055	
Unknown	38	2 (5.3)	36 (94.7)	NE (26.5, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	1.551 (0.138, 17.481)	0.7206	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6453
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	1.448 (0.240, 8.729)	0.6844	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	1.010 (0.292, 3.489)	0.9874	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	3.287 (0.367, 29.432)	0.2594	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9992
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	1.429 (0.320, 6.388)	0.6386	
>25% to ≤50%	141	8 (5.7)	133 (94.3)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	1.527 (0.499, 4.671)	0.4548	
>50%	29	0	29 (100)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4545
Yes	139	8 (5.8)	131 (94.2)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	1.949 (0.586, 6.479)	0.2679	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.983 (0.246, 3.934)	0.9812	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Septic shock

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4875
≤60	164	6 (3.7)	158 (96.3)	NE (NE, NE)	163	5 (3.1)	158 (96.9)	NE (NE, NE)	1.155 (0.352, 3.786)	0.8117	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	2.198 (0.550, 8.795)	0.2529	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6753
<60	159	4 (2.5)	155 (97.5)	NE (NE, NE)	160	2 (1.3)	158 (98.8)	NE (NE, NE)	1.924 (0.352, 10.521)	0.4423	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	3.148 (0.325, 30.449)	0.2962	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	0.965 (0.195, 4.784)	0.9630	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8486
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.927 (0.353, 10.524)	0.4416	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	4 (2.7)	144 (97.3)	NE (NE, NE)	1.538 (0.434, 5.453)	0.5018	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5464
White	157	3 (1.9)	154 (98.1)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	2.948 (0.306, 28.421)	0.3264	
Non-white	108	7 (6.5)	101 (93.5)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	1.389 (0.441, 4.376)	0.5738	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8996
North America	16	2 (12.5)	14 (87.5)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	2.258 (0.205, 24.901)	0.4905	
Europe	161	2 (1.2)	159 (98.8)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	1.865 (0.169, 20.649)	0.6054	
Asia/Other Regions	88	6 (6.8)	82 (93.2)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	1.494 (0.421, 5.300)	0.5322	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0381
< 40x10^9/L	132	1 (0.8)	131 (99.2)	NE (NE, NE)	133	4 (3.0)	129 (97.0)	NE (NE, NE)	0.257 (0.029, 2.300)	0.1900	
≥ 40x10^9/L	133	9 (6.8)	124 (93.2)	NE (NE, NE)	135	2 (1.5)	133 (98.5)	NE (NE, NE)	4.396 (0.949, 20.374)	0.0386	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9901
Daunorubicin	123	3 (2.4)	120 (97.6)	NE (NE, NE)	94	0	94 (100)	NE (NE, NE)	NE (0.000, NE)	0.1291	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	6 (3.5)	165 (96.5)	NE (NE, NE)	1.391 (0.467, 4.143)	0.5512	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.2207	
Intermediate	195	7 (3.6)	188 (96.4)	NE (NE, NE)	190	6 (3.2)	184 (96.8)	NE (NE, NE)	1.081 (0.363, 3.222)	0.8880	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (4.3, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.2482	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.3600	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5670
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	1 (1.0)	96 (99.0)	NE (NE, NE)	3.149 (0.327, 30.305)	0.2946	
1 - Restricted in Physically Strenuous Activity	133	4 (3.0)	129 (97.0)	NE (NE, NE)	134	5 (3.7)	129 (96.3)	NE (NE, NE)	0.794 (0.213, 2.959)	0.7308	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.1113	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8608
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	1.359 (0.365, 5.062)	0.6458	
>25% to ≤50%	141	5 (3.5)	136 (96.5)	NE (NE, NE)	136	2 (1.5)	134 (98.5)	NE (NE, NE)	2.333 (0.452, 12.044)	0.2977	
>50%	29	0	29 (100)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5491
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	1.381 (0.438, 4.356)	0.5796	
No	116	3 (2.6)	113 (97.4)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	3.021 (0.314, 29.049)	0.3141	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Infections and infestations; PT: Bacteraemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5881
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	2 (1.2)	161 (98.8)	NE (NE, NE)	2.374 (0.460, 12.253)	0.2870	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	4 (3.8)	101 (96.2)	NE (NE, NE)	1.332 (0.358, 4.962)	0.6692	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2512
<60	159	45 (28.3)	114 (71.7)	NE (NE, NE)	160	37 (23.1)	123 (76.9)	NE (NE, NE)	1.161 (0.751, 1.795)	0.5001	
≥60 - <65	37	9 (24.3)	28 (75.7)	NE (NE, NE)	43	13 (30.2)	30 (69.8)	NE (NE, NE)	0.747 (0.318, 1.753)	0.5015	
≥65	69	30 (43.5)	39 (56.5)	10.1 (1.9, NE)	65	21 (32.3)	44 (67.7)	NE (7.3, NE)	1.621 (0.926, 2.837)	0.0887	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3146
Male	124	38 (30.6)	86 (69.4)	NE (26.8, NE)	120	26 (21.7)	94 (78.3)	NE (NE, NE)	1.434 (0.870, 2.364)	0.1554	
Female	141	46 (32.6)	95 (67.4)	NE (12.2, NE)	148	45 (30.4)	103 (69.6)	NE (NE, NE)	1.032 (0.684, 1.558)	0.8696	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.0505
White	157	39 (24.8)	118 (75.2)	NE (NE, NE)	161	44 (27.3)	117 (72.7)	NE (NE, NE)	0.889 (0.578, 1.370)	0.5970	
Non-white	108	45 (41.7)	63 (58.3)	11.3 (4.9, NE)	107	27 (25.2)	80 (74.8)	NE (NE, NE)	1.666 (1.033, 2.685)	0.0341	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0028
North America	16	5 (31.3)	11 (68.8)	16.7 (1.9, NE)	18	13 (72.2)	5 (27.8)	2.1 (0.2, 9.1)	0.306 (0.108, 0.869)	0.0199	
Europe	161	41 (25.5)	120 (74.5)	NE (NE, NE)	161	40 (24.8)	121 (75.2)	NE (NE, NE)	1.023 (0.661, 1.583)	0.9145	
Asia/Other Regions	88	38 (43.2)	50 (56.8)	8.0 (4.9, NE)	89	18 (20.2)	71 (79.8)	NE (NE, NE)	2.214 (1.263, 3.879)	0.0044	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6312
< 40x10^9/L	132	39 (29.5)	93 (70.5)	NE (NE, NE)	133	32 (24.1)	101 (75.9)	NE (NE, NE)	1.281 (0.802, 2.045)	0.2979	
≥ 40x10^9/L	133	45 (33.8)	88 (66.2)	NE (16.7, NE)	135	39 (28.9)	96 (71.1)	NE (NE, NE)	1.103 (0.718, 1.696)	0.6489	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9260
Daunorubicin	123	41 (33.3)	82 (66.7)	NE (8.0, NE)	94	25 (26.6)	69 (73.4)	NE (NE, NE)	1.179 (0.717, 1.940)	0.5133	
Idarubicin	142	43 (30.3)	99 (69.7)	NE (26.8, NE)	171	45 (26.3)	126 (73.7)	NE (NE, NE)	1.159 (0.762, 1.761)	0.4881	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.1839
Favorable	13	3 (23.1)	10 (76.9)	NE (5.7, NE)	19	6 (31.6)	13 (68.4)	NE (9.1, NE)	0.844 (0.209, 3.406)	0.8114	
Intermediate	195	63 (32.3)	132 (67.7)	NE (NE, NE)	190	51 (26.8)	139 (73.2)	NE (NE, NE)	1.176 (0.812, 1.702)	0.3877	
Unfavorable	19	8 (42.1)	11 (57.9)	4.9 (0.4, NE)	27	4 (14.8)	23 (85.2)	NE (12.7, NE)	3.460 (1.039, 11.526)	0.0319	
Unknown	38	10 (26.3)	28 (73.7)	NE (26.8, NE)	31	10 (32.3)	21 (67.7)	NE (2.2, NE)	0.765 (0.318, 1.840)	0.5515	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4796
0 - Fully Active	87	20 (23.0)	67 (77.0)	NE (NE, NE)	97	18 (18.6)	79 (81.4)	NE (NE, NE)	1.200 (0.634, 2.270)	0.5739	
1 - Restricted in Physically Strenuous Activity	133	47 (35.3)	86 (64.7)	NE (10.1, NE)	134	38 (28.4)	96 (71.6)	NE (NE, NE)	1.268 (0.827, 1.945)	0.2761	
2 - Ambulatory and Capable of All Selfcare	45	17 (37.8)	28 (62.2)	NE (2.0, NE)	36	15 (41.7)	21 (58.3)	NE (0.7, NE)	0.811 (0.405, 1.628)	0.5640	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.0489
≥3 to ≤25%	94	27 (28.7)	67 (71.3)	NE (26.8, NE)	98	27 (27.6)	71 (72.4)	NE (NE, NE)	1.012 (0.593, 1.726)	0.9635	
>25% to ≤50%	141	52 (36.9)	89 (63.1)	NE (8.0, NE)	136	33 (24.3)	103 (75.7)	NE (NE, NE)	1.599 (1.034, 2.474)	0.0331	
>50%	29	5 (17.2)	24 (82.8)	NE (12.2, NE)	34	11 (32.4)	23 (67.6)	NE (2.7, NE)	0.391 (0.134, 1.144)	0.0769	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4797
Yes	139	48 (34.5)	91 (65.5)	NE (26.8, NE)	137	46 (33.6)	91 (66.4)	NE (9.7, NE)	1.025 (0.684, 1.536)	0.8984	
No	116	33 (28.4)	83 (71.6)	NE (11.3, NE)	120	25 (20.8)	95 (79.2)	NE (NE, NE)	1.296 (0.770, 2.181)	0.3263	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9942
≤60	164	47 (28.7)	117 (71.3)	NE (NE, NE)	163	37 (22.7)	126 (77.3)	NE (NE, NE)	1.198 (0.778, 1.845)	0.4102	
>60	101	37 (36.6)	64 (63.4)	26.8 (10.1, NE)	105	34 (32.4)	71 (67.6)	NE (9.1, NE)	1.199 (0.753, 1.912)	0.4426	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8107
<60	159	27 (17.0)	132 (83.0)	NE (NE, NE)	160	24 (15.0)	136 (85.0)	NE (NE, NE)	1.078 (0.622, 1.871)	0.7862	
≥60 - <65	37	7 (18.9)	30 (81.1)	NE (NE, NE)	43	8 (18.6)	35 (81.4)	NE (NE, NE)	1.028 (0.373, 2.837)	0.9499	
≥65	69	16 (23.2)	53 (76.8)	NE (NE, NE)	65	12 (18.5)	53 (81.5)	NE (36.7, NE)	1.412 (0.667, 2.987)	0.3662	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9460
Male	124	19 (15.3)	105 (84.7)	NE (NE, NE)	120	16 (13.3)	104 (86.7)	NE (NE, NE)	1.185 (0.609, 2.305)	0.6192	
Female	141	31 (22.0)	110 (78.0)	NE (NE, NE)	148	28 (18.9)	120 (81.1)	NE (NE, NE)	1.137 (0.682, 1.896)	0.6154	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.0624
White	157	23 (14.6)	134 (85.4)	NE (NE, NE)	161	29 (18.0)	132 (82.0)	NE (NE, NE)	0.811 (0.469, 1.403)	0.4545	
Non-white	108	27 (25.0)	81 (75.0)	NE (NE, NE)	107	15 (14.0)	92 (86.0)	NE (NE, NE)	1.788 (0.951, 3.362)	0.0664	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.4429
North America	16	4 (25.0)	12 (75.0)	NE (1.9, NE)	18	4 (22.2)	14 (77.8)	36.7 (3.9, NE)	1.243 (0.309, 5.004)	0.7508	
Europe	161	24 (14.9)	137 (85.1)	NE (NE, NE)	161	26 (16.1)	135 (83.9)	NE (NE, NE)	0.917 (0.527, 1.598)	0.7608	
Asia/Other Regions	88	22 (25.0)	66 (75.0)	NE (26.1, NE)	89	14 (15.7)	75 (84.3)	NE (NE, NE)	1.579 (0.807, 3.087)	0.1767	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3497
< 40x10^9/L	132	24 (18.2)	108 (81.8)	NE (NE, NE)	133	18 (13.5)	115 (86.5)	NE (NE, NE)	1.410 (0.765, 2.599)	0.2680	
≥ 40x10^9/L	133	26 (19.5)	107 (80.5)	NE (NE, NE)	135	26 (19.3)	109 (80.7)	NE (36.7, NE)	0.970 (0.563, 1.672)	0.9166	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9360
Daunorubicin	123	25 (20.3)	98 (79.7)	NE (NE, NE)	94	16 (17.0)	78 (83.0)	NE (NE, NE)	1.145 (0.611, 2.147)	0.6709	
Idarubicin	142	25 (17.6)	117 (82.4)	NE (NE, NE)	171	27 (15.8)	144 (84.2)	NE (NE, NE)	1.130 (0.656, 1.948)	0.6575	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.2917
Favorable	13	3 (23.1)	10 (76.9)	26.1 (5.7, NE)	19	4 (21.1)	15 (78.9)	NE (9.7, NE)	1.871 (0.373, 9.383)	0.4389	
Intermediate	195	39 (20.0)	156 (80.0)	NE (NE, NE)	190	31 (16.3)	159 (83.7)	NE (NE, NE)	1.203 (0.751, 1.929)	0.4367	
Unfavorable	19	4 (21.1)	15 (78.9)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	3.338 (0.611, 18.239)	0.1421	
Unknown	38	4 (10.5)	34 (89.5)	NE (NE, NE)	31	7 (22.6)	24 (77.4)	NE (NE, NE)	0.465 (0.136, 1.588)	0.2104	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5326
0 - Fully Active	87	12 (13.8)	75 (86.2)	NE (NE, NE)	97	11 (11.3)	86 (88.7)	NE (NE, NE)	1.220 (0.538, 2.766)	0.6331	
1 - Restricted in Physically Strenuous Activity	133	27 (20.3)	106 (79.7)	NE (NE, NE)	134	22 (16.4)	112 (83.6)	NE (NE, NE)	1.264 (0.720, 2.221)	0.4127	
2 - Ambulatory and Capable of All Selfcare	45	11 (24.4)	34 (75.6)	NE (NE, NE)	36	11 (30.6)	25 (69.4)	NE (2.3, NE)	0.738 (0.319, 1.709)	0.4804	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3145
≥3 to ≤25%	94	18 (19.1)	76 (80.9)	NE (NE, NE)	98	16 (16.3)	82 (83.7)	NE (NE, NE)	1.197 (0.611, 2.348)	0.5992	
>25% to ≤50%	141	28 (19.9)	113 (80.1)	NE (NE, NE)	136	20 (14.7)	116 (85.3)	NE (NE, NE)	1.380 (0.777, 2.450)	0.2686	
>50%	29	4 (13.8)	25 (86.2)	NE (NE, NE)	34	8 (23.5)	26 (76.5)	NE (6.8, NE)	0.454 (0.136, 1.518)	0.1886	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9669
Yes	139	30 (21.6)	109 (78.4)	NE (NE, NE)	137	28 (20.4)	109 (79.6)	NE (NE, NE)	1.082 (0.646, 1.811)	0.7603	
No	116	18 (15.5)	98 (84.5)	NE (NE, NE)	120	16 (13.3)	104 (86.7)	NE (NE, NE)	1.094 (0.558, 2.147)	0.7936	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypokalaemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9951
≤60	164	29 (17.7)	135 (82.3)	NE (NE, NE)	163	24 (14.7)	139 (85.3)	NE (NE, NE)	1.145 (0.666, 1.968)	0.6218	
>60	101	21 (20.8)	80 (79.2)	NE (NE, NE)	105	20 (19.0)	85 (81.0)	NE (36.7, NE)	1.161 (0.629, 2.143)	0.6292	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6219
<60	159	9 (5.7)	150 (94.3)	NE (NE, NE)	160	9 (5.6)	151 (94.4)	NE (NE, NE)	0.984 (0.390, 2.480)	0.9747	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	0.836 (0.187, 3.738)	0.8147	
≥65	69	6 (8.7)	63 (91.3)	NE (26.8, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	2.102 (0.524, 8.438)	0.2842	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.0428
Male	124	11 (8.9)	113 (91.1)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	2.702 (0.860, 8.488)	0.0766	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	12 (8.1)	136 (91.9)	NE (NE, NE)	0.596 (0.235, 1.514)	0.2714	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7560
White	157	9 (5.7)	148 (94.3)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	1.023 (0.406, 2.579)	0.9607	
Non-white	108	9 (8.3)	99 (91.7)	NE (NE, NE)	107	7 (6.5)	100 (93.5)	NE (NE, NE)	1.271 (0.473, 3.412)	0.6344	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.0442
North America	16	2 (12.5)	14 (87.5)	NE (NE, NE)	18	8 (44.4)	10 (55.6)	4.8 (0.2, NE)	0.224 (0.047, 1.061)	0.0396	
Europe	161	8 (5.0)	153 (95.0)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	1.565 (0.511, 4.793)	0.4287	
Asia/Other Regions	88	8 (9.1)	80 (90.9)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	2.791 (0.740, 10.522)	0.1134	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6889
< 40x10^9/L	132	10 (7.6)	122 (92.4)	NE (NE, NE)	133	8 (6.0)	125 (94.0)	NE (NE, NE)	1.301 (0.513, 3.298)	0.5775	
≥ 40x10^9/L	133	8 (6.0)	125 (94.0)	NE (NE, NE)	135	8 (5.9)	127 (94.1)	NE (NE, NE)	0.984 (0.369, 2.628)	0.9755	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.0393
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	9 (9.6)	85 (90.4)	NE (NE, NE)	0.489 (0.174, 1.374)	0.1657	
Idarubicin	142	12 (8.5)	130 (91.5)	NE (NE, NE)	171	7 (4.1)	164 (95.9)	NE (NE, NE)	2.100 (0.826, 5.336)	0.1105	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8526
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	0.000 (0.000, NE)	0.4081	
Intermediate	195	16 (8.2)	179 (91.8)	NE (NE, NE)	190	12 (6.3)	178 (93.7)	NE (NE, NE)	1.283 (0.607, 2.713)	0.5134	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Unknown	38	2 (5.3)	36 (94.7)	NE (26.8, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	0.499 (0.083, 2.998)	0.4382	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9099
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	1.452 (0.325, 6.492)	0.6235	
1 - Restricted in Physically Strenuous Activity	133	10 (7.5)	123 (92.5)	NE (NE, NE)	134	10 (7.5)	124 (92.5)	NE (NE, NE)	1.013 (0.422, 2.434)	0.9783	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	3 (8.3)	33 (91.7)	NE (NE, NE)	1.051 (0.235, 4.696)	0.9480	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7325
≥3 to ≤25%	94	6 (6.4)	88 (93.6)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	1.586 (0.447, 5.622)	0.4719	
>25% to ≤50%	141	10 (7.1)	131 (92.9)	NE (NE, NE)	136	9 (6.6)	127 (93.4)	NE (NE, NE)	1.084 (0.440, 2.668)	0.8589	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	0.736 (0.123, 4.404)	0.7357	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6085
Yes	139	11 (7.9)	128 (92.1)	NE (NE, NE)	137	11 (8.0)	126 (92.0)	NE (NE, NE)	0.979 (0.424, 2.260)	0.9623	
No	116	7 (6.0)	109 (94.0)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	1.432 (0.454, 4.514)	0.5380	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Hypophosphataemia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8426
≤60	164	10 (6.1)	154 (93.9)	NE (NE, NE)	163	9 (5.5)	154 (94.5)	NE (NE, NE)	1.077 (0.437, 2.651)	0.8703	
>60	101	8 (7.9)	93 (92.1)	NE (NE, NE)	105	7 (6.7)	98 (93.3)	NE (NE, NE)	1.245 (0.451, 3.436)	0.6731	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.8560
<60	159	8 (5.0)	151 (95.0)	NE (NE, NE)	160	3 (1.9)	157 (98.1)	NE (NE, NE)	2.532 (0.670, 9.570)	0.1558	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	0.000 (0.000, NE)	0.3536	
≥65	69	5 (7.2)	64 (92.8)	NE (NE, NE)	65	1 (1.5)	64 (98.5)	NE (NE, NE)	4.960 (0.579, 42.468)	0.1042	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5435
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	1.853 (0.462, 7.424)	0.3760	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	2 (1.4)	146 (98.6)	NE (NE, NE)	3.520 (0.731, 16.963)	0.0941	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4636
White	157	5 (3.2)	152 (96.8)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	4.496 (0.523, 38.649)	0.1335	
Non-white	108	8 (7.4)	100 (92.6)	NE (NE, NE)	107	4 (3.7)	103 (96.3)	NE (NE, NE)	1.975 (0.594, 6.559)	0.2573	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9514
North America	16	1 (6.3)	15 (93.8)	NE (16.7, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.1967	
Europe	161	4 (2.5)	157 (97.5)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	1.812 (0.330, 9.943)	0.4876	
Asia/Other Regions	88	8 (9.1)	80 (90.9)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	2.681 (0.711, 10.111)	0.1295	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5363
< 40x10^9/L	132	3 (2.3)	129 (97.7)	NE (NE, NE)	133	2 (1.5)	131 (98.5)	NE (NE, NE)	1.532 (0.256, 9.179)	0.6377	
≥ 40x10^9/L	133	10 (7.5)	123 (92.5)	NE (NE, NE)	135	3 (2.2)	132 (97.8)	NE (NE, NE)	3.053 (0.837, 11.136)	0.0755	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8237
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	2.086 (0.420, 10.370)	0.3576	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	3 (1.8)	168 (98.2)	NE (NE, NE)	2.757 (0.712, 10.673)	0.1256	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9980
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	4 (2.1)	186 (97.9)	NE (NE, NE)	1.994 (0.613, 6.493)	0.2421	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.0830	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	1.763 (0.160, 19.453)	0.6391	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7068
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	0	97 (100)	NE (NE, NE)	NE (0.000, NE)	0.0216	
1 - Restricted in Physically Strenuous Activity	133	6 (4.5)	127 (95.5)	NE (NE, NE)	134	3 (2.2)	131 (97.8)	NE (NE, NE)	1.887 (0.471, 7.556)	0.3616	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.811 (0.114, 5.761)	0.8341	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9531
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	1 (1.0)	97 (99.0)	NE (NE, NE)	3.042 (0.316, 29.279)	0.3109	
>25% to ≤50%	141	10 (7.1)	131 (92.9)	NE (NE, NE)	136	2 (1.5)	134 (98.5)	NE (NE, NE)	4.700 (1.029, 21.467)	0.0277	
>50%	29	0	29 (100)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.000 (0.000, NE)	0.1887	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5601
Yes	139	6 (4.3)	133 (95.7)	NE (NE, NE)	137	3 (2.2)	134 (97.8)	NE (NE, NE)	1.877 (0.468, 7.521)	0.3660	
No	116	7 (6.0)	109 (94.0)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	3.486 (0.724, 16.783)	0.0967	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Metabolism and nutrition disorders; PT: Decreased appetite

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9470
≤60	164	8 (4.9)	156 (95.1)	NE (NE, NE)	163	3 (1.8)	160 (98.2)	NE (NE, NE)	2.493 (0.660, 9.422)	0.1635	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	2.553 (0.495, 13.167)	0.2449	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6168
<60	159	46 (28.9)	113 (71.1)	NE (12.6, NE)	160	38 (23.8)	122 (76.3)	NE (NE, NE)	1.026 (0.666, 1.580)	0.9047	
≥60 - <65	37	8 (21.6)	29 (78.4)	NE (13.6, NE)	43	6 (14.0)	37 (86.0)	NE (NE, NE)	1.564 (0.541, 4.518)	0.4012	
≥65	69	16 (23.2)	53 (76.8)	NE (11.0, NE)	65	11 (16.9)	54 (83.1)	NE (28.1, NE)	1.552 (0.720, 3.347)	0.2594	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5590
Male	124	36 (29.0)	88 (71.0)	28.9 (13.6, NE)	120	25 (20.8)	95 (79.2)	NE (15.4, NE)	1.317 (0.789, 2.197)	0.2914	
Female	141	34 (24.1)	107 (75.9)	NE (18.2, NE)	148	30 (20.3)	118 (79.7)	NE (NE, NE)	1.078 (0.659, 1.763)	0.7608	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3292
White	157	36 (22.9)	121 (77.1)	NE (NE, NE)	161	33 (20.5)	128 (79.5)	NE (28.1, NE)	1.046 (0.651, 1.680)	0.8480	
Non-white	108	34 (31.5)	74 (68.5)	18.0 (10.8, NE)	107	22 (20.6)	85 (79.4)	NE (NE, NE)	1.433 (0.838, 2.451)	0.1866	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.2392
North America	16	3 (18.8)	13 (81.3)	NE (1.9, NE)	18	8 (44.4)	10 (55.6)	28.1 (0.3, NE)	0.389 (0.103, 1.469)	0.1465	
Europe	161	39 (24.2)	122 (75.8)	NE (NE, NE)	161	27 (16.8)	134 (83.2)	NE (NE, NE)	1.357 (0.830, 2.220)	0.2204	
Asia/Other Regions	88	28 (31.8)	60 (68.2)	18.0 (9.3, NE)	89	20 (22.5)	69 (77.5)	NE (11.7, NE)	1.270 (0.714, 2.258)	0.4141	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4734
< 40x10^9/L	132	36 (27.3)	96 (72.7)	NE (12.1, NE)	133	27 (20.3)	106 (79.7)	NE (NE, NE)	1.353 (0.821, 2.230)	0.2325	
≥ 40x10^9/L	133	34 (25.6)	99 (74.4)	NE (18.2, NE)	135	28 (20.7)	107 (79.3)	NE (28.1, NE)	1.060 (0.641, 1.751)	0.8157	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.0508
Daunorubicin	123	25 (20.3)	98 (79.7)	NE (NE, NE)	94	21 (22.3)	73 (77.7)	NE (NE, NE)	0.817 (0.456, 1.463)	0.4980	
Idarubicin	142	45 (31.7)	97 (68.3)	18.0 (11.0, NE)	171	33 (19.3)	138 (80.7)	NE (NE, NE)	1.588 (1.013, 2.489)	0.0417	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8267
Favorable	13	5 (38.5)	8 (61.5)	NE (0.9, NE)	19	6 (31.6)	13 (68.4)	28.1 (3.0, NE)	1.353 (0.410, 4.464)	0.6186	
Intermediate	195	53 (27.2)	142 (72.8)	NE (13.6, NE)	190	38 (20.0)	152 (80.0)	NE (NE, NE)	1.226 (0.807, 1.861)	0.3362	
Unfavorable	19	4 (21.1)	15 (78.9)	NE (5.7, NE)	27	7 (25.9)	20 (74.1)	NE (11.2, NE)	0.737 (0.215, 2.524)	0.6263	
Unknown	38	8 (21.1)	30 (78.9)	NE (8.8, NE)	31	4 (12.9)	27 (87.1)	NE (8.6, NE)	1.510 (0.453, 5.033)	0.4991	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5329
0 - Fully Active	87	23 (26.4)	64 (73.6)	NE (14.2, NE)	97	16 (16.5)	81 (83.5)	NE (NE, NE)	1.556 (0.821, 2.949)	0.1716	
1 - Restricted in Physically Strenuous Activity	133	33 (24.8)	100 (75.2)	NE (15.2, NE)	134	29 (21.6)	105 (78.4)	NE (28.1, NE)	1.068 (0.648, 1.761)	0.7930	
2 - Ambulatory and Capable of All Selfcare	45	14 (31.1)	31 (68.9)	18.0 (7.6, NE)	36	10 (27.8)	26 (72.2)	NE (6.0, NE)	0.829 (0.363, 1.892)	0.6677	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2228
≥3 to ≤25%	94	26 (27.7)	68 (72.3)	NE (18.0, NE)	98	19 (19.4)	79 (80.6)	NE (NE, NE)	1.437 (0.794, 2.599)	0.2279	
>25% to ≤50%	141	40 (28.4)	101 (71.6)	NE (12.1, NE)	136	29 (21.3)	107 (78.7)	NE (28.1, NE)	1.260 (0.780, 2.034)	0.3408	
>50%	29	4 (13.8)	25 (86.2)	NE (11.8, NE)	34	7 (20.6)	27 (79.4)	NE (NE, NE)	0.432 (0.120, 1.549)	0.1871	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9997
Yes	139	39 (28.1)	100 (71.9)	NE (15.2, NE)	137	30 (21.9)	107 (78.1)	NE (28.1, NE)	1.226 (0.761, 1.976)	0.3982	
No	116	26 (22.4)	90 (77.6)	NE (12.1, NE)	120	20 (16.7)	100 (83.3)	NE (NE, NE)	1.207 (0.673, 2.164)	0.5247	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3849
≤60	164	47 (28.7)	117 (71.3)	NE (12.6, NE)	163	38 (23.3)	125 (76.7)	NE (NE, NE)	1.041 (0.678, 1.600)	0.8502	
>60	101	23 (22.8)	78 (77.2)	NE (14.2, NE)	105	17 (16.2)	88 (83.8)	NE (28.1, NE)	1.475 (0.788, 2.762)	0.2208	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9421
<60	159	18 (11.3)	141 (88.7)	NE (NE, NE)	160	7 (4.4)	153 (95.6)	NE (NE, NE)	2.226 (0.928, 5.339)	0.0656	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (25.7, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	2.254 (0.204, 24.901)	0.4957	
≥65	69	3 (4.3)	66 (95.7)	NE (NE, NE)	65	1 (1.5)	64 (98.5)	NE (NE, NE)	3.106 (0.323, 29.891)	0.3011	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5943
Male	124	11 (8.9)	113 (91.1)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	1.993 (0.691, 5.744)	0.1928	
Female	141	12 (8.5)	129 (91.5)	NE (NE, NE)	148	4 (2.7)	144 (97.3)	NE (NE, NE)	2.883 (0.929, 8.945)	0.0549	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4064
White	157	9 (5.7)	148 (94.3)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	1.721 (0.576, 5.143)	0.3251	
Non-white	108	14 (13.0)	94 (87.0)	NE (NE, NE)	107	4 (3.7)	103 (96.3)	NE (NE, NE)	3.241 (1.066, 9.853)	0.0282	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3057
North America	16	1 (6.3)	15 (93.8)	NE (1.5, NE)	18	3 (16.7)	15 (83.3)	NE (NE, NE)	0.386 (0.040, 3.736)	0.3941	
Europe	161	10 (6.2)	151 (93.8)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	4.491 (0.983, 20.523)	0.0336	
Asia/Other Regions	88	12 (13.6)	76 (86.4)	NE (25.7, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	2.660 (0.856, 8.268)	0.0787	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.2181
< 40x10^9/L	132	14 (10.6)	118 (89.4)	NE (NE, NE)	133	4 (3.0)	129 (97.0)	NE (NE, NE)	3.825 (1.259, 11.625)	0.0109	
≥ 40x10^9/L	133	9 (6.8)	124 (93.2)	NE (NE, NE)	135	5 (3.7)	130 (96.3)	NE (NE, NE)	1.440 (0.480, 4.320)	0.5128	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3835
Daunorubicin	123	9 (7.3)	114 (92.7)	NE (NE, NE)	94	1 (1.1)	93 (98.9)	NE (NE, NE)	6.406 (0.810, 50.653)	0.0429	
Idarubicin	142	14 (9.9)	128 (90.1)	NE (NE, NE)	171	7 (4.1)	164 (95.9)	NE (NE, NE)	2.262 (0.913, 5.608)	0.0700	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8530
Favorable	13	2 (15.4)	11 (84.6)	NE (1.7, NE)	19	3 (15.8)	16 (84.2)	NE (NE, NE)	1.103 (0.184, 6.618)	0.9148	
Intermediate	195	17 (8.7)	178 (91.3)	NE (NE, NE)	190	5 (2.6)	185 (97.4)	NE (NE, NE)	2.956 (1.089, 8.020)	0.0256	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (6.2, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	2.405 (0.216, 26.724)	0.4613	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.2196	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9455
0 - Fully Active	87	8 (9.2)	79 (90.8)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	2.675 (0.709, 10.094)	0.1307	
1 - Restricted in Physically Strenuous Activity	133	13 (9.8)	120 (90.2)	NE (NE, NE)	134	6 (4.5)	128 (95.5)	NE (NE, NE)	2.095 (0.796, 5.515)	0.1253	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.3255	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.6795
≥3 to ≤25%	94	13 (13.8)	81 (86.2)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	4.828 (1.376, 16.946)	0.0065	
>25% to ≤50%	141	10 (7.1)	131 (92.9)	NE (NE, NE)	136	4 (2.9)	132 (97.1)	NE (NE, NE)	2.131 (0.667, 6.808)	0.1911	
>50%	29	0	29 (100)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.000 (0.000, NE)	0.1815	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.7682
Yes	139	14 (10.1)	125 (89.9)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	3.227 (1.061, 9.812)	0.0289	
No	116	8 (6.9)	108 (93.1)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	2.509 (0.665, 9.467)	0.1596	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Neutrophil count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8343
≤60	164	18 (11.0)	146 (89.0)	NE (NE, NE)	163	7 (4.3)	156 (95.7)	NE (NE, NE)	2.185 (0.911, 5.240)	0.0725	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	2.828 (0.547, 14.618)	0.1948	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9999
<60	159	13 (8.2)	146 (91.8)	NE (NE, NE)	160	10 (6.3)	150 (93.8)	NE (NE, NE)	1.160 (0.507, 2.652)	0.7250	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.2839	
≥65	69	0	69 (100)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (28.1, NE)	0.000 (0.000, NE)	0.0868	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9205
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.998 (0.334, 2.978)	0.9969	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	7 (4.7)	141 (95.3)	NE (NE, NE)	0.984 (0.345, 2.811)	0.9772	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5518
White	157	10 (6.4)	147 (93.6)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	1.187 (0.467, 3.014)	0.7193	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	0.705 (0.189, 2.629)	0.6006	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8921
North America	16	0	16 (100)	NE (NE, NE)	18	2 (11.1)	16 (88.9)	NE (10.3, NE)	0.000 (0.000, NE)	0.3008	
Europe	161	9 (5.6)	152 (94.4)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	1.392 (0.494, 3.920)	0.5300	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	5 (5.6)	84 (94.4)	NE (NE, NE)	0.873 (0.252, 3.030)	0.8314	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4486
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	0.724 (0.230, 2.281)	0.5796	
≥ 40x10^9/L	133	9 (6.8)	124 (93.2)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	1.240 (0.439, 3.502)	0.6841	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.0946
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	8 (8.5)	86 (91.5)	NE (NE, NE)	0.497 (0.172, 1.436)	0.1878	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	5 (2.9)	166 (97.1)	NE (NE, NE)	1.754 (0.572, 5.376)	0.3193	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9945
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (28.1, NE)	0.000 (0.000, NE)	0.5637	
Intermediate	195	13 (6.7)	182 (93.3)	NE (NE, NE)	190	10 (5.3)	180 (94.7)	NE (NE, NE)	1.102 (0.482, 2.519)	0.8174	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	0.000 (0.000, NE)	0.4142	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	0.797 (0.050, 12.737)	0.8720	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8719
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	1.287 (0.345, 4.802)	0.7061	
1 - Restricted in Physically Strenuous Activity	133	6 (4.5)	127 (95.5)	NE (NE, NE)	134	7 (5.2)	127 (94.8)	NE (NE, NE)	0.806 (0.270, 2.405)	0.6989	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.889 (0.142, 5.553)	0.8998	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8055
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	1.279 (0.343, 4.769)	0.7137	
>25% to ≤50%	141	6 (4.3)	135 (95.7)	NE (NE, NE)	136	7 (5.1)	129 (94.9)	NE (NE, NE)	0.771 (0.259, 2.299)	0.6402	
>50%	29	3 (10.3)	26 (89.7)	NE (11.8, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	1.194 (0.191, 7.476)	0.8496	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5337
Yes	139	9 (6.5)	130 (93.5)	NE (NE, NE)	137	8 (5.8)	129 (94.2)	NE (NE, NE)	1.018 (0.391, 2.647)	0.9715	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.797 (0.328, 9.848)	0.4932	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Gamma-glutamyltransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3371
≤60	164	13 (7.9)	151 (92.1)	NE (NE, NE)	163	10 (6.1)	153 (93.9)	NE (NE, NE)	1.141 (0.499, 2.609)	0.7544	
>60	101	1 (1.0)	100 (99.0)	NE (NE, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	0.362 (0.038, 3.482)	0.3582	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9031
<60	159	8 (5.0)	151 (95.0)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	1.173 (0.405, 3.399)	0.7683	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	2.369 (0.215, 26.125)	0.4662	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	0	65 (100)	NE (NE, NE)	NE (0.000, NE)	0.0381	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6521
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	1.607 (0.469, 5.501)	0.4457	
Female	141	7 (5.0)	134 (95.0)	NE (NE, NE)	148	3 (2.0)	145 (98.0)	NE (NE, NE)	2.338 (0.604, 9.050)	0.2051	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9898
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	1.994 (0.498, 7.982)	0.3199	
Non-white	108	8 (7.4)	100 (92.6)	NE (NE, NE)	107	4 (3.7)	103 (96.3)	NE (NE, NE)	1.864 (0.561, 6.199)	0.3020	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9989
North America	16	2 (12.5)	14 (87.5)	NE (1.9, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.0815	
Europe	161	7 (4.3)	154 (95.7)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	1.632 (0.477, 5.582)	0.4308	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	1.516 (0.361, 6.375)	0.5668	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4062
< 40x10^9/L	132	8 (6.1)	124 (93.9)	NE (NE, NE)	133	3 (2.3)	130 (97.7)	NE (NE, NE)	2.821 (0.748, 10.640)	0.1093	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	4 (3.0)	131 (97.0)	NE (NE, NE)	1.298 (0.364, 4.624)	0.6867	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6073
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	3 (3.2)	91 (96.8)	NE (NE, NE)	1.528 (0.382, 6.110)	0.5466	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	4 (2.3)	167 (97.7)	NE (NE, NE)	2.216 (0.666, 7.371)	0.1829	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8742
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	12 (6.2)	183 (93.8)	NE (NE, NE)	190	5 (2.6)	185 (97.4)	NE (NE, NE)	2.159 (0.759, 6.136)	0.1389	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (5.7, NE)	27	2 (7.4)	25 (92.6)	NE (11.2, NE)	0.654 (0.059, 7.236)	0.7270	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.3664	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.2308
0 - Fully Active	87	2 (2.3)	85 (97.7)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	0.517 (0.095, 2.828)	0.4384	
1 - Restricted in Physically Strenuous Activity	133	10 (7.5)	123 (92.5)	NE (NE, NE)	134	3 (2.2)	131 (97.8)	NE (NE, NE)	3.256 (0.896, 11.840)	0.0577	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.2711	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9068
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	1.811 (0.433, 7.583)	0.4090	
>25% to ≤50%	141	9 (6.4)	132 (93.6)	NE (NE, NE)	136	3 (2.2)	133 (97.8)	NE (NE, NE)	2.677 (0.723, 9.908)	0.1250	
>50%	29	0	29 (100)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.000 (0.000, NE)	0.3557	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1724
Yes	139	5 (3.6)	134 (96.4)	NE (NE, NE)	137	4 (2.9)	133 (97.1)	NE (NE, NE)	1.170 (0.313, 4.372)	0.8150	
No	116	7 (6.0)	109 (94.0)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	6.578 (0.808, 53.560)	0.0423	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Platelet count decreased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1528
≤60	164	8 (4.9)	156 (95.1)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	1.154 (0.398, 3.343)	0.7919	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	1 (1.0)	104 (99.0)	NE (NE, NE)	6.538 (0.787, 54.302)	0.0448	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2823
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	11 (6.9)	149 (93.1)	NE (NE, NE)	0.564 (0.217, 1.462)	0.2320	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	3.049 (0.315, 29.507)	0.3115	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	1 (1.5)	64 (98.5)	NE (NE, NE)	2.179 (0.197, 24.056)	0.5144	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9124
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	6 (5.0)	114 (95.0)	NE (NE, NE)	0.907 (0.292, 2.820)	0.8662	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	7 (4.7)	141 (95.3)	NE (NE, NE)	0.840 (0.282, 2.505)	0.7538	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.5661
White	157	7 (4.5)	150 (95.5)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	0.705 (0.261, 1.901)	0.4868	
Non-white	108	5 (4.6)	103 (95.4)	NE (NE, NE)	107	4 (3.7)	103 (96.3)	NE (NE, NE)	1.221 (0.328, 4.550)	0.7654	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9088
North America	16	1 (6.3)	15 (93.8)	NE (1.6, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.1824	
Europe	161	7 (4.3)	154 (95.7)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	0.851 (0.297, 2.440)	0.7626	
Asia/Other Regions	88	4 (4.5)	84 (95.5)	NE (NE, NE)	89	6 (6.7)	83 (93.3)	NE (NE, NE)	0.648 (0.182, 2.301)	0.5002	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3984
< 40x10^9/L	132	7 (5.3)	125 (94.7)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	1.221 (0.410, 3.640)	0.7187	
≥ 40x10^9/L	133	5 (3.8)	128 (96.2)	NE (NE, NE)	135	7 (5.2)	128 (94.8)	NE (NE, NE)	0.637 (0.201, 2.014)	0.4382	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3736
Daunorubicin	123	3 (2.4)	120 (97.6)	NE (NE, NE)	94	4 (4.3)	90 (95.7)	NE (NE, NE)	0.487 (0.108, 2.194)	0.3388	
Idarubicin	142	9 (6.3)	133 (93.7)	NE (NE, NE)	171	9 (5.3)	162 (94.7)	NE (NE, NE)	1.163 (0.461, 2.935)	0.7483	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9436
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	0.000 (0.000, NE)	0.4561	
Intermediate	195	10 (5.1)	185 (94.9)	NE (NE, NE)	190	10 (5.3)	180 (94.7)	NE (NE, NE)	0.884 (0.367, 2.126)	0.7834	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.2162	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (8.6, NE)	0.314 (0.028, 3.487)	0.3192	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9282
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	5 (5.2)	92 (94.8)	NE (NE, NE)	1.007 (0.291, 3.489)	0.9897	
1 - Restricted in Physically Strenuous Activity	133	5 (3.8)	128 (96.2)	NE (NE, NE)	134	6 (4.5)	128 (95.5)	NE (NE, NE)	0.788 (0.240, 2.588)	0.6928	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.816 (0.115, 5.802)	0.8384	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3655
≥3 to ≤25%	94	7 (7.4)	87 (92.6)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	1.979 (0.579, 6.762)	0.2671	
>25% to ≤50%	141	5 (3.5)	136 (96.5)	NE (NE, NE)	136	8 (5.9)	128 (94.1)	NE (NE, NE)	0.535 (0.174, 1.640)	0.2661	
>50%	29	0	29 (100)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.000 (0.000, NE)	0.3570	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5192
Yes	139	6 (4.3)	133 (95.7)	NE (NE, NE)	137	7 (5.1)	130 (94.9)	NE (NE, NE)	0.806 (0.270, 2.406)	0.6976	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	1.350 (0.380, 4.803)	0.6415	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Alanine aminotransferase increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1022
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	11 (6.7)	152 (93.3)	NE (NE, NE)	0.554 (0.214, 1.438)	0.2184	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	2 (1.9)	103 (98.1)	NE (NE, NE)	2.687 (0.521, 13.864)	0.2191	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9999
<60	159	4 (2.5)	155 (97.5)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	0.639 (0.180, 2.270)	0.4857	
≥60 - <65	37	1 (2.7)	36 (97.3)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.2744	
≥65	69	5 (7.2)	64 (92.8)	NE (NE, NE)	65	0	65 (100)	NE (NE, NE)	NE (0.000, NE)	0.0264	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7455
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	1.943 (0.485, 7.779)	0.3409	
Female	141	4 (2.8)	137 (97.2)	NE (NE, NE)	148	3 (2.0)	145 (98.0)	NE (NE, NE)	1.426 (0.319, 6.374)	0.6400	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.8211
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	1.529 (0.431, 5.428)	0.5078	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	2.023 (0.370, 11.045)	0.4055	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.7366
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	7 (4.3)	154 (95.7)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	2.307 (0.596, 8.936)	0.2125	
Asia/Other Regions	88	3 (3.4)	85 (96.6)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	1.033 (0.208, 5.120)	0.9682	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4484
< 40x10^9/L	132	3 (2.3)	129 (97.7)	NE (NE, NE)	133	3 (2.3)	130 (97.7)	NE (NE, NE)	1.005 (0.203, 4.980)	0.9955	
≥ 40x10^9/L	133	7 (5.3)	126 (94.7)	NE (NE, NE)	135	3 (2.2)	132 (97.8)	NE (NE, NE)	2.390 (0.618, 9.245)	0.1922	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6295
Daunorubicin	123	5 (4.1)	118 (95.9)	NE (NE, NE)	94	3 (3.2)	91 (96.8)	NE (NE, NE)	1.214 (0.289, 5.090)	0.7914	
Idarubicin	142	5 (3.5)	137 (96.5)	NE (NE, NE)	171	3 (1.8)	168 (98.2)	NE (NE, NE)	2.103 (0.502, 8.799)	0.2975	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											1.0000
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.2267	
Intermediate	195	8 (4.1)	187 (95.9)	NE (NE, NE)	190	4 (2.1)	186 (97.9)	NE (NE, NE)	1.919 (0.577, 6.379)	0.2792	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.000 (0.000, NE)	0.2437	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.3600	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.5402
0 - Fully Active	87	2 (2.3)	85 (97.7)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	1.118 (0.157, 7.937)	0.9113	
1 - Restricted in Physically Strenuous Activity	133	6 (4.5)	127 (95.5)	NE (NE, NE)	134	2 (1.5)	132 (98.5)	NE (NE, NE)	3.031 (0.611, 15.037)	0.1536	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.860 (0.121, 6.103)	0.8745	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8872
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	1 (1.0)	97 (99.0)	NE (NE, NE)	3.233 (0.336, 31.080)	0.2828	
>25% to ≤50%	141	7 (5.0)	134 (95.0)	NE (NE, NE)	136	4 (2.9)	132 (97.1)	NE (NE, NE)	1.691 (0.495, 5.781)	0.3962	
>50%	29	0	29 (100)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.000 (0.000, NE)	0.3570	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0428
Yes	139	8 (5.8)	131 (94.2)	NE (NE, NE)	137	1 (0.7)	136 (99.3)	NE (NE, NE)	8.290 (1.037, 66.281)	0.0169	
No	116	2 (1.7)	114 (98.3)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.494 (0.090, 2.701)	0.4064	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Investigations; PT: Blood bilirubin increased

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9885
≤60	164	5 (3.0)	159 (97.0)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	0.798 (0.243, 2.620)	0.7094	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	0	105 (100)	NE (NE, NE)	NE (0.000, NE)	0.0201	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9296
<60	159	37 (23.3)	122 (76.7)	NE (NE, NE)	160	26 (16.3)	134 (83.8)	NE (NE, NE)	1.381 (0.836, 2.283)	0.2039	
≥60 - <65	37	6 (16.2)	31 (83.8)	NE (29.7, NE)	43	4 (9.3)	39 (90.7)	NE (NE, NE)	1.807 (0.510, 6.405)	0.3518	
≥65	69	18 (26.1)	51 (73.9)	NE (12.9, NE)	65	14 (21.5)	51 (78.5)	NE (NE, NE)	1.336 (0.664, 2.687)	0.4201	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9255
Male	124	24 (19.4)	100 (80.6)	NE (NE, NE)	120	16 (13.3)	104 (86.7)	NE (NE, NE)	1.442 (0.765, 2.718)	0.2572	
Female	141	37 (26.2)	104 (73.8)	NE (29.7, NE)	148	28 (18.9)	120 (81.1)	NE (NE, NE)	1.386 (0.848, 2.265)	0.1886	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2237
White	157	34 (21.7)	123 (78.3)	NE (NE, NE)	161	30 (18.6)	131 (81.4)	NE (NE, NE)	1.172 (0.717, 1.916)	0.5276	
Non-white	108	27 (25.0)	81 (75.0)	NE (29.3, NE)	107	14 (13.1)	93 (86.9)	NE (NE, NE)	1.908 (1.000, 3.640)	0.0457	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9882
North America	16	3 (18.8)	13 (81.3)	NE (1.4, NE)	18	3 (16.7)	15 (83.3)	NE (6.1, NE)	1.463 (0.288, 7.434)	0.6445	
Europe	161	37 (23.0)	124 (77.0)	NE (NE, NE)	161	27 (16.8)	134 (83.2)	NE (NE, NE)	1.405 (0.855, 2.308)	0.1786	
Asia/Other Regions	88	21 (23.9)	67 (76.1)	NE (29.3, NE)	89	14 (15.7)	75 (84.3)	NE (NE, NE)	1.414 (0.718, 2.785)	0.3126	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.5811
< 40x10^9/L	132	24 (18.2)	108 (81.8)	NE (NE, NE)	133	16 (12.0)	117 (88.0)	NE (NE, NE)	1.608 (0.854, 3.029)	0.1378	
≥ 40x10^9/L	133	37 (27.8)	96 (72.2)	NE (29.7, NE)	135	28 (20.7)	107 (79.3)	NE (NE, NE)	1.301 (0.795, 2.129)	0.2932	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4313
Daunorubicin	123	26 (21.1)	97 (78.9)	NE (NE, NE)	94	11 (11.7)	83 (88.3)	NE (NE, NE)	1.779 (0.878, 3.605)	0.1046	
Idarubicin	142	35 (24.6)	107 (75.4)	NE (29.7, NE)	171	33 (19.3)	138 (80.7)	NE (NE, NE)	1.282 (0.796, 2.063)	0.3038	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.6489
Favorable	13	4 (30.8)	9 (69.2)	NE (1.1, NE)	19	2 (10.5)	17 (89.5)	NE (6.3, NE)	3.377 (0.614, 18.568)	0.1374	
Intermediate	195	44 (22.6)	151 (77.4)	NE (NE, NE)	190	33 (17.4)	157 (82.6)	NE (NE, NE)	1.259 (0.801, 1.978)	0.3162	
Unfavorable	19	6 (31.6)	13 (68.4)	NE (3.3, NE)	27	6 (22.2)	21 (77.8)	NE (6.1, NE)	1.465 (0.466, 4.610)	0.5159	
Unknown	38	7 (18.4)	31 (81.6)	NE (29.7, NE)	31	3 (9.7)	28 (90.3)	NE (NE, NE)	2.048 (0.529, 7.927)	0.2889	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4192
0 - Fully Active	87	18 (20.7)	69 (79.3)	NE (NE, NE)	97	13 (13.4)	84 (86.6)	NE (NE, NE)	1.621 (0.794, 3.309)	0.1819	
1 - Restricted in Physically Strenuous Activity	133	31 (23.3)	102 (76.7)	NE (29.3, NE)	134	27 (20.1)	107 (79.9)	NE (NE, NE)	1.132 (0.675, 1.897)	0.6297	
2 - Ambulatory and Capable of All Selfcare	45	12 (26.7)	33 (73.3)	NE (11.0, NE)	36	4 (11.1)	32 (88.9)	NE (NE, NE)	2.346 (0.750, 7.331)	0.1318	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.2798
≥3 to ≤25%	94	21 (22.3)	73 (77.7)	NE (NE, NE)	98	21 (21.4)	77 (78.6)	NE (NE, NE)	1.046 (0.571, 1.915)	0.8865	
>25% to ≤50%	141	31 (22.0)	110 (78.0)	NE (NE, NE)	136	15 (11.0)	121 (89.0)	NE (NE, NE)	2.052 (1.107, 3.803)	0.0195	
>50%	29	9 (31.0)	20 (69.0)	29.7 (6.9, NE)	34	8 (23.5)	26 (76.5)	NE (7.5, NE)	1.045 (0.395, 2.765)	0.9327	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0928
Yes	139	33 (23.7)	106 (76.3)	NE (NE, NE)	137	30 (21.9)	107 (78.1)	NE (NE, NE)	1.080 (0.658, 1.772)	0.7635	
No	116	27 (23.3)	89 (76.7)	NE (NE, NE)	120	13 (10.8)	107 (89.2)	NE (NE, NE)	2.172 (1.121, 4.212)	0.0186	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7580
≤60	164	38 (23.2)	126 (76.8)	NE (NE, NE)	163	27 (16.6)	136 (83.4)	NE (NE, NE)	1.345 (0.821, 2.206)	0.2357	
>60	101	23 (22.8)	78 (77.2)	NE (29.7, NE)	105	17 (16.2)	88 (83.8)	NE (NE, NE)	1.516 (0.809, 2.839)	0.1924	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9244
<60	159	8 (5.0)	151 (95.0)	NE (NE, NE)	160	4 (2.5)	156 (97.5)	NE (NE, NE)	1.938 (0.583, 6.444)	0.2714	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	0.000 (0.000, NE)	0.3637	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	1.311 (0.293, 5.859)	0.7238	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7702
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	1.277 (0.286, 5.709)	0.7482	
Female	141	8 (5.7)	133 (94.3)	NE (NE, NE)	148	5 (3.4)	143 (96.6)	NE (NE, NE)	1.681 (0.550, 5.139)	0.3575	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7384
White	157	11 (7.0)	146 (93.0)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	1.608 (0.623, 4.150)	0.3221	
Non-white	108	1 (0.9)	107 (99.1)	NE (NE, NE)	107	1 (0.9)	106 (99.1)	NE (NE, NE)	0.995 (0.062, 15.909)	0.9972	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9463
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.2871	
Europe	161	9 (5.6)	152 (94.4)	NE (NE, NE)	161	7 (4.3)	154 (95.7)	NE (NE, NE)	1.288 (0.479, 3.459)	0.6159	
Asia/Other Regions	88	2 (2.3)	86 (97.7)	NE (NE, NE)	89	1 (1.1)	88 (98.9)	NE (NE, NE)	1.800 (0.162, 19.966)	0.6273	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6460
< 40x10^9/L	132	4 (3.0)	128 (97.0)	NE (NE, NE)	133	2 (1.5)	131 (98.5)	NE (NE, NE)	2.136 (0.391, 11.667)	0.3695	
≥ 40x10^9/L	133	8 (6.0)	125 (94.0)	NE (NE, NE)	135	6 (4.4)	129 (95.6)	NE (NE, NE)	1.308 (0.453, 3.779)	0.6196	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2231
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	1 (1.1)	93 (98.9)	NE (NE, NE)	4.570 (0.550, 37.957)	0.1222	
Idarubicin	142	6 (4.2)	136 (95.8)	NE (NE, NE)	171	7 (4.1)	164 (95.9)	NE (NE, NE)	1.030 (0.346, 3.067)	0.9569	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9852
Favorable	13	2 (15.4)	11 (84.6)	NE (1.8, NE)	19	0	19 (100)	NE (NE, NE)	NE (0.000, NE)	0.0624	
Intermediate	195	7 (3.6)	188 (96.4)	NE (NE, NE)	190	5 (2.6)	185 (97.4)	NE (NE, NE)	1.301 (0.412, 4.104)	0.6534	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	1.555 (0.219, 11.050)	0.6648	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	0.827 (0.052, 13.218)	0.8928	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1690
0 - Fully Active	87	6 (6.9)	81 (93.1)	NE (NE, NE)	97	1 (1.0)	96 (99.0)	NE (NE, NE)	6.878 (0.828, 57.111)	0.0381	
1 - Restricted in Physically Strenuous Activity	133	4 (3.0)	129 (97.0)	NE (NE, NE)	134	4 (3.0)	130 (97.0)	NE (NE, NE)	0.997 (0.249, 3.989)	0.9970	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	3 (8.3)	33 (91.7)	NE (NE, NE)	0.490 (0.081, 2.959)	0.4275	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5054
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	6 (6.1)	92 (93.9)	NE (NE, NE)	0.701 (0.198, 2.485)	0.5810	
>25% to ≤50%	141	5 (3.5)	136 (96.5)	NE (NE, NE)	136	2 (1.5)	134 (98.5)	NE (NE, NE)	2.414 (0.468, 12.444)	0.2768	
>50%	29	3 (10.3)	26 (89.7)	NE (9.3, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.0974	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3535
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	3 (2.2)	134 (97.8)	NE (NE, NE)	2.325 (0.601, 8.994)	0.2081	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	0.986 (0.285, 3.408)	0.9835	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Stomatitis

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9237
≤60	164	8 (4.9)	156 (95.1)	NE (NE, NE)	163	5 (3.1)	158 (96.9)	NE (NE, NE)	1.533 (0.501, 4.689)	0.4511	
>60	101	4 (4.0)	97 (96.0)	NE (NE, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	1.432 (0.320, 6.399)	0.6376	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.7249
<60	159	6 (3.8)	153 (96.2)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	0.938 (0.302, 2.917)	0.9121	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	2.390 (0.217, 26.355)	0.4630	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	0.721 (0.120, 4.332)	0.7195	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.3848
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.740 (0.317, 9.562)	0.5185	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	8 (5.4)	140 (94.6)	NE (NE, NE)	0.761 (0.264, 2.197)	0.6132	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6717
White	157	4 (2.5)	153 (97.5)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	0.808 (0.217, 3.010)	0.7487	
Non-white	108	6 (5.6)	102 (94.4)	NE (NE, NE)	107	5 (4.7)	102 (95.3)	NE (NE, NE)	1.128 (0.344, 3.702)	0.8401	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8967
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	4 (2.5)	157 (97.5)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	0.781 (0.210, 2.911)	0.7111	
Asia/Other Regions	88	6 (6.8)	82 (93.2)	NE (NE, NE)	89	5 (5.6)	84 (94.4)	NE (NE, NE)	1.135 (0.346, 3.726)	0.8325	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9872
< 40x10^9/L	132	3 (2.3)	129 (97.7)	NE (NE, NE)	133	0	133 (100)	NE (NE, NE)	NE (0.000, NE)	0.0881	
≥ 40x10^9/L	133	7 (5.3)	126 (94.7)	NE (NE, NE)	135	10 (7.4)	125 (92.6)	NE (NE, NE)	0.650 (0.247, 1.714)	0.3798	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.7999
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	1 (1.1)	93 (98.9)	NE (NE, NE)	1.302 (0.117, 14.546)	0.8297	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	9 (5.3)	162 (94.7)	NE (NE, NE)	1.041 (0.401, 2.701)	0.9334	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9691
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	1.762 (0.109, 28.519)	0.6861	
Intermediate	195	7 (3.6)	188 (96.4)	NE (NE, NE)	190	8 (4.2)	182 (95.8)	NE (NE, NE)	0.770 (0.279, 2.131)	0.6149	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.2332	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	0.857 (0.054, 13.711)	0.9130	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.9719
0 - Fully Active	87	3 (3.4)	84 (96.6)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	0.807 (0.180, 3.606)	0.7781	
1 - Restricted in Physically Strenuous Activity	133	6 (4.5)	127 (95.5)	NE (NE, NE)	134	6 (4.5)	128 (95.5)	NE (NE, NE)	0.968 (0.312, 3.005)	0.9572	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.3711	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5747
≥3 to ≤25%	94	6 (6.4)	88 (93.6)	NE (NE, NE)	98	4 (4.1)	94 (95.9)	NE (NE, NE)	1.601 (0.451, 5.680)	0.4623	
>25% to ≤50%	141	3 (2.1)	138 (97.9)	NE (NE, NE)	136	4 (2.9)	132 (97.1)	NE (NE, NE)	0.663 (0.148, 2.973)	0.5891	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.514 (0.046, 5.703)	0.5811	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0859
Yes	139	5 (3.6)	134 (96.4)	NE (NE, NE)	137	8 (5.8)	129 (94.2)	NE (NE, NE)	0.600 (0.196, 1.837)	0.3664	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	4.802 (0.560, 41.161)	0.1134	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Gastrointestinal disorders; PT: Diarrhoea

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.8446
≤60	164	6 (3.7)	158 (96.3)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	0.923 (0.297, 2.870)	0.8898	
>60	101	4 (4.0)	97 (96.0)	NE (NE, NE)	105	4 (3.8)	101 (96.2)	NE (NE, NE)	1.087 (0.272, 4.350)	0.9044	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6983
<60	159	16 (10.1)	143 (89.9)	NE (NE, NE)	160	10 (6.3)	150 (93.8)	NE (NE, NE)	1.566 (0.710, 3.456)	0.2624	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	3 (7.0)	40 (93.0)	NE (NE, NE)	1.473 (0.328, 6.612)	0.6107	
≥65	69	10 (14.5)	59 (85.5)	NE (26.5, NE)	65	10 (15.4)	55 (84.6)	NE (NE, NE)	0.973 (0.405, 2.340)	0.9534	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6013
Male	124	13 (10.5)	111 (89.5)	NE (NE, NE)	120	11 (9.2)	109 (90.8)	NE (NE, NE)	1.090 (0.488, 2.436)	0.8317	
Female	141	17 (12.1)	124 (87.9)	NE (NE, NE)	148	12 (8.1)	136 (91.9)	NE (NE, NE)	1.510 (0.721, 3.163)	0.2710	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9298
White	157	17 (10.8)	140 (89.2)	NE (NE, NE)	161	13 (8.1)	148 (91.9)	NE (NE, NE)	1.325 (0.643, 2.731)	0.4434	
Non-white	108	13 (12.0)	95 (88.0)	NE (NE, NE)	107	10 (9.3)	97 (90.7)	NE (NE, NE)	1.264 (0.554, 2.884)	0.5765	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8762
North America	16	2 (12.5)	14 (87.5)	NE (1.6, NE)	18	2 (11.1)	16 (88.9)	NE (NE, NE)	1.500 (0.208, 10.823)	0.6857	
Europe	161	21 (13.0)	140 (87.0)	NE (NE, NE)	161	17 (10.6)	144 (89.4)	NE (NE, NE)	1.214 (0.640, 2.302)	0.5514	
Asia/Other Regions	88	7 (8.0)	81 (92.0)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	1.701 (0.497, 5.816)	0.3915	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4423
< 40x10^9/L	132	14 (10.6)	118 (89.4)	NE (NE, NE)	133	9 (6.8)	124 (93.2)	NE (NE, NE)	1.661 (0.719, 3.838)	0.2288	
≥ 40x10^9/L	133	16 (12.0)	117 (88.0)	NE (NE, NE)	135	14 (10.4)	121 (89.6)	NE (NE, NE)	1.044 (0.508, 2.144)	0.9072	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2764
Daunorubicin	123	17 (13.8)	106 (86.2)	NE (NE, NE)	94	7 (7.4)	87 (92.6)	NE (NE, NE)	1.805 (0.748, 4.355)	0.1823	
Idarubicin	142	13 (9.2)	129 (90.8)	NE (NE, NE)	171	16 (9.4)	155 (90.6)	NE (NE, NE)	0.972 (0.467, 2.021)	0.9394	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4084
Favorable	13	1 (7.7)	12 (92.3)	NE (NE, NE)	19	2 (10.5)	17 (89.5)	NE (9.8, NE)	1.035 (0.092, 11.620)	0.9779	
Intermediate	195	22 (11.3)	173 (88.7)	NE (NE, NE)	190	13 (6.8)	177 (93.2)	NE (NE, NE)	1.590 (0.800, 3.157)	0.1816	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (3.2, NE)	27	6 (22.2)	21 (77.8)	NE (NE, NE)	0.436 (0.088, 2.163)	0.2977	
Unknown	38	5 (13.2)	33 (86.8)	NE (26.5, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	2.049 (0.396, 10.596)	0.3821	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4576
0 - Fully Active	87	10 (11.5)	77 (88.5)	NE (NE, NE)	97	5 (5.2)	92 (94.8)	NE (NE, NE)	2.111 (0.719, 6.192)	0.1640	
1 - Restricted in Physically Strenuous Activity	133	16 (12.0)	117 (88.0)	NE (NE, NE)	134	14 (10.4)	120 (89.6)	NE (NE, NE)	1.131 (0.552, 2.319)	0.7342	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	4 (11.1)	32 (88.9)	NE (NE, NE)	0.803 (0.201, 3.213)	0.7634	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7546
≥3 to ≤25%	94	12 (12.8)	82 (87.2)	NE (NE, NE)	98	10 (10.2)	88 (89.8)	NE (NE, NE)	1.310 (0.566, 3.032)	0.5265	
>25% to ≤50%	141	12 (8.5)	129 (91.5)	NE (NE, NE)	136	10 (7.4)	126 (92.6)	NE (NE, NE)	1.145 (0.494, 2.651)	0.7516	
>50%	29	6 (20.7)	23 (79.3)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (6.9, NE)	2.054 (0.511, 8.254)	0.3004	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1733
Yes	139	17 (12.2)	122 (87.8)	NE (NE, NE)	137	9 (6.6)	128 (93.4)	NE (NE, NE)	1.910 (0.851, 4.288)	0.1104	
No	116	13 (11.2)	103 (88.8)	NE (NE, NE)	120	14 (11.7)	106 (88.3)	NE (NE, NE)	0.873 (0.410, 1.860)	0.7276	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.4289
≤60	164	17 (10.4)	147 (89.6)	NE (NE, NE)	163	10 (6.1)	153 (93.9)	NE (NE, NE)	1.640 (0.750, 3.586)	0.2105	
>60	101	13 (12.9)	88 (87.1)	NE (NE, NE)	105	13 (12.4)	92 (87.6)	NE (NE, NE)	1.058 (0.490, 2.284)	0.8839	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5076
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	1.081 (0.363, 3.226)	0.8881	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	3 (7.0)	40 (93.0)	NE (NE, NE)	0.693 (0.115, 4.183)	0.6878	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	9 (13.8)	56 (86.2)	NE (NE, NE)	0.427 (0.131, 1.388)	0.1450	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9315
Male	124	7 (5.6)	117 (94.4)	NE (NE, NE)	120	9 (7.5)	111 (92.5)	NE (NE, NE)	0.697 (0.259, 1.875)	0.4720	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	9 (6.1)	139 (93.9)	NE (NE, NE)	0.683 (0.243, 1.919)	0.4664	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4125
White	157	9 (5.7)	148 (94.3)	NE (NE, NE)	161	10 (6.2)	151 (93.8)	NE (NE, NE)	0.887 (0.360, 2.186)	0.7937	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	8 (7.5)	99 (92.5)	NE (NE, NE)	0.472 (0.142, 1.570)	0.2106	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9775
North America	16	0	16 (100)	NE (NE, NE)	18	2 (11.1)	16 (88.9)	NE (NE, NE)	0.000 (0.000, NE)	0.2416	
Europe	161	11 (6.8)	150 (93.2)	NE (NE, NE)	161	13 (8.1)	148 (91.9)	NE (NE, NE)	0.804 (0.360, 1.796)	0.5944	
Asia/Other Regions	88	2 (2.3)	86 (97.7)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	0.608 (0.101, 3.651)	0.5829	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3072
< 40x10^9/L	132	7 (5.3)	125 (94.7)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	1.034 (0.363, 2.949)	0.9474	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	11 (8.1)	124 (91.9)	NE (NE, NE)	0.464 (0.171, 1.261)	0.1234	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2256
Daunorubicin	123	8 (6.5)	115 (93.5)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	1.125 (0.367, 3.443)	0.8369	
Idarubicin	142	5 (3.5)	137 (96.5)	NE (NE, NE)	171	13 (7.6)	158 (92.4)	NE (NE, NE)	0.448 (0.160, 1.257)	0.1175	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9343
Favorable	13	0	13 (100)	NE (NE, NE)	19	2 (10.5)	17 (89.5)	NE (9.8, NE)	0.000 (0.000, NE)	0.3520	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	9 (4.7)	181 (95.3)	NE (NE, NE)	0.901 (0.357, 2.272)	0.8253	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (3.2, NE)	27	5 (18.5)	22 (81.5)	NE (NE, NE)	0.529 (0.102, 2.729)	0.4389	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	0.836 (0.118, 5.933)	0.8573	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4507
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	1.301 (0.349, 4.854)	0.6940	
1 - Restricted in Physically Strenuous Activity	133	6 (4.5)	127 (95.5)	NE (NE, NE)	134	12 (9.0)	122 (91.0)	NE (NE, NE)	0.475 (0.178, 1.268)	0.1288	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.825 (0.116, 5.861)	0.8525	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8008
≥3 to ≤25%	94	6 (6.4)	88 (93.6)	NE (NE, NE)	98	8 (8.2)	90 (91.8)	NE (NE, NE)	0.793 (0.275, 2.286)	0.6668	
>25% to ≤50%	141	4 (2.8)	137 (97.2)	NE (NE, NE)	136	7 (5.1)	129 (94.9)	NE (NE, NE)	0.535 (0.157, 1.830)	0.3112	
>50%	29	3 (10.3)	26 (89.7)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (6.9, NE)	0.922 (0.184, 4.617)	0.9210	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1939
Yes	139	8 (5.8)	131 (94.2)	NE (NE, NE)	137	7 (5.1)	130 (94.9)	NE (NE, NE)	1.106 (0.401, 3.053)	0.8444	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	11 (9.2)	109 (90.8)	NE (NE, NE)	0.419 (0.146, 1.209)	0.0973	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Vascular disorders; PT: Hypertension

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3160
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	1.062 (0.356, 3.170)	0.9133	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	12 (11.4)	93 (88.6)	NE (NE, NE)	0.511 (0.192, 1.363)	0.1721	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1135
<60	159	12 (7.5)	147 (92.5)	NE (NE, NE)	160	10 (6.3)	150 (93.8)	NE (NE, NE)	1.121 (0.483, 2.600)	0.7900	
≥60 - <65	37	6 (16.2)	31 (83.8)	NE (NE, NE)	43	5 (11.6)	38 (88.4)	NE (9.9, NE)	1.255 (0.381, 4.138)	0.7079	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	13 (20.0)	52 (80.0)	NE (16.6, NE)	0.296 (0.097, 0.909)	0.0238	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8336
Male	124	13 (10.5)	111 (89.5)	NE (NE, NE)	120	15 (12.5)	105 (87.5)	NE (NE, NE)	0.772 (0.367, 1.625)	0.4934	
Female	141	9 (6.4)	132 (93.6)	NE (NE, NE)	148	13 (8.8)	135 (91.2)	NE (NE, NE)	0.688 (0.294, 1.611)	0.3866	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.7883
White	157	14 (8.9)	143 (91.1)	NE (NE, NE)	161	19 (11.8)	142 (88.2)	NE (NE, NE)	0.721 (0.361, 1.439)	0.3509	
Non-white	108	8 (7.4)	100 (92.6)	NE (NE, NE)	107	9 (8.4)	98 (91.6)	NE (NE, NE)	0.786 (0.302, 2.041)	0.6199	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5480
North America	16	0	16 (100)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	0.000 (0.000, NE)	0.3458	
Europe	161	16 (9.9)	145 (90.1)	NE (NE, NE)	161	23 (14.3)	138 (85.7)	NE (NE, NE)	0.648 (0.342, 1.228)	0.1802	
Asia/Other Regions	88	6 (6.8)	82 (93.2)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	1.277 (0.359, 4.546)	0.7056	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3910
< 40x10^9/L	132	9 (6.8)	123 (93.2)	NE (NE, NE)	133	16 (12.0)	117 (88.0)	NE (NE, NE)	0.578 (0.255, 1.309)	0.1836	
≥ 40x10^9/L	133	13 (9.8)	120 (90.2)	NE (NE, NE)	135	12 (8.9)	123 (91.1)	NE (NE, NE)	0.947 (0.431, 2.083)	0.8934	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8565
Daunorubicin	123	9 (7.3)	114 (92.7)	NE (NE, NE)	94	9 (9.6)	85 (90.4)	NE (NE, NE)	0.719 (0.285, 1.814)	0.4831	
Idarubicin	142	13 (9.2)	129 (90.8)	NE (NE, NE)	171	19 (11.1)	152 (88.9)	NE (NE, NE)	0.765 (0.377, 1.552)	0.4574	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9981
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	17 (8.7)	178 (91.3)	NE (NE, NE)	190	21 (11.1)	169 (88.9)	NE (NE, NE)	0.716 (0.377, 1.360)	0.3057	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.745 (0.068, 8.217)	0.8094	
Unknown	38	4 (10.5)	34 (89.5)	NE (NE, NE)	31	5 (16.1)	26 (83.9)	NE (16.6, NE)	0.540 (0.144, 2.031)	0.3546	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1058
0 - Fully Active	87	11 (12.6)	76 (87.4)	NE (NE, NE)	97	9 (9.3)	88 (90.7)	NE (NE, NE)	1.352 (0.560, 3.262)	0.5021	
1 - Restricted in Physically Strenuous Activity	133	10 (7.5)	123 (92.5)	NE (NE, NE)	134	13 (9.7)	121 (90.3)	NE (NE, NE)	0.702 (0.307, 1.603)	0.3982	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	6 (16.7)	30 (83.3)	NE (8.3, NE)	0.099 (0.012, 0.833)	0.0091	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5029
≥3 to ≤25%	94	8 (8.5)	86 (91.5)	NE (NE, NE)	98	7 (7.1)	91 (92.9)	NE (NE, NE)	1.227 (0.445, 3.383)	0.6924	
>25% to ≤50%	141	9 (6.4)	132 (93.6)	NE (NE, NE)	136	14 (10.3)	122 (89.7)	NE (NE, NE)	0.536 (0.231, 1.243)	0.1403	
>50%	29	5 (17.2)	24 (82.8)	NE (NE, NE)	34	7 (20.6)	27 (79.4)	NE (NE, NE)	0.729 (0.231, 2.304)	0.5919	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.9531
Yes	139	14 (10.1)	125 (89.9)	NE (NE, NE)	137	18 (13.1)	119 (86.9)	NE (NE, NE)	0.723 (0.359, 1.456)	0.3617	
No	116	8 (6.9)	108 (93.1)	NE (NE, NE)	120	10 (8.3)	110 (91.7)	NE (NE, NE)	0.752 (0.296, 1.907)	0.5454	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2906
≤60	164	12 (7.3)	152 (92.7)	NE (NE, NE)	163	10 (6.1)	153 (93.9)	NE (NE, NE)	1.101 (0.475, 2.555)	0.8220	
>60	101	10 (9.9)	91 (90.1)	NE (NE, NE)	105	18 (17.1)	87 (82.9)	NE (NE, NE)	0.580 (0.267, 1.256)	0.1615	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.0883
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	3 (1.9)	157 (98.1)	NE (NE, NE)	2.242 (0.579, 8.685)	0.2299	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	2 (4.7)	41 (95.3)	NE (NE, NE)	1.530 (0.253, 9.237)	0.6408	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	8 (12.3)	57 (87.7)	NE (NE, NE)	0.248 (0.053, 1.169)	0.0563	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4614
Male	124	6 (4.8)	118 (95.2)	NE (NE, NE)	120	8 (6.7)	112 (93.3)	NE (NE, NE)	0.669 (0.231, 1.933)	0.4544	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	5 (3.4)	143 (96.6)	NE (NE, NE)	1.252 (0.382, 4.105)	0.7095	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9229
White	157	9 (5.7)	148 (94.3)	NE (NE, NE)	161	10 (6.2)	151 (93.8)	NE (NE, NE)	0.888 (0.361, 2.189)	0.7969	
Non-white	108	3 (2.8)	105 (97.2)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	0.951 (0.192, 4.720)	0.9509	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9934
North America	16	0	16 (100)	NE (NE, NE)	18	0	18 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Europe	161	10 (6.2)	151 (93.8)	NE (NE, NE)	161	11 (6.8)	150 (93.2)	NE (NE, NE)	0.866 (0.367, 2.042)	0.7425	
Asia/Other Regions	88	2 (2.3)	86 (97.7)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	0.905 (0.127, 6.464)	0.9210	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6790
< 40x10^9/L	132	6 (4.5)	126 (95.5)	NE (NE, NE)	133	8 (6.0)	125 (94.0)	NE (NE, NE)	0.798 (0.277, 2.302)	0.6760	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	5 (3.7)	130 (96.3)	NE (NE, NE)	1.074 (0.326, 3.536)	0.9063	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9817
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	3 (3.2)	91 (96.8)	NE (NE, NE)	0.944 (0.211, 4.230)	0.9405	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	10 (5.8)	161 (94.2)	NE (NE, NE)	0.951 (0.375, 2.413)	0.9158	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9439
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	9 (4.6)	186 (95.4)	NE (NE, NE)	190	9 (4.7)	181 (95.3)	NE (NE, NE)	0.911 (0.361, 2.299)	0.8441	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.531 (0.096, 24.479)	0.7616	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	3 (9.7)	28 (90.3)	NE (16.6, NE)	0.527 (0.088, 3.166)	0.4762	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.8325
0 - Fully Active	87	7 (8.0)	80 (92.0)	NE (NE, NE)	97	7 (7.2)	90 (92.8)	NE (NE, NE)	1.096 (0.384, 3.126)	0.8639	
1 - Restricted in Physically Strenuous Activity	133	4 (3.0)	129 (97.0)	NE (NE, NE)	134	6 (4.5)	128 (95.5)	NE (NE, NE)	0.634 (0.179, 2.249)	0.4764	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.5083	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5237
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	1.766 (0.422, 7.391)	0.4299	
>25% to ≤50%	141	4 (2.8)	137 (97.2)	NE (NE, NE)	136	6 (4.4)	130 (95.6)	NE (NE, NE)	0.612 (0.172, 2.175)	0.4431	
>50%	29	3 (10.3)	26 (89.7)	NE (NE, NE)	34	4 (11.8)	30 (88.2)	NE (NE, NE)	0.809 (0.180, 3.624)	0.7809	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5780
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	9 (6.6)	128 (93.4)	NE (NE, NE)	0.753 (0.280, 2.024)	0.5720	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	1.207 (0.324, 4.503)	0.7785	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: General disorders and administration site conditions; PT: Pyrexia

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.1069
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	3 (1.8)	160 (98.2)	NE (NE, NE)	2.204 (0.569, 8.537)	0.2405	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	10 (9.5)	95 (90.5)	NE (NE, NE)	0.535 (0.183, 1.566)	0.2458	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6659
<60	159	10 (6.3)	149 (93.7)	NE (NE, NE)	160	8 (5.0)	152 (95.0)	NE (NE, NE)	1.173 (0.462, 2.979)	0.7376	
≥60 - <65	37	3 (8.1)	34 (91.9)	NE (NE, NE)	43	6 (14.0)	37 (86.0)	NE (20.2, NE)	0.542 (0.135, 2.173)	0.3799	
≥65	69	7 (10.1)	62 (89.9)	NE (NE, NE)	65	8 (12.3)	57 (87.7)	NE (NE, NE)	0.847 (0.307, 2.337)	0.7478	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.6374
Male	124	12 (9.7)	112 (90.3)	NE (NE, NE)	120	11 (9.2)	109 (90.8)	NE (NE, NE)	0.981 (0.432, 2.228)	0.9626	
Female	141	8 (5.7)	133 (94.3)	NE (NE, NE)	148	11 (7.4)	137 (92.6)	NE (NE, NE)	0.738 (0.297, 1.837)	0.5120	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.2398
White	157	11 (7.0)	146 (93.0)	NE (NE, NE)	161	16 (9.9)	145 (90.1)	NE (NE, NE)	0.654 (0.303, 1.412)	0.2764	
Non-white	108	9 (8.3)	99 (91.7)	NE (NE, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	1.432 (0.509, 4.026)	0.4947	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6699
North America	16	1 (6.3)	15 (93.8)	NE (1.8, NE)	18	2 (11.1)	16 (88.9)	NE (10.2, NE)	0.806 (0.071, 9.101)	0.8612	
Europe	161	13 (8.1)	148 (91.9)	NE (NE, NE)	161	16 (9.9)	145 (90.1)	NE (NE, NE)	0.760 (0.365, 1.583)	0.4616	
Asia/Other Regions	88	6 (6.8)	82 (93.2)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	1.438 (0.405, 5.107)	0.5724	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4282
< 40x10^9/L	132	8 (6.1)	124 (93.9)	NE (NE, NE)	133	12 (9.0)	121 (91.0)	NE (NE, NE)	0.676 (0.276, 1.654)	0.3883	
≥ 40x10^9/L	133	12 (9.0)	121 (91.0)	NE (NE, NE)	135	10 (7.4)	125 (92.6)	NE (NE, NE)	1.088 (0.468, 2.528)	0.8438	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.5667
Daunorubicin	123	11 (8.9)	112 (91.1)	NE (NE, NE)	94	11 (11.7)	83 (88.3)	NE (NE, NE)	0.714 (0.309, 1.649)	0.4280	
Idarubicin	142	9 (6.3)	133 (93.7)	NE (NE, NE)	171	10 (5.8)	161 (94.2)	NE (NE, NE)	1.036 (0.420, 2.553)	0.9394	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.4557
Favorable	13	0	13 (100)	NE (NE, NE)	19	2 (10.5)	17 (89.5)	NE (NE, NE)	0.000 (0.000, NE)	0.3035	
Intermediate	195	12 (6.2)	183 (93.8)	NE (NE, NE)	190	16 (8.4)	174 (91.6)	NE (NE, NE)	0.663 (0.313, 1.405)	0.2803	
Unfavorable	19	3 (15.8)	16 (84.2)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	2.437 (0.407, 14.595)	0.3133	
Unknown	38	5 (13.2)	33 (86.8)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	2.032 (0.393, 10.500)	0.3878	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4767
0 - Fully Active	87	7 (8.0)	80 (92.0)	NE (NE, NE)	97	5 (5.2)	92 (94.8)	NE (NE, NE)	1.508 (0.478, 4.753)	0.4804	
1 - Restricted in Physically Strenuous Activity	133	8 (6.0)	125 (94.0)	NE (NE, NE)	134	12 (9.0)	122 (91.0)	NE (NE, NE)	0.635 (0.259, 1.554)	0.3156	
2 - Ambulatory and Capable of All Selfcare	45	5 (11.1)	40 (88.9)	NE (NE, NE)	36	5 (13.9)	31 (86.1)	NE (13.4, NE)	0.760 (0.217, 2.662)	0.6664	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.8224
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	7 (7.1)	91 (92.9)	NE (NE, NE)	0.740 (0.235, 2.334)	0.6063	
>25% to ≤50%	141	15 (10.6)	126 (89.4)	NE (NE, NE)	136	12 (8.8)	124 (91.2)	NE (NE, NE)	1.166 (0.545, 2.493)	0.6930	
>50%	29	0	29 (100)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	0.000 (0.000, NE)	0.0719	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.1456
Yes	139	8 (5.8)	131 (94.2)	NE (NE, NE)	137	14 (10.2)	123 (89.8)	NE (NE, NE)	0.532 (0.223, 1.271)	0.1486	
No	116	10 (8.6)	106 (91.4)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	1.385 (0.527, 3.641)	0.5070	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Respiratory, thoracic and mediastinal disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.3224
≤60	164	11 (6.7)	153 (93.3)	NE (NE, NE)	163	8 (4.9)	155 (95.1)	NE (NE, NE)	1.282 (0.514, 3.193)	0.5938	
>60	101	9 (8.9)	92 (91.1)	NE (NE, NE)	105	14 (13.3)	91 (86.7)	NE (NE, NE)	0.674 (0.292, 1.559)	0.3529	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9235
<60	159	10 (6.3)	149 (93.7)	NE (NE, NE)	160	9 (5.6)	151 (94.4)	NE (NE, NE)	1.082 (0.439, 2.666)	0.8637	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (14.8, NE)	43	5 (11.6)	38 (88.4)	NE (NE, NE)	0.848 (0.227, 3.163)	0.8084	
≥65	69	4 (5.8)	65 (94.2)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	1.268 (0.284, 5.665)	0.7556	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.8227
Male	124	4 (3.2)	120 (96.8)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.889 (0.222, 3.569)	0.8685	
Female	141	14 (9.9)	127 (90.1)	NE (NE, NE)	148	13 (8.8)	135 (91.2)	NE (NE, NE)	1.124 (0.528, 2.391)	0.7615	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.3877
White	157	9 (5.7)	148 (94.3)	NE (NE, NE)	161	11 (6.8)	150 (93.2)	NE (NE, NE)	0.846 (0.351, 2.042)	0.7099	
Non-white	108	9 (8.3)	99 (91.7)	NE (NE, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	1.449 (0.515, 4.072)	0.4797	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.9986
North America	16	0	16 (100)	NE (NE, NE)	18	4 (22.2)	14 (77.8)	NE (1.3, NE)	0.000 (0.000, NE)	0.0482	
Europe	161	11 (6.8)	150 (93.2)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	1.383 (0.556, 3.439)	0.4825	
Asia/Other Regions	88	7 (8.0)	81 (92.0)	NE (NE, NE)	89	5 (5.6)	84 (94.4)	NE (NE, NE)	1.298 (0.411, 4.098)	0.6562	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.9427
< 40x10^9/L	132	9 (6.8)	123 (93.2)	NE (NE, NE)	133	9 (6.8)	124 (93.2)	NE (NE, NE)	1.022 (0.406, 2.576)	0.9638	
≥ 40x10^9/L	133	9 (6.8)	124 (93.2)	NE (NE, NE)	135	8 (5.9)	127 (94.1)	NE (NE, NE)	1.037 (0.399, 2.696)	0.9412	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.4081
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	6 (6.4)	88 (93.6)	NE (NE, NE)	0.724 (0.233, 2.247)	0.5744	
Idarubicin	142	12 (8.5)	130 (91.5)	NE (NE, NE)	171	11 (6.4)	160 (93.6)	NE (NE, NE)	1.302 (0.574, 2.951)	0.5262	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9993
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (NE, NE)	0.000 (0.000, NE)	0.4268	
Intermediate	195	13 (6.7)	182 (93.3)	NE (NE, NE)	190	11 (5.8)	179 (94.2)	NE (NE, NE)	1.097 (0.491, 2.451)	0.8208	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	0.000 (0.000, NE)	0.4142	
Unknown	38	5 (13.2)	33 (86.8)	NE (NE, NE)	31	4 (12.9)	27 (87.1)	NE (NE, NE)	1.030 (0.276, 3.839)	0.9596	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7934
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	6 (6.2)	91 (93.8)	NE (NE, NE)	0.734 (0.207, 2.600)	0.6300	
1 - Restricted in Physically Strenuous Activity	133	10 (7.5)	123 (92.5)	NE (NE, NE)	134	8 (6.0)	126 (94.0)	NE (NE, NE)	1.201 (0.474, 3.045)	0.6986	
2 - Ambulatory and Capable of All Selfcare	45	4 (8.9)	41 (91.1)	NE (NE, NE)	36	3 (8.3)	33 (91.7)	NE (NE, NE)	1.079 (0.241, 4.819)	0.9176	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7609
≥3 to ≤25%	94	6 (6.4)	88 (93.6)	NE (NE, NE)	98	7 (7.1)	91 (92.9)	NE (NE, NE)	0.888 (0.298, 2.644)	0.8310	
>25% to ≤50%	141	10 (7.1)	131 (92.9)	NE (NE, NE)	136	7 (5.1)	129 (94.9)	NE (NE, NE)	1.329 (0.505, 3.495)	0.5636	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	3 (8.8)	31 (91.2)	NE (NE, NE)	0.813 (0.136, 4.866)	0.8202	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.4691
Yes	139	11 (7.9)	128 (92.1)	NE (NE, NE)	137	9 (6.6)	128 (93.4)	NE (NE, NE)	1.202 (0.498, 2.902)	0.6822	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	7 (5.8)	113 (94.2)	NE (NE, NE)	0.705 (0.224, 2.224)	0.5500	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Skin and subcutaneous tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.6961
≤60	164	11 (6.7)	153 (93.3)	NE (NE, NE)	163	9 (5.5)	154 (94.5)	NE (NE, NE)	1.166 (0.483, 2.817)	0.7328	
>60	101	7 (6.9)	94 (93.1)	NE (NE, NE)	105	8 (7.6)	97 (92.4)	NE (NE, NE)	0.907 (0.329, 2.502)	0.8514	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.4674
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	5 (3.1)	155 (96.9)	NE (NE, NE)	1.297 (0.411, 4.096)	0.6574	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	5 (11.6)	38 (88.4)	NE (20.1, NE)	0.396 (0.076, 2.054)	0.2537	
≥65	69	6 (8.7)	63 (91.3)	NE (NE, NE)	65	5 (7.7)	60 (92.3)	NE (27.7, NE)	1.249 (0.381, 4.096)	0.7131	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5627
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.697 (0.156, 3.121)	0.6349	
Female	141	12 (8.5)	129 (91.5)	NE (NE, NE)	148	11 (7.4)	137 (92.6)	NE (NE, NE)	1.102 (0.485, 2.500)	0.8167	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9910
White	157	9 (5.7)	148 (94.3)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	1.012 (0.401, 2.552)	0.9798	
Non-white	108	6 (5.6)	102 (94.4)	NE (NE, NE)	107	6 (5.6)	101 (94.4)	NE (NE, NE)	0.925 (0.298, 2.871)	0.8927	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.3069
North America	16	1 (6.3)	15 (93.8)	NE (NE, NE)	18	5 (27.8)	13 (72.2)	NE (2.9, NE)	0.248 (0.029, 2.141)	0.1707	
Europe	161	10 (6.2)	151 (93.8)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	1.652 (0.600, 4.550)	0.3265	
Asia/Other Regions	88	4 (4.5)	84 (95.5)	NE (NE, NE)	89	4 (4.5)	85 (95.5)	NE (NE, NE)	0.899 (0.224, 3.605)	0.8808	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.3568
< 40x10^9/L	132	9 (6.8)	123 (93.2)	NE (NE, NE)	133	7 (5.3)	126 (94.7)	NE (NE, NE)	1.324 (0.493, 3.557)	0.5769	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	8 (5.9)	127 (94.1)	NE (NE, NE)	0.654 (0.226, 1.892)	0.4296	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.2905
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	7 (7.4)	87 (92.6)	NE (NE, NE)	0.595 (0.199, 1.775)	0.3465	
Idarubicin	142	9 (6.3)	133 (93.7)	NE (NE, NE)	171	8 (4.7)	163 (95.3)	NE (NE, NE)	1.305 (0.503, 3.390)	0.5839	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9477
Favorable	13	0	13 (100)	NE (NE, NE)	19	3 (15.8)	16 (84.2)	NE (10.0, NE)	0.000 (0.000, NE)	0.2229	
Intermediate	195	12 (6.2)	183 (93.8)	NE (NE, NE)	190	9 (4.7)	181 (95.3)	NE (NE, NE)	1.227 (0.516, 2.916)	0.6428	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (11.3, NE)	0.000 (0.000, NE)	0.2297	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	2.844 (0.295, 27.428)	0.3463	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.6524
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	4 (4.1)	93 (95.9)	NE (NE, NE)	1.331 (0.357, 4.964)	0.6688	
1 - Restricted in Physically Strenuous Activity	133	9 (6.8)	124 (93.2)	NE (NE, NE)	134	9 (6.7)	125 (93.3)	NE (NE, NE)	0.985 (0.391, 2.484)	0.9747	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.355 (0.032, 3.966)	0.3799	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.7830
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	7 (7.1)	91 (92.9)	NE (NE, NE)	0.749 (0.237, 2.361)	0.6203	
>25% to ≤50%	141	10 (7.1)	131 (92.9)	NE (NE, NE)	136	7 (5.1)	129 (94.9)	NE (NE, NE)	1.338 (0.509, 3.522)	0.5536	
>50%	29	0	29 (100)	NE (NE, NE)	34	1 (2.9)	33 (97.1)	NE (NE, NE)	0.000 (0.000, NE)	0.3557	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.0045
Yes	139	4 (2.9)	135 (97.1)	NE (NE, NE)	137	12 (8.8)	125 (91.2)	NE (NE, NE)	0.309 (0.100, 0.961)	0.0319	
No	116	10 (8.6)	106 (91.4)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	4.901 (1.073, 22.383)	0.0230	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Nervous system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5967
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	5 (3.1)	158 (96.9)	NE (NE, NE)	1.274 (0.403, 4.023)	0.6801	
>60	101	8 (7.9)	93 (92.1)	NE (NE, NE)	105	10 (9.5)	95 (90.5)	NE (NE, NE)	0.865 (0.341, 2.193)	0.7600	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.5418
<60	159	9 (5.7)	150 (94.3)	NE (NE, NE)	160	1 (0.6)	159 (99.4)	NE (NE, NE)	8.163 (1.031, 64.619)	0.0178	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (NE, NE)	NE	
≥65	69	6 (8.7)	63 (91.3)	NE (NE, NE)	65	3 (4.6)	62 (95.4)	NE (NE, NE)	2.075 (0.519, 8.300)	0.2908	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.4778
Male	124	5 (4.0)	119 (96.0)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	2.209 (0.426, 11.447)	0.3327	
Female	141	10 (7.1)	131 (92.9)	NE (NE, NE)	148	2 (1.4)	146 (98.6)	NE (NE, NE)	5.303 (1.162, 24.213)	0.0159	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.9883
White	157	8 (5.1)	149 (94.9)	NE (NE, NE)	161	4 (2.5)	157 (97.5)	NE (NE, NE)	1.885 (0.566, 6.282)	0.2941	
Non-white	108	7 (6.5)	101 (93.5)	NE (NE, NE)	107	0	107 (100)	NE (NE, NE)	NE (0.000, NE)	0.0075	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8685
North America	16	1 (6.3)	15 (93.8)	NE (1.9, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	1.886 (0.118, 30.182)	0.6485	
Europe	161	10 (6.2)	151 (93.8)	NE (NE, NE)	161	3 (1.9)	158 (98.1)	NE (NE, NE)	3.126 (0.858, 11.384)	0.0684	
Asia/Other Regions	88	4 (4.5)	84 (95.5)	NE (NE, NE)	89	0	89 (100)	NE (NE, NE)	NE (0.000, NE)	0.0427	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6312
< 40x10^9/L	132	5 (3.8)	127 (96.2)	NE (NE, NE)	133	2 (1.5)	131 (98.5)	NE (NE, NE)	2.554 (0.495, 13.184)	0.2454	
≥ 40x10^9/L	133	10 (7.5)	123 (92.5)	NE (NE, NE)	135	2 (1.5)	133 (98.5)	NE (NE, NE)	4.656 (1.019, 21.282)	0.0290	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.6976
Daunorubicin	123	7 (5.7)	116 (94.3)	NE (NE, NE)	94	1 (1.1)	93 (98.9)	NE (NE, NE)	4.981 (0.611, 40.601)	0.0960	
Idarubicin	142	8 (5.6)	134 (94.4)	NE (NE, NE)	171	3 (1.8)	168 (98.2)	NE (NE, NE)	3.162 (0.838, 11.932)	0.0729	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9404
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	13 (6.7)	182 (93.3)	NE (NE, NE)	190	3 (1.6)	187 (98.4)	NE (NE, NE)	3.942 (1.122, 13.852)	0.0209	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	1 (3.7)	26 (96.3)	NE (NE, NE)	1.651 (0.103, 26.487)	0.7203	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	0	31 (100)	NE (NE, NE)	NE (0.000, NE)	0.3534	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.7194
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	2.554 (0.494, 13.196)	0.2460	
1 - Restricted in Physically Strenuous Activity	133	7 (5.3)	126 (94.7)	NE (NE, NE)	134	1 (0.7)	133 (99.3)	NE (NE, NE)	7.062 (0.868, 57.444)	0.0330	
2 - Ambulatory and Capable of All Selfcare	45	3 (6.7)	42 (93.3)	NE (NE, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	2.462 (0.256, 23.685)	0.4198	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.3899
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	3 (3.1)	95 (96.9)	NE (NE, NE)	1.442 (0.323, 6.444)	0.6300	
>25% to ≤50%	141	9 (6.4)	132 (93.6)	NE (NE, NE)	136	1 (0.7)	135 (99.3)	NE (NE, NE)	8.447 (1.069, 66.764)	0.0152	
>50%	29	2 (6.9)	27 (93.1)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.1549	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.3912
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	1 (0.7)	136 (99.3)	NE (NE, NE)	6.952 (0.855, 56.558)	0.0349	
No	116	7 (6.0)	109 (94.0)	NE (NE, NE)	120	3 (2.5)	117 (97.5)	NE (NE, NE)	2.256 (0.583, 8.740)	0.2259	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Renal and urinary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.2913
≤60	164	9 (5.5)	155 (94.5)	NE (NE, NE)	163	1 (0.6)	162 (99.4)	NE (NE, NE)	8.029 (1.014, 63.560)	0.0190	
>60	101	6 (5.9)	95 (94.1)	NE (NE, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	2.225 (0.556, 8.900)	0.2451	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.1220
<60	159	6 (3.8)	153 (96.2)	NE (NE, NE)	160	6 (3.8)	154 (96.3)	NE (NE, NE)	0.933 (0.300, 2.902)	0.9045	
≥60 - <65	37	4 (10.8)	33 (89.2)	NE (NE, NE)	43	1 (2.3)	42 (97.7)	NE (NE, NE)	4.592 (0.513, 41.096)	0.1339	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	7 (10.8)	58 (89.2)	NE (NE, NE)	0.280 (0.058, 1.349)	0.0900	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.0070
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	11 (9.2)	109 (90.8)	NE (NE, NE)	0.233 (0.065, 0.836)	0.0148	
Female	141	9 (6.4)	132 (93.6)	NE (NE, NE)	148	3 (2.0)	145 (98.0)	NE (NE, NE)	3.117 (0.843, 11.521)	0.0722	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.4965
White	157	7 (4.5)	150 (95.5)	NE (NE, NE)	161	10 (6.2)	151 (93.8)	NE (NE, NE)	0.673 (0.256, 1.771)	0.4184	
Non-white	108	5 (4.6)	103 (95.4)	NE (NE, NE)	107	4 (3.7)	103 (96.3)	NE (NE, NE)	1.191 (0.319, 4.441)	0.7945	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.6132
North America	16	2 (12.5)	14 (87.5)	NE (NE, NE)	18	2 (11.1)	16 (88.9)	NE (10.1, NE)	1.259 (0.176, 9.016)	0.8176	
Europe	161	9 (5.6)	152 (94.4)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	0.911 (0.361, 2.301)	0.8429	
Asia/Other Regions	88	1 (1.1)	87 (98.9)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	0.341 (0.035, 3.279)	0.3278	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.6116
< 40x10^9/L	132	6 (4.5)	126 (95.5)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	1.029 (0.332, 3.194)	0.9602	
≥ 40x10^9/L	133	6 (4.5)	127 (95.5)	NE (NE, NE)	135	8 (5.9)	127 (94.1)	NE (NE, NE)	0.671 (0.232, 1.943)	0.4588	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.8790
Daunorubicin	123	6 (4.9)	117 (95.1)	NE (NE, NE)	94	5 (5.3)	89 (94.7)	NE (NE, NE)	0.861 (0.262, 2.825)	0.8048	
Idarubicin	142	6 (4.2)	136 (95.8)	NE (NE, NE)	171	9 (5.3)	162 (94.7)	NE (NE, NE)	0.765 (0.272, 2.152)	0.6107	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9665
Favorable	13	0	13 (100)	NE (NE, NE)	19	1 (5.3)	18 (94.7)	NE (10.1, NE)	0.000 (0.000, NE)	0.5271	
Intermediate	195	8 (4.1)	187 (95.9)	NE (NE, NE)	190	9 (4.7)	181 (95.3)	NE (NE, NE)	0.816 (0.315, 2.119)	0.6763	
Unfavorable	19	2 (10.5)	17 (89.5)	NE (NE, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	1.558 (0.219, 11.076)	0.6552	
Unknown	38	2 (5.3)	36 (94.7)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (9.6, NE)	0.751 (0.105, 5.390)	0.7752	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.0797
0 - Fully Active	87	4 (4.6)	83 (95.4)	NE (NE, NE)	97	3 (3.1)	94 (96.9)	NE (NE, NE)	1.472 (0.329, 6.577)	0.6107	
1 - Restricted in Physically Strenuous Activity	133	3 (2.3)	130 (97.7)	NE (NE, NE)	134	10 (7.5)	124 (92.5)	NE (NE, NE)	0.280 (0.077, 1.020)	0.0391	
2 - Ambulatory and Capable of All Selfcare	45	5 (11.1)	40 (88.9)	NE (25.1, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	3.804 (0.440, 32.872)	0.1921	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5483
≥3 to ≤25%	94	4 (4.3)	90 (95.7)	NE (NE, NE)	98	7 (7.1)	91 (92.9)	NE (NE, NE)	0.588 (0.172, 2.010)	0.3918	
>25% to ≤50%	141	8 (5.7)	133 (94.3)	NE (NE, NE)	136	5 (3.7)	131 (96.3)	NE (NE, NE)	1.506 (0.492, 4.610)	0.4700	
>50%	29	0	29 (100)	NE (NE, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.000 (0.000, NE)	0.1478	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6381
Yes	139	5 (3.6)	134 (96.4)	NE (NE, NE)	137	5 (3.6)	132 (96.4)	NE (NE, NE)	0.884 (0.255, 3.066)	0.8459	
No	116	6 (5.2)	110 (94.8)	NE (NE, NE)	120	9 (7.5)	111 (92.5)	NE (NE, NE)	0.636 (0.226, 1.789)	0.3861	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Cardiac disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.5616
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	6 (3.7)	157 (96.3)	NE (NE, NE)	1.078 (0.361, 3.218)	0.8925	
>60	101	5 (5.0)	96 (95.0)	NE (NE, NE)	105	8 (7.6)	97 (92.4)	NE (NE, NE)	0.651 (0.213, 1.990)	0.4464	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.6727
<60	159	8 (5.0)	151 (95.0)	NE (NE, NE)	160	5 (3.1)	155 (96.9)	NE (NE, NE)	1.527 (0.498, 4.675)	0.4553	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (19.9, NE)	43	1 (2.3)	42 (97.7)	NE (30.1, NE)	2.240 (0.203, 24.739)	0.4991	
≥65	69	1 (1.4)	68 (98.6)	NE (NE, NE)	65	2 (3.1)	63 (96.9)	NE (NE, NE)	0.563 (0.051, 6.248)	0.6353	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.7482
Male	124	5 (4.0)	119 (96.0)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	1.085 (0.291, 4.053)	0.9040	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	4 (2.7)	144 (97.3)	NE (NE, NE)	1.521 (0.429, 5.397)	0.5120	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6914
White	157	6 (3.8)	151 (96.2)	NE (NE, NE)	161	5 (3.1)	156 (96.9)	NE (NE, NE)	1.097 (0.334, 3.604)	0.8789	
Non-white	108	5 (4.6)	103 (95.4)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	1.606 (0.383, 6.724)	0.5130	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.5752
North America	16	0	16 (100)	NE (NE, NE)	18	1 (5.6)	17 (94.4)	NE (NE, NE)	0.000 (0.000, NE)	0.3458	
Europe	161	7 (4.3)	154 (95.7)	NE (NE, NE)	161	6 (3.7)	155 (96.3)	NE (NE, NE)	1.051 (0.352, 3.138)	0.9293	
Asia/Other Regions	88	4 (4.5)	84 (95.5)	NE (NE, NE)	89	1 (1.1)	88 (98.9)	NE (NE, NE)	3.752 (0.418, 33.669)	0.2047	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4356
< 40x10^9/L	132	7 (5.3)	125 (94.7)	NE (NE, NE)	133	4 (3.0)	129 (97.0)	NE (NE, NE)	1.804 (0.527, 6.172)	0.3400	
≥ 40x10^9/L	133	4 (3.0)	129 (97.0)	NE (NE, NE)	135	4 (3.0)	131 (97.0)	NE (NE, NE)	0.931 (0.232, 3.744)	0.9202	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.9714
Daunorubicin	123	2 (1.6)	121 (98.4)	NE (NE, NE)	94	1 (1.1)	93 (98.9)	NE (NE, NE)	1.541 (0.140, 16.994)	0.7220	
Idarubicin	142	9 (6.3)	133 (93.7)	NE (NE, NE)	171	7 (4.1)	164 (95.9)	NE (NE, NE)	1.447 (0.538, 3.891)	0.4621	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.8889
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	7 (3.6)	188 (96.4)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	0.868 (0.304, 2.481)	0.7926	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (0.000, NE)	0.1967	
Unknown	38	3 (7.9)	35 (92.1)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (NE, NE)	2.620 (0.272, 25.228)	0.3865	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1921
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	1 (1.0)	96 (99.0)	NE (NE, NE)	5.624 (0.657, 48.141)	0.0751	
1 - Restricted in Physically Strenuous Activity	133	4 (3.0)	129 (97.0)	NE (NE, NE)	134	7 (5.2)	127 (94.8)	NE (NE, NE)	0.530 (0.155, 1.811)	0.3029	
2 - Ambulatory and Capable of All Selfcare	45	2 (4.4)	43 (95.6)	NE (NE, NE)	36	0	36 (100)	NE (NE, NE)	NE (0.000, NE)	0.2007	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9338
≥3 to ≤25%	94	5 (5.3)	89 (94.7)	NE (NE, NE)	98	5 (5.1)	93 (94.9)	NE (NE, NE)	1.045 (0.302, 3.612)	0.9446	
>25% to ≤50%	141	5 (3.5)	136 (96.5)	NE (NE, NE)	136	3 (2.2)	133 (97.8)	NE (NE, NE)	1.496 (0.357, 6.270)	0.5794	
>50%	29	1 (3.4)	28 (96.6)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (0.000, NE)	0.2789	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.2725
Yes	139	5 (3.6)	134 (96.4)	NE (NE, NE)	137	6 (4.4)	131 (95.6)	NE (NE, NE)	0.765 (0.233, 2.512)	0.6573	
No	116	5 (4.3)	111 (95.7)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	2.456 (0.476, 12.672)	0.2670	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Hepatobiliary disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.7969
≤60	164	8 (4.9)	156 (95.1)	NE (NE, NE)	163	5 (3.1)	158 (96.9)	NE (NE, NE)	1.503 (0.491, 4.603)	0.4724	
>60	101	3 (3.0)	98 (97.0)	NE (NE, NE)	105	3 (2.9)	102 (97.1)	NE (NE, NE)	1.130 (0.228, 5.607)	0.8815	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.9999
<60	159	7 (4.4)	152 (95.6)	NE (NE, NE)	160	4 (2.5)	156 (97.5)	NE (NE, NE)	1.336 (0.388, 4.594)	0.6450	
≥60 - <65	37	2 (5.4)	35 (94.6)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (0.000, NE)	0.2092	
≥65	69	2 (2.9)	67 (97.1)	NE (NE, NE)	65	0	65 (100)	NE (NE, NE)	NE (0.000, NE)	0.1459	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.9398
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	1 (0.8)	119 (99.2)	NE (NE, NE)	1.940 (0.201, 18.677)	0.5593	
Female	141	8 (5.7)	133 (94.3)	NE (NE, NE)	148	3 (2.0)	145 (98.0)	NE (NE, NE)	2.485 (0.658, 9.383)	0.1647	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.6547
White	157	7 (4.5)	150 (95.5)	NE (NE, NE)	161	2 (1.2)	159 (98.8)	NE (NE, NE)	2.960 (0.613, 14.302)	0.1567	
Non-white	108	4 (3.7)	104 (96.3)	NE (NE, NE)	107	2 (1.9)	105 (98.1)	NE (NE, NE)	1.687 (0.309, 9.218)	0.5416	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.8066
North America	16	2 (12.5)	14 (87.5)	17.4 (9.0, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.0530	
Europe	161	4 (2.5)	157 (97.5)	NE (NE, NE)	161	1 (0.6)	160 (99.4)	NE (NE, NE)	3.598 (0.401, 32.278)	0.2213	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	3 (3.4)	86 (96.6)	NE (NE, NE)	1.261 (0.300, 5.297)	0.7505	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.4480
< 40x10^9/L	132	7 (5.3)	125 (94.7)	NE (NE, NE)	133	2 (1.5)	131 (98.5)	NE (NE, NE)	3.485 (0.724, 16.785)	0.0971	
≥ 40x10^9/L	133	4 (3.0)	129 (97.0)	NE (NE, NE)	135	2 (1.5)	133 (98.5)	NE (NE, NE)	1.433 (0.261, 7.861)	0.6767	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3312
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	1.143 (0.208, 6.292)	0.8777	
Idarubicin	142	7 (4.9)	135 (95.1)	NE (NE, NE)	171	2 (1.2)	169 (98.8)	NE (NE, NE)	3.576 (0.742, 17.242)	0.0899	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9922
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	7 (3.6)	188 (96.4)	NE (NE, NE)	190	3 (1.6)	187 (98.4)	NE (NE, NE)	1.776 (0.458, 6.881)	0.3992	
Unfavorable	19	0	19 (100)	NE (NE, NE)	27	0	27 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Unknown	38	4 (10.5)	34 (89.5)	NE (NE, NE)	31	1 (3.2)	30 (96.8)	NE (8.8, NE)	2.459 (0.273, 22.138)	0.4069	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.4468
0 - Fully Active	87	6 (6.9)	81 (93.1)	NE (NE, NE)	97	0	97 (100)	NE (NE, NE)	NE (0.000, NE)	0.0148	
1 - Restricted in Physically Strenuous Activity	133	4 (3.0)	129 (97.0)	NE (NE, NE)	134	2 (1.5)	132 (98.5)	NE (NE, NE)	1.542 (0.282, 8.421)	0.6141	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (NE, NE)	36	2 (5.6)	34 (94.4)	NE (NE, NE)	0.270 (0.022, 3.376)	0.2850	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.9713
≥3 to ≤25%	94	3 (3.2)	91 (96.8)	NE (NE, NE)	98	1 (1.0)	97 (99.0)	NE (NE, NE)	2.904 (0.301, 28.009)	0.3341	
>25% to ≤50%	141	8 (5.7)	133 (94.3)	NE (NE, NE)	136	3 (2.2)	133 (97.8)	NE (NE, NE)	2.116 (0.560, 7.997)	0.2584	
>50%	29	0	29 (100)	NE (NE, NE)	34	0	34 (100)	NE (NE, NE)	NE (NE, NE)	NE	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.6676
Yes	139	7 (5.0)	132 (95.0)	NE (NE, NE)	137	2 (1.5)	135 (98.5)	NE (NE, NE)	2.854 (0.591, 13.774)	0.1720	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	2 (1.7)	118 (98.3)	NE (NE, NE)	1.774 (0.324, 9.697)	0.5026	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Immune system disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.9895
≤60	164	7 (4.3)	157 (95.7)	NE (NE, NE)	163	4 (2.5)	159 (97.5)	NE (NE, NE)	1.312 (0.381, 4.512)	0.6657	
>60	101	4 (4.0)	97 (96.0)	NE (NE, NE)	105	0	105 (100)	NE (NE, NE)	NE (0.000, NE)	0.0485	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Pooled Age Group 2											0.2143
<60	159	8 (5.0)	151 (95.0)	NE (NE, NE)	160	5 (3.1)	155 (96.9)	NE (NE, NE)	1.398 (0.456, 4.284)	0.5561	
≥60 - <65	37	0	37 (100)	NE (NE, NE)	43	0	43 (100)	NE (NE, NE)	NE (NE, NE)	NE	
≥65	69	1 (1.4)	68 (98.6)	NE (NE, NE)	65	6 (9.2)	59 (90.8)	NE (NE, NE)	0.159 (0.019, 1.319)	0.0507	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Sex											0.5028
Male	124	3 (2.4)	121 (97.6)	NE (NE, NE)	120	5 (4.2)	115 (95.8)	NE (NE, NE)	0.474 (0.113, 1.993)	0.2973	
Female	141	6 (4.3)	135 (95.7)	NE (NE, NE)	148	6 (4.1)	142 (95.9)	NE (NE, NE)	0.980 (0.315, 3.045)	0.9723	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Race by 2 categories											0.0294
White	157	2 (1.3)	155 (98.7)	NE (NE, NE)	161	8 (5.0)	153 (95.0)	NE (NE, NE)	0.223 (0.047, 1.052)	0.0379	
Non-white	108	7 (6.5)	101 (93.5)	NE (NE, NE)	107	3 (2.8)	104 (97.2)	NE (NE, NE)	2.232 (0.577, 8.635)	0.2323	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Geographic Region 1											0.1333
North America	16	1 (6.3)	15 (93.8)	NE (2.0, NE)	18	0	18 (100)	NE (NE, NE)	NE (0.000, NE)	0.1824	
Europe	161	3 (1.9)	158 (98.1)	NE (NE, NE)	161	9 (5.6)	152 (94.4)	NE (NE, NE)	0.281 (0.076, 1.044)	0.0432	
Asia/Other Regions	88	5 (5.7)	83 (94.3)	NE (NE, NE)	89	2 (2.2)	87 (97.8)	NE (NE, NE)	2.302 (0.446, 11.885)	0.3057	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
WBC at initial diagnosis											0.0945
< 40x10^9/L	132	1 (0.8)	131 (99.2)	NE (NE, NE)	133	6 (4.5)	127 (95.5)	NE (NE, NE)	0.168 (0.020, 1.398)	0.0606	
≥ 40x10^9/L	133	8 (6.0)	125 (94.0)	NE (NE, NE)	135	5 (3.7)	130 (96.3)	NE (NE, NE)	1.294 (0.421, 3.975)	0.6518	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Choice of Anthracycline											0.3994
Daunorubicin	123	4 (3.3)	119 (96.7)	NE (NE, NE)	94	2 (2.1)	92 (97.9)	NE (NE, NE)	1.499 (0.274, 8.191)	0.6381	
Idarubicin	142	5 (3.5)	137 (96.5)	NE (NE, NE)	171	9 (5.3)	162 (94.7)	NE (NE, NE)	0.580 (0.194, 1.736)	0.3245	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML Cytogenetic Risk Score											0.9398
Favorable	13	0	13 (100)	NE (NE, NE)	19	0	19 (100)	NE (NE, NE)	NE (NE, NE)	NE	
Intermediate	195	7 (3.6)	188 (96.4)	NE (NE, NE)	190	7 (3.7)	183 (96.3)	NE (NE, NE)	0.847 (0.296, 2.420)	0.7563	
Unfavorable	19	1 (5.3)	18 (94.7)	NE (24.9, NE)	27	2 (7.4)	25 (92.6)	NE (NE, NE)	0.466 (0.037, 5.798)	0.5454	
Unknown	38	1 (2.6)	37 (97.4)	NE (NE, NE)	31	2 (6.5)	29 (93.5)	NE (NE, NE)	0.386 (0.034, 4.348)	0.4247	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
ECOG Performance Status at Baseline											0.1802
0 - Fully Active	87	5 (5.7)	82 (94.3)	NE (NE, NE)	97	2 (2.1)	95 (97.9)	NE (NE, NE)	2.457 (0.475, 12.702)	0.2678	
1 - Restricted in Physically Strenuous Activity	133	3 (2.3)	130 (97.7)	NE (NE, NE)	134	8 (6.0)	126 (94.0)	NE (NE, NE)	0.339 (0.090, 1.281)	0.0944	
2 - Ambulatory and Capable of All Selfcare	45	1 (2.2)	44 (97.8)	NE (32.1, NE)	36	1 (2.8)	35 (97.2)	NE (NE, NE)	0.634 (0.039, 10.343)	0.7473	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
FLT3-ITD category at Baseline											0.5949
≥3 to ≤25%	94	2 (2.1)	92 (97.9)	NE (NE, NE)	98	1 (1.0)	97 (99.0)	NE (NE, NE)	2.063 (0.187, 22.759)	0.5456	
>25% to ≤50%	141	5 (3.5)	136 (96.5)	NE (NE, NE)	136	8 (5.9)	128 (94.1)	NE (NE, NE)	0.544 (0.177, 1.672)	0.2808	
>50%	29	2 (6.9)	27 (93.1)	NE (23.2, NE)	34	2 (5.9)	32 (94.1)	NE (NE, NE)	0.796 (0.110, 5.772)	0.8208	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
AML with Mutated NPM1											0.5446
Yes	139	4 (2.9)	135 (97.1)	NE (NE, NE)	137	7 (5.1)	130 (94.9)	NE (NE, NE)	0.521 (0.152, 1.784)	0.2904	
No	116	4 (3.4)	112 (96.6)	NE (NE, NE)	120	4 (3.3)	116 (96.7)	NE (NE, NE)	0.895 (0.223, 3.583)	0.8755	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf

Daiichi Sankyo | Data Intelligence – Evidence Generation | Final | AC220-A-U302 QUANTUM-First (DCO 13 Aug 2021) | Statistical analyses for AMNOG (HTA Germany)
Table 3.13.2 Severe Treatment-emergent adverse events (NCI CTCAE grade ≥3) by system organ class (SOC) and preferred term (PT) observed for ≥ 10 patients in at least one arm and ≥ 1% of the patients in at least one arm - Time-to-event analysis - subgroup analysis - DCO 13-Aug-2021 - Safety Analysis Set

SOC: Musculoskeletal and connective tissue disorders; PT: Any PT

	Quizartinib (N=265)				Placebo (N=268)				Quizartinib vs Placebo		Interaction
Subgroup	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	n	No. of subjects with events (%)	No. of subjects censored (%)	Median (95 % CI) (months) [a]	Hazard Ratio (95 % CI) [b]	Unstratified log-rank p-value [c]	P-value [d]
Age by 2 categories											0.0933
≤60	164	8 (4.9)	156 (95.1)	NE (NE, NE)	163	5 (3.1)	158 (96.9)	NE (NE, NE)	1.365 (0.445, 4.186)	0.5843	
>60	101	1 (1.0)	100 (99.0)	NE (NE, NE)	105	6 (5.7)	99 (94.3)	NE (NE, NE)	0.164 (0.020, 1.366)	0.0565	

N: number of subjects in analysis set; n: number of subjects in subgroup category; %: proportion of number of subjects in n; CI: confidence interval; NE: not estimable. PT: Preferred Term, SOC: System Organ Class.
[a] Median time to first event is from Kaplan-Meier estimate. Confidence Interval for median was computed using the Brookmeyer-Crowley method.
[b] Hazard ratio is from unstratified Cox proportional hazards model with treatment as the only categorical variable in the model. Confidence limits are based on the Wald test.
[c] Two-sided p-value from unstratified log-rank test.
[d] Two-sided interaction p-value is for the interaction term from unstratified Cox proportional hazards model with treatment, subgroup, and treatment-by-subgroup interaction as categorical variables in the model. The p-value is based on the Wald test.
Data source: \\AC220-A-U302\Production\Raw\Data_Restricted\rstrct_eg\rstrct_20211102_eg\rstrct_valos\20230516_AMNOG\ADAM\
Run date: 21JUL2023 – 22:30; Program name: DE_T_3_11_2.sas; Output name: DE_T_3_13_2_TEAESEVSOCPT_SUB_SAS.rtf